,Name_VH,Name_VL,Genbank_protein_id_vh,Genbank_protein_id_vl,Binds_to,Origin,VH,VL,Reference,doi,Description_VH,Description_VL,Date_added,Description_VB,Description_VA
0,H11-H4,NaN,7Z1E_FFF,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Lama glama (llama),qvqlvesggglmqaggslrlscavsgrtfstaamgwfrqapgkerefvaairwsggsayyadsvkgrftisrdkakntvylqmnslkyedtavyycarteyvsyllsdyatwpydywgqgtqvtvsskhhhhhh,NaN,"Mikolajek,H. et al.; Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes; Proc Natl Acad Sci U S A 119 (31), e2205412119 (2022); 2022.",10.1073/pnas.2205412119,"Chain FFF, H11-H4 Q98R H100E",NaN,2022-10-12,NaN,NaN
1,NaN,NaN,UOL67274,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgyifsnyyiawvrqipgkglecmgfiypddsdttynpsfrgqviisadksintaylqwnslkasdtamyycarsntgytstwfrdwgqgtlvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2,NaN,NaN,UOL67273,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipvfditnyaqkfqgrvtitadkstntahmelsslrsedtavyycarppspyyydrsghpqadhyfdywgqgtlvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3,NaN,NaN,UOL67272,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfntyainwvrqapgqglewmgriipmfgianyaqkfqgtvtftadkststaymelsslryedtavyycarsayysessgyyldywgqgtlvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4,NaN,NaN,UOL67271,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfsrysiswvrqapgqglewmgriipmfatanyaqkfqgrvtitadkttsiaymelsslrsedtavyycaranyyyesggyhfdnwgqgtlvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5,NaN,NaN,UOL67270,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysiiwvrqapgqglewmgriipilgvanyaqnfqgrvtitadkststaymevsslrvddtavyycardprplippasqishgmdvwgqgttvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6,NaN,NaN,UOL67269,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytfswvrqapgqglewmgriipflgiadyaqtfegrvtitadkstntvymelpslrfedtavyycarergrsgygsawafdlwgqgtmvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
7,NaN,NaN,UOL67268,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpggslrlscaasgftfssypmhwvrqapgkglewvavisydgsnryyadsvkgrftisrdnskntlflqmnslrtddtavyycardlvvvvaasshyyngmdvwgqgttvtvsa,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
8,NaN,NaN,UOL67267,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglmqpggslrlscvaseiivsrnymswvrqapgkglewvsviypggstfyagsvrgrftisrdnskntlylqmnslrvddtavyfcardrgnaafdfwgqgtmvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
9,NaN,NaN,UOL67266,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlsctasgvivtwnymswvrqapgkglewvsvvypggspfyaesvkgrftisrdnsnntlylqmsslraedtavyycardrgngafdiwgqgtmvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
10,NaN,NaN,UOL67265,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvsanymnwvrqapgkglewvsvmypggttyyedsvkgrftisrdnakntlylqmnylraedtalyfcarevyaldvwgqgttvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
11,NaN,NaN,UOL67264,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivtsnymtwvrqapgkglewvstiysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarvlpvagdsfdfwgqgtmvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
12,NaN,NaN,UOL67263,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswirqapgkglewvalmypggstfyadavkgrftisrdgskntlflqmsslraedsamyycarlpygtdvwgqgttvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
13,NaN,NaN,UOL67262,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaateiivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdaskntlylqmnslraedtavyycardfgefyfdfwgqgtlvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
14,NaN,NaN,UOL67261,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscevsefivsrnymswvrqapgkglewisvifpggstfyadsvkgrfsisrdnskntlylqmnslraedtavyycardfgefyfdywgqgtlvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
15,NaN,NaN,UOL67260,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),dvhlvesgggliqpggslrlscaasefivsanymswvrqapgeglqwvsviypggstfyaesvkgrftisrdnsrntlylqmnslraedtgvyycardygdfyfdywgqgtlvtvss,NaN,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
16,NaN,NaN,NaN,UOL67259,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsaapgktaritcgensiggkivhwyqqkpgqapvlvisydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssidhfvvfgggtkltv,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
17,NaN,NaN,NaN,UOL67258,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqfagkapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
18,NaN,NaN,NaN,UOL67257,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsgsylawyqqkpgqapslliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvnsprtfgqgtkle,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
19,NaN,NaN,NaN,UOL67256,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvgssylawyqqkpgqaprlliygastratgiphrfsgsgsgtdftltisrlepedfavyycqqyhnsprtfgqgtkv,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
20,NaN,NaN,NaN,UOL67255,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllqsngytyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkistveaedvgvyycmqalqippatfgqgtrlei,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
21,NaN,NaN,NaN,UOL67254,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapklliyansdrpsglpdrfsgsksdtsaslaitglqaedeadyycqsydssltgvvfgggtkvtv,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
22,NaN,NaN,NaN,UOL67253,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswfawyqqkpgkapklliydasslqsgvpsrfsgsgfgtdftltisslqpedfatyycqqvksfpltfgqgtrle,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
23,NaN,NaN,NaN,UOL67252,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsllsasigdrititcrasqgisnylawyqqkpgkapnlliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldtypgdtfgqgtkle,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
24,NaN,NaN,NaN,UOL67251,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtiscrasqgissdlawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypgdtfgqgtklei,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
25,NaN,NaN,NaN,UOL67250,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspfflsasvgdrvtitcrasqdinkdlawyqqkpgkapklliyaastleggvpsrfsgsgfgteftltisslqaedfatyhcqrvnshppafgggtkveik,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
26,NaN,NaN,NaN,UOL67249,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqanqdinkylnwyqqkpgkapklliylasslqsgvpsrfsgsgsgtefsftisslqpedvatyycqhynnflvtwtfgqgtkve,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
27,NaN,NaN,NaN,UOL67248,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsgsvgdrvtitcqasqdinkylnwyqqkpgkapkllihdasnleagvpprfsgsgsgtdfsftisslqpediatyycqqydnlpitfgqgtrlei,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
28,NaN,NaN,NaN,UOL67247,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqtvsssslawyqqkpgqaprlliygassrvagipdrfsgsgsgtdftlaisrlepedfavyycqqygssprtfgqgtkvei,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
29,NaN,NaN,NaN,UOL67246,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eiiltqspgtlslspgeratlscrasqsagsnflawyqqkpgqaprlliygassraagvadrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkvev,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
30,NaN,NaN,NaN,UOL67245,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeraslscrasqslstylawyqqkpgqaprllifgassrasgipdrfsgggsgtdftltisrlepedfavyycqqygssprtfgqgtkvei,"Pushparaj,P. et al.; Influence of immunoglobulin genotype on the elicitation of SARS-CoV-2 neutralizing antibodies; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
31,NaN,NaN,UOF83927,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsyywigwvrqmpgkglewmgivypadsdtryspsfqgqvtisadksistaylqwsslkasdtamyycvrhpgggdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Song,D. et al.; Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
32,NaN,NaN,UOF83925,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarasitttddgmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Song,D. et al.; Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
33,NaN,NaN,UOF83923,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqqwgagllkpsetlsltcavygesfsgyywswirqspgkglewigqinhsgntnynpslksrvtmsvdtsknqfslklssvtaadtavyycarelghdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Song,D. et al.; Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
34,NaN,NaN,UOF83921,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsyywigwvrqmpgkglewmgivypddsdtryspsfqgqvtisadksistaylqwsslkasdtamyycvrhpgggdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Song,D. et al.; Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
35,NaN,NaN,NaN,UOF83928,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqydsfswtfgqgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
36,NaN,NaN,NaN,UOF83926,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpfsfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
37,NaN,NaN,NaN,UOF83924,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsisssylawfqqkpgqaprlliygassrapgipdrfsgsgsgtdftltisrlepedfavyycqqygdspltfgggtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
38,NaN,NaN,NaN,UOF83922,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltitslqpddfatyycqqydsfswtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Song,D. et al.; Ultra-potent human antibodies broadly and effectively neutralize various SARS-CoV-2 variants including Omicron; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
39,NaN,NaN,7V6O_I,NaN,['MERS'],Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfsnygmhwvrqapgkglewvaviwsagslkyyadsvkgrfiisrdnskntlylqmdslrpedtavyycarenttyyyetsgswgasyyfdfwgqgtlvtvssstkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrv,NaN,"Wang,X. et al.; MERS S ectodomain trimer in complex with neutralizing antibody 111 (state 2); Unpublished; 2022.",NaN,"Chain I, H",NaN,2022-10-12,NaN,NaN
40,NaN,NaN,7V6O_G,NaN,['MERS'],Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfsnygmhwvrqapgkglewvaviwsagslkyyadsvkgrfiisrdnskntlylqmdslrpedtavyycarenttyyyetsgswgasyyfdfwgqgtlvtvssstkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrv,NaN,"Wang,X. et al.; MERS S ectodomain trimer in complex with neutralizing antibody 111 (state 2); Unpublished; 2022.",NaN,"Chain G, H",NaN,2022-10-12,NaN,NaN
41,NaN,NaN,7V6O_E,NaN,['MERS'],Homo sapiens (human),evqlvesgggvvqpgrslrlscaasaftfsnygmhwvrqapgkglewvaviwsagslkyyadsvkgrfiisrdnskntlylqmdslrpedtavyycarenttyyyetsgswgasyyfdfwgqgtlvtvssstkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrv,NaN,"Wang,X. et al.; MERS S ectodomain trimer in complex with neutralizing antibody 111 (state 2); Unpublished; 2022.",NaN,"Chain E, H",NaN,2022-10-12,NaN,NaN
42,NaN,NaN,NaN,7V6O_H,['MERS'],Homo sapiens (human),NaN,diqmtqtpaslsasvgdrvtitcrasqnissylnwyqqkpgkapkvliydtsrlqsgvpsrfsgsasgtdftltisslqpedfatyycqqscttlrcwtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,X. et al.; MERS S ectodomain trimer in complex with neutralizing antibody 111 (state 2); Unpublished; 2022.",NaN,NaN,"Chain H, L",2022-10-12,NaN,NaN
43,NaN,NaN,NaN,7V6O_F,['MERS'],Homo sapiens (human),NaN,diqmtqtpaslsasvgdrvtitcrasqnissylnwyqqkpgkapkvliydtsrlqsgvpsrfsgsasgtdftltisslqpedfatyycqqscttlrcwtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,X. et al.; MERS S ectodomain trimer in complex with neutralizing antibody 111 (state 2); Unpublished; 2022.",NaN,NaN,"Chain F, L",2022-10-12,NaN,NaN
44,NaN,NaN,NaN,7V6O_D,['MERS'],Homo sapiens (human),NaN,diqmtqtpaslsasvgdrvtitcrasqnissylnwyqqkpgkapkvliydtsrlqsgvpsrfsgsasgtdftltisslqpedfatyycqqscttlrcwtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wang,X. et al.; MERS S ectodomain trimer in complex with neutralizing antibody 111 (state 2); Unpublished; 2022.",NaN,NaN,"Chain D, L",2022-10-12,NaN,NaN
45,NaN,NaN,7WBZ_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvrsnymswvrqapgkglewvsliysggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdk,NaN,"Li,R. et al.; Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies; Commun Biol 5 (1), 789 (2022); 2022.",10.1038/s42003-022-03739-5,"Chain H, heavy chain",NaN,2022-10-12,NaN,NaN
46,NaN,NaN,7WCD_A,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargwatyydiltgyslfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppc,NaN,"Li,R. et al.; Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies; Commun Biol 5 (1), 789 (2022); 2022.",10.1038/s42003-022-03739-5,"Chain A, Heavy chain",NaN,2022-10-12,NaN,NaN
47,NaN,NaN,7WCD_G,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargwatyydiltgyslfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppc,NaN,"Li,R. et al.; Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies; Commun Biol 5 (1), 789 (2022); 2022.",10.1038/s42003-022-03739-5,"Chain G, Heavy chain",NaN,2022-10-12,NaN,NaN
48,NaN,NaN,7WCD_E,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargwatyydiltgyslfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppc,NaN,"Li,R. et al.; Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies; Commun Biol 5 (1), 789 (2022); 2022.",10.1038/s42003-022-03739-5,"Chain E, Heavy chain",NaN,2022-10-12,NaN,NaN
49,NaN,NaN,NaN,7WBZ_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgtefkltisslqpedfatyycqqlnnyppvtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Li,R. et al.; Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies; Commun Biol 5 (1), 789 (2022); 2022.",10.1038/s42003-022-03739-5,NaN,"Chain L, light chain",2022-10-12,NaN,NaN
50,NaN,NaN,URN46108,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggafsiyaitwvrqapgqglewmggiipirgtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsetrcyfwfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
51,NaN,NaN,URN46107,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggtfaiyaitwvrqapgqglewmgniipiigtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsstqcyfwfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
52,NaN,NaN,URN46106,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggifsiyaitwvrqapgqglewmgaiipiigtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsstrcyfnfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
53,NaN,NaN,URN46105,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggpfsiyaitwvrqapgqglewmggiipirgtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsstrcyfwfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
54,NaN,NaN,URN46104,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggtfsiyaitwvrqapgqglewmgniipiigtanyaqkfqgrvtitadkststaymelsslrsedtavyycaydfrycsstrcyfwfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
55,NaN,NaN,URN46103,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggtfsiyaltwvrqapgqglewmggiipiqgtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsgtrcyfwfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
56,NaN,NaN,URN46102,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggafsiyaitwvrqapgqglewmggiipiigtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycestrcyfwfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
57,NaN,NaN,URN46101,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggtfdiyaitwvrqapgqglewmggiipirgtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsstrcyfwfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
58,NaN,NaN,URN46100,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckvsggwfsiyaitwvrqapgqglewmggiipiqgtanyaqkfqgrvtitadkststaymelsslrsedtavyycaldfrycsstrcyfwfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
59,NaN,NaN,URN46099,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggafsiysitwvrqapgqglewmggiipirgtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycssdrcyfwfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
60,NaN,NaN,URN46098,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggtfsiyaitwvrqapgqglewmgniipiigtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsstrcyfwfdpwgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
61,NaN,NaN,URN46097,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasgglfsssaiswvrqapgqglewmggiipilditnyaqkfqgrvtitadkststafmelsslrsedtavyycaltnqwdllvywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
62,NaN,NaN,URN46096,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckisggyfsssaiswvrqapgqglewmggiipvlditnyaqkfqgrvtitadkststafmelsslrsedtavyycaltnqwdllvywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
63,NaN,NaN,URN46095,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckapggtfsssaiswvrqapgqglewmggiipildithyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdllvywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
64,NaN,NaN,URN46094,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckssggtfsssayswvrqapgqglewmgtiipilditnyaqkfqgrvtitadkststafmelsslrsedtavyycaqrnqwdlivywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
65,NaN,NaN,URN46093,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckvsggtfsssaiswvrqapgqglewmgkiipilditnyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdllvywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
66,NaN,NaN,URN46092,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggifsssaiswvrqapgqglewmggiipildytnyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdllvywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
67,NaN,NaN,URN46091,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckapggtfsssaiswvrqapgqglewmggiipildittyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdlliywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
68,NaN,NaN,URN46090,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckavggtfsssaiywvrqapgqglewmggiipildianyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdlvvywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
69,NaN,NaN,URN46089,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggifsssaiswvrqapgqglewmggiipilditnyaqkfqgrvtitadkststafmelsslrsedtavyycaltnqwdllvywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
70,NaN,NaN,URN46088,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckapggtfsssaiswvrqapgqglewmggiipildithyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdllvywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
71,NaN,NaN,URN46087,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckapggtfsssaiswvrqapgqglewmgtiipilditnyaqkfqgrvtitadkststafmelsslrsedtavyycaqrnqwdllvywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
72,NaN,NaN,URN46086,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgssvkvsckasggifsssaiswvrqapgqglewmggiipildisnyaqkfqgrvtitadkststafmelsslrsedtavyycaltnqwdllvywgqgtlvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
73,NaN,NaN,URN46085,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaasgltvssnymtwvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvfgldvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
74,NaN,NaN,URN46084,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaasgltvssnymvwvrqapgkglewvsqiysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
75,NaN,NaN,URN46083,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaafgltvssnymswvrqapgkglewvsqiysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygvdvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
76,NaN,NaN,URN46082,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaasglwvssnymswvrqapgkglewvsqiysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygidvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
77,NaN,NaN,URN46081,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlschasgltvssnymlwvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygvdvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
78,NaN,NaN,URN46080,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaasgltvssnymtwvrqapgkglewvsviyaggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygvdvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
79,NaN,NaN,URN46079,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaasgltvssnymawvrqapgkglewvsviyaggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygidvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
80,NaN,NaN,URN46078,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaasgltvssnymvwvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygidvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
81,NaN,NaN,URN46077,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaasgltvslnymswvrqapgkglewvseiysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
82,NaN,NaN,URN46076,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygvdvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
83,NaN,NaN,URN46075,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaafgltvssnymswvrqapgkglewvsqiysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygvdvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
84,NaN,NaN,URN46074,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesgggliqpggslrlscaasgltvssnymvwvrqapgkglewvsviysggsifyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,NaN,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
85,NaN,NaN,NaN,URN46143,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcrasqdissylnwyqqeagkapklliyrasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprsfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
86,NaN,NaN,NaN,URN46142,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcrasqpissylnwyqqeagkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
87,NaN,NaN,NaN,URN46141,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqeagkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
88,NaN,NaN,NaN,URN46140,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqsissylnwyqqeagkapklliytasslqsgvpsrfsgsgygtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
89,NaN,NaN,NaN,URN46139,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcrasqsiseylnwyqqeagkapklliyqasslqsgvpsrfsgsgsgtdftltisslqpedfatyycgqsystprtfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
90,NaN,NaN,NaN,URN46138,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqeagkapklliysasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
91,NaN,NaN,NaN,URN46137,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitchasqsissylnwyqqeagkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
92,NaN,NaN,NaN,URN46136,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcrasqsiseylnwyqqeagkapklliyrasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
93,NaN,NaN,NaN,URN46135,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcrasqsiseylnwyqqeagkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
94,NaN,NaN,NaN,URN46134,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcrasqsigsylnwyqqeagkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
95,NaN,NaN,NaN,URN46133,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcrasqsiqsylnwyqqeagkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprsfgqgtkvdik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
96,NaN,NaN,NaN,URN46132,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrwtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
97,NaN,NaN,NaN,URN46131,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscsasqsvsssylawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygsshwtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
98,NaN,NaN,NaN,URN46130,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygssvwtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
99,NaN,NaN,NaN,URN46129,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscrasqwvsssyiawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygssswtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
100,NaN,NaN,NaN,URN46128,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscrasqsvsshylawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygsspwtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
101,NaN,NaN,NaN,URN46127,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscrasqevsssylawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygssawtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
102,NaN,NaN,NaN,URN46126,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscrasqsvsshylawyqqkpgqaprlliygassrytgipdrfsgsgsgtdftltisrlepedfavyycqhygsshwtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
103,NaN,NaN,NaN,URN46125,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlschasqsvsssylawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygsstwtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
104,NaN,NaN,NaN,URN46124,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygssawtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
105,NaN,NaN,NaN,URN46123,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscrasqdvsssylawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygssewtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
106,NaN,NaN,NaN,URN46122,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscrasqsvsasylawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrwtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
107,NaN,NaN,NaN,URN46121,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,eivltqspgtlslspgeratlscrasqrvsssylawyqqkpgqaprlliygaesratgipdrfsgsgsgtdftltisrlepedfavyycqhygsslwtfgqgtkleik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
108,NaN,NaN,NaN,URN46120,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrvsqgissylawyqqkpgkapklliyfastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypppftfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
109,NaN,NaN,NaN,URN46119,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqhgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypppftfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
110,NaN,NaN,NaN,URN46118,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastiqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypppftfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
111,NaN,NaN,NaN,URN46117,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgishylawyqqkpgkapklliyaasnlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypppftfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
112,NaN,NaN,NaN,URN46116,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqrgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypppftfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
113,NaN,NaN,NaN,URN46115,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgisrylawyqqkpgkapklliyaastlqygvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkytfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
114,NaN,NaN,NaN,URN46114,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgiswylawyqqkpgkapklliyaastlqwgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkstfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
115,NaN,NaN,NaN,URN46113,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqwgvpsrfsgsgsgteftltisslqpedfatyycvqlnsyppkftfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
116,NaN,NaN,NaN,URN46112,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqwgvpsrfsgsgsgteftltisslqpedfatyycqqlnsepppftfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
117,NaN,NaN,NaN,URN46111,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgishylawyqqkpgkapklliyaasylqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkptfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
118,NaN,NaN,NaN,URN46110,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastiqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypppftfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
119,NaN,NaN,NaN,URN46109,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqwgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypppftfgpgtkveik,"Zhao,F. et al.; Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
120,ARBD-2-7,NaN,7FH0_C,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Vicugna pacos (alpaca),qvqlvesggglvqaggslrlscaasgrtytmgwfrqapgkerefvaamrwsdtdyadslkgrftisrdnannamylqmnslgpedtavyycaageawlarsthhydywgqgtqvtvssggggsggggsggggsqlqlvesggglvqaggslrlscaasertfsggvmgwfrqrpgkerefvaairwngastfyadsvkgrftcsrdnakntgylqmnsltpedtavyycaravrtyassdyyfqertydywgqgtqvtvss,NaN,"Ma,H. et al.; Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron; Cell Res 32 (9), 831-842 (2022); 2022.",10.1038/s41422-022-00700-3,"Chain C, nanobodies aRBD-2-7",NaN,2022-10-12,NaN,NaN
121,ARBD-2-7,NaN,7FH0_B,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Vicugna pacos (alpaca),qvqlvesggglvqaggslrlscaasgrtytmgwfrqapgkerefvaamrwsdtdyadslkgrftisrdnannamylqmnslgpedtavyycaageawlarsthhydywgqgtqvtvssggggsggggsggggsqlqlvesggglvqaggslrlscaasertfsggvmgwfrqrpgkerefvaairwngastfyadsvkgrftcsrdnakntgylqmnsltpedtavyycaravrtyassdyyfqertydywgqgtqvtvss,NaN,"Ma,H. et al.; Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron; Cell Res 32 (9), 831-842 (2022); 2022.",10.1038/s41422-022-00700-3,"Chain B, nanobodies aRBD-2-7",NaN,2022-10-12,NaN,NaN
122,NaN,NaN,USQ90174,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckaseytftgyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvsmtgdtsirtaymelsrlrsddtavfycardpltgifdywgqgttltvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
123,NaN,NaN,USQ90173,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftgyylhwvrqapgqglewmgwinpnsgdthyaqkfqgrvtmprdtsistaymelsrlrsddtavyycargrggtswfaywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
124,NaN,NaN,USQ90172,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsgdtnyaqkfqvrvtmtrdtsistaymelsrlrsddtavyycargkggtswfaywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
125,NaN,NaN,USQ90171,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsgdtnyaqkfqvrvtmtrdtsistaymelsrlrsddtavyycargkggtswfaywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
126,NaN,NaN,USQ90170,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgyiftgynmhwvrqapgqglewmgwinpnsdftnyaqkfqgrvtmtrdtsintaymeltrlrsddtavyycargrggtswlaywgqgtlvtvta,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
127,NaN,NaN,USQ90169,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftghqihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittaymelsrlrsddtavyycarrncdnwgqgttltvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
128,NaN,NaN,USQ90168,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgftftgyqihwvrqapgqglewmgwinpksggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarrncdywgqgttltvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
129,NaN,NaN,USQ90167,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgftftgyqihwvrqapgqglewmgwinpnsgvtnyahkfqgrvtmtrdtsistaymelsrlrsddtavyycarrncdywgqgttltvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
130,NaN,NaN,USQ90166,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvrvsckasgftftgyqihwvrqapgqglewmgwinpksggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarrncdywgqgttltvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
131,NaN,NaN,USQ90165,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsggshyaqkfqgrvtltrdtsistaymeltrlrsddtavyycardrvgqrfpywgqgtlvtvsp,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
132,NaN,NaN,USQ90164,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftdfyihwvrqapgqglewmgwinpnsvvtfyapkfqgrvtmtrdtsistaymelnrlrsddsavyycardrvgqrfpywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
133,NaN,NaN,USQ90163,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgyiftgyyihwirqapgqglewmgwinpdsggthfakkfqgrvtltrdtsittaymelsrlrsddtavyycardrvgqrfvywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
134,NaN,NaN,USQ90162,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycardlgdydawfaywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
135,NaN,NaN,USQ90161,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycardlgdydawfaywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
136,NaN,NaN,USQ90160,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasmkvsckasgytfttyhihwvrqapgqglewmgwiipnngdtnyaqkfqgrvtmtrdtsintaymeltrlrsddtavyycarggrrtwfaywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
137,NaN,NaN,USQ90159,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvnvsckasgytftvynmhwvrqapgqglewmgwitpysgatnyaqkfqgrvtmtrdtsiptvymelnrlrsddtamyycargarrtwfaywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
138,NaN,NaN,USQ90158,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasmkvsckasgytfttyhihwvrqapgqglewmgwiiphsgdtnyaqkfqgrvtmtrdtsintaymeltrlrsddtavyycarggrrtwfaywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
139,NaN,NaN,USQ90157,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaelkkpgasvkvsckasgytftvynihwirqapgqglewmgwinpysggtnsaqnfqgrvtmtrdtsistaymelsslrsddtalyycargerrswftywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
140,NaN,NaN,USQ90156,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftvynvhwirqvpgqglewmgwinpysggtnsaqnfqgrvtmtrdtsittaymelsslrsddtalyycargerrswftywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
141,NaN,NaN,USQ90155,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftvynihwirqapgqglewmgwinpysggtnsaqnfqgrvtmtrdtsittaymelsslrsddtalyycargerrswftyggqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
142,NaN,NaN,USQ90154,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftayyihwmrqapgqglewmgwinpnrgdtnyaqkfqgrvtmtrdtsirtaymelsrlksddtavyyctitgrrpffpywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
143,NaN,NaN,USQ90153,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckssgytftayymhwvrqapgqglkwmgwinphnggtnyaqefqgrvtmtrdtsiktvymelsrlrsddtavyycaitgrrpwfanwgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
144,NaN,NaN,USQ90152,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftayyihwmrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsvrtaymelsrltsddtavyycaitgrrpwfpywgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
145,NaN,NaN,USQ90151,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftayyihwfrqvpgqglewmgwinpitggtnyaqnfqgrvtmtrdtpirtaymelrrlrsddtavfycaitgrrpwfpfwgqgtlvtvsa,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
146,NaN,NaN,USQ90150,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgdtltgyymhwvrqapgqglewmgwinpnsggtnyvqkfqgrvtmtrdtsistaymelsrlrsddtavyycarerrvihyygilyamdywgqgtavtvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
147,NaN,NaN,USQ90149,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgdpftgyymhwvrqapgqglewmgwinpnsggtnyvqkfqgrvtmtrdtsistaymelsrlrsddtavyycarerrvihysgilyaldywgqgtaltvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
148,NaN,NaN,USQ90148,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgdtftgysmhwvrqapgqglewmgwinpnsggtnyvqnfqdrvtmtrdtsistaymelsrlrsddtavyycarerrvihyygilyaldywgqgtaltvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
149,NaN,NaN,USQ90147,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgdifigyymhwvrqapgqglewmgwinpnsggtnyvkkfqgrvtmtrdtsiskaymelrrlrsddtavyycarerrvihysgilyaldywgqgtaltvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
150,NaN,NaN,USQ90146,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftdsyihwvrqapgqglewmgwinpnsggtnyaqnfqgrvtmtrdtsistaymdlsrlksddtavyycardrvlygrsygwyfdvwgagttvtvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
151,NaN,NaN,USQ90145,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftgtyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycardrvlygrsygwyfdvwgagttvtvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
152,NaN,NaN,USQ90144,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvscktsgytfsdsyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymdlsrlksddtavyycardrvlygrsygwyfdvwgagttvtvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
153,NaN,NaN,USQ90143,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvtvsckasgytftdsylhwvrqapgqglewmgwinphsggtnyaqkfqgrvtmtrdtsistvymelsrlrsddtavyycardrvlygrsygwyfdvwgagttvtvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
154,NaN,NaN,USQ90142,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,qvqlvqsgaevkkpgasvkvsckasgytftgtyihwvrqapgqglewmgwinpnsggtnfaqifqgrvtltrdtsistaymdlnrlksddtavyycardrvlygrsfgwyfdvwgagttvtvss,NaN,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
155,NaN,NaN,NaN,USQ90207,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlpymytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
156,NaN,NaN,NaN,USQ90206,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdiynylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
157,NaN,NaN,NaN,USQ90205,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdiynylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
158,NaN,NaN,NaN,USQ90204,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdiynylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlctfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
159,NaN,NaN,NaN,USQ90203,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdignylnwfqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
160,NaN,NaN,NaN,USQ90202,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdistylnwyqqkpgkapkllifdasnletgvpsrfsgggsgtdftftisslqpediatyycqqydnlpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
161,NaN,NaN,NaN,USQ90201,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdistylnwyqqkpgkapnlliydasnletgvpsrfsgsgsgtdftfnisslqpediatyycqqydnlpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
162,NaN,NaN,NaN,USQ90200,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdistylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
163,NaN,NaN,NaN,USQ90199,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdistylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
164,NaN,NaN,NaN,USQ90198,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdifnclnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedvatyfcqqydnlwtfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
165,NaN,NaN,NaN,USQ90197,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtvtcqasqdisnclnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqqydylwtfgggskleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
166,NaN,NaN,NaN,USQ90196,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqgsqdisnylngyqqklgkapkllisdasnletgvpsrfsgrgsgtvftftisspqpediatyycqqydnlwtfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
167,NaN,NaN,NaN,USQ90195,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdisnhlnwyqqkpgkapkvliydafnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrwtfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
168,NaN,NaN,NaN,USQ90194,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdisnhlnwyqqkpgkapkvliydtfnletgvpsrfsgsgsgtdftftvrslqpediatyycqqydnlrwtfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
169,NaN,NaN,NaN,USQ90193,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapkfliydasnletgvpsrfsgsrsgtdftftisslqpediatyycqqydylpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
170,NaN,NaN,NaN,USQ90192,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkfliydasnletgvpsrfsgsrsgtdftftisslqpediatyycqqydnlpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
171,NaN,NaN,NaN,USQ90191,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapkiliydasnletgvpsrfsgsrsgthftftisslqpediatyycqqydylpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
172,NaN,NaN,NaN,USQ90190,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdintylnwyqqkagkapkvliydasnletgvpsrfsgsrsgtdftftisslqpediatyycqqydnlpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
173,NaN,NaN,NaN,USQ90189,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmnqspsslsasvgdrvtitcqasqdintylnwyqqkagkapkvliydasnletgvpsrfsgsrsgtdfiftisslqpediatyycqqydnlpytfggwtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
174,NaN,NaN,NaN,USQ90188,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmnqspsslsasvgdrvtitcqasqdintylnwyqqkagkapkvliydasnletgvpsrfsgslsgsdficiisslqpediatyycqqydnlpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
175,NaN,NaN,NaN,USQ90187,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmnqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkvpklliydasnletgvpsrfsgsrsgtdfsftisslqpediatyycqqydnlpytfggwtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
176,NaN,NaN,NaN,USQ90186,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapkvliydvsnletgvpsrfsgsrsgtdftftisslqpediaryfcqqydylpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
177,NaN,NaN,NaN,USQ90185,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmnqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapkvliydtsnletgvpsrfsgrrsgtdftftisslhpediatyycqqydylpytfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
178,NaN,NaN,NaN,USQ90184,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmnqspsslsasvgdrvtitcqarqdinnylnwyqqkpgkapkvliydvsnletgvpsrfsgsrsgtdftftisslqpedigtyycqqydnlpytfggwtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
179,NaN,NaN,NaN,USQ90183,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyddlhmftfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
180,NaN,NaN,NaN,USQ90182,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmnqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlhmftfggwtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
181,NaN,NaN,NaN,USQ90181,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlhmftfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
182,NaN,NaN,NaN,USQ90180,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmnqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlhmftfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
183,NaN,NaN,NaN,USQ90179,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtftcqasqdisdylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlptfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
184,NaN,NaN,NaN,USQ90178,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmnqspsslsasvgdrvtitcqasqdisdylnwyqqhpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedigtyfcqqydnlptfggwtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
185,NaN,NaN,NaN,USQ90177,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdindylnwyqqqpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedigtyycqqydnlptfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
186,NaN,NaN,NaN,USQ90176,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtftcqasqdisdylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftfiisslqpediatyycqqydnlptfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
187,NaN,NaN,NaN,USQ90175,"['COVID', 'SARS-COV-2']",synthetic construct,NaN,diqmtqspsslsasvgdrvtitcqasqdisdylnwyqqqpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedigtyycqqydnlptfgggtkleik,"Luo,S. et al.; An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion; Sci Immunol, eadd5446 (2022) In press; 2022.",10.1126/sciimmunol.add5446,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [synthetic construct]",2022-10-12,NaN,NaN
188,NaN,NaN,UVJ49744,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglakpggslrlscaasgftfttyamhwvrqapgkglewvsgisndgntyyadsvkgrfsisrdnskntlslqmnslraedtaiyysakgaangfyrfdvwgpgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
189,NaN,NaN,UVJ49743,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlaesggglvqpggslrlscaasgftfsdygmswvrqtpgkglewvtvlwfdgnekyyadsvkdrftisrdnsknmlylqmndlkmddtavyycargtkpldvwgrgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
190,NaN,NaN,UVJ49742,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvqsgaevkkpgasvkvsckasgftfggsaiswvrqapgqglewmgliiplvggtsyaekfqdrvtitadtstgtaymelsslksedtavyycargsiaagrfdfwgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
191,NaN,NaN,UVJ49741,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvqpgrslrlscvasgftlggygmhwvrqapgkglewvglisydgsvqkygssvkgrftiskdnskntlylemnglrtddtavyfcvkgaslgdnwgqgtlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
192,NaN,NaN,UVJ49740,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvqpggslrlscaasgftfssyamhwvrlapgkglewvtlisydgdkkyyadslkdrftisrdnskdilylqmnnlkledtavyycarangggyysgldswgqgvvvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
193,NaN,NaN,UVJ49739,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvkpggslrlscaasgftfssyemhwvrqapgkglewvsviseigytthyadsvkgrftisrdnaknslflqmnslraedtavyyctrvvtspvglvitnfdywgegvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
194,NaN,NaN,UVJ49738,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvqpggslrlscaasgftfsndwmnwvrqapgkglewvgfirtkvdgstaayaesvkgrvtisrddsintlylqmnglktedtavyyctrerpggycsggvcydvgygldswgqgvvvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
195,NaN,NaN,UVJ49737,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqrvesgaevkrpgetlkiscktsgysfisyqinwvrqmpgkglewmgaidprdsdtrynpsfqgqvtisadksintaylqwrslkasdtatyfcakgydygygfdywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
196,NaN,NaN,UVJ49736,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvqpggslrlsctasgftfsdygmtwvrqtpgkglewvstiwhdgsekyyadsvkdrftisrdnsknmlylqmnnlklddtavyycgrgsgtidywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
197,NaN,NaN,UVJ49735,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),dvqlvesgaevkrpgeslkiscktsgysfasywiswvrqmpgkglewmgainpfdsdtrynpsfqgqvtisadksittaylqwsrlkasdtatyycakgeefsvaawlywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
198,NaN,NaN,UVJ49734,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvqsgaevkrpgetlkiscktsgysfisyqinwvrqmpgkglewmgaidprdsdtrynpsfqgqvtisadksintaylqwrslkasdtatyfcakgydygygfdywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
199,NaN,NaN,UVJ49733,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvqpggslrlsctasgftfsdygmtwvrqtpgkglewvstiwhdgsekyyadsvkdrftisrdnsknmlylqmnnlrlddtavyycgrgsgtidywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
200,NaN,NaN,UVJ49732,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),qlqlqesgpglvkpsetlsltcavsgasirgywwswirqppgkglewigeingnsggtyynpslksrvtisqdasknqfslslssvtaadtavyycgrasrtadnywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
201,NaN,NaN,UVJ49731,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvqpggslrvscaasgfafsdyyiqwvrqapgkgpewvglirnkakggtaeyvasvkgrftisrddsksiaslqmnslktedtavyycarycstiycdarfdywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
202,NaN,NaN,UVJ49730,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvqsgaevkkpgasvkvscrasgftfgsyaiswvrqapgqglewigmifpllgvtnyaekfqgrgtitadtststaymelsslksedtavyycarqevvvvsasyyfdfwgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
203,NaN,NaN,UVJ49729,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvqsggglakpggslrlscevsgftfstypihwvrqapgkglewvsgissggstyytdsvkgrftisrdnskntlslqmnglrpddtamyycakgaangfyrfdvwgpgdlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
204,NaN,NaN,UVJ49728,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvqsgaevkepgasvkvsckasgysfptyminwvrqapgqglewigwinpsngdtgygqklqgrvtmtrdtstktaymevtslrsedtavyycvrsmgqlgrfdvwgpgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
205,NaN,NaN,UVJ49727,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglakpggslrlscaasgfsfstnwmnwvrqtpgkglewisainggghntyyadsvkgrftisrdnskntlslqmnslrtedtavyycsstilpsrldswgqgvvvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
206,NaN,NaN,UVJ49726,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvqsgaevkrpgeslkiscktsgysftdnwitwvrqvpgkglewmgaidpsdsearlnpsfqgqvtmsadksistaylhwsrlkasdtatyfcarvggyrniydaldswgqgavvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
207,NaN,NaN,UVJ49725,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvqsgpevkqpgasvkvsckasgyrfdtyainwvrqapgqglewmgwmntytgnptfaqgfterfvfsmdtsvstvylqisslkgedtavyycarsqiygpsldvwgrgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
208,NaN,NaN,UVJ49724,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvqpggslrlscgasgftfrsygmhwvrrapgkglewvavtsfdeskkyyvdsvkdrftisrdnsknmqylqmnnlkvedtamyycargacsggvcnpdywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
209,NaN,NaN,UVJ49723,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvqpgrslrlscvasgftlggygmhwvrqapgkglewvglisydgsvqkygssvkgrftiskdnskntlylemnglrtddtavyfcvkgaslgdnwgqgtlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
210,NaN,NaN,UVJ49722,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesgaevkkpgasvklsckasgytfssyaitwvrqapgqglewmggiiplvditnyaqkfqdrvtiiadtststvymelsslrsedtavyycarggesgnyrglyyfaywgqgalvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
211,NaN,NaN,UVJ49721,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),qvtlkesgpalvkptqtltltctfsgfsitttglgvgwirqppgkalewlthiywnddihyntslksrltiskdtsknqviltmtdmdpvdtatyycarisrpgfsvsnvidywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
212,NaN,NaN,UVJ49720,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),qvtlkesgpalvkptqtltltctfsgfslntrgmgvgwirqpsrktlewlahiywdddkrystslksrltiskdtsknqvvltvtnmdpldtatyycarvtmatgpvfenwldvwgpgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
213,NaN,NaN,UKB93113,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlaesggglvkpggslrlscvasgfafstyemhwvrqapgkglewvsvisesgatthyadsvkgrftisrdnaknslflqmnslrpedtavyyctrveitrmivatnyfdywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
214,NaN,NaN,UKB93112,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesgpemkrpgssvkvsckasgytftdyyihwvrraprqglewmgwinpyngntkyaqkfqgrvtmtrdtsastaymelsglrsedtavfycatssntvlvavatfeyfefwgqgalvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
215,NaN,NaN,UKB93111,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvkpggslrlscvasgftfsryeihwvrqapgkglervsvisesgyttdyadsvkgrftisrdnaknsvflqmnslrvedtavyfctrpyldweldswgqgvvvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
216,NaN,NaN,UKB93110,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evrlvesggglvkpggslrlscvasgftfssyemhwvrqapgkglewvsvisesgatthytdsvkgrftisrdnaknslflqmnslraedtavyyctrpqsvtvfgvaatsyeafdfwgqglrvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
217,NaN,NaN,UKB93109,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlaesggglvkpggslrlscvasgftfssnemhwvrqapgkglewvsvisesgftteyadsvkgrftisrdnaknslflqmnslraedtavyyctrvsifgqfivatyfdywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
218,NaN,NaN,UKB93108,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvepggslrlscvasgfsftssemywvrqapgkglewvsvisgsgytthyadsvkgrftisrdnaknslflqmnslraedtavyycisrsldssgwsprpldywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
219,NaN,NaN,UKB93107,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evrlvesggglvkpggslrlscvasgfsfrsyemhwvrqapakglewvavisesggtaeyadsvkgrltisrdnaknsvflqmnrlraedtavyfctrvsiagglvvadwfdvwgpgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
220,NaN,NaN,UKB93106,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvkpggslrlscvasgftfssyemhwvrqapgkglewvsvisesgyttyyadsvkgrftisrdnaknslflqmnspraedtavyfctrdrsqgaggsiwtgylsdgldfwgqgvvvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
221,NaN,NaN,UKB93105,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evrlvesggglvkpggslrlscvasgftfssyemhwvrqapgkglewvsvisesgytteyadsvkgrftisrdnaknslflqmnslraedtaiyyccrvtilgmvivrpfdywgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
222,NaN,NaN,UKB93104,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvkpggslrlscigsgftfssyemhwvrqspgkglewvsvvsesgyttyyadsvkgrftisrdnakssvflqmdslraedtavyfcsrprpdiygayvyngldswgqgvvvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
223,NaN,NaN,UKB93103,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvkpggslrlscvasgftfssyemhwvrqapgkglewlsvisesgfttyyadsvkgrftisrdnaknslflqmgslraedtavyyctfpkgswadyyglgswgqgavvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
224,NaN,NaN,UKB93102,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvqsgaevkrpgeslriscktsgdaftitwiswvrqmpgkglewmgsiypddsdtrynpsfqghvtisadksitttylqwnslkasdtatyycailtwnlwrfdvwgpgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
225,NaN,NaN,UKB93101,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesgaevkrpgeslkiscktsgysftnywiswvrqmpgkglewmgaidpidsdttyspsfeghvtisvdksnstaylqwsrlkasdtatyycakdgfystrwhyfgswgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
226,NaN,NaN,UKB93100,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlqesgpglvkpsetlsltcavsggsfsnywwnwirqtpgkglewigdingnsgstnynpslksrvtiskdasknqyslkltsvtaadtafyfcarcegatypywyfdvwgpgtpitiss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
227,NaN,NaN,UKB93099,NaN,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),evqlvesggglvkpggslrlscvasgftfnryemhwvrqapgkglewvsvisesgytteyadsvkgrftisrdngknslflqmnslraedtavyycsrigittfglinrpfdlwgqgvlvtvss,NaN,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",NaN,2022-10-12,NaN,NaN
228,NaN,NaN,NaN,UVJ49769,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,setvmtqspsslsasvgdrvtitcrasqginnylgwyqqkpgkapksliyyasrletgvpsrfggsgsgtdytltisglqpediatyycqqynnspptfgggtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
229,NaN,NaN,NaN,UVJ49768,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,saiqmtqspsslsasvgdrvtvtcrasqgvsnwlawyqqkpgkapklliyrasnlqtgvpsrfsgsgsgtdftltisslqpedigtyycqqhdnspysfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
230,NaN,NaN,NaN,UVJ49767,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,fetvmtqspsslsasvgdrvtiscrasqginnylswyqqkpgkapkpliyyasslqtgvpsrfsgsrfgtdytltisslqsedvatyycqqydnspysfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
231,NaN,NaN,NaN,UVJ49766,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sdivmtqspsslsasvgdrvtitcrasenvnnylnwyqqksgkapklliykastlqsgvpsrfsgsgsgtdytftisslqsedvatyycqhnygtpcsfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
232,NaN,NaN,NaN,UVJ49765,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,fdiqmtqspsslsasvgdrvtitcrasenannylnwyqqksgkapklliykastlqsgvpsrfsgsgsgtdytftisslqsedvatyycqhnygspytfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
233,NaN,NaN,NaN,UVJ49764,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,fqaaltqprsvsgspgqsvtisctgsssdiggynyvswyqqlpgtapkimiyavnkrpsgvsdrfsgsksgntasltisglqaedeadyyccsfagpsyifgagtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
234,NaN,NaN,NaN,UVJ49763,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,fdiqmtqspsslsasvgdrvtitcrasrgisdylswyqqkpgkapkrliyavssldggvpsrfsgsgsgaeftltitslqpedfavyfclqsyttpytfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
235,NaN,NaN,NaN,UVJ49762,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqsvltqppsvsaapgqkvtiscsgsmsnigrsyvswyqqvpgaapkpliydnnkrpsgvsdrfsgsksgtsaslaitglqtgdeadyycgawdsslsvwlfgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
236,NaN,NaN,NaN,UVJ49761,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqsvltqppsasgapgqsvtiscsgsssnigsnyvywyqqlpgtaptlliyysnrrpsgvpdrfsasksgtsaslaitglrsedeadyycaawdnslnnglfgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
237,NaN,NaN,NaN,UVJ49760,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,fdiqltqspsslsasvgdrvtitcrasqginsyvnwyqqkpgkapklliyhanrlesgvpsrfsgsgsgtefaltirslqpedfatyycqqynnlpysfgqgtkldikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
238,NaN,NaN,NaN,UVJ49759,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sdivmtqspsslstsvgdrvtitcrasqgisrylnwyqqkpgkapkllmhygnrlesgvpsrfsgsgsgteftltisslqsedfatyycqqynsfpptfgggtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
239,NaN,NaN,NaN,UVJ49758,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,fdiqmtqspsslsasvgdkvtitcrasqgirnalawyqqkpgkapklliygasnlqsgapsrfsgsgsgtdftltisslqpedfavyycqqrntypltfgggtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
240,NaN,NaN,NaN,UVJ49757,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,saiqmtqspsslsasvgdtvtitcrasqdissylnwfqqkpgkapkrlihgastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqhssyphtfgpgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
241,NaN,NaN,NaN,UVJ49756,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqaaptqppsvskslgqsvtisctgtssdiggyndvswfqqhpdtaprlliyavskwpsgvsdrfsgsksgntasltiaglqaedeadyyccsyrsggtwvfgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
242,NaN,NaN,NaN,UVJ49755,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqsvltqprsvsgspgqsvtisctgtssdighynyvswyqqhpgtapkliiyavskrpsgvsdrfsasksgntasltisglqaedeadyyccsyavsyslmlfgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
243,NaN,NaN,NaN,UVJ49754,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sdivmtqspsslsasvgdrititcrasqginnylswyqqkpgkapkpliyyasrletgvpsrfsgsgsgtdytltisslqpediatyycqqydnfpptfgggtkldikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
244,NaN,NaN,NaN,UVJ49753,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sdivltqspsslsasvgdrvtitcrtsqginnyllwyqqkpgkapklliyytsrlesgvpsrfsgsgsgteftltisslqpedfatyycqqydslpftfgpgtkldikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
245,NaN,NaN,NaN,UVJ49752,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,skpmltqptslsaspgasarltctlrsdisvdsyrifwyqqkpgsppryllnyhtdsdkhqgsgvpsrfsgskdasanagillisglqsedeadyhcmiwhtnayifgagtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
246,NaN,NaN,NaN,UVJ49751,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqsvltqspsasaslgasvkltctltsghsifaiawhqqqqgqaprflmrlnsdgshtkgdgipdrfsgsssgaerylsisnlqsedeadyycqtwatgivlfgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
247,NaN,NaN,NaN,UVJ49750,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqpvltqppsvsvspgqtatitcsgdalpkqyaywfqqkpgqspvliiyedskrpsgiperfsgsssgtvatltlsgaqvedeadyycystyssgnyglfgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
248,NaN,NaN,NaN,UVJ49749,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,slpvltqptslsaspgasarltctlssginvagysiywyqqkpgsppryllyyysdssnqqgsgvpsrfsgskdasanaglllisglqpedeadyycviwhsgawvfgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
249,NaN,NaN,NaN,UVJ49748,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sdivmtqspsslsasvgdrvtitcqasqdiyndlawyqqkpgkapklliykastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhgygiltfgggtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
250,NaN,NaN,NaN,UVJ49747,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,savvmtqsppamsasvgdrvtiscrssqniesnlawyqqkagkaprlltyaasklqsgipsrfsgsgsgtdftltisslqpedsatyycqqvyshpftfgpgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
251,NaN,NaN,NaN,UVJ49746,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqaaltqppsvskslgqsvtisctgtssdiggyngvswyqqhsgtaprlliyevtkrpsgvsdrfsgsksantasltisglqaedeadyycgsyrsgstyifgvgtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
252,NaN,NaN,NaN,UVJ49745,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqpvltqppsaseaarksvtiscsgsssnigrnsvswyqqlpetapklliyytdrrasgvsdrfsgsesgtsaslaitglqtedeadyycaawddslggfifgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
253,NaN,NaN,NaN,UKB93128,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqaaltqprsvsgspgqsvtisctgtssdiggynyvswyqqhpgtapklmiyavserpsgvsdrfsgsksgntasltisglqaedeadyyccsyagtvlfgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
254,NaN,NaN,NaN,UKB93127,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqaaltqpssvsvspgqtasitcggdnfgskyvhwyqqkppqapvlviyydsdrpsgiperfsgsksgntatltisgvevgdeadyfcqvwdsssdhrifgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
255,NaN,NaN,NaN,UKB93126,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqagltqppsvsgspgqsvtisctgsdigtynyvswfqqhpgkapklmiydvnkrpsgvsdrfsgskpgntasltisglqaedesdyycgsyagsvlfgrgtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
256,NaN,NaN,NaN,UKB93125,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqagltqprsvsgspgqsvtisctgtstdigaynyvswyqqhpgtapkliiyevskrpsgvsdrfsgsksgntasltisglqaedeadyyccsyaasytfyifgvgtrltvp,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
257,NaN,NaN,NaN,UKB93124,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqpvltqprsvsgspgqsvtisctgtssdigdynyvswyqqhpgtapklmiyavskrpsgvsdrfsgsksgntasltisglqaedeadyyccsyagtyifgvgtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
258,NaN,NaN,NaN,UKB93123,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,setvvtqepslsvspggtvtltcglrsgsvstsnypswyqqtpgqaprtviyttnsrpsgvpdrfsgsilgnkaaltitgaqaddechyycllymgngiwafgggtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
259,NaN,NaN,NaN,UKB93122,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sqpvltqppsvskslgqsvtisctgtssdiggyngvswyqqhsdtaprllifevskrpsgvsdrfsgsksgntasltisglqaedeadyycgsyrsgatfifgvgtrltvl,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
260,NaN,NaN,NaN,UKB93121,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,fdiqmtqspsslsasvgdtvtitcrasqdintylnwfqqkpgkapkfliydasslesgvpprfsgsgsgteftltisslqpedfatysclqyknypytfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
261,NaN,NaN,NaN,UKB93120,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sdivmtqspdtlslspgetatlscrasqsvssyvawyqqkpeqpprlliygsssratgmpdrfsgsgsgtdftltisslepddfavyycqqytnwpltfgggtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
262,NaN,NaN,NaN,UKB93119,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sdvvmtqspdtlslspgeratlscrasqtvnnyvawyqqkpeqaprlllygassratgvpdrfsgsgsgtdftltisslepedvgvfycqqynswwtfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
263,NaN,NaN,NaN,UKB93118,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,fdivmtqspsslsasvgdtvtitcrasqdiysylnwfqqkpgkapklliyaasslesgvpsrfsgsgfgteftltisslqpedfatyyclqyktyprtfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
264,NaN,NaN,NaN,UKB93117,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sdivmtqspsslsasvgdtvtitcrasqdissylnwfqqkpgkapklliyaasslesgvpsrfsgsgfgteftltisslqpedfatyyclqyksyppltfgggtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
265,NaN,NaN,NaN,UKB93116,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sdivltqspsslsasvgdrvtitcrasqdintylnwyqqkpgkapklliygasslqdgvpsrfsasgsgteftltisslqpedfatyyclrygsypwtfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
266,NaN,NaN,NaN,UKB93115,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,sdivmtqspsslsasvgdkvtitcrgsqgfsnwlawyqqkpgkapklliyaasslqsgvpsrfsasgsgtdytltisslqpedfatyycqqgyntpptfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
267,NaN,NaN,NaN,UKB93114,"['COVID', 'SARS-COV-2']",Macaca mulatta (Rhesus monkey),NaN,feivmtqspsslsasvgdtvtitcqasqgiannlnwyqqkpgkapklliyrasslesgipsrfsgsgfgtdftltmsslqpedsatyycqqgynypwtfgqgtkveikr,"He,W.T. et al.; Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques; Sci Transl Med 14 (657), eabl9605 (2022); 2022.",10.1126/scitranslmed.abl9605,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Macaca mulatta]",2022-10-12,NaN,NaN
268,NaN,NaN,7UMS_6,NaN,unknown,Homo sapiens (human),evqlvesgggpvqpggslklscaasgftfsnyemywvrqapgkglewvsyistspaityyadsvrgrftisrdnaksslylhmnslraedtavyycatishqqfssgwnawfdpwgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,NaN,"Jenni,S. et al.; Rotavirus VP4 Epitope of a Broadly Neutralizing Human Antibody Defined by Its Structure Bound with an Attenuated-Strain Virion; J Virol 96 (16), e0062722 (2022); 2022.",10.1128/jvi.00627-22,"Chain 6, Fab 41 heavy chain",NaN,2022-10-12,NaN,NaN
269,NaN,NaN,7UMS_4,NaN,unknown,Homo sapiens (human),evqlvesgggpvqpggslklscaasgftfsnyemywvrqapgkglewvsyistspaityyadsvrgrftisrdnaksslylhmnslraedtavyycatishqqfssgwnawfdpwgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkhhhhhh,NaN,"Jenni,S. et al.; Rotavirus VP4 Epitope of a Broadly Neutralizing Human Antibody Defined by Its Structure Bound with an Attenuated-Strain Virion; J Virol 96 (16), e0062722 (2022); 2022.",10.1128/jvi.00627-22,"Chain 4, Fab 41 heavy chain",NaN,2022-10-12,NaN,NaN
270,NaN,NaN,NaN,7UMS_7,unknown,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyrqrpgsapttviyenyqrpsgvparfsgsidrssnsasltisglqtddeadyycqsydnnnlwvfgggtkltvlgqpkgapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Jenni,S. et al.; Rotavirus VP4 Epitope of a Broadly Neutralizing Human Antibody Defined by Its Structure Bound with an Attenuated-Strain Virion; J Virol 96 (16), e0062722 (2022); 2022.",10.1128/jvi.00627-22,NaN,"Chain 7, Fab 41 light chain",2022-10-12,NaN,NaN
271,NaN,NaN,NaN,7UMS_5,unknown,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyrqrpgsapttviyenyqrpsgvparfsgsidrssnsasltisglqtddeadyycqsydnnnlwvfgggtkltvlgqpkgapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Jenni,S. et al.; Rotavirus VP4 Epitope of a Broadly Neutralizing Human Antibody Defined by Its Structure Bound with an Attenuated-Strain Virion; J Virol 96 (16), e0062722 (2022); 2022.",10.1128/jvi.00627-22,NaN,"Chain 5, Fab 41 light chain",2022-10-12,NaN,NaN
272,NaN,NaN,7COE_B,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkrpgssvkvscktsggtfnnnainwvrqapgqglewmggiipffgiakyaqkfqgrvtitadeststaymelsslrsedtavyycardlpressygsgsyythyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,NaN,"Jang,T.H. et al.; The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections; Sci Rep 12 (1), 1260 (2022); 2021.",10.1038/s41598-022-05318-4,"Chain B, Heavy chain",NaN,2022-10-12,NaN,NaN
273,NaN,NaN,7COE_H,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkrpgssvkvscktsggtfnnnainwvrqapgqglewmggiipffgiakyaqkfqgrvtitadeststaymelsslrsedtavyycardlpressygsgsyythyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkt,NaN,"Jang,T.H. et al.; The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections; Sci Rep 12 (1), 1260 (2022); 2021.",10.1038/s41598-022-05318-4,"Chain H, Heavy chain",NaN,2022-10-12,NaN,NaN
274,NaN,NaN,NaN,7COE_C,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscgasqsvsssylawyqqkpglaprlliydassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Jang,T.H. et al.; The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections; Sci Rep 12 (1), 1260 (2022); 2021.",10.1038/s41598-022-05318-4,NaN,"Chain C, Light chain",2022-10-12,NaN,NaN
275,NaN,NaN,NaN,7COE_L,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscgasqsvsssylawyqqkpglaprlliydassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Jang,T.H. et al.; The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections; Sci Rep 12 (1), 1260 (2022); 2021.",10.1038/s41598-022-05318-4,NaN,"Chain L, Light chain",2022-10-12,NaN,NaN
276,NaN,NaN,3J42_K,NaN,unknown,Mus musculus (house mouse),dvqlvesggglvqpggsrklscaasgftfssfgmhwvrqapekglewvayissgsstlhyadtvkgrftisrdnpkntlflqmtslrsedtamyycarwgnyphyamdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsglytlsssvtvtsstwpsqtitcnvahpasstkvdkkieprv,NaN,"Wang,Z. et al.; Obstruction of dengue virus maturation by Fab fragments of the 2H2 antibody; J. Virol. 87 (16), 8909-8915 (2013); 2013.",10.1128/JVI.00472-13,"Chain K, Ig heavy chain V region MOPC 21, Igh protein chimera",NaN,2022-10-12,NaN,NaN
277,NaN,NaN,3J42_I,NaN,unknown,Mus musculus (house mouse),dvqlvesggglvqpggsrklscaasgftfssfgmhwvrqapekglewvayissgsstlhyadtvkgrftisrdnpkntlflqmtslrsedtamyycarwgnyphyamdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsglytlsssvtvtsstwpsqtitcnvahpasstkvdkkieprv,NaN,"Wang,Z. et al.; Obstruction of dengue virus maturation by Fab fragments of the 2H2 antibody; J. Virol. 87 (16), 8909-8915 (2013); 2013.",10.1128/JVI.00472-13,"Chain I, Ig heavy chain V region MOPC 21, Igh protein chimera",NaN,2022-10-12,NaN,NaN
278,NaN,NaN,3J42_G,NaN,unknown,Mus musculus (house mouse),dvqlvesggglvqpggsrklscaasgftfssfgmhwvrqapekglewvayissgsstlhyadtvkgrftisrdnpkntlflqmtslrsedtamyycarwgnyphyamdywgqgtsvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsglytlsssvtvtsstwpsqtitcnvahpasstkvdkkieprv,NaN,"Wang,Z. et al.; Obstruction of dengue virus maturation by Fab fragments of the 2H2 antibody; J. Virol. 87 (16), 8909-8915 (2013); 2013.",10.1128/JVI.00472-13,"Chain G, Ig heavy chain V region MOPC 21, Igh protein chimera",NaN,2022-10-12,NaN,NaN
279,NaN,NaN,4KVC_H,NaN,unknown,Mus musculus (house mouse),dvqlvesggglvqpggsrklscaasgftfssfgmhwvrqapekglewvayissgsstlhyadtvkgrftisrdnpkntlflqmtslrsedtamyycarwgnyphyamdywgqgtsvtvssakttapsvyplapvcdgttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkiepr,NaN,"Wang,Z. et al.; Obstruction of dengue virus maturation by Fab fragments of the 2H2 antibody; J. Virol. 87 (16), 8909-8915 (2013); 2013.",10.1128/JVI.00472-13,"Chain H, Ig heavy chain V region MOPC 21, Igh protein",NaN,2022-10-12,NaN,NaN
280,NaN,NaN,7TTX_H,NaN,unknown,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnfywgwirqppgkglewiasitysgrtfynpslksrvaisvdtsknqfslklssvtaadtavyycartfpsyydrsgyhylnygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Liu,L. et al.; An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses; Sci Transl Med 14 (646), eabn6859 (2022); 2022.",10.1126/scitranslmed.abn6859,"Chain H, heavy chain",NaN,2022-10-12,NaN,NaN
281,NaN,NaN,7TTY_H,NaN,unknown,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnfywgwirqppgkglewiasitysgrtfynpslksrvaisvdtsknqfslklssvtaadtavyycartfpsyydrsgyhylnygmdvwgqgttvtvssastkgpsvfplapssxxxsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Liu,L. et al.; An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses; Sci Transl Med 14 (646), eabn6859 (2022); 2022.",10.1126/scitranslmed.abn6859,"Chain H, heavy chain",NaN,2022-10-12,NaN,NaN
282,NaN,NaN,7TTM_H,NaN,unknown,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnfywgwirqppgkglewiasitysgrtfynpslksrvaisvdtsknqfslklssvtaadtavyycartfpsyydrsgyhylnygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Liu,L. et al.; An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses; Sci Transl Med 14 (646), eabn6859 (2022); 2022.",10.1126/scitranslmed.abn6859,"Chain H, heavy chain",NaN,2022-10-12,NaN,NaN
283,NaN,NaN,NaN,7TTM_L,unknown,Homo sapiens (human),NaN,nfmltqphsmsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssswvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Liu,L. et al.; An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses; Sci Transl Med 14 (646), eabn6859 (2022); 2022.",10.1126/scitranslmed.abn6859,NaN,"Chain L, light chain",2022-10-12,NaN,NaN
284,NaN,NaN,UTS77907,NaN,['COVID'],Homo sapiens (human),qvqlvesgggvvhpggslrlscaasgftfsdfamnwvrqapgeglqwvaiisydgrnkhfaasvrgrftisrdnskntmflqmsslraedtaiyycatlggwfeeasptywgrgtlvtvss,NaN,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
285,NaN,NaN,UTS77905,NaN,['COVID'],Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysfsnswitwvrqmpgkglewvgridtrdsrtayspsfeghvffsadrssdtvyvqwrslrasdtavyycttgagvviaasyfwgqgtlvtvss,NaN,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
286,NaN,NaN,UTS77903,NaN,['COVID'],Homo sapiens (human),rvqlqesgpglvkpsetlsltctvsggsitddywnwirqppgkglewigyvhdsgttnynpslksrvtlslhtsgnkfslrltsvtaadtamyycarttttfpfdswgqgtlvivss,NaN,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
287,NaN,NaN,UTS77901,NaN,['COVID'],Homo sapiens (human),qvrlqesgpglvkpsetlsvtctvsgvsisnyywswirqppgkglewigyisdtgstnyspslqsrvtisvdmsknqvslevtsvtatdtavyycartttsvpfdywgkgvlvtvss,NaN,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
288,NaN,NaN,UTS77899,NaN,['COVID'],Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfsgyamhwvrqapgkglewvavisrdarnkyyadsvkgrftisrdnskktvylemnslrvedtavyycailiipgitepgspdaldiwgqgtmvsvss,NaN,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
289,NaN,NaN,UTS77897,NaN,['COVID'],Homo sapiens (human),qmqlmqsgaevkkpgasvtvsckasgdtfsdyrihwvrqapgqglewmgrmnpksgdtnfaqkfqgrvtmtrdmsintaymtlsgltfddtalyycasllivggfdplddfevwgqgtmvtiss,NaN,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
290,NaN,NaN,NaN,UTS77908,['COVID'],Homo sapiens (human),NaN,evvltqspaivslspgeratlscrasqsvgsrlawhqqkpglaprvliydasnratgiparfsgsgsgtdftltissiepedsavyycqqrgdwplitfgqgtrleik,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
291,NaN,NaN,NaN,UTS77904,['COVID'],Homo sapiens (human),NaN,syeltqppsvsvslgqmaritcsgealpkkyvywyqqkpgqfpvlviykdrerpsgiperfsgsssgtivtltisgvqaedeadyyclsvdstanwvfgggtkltvl,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
292,NaN,NaN,NaN,UTS77906,['COVID'],Homo sapiens (human),NaN,qsaltqppsasgspgqpvtisctgtssdvggyeyvswyqqlpgkvptliihevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssysadssiifgggtkltvl,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
293,NaN,NaN,NaN,UTS77902,['COVID'],Homo sapiens (human),NaN,syeltqppsvsvspgqvaritcsgealpkkyaywyqhkpgqfpllvihkdserpsgiperfsgsssgtvvtltisgvqaedeadyfclstdgsttwvfgggtkltvl,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
294,NaN,NaN,NaN,UTS77900,['COVID'],Homo sapiens (human),NaN,diqmtqspssmsasvgdrvtitcrasqdiskwlawyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqassfpwsitfgqgtrleir,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
295,NaN,NaN,NaN,UTS77898,['COVID'],Homo sapiens (human),NaN,qsaltqppsasgspgqsvtiscsgtssdvggynfvswyqhhpgkapkiliyevtkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyggtnnllfgggtkltvl,"Dacon,C. et al.; Broadly neutralizing antibodies target the coronavirus fusion peptide; bioRxiv (2022) In press; 2022.",10.1101/2022.04.11.487879,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
296,NaN,NaN,USW88780,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssygiswvrqapgqglewmgriipilaiasyaqkfqgrvtitadkststvymemrslrsedtavyycardgynpsfdywgpgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
297,NaN,NaN,USW88779,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarsdsssytlwwfdpwgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
298,NaN,NaN,USW88778,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdftfstywiswvrqapgkglewvasikedgsdkyyvdsmkgrftisrdnaknslylqmyslraedtavyycarskkpvpaatyieyfdlwgrgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
299,NaN,NaN,USW88777,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsvtigyadsvkgrftisrdnaknslylqmnslraedtalyycaklsqrsrwffdafdiwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
300,NaN,NaN,USW88776,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgityynpslksrvtisvdtsknqfslklssvtaadtalyycarvarhcsstscynidywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
301,NaN,NaN,USW88775,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvstigtggdtyypgsvkgrftisrenaknslylqmnslragdtavyycargssaativldywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
302,NaN,NaN,USW88774,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltefsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgmdwikdvvlvpgarawnafdiwgqgtvvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
303,NaN,NaN,USW88773,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscagsgftfstywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardlgvlwfgeltnafdpwgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
304,NaN,NaN,USW88772,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfrhygmhwvrqapgkglewvavisydgsdkyyadsvkgrftisrdyakntlylqmnsltaddtavyycakvqgtycsggscysgsfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
305,NaN,NaN,USW88771,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfrsygmhwvrqapgkglewvafisydgsdkyyadsvkgrftisrdnskntlylqmnslraedtavyycardlsaghctggvcytaggidywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
306,NaN,NaN,USW88770,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyeinwvrqatgqglewmgwvnpnsgntgyaqkfqgrvtmtrntsittaymelsslrsedtavyycvrglwsrvastpfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
307,NaN,NaN,USW88769,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgfsissayywvwirqppgkglewigsvyhsgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycardyggnsalyscwgpgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
308,NaN,NaN,USW88768,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsesivyadsvkgrftisrdnaknflylqmnslraedtalyycaksssitcyrscsfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
309,NaN,NaN,USW88767,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgselkkpgasvelsckasgytfssyvmnwvrqapgqglewmgwintntgnatyaqgftgrfvfssdnsastaylqisslkaedtavyyctrardcsngicseiprrsnwldpwgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
310,NaN,NaN,USW88766,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvstigtggdtyypgsvkgrftisrenaknslylqmnslragdtavyycargssaativldywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
311,NaN,NaN,USW88765,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsilysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaraltpysgfaywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
312,NaN,NaN,USW88764,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyninwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycastydaeyfqhwgrgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
313,NaN,NaN,USW88763,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtftnyciswvrqapgqglewmgriipilglanyaqkfqgrvtitadkststaymelsslrsedsavyycgrattpgvnsygydfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
314,NaN,NaN,USW88762,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhgglqriaaagtdfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
315,NaN,NaN,USW88761,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgselkkpgasmkvsckasgysfsnlamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvrtaylqisnlkaedtavyycakvggkavaalddafdiwgqgtmvivss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
316,NaN,NaN,USW88760,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytisgvrqapgqglewmgriipslgipnyaqkfqgrvtitadkstntaymdlsslrsedtavyhcarergysgygsswyfdlwgrgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
317,NaN,NaN,USW88759,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgynfayywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycargemtavfgdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
318,NaN,NaN,USW88758,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaaseitvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsrntlylqmnslraddtavyycardygdfyfdywsqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
319,NaN,NaN,USW88757,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfshygmhwvrqapgkglewvaviwfdgsnqyyadsvkgrftisrdnskntlylqmnslraedtavyycakvggpycggdcssgyfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
320,NaN,NaN,USW88756,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggsafyadsvkgrftisrdnskntlylqmnslraedtavyycardvtdfswgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
321,NaN,NaN,USW88755,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqrggslrlscaasgftfsnyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnsrntlylqmnslraedtavyycakaegycrstscfaegyyyyygmdvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
322,NaN,NaN,USW88754,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgfsissayywvwirqppgkglewigsvyhsgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycardyggnsalysywgpgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
323,NaN,NaN,USW88753,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaaseitvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsrntlylqmnslraddtavyycardygdfyfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
324,NaN,NaN,USW88752,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpgrslrlscvasgftfadhamhwvrqtpgkglewvsgiswnsgnigyadsvkgrftisrdnaknslylqmnslraedtalyycakdlggweycsgticypsdafdiwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
325,NaN,NaN,USW88751,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qitlkesgptlvkstqtltltctfsgfslstygvgvgwirqppgkalewlaliywdddkrytpslksrltitkdtsknqvvltmtnmdpldtatyycaqhtvptifdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
326,NaN,NaN,USW88750,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviytagstyyadsvkgrftisrdiskntlylqmnslrvedtavyycargysgydlwdmvldywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
327,NaN,NaN,USW88749,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyafswvrqapgqglewmgriipllgtanyaqkfqgrvtitadkstttaymelsslrsedtavyycffggynyrsffdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
328,NaN,NaN,USW88748,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqvvesggglvqpggslrlscaasgftfstydmhwvrqatgkglewvstigtagdtyypdsvkgrftisrdnvknslylqmnslragdtavyycarggdcgadcytnwyfdlwgrgalvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
329,NaN,NaN,USW88747,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslsssgvsvgwirrppgkalewlaliywdddkryspslksrltvtkytsknqvvltmtnmdpvdtatyycahnshnrlwfgdnwfdpwgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
330,NaN,NaN,USW88746,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnsmdtlylqmnslrtedtavyycarggdvtpldywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
331,NaN,NaN,USW88745,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvhlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyyggitkhnpslksrvtisgdtsknqfslkltsvtaadtavyycarlgycsgdscydgwyhdyfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
332,NaN,NaN,USW88744,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnfamywvrqapgkglewvavisydgrnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardlegeqwllrddyyyyyyygmdvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
333,NaN,NaN,USW88743,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvetggsliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggntyyvdsvkgrftisrdnskntlylqmnslrtedtavyycarvvsdafdiwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
334,NaN,NaN,USW88742,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycartlplmgdyfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
335,NaN,NaN,USW88741,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggdlvqpggslrlscaasgftfgsywmtwvrqapgkglewvaninqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardeitvtagawgnyyygmdvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
336,NaN,NaN,USW88740,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakglgsycggtscyagyfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
337,NaN,NaN,USW88739,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycarepycrgggchswgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
338,NaN,NaN,USW88738,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvetgggliqpggslrlscaasgvtvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdssrntvflqmkglraedtavyycarevrgafdiwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
339,NaN,NaN,USW88737,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakglgsycggtscyagyfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
340,NaN,NaN,USW88736,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfsfsdawmswvrqapgkglewvgrikteidggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgvdivvmgavddafdiwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
341,NaN,NaN,USW88735,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnfamywvrqapgkglewvavisydgrnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardlegeqwllrddyyyyygmdvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
342,NaN,NaN,USW88734,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvetgggliqpggslrlscaasgitassnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlpqydvfdiwgqgtrvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
343,NaN,NaN,USW88733,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvsgyrsyyyygmdvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
344,NaN,NaN,USW88732,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvrlvqsgaevkkpgssvkvsckasggtfsshtiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymevsslrsedtavyycardrgysgygssyyfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
345,NaN,NaN,USW88731,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytitwvrqapgqglewmgriipflgianyaqkfqgrvtitadkststaymelsslrsedtavyycarergysssssawyfdlwgrgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
346,NaN,NaN,USW88730,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasvftvssnymswvrqapgkglewvsiiysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarvmpgivdyfdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
347,NaN,NaN,USW88729,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsshymswvrqapgkglewvsaiysggttyyedsvkgrftisrdnskntlylqmnslrpedtavyycardsswgpgyygldvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
348,NaN,NaN,USW88728,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),llklvesggglvqpggtlrlscaasgfsfrkhwmswfrqapgkglewvanmdqegsenyyidsvkgrftisrdnannllylqmnsvraedaavyhcareecsssvckakswyfdlwgrgtpvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
349,NaN,NaN,USW88727,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviyaggstfyadsvkgrftisrdnskntlylqmsslrvedtavyycardldyygmdvwgrgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
350,NaN,NaN,USW88726,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggmvqpgrslrlscaasgftfrsygmhwvrqapgkglewvaviwydgsnkyyadslkgrftisrdnskntlylqmnslraedtavyycareiydnivvlpadiggmdvwgqgttvtspq,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
351,NaN,NaN,USW88725,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qlqlqesgpglvkpsetlsltcavsgdsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknhfslklssvtatdtavyycarlavsppfyyyydmdvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
352,NaN,NaN,USW88724,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglaqpgrslrlscaasgftfddyamhwvrqapgkglewvssiswnsgsiayadsvkgrftisrdnaknslylqmnslraedtafyycakaevpgygsgwyqgfaswgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
353,NaN,NaN,USW88723,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaastftfssynmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardlgggysnvyvnhyygmdvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
354,NaN,NaN,USW88722,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgyrfnsywiawvrqtpgkglewmgiiypsdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarledrsssafdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
355,NaN,NaN,USW88721,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsintaymelsrlrsddtavyycasrrgtyyydsstdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
356,NaN,NaN,USW88720,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhgvrtifgvvpnwfdpwgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
357,NaN,NaN,USW88719,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvawirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltltnmdpvdtatyycahfyydfrsgfyddyygmdvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
358,NaN,NaN,USW88718,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvnanymswvrqapgkglewvsiiyssggtyyadsvkgrftisrdnsnntlylqmnslrpedtavyycarysvgcrvyysdssspcrdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
359,NaN,NaN,USW88717,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvntsknqfslnlssvtaadtavyycagdfwsnyfnyyyygmdvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
360,NaN,NaN,USW88716,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgtgvgwirqppgkalewlalifwdddkryspslktrltitkdtsknqvvltltnmdpvdtatyycaqslydsgltaafemwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
361,NaN,NaN,USW88715,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgytfsnawmtwvrqapgkglewvgrikretdggttdyaapvkgrftisrddskntlylqmnslkaedtavyycttdapyyydssgdafdiwgrgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
362,NaN,NaN,USW88714,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargrgydiltgyprthdafdiwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
363,NaN,NaN,USW88713,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglaqpggslrlsciasgftfsnyamnwvrqapgkglewvsfirssgstilyadsvkgrftisrdnannslflqmnslrdddtavyycarglysgsqsasdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
364,NaN,NaN,USW88712,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgsyywswirqpagkglewigriytsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarsfstnhyctnarcafdiwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
365,NaN,NaN,USW88711,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqvvesggglvqpggslrlscaasgfplssydmhwvrqrtgkglewvsgigtagdtyyqgsvkgrftisrenaknslylqmnslragdtavyycaraqgycgggscysayafaiwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
366,NaN,NaN,USW88710,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfgaygmnwvrqapgkglewvssitsgsdyiyygdsvkgrftisrdnakkslylqmntltaedtavyycariagyymdvwgtgttvtvsp,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
367,NaN,NaN,USW88709,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qlqlqesgpglvrpsetlsltcavsggsitsinnfwgwirqppgkglewigsifysgttsynpslwsrvtisidesrnqfslklssvtaadtaayycarvipavrsswtgfdywgqgtlvivss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
368,NaN,NaN,USW88708,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvavisydgsnkyfadsvkgrftisrdnskntlylqmnslraedtavyycakgdwyssswyppdywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
369,NaN,NaN,USW88707,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),egqlvesggrlvqpgrslrlscaasgftfddyamhwvrqgpgkglewvsglnwdgvrtgyvdsvkgrftisrdnaknflylqmnsirsedtavyycvkdgnsdyggnpiwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
370,NaN,NaN,USW88706,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycarseysssslieggwfdpwgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
371,NaN,NaN,USW88705,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaregysygtswlgssyyyymdvwgkgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
372,NaN,NaN,USW88704,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycareiyeyfdlwgrgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
373,NaN,NaN,USW88703,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaapglsfrnygmhwvrqapgkglewvafiffdgsnkyhadslkgrftisrdnskntlylqmnslraedtavyfcardrsgkdvltgypmfpagmdvwgkgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
374,NaN,NaN,USW88702,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qlqlvesgggvvqpgrslrlscaasgfnfrtfgmhwvrqspgkglewlavlsfdekttyygnsakgrftisrdnsrnvlflqmnslrvedtaiyycakgsgvaavmdlwgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
375,NaN,NaN,USW88701,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),egqlvesggrlvqpgrslrlscaasgftfddyamhwvrqapgkglewvsglnwdgvrtgyadsvkgrftisrdnaknslylqmnslrsedtalyycvkdgnsdyggnpiwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
376,NaN,NaN,USW88700,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargalrflewpilaywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
377,NaN,NaN,USW88699,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qlqlqqsgpglvkpsetlsltctvsggsisssnhywgwirqppgkglewigsiyesgstnynpslksrvsmsvdtsknlfslklisvtaadtalyycarhrggrftygpnywyfdlwgrgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
378,NaN,NaN,USW88698,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssnywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarprgggynylswyfdlwgrgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
379,NaN,NaN,USW88697,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qlqlqesgsglvkpsqtlsltcavsggsissggyswswirqppgkglewigyiyhsgstyynpslksrvtisvdrsknqfslklssvtaadtavyycarvasyyyymdvwgkgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
380,NaN,NaN,USW88696,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qmqmvqsgpemkkpgtsvkvsckasgftftrsamqwvrqargqrpewigwivvgsgntkyaqkfqervtftrdksrstvymelsslrsedtavyycaadlggpeyfqhwgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
381,NaN,NaN,USW88695,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfggyywtwlrqpprrglewigeidhsgstsynpslksrviisvdtsknqfslnlssvtaadtavyycarglhrggfsywgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
382,NaN,NaN,USW88694,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvesgggvvqpggslrlsctasgftfgsyamhwvrhtpgtglewaavissdgdskdhadsvrgrftisrdnskntlylqmdslrgddtalyycareyydnsghynpdivwgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
383,NaN,NaN,USW88693,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasrftfanywmswvrqapgkglewvasikedgsekyyvdsvkgrftisrdnaknslylqmnslraedttvyycarggpsrgtevrpddvfdmwgqgtmvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
384,NaN,NaN,USW88692,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvqsgaevkkpreslkisckgsgynftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadkststaylqwsslkasdtamyycsrppycsgtscldfwgqgtlvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
385,NaN,NaN,USW88691,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlvqsgaevkrpgasvkvlcmasgysftnyginwvrqapgqglewmgwinphnenthyaqkfqgrvtlttdtskttahmelrslrsddsamyycargsvlreadywgqgtrvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
386,NaN,NaN,USW88690,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvqsggglvqpggslrlsclasgltfssyefnwirqapgkglewishitrnsrviyyadsvkgrftisrdnaknslwlqmnslraedtavyycvtdlpgdlefdfwgqgalvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
387,NaN,NaN,USW88689,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarfrwgdvwgqgttvtvss,NaN,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
388,NaN,NaN,NaN,USW88688,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvtsgylawyqqkpgqaprlliygassrasgipdrfsgsgsgtdftltigrlepedfavyycqqygssptfgqgtklein,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
389,NaN,NaN,NaN,USW88687,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
390,NaN,NaN,NaN,USW88686,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,sydltqrpsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgvvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
391,NaN,NaN,NaN,USW88685,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyrqkpgqaprlliygastratgiparfsgsglgqsslspsaacslkilqfitvssiitgqslsalgpkwisn,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
392,NaN,NaN,NaN,USW88684,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyyccsyagsnnvlfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
393,NaN,NaN,NaN,USW88683,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpeytfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
394,NaN,NaN,NaN,USW88682,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygaisratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspptfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
395,NaN,NaN,NaN,USW88681,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnslawyqqktgkapklllygastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqyystpprtfgqrtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
396,NaN,NaN,NaN,USW88680,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdignylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyhcqqyfnlptfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
397,NaN,NaN,NaN,USW88679,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrnsgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyychsydsdnvvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
398,NaN,NaN,NaN,USW88678,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnlgsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
399,NaN,NaN,NaN,USW88677,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyedllpitfgqgtrldlk,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
400,NaN,NaN,NaN,USW88676,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvsstlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppltfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
401,NaN,NaN,NaN,USW88675,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspatlslspgeraalscrasqsvssylawyqhkpgqaprlliydasnratgiparfsgsgsgtdftliisslepedfavyycqqrgnwppitfgqgtrleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
402,NaN,NaN,NaN,USW88674,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpeytfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
403,NaN,NaN,NaN,USW88673,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgyiasnyvhwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasliisglktedeaayycqsyhsstwvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
404,NaN,NaN,NaN,USW88672,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,divmtqspdsltvslgeratinckssqsvlyssynknylawyqqrpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvvvyycqqyyntpvtfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
405,NaN,NaN,NaN,USW88671,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliygasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnmytfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
406,NaN,NaN,NaN,USW88670,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
407,NaN,NaN,NaN,USW88669,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssdnknflawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
408,NaN,NaN,NaN,USW88668,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliyvnsdrpsgvparfsgsksgtsaslaitglqaedeadyycqsydsslsavvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
409,NaN,NaN,NaN,USW88667,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpediatyycqqykilltwtfgqgtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
410,NaN,NaN,NaN,USW88666,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsissylawyqqkpgqaprlliygassratgipdrfsgsgsetdftltisrlepedfavyfcqqygssprtfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
411,NaN,NaN,NaN,USW88665,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsssvgdrvtitcqasqdignylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdfsftisslqpediatyfcqqydslpltfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
412,NaN,NaN,NaN,USW88664,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkaprlliydasnletgvpsrfsgsgsgtdftftisslqpedfatyfchqydnlpqtfgqgtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
413,NaN,NaN,NaN,USW88663,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,syvltqppsvsvapgqtaritcggdnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyccqvwdntsdhvvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
414,NaN,NaN,NaN,USW88662,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyedllpitfgqgtrldlk,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
415,NaN,NaN,NaN,USW88661,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsissylawyqqkpgqaprlliygassratgipdrfsgsgsetdftltisrlepedfavyfcqqygssprtfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
416,NaN,NaN,NaN,USW88660,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsissylawyqqkpgqaprlliygassratgipdrfsgsgsetdftltisrlepedfavyfcqqygssprtfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
417,NaN,NaN,NaN,USW88659,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsaltqpasvsgspeqsitiscsgtsrdiggynyvawyqhhpgkapklmiyevsnrpsgvsnrfsgsksgnmasltisglqaedkadyyctsyttgstvvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
418,NaN,NaN,NaN,USW88658,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsissylawyqqkpgqaprlliygassratgipdrfsgsgsetdftltisrlepedfavyfcqqygssprtfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
419,NaN,NaN,NaN,USW88657,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqspqlliyevssrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgihlpwtfgqgtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
420,NaN,NaN,NaN,USW88656,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirnslawyqqkpgkapklllyaasrlesgvpsrfsgsgsgtdytltisslqpedfatyycqqyyntppatfgqgtkvvvk,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
421,NaN,NaN,NaN,USW88655,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvlthppstsgtpgqrvtiscsgsssnigsntvnwyhhlpgtapklliyshnqrpsgvpdrfsgsksgtspslainglqsedeadyycatwddslngptfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
422,NaN,NaN,NaN,USW88654,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdtskylnwyqqkrgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqynnppgftfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
423,NaN,NaN,NaN,USW88653,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvvtqppsasgtpgqrvtiscsgsssnigsnpvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngyvvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
424,NaN,NaN,NaN,USW88652,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqkkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
425,NaN,NaN,NaN,USW88651,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,sndckrgpstlsasvgdrvtitcrasqsigswlawyqqkpgkapklliymasrlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysytfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
426,NaN,NaN,NaN,USW88650,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapklliyaastlqsevpsrfsgsgsgtdftltisslqpedfatyscqqgystpwtfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
427,NaN,NaN,NaN,USW88649,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,syeltqpssvsvspgqtaritcsgdvlskkyarwfqqkpgqapvlviyrdnerpsgiperfsgsnsgttvtltisgaqvedeadyycysaadnngvfgggtklnvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
428,NaN,NaN,NaN,USW88648,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdtnnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedlatyyclqydnlpftfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
429,NaN,NaN,NaN,USW88647,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyychqydnlpltfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
430,NaN,NaN,NaN,USW88646,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqsppslsasvgdrvtitcqasqgisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpediatyycqqfdnlpsftfgpgtkvdik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
431,NaN,NaN,NaN,USW88645,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdtnnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedlatyyclqydnlpftfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
432,NaN,NaN,NaN,USW88644,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,dirmtqspsslsasvgdrvtiscrtsqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgtgsgtdftltitslqpedfatyycqqsysspltfgggtkveit,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
433,NaN,NaN,NaN,USW88643,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqkkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
434,NaN,NaN,NaN,USW88642,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgyiasnyvhwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasliisglktedeaayycqsyhsstwvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
435,NaN,NaN,NaN,USW88641,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvssrfsgsgsetdftltisslqpedfatyycqqsystpatfgpgtkvdik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
436,NaN,NaN,NaN,USW88640,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliyvnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
437,NaN,NaN,NaN,USW88639,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qslltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapklliygssnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydssltgslfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
438,NaN,NaN,NaN,USW88638,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qyvltqppsvsgapgqrvtisctggssnigtgydvhwyqqlpgtapklliysnshrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
439,NaN,NaN,NaN,USW88637,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnslftfgpgtkvdik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
440,NaN,NaN,NaN,USW88636,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,divltqspdtlslspgeraalscrasqsidttylawyqlkpgqaprllifgpasratgipdrfsasgsgtdftltisrlepedfamyychhyhssrtfgqgtrveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
441,NaN,NaN,NaN,USW88635,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgistylawyqqkpgkapklliygastlqsgvpsrfsgsgsgtdftltisslqpedfaayycqqvnsyppitfgpgtkvdik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
442,NaN,NaN,NaN,USW88634,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,dvvltqspgslslspgeratlscrasqslsssylawyqqkpgqaprlliygassratgipdrfsvsgsgtdftltinrlepedfavyfcqqygrspltfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
443,NaN,NaN,NaN,USW88633,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqvlpgtapklliyrsnqrpsgvpdrfsgsksatsaslaisglrsedeadyycavwdgglsgpgvvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
444,NaN,NaN,NaN,USW88632,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvsqrpsgvpdrfsgsksgntasltisglhvddeadyyccsyagsytglfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
445,NaN,NaN,NaN,USW88631,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtasdvgdynyvswyqqhpgkdpklmiyevsnrpsgvsdrfsgsksgntasltisglqaedeadyycssytstsipvvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
446,NaN,NaN,NaN,USW88630,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrtsqsvnnylawyqqkpgqaprlliydvsnratgiparfsgsgsgtdftltisslepedfavyycqqrsgwprftfgpgtkvdik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
447,NaN,NaN,NaN,USW88629,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygastrvngipdrfsgsgsgtdftlsinrlepedfavyycqhydsspqwtfgrgtkvevr,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
448,NaN,NaN,NaN,USW88628,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppkitfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
449,NaN,NaN,NaN,USW88627,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,divmtqsplsvpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpstfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
450,NaN,NaN,NaN,USW88626,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqninswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqhysspwtfgqgtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
451,NaN,NaN,NaN,USW88625,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyfcqqtnnfprtfgqgtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
452,NaN,NaN,NaN,USW88624,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitiscfgtssdigtyslvswyqqhpgkapklviyevskrpsgvfnrfsgsksgntasltisglqaedeaeyycsayagvnnpvifgggslltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
453,NaN,NaN,NaN,USW88623,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagynvhwfqqlpgrapkllvygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
454,NaN,NaN,NaN,USW88622,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtnsdvggynyvswyqqhpgkapklmiyevsnrpsgdsnrfsgsksgntasltisglqaedeadyycssytssstwvfggrtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
455,NaN,NaN,NaN,USW88621,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,airmtqspsslsasigdrvtitcrasqgissylawyqqkpgrapklliyaastlqsgvpsrfsgsgsgtdftltigclqsedfatyhcqqyytdphtfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
456,NaN,NaN,NaN,USW88620,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpptwtfgqgtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
457,NaN,NaN,NaN,USW88619,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggfhyvswyqqhpgkapklmiyevsnrpsgvsarfsgsksgntasltisglqaddeadyycssytssstwvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
458,NaN,NaN,NaN,USW88618,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,evvltqspdtlslspgeratlscrasqsvsisylawyqqkpgqaprlliygafsrapgipdrfsgsgsgtdftltisrlepedfavyycqlygssrltfgpgtkvdik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
459,NaN,NaN,NaN,USW88617,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgsssdlgeynyvswyqqhpgkapklliyvvtnrpsgvsdrfsgsksgntasltisglqaedeadyycssyagtgtllfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
460,NaN,NaN,NaN,USW88616,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,evvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssritfgqgtrleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
461,NaN,NaN,NaN,USW88615,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspptlsvspgetatlscraslsldrnlawyqqrpgqaprllvygtsiratgipdrfrgsgsgteftltisglqsedsavyycqnynkwpplftfgpgskvdik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
462,NaN,NaN,NaN,USW88614,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpftfgpgtkvdik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
463,NaN,NaN,NaN,USW88613,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpvrtfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
464,NaN,NaN,NaN,USW88612,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqhlnsyprytfgqgtkleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
465,NaN,NaN,NaN,USW88611,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,syvltqppsvsvspgqtaritcggnniggksvhwyqqkpgqapvlivyndgdrpsgiperfsgsnsgntatltisrveagdeadymcqvwdvssdhvvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
466,NaN,NaN,NaN,USW88610,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,divmtqspdslavslgeratvrcrssqslfyrsnnknylawyqqkprqppklliywastrasgvperfsgsgsgtdftltisslqaedaavyfcqhyytapftfgpgtkvnvk,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
467,NaN,NaN,NaN,USW88609,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspptlsvspgetatlscraslsldrnlawyqqkpgqaprllvygtsiratgipdrfrgsgsgteftltisglqsedsavyycqnynkwpplftfgpgskvdik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
468,NaN,NaN,NaN,USW88608,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtiicrasqyinsflnwyqqkpgqapklliyaasslqsgvpsrfsgggsgtdftltisslqpedfatyycqqsystppytfgqgtkleir,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
469,NaN,NaN,NaN,USW88607,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvmtqppsvsgapgqrvtisctgsssnigasydvhwyqqlpgtapklliynnnfrpsgvpgrfsgsksgtsaslaitglqaedeadyycqsydsslrsyvfgtgtkvtvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
470,NaN,NaN,NaN,USW88606,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadfyccsyagsygvlfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
471,NaN,NaN,NaN,USW88605,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
472,NaN,NaN,NaN,USW88604,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qavvtqepsltvspggtvtltcdsctgavtsghypywfqqkpgqaprtliydtnnkhswtparfsgsllggkaaltlsgaqpedeaeyycllsysaarvfgggtkltvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
473,NaN,NaN,NaN,USW88603,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqaserinnylnwyqqkpgsapqlliylasslqtgvpsrfrgsgfgtaftltisslqpedsatyycqqsystprtfgggtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
474,NaN,NaN,NaN,USW88602,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrititcrasqaissylawfqqkpgrapksliyatsrlhsgvpskfsgggsrteftltinnlqpedsatyychqysayprtfgqgtrveir,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
475,NaN,NaN,NaN,USW88601,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqaisnwlawyqqkpekapksliyaasnlqsgvpprfsgsgsgtdftltisslqpedfatyycqqyssypltfgggtkveir,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
476,NaN,NaN,NaN,USW88600,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqgfssnslawyqqrpgqaprlliygtsnratgipdrfsgsgsgtdftltisrlepedfavyycqqshrssmytfgqgtkveik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
477,NaN,NaN,NaN,USW88599,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsvaaapgqkvtiswsgsssnignnyvswyqqvpgtapklliydnnerfpgipdrfsasksgtsatlditdlqtgdeadyycgtwdsslnslvvfggrtkvtvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
478,NaN,NaN,NaN,USW88598,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qagltqppsvskglrqtatltctgnsndvgrqgaawlqqhqghppkllfyrnngrpsgiserfsasrsgntasltitglqpedeadyycsswdssrggyvlgtgtkvtvl,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
479,NaN,NaN,NaN,USW88597,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Kumar,S. et al.; Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody; Unpublished; 2022.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
480,NaN,NaN,7F15_B,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkiscktsgytfteytmywvrqapgqrlewmgginpnqgdtsynqkfkgratltvdksattaymelsslrsedtavyycardgypyyfamdywgqgttvtvssggggsggggsggggsdiqmtqspsslsasvgdrvtitckasqnvdtnvawyqqkpgkapkgliysassrysgvpsrfsgsgsgtdftltissvqpedlatyfcqqyntypwtfgqgtkveikaaahhhhhhhh,NaN,"Zhang,G. et al.; A SARS-CoV-2 neutralizingantibody; Unpublished; 2022.",NaN,"Chain B, Antibody",NaN,2022-10-12,NaN,NaN
481,NaN,NaN,7F12_B,NaN,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewfgginpnngdtsynqkfkgkatltvdkssttaymdlrsltsedsavyycardgypyyfamdywgqgtsvtvssggggsggggsggggsdivmtqsqkfmstsvgdrvsvtckasqnvdtnvawyqqkpgqspkgliysashrysgvpdrftgsgsgtdftltisnvqsedladyfcqqyntypwtfgggtkleikaaahhhhhhhh,NaN,"Zhang,G. et al.; A SARS-CoV-2 neutralizingantibody; Unpublished; 2022.",NaN,"Chain B, Antibody",NaN,2022-10-12,NaN,NaN
482,NaN,NaN,7F0X_B,NaN,"['COVID', 'SARS-COV-2']",Mus musculus (house mouse),evqlqqsgpelvkpgasvkiscktsgytfteytmywvkqshgkslewfgginpnngdtsynqkfkgkatltvdkssttaymdlrsltsedsavyycardgypyyfamdywgqgtsvtvssggggsggggsggggsdivmtqsqkfmstsvgdrvsvtckasqnvdtnvawyqqkpgqspkgliysashrysgvpdrftgsgsgtdftltisnvqsedladyfcqqyntypwtfgggtkleikaaahhhhhhhh,NaN,"Zhang,G. et al.; A SARS-CoV-2 neutralizingantibody; Unpublished; 2022.",NaN,"Chain B, Antibody",NaN,2022-10-12,NaN,NaN
483,NB_1B11,NaN,7FAU_D,NaN,"['COVID', 'SARS-COV-2']",Camelidae,qvqlqesgggsvqaggslrlscaasgytvsvgcmawfrqapgkeregvagidasgitkysdsvkgrftiskdnaknaldlqmnglkpedtamyhcaaglvrgsctdvldhpsylgvwgqgtqvtvss,NaN,"Shi,Z. et al.; Structural basis of nanobodies neutralizing SARS-CoV-2 variants; Structure 30 (5), 707-720 (2022); 2022.",10.1016/j.str.2022.02.011,"Chain D, NB_1B11",NaN,2022-10-12,NaN,NaN
484,NB_1B11,NaN,7FAU_B,NaN,"['COVID', 'SARS-COV-2']",Camelidae,qvqlqesgggsvqaggslrlscaasgytvsvgcmawfrqapgkeregvagidasgitkysdsvkgrftiskdnaknaldlqmnglkpedtamyhcaaglvrgsctdvldhpsylgvwgqgtqvtvss,NaN,"Shi,Z. et al.; Structural basis of nanobodies neutralizing SARS-CoV-2 variants; Structure 30 (5), 707-720 (2022); 2022.",10.1016/j.str.2022.02.011,"Chain B, NB_1B11",NaN,2022-10-12,NaN,NaN
485,NB_1A7,NaN,7FAT_B,NaN,"['COVID', 'SARS-COV-2']",Camelus bactrianus (Bactrian camel),qvqlqesgggsvqaggslrlscaasgytfssyclgwfrqapgkeregvaaidsdgstsyadsvkgrftisrdnakntlylqmnslkpedtamyycaaeggpslsyctggygfllsglmynswgqgtqvtvsshhhhhh,NaN,"Shi,Z. et al.; Structural basis of nanobodies neutralizing SARS-CoV-2 variants; Structure 30 (5), 707-720 (2022); 2022.",10.1016/j.str.2022.02.011,"Chain B, nb_1A7",NaN,2022-10-12,NaN,NaN
486,NaN,NaN,UQK61766,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqvvqsgaevkkpgtsvkvsckvsgyslievsmhwvrqapgkglewmggfdpedgktiyaqkfqgrvtmtedtsadtaymelsslrsedtavyycataiavagspeyyyyyhgmdvwgqgttvtvss,NaN,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,"anti-SARS-CoV-2 NTD immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
487,NaN,NaN,UQK61764,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgftlpelsihwvrqapgkglewlggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsddtavyycatsspivgttgwfdpwgqgtlvtvss,NaN,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,"anti-SARS-CoV-2 NTD immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
488,NaN,NaN,UQK61762,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckvsgftlvelsihwvrqapgkglewmggfdpedaktiyaqkfqgrvtmtedtstdtaymdlssltsddtavyycaispaivaagwldpwgqgtlvtvss,NaN,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,"anti-SARS-CoV-2 NTD immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
489,NaN,NaN,UQK61760,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgpevkkpgasvrvscklsgytltelsihwvrqapgkglewmggfdpqegkithaqkfqgrvtmtedtstdtaymdlnslrfedtavyycatghqllvhwfdpwgqgtlvtvss,NaN,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,"anti-SARS-CoV-2 NTD immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
490,NaN,NaN,UQK61758,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlpelsihwvrqapgkglewmggfdtedvetiysqkfqarvtmtedtstdtaymelsslrsedtavyycatvfaifgvvrfdywgqgtlvtvss,NaN,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,"anti-SARS-CoV-2 NTD immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
491,NaN,NaN,UQK61756,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qaqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpksgdtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaslslvsgwyrfddfdiwgqgtmvtvss,NaN,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,"anti-SARS-CoV-2 NTD immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
492,NaN,NaN,UQK61754,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggttnyadsvkgrftisrdnskntlylkmnnlraedtavyycaratpycdgdcpvgdafdiwgegtmvtvss,NaN,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,"anti-SARS-CoV-2 NTD immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
493,NaN,NaN,UQK61752,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),eaqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsgisssgestysadsvkgrftisrdnskntlylqmnslraedtavyycardlggalgywgqgtlvsvss,NaN,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,"anti-SARS-CoV-2 NTD immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
494,NaN,NaN,NaN,UQK61767,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnignntvhwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaarddslngwvfgggtkltvl,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,NaN,"anti-SARS-CoV-2 NTD immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
495,NaN,NaN,NaN,UQK61765,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqvtqspsslsasvgdrvtitcrasqsissflnwyqqepgkapklliygasslrrgvpsrfsgsgsgtdftltisslqpedfatyycqqsystwtfgqgtkveik,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,NaN,"anti-SARS-CoV-2 NTD immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
496,NaN,NaN,NaN,UQK61763,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgpssdvgtynlvswyqqhpgkvpkliiyevnkrpsgvsyrfsgsksgntasltisglqaedeadyycssyarsllfgggtkltvl,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,NaN,"anti-SARS-CoV-2 NTD immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
497,NaN,NaN,NaN,UQK61761,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlsvspgeratlscrasqsvssnylawyqqkpgqaprlliydassrasgipnrfsgsgsgtdftlsitrlepedfavyycqqygssprwtfgqgtkveik,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,NaN,"anti-SARS-CoV-2 NTD immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
498,NaN,NaN,NaN,UQK61759,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagcdfhwyqqlpgaaprlliygnsnrpsgvpdrfsgsksgtsaslaitglqtedeadyycqsydsslsrssvvfgggtkltvl,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,NaN,"anti-SARS-CoV-2 NTD immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
499,NaN,NaN,NaN,UQK61757,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsgsnigsntvnwyqqlpgtapklliysydqrpsgvpdrfsgsksgtsaslaisglhsedeadyycaawddslngrvfgggtkltvl,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,NaN,"anti-SARS-CoV-2 NTD immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
500,NaN,NaN,NaN,UQK61755,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpekapklliytastlesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysrtfgqgtkveik,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,NaN,"anti-SARS-CoV-2 NTD immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
501,NaN,NaN,NaN,UQK61753,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstyvfgtgtkvtvv,"Suryadevara,N. et al.; An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer; J Clin Invest (2022) In press; 2022.",10.1172/JCI159062,NaN,"anti-SARS-CoV-2 NTD immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
502,BN03_NANO2,NaN,7WHK_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdfyfdyyemswvrqapgqglewvstisglggatyyadsvkgrftisrdnskntlylqmnslraedtalyycatrspfgdyafsywgqgtlvtvss,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain H, Bn03_nano2",NaN,2022-10-12,NaN,NaN
503,BN03_NANO1,NaN,7WHK_G,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqvpgktpewigsmypsgrtyinpslkslvtisrdnsenmlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvssggggsggggsggggsggggs,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain G, Bn03_nano1",NaN,2022-10-12,NaN,NaN
504,BN03_NANO1,NaN,7WHK_F,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqvpgktpewigsmypsgrtyinpslkslvtisrdnsenmlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvssggggsggggsggggsggggs,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain F, Bn03_nano1",NaN,2022-10-12,NaN,NaN
505,BN03_NANO1,NaN,7WHK_E,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqvpgktpewigsmypsgrtyinpslkslvtisrdnsenmlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvssggggsggggsggggsggggs,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain E, Bn03_nano1",NaN,2022-10-12,NaN,NaN
506,BN03_NANO2,NaN,7WHK_D,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdfyfdyyemswvrqapgqglewvstisglggatyyadsvkgrftisrdnskntlylqmnslraedtalyycatrspfgdyafsywgqgtlvtvss,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain D, Bn03_nano2",NaN,2022-10-12,NaN,NaN
507,BN03_NANO2,NaN,7WHJ_F,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdfyfdyyemswvrqapgqglewvstisglggatyyadsvkgrftisrdnskntlylqmnslraedtalyycatrspfgdyafsywgqgtlvtvss,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain F, Bn03_nano2",NaN,2022-10-12,NaN,NaN
508,BN03_NANO1,NaN,7WHJ_E,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqvpgktpewigsmypsgrtyinpslkslvtisrdnsenmlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvssggggsggggsggggsggggs,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain E, Bn03_nano1",NaN,2022-10-12,NaN,NaN
509,BN03_NANO1,NaN,7WHJ_D,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqvpgktpewigsmypsgrtyinpslkslvtisrdnsenmlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvssggggsggggsggggsggggs,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain D, Bn03_nano1",NaN,2022-10-12,NaN,NaN
510,BN03_NANO2,NaN,7WHI_G,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdfyfdyyemswvrqapgqglewvstisglggatyyadsvkgrftisrdnskntlylqmnslraedtalyycatrspfgdyafsywgqgtlvtvss,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain G, Bn03_nano2",NaN,2022-10-12,NaN,NaN
511,BN03_NANO1,NaN,7WHI_F,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqvpgktpewigsmypsgrtyinpslkslvtisrdnsenmlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvssggggsggggsggggsggggs,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain F, Bn03_nano1",NaN,2022-10-12,NaN,NaN
512,BN03_NANO1,NaN,7WHI_E,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqvpgktpewigsmypsgrtyinpslkslvtisrdnsenmlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvssggggsggggsggggsggggs,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain E, Bn03_nano1",NaN,2022-10-12,NaN,NaN
513,BN03_NANO1,NaN,7WHI_D,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqvpgktpewigsmypsgrtyinpslkslvtisrdnsenmlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvssggggsggggsggggsggggs,NaN,"Li,C. et al.; Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody; Cell 185 (8), 1389-1401 (2022); 2022.",10.1016/j.cell.2022.03.009,"Chain D, Bn03_nano1",NaN,2022-10-12,NaN,NaN
514,NaN,NaN,UPX76066,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgggvvqpgrslrlscaasgftfstyamhwvrqtpgkglewvavmsydgrdkyyadsvkgrftisranskntlylqmnslkaedtaiyycardqftadlsgddyyyyygmgvwglgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
515,NaN,NaN,UPX76065,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgggliqpggslrlscvaseiivssnymswvrqapgkgldwvsliysggstyyadsvkgrftisrdkskntlylqmnslraedtavyycardlrerggmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
516,NaN,NaN,UPX76064,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvsgdsissggyywgwirhhpgkglewigyiyysgssyynpslksrvtisvdtsknqfslklssvtaadtavyycardamvqgvfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
517,NaN,NaN,UPX76063,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvplkqsgggvvqpgrslrlscaasgfifstygmhwvrqapgkglewvavisydrinkyyadsvkgrftisrdnskntlylhmnslraedtavyycakdryggnshfdnwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
518,NaN,NaN,UPX76062,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlsctvsgftfssyamhwvrqgpgkglewvavisydgsnefyadsvkgrfiisrdnskntlflqmnslrpedtavyycargqnhgnllwfgeltmggmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
519,NaN,NaN,UPX76061,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsistggyywswirqhpgkglewigyiyyrgstnynpslksrvtisvdtsknqfslkldsmtaadtavyycargiavlryfeagrgfdfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
520,NaN,NaN,UPX76060,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgfpftvytihwvrqapgqrlewvgwinvgngntrysqkfqvrvtitrdtsastvymelsrlrsedtavyycargnsyyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
521,NaN,NaN,UPX76059,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgaevkkpgasvkvsckasgytfttsgiswvrqapgqglewmgwisayngdtnyaqkfqgrvtmttdtytstaymelrglrsddtavyycaketdyasslgvywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
522,NaN,NaN,UPX76058,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgseknyvdsvkgrftisrdnaknslylqmnslraedtavyycardanpytsssfyyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
523,NaN,NaN,UPX76057,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),flflassraqitlkesgssvkvsckasggtfsnyaiswvrqapgqglewmggiivisgiadyaqkfqgrvtitadeststvymelsslrsedtavyycaslgryfdwlfsrkqfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
524,NaN,NaN,UPX76056,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvmpsqtlsltcavsggsintgyyywswirqppgkglewignifysgstsynpslksrviisldtsknqfslklssvtaadtavyycarvvmeyqelrelphfdswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
525,NaN,NaN,UPX76055,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlsceasgftfsshgmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregplddiltgpyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
526,NaN,NaN,UPX76054,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfsshamswvrqapgkglewvsgisgsdvstyyadsvkgrftisrdnskntlylqmnslraedtaiyycakdftqrplvvdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
527,NaN,NaN,UPX76053,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysftsywiawvrqmpgkglewmgiiypgdsdtryrpsfqgqvtmsadksistiylqwsslkasdtamyycarlgygagtyvsymgldvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
528,NaN,NaN,UPX76052,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgeslkisckgsgysftsywiawvrqmpgkglewmgiiypgdsdtryrpsfqgqvtmsadksistiylqwsslkasdtamyycarlgygagtyvsymgldvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
529,NaN,NaN,UPX76051,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisfdginkyyadsvrgrftisrdnskntmyvqmnslrsedtavyycarsssggyrggfdnwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
530,NaN,NaN,UPX76050,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsdygmhwvrqapgkglewvaviwndgskkyyadsvkgrftisrdnskntlylqmnslraedtavfycarprrysgydgfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
531,NaN,NaN,UPX76049,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgpglvkpsgtlsltctvsggsissinwwswvrqppgkglewigeiydsgstnynynpslksrvtisvdksknqfslkltsvsaadtavyyctnrgysngfrgwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
532,NaN,NaN,UPX76048,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarghydssgyspgdyyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
533,NaN,NaN,UPX76047,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpgrslrlsctaseftfgdsamswvrqapgkglewvglirskayggttefaasvkgrftisrddsksiaylqmnslktedtavyyctrgrggyyygsgsyynwnygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
534,NaN,NaN,UPX76046,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfpfsdyymswirqapgkglqwvsyitssgstihyadsvkgrftisrdnakktlylqmnslraedtavyycaswgyyydsrgffsnywghgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
535,NaN,NaN,UPX76045,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfstyaihwvrqapgkglewvavisydginkyyadsvkgrfnisrdnskntlylqmnslrtedtavyycargmwgliavapfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
536,NaN,NaN,UPX76044,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpalvrptqtltltctfsgfslntygmcvswirqppgkalewlalidwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycarwanraaesfyamdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
537,NaN,NaN,UPX76043,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsgdsisgyywswirqspgkglewigyiyysgstnfnpslksrvtmsvdtsknqfylklrsvtaadtavyycargfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
538,NaN,NaN,UPX76042,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsggsvsgyywswirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkltsvtaadtavyycargfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
539,NaN,NaN,UPX76041,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsiywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaalsssdwhfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
540,NaN,NaN,UPX76040,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltcnvsggsinsggsywswirqhpgkglewigyisysgstyynpslksrltisvdtsknqfslnlrsvtaadtavyycargvgvgdfdywgqgalvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
541,NaN,NaN,UPX76039,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsetlsltcsvsggsissfywswfrqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssltaadtavyfcargfdfwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
542,NaN,NaN,UPX76038,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvkpggslrlscaasgftfssyrmnwvrqapgkglewvssisssssniyyadsvkgrftisrdnaknslylhmnslraedtavyycardqiwwrgqqlgyhyfygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
543,NaN,NaN,UPX76037,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqesgpglvrpsgtlsltcavsggsissfnwwswvrqppgkglewigeiyhsgstsynpslksrvtisidmsknqfslrltsvtaadtavyycargsdkivaagiyyfdhwgqgnlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
544,NaN,NaN,UPX76036,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvkpggslrlscaasgftfsdysmswvrqapgkglqwvssisrsstyiyyadsvkgrftisrdnaknslylqmnslraedtavyycaiicistscfpgfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
545,NaN,NaN,UPX76035,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscvasgftfssygmhwvrqapgkglewvaviwddgsgkhyadsvkgrftisrdnskntlylqmnslraedtavyycardedrqqlvtlfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
546,NaN,NaN,UPX76034,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycantnsgnyfpfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
547,NaN,NaN,UPX76033,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),pgavvqsgggvvqpgrslrlscaasgfpfsgyamhwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqlsslraedtavyycaralnggyvstfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
548,NaN,NaN,UPX76032,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqlgrslrlscaasgftfsiygmywvrqapgkglewvalisydgnnkyyagsvkgrftisrdnskntlylqmnslgaedtavyycaktssgsyneafdswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
549,NaN,NaN,UPX76031,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvavisydgsnkyyadsvkgrftlsrdnskntlylqmnslraedtavyycakggsgkyyswfdpwgpgtpvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
550,NaN,NaN,UPX76030,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarghydssgyspgdyyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
551,NaN,NaN,UPX76029,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfshypmhwvrqapgkglewvasisydennkyhvdsvkgrftisrdnskntlylqmnslrsedtavyycargrgaavgapehnwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
552,NaN,NaN,UPX76028,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesggglvqpggslklscaasgftfsdstlhwvrqasgkglewvgrirskahsyatayaesvkdrftisrddskntaylqmnslktedtavyyctrgryyfgldvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
553,NaN,NaN,UPX76027,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregdivvaaiafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
554,NaN,NaN,UPX76026,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfssyamywvrqapgrglewvavisydgnnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycarpasgnyigyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
555,NaN,NaN,UPX76025,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgpglvkpsetlsltctvsggsissyywswmrqspgkglewigyifysgstnynpslrgrvtisvdtsknqfslklssvtaadtavyycardrggldcfggvcpnnwyldlwgrgtpvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
556,NaN,NaN,UPX76024,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscatsgftfstfgmhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraedtavyycakdktvvilpvsnfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
557,NaN,NaN,UPX76023,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpgrslrlscaasgltfedyamhwvrqapgkglewvsgiswnsgtigyadsvkgrffisrdnaknslylqmnslrtedtalyycaklviggtlydfhqgrvvgmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
558,NaN,NaN,UPX76022,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvetggglvkpggslrlscaasgfsftayslhwvrqapgkglewvssitssgdyiyyadslkgrftisrdngknslylqmhslrgedtavyycarakysstwslgdyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
559,NaN,NaN,UPX76021,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsssamswvrqapgkglewvsaisdsgdsiyyadsvkgrftisrdtskntlflqmnslraddtavyycvkpgaevagtgaeyfqhwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
560,NaN,NaN,UPX76020,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvkpggslrlscaasgfsftayslhwvrqapgkglewvssitssgdyiyyadslkgrftisrdnaknslylqmhslrgedtavyycarakysstwslgdyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
561,NaN,NaN,UPX76019,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgliksrtdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttgrgpgkganwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
562,NaN,NaN,UPX76018,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsryalhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsgegdadvgimiafggviptpyfaywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
563,NaN,NaN,UPX76017,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgggvvhpgrslrlscaasgftfsiyamhwvrqapgrglewvavisydgtnkyyadsvkgrftisrdnskntlflqmnslraedtavfycakswsgsyfshfeswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
564,NaN,NaN,UPX76016,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfstygihwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarhsnlgvlitgtidywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
565,NaN,NaN,UPX76015,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqqsgggvvhpgrslrlscaasgftfstyamhwvrqapgkgldwvavisfdgndkyyadsvkgrftisrdnskntlylqmnslraedtavyycarappgsyyedyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
566,NaN,NaN,UPX76014,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgptlvkptqtltltctfsgfslstsgagvgwirqppgkalewlaliywnddkrcspslksrltitkdtsknqvvltmtnmdpvdtatyycahtllfnncpfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
567,NaN,NaN,UPX76013,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpgrslrlsctaseftfgdsamswvrqapgkglewvglirskayggttefaasvkgrftisrddsksiaylqmnslktedtavyyctrgrggyyygsgsyynwnygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
568,NaN,NaN,UPX76012,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvagilydgsnkayadsvkgrftisrdnsmntlylqmnslraedtavyycakqgapycsggncyssyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
569,NaN,NaN,UPX76011,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgggvvqpgrslrlscaasgftfnvyamnwvrqapgkglewlalisydgfnkyyadsvkgrftisrdnskntlylqmnslrpedtalyycarlgggsyfspfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
570,NaN,NaN,UPX76010,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytstsygiswvrqapgqglewmgwisvyngdtnyaqkvqgritmttdtststaylelrslrsddtamyyctrdapnlgelsfydsfdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
571,NaN,NaN,UPX76009,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpvlvkptetltltctvsgfslinarmgvswirqppgkalewlahifsndeksystslksrltiskdtfrsqvvltmtnmdpvdtatyycarinyasgsyyipfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
572,NaN,NaN,UPX76008,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgselkkpgasvkvsckafgytftdypmnwvrqapgqglewlgwintntgnptyaqgftgrfvlssdtsvttaylqisslkaedtavyycareqhsgrgwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
573,NaN,NaN,UPX76007,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqrggslrlscaasgftfsryamswvrqapgkglewvsgisgsggntnyadsvkgrftisrdnskntlylqmnslraedtavyycakgprynvdyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
574,NaN,NaN,UPX76006,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpgrslrlscaasgfifrsyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntpylqmnslraedtavydcarpdsgsyyadfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
575,NaN,NaN,UPX76005,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesggglvkpggslrlscaasgftfsdyymswirqapgkglqwvsyisssgdtksyadsakgrvtisrdnaknslylqmnslraedtavyycarggfdiftgpahqgnyyyamdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
576,NaN,NaN,UPX76004,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgggvvqpgrslrlscaasgftfnvyamnwvrqapgkglewlalisydgfnkyyadsvkgrftisrdnskntlylqmnslrpedtalyycarlrggsysspfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
577,NaN,NaN,UPX76003,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargfdywghgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
578,NaN,NaN,UPX76002,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvplkesggnlvqpgrslrlsctasgftfddyamhwvrqapgrglewvsgigwngrfivyadsvkgrftisrdnaknslylqmnsltaedtalyycakdigleyqlpsiaaggtvgsmvfdywgqgtpvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
579,NaN,NaN,UPX76001,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgasissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
580,NaN,NaN,UPX76000,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesggglvkpggslrlscaasgftfsdyslswvrqapgkglewvssmtssgdyiyyadsvkgrftisrdnaknslylqmrslraedtavyycarakysstwslgdyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
581,NaN,NaN,UPX75999,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyslswvrqapgkglewvssmtssgdyiyyadsvkgrftisrdnaknslylqmrslraedtavyycarakysstwslgdyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
582,NaN,NaN,UPX75998,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgggvvqpgrslrlscaasgfslrsysmhwvrqapgkglewvtvisydgsnkyyadsvkgrftisrdiskntlylqmnslrsedtavyycarayritmipgaggmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
583,NaN,NaN,UPX75997,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvtvisydglnkyyadsvkgrftisrdntkntlhlqmnslraedtavyycaranggnyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
584,NaN,NaN,UPX75996,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvscetsgytfstydiiwvrqaagqglewmgwmnpnsgntgfaqkfqgrvtltsnspistaymelsslgsddtavyfcarairnqllsdfwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
585,NaN,NaN,UPX75995,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),rstlkqsgggliqpggslrlscaasgftvssnymswvrqapgkglewvsvidsggstyyadsvkgrftisrdnskntvylqmnslraedtavyycamvlwlrggfeywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
586,NaN,NaN,UPX75994,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsfiysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardldivggmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
587,NaN,NaN,UPX75993,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewmgiinpssgsrgyaqkfqgrvtmtrdtststvymelsslrsedtavyyctrkvvvpadtgffdnwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
588,NaN,NaN,UPX75992,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriktktdggttdyaapvkgrftisrddskntlylqmnslktddtavyycttdreydyiwgsyryvdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
589,NaN,NaN,UPX75991,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpglvkpsetlsltctvsggslssyywswirqppgkglewigyiyysgttnynpslksrvtlsvdtskkqislrlssvtaadtavyycarqpvdgitmvkgvmardsygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
590,NaN,NaN,UPX75990,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgpglvkpsqtlsltctvsggsissdgyywswirqhpgkglewighiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyfcardivattqfnywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
591,NaN,NaN,UPX75989,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltcaisgdsvstngaawnwirqspsrglewlgrayygsetsyeyavsvesrisiktdtfknefslhlnsvipedtavyycardpptawgaldiwsqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
592,NaN,NaN,UPX75988,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsgtlsltcavsggsitssnwwswvrqppgkglewigeiydsgstnynpslksrvtisvdksknqfslklssvtaadtavyycarevivyeseggyyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
593,NaN,NaN,UPX75987,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllqsgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavisytgsnkyyadsvkgrftisrdnskdtlylqmnslrvedtamyycakdlvydfwggyegqmdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
594,NaN,NaN,UPX75986,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkiscqgsgytfgnhwiawvrqmpgkglewmgiiypgdsdtrynpsfqgqvtmsadksistaylqwsslkasdtamyycarregscsggsctgykwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
595,NaN,NaN,UPX75985,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevrkpgasvkvsckasgytfttyamhwvrqapgqrlewmgwinaantntkysqkfqgrvtitrdtsastaymelsslrsedtavyycardlevqgiiinddyfyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
596,NaN,NaN,UPX75984,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarfgakggfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
597,NaN,NaN,UPX75983,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgsdkyfadsvkgrftiskdnskntlylqmnslraedtavyycakemsgyyyyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
598,NaN,NaN,UPX75982,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslriscrasgysfsnywigwvrqmsgkglewmgmiypgdsdtryspsfqgqvtvsadksvttaylewtslkasdaamyycamrtahkpgywssgytsywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
599,NaN,NaN,UPX75981,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissdgyywswirqhpgkglewighiyysgstyynpslksrvtisvdtsknqfslkltsataadtavyfcardivattqfnywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
600,NaN,NaN,UPX75980,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgpglvkpsqtlsltctvsggsistggyywswirqhpvrglewigyiyysgntyyspslksrvtisvdtsknqfslklssvtaadtavyycardpptggwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
601,NaN,NaN,UPX75979,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgpglvkpsqtlsltctvsggsissgnhywswirqhprkglewigsiyysgrtyynpslksrvsisvdtsknqfslrlssvtaadtavyycareswgphsgsfyadnwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
602,NaN,NaN,UPX75978,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyyctrgsdkgarggyaywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
603,NaN,NaN,UPX75977,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvsggsissgghywswirqhpgkglewigyiyhsgstyynpslksritlsldtsknqfslklrsvtaadtavyycarvytsslrgdyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
604,NaN,NaN,UPX75976,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsgtlsltcdvsgdsisssnwwswvrqppgkglewigeiyhsgntnynpslksrvtmsvdksknhfslklisvtaadtavyycarrycgggrcsvfdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
605,NaN,NaN,UPX75975,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggpvssgsyywswirqppgkglewighinysgntnynpslksrvtisvdtsknqfslklssvtaadtavyfcarvdpgpggtldywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
606,NaN,NaN,UPX75974,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrrasdfwgdwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
607,NaN,NaN,UPX75973,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhggstndnpslksrvtisvdtsknqfslklssvtaadtavyycargvlrhldwlmrgdsyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
608,NaN,NaN,UPX75972,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarlritifhyyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
609,NaN,NaN,UPX75971,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpggsltlscaasgfnfnnygihwvrqapgkglewvavisyegskkyyadsvkgrftiskdslkntlhlqmnslrpedtavyycakcrgvlwfktsygmdvwgrgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
610,NaN,NaN,UPX75970,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqapgkglewmgiiypggsdtryspsfqgqvtisadksistaylqwsslkasdtavyycardlrgttfgghttwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
611,NaN,NaN,UPX75969,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgpglvkpsetlsltctvsggsisrssnywgwirqppgkglewigsisdrgstyyspslksrvtifvdtsknqfslklssvtaadtavyycarqnrgsldwlfssgnyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
612,NaN,NaN,UPX75968,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissdgyywgwirqhpgkglewigyvyhtgraqynpslksrvtisvdtsknqfslnlssvtaadtavyycardnrmapdkrgafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
613,NaN,NaN,UPX75967,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpgksvrlscaasgftfssygihwarqapgkglewvavvsydgnnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdgaysgyeayyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
614,NaN,NaN,UPX75966,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkassytteyaasvkgrftisrddsknslylqmnslktedtavyycaraeghivvvtagfeywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
615,NaN,NaN,UPX75965,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarasysnygphyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
616,NaN,NaN,UPX75964,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvsggsissggyfwswirqhpgkglewigyiyysgstfynpslksrvsisvdtsknqfslrlssvtaadtaiyycaregganwgsrvfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
617,NaN,NaN,UPX75963,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarrgylssgwsyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
618,NaN,NaN,UPX75962,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsnyamswvrqapgkglewvstisgssvktyyadsvkgrftvsrddskstlylqmnslraddtavyycarnsrafsyyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
619,NaN,NaN,UPX75961,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfsnawmswvrqapgkglewvgriksksdggttdyaapvkgrftisrddskntlylqmtslvaedtavyycttvravttpnwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
620,NaN,NaN,UPX75960,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaksvrflewladyyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
621,NaN,NaN,UPX75959,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgksvrlscaaagftfssygihwarqapgkglewvavvsydgnnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdgaysgyeayyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
622,NaN,NaN,UPX75958,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsggglvqpggslrlscaasgitfssytmswvrqapgkglewvsatvgsvgstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdswgtifgveyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
623,NaN,NaN,UPX75957,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaaseftfrsytmswvrqapgkglelvsgiagsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdswgtifggesyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
624,NaN,NaN,UPX75956,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycartswywafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
625,NaN,NaN,UPX75955,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycatktvqlehagsyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
626,NaN,NaN,UPX75954,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfsrtpyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
627,NaN,NaN,UPX75953,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvstisddgaityyadsvkgrftisrdnskntlylqmsslrtedtavyycvkdslttvtdlfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
628,NaN,NaN,UPX75952,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygihwvrqapgkglewvaliiydgsnkhyadsvegrftisrdnskntlylqmnslrpddtavyycakdggggycgggscyggyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
629,NaN,NaN,UPX75951,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvsviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardryydsiwgsyrlqnfdywgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
630,NaN,NaN,UPX75950,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),daslvqsgptllkptqtltltctfsglslstsgvsvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpadtgtyycahrratdfwgdwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
631,NaN,NaN,UPX75949,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsnygmywvrqapgkglewvavisydgnnkyyadsvkgrftisrdlskhtlylqlnslraedtavyycakdgtyydfwsgymgprdyyyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
632,NaN,NaN,UPX75948,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsnyamhwvrrapgkglewvagtsynggnkyyadsvkgrftisrdnskntlylqmnglraedtavyycakdlvydfwggyegqldnwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
633,NaN,NaN,UPX75947,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdlyssgwynpdfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
634,NaN,NaN,UPX75946,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrrasdfwgdwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
635,NaN,NaN,UPX75945,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargvhdfwsgyytgispayygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
636,NaN,NaN,UPX75944,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgggvvhpgrslrlscaasgfsfnifgmhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnsknslflqmnslraedtavyfcakdisivvvpaatmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
637,NaN,NaN,UPX75943,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgptlvkptqtltltctfsgvslstnavsvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrrapdfwgdwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
638,NaN,NaN,UPX75942,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggavvqpgrslrlscaasgftfsahgmhwvrqapgkglewvaiiwydgskryygesvkgrftisrdnskntlylqmnslrvedtaiyycarnpggsataayvdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
639,NaN,NaN,UPX75941,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscqasggtfssytiswvrqapgqglewmgriipilgitnyaqkfqgrvtitadkstttaymelsslrsadtavyycarssvvqgvmtnyeywaqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
640,NaN,NaN,UPX75940,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscavsgfifssfgmhwvrqapgkglewvaviwndgsqkyfadsvkgrftisrdnskntvylqmnslraedtavyycarevrgyydrsgnyqllgfdywgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
641,NaN,NaN,UPX75939,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgfifssfgmhwvrqapgkglewvaviwndgsqkyfadsvkgrftisrdnskntvylqmnslraedtavyycarevrgyydrsgnyqllgfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
642,NaN,NaN,UPX75938,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgptlvkptqtltltctfsgfslsttgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyfcahhntifgvliqssnwfdpwglgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
643,NaN,NaN,UPX75937,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycarlgsevgatrggysydvldvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
644,NaN,NaN,UPX75936,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsgtlsltcavsggsitsnnwwswvrqppgkglewvgeiyhsgntnyspslksrvtmsvdksknqfflklssvtaadtavyhcargwgsgppldywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
645,NaN,NaN,UPX75935,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgggvvqpgrslrlscaasgftfstfyvhwvrqtpgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggpyyydssgpldywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
646,NaN,NaN,UPX75934,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslslscaasgftfstyamhwvrqapgkglewvtvisydgdnkyyadsvkgrftisrdnskntmylqmnslrpedtavyycarpmggsyyggfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
647,NaN,NaN,UPX75933,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvplqesggglvqpggslrlscaasgftfnsydmtwirqvpgkglewvsaisgsgdityyansvkgrftisrdnskntlylqmnslraedtavyycakewtwkqlwkttwgyrdafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
648,NaN,NaN,UPX75932,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpgrslrlscaasgftfttyamhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycaranrgsyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
649,NaN,NaN,UPX75931,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrltcvasgftfseswmnwvrqspgkglewvanikhngrekyygdsvkgrfsisrdnaknslylqmsglrdddtavyycardlalvgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
650,NaN,NaN,UPX75930,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytytsyyihwvrqapgqglewmglinpsggstsyaqkfqgrvtmtrdtststvymelsslksddtavyycardsvemgtfweeprqnhgefnywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
651,NaN,NaN,UPX75929,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkrpgasvkvsckasgytftgyamhwvrqapgqrlewmgwintgnrntkysqsfqgrvtitrdtsastaymelsslrsedtavyycassalvglfdyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
652,NaN,NaN,UPX75928,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfstysmhwvrqapgkglewvavisndgsikynadsvkgrftlsrdnskntlylqmnslrpedtavyycardpnyydssgfpvdafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
653,NaN,NaN,UPX75927,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgggvvqpgrslrlscaasgftfnsygmhwvrqapgkglewvafiwfdgsnrfyadsvkgrftvsrdnskntlylqmnslraedtavyycahlegssgggagafdiwgrgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
654,NaN,NaN,UPX75926,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsryamswvrqapgkglewvsaisgsgdktyntdsvkgrftisrdnskntlylqmnslraedtavyycakdpryapdyfddwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
655,NaN,NaN,UPX75925,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesggglvqpggslrlscaasgftfrsyemnwvrqapgkglewlshisssgsietyadsvkgrftisrdnaknslylqmkslraedtavyycaargysstwtyyygmavwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
656,NaN,NaN,UPX75924,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigniyhsgstyynpslksrvtisvdtsknqfslrlssvttadtavyfcasehvsgwfprrvdygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
657,NaN,NaN,UPX75923,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvaviwhdgsnknyadfvkgrftisrdnskntlylqmnsvraddtavyycardkegvwgdyrsayhqdygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
658,NaN,NaN,UPX75922,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgeslkisckafgysfntywigwvrqkpgkglewvgiiypgdsetryspsfqgqvtisvdksintaylqwsslkasdtamyfcardfcggdcpsdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
659,NaN,NaN,UPX75921,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvavgwirqppgkalewlaliywdddkryrpslksrltitkdtsknqvvltminmdpvdtatyycgrqqliyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
660,NaN,NaN,UPX75920,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgssvkvsckasggtfnnyainwvrqapgqglewmgriipmlgianyaqkfqdrvtitadkststaymelsslrsedtavyycaatdyydssgfdafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
661,NaN,NaN,UPX75919,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesggglvqpggslrlscaasgitvsrnymtwvrqapgkglewvsliysggttyygdsvkgrfsisrdnskntlylqmnslraedtavyycardlvsygldvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
662,NaN,NaN,UPX75918,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasrfnfrnygmhwvrqapgkglqwvaviwydgsnkyyadsvkgrfiisrdnskntlylqmnslraedtavyfcardvgvgatmddyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
663,NaN,NaN,UPX75917,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),rcswcnsgggvvqpgrslrlscavsgftfshygmhwvrqapgkglewvavisydgsnkyyadfvkgrftisrdnskntlylqmnslrpedtavyycakngalyefwsgyldywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
664,NaN,NaN,UPX75916,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiyamhwvrhapgkglewatlisydgnneyyadsvkgrftisrdnskntlylqmnslraedtavyycargfggtyyyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
665,NaN,NaN,UPX75915,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgsevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisgyksntdiaqkfqervtmtadtstttaymelrslrsddtavyycarlatyfydgsaygpfdywgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
666,NaN,NaN,UPX75914,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvpleqsgaevkkpgasvkvsckafgytftnyamswvrqapgqglewmgwistyngdtnsaqkfqgrvtmttdtstrtaymelrslrsddtavyycargprsnydyfeywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
667,NaN,NaN,UPX75913,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpggslrlscaasgftfddfvmhwvrqppgkglewvslifgdgggpeyedsvqgrftisrdnsknslllqmdslrpedtalyfcvkggfrggpafdvwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
668,NaN,NaN,UPX75912,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfngyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslrlssvtaadtavyycatprcsgvscyryygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
669,NaN,NaN,UPX75911,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgpalvkptqsltltctfsgfslstsemcvswirqppgkalewlalidgddakkystslktrltiskdtsknqvvltmtnmdpvdtatyycahnfrkfyyydrsgyyyldafdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
670,NaN,NaN,UPX75910,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgyrfttywigwvrqmpgkglewmgiiypgdsdtryspslqgqvtisadksistaylqwsslkasdtamyycarlqqtnyfdywgqgtvvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
671,NaN,NaN,UPX75909,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgfpftvytihwvrqapgqrlewvgwinvgngntrysqkfqvrvtitrdtsastvymelsrlrsedtavyycargnsyyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
672,NaN,NaN,UPX75908,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpglvkpsqtlsltctvsggsisnggyywswirqhpgkglewigyiyssgttyynpslksrvtisvdtsknqfsmrlssvtaadtavyycarvrtagtwyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
673,NaN,NaN,UPX75907,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgggvvqpgrslrlscaasgftfttyamhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycaranrgsyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
674,NaN,NaN,UPX75906,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpalvkptqtltltctfsgfslsssgmrvhwirqppgkalewlahidwdddkfystslktrltiskdtsknqvvltmtnmdpvdtatyycarsyrpvapfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
675,NaN,NaN,UPX75905,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpggslrlscaasgftfddfvmhwvrqppgkglewvslifgdgggpeyedsvqgrftisrdnsknslllqmdslrpedtalyfcvkggfrggpafdvwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
676,NaN,NaN,UPX75904,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesggglvqpggslrlscaasgftfstyvmswvrqapgkglewvsgisggggrsyyadsvkgrfsisrdnsknmlylqmnslrpedtaayycakeaypgeswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
677,NaN,NaN,UPX75903,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsitygyywswirqhpgkglewigyiyysgstyynpslksrltisvdtsknqfslklssvtaadtavyycardyitgrgafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
678,NaN,NaN,UPX75902,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfmfsryamswvrqvpgkglewvsaisgsgdstyyadsvkgrftisrdnskntvylqmnslrvedtaiyycakdprynwnygeywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
679,NaN,NaN,UPX75901,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvaqpggslrlsceasgftfddyamhwvrqppgkslewvslisgdgggafyadsvkgrftisrdnsknslhlqmnslrtedtalyycakdlgrlygdptfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
680,NaN,NaN,UPX75900,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfttyamhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycaranrgsyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
681,NaN,NaN,UPX75899,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkrpgasvkvsckasgytftgyamhwvrqapgqrlewmgwintgnrntkysqsfqgrvtitrdtsastaymelsslrsedtavyycassalvglfdyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
682,NaN,NaN,UPX75898,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgeslrlscaasgftvssnyvswvrqapgkglewvsviysggdtdyadsvkgrftvsrdtskntlylqmnslraedtalyycastamppfyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
683,NaN,NaN,UPX75897,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrvscaasgftfssyaihwvrqapgkglewvavisydginkyyadsvkgrftisrdnskntvyvqmnslrtedtaiyycaratsgayrasfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
684,NaN,NaN,UPX75896,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqrgagllkpsetlsltcavyggsfsgfywnwirqspgkglewigeidhrgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycarwlrwfgelgpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
685,NaN,NaN,UPX75895,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsrygmhwvrqapgkgleyvaiisddggnkyyadsvkgrftvsrdnskntlylqmnslraedtavyycaklyyygsggdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
686,NaN,NaN,UPX75894,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvplkesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsvfysggstyyadsvkgrftisrddskntlylqmnslraedtavyyctrghgngwsyyydywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
687,NaN,NaN,UPX75893,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscvasgftfsnygmhwvrqapgkglewlaviyfdgskkyyadsvkgrftisrdnskntlflqmnslrvedtavyfctrdipwgeqsfggdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
688,NaN,NaN,UPX75892,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpgeslrlscaasgftvssnyvswvrqapgkglewvsviysggdtdyadsvkgrftvsrdtskntlylqmnslraedtalyycastamppfyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
689,NaN,NaN,UPX75891,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvaviwydgrnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvsltvttfhdafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
690,NaN,NaN,UPX75890,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfnnyamtwvrqapgkglewvaaisgsgssryyadsvkgrftisrdnskntlylqmnslrgddtavyycakahvfgeliygqllyfecwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
691,NaN,NaN,UPX75889,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisssgyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycathtydisgyyfyfdnwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
692,NaN,NaN,UPX75888,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpgrslrlscaasgftfstysmhwvrqapgkglewvavisydginkyytdsvkgrftisrdnskntlhlqmnslraddtafyycartngynsnfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
693,NaN,NaN,UPX75887,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsggglvqpggslrltcvasgftfseswmnwvrqspgkglewvanikhngrekyygdsvkgrfsisrdnaknslylqmsglrdddtavyycardlalvgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
694,NaN,NaN,UPX75886,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfstydmhwvrqatgkglewvsgigtggdtyypdsvkgrftisrenaknslylqmnslragdtavyycarggdgyslgnwyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
695,NaN,NaN,UPX75885,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnfamhwvrqapgkgpewvavisydgntkyyadsvkgrftisrdnskntlylqmnslraedtavyycardfpglrssgwdgfdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
696,NaN,NaN,UPX75884,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgggvvqpgrslrlscaasgftfssfamhwvrqapgkglewvavisydgsnkyyadsvkgrftvsrdnskntlylqmhslriedtavyycarpdsgsyyhpfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
697,NaN,NaN,UPX75883,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfssygihwvrqapgkglewvavisfdgsyqysadsvkgrftisrdnskntvdlqmnslrpedtavyycakemgleggnafdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
698,NaN,NaN,UPX75882,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgfpfsssamswvrqapgkglewvsgisatggstyyadsvkgrftisrdnskstlylqmnslraedtavyfcanggfgvtprlrvfdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
699,NaN,NaN,UPX75881,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgssvkvsckpsggtftsyviswvrqapgqglewmgriipvldvtnyaqkfqgrvtitadkststaymelsslrsadtavyycargprwhyygsgspngnqyyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
700,NaN,NaN,UPX75880,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgggvvqpgrslrlscaasgftfstyamhwvrrapgkglewvtvisydgsnqyyadsvkgrftisrdnskntlylqmnslraedtalyhcartlsgsyrppfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
701,NaN,NaN,UPX75879,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsshgmhwvrqapgkglewvaiisydgsntnyadsvkgrftisrdnsknmvyvemnnlrpedtavyycvksgirwfyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
702,NaN,NaN,UPX75878,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfntfamhwvrqapgnglewvtvisydginkyyadsvrgrftiardnskntlylqmsslraedtavyycaravrggyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
703,NaN,NaN,UPX75877,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscvasgftfsnygmhwvrqapgkglewlaviyfdgskkyyadsvkgrftisrdnskntlflqmnslrvedtavyfctrdipwgeqsfggdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
704,NaN,NaN,UPX75876,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckapggtfssyainwvrqapgqglewmgriipildivnyaekfqgrvtiiadkststaymelsslrsedtavyycardggldivvvptafrkpdfdyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
705,NaN,NaN,UPX75875,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggalvkpggslrlscaasgftfsyawmtwvrqapgkglewvgrmktkteggtteyaaavkgrftisrddsrntlylqmnslktedtavyyctthsspdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
706,NaN,NaN,UPX75874,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscvasgftfssygmhwvrqapgkglewvaviwddgsgkhyadsvkgrftisrdnskntlylqmnslraedtavyycardedrqqlvtlfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
707,NaN,NaN,UPX75873,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgggvaqpgrslrlscaasgftfsahgmhwvrqapgkglewvaiiwydgskryygesvkgrftisrdnskntlylqmnslrvedtaiyycarnpggsataayvdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
708,NaN,NaN,UPX75872,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgptlvkptqtltltctfsgfslstsgvgvawirqppgkalewlaviywsddkryspslknrlsitqdtsknqvvltmtnmdpvdtatyycahspviaaggksfwyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
709,NaN,NaN,UPX75871,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesggglvqpggslrlscaesgftvssnymtwvrqapgkglecvsiiysggntyyadsvkgrftisrdnskntlylqmnslraedtavyycasaimitfggvigktdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
710,NaN,NaN,UPX75870,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgdggntyyadsvkgrftmsrdnskntlylqmnslraedtavyycasrwfgefswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
711,NaN,NaN,UPX75869,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpggslrlscaasgfivsnnymswvrqapgkglewvsiiysggntyyadsvkgrftisrhsskntlylqmntlraedtavyycartwhyydrsgyltywfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
712,NaN,NaN,UPX75868,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiysggstyynpslksrvtisvdtsknqfslklssvtaadtavyycatprlmitfggvsnafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
713,NaN,NaN,UPX75867,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsiyamhwvrqapgkglewvavisydgsnkyyadsvkgrftlsrdnskntlylqmnslrvedtavyycardpsgsyyvgfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
714,NaN,NaN,UPX75866,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgprlvkpsetlsltctvsggsissyywnwirqppgkglewigyiynsgstnynpslksrvtisvdtsksqfslklssvtaadtavyfcaravgftnfeywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
715,NaN,NaN,UPX75865,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfsnydmhwvrqvtgkglewvstigtagdthysdsvkgrftisrenaknslylqmnslragdtavyycarggdyaafwyfdlwgrgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
716,NaN,NaN,UPX75864,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgggvvqpgrslrlscaasgftfssfamhwvrqapgkglewvalisydgtnkyyadsvkgrftisrdnskntlylqmnslraeatavyycaratgggyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
717,NaN,NaN,UPX75863,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftftnyamhwvrqapgkglewvavisydglnkyyagsvkgrftisrdnskntlylqmnslrpedtavyycarsfggnyhyfgywgqgalvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
718,NaN,NaN,UPX75862,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaqgdtfevvslwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
719,NaN,NaN,UPX75861,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsiywmswvrqapgkglewvatikqdgseryyvdsvkgrftisrdnaknsvylqmnslraedtavyycascsssswhwnywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
720,NaN,NaN,UPX75860,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesggglvqpgrslrlsctasgftfgdyamswvrqapgkglewvgfirsktyggtteyaasvkgrftisredskniaylqmnslksedtavyhctggiywfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
721,NaN,NaN,UPX75859,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvkpggslrlscaasgftfssynmnwvrqapgkglewvssissnsnyiyhtdsvkgrftisrdnaknslflqmnslraedtavyycvrdrtgyssswyndafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
722,NaN,NaN,UPX75858,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrrapgkglewvtvisydgsnqyyadsvkgrftisrdnskntlylqmnslraedtalyhcartlsgsyrppfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
723,NaN,NaN,UPX75857,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavilydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgstsssswyvaidyyysnmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
724,NaN,NaN,UPX75856,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvkpgvslrlscaasgftfsdyymswirqapgkglewvsyisnsstytnyadsvkgrftisrdnaknslylqmnslraedtavyycardlygiyydsngrgyyyygldvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
725,NaN,NaN,UPX75855,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgfifssyaihwvrqapgkglewvavisydgnnkyyvdsvrgrftisrdnskntlylqmnslraddtavyycarprsgnyfnafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
726,NaN,NaN,UPX75854,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgdggntyyadsvkgrftmsrdnskntlylqmnslraedtavyycasrwfgefswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
727,NaN,NaN,UPX75853,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpvlvkptetltltctvsgfslsnakvgvswirqapgkalewlahifsddeksysaslksrltiskdtsksqvvlsmtnmdpvdtatyfcarlrygyssgwyaafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
728,NaN,NaN,UPX75852,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrhnsnntlylqmnslraddtavyycarlpysrdeywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
729,NaN,NaN,UPX75851,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyaiywvrqtpgkglewvavisydgsnkyyaesvkgrfiisrdnskntlylqmnslrvedtavyycarphsgsynswfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
730,NaN,NaN,UPX75850,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavilydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgstsssswyvaidyyysnmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
731,NaN,NaN,UPX75849,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgggvvqpgrslrlscaasgfiftiyamhwvrqapgkglewvavisydgsntyyadsvrgrftisrdnskntlylqmnslraedtavyycaragsgsyrsgfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
732,NaN,NaN,UPX75848,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissfywnwirqppgkglewigyiynsgstnynpslksrvtilvdtstnqfslklssvtaadtaeyycaravgftkyeywgqgipvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
733,NaN,NaN,UPX75847,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsnydmhwvrqvtgkglewvstigtagdtyysdsvkgrftisrenaknslylqmnslragdtavyycarggdyaafwyfdlwgrgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
734,NaN,NaN,UPX75846,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfstyvmswvrqapgkglewvsgisgsggrsyyadsvkgrfsisrdnsknmlylqmnslrpedtaayycakeaypgeswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
735,NaN,NaN,UPX75845,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvavisydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycakpgvdadmvvfdafdnwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
736,NaN,NaN,UPX75844,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvavisydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycakpgvdaamvvfdafdnwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
737,NaN,NaN,UPX75843,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipisgianyaqkfqgrvtitadkststaymelsslrsedtavyycasisdfwrdyiggdyyyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
738,NaN,NaN,UPX75842,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgggvvqpgrslrlscaasgftfsnypmhwvrqapgkglewvavisydgtnkyyadsvkgrftisrdnskntlylqmnslraedtalyycardylmmvaanswyygmdvwgqgntvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
739,NaN,NaN,UPX75841,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisidtsknqfslklssvtaadtavyycargfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
740,NaN,NaN,UPX75840,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisdyywswirqppgkglewigyiyysgstkynpslksrvtisadasknqfslnlssvtaadtavyycarhdgygfsgyqhyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
741,NaN,NaN,UPX75839,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsrygmhwvrqapgegleyvalisddgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaklyyygsggdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
742,NaN,NaN,UPX75838,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsissyywswfrqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslkltsvtaadtavyycaqgfdywgqgalvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
743,NaN,NaN,UPX75837,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpgrslrlscaasgfifstyaihwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycargwgtramdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
744,NaN,NaN,UPX75836,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpalvkstqtltltctffgfslstsgmcvtwirqppgkalewlaridweddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycarilaptvtadywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
745,NaN,NaN,UPX75835,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfndygmhwvrqapgkglewvaviwsdgsnryyadsvkgrftisrdnskntlylqmnslraedtavyycardppvmifgvvfmkgmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
746,NaN,NaN,UPX75834,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllqsggglvqpggslrlscsasgftfstyamhwvrqapgqgleyvsaisynggstyyadsvkgrftisrdnskntlyllmsslraedtsiyycvkgdtamvpfnwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
747,NaN,NaN,UPX75833,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkqsgggvvqpgrslrlscvasgftfsnygmhwvrqapgkglewlaviyfdgskkyyadsvkgrftisrdnskntlflqmnslrvedtavyfctrdipwgeqsfggdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
748,NaN,NaN,UPX75832,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssytmnwvrqapgkglewvsyisssgnsiyyadslkgrftisrdnaknslylqmnslrdedtaiyycardtgsgfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
749,NaN,NaN,UPX75831,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfivssnymtwvrqapgkglewvsliysggsphyadsvkgrftisrhnsknslylqmnslrpedtavyycargfsgpyqldywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
750,NaN,NaN,UPX75830,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgptlvkptqtltltctfsgfslstsgmgvgwirqppgkalewlaliywnddkryspslknrltitkdtsksqvvltmtnldpvdtatyycarlpwydyrlyyfdswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
751,NaN,NaN,UPX75829,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgtslrlscvtsglifrnygmhwvrqapgkglewvalikydgtktyyadsvrgrftisrddsrntlflqmnslrvedtavyycatdrrshvhdrwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
752,NaN,NaN,UPX75828,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfskyainwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymdlsslrsedtavyycareyssssgyyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
753,NaN,NaN,UPX75827,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesggglvkpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsvsigyadsvkgrftvsrdngkkslylqmnslgvedtalyycakgfdsdwtqpidywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
754,NaN,NaN,UPX75826,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycargrsnyydssgyygagdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
755,NaN,NaN,UPX75825,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsggglvqpggslrlscaasgftfssdwmtwvrqapgkglewvanikedgieknyvdsvkgrftisrdnakkslylqmnslraedtavyycaretfyydrgdyyfyfdywgqgalvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
756,NaN,NaN,UPX75824,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfrrygmhwvrqapgkglewvavilydgsdkyyadsvkgrftisrdnskntlylqmnslraedtavyycaklggeycsggncysgyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
757,NaN,NaN,UPX75823,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrvscaasgftfsnygmywvrqapgkglewvavisydgsnkhygdsvkgrftisrdnskntlylqmnslraedtavyycakegpgysgmnyfhywgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
758,NaN,NaN,UPX75822,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfsnyamswvrqapgkglecvsalsgsggntyyadsvkgrftitrdnskntlylqmnslraedtavyycakysvkqlwlrsatdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
759,NaN,NaN,UPX75821,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlgcnswgrpwyslggslrlscaasgftfsnyamswvrqapgkglewvsgiiagggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvmapiaagatcgidywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
760,NaN,NaN,UPX75820,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqesgpglvkpsgtlsltctvsggsisssnyfwawirqppgkglewigniyysgstyynpslrsrvtisvdtsknqfslkltsvtaadtavyycatlirgwaedeafdnwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
761,NaN,NaN,UPX75819,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfrnygiswvrqapgrglewmggfipffgttnyaqkfqgrvtitadeststaymelsslrsedtavyycargdyydnsgynyvywfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
762,NaN,NaN,UPX75818,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggtfgtyafswvrqapgqglewmggiipifgttnyaqkfqgaqkfqgrvtiiadestttvymelsslrsddtavyycarerptpagkpsyyyyamdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
763,NaN,NaN,UPX75817,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgpglvkpsetlsltctvsggsvrsyywswirqpagkglecigriygsgntnynpslksrvtmsvdtsknqfflnlssvtaadtavyycvreglgyydfssgppeaafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
764,NaN,NaN,UPX75816,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwistyngntnyaqklqdrvtmttdtststaymelrslrsddtavyycarsyyydssfnywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
765,NaN,NaN,UPX75815,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpgrslrlscaasgftfssfgmhwvrqapgkglewvalisydgsnkyyadsmkgrftisrdnskntlylqmnslraedtaiyycakdygyiavtdrrggeyyynyhgmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
766,NaN,NaN,UPX75814,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycararsgnyyfltywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
767,NaN,NaN,UPX75813,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvavisfdggdknyvdsvkgrftisrdnskntvylqmnslraedtavyycakqlyyyasgsypdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
768,NaN,NaN,UPX75812,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsggglvqpggslrlscaasgftfsnhamswvrqapgkglewvssisasggttyyadsvkgrftisrdnsrntlyllmnslraegtalyfcakagdyfpdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
769,NaN,NaN,UPX75811,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglihpggslrlscaasglmfsryamswvrqapgkgpewvsvinydgtftryadsvkgrftisrdnskntlvlqmnslrvedtaiyycattyrdadyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
770,NaN,NaN,UPX75810,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvrpggslrlscaasgltssiyamswvrqapgkglewvstisgnggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakeglgsmrlvvifywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
771,NaN,NaN,UPX75809,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckaseytftgyymhwvrqapgqglewmgwinptsggtkyvqkfqgrvtmtrdrtistaymelnrlrsddtavyycasewlaeqernlwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
772,NaN,NaN,UPX75808,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardptgltyydiltgptpsyyfdywgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
773,NaN,NaN,UPX75807,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsdkyyadsvkgrftvsrdnskntlylqmnslraedtavyycakqqysyayppsyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
774,NaN,NaN,UPX75806,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssyvitwvrqapgqglewmggivpmfgttnyaqkfqgrvtftadeststaymelsslrsddtaiyycargewsyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
775,NaN,NaN,UPX75805,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfgthaihwvrqapgkglewvavisydannkyyadfvkgrftisrdnskntlylqmnslraedtavyycartisgyyyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
776,NaN,NaN,UPX75804,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfnfttygmhwvrqapgkgpewvamiwsdgsnkyyaesvkgrftisrdnsrdtlylqmnnlraedtaiyycardrpqyisgsyyvdyyfeywgqgslvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
777,NaN,NaN,UPX75803,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfilsdywmhwvrqapgkglvwvsrinniddgntityvdsvegrftisrdnakntlylqmnslraedtavyycarggvggsfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
778,NaN,NaN,UPX75802,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstnynpslysrvtisvdtsknqfslklssvtaadtavyycaregggsgtyfndafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
779,NaN,NaN,UPX75801,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakaidelagslwdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
780,NaN,NaN,UPX75800,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgggvvqsgrslrlscaasgftfaiyamhwvrqapgkgldwvalisfdgtnkyytdsvkgrftisrdnskntiylemnslrtddtalyycvrgdgynildfwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
781,NaN,NaN,UPX75799,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggpfsiyaitwvrqapgqglewmggiipmsgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardlryctsticyfwfdpwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
782,NaN,NaN,UPX75798,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),daarmswgagllkpsetlsltcgvygasfrgyywtwirhlpgkglewigeitdiggvyynpslrsrvtlstdtsknqfslrlssvtaadtaiyycatgstgprlrdwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
783,NaN,NaN,UPX75797,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsshtihwvrqapgkglewvalisydgynkyfadsvkgrftisrdnskntlylhmnslrtedtavyycargggyydsfdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
784,NaN,NaN,UPX75796,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyycardgqqlvlwafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
785,NaN,NaN,UPX75795,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycaraqsgvitifgvvistyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
786,NaN,NaN,UPX75794,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgvsissggyywswirqhpgndlewigyiyysgntyynpslksrlaisvdtsknqfslklssvtaadtavyycardyggnsnyfnywgqgipvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
787,NaN,NaN,UPX75793,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgaevkkpgssvkvsckasggtfsnyatswvrqapgqglewmggiiplygtanyaqkfqdrvtitadkstrtaymelsslrsedtavyycarveldhdyvwggyrdywyfhlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
788,NaN,NaN,UPX75792,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssswmnwvrqapgkgpvwvaiikqdgseryyadsvkgrftisrdnaknslylqmnslraedtaiyycardlriapvpqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
789,NaN,NaN,UPX75791,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgynkyyadsvkgrftisrdnskntlylqmnslraedtavyycasgfsgnyyyfdswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
790,NaN,NaN,UPX75790,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgeslkiscqgsgytfgnhwiawvrqmpgkglewmgiiypgdsdtrynpsfqgqvtmsadksistaylqwsslkasdtamyycarregscsggsctgykwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
791,NaN,NaN,UPX75789,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfrsywmtwvrqapgkglewvasikqdggekfymdsvkgrftisrdnarnslflqmnslraedtavyycarlgqgswyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
792,NaN,NaN,UPX75788,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfifnnylmswvrqapgkglewvanikqdgsdkyyvdsvkgrftisrdnaknslflqmnslraedtavyycardlsesayssgwyryyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
793,NaN,NaN,UPX75787,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvklkesggglvkpggslrlscaasgftfsdyymtwirqapgkglefvsyiggsgssiyyadsvrgrftisrdnaknslylqmnslraddtavyyctrepvgynawglntrqfhfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
794,NaN,NaN,UPX75786,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycargfggsynwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
795,NaN,NaN,UPX75785,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsnfamhwvrqapgkglewvaiisydgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaahyygsgsyfidywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
796,NaN,NaN,UPX75784,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsvaevkkpgasvkvsckasgytftsydvnwvrqatgqrpewmgwmnpnsgntgyaqklqgrvtltrdtststaymelsslrsedtavyycargpvwsgydlsrssdssgfdswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
797,NaN,NaN,UPX75783,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvtvsckasggtfsnyavswvrqapgqglewmggitpifgtsnyaqkfqgrvtftadestttaymeltsltsedtatyycarevgddynsevgdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
798,NaN,NaN,UPX75782,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfsnyatswvrqapgqglewmggiiplygtanyaqkfqdrvtitadkstrtaymelsslrsedtavyycarveldhdyvwggyrdywyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
799,NaN,NaN,UPX75781,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgagllkpsetlsltctvyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargyryfdwniigydyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
800,NaN,NaN,UPX75780,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvppgkslrlscaasgfrfddypmhwvrqapgkglewvsgiswngdrtgyadsvkgrftisrdnaknslslqmnslttedtadyfcvkdvgkypnyyhfsyidvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
801,NaN,NaN,UPX75779,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvrpggslrlscaasgftfddyamswvrqapgkglewvssinwnggstgyadsvkgrytisrdnaknalylqmnslraedtafyhcarggycsggscyggyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
802,NaN,NaN,UPX75778,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqqsggglvkpggslrlscaasgftfssytmnwvrqapgkglewvssissrsnyiyyadslrgrftisrdnaknslylqmnslraedtavyycardetrygdyvwdymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
803,NaN,NaN,UPX75777,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkiscqgsgyrftsswiawvrqtpgkglewmgiiypgdsdtkyspsfqgqvtisadkstssaylqwsslrasdtaiyfcarklycsdgpchpntfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
804,NaN,NaN,UPX75776,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysftrywigwvrqmpgkglewmgiiypgdcdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrpqycsggncyhnwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
805,NaN,NaN,UPX75775,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfitywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnannslslqmnslraedtavyycaalssnswefeywgqgalvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
806,NaN,NaN,UPX75774,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgggliqpggslrlscaasgftvssnymswvrqgpgkglewvsiiysggstysadsvkgrftisrdnsrntlylqmnslraedtavyycvtgygsglywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
807,NaN,NaN,UPX75773,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsgdsisnyywswirqppgkglewigyiyssgstnynpslksrvtisvdtsknqfslkltsvtaadtavyycargfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
808,NaN,NaN,UPX75772,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgpalvkptqtltltctfsgfslstsetrvswirqppgkapewlaridwdddefystslrtrltiskdtsknqvvltmanldpmdtatyfcarsktpgwdsfdfwgpgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
809,NaN,NaN,UPX75771,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrsvrlscaasgftfssyaihwvrqapgkglewmavisydgsnkyyadsvrgrftisrdnskntlylqmnslrvedtavyycargdggyfsafdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
810,NaN,NaN,UPX75770,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkiscqgsgytfgnhwiawvrqmpgkglewmgiiypgdsdtrynpsfqgqvtmsadksistaylqwsslkasdtamyycarregscsggsctgykwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
811,NaN,NaN,UPX75769,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfmnygiswvrqapgqglewmgwisayngntknaqklqgrvtmttdtststaymelrslrsddtavyycaniagnsrefdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
812,NaN,NaN,UPX75768,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfsssdmhwvrqatgkslewvsgigtagdtyyadsvkgrftisredaknslflqmhslragdtavyfcargdssgyeyyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
813,NaN,NaN,UPX75767,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfitywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnannslslqmnslraedtavyycaalssnswefeywgqgalvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
814,NaN,NaN,UPX75766,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycantnsgnyfpfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
815,NaN,NaN,UPX75765,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvavisydgsdkyyadsvkgrfiisrdnskntlylqvnslraedtavyycalspggygshegpfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
816,NaN,NaN,UPX75764,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgaevkkpgasvkvsckasgytfmnygiswvrqapgqglewmgwisayngntknaqklqgrvtmttdtststaymelrslrsddtavyycaniagnsrefdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
817,NaN,NaN,UPX75763,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvetggglvqpggslrlscaasgftfssywmtwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyfcardrivvvtaisgvswfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
818,NaN,NaN,UPX75762,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaksslylqmnslraedtavyycarvsysygykgvrtyqyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
819,NaN,NaN,UPX75761,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssygiswvrqapgqglewmggiipifgtakyaqkfqgrvtitadeststaymelsslrsddtavyycardrrpcsssscrhyyyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
820,NaN,NaN,UPX75760,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisctgseysftnywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrrsleyisgwysggwyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
821,NaN,NaN,UPX75759,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaelkksgasvrvscqasgytftdyyfhwvrqapgqglqwmgwispktggtrhaqkfqgrvtmtrdtsittvymdlnsltsddtaiyycaragwqgptsvnwapldswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
822,NaN,NaN,UPX75758,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsftsssyywgwirqppgkglewigsiyysgstysnpslksrvtisadtsknqfslrlssvtaadtavyycarqryydpllfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
823,NaN,NaN,UPX75757,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfssytmnwvrqapgkglewvssissasnfiyyadsvkgrltisrdnaknslylqmnslraedtamyycareahsnshfyyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
824,NaN,NaN,UPX75756,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpgrslrlscaasgftfddygmhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslrvedtalyycakdigyssgspdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
825,NaN,NaN,UPX75755,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfnnyaitwvrqtpgqglewmggiipffgssnyaqkfqgrvsltadestttaymelsslrsedtaiyfcarvgpydssgryldywdqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
826,NaN,NaN,UPX75754,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavydgsfsgyywnwirqppgkglewigeinhsgstnynpslksrvtvsvdtsknqfslklssvtaadtavyycargrtvttffgphkffdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
827,NaN,NaN,UPX75753,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakpgrryyyyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
828,NaN,NaN,UPX75752,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesgaevkkpgssvkvsckasggtfsshamswvrqapgqglewmggiipifgtpnyaqkfqgrvtitadestsraymelsslrsedtavyycardshghwgfgtfdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
829,NaN,NaN,UPX75751,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggsvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgvigyaasvkgrfiisrdnaknslylqmnslraedtalyycakdishydssdygefdgggfdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
830,NaN,NaN,UPX75750,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscgasgftfsnywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslrvedtamyycardlsesayssgwylyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
831,NaN,NaN,UPX75749,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgggvvqpgrslrlscaasgftfstyamhwvrqapgkgpewvavisfdgdkkyyadsvkgrftisrdnskntlylqmnslrgedsavfhcaraatgsyfshldywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
832,NaN,NaN,UPX75748,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftfssywmhwvrqapgkglvwvsrinsdgsstsyadsvkgrftisrdnakntlflqmnslraedtavyycaregitaagiyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
833,NaN,NaN,UPX75747,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslklscaasgftfsdsgmhwvrqasgkglewvgrirskansyatayaasmkgrftisrddskntaylqmnslktedtavyyctspavfnywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
834,NaN,NaN,UPX75746,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgeslkisckgseytftnywiawvrqmpgkglewmgiispsdsdtryspsfqgqvtisvdrststaylqwsslkasdtamyycarqliqkyssgwyhyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
835,NaN,NaN,UPX75745,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgqslrisckgsgysftnywigwvrqmpgkglewmgiispgdsntryspsfqgqvtisadksistaylqwsslkasdtaiyycarhlplsryssgwysyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
836,NaN,NaN,UPX75744,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsayamywvrqapgkglewvavisydgtnkyfadsvkgrftisrdnskntlylqmnslraedtavyfcarprsgsyfaafdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
837,NaN,NaN,UPX75743,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvrpggslrlscaasgytfddygmswvrqapgkglewvsginwnggstgyadsvkgrftisrdyaknslylqmnslraedtalyycarwtcggdcyslilsggdyfdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
838,NaN,NaN,UPX75742,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysfssswigwvrqmpgkglesigviypgdsdtrysptfqgqvtlsvdksistaylqwsslkasdtamyycarrgdyenfvywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
839,NaN,NaN,UPX75741,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpvlvkptetltltctvsgfslinarmgvswirqppgkalewlahifsddeksyitslknrltiskdtsksqvvltmtnmdpvdtatyycarlqwfgelyyfdswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
840,NaN,NaN,UPX75740,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssyamswvrqapgqglewvsgisasggstyyadsvkgrftisrdnskntlylqmnglraedtavyycakdgggflgywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
841,NaN,NaN,UPX75739,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),nrfgailglrlkkpgssvkvsckasggtfsnyainwvrqapgqglewmgriipilgienyaqkfqgrvtitadkststaymelsslrsedtavyycarddgsitffgeshyyhgmdvwgpkgppvtvlp,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
842,NaN,NaN,UPX75738,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgrneyyadsvkgrftisrdnskntlylqmnslraedtavyycarenswelgryfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
843,NaN,NaN,UPX75737,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslraedtavyycardygdfyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
844,NaN,NaN,UPX75736,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssyamswvrqapgqglewvsgisasggstyyadsvkgrftisrdnskntlylqmnglraedtavyycakdgggflgywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
845,NaN,NaN,UPX75735,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyycardlgpsggfdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
846,NaN,NaN,UPX75734,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvsggaissggyywswirqhpgkglewigniyysgssyynpslksrvsisvdtsknqfslrlssvtaadtavyycaservviikslnygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
847,NaN,NaN,UPX75733,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisysgsstyyadsvkgrftisrdnskntlylqmnslraedtavyycangavagidwyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
848,NaN,NaN,UPX75732,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavilydgnsqyyadsvkgrftisrddskntlylqmnrlraedtavyycatfydyydsstwnddafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
849,NaN,NaN,UPX75731,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsgyamhwvrqapgrglewvavisfdgnnkyyadsvkgrftisrdnskntlylqvislraedtavyycardrsgsylgafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
850,NaN,NaN,UPX75730,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvkpggslrlscvasgfifstynmnwvrqapgkglewvssisssssfiyyadsvkgrftisrdnaknslylqmnslraedtalyycarrrsdprflewhevsgadywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
851,NaN,NaN,UPX75729,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvklsckasgytftyyamhwvrqvpgqrlewmgwinagngntkyspkfqgrvtiardpsastaymgltslrsedtavyycatsrgtyddafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
852,NaN,NaN,UPX75728,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvklkesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaktsfglavagnwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
853,NaN,NaN,UPX75727,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrltcaasgftfsrygmhwvrqapgkglewvaaisyderikehvdsvqgrfsisrdnskytlslqmnnlrpedtavfycvrgstgyghthdnyfgldvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
854,NaN,NaN,UPX75726,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsggglvqpgrslrlscaasgftfgdfamhwvrqvpgkglewvsgiswnsgsigygdsvkgrftisrdnaknslylqmnslraedtalyycakdwgpqykgellrwldpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
855,NaN,NaN,UPX75725,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpglvkpsqtlsltctvsggsissgfyywswirqhpgkglewigyihysgstcynpslksrvtisvdtsknqfslklssvtaadtavyycarghydiltglgyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
856,NaN,NaN,UPX75724,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarevkglewlfregyyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
857,NaN,NaN,UPX75723,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvsggsissgdyywiwirqppgkglewigniyysgstyynpslesrvtisgdtsknqfslkltsvtaadtavyycarekggmvrgaaiplfgmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
858,NaN,NaN,UPX75722,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsnfwmtwvrqapgkglewvaninqdgsdkyyvdsvkgrftisrdnaknslylqmnslraedtavyycarglrearvavvippdgfdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
859,NaN,NaN,UPX75721,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvkpggslrvscaasgftfsnawmswvrqapgkglewvgriqsetdggttdyaapvkgrfaisrddskntlflqmnslktedtavyscttdagdsygynyyieywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
860,NaN,NaN,UPX75720,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakwagvgslevyavyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
861,NaN,NaN,UPX75719,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgftfsnyemnwvrqapgkglewvsyisgsgsmksyadsakgrftisrdnaknslflqmsglraedtalyycarggnprwellyepfafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
862,NaN,NaN,UPX75718,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggsrrlscaasgfifssyvmswvrqapgkglewvsdisgsgdityyadsvkgrftisrdnskntlylqmnslraedtavyycakdlgklttvvtpefdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
863,NaN,NaN,UPX75717,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgdevkkpgasvkvsckasgytftshgiswvrqapgqglewmgwistyngntnyaqkfqgrvtmttdtststvymevrslksddtavfycarlggelwfgelrepyfdmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
864,NaN,NaN,UPX75716,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggwvqpggslrlscavsgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnakkslylqmnslraedtamyycarlagdywyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
865,NaN,NaN,UPX75715,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgvtvssnymtwvrqapgkglewvsviypggstfyadsvkgrftisrdnsknmlylqmnslraedtavfycardlndygamdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
866,NaN,NaN,UPX75714,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvrpggslrlscaasgftfsdyymswirqapgkglewvshisrsgstiyyadsvkgritisrdnaknsvylqmnslraedtamyycardrsgydpfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
867,NaN,NaN,UPX75713,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsnynmnwvrqapgkglewvscisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardsgalgwlqnyamdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
868,NaN,NaN,UPX75712,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgfsfssyamnwvrqapgkglewvaaishdgsnkyyadsvkgrvtisrdnskntlylqmnslraedtavyycargspydylvsglfggvnyyhytmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
869,NaN,NaN,UPX75711,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggmvqpgrslrlscaasgftfntyamnwvrqapgkglewmaivsfdgnnkyyadsvrgrftisrdnskntlylqmnslrgedtgvyycardgprasgatyyyfnmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
870,NaN,NaN,UPX75710,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgasvkvsckasdytftsygiswvrqapgqglewmgwisayngntnyaqkfqgrvtmttdtststaymelrslrsddtamyycardrglsdfdwlpkwvyyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
871,NaN,NaN,UPX75709,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewasgisangdgtyyaesvkgrftisrdnskntlylemnslraedtavyycakslgsgsyyfpvfdwyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
872,NaN,NaN,UPX75708,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardrglsdfdwlpkwayyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
873,NaN,NaN,UPX75707,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsggglvkpgrslrlscaasgftfsnawmtwvrqapgkglewvgriktkteggtidygapvkgrftisrddskntlylqmnslktedtavyycttsstpdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
874,NaN,NaN,UPX75706,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyainwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaflqisslkaedtavyycarehatgtpmwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
875,NaN,NaN,UPX75705,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgnsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhpvsfarggffgvddyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
876,NaN,NaN,UPX75704,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggdlvqpggslrlscagsgftfssygmswvrqapgkglewvstisgsggstyyadsvkgrftisrdnsknmlflqmnslrgddtaayycakdgdrggsvdfwsviraaaehfqhwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
877,NaN,NaN,UPX75703,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgpalvkptqtltltctfsgfslktsgmcvswirqppgkalewlaridwdddkyystslqtrltiskdtsknqvvltmtnmdpvdtatcycarytpattfdywgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
878,NaN,NaN,UPX75702,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavilydgtnkhyadsvkgrftisrdnskdtlylqmnslraedtavyycatfydyydsstwnddafdfwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
879,NaN,NaN,UPX75701,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvklvqsggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdryypgsvkgrftisrenaknslylqmnslragdtavyycargtvttqgyyyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
880,NaN,NaN,UPX75700,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsirsyywswirqypgkglewigyinytgstnynpslksrvtisvdtsknqfslklssvtaadtavfycalgfgeywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
881,NaN,NaN,UPX75699,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgltfssysmnwvrqapgkglewvsyistssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycaslgaadtlyyyygmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
882,NaN,NaN,UPX75698,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavilydgsstyyvdsvkgrftisrdnskntmylqmnslraedtavyycakgggpycsggscytsyfdywgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
883,NaN,NaN,UPX75697,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggdlvqpggslrlscgasgftfrnywmhwvrqtpgkgpewvsrinddgtvtnyadsvqgrftisrdnsentlhlqmhslraedtalyycargradsappffdkwghgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
884,NaN,NaN,UPX75696,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgggvvqpgrslrlscaaseftfssygmhwvrqapgrglewvafiwfdgnkkyyadslkgrftisrdnskntlylqmnslraedtavyycardaisaiggafdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
885,NaN,NaN,UPX75695,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgaevkktgssvkvsckasggtfssyalswvrqapgqglewmggiipilgaenyaqkfqgrvtitadkststvymelsslrsedtavyycargaerwsqfqllywyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
886,NaN,NaN,UPX75694,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyldfsgstfhnpslksrvsisvdtsknqfslklssvtagdtavyycardrissastinyhyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
887,NaN,NaN,UPX75693,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssyaihwvrqapgkglkwvavisydgdkkyyadsvkgrftisrdnskntlylqmnslrandtavyycarsysggysaafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
888,NaN,NaN,UPX75692,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgasvkvscrasgytfthhhihwvrqapgqglewmgwinpnsgatnyaqmfqgrvtmtrdtsistaymevsrlrsddtavyycarvsgdsyyisgwykyfyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
889,NaN,NaN,UPX75691,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakfsfgycsttkcyqsgwldywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
890,NaN,NaN,UPX75690,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcgvyggsfsgfywswirqppgkglewigevnhsgstnynpslkgrvtisvdtsknqfslklssvtaadtavyycargsfakgivvvpptqswaydywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
891,NaN,NaN,UPX75689,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsgyamhwvrqapgrglewvavisfdgnnkyyadsvkgrftisrdnskntlylqvislraedtavyycardrsgsylgafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
892,NaN,NaN,UPX75688,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggglvqpgrslrlscaasgftfgdyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakvrdnvyffdsssfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
893,NaN,NaN,UPX75687,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfsgyaihwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlfllmnslraedtavyycarggggygeafdswgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
894,NaN,NaN,UPX75686,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggsrrlscaasgfifssyvmswvrqapgkglewvsdisgsgdityyadsvkgrftisrdnskntlylqmnslraedtavyycakdlgklttvvtpefdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
895,NaN,NaN,UPX75685,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqinslraddtavyycvrvyggnyfggmdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
896,NaN,NaN,UPX75684,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitedeststvymelsslrsedtavyycarvpsiaeagtevwgqgslvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
897,NaN,NaN,UPX75683,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytkyspsfqghvtisadksistaylqwsslkasdtamyycarqfagglldwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
898,NaN,NaN,UPX75682,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmywvrqapgkglewvavisydgshkyyadsvkgrftisrdnskntlylqmnslrgedtavyycakskgggyfyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
899,NaN,NaN,UPX75681,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftftsyglhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntvylqmnslraedtavyycakahgggyyylhfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
900,NaN,NaN,UPX75680,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsggsisryswswirqppgkglewighiynsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarrgastyyydssgqpyyyyamdvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
901,NaN,NaN,UPX75679,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscsasgftfssfamhwvrqvpgkglewvavisydgsnkyyadsvkgrftisrdnskntlflqmnnlraedtavyycarprggsyygafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
902,NaN,NaN,UPX75678,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkassytteyaasvkgrftisrddsknslylqmnslktedtavyycarsgllwfgershldwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
903,NaN,NaN,UPX75677,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgggvvqpgrslrlscaasgfafssyamhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpysgsyrswfdpwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
904,NaN,NaN,UPX75676,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlkesggglvqpgrslrlscaasgftfgdyamhwvrqapgkglewvsgitwnsgtigyadsvkgrftisrdnaknslylqmnslraedtalyycasyygsgsyynllgndafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
905,NaN,NaN,UPX75675,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgtsvkvsckasgytftnyfihwvrqapgqglewmgiinasggstsyalkfqgrvtmtrdtststlymelsslrsedtaiyycaisgwargafdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
906,NaN,NaN,UPX75674,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsirsggyywswirqhpgkglewigysyysgstyynpslksrvtisvdtsknqfslklnsvtaadtavyycarcimgatwwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
907,NaN,NaN,UPX75673,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpggslrlscaasgvtfsqshmhwvrqapgkglewvagisddgnskyyidsvkdrftvsrdntqdtlylqlnglglddmavyycareagssgraaffdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
908,NaN,NaN,UPX75672,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgaemkkpgeslrisckgsgysftsywiswvrqmagkglewmgtidpsdsytnyspsfqghvtmsadksistaylqwrslkasdtaiyycarhwriyctggsclnwfdpwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
909,NaN,NaN,UPX75671,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycartysgsyfsyfdywgqgspvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
910,NaN,NaN,UPX75670,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftlssfwmhwvrqapgkglvwvshinrdgtitsyadsvkgrftisrdnakntlylqmnslraedtavyycaredwtrattptldywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
911,NaN,NaN,UPX75669,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsgdsissggyywswirqhpgkglewigyiyysgntyynpslksrltisvdtsknqfslklssvtaadtavyycarvttmirgvtpifdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
912,NaN,NaN,UPX75668,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssyamhwvrqapgkgpewvalisydgsnkyyadsvkgrftisrdnskntvylqmnslraedtavyycasahsgtyfdafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
913,NaN,NaN,UPX75667,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfgsyaiswvrqapgqglewmggiipifdttnyaqrfqgrltitadeststaymelsslksddtaiyycagimgwfgernnfysygldvwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
914,NaN,NaN,UPX75666,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkrpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtretsistaymelrrlksddtavyycarfegytygllwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
915,NaN,NaN,UPX75665,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftfstfgmhwvrqapgkglewvavisydgsnkyytdsvkgrftisrdnskntlylqmnslraedtavyycakdktivvvpaatpdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
916,NaN,NaN,UPX75664,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwistyngntkyaqkfqgrvtmttdtststaymelrslrsddtavyscargnpwglwfgelynegyfdlwgrgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
917,NaN,NaN,UPX75663,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsettyspsfqgqvtisadksistaylhwsslkaadtamyycagrdaynsyafdiwgqgtmvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
918,NaN,NaN,UPX75662,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfsfssdwmhwvrqapgkglvwvsrihsdgsstsyadsvkgrftisrdnakntlylqmnslraedtavyycarsgwlrgafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
919,NaN,NaN,UPX75661,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggavvqpgrslrlscaasgftfssfamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycaraaggnyyymdvwgkgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
920,NaN,NaN,UPX75660,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylemnslrvedtavyycardygdfyfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
921,NaN,NaN,UPX75659,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgskkyyvdsvkgrftvsrdnskntlylqmnslrpedtavyycareeqwpknaldvwgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
922,NaN,NaN,UPX75658,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgpglvkpsetlsltctvsggsistspyfwgwirqppgkglewigsvsysgntyynpslksrvtisvdtsknhfslklssvtaadtavyycargvrsgfynggsrfdywgqgtlvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
923,NaN,NaN,UPX75657,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgggvvqpgrslrlscaasgftfsgyamhwvrqapgrglewvavisfdgnnkyyadsvkgrftisrdnskntlylqvislraedtavyycardrsgsylgafdiwgqgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
924,NaN,NaN,UPX75656,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdiskntvylqmnslraedtavyycvkalatygyyyymdvwgkgttvtvss,NaN,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
925,NaN,NaN,NaN,UPX76475,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppslsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltitgvqaedeadyfcqsaastgtlvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
926,NaN,NaN,NaN,UPX76474,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvgssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
927,NaN,NaN,NaN,UPX76473,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspsslsasvgdrvtitcrasqsittylnwyqqkpgkapqlliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyychqsystpltfgpgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
928,NaN,NaN,NaN,UPX76472,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycfstdssgnppfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
929,NaN,NaN,NaN,UPX76471,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspdslavslgeratinckssqsvlyssnnrnylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
930,NaN,NaN,NaN,UPX76470,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnignkgvhwyqqrpgqapvlvvyddsarpsgiperfsgsnsgntatltisrveagdeadyycqvcdsgtdhvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
931,NaN,NaN,NaN,UPX76469,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdtkrpsgiperysgsnsgntatltisgtqamdeadyycqawdsshvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
932,NaN,NaN,NaN,UPX76468,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspstlsasvgdrvtitcrasqristwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqhynsfvafgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
933,NaN,NaN,NaN,UPX76467,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspstlsasvgdrvtitcrasqristwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqhynsfvafgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
934,NaN,NaN,NaN,UPX76466,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqsplslpvtpgepasiscrssqsllhrngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprltfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
935,NaN,NaN,NaN,UPX76465,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspssvsasvgdrvtitcrasqgigswlawyqqkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfptfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
936,NaN,NaN,NaN,UPX76464,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlsmspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgggsgteftltisslqsedfavyycqqynnwpsitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
937,NaN,NaN,NaN,UPX76463,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpatlsmspgeratlscrasqsissnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpsitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
938,NaN,NaN,NaN,UPX76462,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassraigipdrfsgsgsgtdftltisrlepedfavyycqhysssplmytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
939,NaN,NaN,NaN,UPX76461,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlynpnnkkylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysapftfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
940,NaN,NaN,NaN,UPX76460,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspstlsasvgdrvtitcrasqsistwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsywtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
941,NaN,NaN,NaN,UPX76459,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqprsvsgspgqsvtisctgtssavggytyvswyqqypgkapkvmiydvnkgpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
942,NaN,NaN,NaN,UPX76458,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgseteftltisslqsedcalyycqqynnwppvytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
943,NaN,NaN,NaN,UPX76457,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspsslsasvgdrvtitcrasqrissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysmppwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
944,NaN,NaN,NaN,UPX76456,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syelmqppsvsvspgqtasitcsgdklgdkyvcwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
945,NaN,NaN,NaN,UPX76455,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrasqrigssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydsspwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
946,NaN,NaN,NaN,UPX76454,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslengvpsrfsgsgsgteftltisslqpddfatyycqqyksywtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
947,NaN,NaN,NaN,UPX76453,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqarqlwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
948,NaN,NaN,NaN,UPX76452,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqgvssylawyqqkrgqaprlliydassraigipdrfsgsgsgtdftltisrlepedfavyycqqsaispwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
949,NaN,NaN,NaN,UPX76451,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,etaitqspgtlslspgerttlscrasqsvsniylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
950,NaN,NaN,NaN,UPX76450,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvspgqtasitcsgdklgdkyaswyqqkpgqspvlviyqdakrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
951,NaN,NaN,NaN,UPX76449,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvssrylawyqqkpgqaprlliygasrratgisdrfsasgsgtdftltisrlepedfavyycqqygssqntfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
952,NaN,NaN,NaN,UPX76448,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspdtlslspgeratlscrasqsvgssylawyqqkpgqaprlliygassraigipdrfsgsgsgtdftltisrlepedfavyycqqygsslswtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
953,NaN,NaN,NaN,UPX76447,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrfnwpptfgqgtrveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
954,NaN,NaN,NaN,UPX76446,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqspsvsvapgqtaritcggnsigsksvnwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhnvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
955,NaN,NaN,NaN,UPX76445,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslyasvgdrvtitcqasqdisnllnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpedigtyycqrydhlptfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
956,NaN,NaN,NaN,UPX76444,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsgsnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydadlssvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
957,NaN,NaN,NaN,UPX76443,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfaiyycqqrntfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
958,NaN,NaN,NaN,UPX76442,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
959,NaN,NaN,NaN,UPX76441,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,vlsatqnsatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygsstratgiparfsgsgsgaeftltisslqsedfavyycqqytlgytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
960,NaN,NaN,NaN,UPX76440,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspvtlsvspgeratlscrasqtvssnlawyqqkpgqaprlliygaftratgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
961,NaN,NaN,NaN,UPX76439,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspsslsasvgdrvtitcrasqrissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysmppwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
962,NaN,NaN,NaN,UPX76438,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sheliqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgipervsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
963,NaN,NaN,NaN,UPX76437,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspsslsasvgdtvtitcrasqsittylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisglqpedfasyycqhtyntpctfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
964,NaN,NaN,NaN,UPX76436,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvspgqtaritcsgdalprkyaswyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssakgvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
965,NaN,NaN,NaN,UPX76435,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftlttsrlepedfavyycqqygsltltfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
966,NaN,NaN,NaN,UPX76434,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dialtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastrataiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
967,NaN,NaN,NaN,UPX76433,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapkvmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssykrssilvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
968,NaN,NaN,NaN,UPX76432,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsvsksgtsaslaisglrsedeadyycatwddslsgpgvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
969,NaN,NaN,NaN,UPX76431,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspsslsasigdrvtitcrasqginnylawyqqkpgkvpkvlisaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsapftfgpgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
970,NaN,NaN,NaN,UPX76430,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qhvltqppsvsvapgktaritcagnnigsksvhwyqqkpgqapvlviyfdsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
971,NaN,NaN,NaN,UPX76429,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqtpsslsasigdrvtitcrasqginnylawyqqkpgkvpkvlisaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsapftfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
972,NaN,NaN,NaN,UPX76428,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
973,NaN,NaN,NaN,UPX76427,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysvtfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
974,NaN,NaN,NaN,UPX76426,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspatlsvspgeratlscrasqsfgnnlawyqqkpgqaprlliygastratgiparfigsgsgteftliisslqsedfavyycqqynnwpftfgpgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
975,NaN,NaN,NaN,UPX76425,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvliqpasvsgspgqsitisctgtssdvagynyvswyqqypgkapklmiydvssrpsgisnrfsgsksgntasltisglqaedeadyycssytssrtlvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
976,NaN,NaN,NaN,UPX76424,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspssvsasvgdrvtitcrasqgissswlawyqqkpgkapklliyaasslqngvpsrfsgsgsgtdftltisslqpedfatyycqqanslpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
977,NaN,NaN,NaN,UPX76423,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,giqvtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasnlksgvpsrfsgsgsgteftltisslqpddfatyhcqqysgyswtfsqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
978,NaN,NaN,NaN,UPX76422,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
979,NaN,NaN,NaN,UPX76421,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eiqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysqtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
980,NaN,NaN,NaN,UPX76420,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysstplytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
981,NaN,NaN,NaN,UPX76419,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eialtqspatlslspgeratlscrasqsvsrylawyqqkpgqaprlliydastratgiparfsgsgsgtdftltisslepedfavyycqqrsnwrgftfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
982,NaN,NaN,NaN,UPX76418,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapelmiyeankrpsgisnrfsgsksgntasltisglqaedeadyyccsyagsstlvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
983,NaN,NaN,NaN,UPX76417,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvapgqtaritcggnnigsksvhwyhqkagqapvlvvyedadrpsgiperfsgsnsgntatltisrvevgdeadyycqvwdgsgdhpswvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
984,NaN,NaN,NaN,UPX76416,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspsslsasigdrvtitcrasqgissalawyqqkpgkppklliydasslesgvpsrfsgsgsgtdftltisslqpddfatyycqqfisyppytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
985,NaN,NaN,NaN,UPX76415,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssftfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
986,NaN,NaN,NaN,UPX76414,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqsplslpvtlgqpasiscrssqglvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgthwpwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
987,NaN,NaN,NaN,UPX76413,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysstplytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
988,NaN,NaN,NaN,UPX76412,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,emtmtqspgtlslspgeratlscrasqsvssnylawfqqkpgqaprlliyaassraigipdrfsgsgsgtdfalsisrvepedfavyycqqygsspwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
989,NaN,NaN,NaN,UPX76411,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspdslavslgeratinckssqsvlhrsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyfcqqcyssptfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
990,NaN,NaN,NaN,UPX76410,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawfqqkpgqaprlliyaassrvigipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
991,NaN,NaN,NaN,UPX76409,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspsslsasvgdrvtitcrasqginnylawyqqkpgkvpkvliyaasslqsgvpsrfsgsgsgtdftltisslqpedvatyfcqkynsapftfgpgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
992,NaN,NaN,NaN,UPX76408,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslsasvgdrvtitcrasqginnylawyqqkpgkvpkvliyaasslqsgvpsrfsgsgsgtdftltisslqpedvatyfcqkynsapftfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
993,NaN,NaN,NaN,UPX76407,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpgliqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvshrfsgsksgntasltisglqtedeadfycssyrtsstvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
994,NaN,NaN,NaN,UPX76406,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspgtlslspgeratlscrtsqsvssnslawyqqkpgqaprlllygaftratgipdrfsgsgsgtdftltisrleaedfavyychkygsyprtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
995,NaN,NaN,NaN,UPX76405,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslsasvgdrviitcrasqsintylnwyqhkprkapnlliygasslqsgvpsrfsgsgsrtdftltisnlqpedfatyycqqsystpptfgqgtkvrsn,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
996,NaN,NaN,NaN,UPX76404,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsylgtfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
997,NaN,NaN,NaN,UPX76403,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qheliqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltinrveagdeadyycqvwdsnrdrhyvfgtgtqvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
998,NaN,NaN,NaN,UPX76402,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslrtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
999,NaN,NaN,NaN,UPX76401,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsintflnwyqqkpgkapklliyaastlqigvpsrfsgsgsgtdftltitslqpedfatyfcqqsysslpitlgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1000,NaN,NaN,NaN,UPX76400,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqsptslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggfgtdftftisslqpediatyfcqqydnfpitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1001,NaN,NaN,NaN,UPX76399,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspsvsaapgqkvtiscsgsssnigtnyvswyqdlpgtapkliiyendkrpsgipdrfsgsksgtsatlgitglqtgdeadyycltwdtslrggvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1002,NaN,NaN,NaN,UPX76398,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1003,NaN,NaN,NaN,UPX76397,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvvvvyndsdrpsgiperfsgsnsgntatltisrvedgdeadyycqvwdsssdhvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1004,NaN,NaN,NaN,UPX76396,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvliqprsvsgspgqsvtisctgtssdigtynsvswyqqhpgkapkvliydvnkrpsgvpdrfsgsksgytasltisglqaedeadysccsyapgytfvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1005,NaN,NaN,NaN,UPX76395,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqlpsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqspdssgtyvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1006,NaN,NaN,NaN,UPX76394,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlaiykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgthvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1007,NaN,NaN,NaN,UPX76393,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedftvyycqqrsnwpgtfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1008,NaN,NaN,NaN,UPX76392,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqsplslsvtleepasiscrssqsllysdgntylhwfhqrpgqsprrliyqvsnresgvpdrfsgsgsdtdftlkisrveaedvgiyycmqdrewpwsfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1009,NaN,NaN,NaN,UPX76391,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eirmtqsptslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggfgtdftftisslqpediatyfcqqydnfpitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1010,NaN,NaN,NaN,UPX76390,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspatlslspgeratlscrasqtvynylawyqqkpgqaprlliydasnratgiptrfsgsgsgtdftltisslepedfavyycqhrsvwpprftfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1011,NaN,NaN,NaN,UPX76389,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspatlslspgeratlscrasqsvssylawyqqrpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpssytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1012,NaN,NaN,NaN,UPX76388,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqatqfpvtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1013,NaN,NaN,NaN,UPX76387,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeliqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqtpvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtshlifgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1014,NaN,NaN,NaN,UPX76386,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmifevskwpsgisnrfsgsksgntasltisglqaedeahyycfsyagsstwvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1015,NaN,NaN,NaN,UPX76385,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,snvltqspsvsvspgqtaritcsgdalpkqyvfwyqqksgrapvlvmykdtkrpsgiperfsgsssgtivtltisgvqaddeadyycqsvdtslawvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1016,NaN,NaN,NaN,UPX76384,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvliqppsasgtpgqrvtiscfgsssnmgsntvkwyqqlpgtapklliysnnqrpsgvpdrfsgskygtsaslaisgfqsedeadyycaawddsmngpvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1017,NaN,NaN,NaN,UPX76383,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspsflsasvgdrvtitcrasqgissylawyqqtpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnssprtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1018,NaN,NaN,NaN,UPX76382,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1019,NaN,NaN,NaN,UPX76381,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsasgtpgqrvaiscsgsdsniesntvnwyqelpggaptlliysdnqrpsgvpdrfsgsksgtsaslaiiglqsedeadyycaawddslngyvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1020,NaN,NaN,NaN,UPX76380,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1021,NaN,NaN,NaN,UPX76379,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspsflsasvgdsvtitcrasqgiysylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyphfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1022,NaN,NaN,NaN,UPX76378,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgqratlscrasqsvsssflawyqqkpgqaprlliygasiratgipdsftgsgsgtdftltisrlepedfalyycqqygdspytfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1023,NaN,NaN,NaN,UPX76377,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslsasagdrvtitcrasrrissylnwyqqtpgkaprllvsaastlesgvpsrfsgsgfgtdftltisslqpedfatyycqqsystpptfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1024,NaN,NaN,NaN,UPX76376,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklliydvskrpsgvpdrfsgsksgntasltisglqaedeadyycssyagvyfrvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1025,NaN,NaN,NaN,UPX76375,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1026,NaN,NaN,NaN,UPX76374,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvavapgqtaritcggtnigsksvhwyqqkpgqapvvvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdgssdcvifgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1027,NaN,NaN,NaN,UPX76373,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqtpstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyltfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1028,NaN,NaN,NaN,UPX76372,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkvpklmiygvdkrpsgvsdrfsgsksgntasltisglqtedeadyyccsyagsstfvvfgggtqltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1029,NaN,NaN,NaN,UPX76371,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvliiyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdnsgnlgevfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1030,NaN,NaN,NaN,UPX76370,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1031,NaN,NaN,NaN,UPX76369,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasagdrvtitcrasrrissylnwyqqtpgkaprllvsaastlesgvpsrfsgsgfgtdftltisslqpedfatyycqqsystpptfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1032,NaN,NaN,NaN,UPX76368,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspatlsvspgeratlscrasqsvssnlawyqqkpgqpprlliygasaratgiparfsgsgsgteftltisslqyedfavyycqqynnwprtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1033,NaN,NaN,NaN,UPX76367,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1034,NaN,NaN,NaN,UPX76366,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpqtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1035,NaN,NaN,NaN,UPX76365,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvgrykyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytttstlvfgrgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1036,NaN,NaN,NaN,UPX76364,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1037,NaN,NaN,NaN,UPX76363,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqtissylnwfqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpytfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1038,NaN,NaN,NaN,UPX76362,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisslqpediatyycqkydnfpltfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1039,NaN,NaN,NaN,UPX76361,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvseaprqrvtiscsgsssnignnavnwyqqlpgkapklltyydhllpsgvsdrfsgsksgtsaslaisglqsedeadyycaawddsligvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1040,NaN,NaN,NaN,UPX76360,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsasgtpgqrvtiscsgsssnigsnivnwyqqipgtapklliysndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1041,NaN,NaN,NaN,UPX76359,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvssdylawyqqkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1042,NaN,NaN,NaN,UPX76358,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sheltqppsasvapgqtariscggnnigrknvhwhqqkpgqapvlvvygdsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssehvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1043,NaN,NaN,NaN,UPX76357,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksdtsatlgitglqtgdeadyycgtwdsslsagkvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1044,NaN,NaN,NaN,UPX76356,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1045,NaN,NaN,NaN,UPX76355,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1046,NaN,NaN,NaN,UPX76354,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslpasvgdrvtitcqasqdiynylnwyhqkpgkapklliydasnletgvpsrfsgggsgtdftftisslqpediatyycqqyrslpftfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1047,NaN,NaN,NaN,UPX76353,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsasgtpgqrvtvsrsgsssnigdntvnwyqqlpgtapkllicsndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1048,NaN,NaN,NaN,UPX76352,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qhvltqppsvsvapgqtaritcggsnigsksmhwyqqkpgqapvlvvyddrdrpsgiperfsgsnsgntatltisrveagdeadyycqlwdsgsehvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1049,NaN,NaN,NaN,UPX76351,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvspgqtasitcsgdklgdkyacwyhqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdssadvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1050,NaN,NaN,NaN,UPX76350,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrviitcrasqsintylnwyqhkprkapnlliygasslqsgvpsrfsgsgsrtdftltisnlqpedfatyycqqsystpptfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1051,NaN,NaN,NaN,UPX76349,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeliqppsvsvapgqtaritcggnnigskrvhwyqqmpgqapvllvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdlyvvfgggtqltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1052,NaN,NaN,NaN,UPX76348,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygtstratgiptrfsgsgsgteftltisslqsedfavyycqhynnwppaytfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1053,NaN,NaN,NaN,UPX76347,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvspgqtaritcsgdafpnqyaywyqqkpgqapvlvifkdterpsgiperfsgsslgttvtltisgvqaedeadyycqsadssgtvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1054,NaN,NaN,NaN,UPX76346,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgaisnvgsynlvswyqqhpgkapqvmiyeaikrpsgvsnrfsgsksgntasltisglqaedeadyycysyagtstwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1055,NaN,NaN,NaN,UPX76345,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydastlesgvpsrftgsgsgteftltisslqpddfasyycqqynsywtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1056,NaN,NaN,NaN,UPX76344,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsasgtpgqrvtiscsgsnsnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgpwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1057,NaN,NaN,NaN,UPX76343,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dialtqspsslsasvgdrvtitcrasqsittylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttprtfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1058,NaN,NaN,NaN,UPX76342,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyhsysfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1059,NaN,NaN,NaN,UPX76341,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtvscfgsssnigehyvywyqllpgtapkvliyydnrrpsgvpdrfpgsksgtsaslaisglrsedeadyycaawddrlsayvfatgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1060,NaN,NaN,NaN,UPX76340,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqydsysftfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1061,NaN,NaN,NaN,UPX76339,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasnlksgvpsrfsgsgsgteftltisslqpddfatyhcqqysgyswtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1062,NaN,NaN,NaN,UPX76338,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcrasqsisrylnwyqqkagkapklliyaasslqsgvpsrfsgsgsgtdftltisslrpedfatyycqqsystaeytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1063,NaN,NaN,NaN,UPX76337,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyscqawdssthvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1064,NaN,NaN,NaN,UPX76336,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysgtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1065,NaN,NaN,NaN,UPX76335,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsflsasvgdrvtitcrasqgissylawyqqkpgrapnllisaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1066,NaN,NaN,NaN,UPX76334,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsdrfsgsksgntasltisglqaedeadyycssftsistvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1067,NaN,NaN,NaN,UPX76333,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpsslsasvgdrvtitcrasqsissflnwykhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyrtpltfaggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1068,NaN,NaN,NaN,UPX76332,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspstlsasvgdrvtitcrasqnigswlawyqqkpgkapklliydasnlesgvpvrfsgsgsgtefsltisslqpddfatyycqqyssyrtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1069,NaN,NaN,NaN,UPX76331,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqvdilpitfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1070,NaN,NaN,NaN,UPX76330,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspstlsasvgdrvtitcrasqnigswlawyqqkpgkapklliydasnlesgvplrfsgsgsgtefsltisslqpddfatyycqqyssyrtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1071,NaN,NaN,NaN,UPX76329,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsdsytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1072,NaN,NaN,NaN,UPX76328,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyhcaawdgslggwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1073,NaN,NaN,NaN,UPX76327,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcqasqdishylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedlatyycqqydnllwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1074,NaN,NaN,NaN,UPX76326,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dipltqspatlslspgeratlscrasqgvssylawyqqkagqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqsrrgkitfgqgtrveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1075,NaN,NaN,NaN,UPX76325,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkppklliydasyletgvpsrfsgsgseteftltisslqpddfatyycqqynsysgtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1076,NaN,NaN,NaN,UPX76324,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkppklliydasyletgvpsrfsgsgseteftltisslqpddfatyycqqynsysgtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1077,NaN,NaN,NaN,UPX76323,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgervtlscrasqsvasklawyqhrpgqpprlliygastratgiparfsgsgsgtdfaltisslqsgdfalyycqqynawprlltfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1078,NaN,NaN,NaN,UPX76322,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,emtltqspvtlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsateftltisslqsedfavyycqqynkwprtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1079,NaN,NaN,NaN,UPX76321,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevrnrpsgisnrfsasksantasltisglraedeadyycssyttssivvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1080,NaN,NaN,NaN,UPX76320,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspstlsasvgdrvtitcrasqsisswlawyqqkagkapkfliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntypwtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1081,NaN,NaN,NaN,UPX76319,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdtkrpsgiperysgsnsgntatltisgtqamdeadyycqawdsshvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1082,NaN,NaN,NaN,UPX76318,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpsslsastgdrvtitcrasqgigsyvawyqqksgnapkvliyaastlqsgvpsrfsgsgsgtdftltisclqsedfatyycqqyynyprtfghgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1083,NaN,NaN,NaN,UPX76317,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyhsysfgpgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1084,NaN,NaN,NaN,UPX76316,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspdslavslgeratinckssqsvlyssnnknyltwyqqkpgqppklliywastresgvpdrfrgsgsgtdftltisslqaedvavyycqqyysipwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1085,NaN,NaN,NaN,UPX76315,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dipltqspsslsasvgdrvtitcrasqsiniylnwyqqkagkapklliyhasslesglpsrfsgsgsgtdftltisslqaedfatyycqqsystpvtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1086,NaN,NaN,NaN,UPX76314,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsistslnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpsfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1087,NaN,NaN,NaN,UPX76313,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpptfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1088,NaN,NaN,NaN,UPX76312,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydassletgvpsrfsgsgsgtaftltisslqpddfatyycqqynsysytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1089,NaN,NaN,NaN,UPX76311,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslrpedfasyycqhlnsypftfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1090,NaN,NaN,NaN,UPX76310,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyhsysfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1091,NaN,NaN,NaN,UPX76309,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasnlksgvpsrfsgsgsgteftltisslqpddfatyhcqqysgyswtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1092,NaN,NaN,NaN,UPX76308,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,kpvltqppsvsvspgqtaritcsgdalpkeyvywyqqkpgqapvlvinkdserpsgiperfsgfslgttvtltisgvqagdeadyycqsadsrgnyvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1093,NaN,NaN,NaN,UPX76307,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgygteftltisslqsedfavyycqqynnwppltfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1094,NaN,NaN,NaN,UPX76306,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpgltqppsasgtpgqrvtiscsgsssnigrnyvswyqqfpqtapkpliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedesdyycatwddslsgwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1095,NaN,NaN,NaN,UPX76305,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyednkrpsgiperfsgsssgtmatltisgaqvedegdyyccstdssgnlfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1096,NaN,NaN,NaN,UPX76304,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,emtvtqspsslsayvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqtgvpsrfsgsgsgtdftltisslqpedfaayycqqsysipwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1097,NaN,NaN,NaN,UPX76303,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,speltqppsvsvspgqtaritcsgdalpkkyaywylqksgqapvlviyddnkrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrvfgtgtqltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1098,NaN,NaN,NaN,UPX76302,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgdtatlscrasqsvrssylawyqqkpgqaprlliygafsrasgiparfsgggsgtdftltisrlepadfavyychqygsspwtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1099,NaN,NaN,NaN,UPX76301,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvppgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycsstdssgnhvifgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1100,NaN,NaN,NaN,UPX76300,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqsppsfsasrgdrvtitcrasqgissnlawyqqkpgqapkllihaastlqsgvpsrfsgsgsgtdftltissvqsedfatyycqqyyiyqytfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1101,NaN,NaN,NaN,UPX76299,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sseltqpasvsgslgqsitisctgtrsdvggynyvswyqqhpgkapklmiydvsnrpsevsdrfsgsksantasltisglqaedeadyycssytsistwvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1102,NaN,NaN,NaN,UPX76298,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspdslavslgeratisckssqsilyssnnknylawyqqnpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysswtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1103,NaN,NaN,NaN,UPX76297,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sasadsapsasgtpgqrvtvscfgsssnigehyvywyqllpgtapkvliyydnrrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddrlsayvfatgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1104,NaN,NaN,NaN,UPX76296,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqtpsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedvatyycqqsysmpeitfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1105,NaN,NaN,NaN,UPX76295,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspsslsasvgdrvtitcrasqsigsyltwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltinnlqpedfatyycqqsystpltfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1106,NaN,NaN,NaN,UPX76294,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsasaslgasvkltctlssghnsyaiawhqqqpekgprylmkvnsdgshskgdgipdrfsgsssgaeryltisslqsedeavyycqtwgtgivgvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1107,NaN,NaN,NaN,UPX76293,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsarpsgiperfsgsnsgntatltisrveagdeagyycqvwgsssahwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1108,NaN,NaN,NaN,UPX76292,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspsllsastgdrvtiscrlsqgissylawyqqkpgkapelliyaastlqsgvpsrfsgsgsgtdftltisclqsedfatyycqqyysfpwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1109,NaN,NaN,NaN,UPX76291,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliydntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydgslsgsgevfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1110,NaN,NaN,NaN,UPX76290,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspsslsasvgdrviitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyyclqdynypwtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1111,NaN,NaN,NaN,UPX76289,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlsctasqsltnnlawyqqkpgqaprlliygastratgvparfsgsgsgteftltisslqsadfavyycqqyhywpltlgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1112,NaN,NaN,NaN,UPX76288,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqsplslpvtpgepasiscrssqslldsddgntyldwylqkpgqspqlliytvsyrasgvpdrfsgsgsgtdfklkisrveaedvgvyyciqrkefpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1113,NaN,NaN,NaN,UPX76287,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qhvltqppsvsvspgqtaritcsgdalpkkyaywylqksgqapvlviyddnkrppgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrvfgtgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1114,NaN,NaN,NaN,UPX76286,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqgvssgylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisslepedfavyycqqygssrwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1115,NaN,NaN,NaN,UPX76285,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnsllwyqqkpgnvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqrynsapltfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1116,NaN,NaN,NaN,UPX76284,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,emaltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlfiygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygnspaltfgggtkveyq,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1117,NaN,NaN,NaN,UPX76283,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpsslsaspgasasltctlrsginvgtyriywyqqkpgsppqfllryksdsdrqqgsgvpsrfsgskdtsanagillisglqsedeadyycmiwhssavvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1118,NaN,NaN,NaN,UPX76282,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapelliykasilesgvpsrfsgsgsgteftltisslqpddfatyycqqygtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1119,NaN,NaN,NaN,UPX76281,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspatlslspgeratlsctasqsvgsylvwyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepddfavyycqqrsnwprtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1120,NaN,NaN,NaN,UPX76280,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgyiasnyvrwfqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsskwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1121,NaN,NaN,NaN,UPX76279,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sselsqppsvlvapgqtaritcggnnigskrvhwyqqqpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvcdsssyvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1122,NaN,NaN,NaN,UPX76278,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevtnrpsgvsnhfsgsksgntasltisglqaedeadyycssytsistwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1123,NaN,NaN,NaN,UPX76277,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyplytfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1124,NaN,NaN,NaN,UPX76276,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqpasipcsgdklgdkyacwyqqkpgqspvvviyqdsrrpsgiperfsgsnsgntatltisgtqamdeadyycqawdnynvifgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1125,NaN,NaN,NaN,UPX76275,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysmppctfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1126,NaN,NaN,NaN,UPX76274,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliyssnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslsanyvfgtgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1127,NaN,NaN,NaN,UPX76273,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspatlslspgeratlscrasqsvssylawyqhkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfgvyycqqreltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1128,NaN,NaN,NaN,UPX76272,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpgltqppsvsvapgqtaritcggnnigsnsvqsvhwyqqkpgqapalvaydgsdrpsgiperfsgsksgntatltitrveagdeadyscqvwdsssdhpvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1129,NaN,NaN,NaN,UPX76271,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syelmqppsvsvspgqtasitcsgdklgdkyvcwyqqkpgqspmlviyqdserpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1130,NaN,NaN,NaN,UPX76270,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppkvliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1131,NaN,NaN,NaN,UPX76269,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhyynwppwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1132,NaN,NaN,NaN,UPX76268,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspsslsasvgdrviitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyyclqdynypwtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1133,NaN,NaN,NaN,UPX76267,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprllihdasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwplsfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1134,NaN,NaN,NaN,UPX76266,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprllihdasnratgiparfsgsgsgtdftltisslehedfavyycqqrsnwpfslgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1135,NaN,NaN,NaN,UPX76265,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspstlsasvgdrvtitcrasqtinnwlawyqqkpgtapklliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqhynsywtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1136,NaN,NaN,NaN,UPX76264,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ksvltqphsvsespgktvtisctgssgyiasnyvrwfqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsskwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1137,NaN,NaN,NaN,UPX76263,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystftfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1138,NaN,NaN,NaN,UPX76262,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcqasqdirkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediaayycqqydnlpitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1139,NaN,NaN,NaN,UPX76261,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassgatgipdrfsgsgsgtdftltisrlepedfavyycqqygnapltfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1140,NaN,NaN,NaN,UPX76260,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprllihdasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwplsfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1141,NaN,NaN,NaN,UPX76259,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspstlsasvgdrvtitcrasqsisgwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqydsywtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1142,NaN,NaN,NaN,UPX76258,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspsflsasvgdrvtitcrasqginsylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsysfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1143,NaN,NaN,NaN,UPX76257,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysmppctfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1144,NaN,NaN,NaN,UPX76256,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspstlsasvgdrvtitcrasqsisrwlawyqqkpgkapkllifkasslesgvpsrfsgsgsgaeftltisslqpddfatyycqqyhsypytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1145,NaN,NaN,NaN,UPX76255,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspatlsvspgeratlscrtsqsvssnlawyqqkpgqaprllmhgasaratgvparfsgsgsgteftltisslqsedyavyycqqynhwpftfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1146,NaN,NaN,NaN,UPX76254,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dtpltqspdslavplgeratinckssqnvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyraltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1147,NaN,NaN,NaN,UPX76253,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrtsqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdfiltisrlepedlavyycqqygsyfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1148,NaN,NaN,NaN,UPX76252,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpsslsaspgasasltctlrsginvgtyriywyqqkpgsppqfllryksdsdyqrgsgvpsrfsgskdasanagillisglqsedeadyycmiwhtsavvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1149,NaN,NaN,NaN,UPX76251,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvgsnylgwfqqkpgqaprlliyatssraigipdrfsgsgsgtdftltisrlepedfavyycqqyglspwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1150,NaN,NaN,NaN,UPX76250,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvapgktariscggnnigsksvhwyqqrpgqapvlvicynsdrpsgiperfsgsnsgntatltisraeagdeadyycqvwdsssdvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1151,NaN,NaN,NaN,UPX76249,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyednkrpsgiperfsgsssgtmatltisgaqvedeadyycsstdisgnvfgtgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1152,NaN,NaN,NaN,UPX76248,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvnsiylawyqqkpgqaprllifgassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfglgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1153,NaN,NaN,NaN,UPX76247,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpsslsasvgdrvtitcqasqdisnclnwyqqkpgkapklliydasnletgvpsrfsgsgcgtdfsftisslqpediatyycqqyynlftfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1154,NaN,NaN,NaN,UPX76246,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcqasqdisnslnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdfsftisslqpediatyycqqyynlftfgpgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1155,NaN,NaN,NaN,UPX76245,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpshlsaspgasasltctlrsginvgtyriywyqqkpgsppqfllrynsdsdkqqgsgvpsrfsgskdasanagillisglqsedegdyycmiwhssawvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1156,NaN,NaN,NaN,UPX76244,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlsctasqsirtylawyqqkpgqaprlliydvsnratgiparfsgsgsgtdftltisslepedfavyfcqhrsnwpitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1157,NaN,NaN,NaN,UPX76243,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qhvltqppsvsvspgqtaritcsgdalpkkyaywylqksgqapvlviyddnkrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrvfgtgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1158,NaN,NaN,NaN,UPX76242,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgtrvtltisgvqaedeadyycqsadssgtpgyvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1159,NaN,NaN,NaN,UPX76241,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvspgqtasitcsadklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqtwdsstgvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1160,NaN,NaN,NaN,UPX76240,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpsflsasvgdrvtitcrasqginsylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsysfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1161,NaN,NaN,NaN,UPX76239,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslsasvgdrvtitcqashninnhlnwyqqkpgkapklliydasnlepgvpsrfsgsasgtdftltisslqpediavyfcqqyndlprfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1162,NaN,NaN,NaN,UPX76238,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvgsynfvswyqhhpgkapklmiyevskrpsgvsnrfsgsrsgntafltisglqaedeadyyccsyagsstwvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1163,NaN,NaN,NaN,UPX76237,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsvsvapgqaaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdtnsdhpvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1164,NaN,NaN,NaN,UPX76236,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyslpffgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1165,NaN,NaN,NaN,UPX76235,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dipitqspsslsasvgdrvtitcrasqsiknclnwyqqkpgkapilliyaayslqsgvpsrfsgsasgsdfsltisslqpedsatyycqqthiaprtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1166,NaN,NaN,NaN,UPX76234,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcqasqdisnhlnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1167,NaN,NaN,NaN,UPX76233,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnsigsknvhwyqqkpgqapvlvvyddtdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpwvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1168,NaN,NaN,NaN,UPX76232,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspatlsvsageratlscsasqsvssnlawyqqkpgqaprlliydastratgiparfsgsgsgteftltlsslqsedfavyycqqyhnwprtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1169,NaN,NaN,NaN,UPX76231,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpdslavslgeratinckssqsvlyssnnknylawyqqkagqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyychqyyttpvtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1170,NaN,NaN,NaN,UPX76230,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1171,NaN,NaN,NaN,UPX76229,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsywppftlgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1172,NaN,NaN,NaN,UPX76228,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspsslsaslgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqaediatyscqqydtlpltfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1173,NaN,NaN,NaN,UPX76227,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsirkylnwyqqkpgkapklliyatsnlqsgvpsrfsgsgsgtdftliisslqpedfatyycqqsyitpgtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1174,NaN,NaN,NaN,UPX76226,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyinnqrpsgvpdrfsgsksgtsaslaisglrsedeavyycaacddslsdvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1175,NaN,NaN,NaN,UPX76225,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqplqtppitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1176,NaN,NaN,NaN,UPX76224,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfifgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1177,NaN,NaN,NaN,UPX76223,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,rlvmtqspsslsasvgdrvtitcqasqdisnflnwyqqkpgkapnlviydasnleagvpsrfsgsgwgtdftftisslqpediatyycqhydtllltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1178,NaN,NaN,NaN,UPX76222,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslsasvgdrvtitcrasqgirndldwyqqkpgrapkrliyaasslqdgvpsrfsgsgsgteftltisslqpedfatyyclqhntyppltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1179,NaN,NaN,NaN,UPX76221,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslsasvgdrititcrashdinkyltwyqqkpgtvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkydaspftfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1180,NaN,NaN,NaN,UPX76220,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdigiynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1181,NaN,NaN,NaN,UPX76219,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ilsaradsatlslspgeranlscrasqsvsnylawyqqkpgqaprlliydasnraagiparfsgsgsgtdftltigslepedfavyycqqrsnwpptwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1182,NaN,NaN,NaN,UPX76218,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1183,NaN,NaN,NaN,UPX76217,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnleagvpsrfsgsgsgtdftfsisslqpediatyycqqydnlpltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1184,NaN,NaN,NaN,UPX76216,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspstvstsvgdrvtitcrasqsisswlawyqqkpgkapklliykasslasgvpsrfsgsgsgteftltisslqpddfatyycqhsnsppwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1185,NaN,NaN,NaN,UPX76215,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvliqprsvsgspgqsvtisctgnssdlggynyvswyqqypgkapklmiydvtkrpsgvpdrfsgsksgntasltisglqaedeadyyccsynwvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1186,NaN,NaN,NaN,UPX76214,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqspsilsasvgdrvtitsrasqsisswlawyrqkpgkapnlliykassletgvpsrfsgsgsgteftltisslqpddfaiyycqqyityptfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1187,NaN,NaN,NaN,UPX76213,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspgtlslspgdratlscrasqsvtsrylawyqqkfgqaprlliygaysratgipgrfsgsgsgtdftltisrlepedfavyycqqydnsrwtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1188,NaN,NaN,NaN,UPX76212,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyntprtfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1189,NaN,NaN,NaN,UPX76211,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcrasqsiniylnwyqkkpgkapklliyaasnlhsgvpsrfsgsgsgthftltisslqpedfatyycqqsyttplsltfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1190,NaN,NaN,NaN,UPX76210,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsasgtpgqrvtiscsgsgsnigstyvywyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddrlsdyvfgsgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1191,NaN,NaN,NaN,UPX76209,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapnlliyaasslqggvpsrfsgsgsgthftltisslqpedfatyycqqsystprtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1192,NaN,NaN,NaN,UPX76208,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspdslavslgetatinckssqsvlftsnnknylawyqhkpgqppklliywastresgvpdrfsgsgsgtdftltisnlqaedvavyycqqyyngptltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1193,NaN,NaN,NaN,UPX76207,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplytfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1194,NaN,NaN,NaN,UPX76206,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspatlslspgeratlscrasqsvnrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrinwltfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1195,NaN,NaN,NaN,UPX76205,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1196,NaN,NaN,NaN,UPX76204,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqtpsslsisvgdrvtitcqasqdirnylswyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1197,NaN,NaN,NaN,UPX76203,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliydastratgiparfsgsgsgteftltisslqsedfavyycqqynnwrpsitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1198,NaN,NaN,NaN,UPX76202,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsasatpgqrvtiscsgstsnigtyyiywyqvipgtapkllvygnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddrlkayvfaagtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1199,NaN,NaN,NaN,UPX76201,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpatlslspgeratlscrasqsvsnylawyqqkpgqaprlliydasyratgvparfsgsgsgtdftltisslepedfaayycqqrsnlftfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1200,NaN,NaN,NaN,UPX76200,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqprsvsgspgqsvtisctgtssdigtynsvswyqqhpgkapkvliydvskrpsgvpdrfsgsksgytasltisglqaedeadysccsyapgytfvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1201,NaN,NaN,NaN,UPX76199,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyednkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsgtavfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1202,NaN,NaN,NaN,UPX76198,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslksgvpsrftgsgsgteftltisslqpddfatyycqhynsypwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1203,NaN,NaN,NaN,UPX76197,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqypgkapklmiyevsnrpsgvsnrfsgsksantasltisglqtedeadyycssytssttlvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1204,NaN,NaN,NaN,UPX76196,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1205,NaN,NaN,NaN,UPX76195,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsateftltisslqpedfatyycqqlnsypltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1206,NaN,NaN,NaN,UPX76194,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqtpdslavslgeratinckssqsllyssnnknylawyqqklgqppkllihwastresgvpdrfsgsgsgtdftltisglqaedvavyycqeyydtlrtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1207,NaN,NaN,NaN,UPX76193,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspvtlslspgeratlscsarqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqrrsnwppytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1208,NaN,NaN,NaN,UPX76192,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliydastratgiparfsgsgsgteftltisslqsedfavyycqqynnwrpsitfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1209,NaN,NaN,NaN,UPX76191,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1210,NaN,NaN,NaN,UPX76190,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlsvspgdranvscrasqsinsnlawyqqrprqaprlliydastratgisarfsgsgsgtdftltisslqsedfavyycqqynfwprtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1211,NaN,NaN,NaN,UPX76189,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsasgtpgqrvaiscsgsssnignnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgwvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1212,NaN,NaN,NaN,UPX76188,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgrssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydnthvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1213,NaN,NaN,NaN,UPX76187,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsvsgtpgqrvtiscsgsgsnigsntvnwyqhvpgttpklliysnnqrpsgvpdrfsgsksgtsaslaisalqsedeadyycatwdhslggglfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1214,NaN,NaN,NaN,UPX76186,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttaptfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1215,NaN,NaN,NaN,UPX76185,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspstlsasvgdrvtitcrasqsinswlawyqqkpgkapnvliykasnlksgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1216,NaN,NaN,NaN,UPX76184,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyychqyntyswtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1217,NaN,NaN,NaN,UPX76183,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvsniylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1218,NaN,NaN,NaN,UPX76182,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspatlsfspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1219,NaN,NaN,NaN,UPX76181,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqtedvavyycqqyysspstfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1220,NaN,NaN,NaN,UPX76180,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqprsvsgspgqsvtisctgtssdigtynsvswyqqhpgkapkvliydvskrpsgvpdrfsgsksgytasltisglqaedeadysccsyapgytfvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1221,NaN,NaN,NaN,UPX76179,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,shvltqppsvsvspgqtasitcsgdklgdkyvcwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgktatltisgtqamdeadyycqawdssivvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1222,NaN,NaN,NaN,UPX76178,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslfasvgdrvtitcrasqtigsylnwyqqkpgkapklliyaasslqrgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1223,NaN,NaN,NaN,UPX76177,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1224,NaN,NaN,NaN,UPX76176,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfaiyycqqrntfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1225,NaN,NaN,NaN,UPX76175,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspatlslspgeratlscgasqsvssylawyqqkpglaprllmydassratgipdrfsgsgsgtdfsltisrlepedfavyycqqygrspitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1226,NaN,NaN,NaN,UPX76174,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvspgqtasitcsgdklgdkyvcwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgktatltisgtqamdeadyycqawdssivvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1227,NaN,NaN,NaN,UPX76173,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettlnslqppglvsreratfscrasqsvgsylawyqqkpgqvprffiyeasnratgfparfrargfgtnfiftfsslklkdfavyycqqrgnwprgpvtfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1228,NaN,NaN,NaN,UPX76172,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslsasvgdrvtitcrasqsissylnwfqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysapgytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1229,NaN,NaN,NaN,UPX76171,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgervtlscrasqsvssylawhqqkpgqaprlliydasnrasgiparfsgsgsgtdftltisslepedfavyycqqrsdwpptfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1230,NaN,NaN,NaN,UPX76170,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqprsvsgspgrsvtisctgtssdvggynyvswyqqhpgkapklliydvtkrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagrylvlfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1231,NaN,NaN,NaN,UPX76169,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsgapgqgvtisctgsnsnigtgynvhwyqqlpgtapkllifgnnnrpsgvpdrfsgsksdtsaslaitglqpedeadyycqsydnslsavvfgggtqltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1232,NaN,NaN,NaN,UPX76168,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpgltqppsvsvapgqtamitcggdnigsknvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsitdslwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1233,NaN,NaN,NaN,UPX76167,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynlvswyqqhpgkapklmlyevtkrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsttssyvfgtgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1234,NaN,NaN,NaN,UPX76166,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeliqlpsasgtpgqrvtiscsggsssigsnyvywyqqlpgtapklliyrndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddslscpvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1235,NaN,NaN,NaN,UPX76165,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspatlslspgeratlscrarqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppritfgpgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1236,NaN,NaN,NaN,UPX76164,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qavvtqepsltvspggtvtltcasstgavtsgsypnwfhqkpgqapraliysttnkhswtparfsgsllggkaaltlsgvqpedeaeyycllyyggaqlvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1237,NaN,NaN,NaN,UPX76163,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlhssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1238,NaN,NaN,NaN,UPX76162,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvmtqppsvsgatgqrvtiscsgsssnigagsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqgedeadyycqsydsslsglrvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1239,NaN,NaN,NaN,UPX76161,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1240,NaN,NaN,NaN,UPX76160,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspstlspsvgdrvtitcrasqsisswlawyqqkpgkapklliykasslqsgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1241,NaN,NaN,NaN,UPX76159,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgesatlscrasqsvsssylawyqqkpgqaprllifgassratgipdrfsgggsgtdfsltisrlepedfavyycqqygssplytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1242,NaN,NaN,NaN,UPX76158,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftlaisslqaedvavyycqqyystswtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1243,NaN,NaN,NaN,UPX76157,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,pvavnaaasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycsshtssstlvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1244,NaN,NaN,NaN,UPX76156,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapnlliyaasslqggvpsrfsgsgsgtdftltisslqpedlatyycqqsysntytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1245,NaN,NaN,NaN,UPX76155,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvsssslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1246,NaN,NaN,NaN,UPX76154,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsglsgswvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1247,NaN,NaN,NaN,UPX76153,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspssvsasvgdrvtitcraserisswlawyqqkpgkapklliyatsslqsgvpsrfsgsgsgtdftltitnlqpedfatyycqqansfvwtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1248,NaN,NaN,NaN,UPX76152,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkhaywyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstyvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1249,NaN,NaN,NaN,UPX76151,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eialtqspgtlslspgerttlscrasqsisssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltitrlepedfavyycqqydtsppgttfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1250,NaN,NaN,NaN,UPX76150,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvpvspgqtaritcsgdalpkkyaywyqqksgqapvvviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrgvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1251,NaN,NaN,NaN,UPX76149,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspssfsastgdrvtitcrasqgvssylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisylqsedfatyycqqygsyprtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1252,NaN,NaN,NaN,UPX76148,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syelmqlpsvsvspgqtasitcsgdklgdkyaywyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstyvfgtgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1253,NaN,NaN,NaN,UPX76147,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvsssylawyqqkpgqgprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssvtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1254,NaN,NaN,NaN,UPX76146,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qhvltqpasvsgspgqsitisctgtssdvagynyvswyqhhpgkapkliiydvnkgpsgvsnrfsgsksgntasltisglqaedeadyycssftsistlvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1255,NaN,NaN,NaN,UPX76145,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswfqqhpgkapkliiydvttrpsgvsnrfsgsksgntasltisglqaedeadyyctsytssstsvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1256,NaN,NaN,NaN,UPX76144,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpssvsasvgdrvtitcrasqgisswlawyqqipgkapklliyaasylqsgvpsrfsgsgsgtdftltisslqpedfatyycqqvnsfpftfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1257,NaN,NaN,NaN,UPX76143,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqdfgssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1258,NaN,NaN,NaN,UPX76142,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapkpmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssyrssstlgvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1259,NaN,NaN,NaN,UPX76141,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtatiscsgdklgdqyaswyqqkpgqspvlviyqdskrpsgiperfsgsnsgnsatltiggtqpmdeadyycqawdsssasyvfgtgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1260,NaN,NaN,NaN,UPX76140,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgnklgdkyvywyhqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsrivvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1261,NaN,NaN,NaN,UPX76139,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqsplslpvtpgesasiscwssqsllhsngnnyldwylqkpgqspqllislgsnrasgvpdrfsgsgsgtdfklkisrveaedvgvyycmqalqaprtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1262,NaN,NaN,NaN,UPX76138,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsisgylnwyqqkpgkapklliyatynlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1263,NaN,NaN,NaN,UPX76137,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsdtgifgtgtqltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1264,NaN,NaN,NaN,UPX76136,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfprtfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1265,NaN,NaN,NaN,UPX76135,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqppqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmpplqtpftfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1266,NaN,NaN,NaN,UPX76134,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftitslqpedvatyycqqfddlpitfgpgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1267,NaN,NaN,NaN,UPX76133,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsvsvspgqtaritcsgdalpnqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsrgvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1268,NaN,NaN,NaN,UPX76132,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsvsvspgqtasitcsgdelgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawesstgvvfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1269,NaN,NaN,NaN,UPX76131,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1270,NaN,NaN,NaN,UPX76130,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqqrpgqaprllifgaytratgiparfsgsgsgteftltisslqsedfavyycqqyhnwpwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1271,NaN,NaN,NaN,UPX76129,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsasgtpgqrvtiscsggtsnigsnyvnwykqvpgtapklliytnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddslsgyvfgtgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1272,NaN,NaN,NaN,UPX76128,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgayvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1273,NaN,NaN,NaN,UPX76127,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpdslavslgeratinckssqsvlyssnnknylawyqqrprqpprlliywastresgvpdrfsgsgsgtdftltisslqvedvavyycqqyydtpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1274,NaN,NaN,NaN,UPX76126,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqhkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqvdtyrfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1275,NaN,NaN,NaN,UPX76125,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvvtqppsgsvapgktaritcggnsigsksvhwyqhkpgqapviiiyydsdrpsgiperlfgsnsgntttltisrveagdeadyycqvwdissvfgtrtkltvi,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1276,NaN,NaN,NaN,UPX76124,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspatlsvspgetatlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsadfavyycqqynnwlrtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1277,NaN,NaN,NaN,UPX76123,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvperfsgsgsgtdftlkisrveaedvgvyycmqsthwpltfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1278,NaN,NaN,NaN,UPX76122,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqsplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmlatqfppryifgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1279,NaN,NaN,NaN,UPX76121,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspdslavslgeratinckssqsvlyssnnknylawyqqrprqpprlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyydtpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1280,NaN,NaN,NaN,UPX76120,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspstlsasvgdrvtitcrasqsisnwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyswtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1281,NaN,NaN,NaN,UPX76119,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1282,NaN,NaN,NaN,UPX76118,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsslsasvadrvtitcrasqgisnsllwyqqkpgkapklllyaasrlesgvpsrfsgsasgtdytltisslqpedfatyycqqyystpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1283,NaN,NaN,NaN,UPX76117,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsvspgqtaritcsgdalpkqydywyqqkpgqaplvvmyqdtkrpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtnwvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1284,NaN,NaN,NaN,UPX76116,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlftfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1285,NaN,NaN,NaN,UPX76115,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,emtltqspgtlsvspgeratlscrasqgvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyykwppltfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1286,NaN,NaN,NaN,UPX76114,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspsslsasvgdrvtitcrashsissylnwyqqkpgkapklliylasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1287,NaN,NaN,NaN,UPX76113,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspssvsasvgdrviitcrasqgmgsglawyqqipgkapklliyaasylqsgvpsrfsgsgsgtdftltisslqpedfatyycqqvnsfpftfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1288,NaN,NaN,NaN,UPX76112,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspfslsasvgdrvtitcrasqtissylnwyqqkpgkapnlliyaasslqsgvpsrfsgngsgtdftltisslqaedfatyycqqsyssppwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1289,NaN,NaN,NaN,UPX76111,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqfvstsnlawyqqkpgqaprlliyaassraigipdrfsgsgsgtdftltisrlgpedfalyycqqygsspwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1290,NaN,NaN,NaN,UPX76110,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1291,NaN,NaN,NaN,UPX76109,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkvpklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnvpltfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1292,NaN,NaN,NaN,UPX76108,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspeslavslgeratinckcsqsvlfstndkhylawyqqkaghpprlllywastreagvpdrfsgsgsetdftltisslqaedvavyycqqyysrpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1293,NaN,NaN,NaN,UPX76107,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsiasvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1294,NaN,NaN,NaN,UPX76106,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqhdnlppsfgpgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1295,NaN,NaN,NaN,UPX76105,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppmitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1296,NaN,NaN,NaN,UPX76104,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltirslqsedfavyycqqydnwygfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1297,NaN,NaN,NaN,UPX76103,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspatlsvspgeratlscrasqsvssnlawyqqksgqaprlliygastratdiparfsgsgsgteftltisslqsedfavyychqynnwppytfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1298,NaN,NaN,NaN,UPX76102,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdklgdkyvswyqqkpgqspilviyqdnkrpsgiperfsgsgsgntatltisgtqamdeadyycqawdsstayhvfgtgtkvtvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1299,NaN,NaN,NaN,UPX76101,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgatgqrvtisctgsssnigagsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsrvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1300,NaN,NaN,NaN,UPX76100,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqsplslpvtpgepasiscrsslsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaddvgvyycmqalqtprtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1301,NaN,NaN,NaN,UPX76099,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrashsvstsylawyrqkpgqaprlliydassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1302,NaN,NaN,NaN,UPX76098,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqsplslpftpgepasiscrssqsllhsngynylhwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpmytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1303,NaN,NaN,NaN,UPX76097,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisglqpedfatyycqqsystltfgpgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1304,NaN,NaN,NaN,UPX76096,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqtpgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygasnratgipdrfsgsgsgtdftltisrlesedfavyycqqygsfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1305,NaN,NaN,NaN,UPX76095,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirvtqspatlslspgeratlscrasqsvstylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyfchqrsnwpprltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1306,NaN,NaN,NaN,UPX76094,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpitfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1307,NaN,NaN,NaN,UPX76093,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltinslqpedfatyycqqyntypptfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1308,NaN,NaN,NaN,UPX76092,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtftcrasqgitnllawfqqkpgkapksliyaasrlqsgvpskfsgsgsgtdftltisslqpedfatyycqqynsypptfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1309,NaN,NaN,NaN,UPX76091,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1310,NaN,NaN,NaN,UPX76090,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssyassstpyvfgtgtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1311,NaN,NaN,NaN,UPX76089,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqvtqspsslsasvgdrvtitcrasqsigsylnwyqqkpgkapnlliygasrlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysiprtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1312,NaN,NaN,NaN,UPX76088,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygaasratgvpdrfsgsgsgtdftltisrlepedfavyycqqygmsltfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1313,NaN,NaN,NaN,UPX76087,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ilflcadsatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliydastratgiparfsgsgsgteftltisslqsedfavyccqqynnwpytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1314,NaN,NaN,NaN,UPX76086,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgisgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltifglktedeadyycqsydstnhayvfgtgtnheyvfgtrtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1315,NaN,NaN,NaN,UPX76085,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsiltqprsvsgspgqsvtisctgtssdvggynyvswyhphpgkapklilydvnkrpsgvpdrfsgsksgntasltisglqaedeadyyccsyvgsyswvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1316,NaN,NaN,NaN,UPX76084,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspstlsasvgdrvtitcrasqsittwlawyqqrpgkvpklliskasslesgvpsrfsgsgygtefsltisslqpddfatyycqqynsysitfgqgtrleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1317,NaN,NaN,NaN,UPX76083,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyycqhygslpltfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1318,NaN,NaN,NaN,UPX76082,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspstlsasvgdrvtitcrasqsisswlawyqqqpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynslwtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1319,NaN,NaN,NaN,UPX76081,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpgltqppsvsvspgqtasitcsgdklgdkyacwfqqrpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawasstavvfgggtqltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1320,NaN,NaN,NaN,UPX76080,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eirltqspssvsasvgdtvtitcrasqgisswlawyqqtpgkapklliyaasslqsgvpsrfsvsgsgtdftltisslqpedfatyycqqansfpltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1321,NaN,NaN,NaN,UPX76079,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspgtlsvspgeratlscrasqslssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisglepedfavyycqqygsspmytfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1322,NaN,NaN,NaN,UPX76078,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppkitfgqgtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1323,NaN,NaN,NaN,UPX76077,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nflltqppsvsvspgqtvsitcsgdklgnkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsghtatltisgtqamdeadyycqawdsssvvfgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1324,NaN,NaN,NaN,UPX76076,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirmtqspsslsasvgdrvtitcqasqdiynylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpftfgpgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1325,NaN,NaN,NaN,UPX76075,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllmygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydsspltfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1326,NaN,NaN,NaN,UPX76074,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqsplslpvtpgepasiscrssqsllhstgynylhwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvfycmqalqipytfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1327,NaN,NaN,NaN,UPX76073,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsfdssvhvifgggtkltvl,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1328,NaN,NaN,NaN,UPX76072,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspscvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansftfgpgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1329,NaN,NaN,NaN,UPX76071,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqtpssfsastgdrvtitcrasqhissylawyqqkpgkapklliydastlqsgvpsrfsgsgsgtdftltisslqsedfatyycqhyysyprtfgqgtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1330,NaN,NaN,NaN,UPX76070,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqsplslpvtpgepasiscrssqsllhssgynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalgtpwtfgggtkveik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1331,NaN,NaN,NaN,UPX76069,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dirltqspdslavslgeratinckssqsvlysfnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyychqyhstpqtfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1332,NaN,NaN,NaN,UPX76068,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ettltqsplslpvtpgepasiscrsslsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaddvgvyycmqalqtprtfgqgtkleik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1333,NaN,NaN,NaN,UPX76067,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasdletgvpsrfsgsgsgtdftftisslqpedlatyycqqyddlpltfgggtkvdik,"Laura,W. et al.; Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1334,NB2B4,NaN,7VFB_B,NaN,"['COVID', 'SARS-COV-2']",Camelus bactrianus (Bactrian camel),qvqlqesgggsvqaggslrlscavsgytysskclgwfrqapgkeregiatiytgggstyyvdsvkgrftisqdnakntvalqmnslkpedtamyycaasgaiagirlclpghtfytywgqgtqvtvsshhhhhh,NaN,"Sun,Z. et al.; An extended conformation of SARS-CoV-2 main protease reveals allosteric targets; Proc Natl Acad Sci U S A 119 (15), e2120913119 (2022); 2022.",10.1073/pnas.2120913119,"Chain B, nb2b4",NaN,2022-10-12,NaN,NaN
1335,NB1A2,NaN,7VFA_D,NaN,"['COVID', 'SARS-COV-2']",Camelus bactrianus (Bactrian camel),mkyllptaaagllllaaqpamaqvqlqesgggsvaaggslrlscavsgvtassvymawfrqapgkereglagintvgyttyadsvkgrftiskdnsentlylqmnslkpedialyycaatyllrfaslsatnfpywgqgtqvtvsshhhhhh,NaN,"Sun,Z. et al.; An extended conformation of SARS-CoV-2 main protease reveals allosteric targets; Proc Natl Acad Sci U S A 119 (15), e2120913119 (2022); 2022.",10.1073/pnas.2120913119,"Chain D, NB1A2",NaN,2022-10-12,NaN,NaN
1336,NaN,NaN,UFQ04592,NaN,unknown,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssydmhwvrqapgkglewvavisydgsskfyaesvkgrftisrdnskntlylqmnslraeetavyycvkdgeqlvplfdywgqgtlvtvss,NaN,"Liu,L. et al.; Identification and comparative analysis of antibodies that broadly neutralize sarbecoviruses; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1337,NaN,NaN,UFQ04591,NaN,unknown,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnfywgwirqppgkglewiasitysgrtfynpslksrvaisvdtsknqfslklssvtaadtavyycartfpsyydrsgyhylnygmdvwgqgttvtvss,NaN,"Liu,L. et al.; Identification and comparative analysis of antibodies that broadly neutralize sarbecoviruses; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1338,NaN,NaN,UFQ04590,NaN,unknown,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslkvssvtaadtavyycassnyydgsgynllesygmdvwgqgtsvtvss,NaN,"Liu,L. et al.; Identification and comparative analysis of antibodies that broadly neutralize sarbecoviruses; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1339,NaN,NaN,NaN,UFQ04595,unknown,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpgvtfgpgtkvdik,"Liu,L. et al.; Identification and comparative analysis of antibodies that broadly neutralize sarbecoviruses; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1340,NaN,NaN,NaN,UFQ04594,unknown,Homo sapiens (human),NaN,nfmltqphsmsespgktvtisctrssgsiasnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssswvfgggtkltvl,"Liu,L. et al.; Identification and comparative analysis of antibodies that broadly neutralize sarbecoviruses; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1341,NaN,NaN,NaN,UFQ04593,unknown,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsrsgtsaslaitglqaedeadyycqsydsslsgswvfgggtkvtvl,"Liu,L. et al.; Identification and comparative analysis of antibodies that broadly neutralize sarbecoviruses; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1342,NaN,NaN,6YOR_B,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),tqmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,NaN,"Huo,J. et al.; Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike; Cell Host Microbe 28 (3), 445-454 (2020); 2020.",10.1016/j.chom.2020.06.010,"Chain B, IgG H chain",NaN,2022-10-12,NaN,NaN
1343,NaN,NaN,6YOR_H,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),tqmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkhhhhhh,NaN,"Huo,J. et al.; Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike; Cell Host Microbe 28 (3), 445-454 (2020); 2020.",10.1016/j.chom.2020.06.010,"Chain H, IgG H chain",NaN,2022-10-12,NaN,NaN
1344,NaN,NaN,UPG19298,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqmvesgggvvqpgrslrlscaasgfsfssygmhwvrqapgkglewvaviwsdvnykfyadsvkgrftisrdnskntlslqmnslraedtavyycardsglryfdwdyrgyfdlwgrgtlvtvss,NaN,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1345,NaN,NaN,UPG19297,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlisddtavyycarddivtgysvmdawgqgasvtvss,NaN,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1346,NaN,NaN,UPG19296,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsisgyywswirqppgkglewigyifyngntnynpslksrvttsldtsknqfslklisvtgadtavyycvrtslyyfdywgqgtlvtvss,NaN,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1347,NaN,NaN,UPG19295,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgdsisstnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdkskhqfslklssvtaadtavyycaredfdiltdrykgfdywgqgtlvtvss,NaN,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1348,NaN,NaN,UPG19294,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisstynwwswvrqppgkglewigeiyhsgntnynpslksrvtisvdksknqfslklssvtaadtavyycaredfdwlrdyyygldvwgqgttvtvss,NaN,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1349,NaN,NaN,UPG19293,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywnwirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargnyygsgsyvdygmdvwgqgttvtvss,NaN,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1350,NaN,NaN,UPG19292,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywnwirqspgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargnyygsgsyvdygmdvwgqgttvtvss,NaN,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1351,NaN,NaN,UPG19291,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvaviwfdgdnkyyaesvkarftisrdnskntlylqmnslraedravyycardpqwldyhdldvwgqgttvtvss,NaN,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1352,NaN,NaN,UPG19290,NaN,"['COVID', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvaviwydgsdryyvdsvkgrftisrdnskntlylqmnslraedtavyycardpqwldyynmdvwgqgttvtvss,NaN,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1353,NaN,NaN,NaN,UPG19307,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtlitfgqgtrleik,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1354,NaN,NaN,NaN,UPG19306,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkaptlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqpsysspytfgqgtkleik,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1355,NaN,NaN,NaN,UPG19305,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnflnwyqqkpgkapklliydtssletgvpsrfsgsgsetdftftisslqpediatyycqqydnlpltfgggtkveik,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1356,NaN,NaN,NaN,UPG19304,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqdiisylawyqqkpgkapkfliyaastlqsgvssrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1357,NaN,NaN,NaN,UPG19303,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgiasflawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyfcqqlnsypytfgqgtkleik,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1358,NaN,NaN,NaN,UPG19302,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsissnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqsnnwpltfgggtkveik,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1359,NaN,NaN,NaN,UPG19301,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsissnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqsnswpltfgggtkveik,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1360,NaN,NaN,NaN,UPG19300,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslsvtpgepasiscrssqsllhsngykyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgsdftlkisrveaedvgvyycmqalqtpltfgggtkveik,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1361,NaN,NaN,NaN,UPG19299,"['COVID', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngyiyldwylqkpgqsphlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveik,"Wang,C. et al.; Exposed and cryptic neutralizing epitopes on the human coronavirus OC43 spike trimer; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1362,NaN,NaN,UKB92417,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlvqsgaevkkpgeslkisckgsgysfttywvgwvrqmpgkglewmgiiypgdsettyspsfegqvtisadksistaylqwsrlrasdtamyfcarqwnypdgafdvwghgtmvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1363,NaN,NaN,UKB92416,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisctgsgysftsywvgwvrqmpgkglewmgiiypgdsettyspsfqgqviisadnsittaylqwstlkasdtamyycarqwnypdgafdiwgqgtmvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1364,NaN,NaN,UKB92415,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysfttywvawvrqmpgkglewmgiiypddsettyspsfegqvtisvdksittaylqwsglrssdtavyycarqwnypdgaldiwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1365,NaN,NaN,UKB92414,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgygynfanywigwvrqtpgkglewmgiiypgdsetryspsfqgqvsisadksintaylqwsslkasdtaiyfcarhyvvvaeiafdiwgqgtmvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1366,NaN,NaN,UKB92413,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaemkkpgeslkisckgsgysfsnywigwvrqmpgkglewmgliypgdsetryspsfqgqvtisadrsintaylqwtslrasdtamyycarhyvvvaeiafdvwgqgtmvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1367,NaN,NaN,UKB92412,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaemkkpgeslkisckgsgysfsnywigwvrqtpgkglewmgliypgdsetryspsfqgqvtisadrsintaylqwtslrasdtamyycarhyvvvaeiafdvwgqgtmvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1368,NaN,NaN,UKB92411,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsinnyywtwirqppgkglewigyinnsgsskynpslksrvtisidtsknqfslkltsvtaadtavyycvmgfdnwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1369,NaN,NaN,UKB92410,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgasissssnwwgwlrqppgkglewigeipqsgstnynasvksrvtisvdksknqfslkltsvtaadtamyycarptvtvggafdiwgqgtmvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1370,NaN,NaN,UKB92409,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqesgpglvkpsgtlsltcavsggsissrnwwswirqppgkglewigeiyysgntnyktslksrivisidksknqlslkltsvtaadtavyycvrgevvsnsphldlwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1371,NaN,NaN,UKB92408,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcavsgysitsghlwgwirqppgkglewigtvhhsgtsyynpslksrvttavdtsknqfsmnlrsvtaadtavyycarsllrflephncfapwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1372,NaN,NaN,UKB92407,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggdlvhpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswngvsigyadsvkgrftisrdnaknslslqmnslraedtafyycakdtgsdwtgalgvwgqgttvtiss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1373,NaN,NaN,UKB92406,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgfnfstygmhwvrqapgkglvwvafissdgsnefyvnsvkgrftisrdnsentlflrmnglrvedtaayycakdsiaivdqtgtwygweiidswgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1374,NaN,NaN,UKB92405,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrmgycsstscyggsfwfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1375,NaN,NaN,UKB92404,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscsasgftfrtygmhwvrqapgkglewvavisydgsnkyygdsvkgrftisrdnskntlylqmnslrtedtavyycakdreivvvvadiedwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1376,NaN,NaN,UKB92403,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscavsgltfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtalyycakdqeivvvagtgfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1377,NaN,NaN,UKB92402,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscvasgftfsifgmhwvrrapgkglewvavisydgsneyyadsvkgrftisrdnsentlylqmnslrvedsalyycakdqeivvvagtgfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1378,NaN,NaN,UKB92401,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvdsgggvvqpgrslrlscaasglsfsiygmhwvrqapgkglewvavisydgtnqyyadsvrgrftisrdnsknmvflqmnslrvedtavyycakdqeivvvgatgfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1379,NaN,NaN,UKB92400,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgfsfstfgmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlslqmnslrtedtaiyycakdttivvvptatfeywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1380,NaN,NaN,UKB92399,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvlpgrslrlsctasgfsfstygihwvrqapgrglewvavisydgsnqyyadsvrgrftisrdnsrntvflemnnlrpedtslyycakdssmtiivapawfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1381,NaN,NaN,UKB92398,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlsceasgfifsnygmhwvrqapgkglewvagilydgsnkyyadsvkdrftisrdnskntlylqmnslrtedtavyycakvlgpycsggpcssgkfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1382,NaN,NaN,UKB92397,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvrpgrslrlscaasgftfshygmhwvrqapgkglewvaviiydgsnkeyadsvkgrftisrdnskntlylqmnslrtedtavyycakssgpycgggscfspkldywgqgilvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1383,NaN,NaN,UKB92396,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwirqapgkglewvavisydgsdtyygdsvkgrftisrdnskttlylqmnglraedtavyycvkqegvycsagscysphfdfwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1384,NaN,NaN,UKB92395,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscavsgftfshyamhwvrqapgkglewvavisydgsnkyyvdsvkgrfaifrddskntlylqmnslrpedtatyycakqngpycsggncysgsydywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1385,NaN,NaN,UKB92394,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscavsgltfknygfhwvrqapgkglewvavisydgsdkyyvdsvkgrftvsrddskntlylqmnslrredtavyycaksggggfcsggscyrnyldywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1386,NaN,NaN,UKB92393,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgggvvqpgrslrlsctisgftfshygfhwvrqapgkglewvavisydgmnkyyadsvkgrftisrdnskntlylqmsslgtedtalyycaksgggpycgggdcyrayfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1387,NaN,NaN,UKB92392,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyalswvrqapgkglewvsaivngggstyyadsvkgrftvsrdnskntlylqmtslraedtavyycakpppagptldlnwyyyhgmdvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1388,NaN,NaN,UKB92391,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyvmswvrqapgkglewvsgisggdgstyyadsvkgrftisrdnskntlylqmnslraedtavyycakggqlellgywgrgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1389,NaN,NaN,UKB92390,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfspysmnwvrqapgkglewvssirssgnyisyadsvkgrftisrdnaknslylqmnslraedmavyycaragrdyydrsgyqrfpgfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1390,NaN,NaN,UKB92389,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),gwsciilflvatatgvhsevqlvesgftfsnawmswvrqapgkglewvgriksetdggttdyaapvkgrftisrddskntlylqmnslktedtavyyctteepgagslyyyyymdvwgkgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1391,NaN,NaN,UKB92388,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsceasggifstyaitwvrqapgqglewmgsiiptfgtanyaqkfqdrvtitadestsaaymelsrlrsedtavyycarvstfdgsghyweywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1392,NaN,NaN,UKB92387,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgagvkkpgssvkvsckasggtfsnyaiswvrlapgqglewmggiililgtanyaqkfqgrvtitadkspstaylelsslrsedtavyycarstfyydrsgnprpddvfdiwgqgtmvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1393,NaN,NaN,UKB92386,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyafswvrqapgqglewmggiipifgtvnyaqkfqgrvtitadkststtymelsspksedtavyycaitysydssgyapeywgqgtqvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1394,NaN,NaN,UKB92385,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),sgaevkkpgssvkvscrasggtfntyaitwlrqapgqqqapgqglewmggiipmfgttkyaqklqgrvtitadeststaymelsslrsedtavyycarvdhydssgyysdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1395,NaN,NaN,UKB92384,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvscktsggthsshaitwvrqapgqglewtggiipifgatnyaqrfqgrvtitadastdtvymemnsltyddtavyycarlnghaemgvtvdywgrgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1396,NaN,NaN,UKB92383,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgagvkkpgssvkvscrasgdsfrnyaiswvrqapgqglewvggiipifntvdyaqkfqgrvtitadaststaymelsslrsedtavyycatqsgydsrgyysdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1397,NaN,NaN,UKB92382,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaavkkpgssvrvsckasgdtfniyginwvrqapgqglewmggfiftfgapnyaqkfqgrititadestttaymelsslksedtavyfcardsvsygdyvpvdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1398,NaN,NaN,UKB92381,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvscktsggtfnnyaiswvrqapglglewmggiipifgtpnytqkfqgrvtisadeststaymevsslrsddtavfycargglpaagynwfgpwgqgtlvtiss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1399,NaN,NaN,UKB92380,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfrsyaiswvrqapgqglewmggiipifgtpnyaqkfqgrvtitadeststaymevsslrsddtavyycargglpaagynwfgpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1400,NaN,NaN,UKB92379,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckgsgdtftsyaiswvrqapgqglewmgviiplfgtanyaqrfqgrvtitadeftstaymelrsltsedtavyyctrdgssgryphnwfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1401,NaN,NaN,UKB92378,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssdaiswvrqapgqglewmgglipisgkadyaqkfqgrvtidadestktaymelsslrpedtavyycarersdshqlyyyygmdvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1402,NaN,NaN,UKB92377,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfnsyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitedeststvymelssvrsadtavyycarvegwdydsrglvsvefwgqgtqvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1403,NaN,NaN,UKB92376,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaemkkpgssvkvsckssggtfnnypiswvrqapgqglewmggiiplfsttnyaqnfqgrvtitadestgtaymeltglrsedtavyfcardggpffydrnghprkenyfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1404,NaN,NaN,UKB92375,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckssgdflsnyaiswlrqapgqglewvggiipifgsenyaqkfqgrvtitadeststayveltslrsedtavyycarfegatyyfdsrgypdssgnspkmdvwgqgttvtiss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1405,NaN,NaN,UKB92374,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqleqsggevkkpgasvkvsckasgytftshyihwvrqapgqglewmgiinpdggsttyaqkfqgrvtmtsdtststvymdlsslrsedsavyhcarsgsylpadyfgldvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1406,NaN,NaN,UKB92373,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvklsckasgytfttyyihwvrqvpgqglqwmgiispsggsttyeqpfqgrvtmtrdtststvymelsslrsedtavyycardstafdfwsgyslqeptwfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1407,NaN,NaN,UKB92372,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfttyyihwvrqapgqglewmgiitpvsgsadyaqkfqgrvamtrdtstatvymelsslrsedtavyycarhstdfdfrtgyslqepnwfdpwgqgtlvtvs,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1408,NaN,NaN,UKB92371,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkrpgasvkiscktsgytfttfyihwvrqvpgqglqwmgiinpsggqttyeqpfqgritmtrgtststvymelsslrsedtaiyycardstafdfrsgyslqeptwfapwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1409,NaN,NaN,UKB92370,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgsevkkpgasvkisckasgytfsshymhwvrqapgqglewmgiinpdagsttyapnfqgrltmtsdtstttvylemsslrsedtamyyctrdqgfvpnrdgidfwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1410,NaN,NaN,UKB92369,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfiaytihwvrqapgqslewmgwinagngntkfsqkfqgrvtitrdtsantaymeltsltsedtavyycarseivlvnhdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1411,NaN,NaN,UKB92368,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftryamhwvrqapgqslecmgwinagngntkysknfqgrvtitrdtsantvymelsslrsedtavyycardlyyydssgyqhinyqldywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1412,NaN,NaN,UKB92367,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsgdtnyaqrfqgrvtmtrdtsistaymelsrlrsddtavyycardlfphepfcvsdvcsrgwfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1413,NaN,NaN,UKB92366,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgytftrhwigwvrqmpgkglewmgviypgdsdtryspsfqgqvtvsadksistaylqwsslkasdtamyfcarggiavasgafdiwgqgtmvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1414,NaN,NaN,UKB92365,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkrpgdslrisckgsgyiftnywinwvrqmpgkglewmgridpsdsytnyspsfeglviisvdksintaylqwsslkasdtamyyctrqspvsgyypiptyyldywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1415,NaN,NaN,UKB92364,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqesgpglvkpsetlsltctvsggsvsshnfhwswirqppgkgleligeiyysgstihspslksrttnynpslksrvtmsvdtsknqvslklgsvtaadtavyycarelyyydrsgyyvhdgfdiwgpgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1416,NaN,NaN,UKB92363,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqesgpglvkpsetlsltctvsggsvnsrnfywswirqppgkglvwigyisnsgstkynpslksrvtmtvdtsknqfslrlnsvtaadtaiyycarevfyydrsgyfssdafdiwgqgtmvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1417,NaN,NaN,UKB92362,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetvsltcsvsggslssyhwswirqppgkglewighiyisastnynpsnynpslrgrvvisvdrsknqfslkltsvtaadtavyycaslsycgadcytefdywgqgtllsvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1418,NaN,NaN,UKB92361,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqesgpglvkpsgtlsltctvsggsisssnwwswvrqppgmglewigeiyhygstnynpslmsrvtisvdksknqfslqltsvtaadtamyycasycsssncyprggmdvwgqgtavtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1419,NaN,NaN,UKB92360,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqesgpglvkpsetlsltctvsggsisssayywgwirqppgkglewigsmfhsgstyynpslksrvtmsvdtaknqfslklssvtaadtavyycaspsislvwvgetisywyfdlw,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1420,NaN,NaN,UKB92359,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsatlsltctvsggsissstyywgwirqppgkglewigtiysggstyyspslksrltismdtsknqfslrlssvtaadtavyycasprglsysdsggyypyyfdhwgqgtlvtiss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1421,NaN,NaN,UKB92358,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgasigrsnnywgwirqppgkglewigtifysgntyynpslrsrlsisvdtsknqfslrlssmtaadtavyycarqdfyydssgyyfreyhwfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1422,NaN,NaN,UKB92357,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggpisssnyycawlrkppgkglewigsivysgstqysaslrsrvtisvdtsknqfslrlrsvtaadtavyycarhlteivsegaaiyyyhyamdvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1423,NaN,NaN,UKB92356,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqesgpglvkpsetlsltctvsggpisssnyycawlrkppgkglewigsivysgstqysaslrsrvtisvdtsknqfslrlrsvtaadtavyycarhlteivsegaaiyyyhyamdvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1424,NaN,NaN,UKB92355,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltcsvsgdsvstsgyywswirqhpgkglewigfiyysgntyynpslksrisisldtsknqfslkltsvtaadtavyyrarvgnfdwldywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1425,NaN,NaN,UKB92354,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfenyamhwvrqapgkglewvagitwnsgnreyadsvkgrftisrdnakkslylqmsslraedtalyfcakdpnsgiliygldvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1426,NaN,NaN,UKB92353,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslklscsasgftlsdsamhwvrqasgkglewvgrissnvnndatvyaaslkgrftisrdesknmaylqmnslknedtavyyctvvpvleyyqygmdvwgqgttvtiss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1427,NaN,NaN,UKB92352,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfifsnywmswvrqapgkglewvanikpvgnekyyvdsvkgrfsisrdnarnslylqmnslrvedtavyycareglgytgddnfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1428,NaN,NaN,UKB92351,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvgqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrtedtavyycakggfyyygsgsydygmdvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1429,NaN,NaN,UKB92350,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1430,NaN,NaN,UKB92349,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqsggslrlscaasgftfsnynmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnsltdedtavyycarvvgrtsyynygldvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1431,NaN,NaN,UKB92348,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfifssynmnwvrqapgkglewvsyissdsstkyyadsmkgrftisrdnaknslylqmnslrdedtavyycarvvgqrsyyyygmdvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1432,NaN,NaN,UKB92347,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggdlvqpggslrlscvasrftfsrynmnwvrqapgkglewisyissssgsifyadsvkgrftisrdnarnslylqmnslrdedtavyycargvvdyydvlggppdnwcdawgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1433,NaN,NaN,UKB92346,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssrnmnwvrqapgkglewvsyisssgsiyyadsvkgrfsisrdnvknslylqmnslrdedtavyycargvvgyydmltgppdnwldawgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1434,NaN,NaN,UKB92345,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggfvqpggslrlscaasgftfssyninwvrqapgkgpewvsyisssgtttfyadsvkgrftisrgngknslflqmnslrnedtavyycargvvgyydvlsgppdnwfdrwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1435,NaN,NaN,UKB92344,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmtwvrqapgkglewvsyisgrsntkyyahsvkgrftisrdnaknslylqmnslrdedtavyycardevpagpdasssspwgvavpygldvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1436,NaN,NaN,UKB92343,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsdygmhwvrqapgkglewvaviwydgsnkkyvdsvkgrftisrdnsrntvflqmnslrdedtavyycakdagrglrffyfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1437,NaN,NaN,UKB92342,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnhgmhwvrqapgkglewvavisydgsikdyadsvkgrfttardsskntlylqmsslkaddtavyycardygdygaidywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1438,NaN,NaN,UKB92341,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfntyamhwvrqapgkglewvalisydginkyyadsvkgrftisrdnskntlylqmnslgaedtavyycakslggsyyygmdvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1439,NaN,NaN,UKB92340,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftvshygmhwvrqapgkglewvavipydgsnkfyadsvkgrftisrdnsestlylhlnslsaedtavyfcvkdleivlipspmrgdswgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1440,NaN,NaN,UKB92339,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfsrygmhwvrqapgkglewvavisydgsdkyysdsvkgrftiskdnsqntlylqmnslrtedtavyycakgsyydlltgyygmdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1441,NaN,NaN,UKB92338,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgeslrvscaasgftfshygmhwvrqapgkglewvtfisydgsdtyytdsvkgrfsisrdnskntlylqlnslraedtavyycaknngnygsvwfanffdywgrgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1442,NaN,NaN,UKB92336,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscassgfpfstygmnwvrqapgkglewvavisydgsneyyaesvkgrftisrdnskhtlylqmtslraedtavyycaktsgpycsdgncysgsfdywgqgtlvtfss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1443,NaN,NaN,UKB92335,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscavsgftfrhygmhwvrqapgkglewvavisydggntyygdsvkgrftisrdnskntldlqmnslraedtavyycakgggqycsggnclvhyldywgpgtrvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1444,NaN,NaN,UKB92334,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscvasgftfrhygmhwvrqapgkglewvavilydgsseyyadsvkgrftisrdnsrntlylqvnslrpedtavyycakgggqycsggncyghyfdywgqgtpvtiss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1445,NaN,NaN,UKB92333,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscavsgftfshygmhwvrqapgkglewvavilydgsnehyadsvkgrftvsrdnskntlylqmdslraedtavyycaklgspycgggncysgyldywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1446,NaN,NaN,UKB92332,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvrpgrslrlscaasgftfshygmhwvrqapgkglewvavilydgsnklyadsvkgrftisrdnskntlylqmnslraedtavyycakadspycsagdcyssdfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1447,NaN,NaN,UKB92331,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfrhygmhwvrqapgkglewvavisydgghkyygnsvkgrltisrddskntlylqinslraedtavyfcvkqggpycsggncysgyfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1448,NaN,NaN,UKB92330,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscvvsgftfstygmhwvrqapgkglewvavilydgsdkyyadsvkgrftisrdnskntlylqmnslsaedtavyycakqggpycsagpcysgyfdfwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1449,NaN,NaN,UKB92329,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfshygmhwvrqapgkglewvavilydgsntyyadsvkgrftvsrdnskntlylqmnslrpedtavyfcakqlgpycsggscyggifdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1450,NaN,NaN,UKB92328,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfpfssygmhwvrqapgkglkwvavisydgnnkyfadpvkgrftisrdnskntvylqmnslraedtavyycakqlgtycsggncysghfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1451,NaN,NaN,UKB92327,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslklscavsgftfrtygmhwvrqapgkglewvavisydgsdthyadsvkgrftisrdsskntlylqmnslrpedtavyyctkmgggpycgggncysgyldywgqgtlvtiss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1452,NaN,NaN,UKB92326,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlsctasgftfrtygmhwvrqapgkglewvavisydgsnkyygdsvkgrftisrddskntlylqmnslraedtavyycakmgggpycgggncysgyfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1453,NaN,NaN,UKB92325,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscsasgftfrhyamhwvrqapgkglqwvaaisydgsytyyadsvkgrftisrdssrntlylqmnslraedtavyycaklgggpycsggnclggyldywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1454,NaN,NaN,UKB92324,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfnkyamswvrqapdkgpewvsgissrgaityyadsvkgrftisrdnsnnilhlqmnslraedtavyycakdlgtviavevldswgqgtlvtvys,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1455,NaN,NaN,UKB92323,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgfslrdyfmswirqapgkglewvgyisrrssdtnyadslkgrftisrdnaknslylqmnslrvedtavyycarqyydiltgystgeywfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1456,NaN,NaN,UKB92322,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasgatfgsyaiswvrqapgqgldwmggiipildivnyaqkfqgrvtitadkstttaymelsslrsedtavyycardaaagnawfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1457,NaN,NaN,UKB92321,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasevtfnsygiswvrqapgqglewmgrlipifdttdyaqkfqdrvtisadtstnttymelsslksedtavyycarevvvigatyldswgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1458,NaN,NaN,UKB92320,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevktpgssvkvsceasggtfssyslnwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststaymelsslgsedtavyycarvqggydiltayfdfwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1459,NaN,NaN,UKB92318,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewlgiinpsdgrtlyaqrfrgrvtitrdtststvymdlsslrsedtavyycsrahssgqsfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1460,NaN,NaN,UKB92317,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgvsvkvsckasgytftnyymhwvrqapgqglewlgiinpsdgrtlyaqrfrgrvtitrdtststlymdlsslrsedtavyycsrahssgqsfdywgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1461,NaN,NaN,UKB92316,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtftsyymhwvrqapgqglewmgiinpsggitnyaqkfqgrvtlttdtstnaiymelsslrsedtaifhcaralkrystvgygldvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1462,NaN,NaN,UKB92315,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkhgasvkvsckasgdtftsyymhwvrqapgqglewmgiinpsggitnyaqkfqgrvtlttdtstnaiymelsslrsedtaifhcaralkrystvgygldvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1463,NaN,NaN,UKB92314,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlvqsgaevkrpgasvkvsckasgytftfagyymhwvrqapgqglewmgsinpksgvtnyeqrfqgrvtltrdtsistaymelsglrsddtavyycardnydaltgyqlsdnwfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1464,NaN,NaN,UKB92313,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyflhwvrqapgqglewmgwinpdsggtnyaqrfqgrvtmtrdtsistaymevsrlrsddtavyycardneryqmqnyyhyygmdvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1465,NaN,NaN,UKB92312,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgyifidyyihwvrqapgqglewmgwinphsgganfapkfqdrvtmtrdtsistaymelsrlrsddtavyycakdrfryyydrsgnyqrepnswfdpwgqgtlvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1466,NaN,NaN,UKB92311,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvtvsckasgyiftaygigwvrqapgqglewmgwisaysgdtnyaqkfqgrvtmttdtstttaymelrslraddtavyycareglvmitsdgmdvwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1467,NaN,NaN,UKB92310,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwinaydsntdyaqkfqgrvtmttdtststafmdlrglrsddtavyycardlgryydnsgyyyryyyfgmdiwgqgttvtvss,NaN,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1468,NaN,NaN,NaN,UKB92523,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqnirnwvawyqqkpgkapkfliykassletgvpsrfsgsgsgteftltisslqpddfatyycqqynsyfptfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1469,NaN,NaN,NaN,UKB92522,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysptfgqgtqvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1470,NaN,NaN,NaN,UKB92521,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspstlsasvgdrvtitcrasqsirnwlawyqqkpgkapkfliykassledgvpsrfsgsgsgteftltisslqpddfatyycqqyntysptfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1471,NaN,NaN,NaN,UKB92520,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgkratlscrasqsvstnlawyqqkpgqapslliygastratgiparfsgtgsgteftltisslqsedfavyycqqynnwppitfgqgtrleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1472,NaN,NaN,NaN,UKB92519,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvsshlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppitfgqgtrleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1473,NaN,NaN,NaN,UKB92518,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvashlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppitfgqgtrleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1474,NaN,NaN,NaN,UKB92517,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqklgqaprlliystssraigipdrfsgsgsgtdftltisrlepedfalyyclqyagspwtfgpgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1475,NaN,NaN,NaN,UKB92516,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgrslnigpktvhwyqhlpgtapklliyrnnerpsgvpdrfsgsrsgtsaslaisdlqsedeadyycatwddnlngpvfgggtrlavl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1476,NaN,NaN,NaN,UKB92515,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscranqivsnsylawyqlrpgqaprvliygasiratgipdrfsgsgsgtdftltisrmepedfavyycqqsgrsptfgpgtsvhik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1477,NaN,NaN,NaN,UKB92514,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvrsnylawyqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqdgtsppgvtfgpgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1478,NaN,NaN,NaN,UKB92513,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgqtariacgetnigsksvnwyqqkpgqapvlvvyedsarpsgiperfsgsnsgntatltisrveagdeadyycqvwdtssdhpvvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1479,NaN,NaN,NaN,UKB92512,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspeslavslgeraainckssqtvldiskkknylawfqqkpgqpprlliywastresgvpdrfsgsgsgtdftltisslqtedvavyycqqyyrtpltfgggtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1480,NaN,NaN,NaN,UKB92511,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgiyycmqalqtpytfgqgtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1481,NaN,NaN,NaN,UKB92510,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvfaapgqkvtiscsgsnsnigkhyvfwyqhlpgtapklliydgnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgawdsslsagswvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1482,NaN,NaN,NaN,UKB92509,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqppsasgtpgqrvsiscsgsssyigghyvywyqhvpgmapklliyrtdqrhsgvpgrfsgsksgtsaslvisglrsedeadyycavwhdslsgyvfgtgtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1483,NaN,NaN,NaN,UKB92508,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsnsyigghyvywyqqlpgtapklliyktyerhsgvpdrfsgpksgtsaslaisglrsedeadyycavwvdslstyvfgtgtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1484,NaN,NaN,NaN,UKB92507,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,tvlsqppsasgtpgqrvtiscsggnsnigskdiywyqqlpgtapklliyknyqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawd,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1485,NaN,NaN,NaN,UKB92506,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlsvspgesatlscrasqsvtsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhyynwppytfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1486,NaN,NaN,NaN,UKB92505,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmisdvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssysrsstpvlfgggtrltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1487,NaN,NaN,NaN,UKB92504,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdisnllnryqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlntfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1488,NaN,NaN,NaN,UKB92503,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqksgrapnlliydtsnleigvpsrfsgsgsgtdftltisslqpediatyycqqyenlpftfgpgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1489,NaN,NaN,NaN,UKB92502,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqslvyadgntylnwfqqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpltfgggtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1490,NaN,NaN,NaN,UKB92501,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlplgfgpgtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1491,NaN,NaN,NaN,UKB92500,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtinchasqdithylnwyqqkpgkapklliydasnletgvpsrfrgsgsgtnftftiislqpedfttfycqqydnlpltfgggtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1492,NaN,NaN,NaN,UKB92499,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrviitcqasqditnylnwyqqkpgkapklliydashletgvpsrfsgsgsgtdftftftlqpediatyycqqyhnlpltfgggtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1493,NaN,NaN,NaN,UKB92498,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynsvswyqqhpgkvpklmiyevsnrpsgvfnrfsgsksgntasltisglqaedeadyycssytsastlvfgggtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1494,NaN,NaN,NaN,UKB92497,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapkfliytastfqsgvpsrfsgsgsgteftltisslqpedfatyycqqfntypltfgpgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1495,NaN,NaN,NaN,UKB92496,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsvapgqtaritcggnnigskgvqwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1496,NaN,NaN,NaN,UKB92495,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrasqsisnnylawyqqkpgqaprllicgassratgipdrfsgsgsgtdftltisrlepedfavyycqqdatsppgvtfgpgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1497,NaN,NaN,NaN,UKB92494,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspvtlslspgeratlscrasqsvsnflawyqqkpgqaprlliydasnratgiparfsgggsgtdftltisslepedftvyycqhrrnwpplytfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1498,NaN,NaN,NaN,UKB92493,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqhlpgtapkllifgnsnrpsgvperfsgsksgtsaslaitglqaedeaqyycqsydsslsgwvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1499,NaN,NaN,NaN,UKB92492,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwppkytfgqgtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1500,NaN,NaN,NaN,UKB92491,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasrsvsnflawyqqipgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqyrsnwppmytfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1501,NaN,NaN,NaN,UKB92490,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspvtlalspgeratlscrasqsvsnflawyqqkpgqaprlliydasnrasgiparfsgsgsgtdftltisslepedfavyychhrsnwppalsfgggtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1502,NaN,NaN,NaN,UKB92489,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspatlslspgeratlsckasqsvsnflawyqqkpgqaprlliydafnratgiparfsgsgsgtdftltisslepedfavyychhrtnwpprntfgqgtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1503,NaN,NaN,NaN,UKB92488,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvtsnylawyqqkagqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyggsprtfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1504,NaN,NaN,NaN,UKB92487,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqphsvsespgktitisctrssgsiatnyvqwyqqrpgsspttviyedyqrpsgvpdrfsgsidsssnsasltisglktedeaeyfcqsydttnvvfgggtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1505,NaN,NaN,NaN,UKB92486,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktitisctrssgsiatnyvqwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisgletedeadyycqsydssnvlfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1506,NaN,NaN,NaN,UKB92485,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtvpklliyantnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydtslsgvfgtgtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1507,NaN,NaN,NaN,UKB92484,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvstylawyqqkpgqaprlliydasnratgiparfsgsgfgtdftltisslepedfaiyycqqrsspafgqgtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1508,NaN,NaN,NaN,UKB92483,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqtvssflawyqqkpgqaprllifdasnratgiparfsgsgsgtdftltisslepedfavyycqyrsnwpphltfgpgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1509,NaN,NaN,NaN,UKB92482,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrltisctgvssnigadsdvhwyqqvpgaapklliygnsnrpsgvpdrfsgsksgtsasltitglqaedeadyycqsydsslssvifgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1510,NaN,NaN,NaN,UKB92481,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsetdftlkisrveaedvgvyycmqgtnwpptfgpgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1511,NaN,NaN,NaN,UKB92480,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgirnylawyqqkpgkapklliytastlqsgvpsrfsgsgsgteftlkisslqpedfatyycqqlnsyprtfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1512,NaN,NaN,NaN,UKB92479,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspaalsvspgeratlscrasqslssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywpgtfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1513,NaN,NaN,NaN,UKB92478,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlsvspgqratlscratqslssnlawyqqtpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywpgtfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1514,NaN,NaN,NaN,UKB92477,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspatlsvspgeratlscrasqslssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywpgtfgqgtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1515,NaN,NaN,NaN,UKB92476,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspatlsvspgeratlscrasqsissnlawyqqkpgqaprllifgastratgiparfsgsgsgteftltisglqsedfavyyclqynkwppysfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1516,NaN,NaN,NaN,UKB92475,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvaitcrasqrisswlawyqqkpgkapklliyrtstlqngvpsrfsgsgsgteftltisglqpddfatyycqqynsypltfgggtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1517,NaN,NaN,NaN,UKB92474,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvaisctgsspnigagydvhwyqqlpgtapklviygntnrpsgvpdrfsasksgtsaslaitglqtedeadyycqsydinlsgspvifgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1518,NaN,NaN,NaN,UKB92473,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspatlsvspgeratlscrasqslssnlawyqqkpgqaprlliydastratgiparfsgsgsgteftltisslqsedfavyycqqynswltfgggtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1519,NaN,NaN,NaN,UKB92472,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsvapgktaritcggnnigsksvhwyqqkagqapvvviyypsdrpsgiperfsgsnsentatltisgveagdeadyycqlwdtnsdhwvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1520,NaN,NaN,NaN,UKB92471,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppslsgapgqrvsiactgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsvsksgtsaslaitglqaedeadyycqsydtslsawvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1521,NaN,NaN,NaN,UKB92470,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdsvsitcrasqsisswlawyqqkpgtapklliykasslesgvpsrfsgrgsgteftltisslqpddfatyycqqyntypwtfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1522,NaN,NaN,NaN,UKB92469,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqfpdslavslgeratinckssqsvlhssnnknylawyqqrpgqcpklliywastresgvpdrfsgsgsgtdftltvsslqaedvalyycqqyyrtpytfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1523,NaN,NaN,NaN,UKB92468,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnignnfvfwyqqfpgtapklliyrsnqrpsgvpdrfsgsksgtsaslaisglrsedetdyycaawddslsamvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1524,NaN,NaN,NaN,UKB92467,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcratqgirndlgwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyyclqdynspwtfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1525,NaN,NaN,NaN,UKB92466,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtgsdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssftsistfvfgtgtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1526,NaN,NaN,NaN,UKB92465,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgksitisctgtssdvgrydyvswyqqhagkapkltifdvshrpsgvsdrfsgsksgntasltisglqaedeadyyccaytststwvfgggtrltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1527,NaN,NaN,NaN,UKB92464,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwptfgqgtrleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1528,NaN,NaN,NaN,UKB92463,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngvnyldwylqksgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgiyycmqalqtptfgqgtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1529,NaN,NaN,NaN,UKB92462,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngvnyldwylqksgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgiyycmqalqtptfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1530,NaN,NaN,NaN,UKB92461,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvrsylawyqqkpgqaprlliydasyratgiparfsgsgsgtdftltisslepedfavyycqqrynwppltfgggtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1531,NaN,NaN,NaN,UKB92460,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmegthwpptfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1532,NaN,NaN,NaN,UKB92459,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspstlsasvgdrviitcrasqsistwlawyqqrpgqapklliykasilqsgvpprfsgsgsgtdftltisrlqpddfatyycqqydsdsqpltfgggtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1533,NaN,NaN,NaN,UKB92458,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwqgqitfgqgtrleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1534,NaN,NaN,NaN,UKB92457,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspstlsasvgdrvtitcrasqsisdwlawyqqkpgkapklliytasnlesgvpsrfsgsgsgteftltisslqpddfatyycqqysaypytfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1535,NaN,NaN,NaN,UKB92456,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedfaiyycqqfdnvpltfgggtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1536,NaN,NaN,NaN,UKB92455,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqdihmylnwyqqkpgkapqlliygasslqsgvssrfngsgsgtdftltinslqpedfatyycqqtystpstfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1537,NaN,NaN,NaN,UKB92454,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsihnylnwyqqkpgkapklliyaasslqsevpsrfsgsesgtdftltisslqpedfatyycqqsystpptfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1538,NaN,NaN,NaN,UKB92453,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvfgspgqsisisctgtssdvgnynfvswfqqhpgkapklmiyevsnrpsgvfnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1539,NaN,NaN,NaN,UKB92452,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1540,NaN,NaN,NaN,UKB92451,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqfpgtapklliygnsngpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtrltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1541,NaN,NaN,NaN,UKB92450,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqsplslpvtlgqpasmscrssqslvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfggsgsgtdftlkisrveaedvgvyycmqgahwplytfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1542,NaN,NaN,NaN,UKB92449,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqppsvsgapgqrvtisctgsssnigagydvhwyqhlpgtapkllifgdnnrpsgvpdrfsasksgtsaslaitglqaedeadyycqsyesslsasvf,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1543,NaN,NaN,NaN,UKB92448,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ivmtqspdslavslgeratinckssqsvlysannknylawyqqkpgqspklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpffgpgtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1544,NaN,NaN,NaN,UKB92447,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcrasqninnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystftfgpgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1545,NaN,NaN,NaN,UKB92446,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvfgspgqsitisctgtssdiggynyvswyqhhpgtapklmiydvnerpsgvfdrfsgsksgntasltifglqaedeadyyccsyagrtiyvvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1546,NaN,NaN,NaN,UKB92445,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsadalskqdaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgiyvvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1547,NaN,NaN,NaN,UKB92444,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitiscngtsndvggyesvswyqqhpgkapkvviydvskrpsgvsnrfsgsksgntasltisglqaedegdyycksltstrrrvfgtgtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1548,NaN,NaN,NaN,UKB92443,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslpasvgdrvtitcqasqgitnylswyqqkpgkapklliydasnlepgvpsrfsgsgsgtdftftisslqrediatyycqqydnlpltfgggtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1549,NaN,NaN,NaN,UKB92442,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqhkpgqaprllidgastraagiparfsgsgsgteftltisslqsedfavyycqqynswppltfgggtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1550,NaN,NaN,NaN,UKB92441,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsppslsasvgdrvtitcqasqgisnslnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftisslqpediatyycqqydnlpltfgggtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1551,NaN,NaN,NaN,UKB92440,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dilltqspsslsasvgdrvtiacqasqditnylnwyqhkpgkaprlliydasnletgvpsrfsgsgsgtvftftisglqpediatyycqqyhnlpitfgqgtrleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1552,NaN,NaN,NaN,UKB92439,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsaslgdrvtitcqasqdisnylnwyqqkpgkapklliygasnletgvpsrfrgdgfateftltisslqpediatyycqqydglpitfgpgtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1553,NaN,NaN,NaN,UKB92438,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspgtlslspgeratlscrasqsvsssylawyqqkagqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgpgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1554,NaN,NaN,NaN,UKB92437,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcqasqdisnhlnwyqqkpgkapklliydasnletgvpprfsgsgsvtdftfiisslqpedfatyychqyhnvpltfgggtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1555,NaN,NaN,NaN,UKB92436,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgfgthftftisslqpediatyycqkydnlpltfgggtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1556,NaN,NaN,NaN,UKB92435,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqhisnhlnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlppytfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1557,NaN,NaN,NaN,UKB92434,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliygvsnraagiparfsgsgsgtdftltisslepedfavyycqqhsnwptfgggtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1558,NaN,NaN,NaN,UKB92433,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcratqsigswlawyqqrpgkvpklliyeasnlesgvpsrfsgsgsgteftltisslhpddfatyycqqyesystfgggtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1559,NaN,NaN,NaN,UKB92432,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspstlsasigdrvtitcrasqsisswlawyqqkpgkapklliyeasnlesgvpsrfsgsgsgteftltisslqpddfatyycqqyntystfgggtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1560,NaN,NaN,NaN,UKB92431,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlysannknylawyqqkpgqspklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpffgpgtkvdik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1561,NaN,NaN,NaN,UKB92430,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtiscrasqsissylnwfqqkpgkapklliyaasslqsgvpsrfsgggsgtgftltisslqpedfatyycqqsystpgtfgqgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1562,NaN,NaN,NaN,UKB92429,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvfgapgqrvtisctgtssnigagydvnwyqqllgtapklliygnknrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsmvfgggtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1563,NaN,NaN,NaN,UKB92428,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsasswlawyqqkpgkapklliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqyksysrtfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1564,NaN,NaN,NaN,UKB92427,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissletedfavyycqqrsswppgftfgpgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1565,NaN,NaN,NaN,UKB92426,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliynasnratgiparfsgsgsgtdftltigslepedfavyycqqrshwppgslftfgpgtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1566,NaN,NaN,NaN,UKB92425,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkyswtparfsgsllggkaaltlsgaqpedeaeyyclvsysgarvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1567,NaN,NaN,NaN,UKB92424,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvfgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegnkrpsgvfdrfsgsksgntasltisglqsedeadyyccsymgsttfgyvfgtgtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1568,NaN,NaN,NaN,UKB92423,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegnkrpsgvfdrfsgsksgntasltisglqsedeadyyccsymgsttfgyvfgtgtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1569,NaN,NaN,NaN,UKB92422,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvfgspgksitisctgtssdvgrydyvswyqqhagkapkltifdvshrpsgvfdrfsgsksgntasltisglqaedeadyyccaytststwvfgggtrltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1570,NaN,NaN,NaN,UKB92421,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslansglqsedeadyycaawddslngyvvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1571,NaN,NaN,NaN,UKB92420,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirddlgwyqqksgkapklliyaasslqsgvpsrfsgsgsgtdftltinslqpedfatyyclqdysypytfgqgtkveik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1572,NaN,NaN,NaN,UKB92419,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvgnynyvswyqhhpgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsntlvfgggtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1573,NaN,NaN,NaN,UKB92418,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qlvltqppsasgspgqsvtisctgtssdvgdydyvswyqqhpgkapeliiyevtkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagrdnlvfgggtkvtvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1574,NaN,NaN,NaN,UKB92337,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcqasqgitnylswyqqkpgkapklliydasnlepgvpsrfsgsgsgtdftfaisslqrediatyycqqydnlpltfgggtkleik,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1575,NaN,NaN,NaN,UKB92319,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qlvltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkyswtparfsgsllggkaaltlsgaqpedeaeyyclvsysgarvfgggtkltvl,"He,W. et al.; Targeted isolation of panels of diverse human broadly neutralizing antibodies against SARS-like viruses; Unpublished; 2022.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1576,NaN,NaN,UOL46889,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgatllkpsetlsltcevyggsfsgyywnwirqapgkglgwiaeinhsgrfnynpslksrvtisvdtaknqfslkltsltaadtavyycarfgygdygwdfdqnmdvwgkgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1577,NaN,NaN,UOL46888,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpggslrlscaasgftfddyamhwvrqapgkglewvsvisgdggstysadsvkgrftisrdnrkhslylqmnslrsedtalyycakdmgyvpaaidgafdiwgqgtmvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1578,NaN,NaN,UOL46887,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggliqpggslrlscaasglivssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslraddtavyycareldvvgatdswgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1579,NaN,NaN,UOL46886,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqvggslrlscttsgfivsrnyvmwvrqapgqglewvstiypggstyfadsvkgrftisrddsknrlylqmnslraedtafyycaryigninwgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1580,NaN,NaN,UOL46885,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgpglvkpsetlsltcsvsgvsvtnnywswirqppgkglewigyifyyggtnynpslksrvtlsidtsanqlslklssvsaadtavyycarhaadrsvtpwfdpwgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1581,NaN,NaN,UOL46884,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckasgyiftsywiawvrqmpgkglewmgiiypddsdtryspsfqgqvtisadksittaylqwsslkasdtamyycarletmgvimpaaswggtygldvwgqgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1582,NaN,NaN,UOL46883,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesggglvkpggslrlscvasgftfssysmnwvrqapgkglewvssisssssyiyhadsvkgrftisrdnaknslylqvnslraedmavyycargssptgdeawdafdiwgqgtmltvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1583,NaN,NaN,UOL46882,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfsfsdyymdwvrqapgkglewvgrtrnkaksyttgyaasvkgrfiisrddsknslylqmnslktedtavyycaramaearyssgwyyyqyymdvwgkgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1584,NaN,NaN,UOL46881,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevekpgssvkvsckasggtfisntinwvrqapgqgleclggiipivgianyaqkfqgrvtitadkststvymelsslrsedtavyycareiyppggfdlwgqgtmvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1585,NaN,NaN,UOL46880,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmdpstgdtgfaqkfhgrvtltrntsintaymelsslrsedtavyyctrgssswtyyfdswgrgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1586,NaN,NaN,UOL46879,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvktsetlsltctvsggsvtsgnyywswirqspekrlewigyiyytggtnynpsfrsrvaisadtsknqfslklssvsaadtavyycarginlkdfssgynwfdpwgqgilvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1587,NaN,NaN,UOL46878,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftftthamhwvrqapgkgldwvavisydglnkyyadsvrgrftisrdntkttvylqmnslrpddtavyycaratvaykwfdpwgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1588,NaN,NaN,UOL46877,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisayngninyeqkfqgrvtmttdtststaymelrslrsddtavyycardlgwfgelsggfdiwgqgtmvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1589,NaN,NaN,UOL46876,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfrnygihwvrqapgkglewvafisfdgddtyyadsvkgrftisrdnskntlylqmnslrtedtavyycakqigsygrpdyyfdywgqgalvtiss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1590,NaN,NaN,UOL46875,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyaihwvrqapgkglewvavisydgmnkyyadsvrgrftisrdnsqntvflqmntlraedtalyycarsssgywsafdiwgqgtvvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1591,NaN,NaN,UOL46874,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscggsgftfsshamhwvrqapgkglewvavisydgsyqyyadsvkgrftisrdnsknalylqmnslrvedtaiyycardtpdletyyfdcwgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1592,NaN,NaN,UOL46873,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkmpgssvkvsckasggsfdnygiswvrqapgqglewmggiipilgstknaqkfqgrititadkstntaymelsslrsedtavyhcarggitlgqgimltyyymdvwgkgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1593,NaN,NaN,UOL46872,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsvifpggstfyadsvkgrftisrhnskntlylqmdslraedtavyycardffegafdiwgqgtmvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1594,NaN,NaN,UOL46871,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscvasgftfsdyamhwvrqapgkglewvalissdgrmdfypdsvkgrftisrdnsknalylqmnglraedtavyycardkelntpaldywgqgslvtiss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1595,NaN,NaN,UOL46870,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqesgpglvkpsetlsltctvsggsisnyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslkltsvtaadtavyfcaksrgysyglglgwfdpwgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1596,NaN,NaN,UOL46869,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsggtnyahkfqgrvtmtrdtsistaymelrrlrsddtalyycargevatifgfyyyyglavwgqgttvtiss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1597,NaN,NaN,UOL46868,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggdlvqpggslrlscgasgftfstywmhwvrqgpgkglvwvsrisgdgssttyadsvkgrftisrdnakntlylqmnslraedtaiyycatsthydfwsgplvhmdvwgkgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1598,NaN,NaN,UOL46867,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsgyywswirqppgkglewigeinhigttnynpslksrviisvdtsknqfslklssvtaadtavyyctrgrglytsgayyfdfwgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1599,NaN,NaN,UOL46866,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgyrftsywiawvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkapdtamyycarietmgvvmpaaswggtygmdvwgqgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1600,NaN,NaN,UOL46865,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsdtlsltcgisggpfsgyywswirqppgkglewlgeinhsgittynpslksrgtisvdtskrqislklasvtaadtavyycarfaygdygwdyssdmdvwgkgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1601,NaN,NaN,UOL46864,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnygitwlrqapgqglewmggiipilgvekyaqkfqgrvtitadkstgtaymqlsslrsedtavyycargginmgqgfiispyyfdywgqgtlvtiss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1602,NaN,NaN,UOL46863,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggalvkpggsltlscaasgfafnnawmswvrqapgkglewvgriktktdggttdyvapvkgrftisrddskntlylqmnslktedtavyyctterdydyiwgsyrpfqnwgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1603,NaN,NaN,UOL46862,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisstnyywgwirqtpgkglewigsiyysgstyynpslksrltisvdrsknhfslqlssvtaadtavyycargsfillifsalatgyfdfwgqgtlvtiss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1604,NaN,NaN,UOL46861,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftsssysmnwvrqvpgkglewisyissssgtlyyadsvkgrftisrdnaknslylqmnslrdegtavyycarvpaediviippalyyyygmdvwgqgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1605,NaN,NaN,UOL46860,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaelkkpgssvkisckasagtfttfgiswvrqapgqglewmggimpvfqivnyaqnlqgritisadkstttaymelsslrsedtavyycartqfvlrflewseasmcasdiwgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1606,NaN,NaN,UOL46859,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscvasgfsfsdawlswvrqapgkglewvgrikskldaettdyakpvkgrftisrddsentlylqmnslktddtavyycttgglmwfgeeegywgqgtlvtiss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1607,NaN,NaN,UOL46858,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsgygmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardltgeyngfwseystkpmdvwgkgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1608,NaN,NaN,UOL46857,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggdlvqpggslrlscaasgftfntysmnwvrqapgkglewvssitsgsttiyyadsvkgrftisrdnaknslylqmnslrdedtavyycardcyssgwytcdyldpwgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1609,NaN,NaN,UOL46856,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsisfyywswirqppgkglewigyfyysgdtgsnpslksrltmsldtsknqfslnltsvtaadtavyycarrsltvtptsgrnayhymdvwgkgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1610,NaN,NaN,UOL46855,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswlrqppgkglewigyiyysgssnynpslksrvtisvdtsksqlslkltsvtaadtavyycargfdywgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1611,NaN,NaN,UOL46854,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvqesgpglvkpsetlsltctisgdsvstsywnwirqpagkglqwigriynsgstnynpslenrvtlsvdtsknqfslkltsvtaadtavyycardpgsryssgwyyysfamdvwgqgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1612,NaN,NaN,UOL46853,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasrfmfnryamswvrqapgkglewvsgisgsgdstqyadsvkgrftisrdnskntlylqmnslraedtavyycakdlyggsssstleywgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1613,NaN,NaN,UOL46852,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgtevkkpgasvkvsckasgytfstygiswvrqapgqglewmgwisahngesnypqkfqgrvtmttdtststahmelrslrsddtavyycardlgwfgelsggfdlwgpgtmvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1614,NaN,NaN,UOL46851,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlveagpglvkpsetlsltctvsggsisnrnydwgwirqppgrglewigtisysgstshnpslksrvsifidtsknqfslklssvtpsdtalyfcardgglgwfgeqmdwyfdlwgrgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1615,NaN,NaN,UOL46850,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgggvvqpgrslrlscaasgftfsgfainwvrqapgkglewvavisydginkyyadsvkgrftisrdnsnntlylqmnslrevdtavyfcasgrgsyrspfdywgpgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1616,NaN,NaN,UOL46849,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgeslrlscagsgftfsaydmhwvrqgtgeglewvsaigtsgdtyyadsvkgrftisrdnaknslflqmdsltvgdtavyycargdaisgveyyfdywgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1617,NaN,NaN,UOL46848,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfmfsdygmnwvrqapgkglewvsyisdsgttihyadsvkgrftisrdnaknslylqmtglrdgdtavyycararppydfwsgyhyfghfdywgqgtlvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1618,NaN,NaN,UOL46847,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslglscvasgftfsyfwmswvrqapgkglewvaninldgsekyyvdsvkgrftisrdnaknslflqmnslrvedtavyycardlryfdwlsmgndywgqgtlitvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1619,NaN,NaN,UOL46846,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggsvrlscaasgftftsydmhwvrqatgkglewisiigtagdpyyadsvkgrfsvsrenaknslylqinslragdtavyycarggvtmlqgairrhyyyymdvwgkgttvtvss,NaN,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1620,NaN,NaN,NaN,UOL46845,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtiacrasqsigtwlawhqqkpgkapnlliykastletgvpsrfsgsgsgteftltisslqpddfatyycqqynsgrtfgqgtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1621,NaN,NaN,NaN,UOL46844,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspgtlslspgeratlscrashsvsanylawyqhkpgqaprlliyaassratgipdrfsgsgsgtdftltvsrlepedfavyycqhyggspltfgggtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1622,NaN,NaN,NaN,UOL46843,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgesatlscrasqsvsssyiawyqqkpgqsprlliygasnratgipdrfsgsgsgtdftlainrlepedfavyycqrcdtspmytfgqgtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1623,NaN,NaN,NaN,UOL46842,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqksgkapkllifdasnlqtgvpsrfsgsgsgtdftftisslqpediatyychqydnlpltfgggtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1624,NaN,NaN,NaN,UOL46841,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqnvflssnnknylawyqqkpgqppklliywasiresgvpdrfsgggsgtdftltisslqaedvavyfcqqyystpltfgggtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1625,NaN,NaN,NaN,UOL46840,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcrasqniltflnwyqhkpgkapelliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsynipetfgqgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1626,NaN,NaN,NaN,UOL46839,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsiniylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqssstprtfgqgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1627,NaN,NaN,NaN,UOL46838,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkcgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1628,NaN,NaN,NaN,UOL46837,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgdratinckssqsvldtsnnrnylawyqhkpgqppklliywastresgvpdrfsgsgsgadftltisslqaedvavyycqqyystpmysfgqgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1629,NaN,NaN,NaN,UOL46836,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspatlslspgeratlscraseslgsylawyqqkpgqaprllifdasnratgiparfsgsgsgtdftltisslepedfavyfcqqrgswpltfgpgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1630,NaN,NaN,NaN,UOL46835,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssnlawyqqtpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprsfgqgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1631,NaN,NaN,NaN,UOL46834,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsflsasvgdrvtitcrasqginnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlntyplftfgpgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1632,NaN,NaN,NaN,UOL46833,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspatlslspgeratlscrasqsvsrflawyqqrpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyychqrsnpltfgggtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1633,NaN,NaN,NaN,UOL46832,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtiacqasqdisnylswyqqkpgkapkvliydasnleagvpsrfsgsgsgtdftftinslqpediatyycqqydnfppitfgqgtrleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1634,NaN,NaN,NaN,UOL46831,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsstylawhqqrpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygpspwtfgqgtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1635,NaN,NaN,NaN,UOL46830,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysacsratgipdrfsgsgsgtdftltisrlepedfavyycqqygdsprgsfgqgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1636,NaN,NaN,NaN,UOL46829,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvgsrylvwyqqksgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslsfgqgtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1637,NaN,NaN,NaN,UOL46828,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisnylawyqhkpgkapklliyaastlqsgvpsrfsgsgsgteftltidslqpedfatyycqhlnsyprltfgggtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1638,NaN,NaN,NaN,UOL46827,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspstlsasvgdrvtitwrasqsissylnwyqqkpgkapnlliyaasnlqsgvpsrfsgrgsgtdfsltitslqpedfatyycqqsystppltfgggtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1639,NaN,NaN,NaN,UOL46826,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasediryflnwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqyddlpptfgpgtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1640,NaN,NaN,NaN,UOL46825,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlsvspgerttlscrasqsvssdlawyqqkpgqaprlliyaastrapgiparfsgsgsgteftltisslqsedfavyhcqqnnnwpwtfgqgtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1641,NaN,NaN,NaN,UOL46824,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsaptsviyednqrpsgvpdrfsgsidsssnsasliisglktedeadyycqsydsrlrvvfgggtkltvl,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1642,NaN,NaN,NaN,UOL46823,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvsinlawyqqkpgqaprllmygastrvtdiparfsgsgsgteftltisslqsedfalyycqqynnwprtfgqgtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1643,NaN,NaN,NaN,UOL46822,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtvtcrasqsiitylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsynipetfgqgtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1644,NaN,NaN,NaN,UOL46821,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspstlsasvgdrvtitcrasqsistwlawhqqipgkapklliyrastlqsgvpsrfsgsgsgteftltisslqpddfatyycqqyysvrtfgqgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1645,NaN,NaN,NaN,UOL46820,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgervtlscrasqsvssnlawyqqkpgqaprllifgastratgiparfsgsgsgteftltisslqsedfavyycqqyndwpikfgqgtrleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1646,NaN,NaN,NaN,UOL46819,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqrintylnwyqqkpgkapklliyaasalqsgvpsrfsgsgsgthstltisslqpedfgtyycqqsyrtsftfgpgtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1647,NaN,NaN,NaN,UOL46818,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssnyvawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedsavyycqqygsspqtfgqgtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1648,NaN,NaN,NaN,UOL46817,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansspygftfgpgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1649,NaN,NaN,NaN,UOL46816,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspdsqavslgeratinckssqsvlfssnnknylawyqqkpgqppkllinwastresgvpdrfsgsgsgtdftltisglqaedvavyycqqyyrspptfgqgtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1650,NaN,NaN,NaN,UOL46815,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtiscrasqsisnylswfqqkpgkapklliyaasrlrsgvpsrfsgsgsgtdftltisslqpedfatyycqqsygtlptfgggtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1651,NaN,NaN,NaN,UOL46814,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkagqaprlliygastratgiparfsgsgsgteftltitslqsedfavyycqhyynwppwtfgqgtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1652,NaN,NaN,NaN,UOL46813,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirsdlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqyntypaltfgggtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1653,NaN,NaN,NaN,UOL46812,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqspftfgpgtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1654,NaN,NaN,NaN,UOL46811,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqslssnylawfqqkhgqaprlliyaasnraigipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1655,NaN,NaN,NaN,UOL46810,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlsckasqsvtsnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyggspqytfgqgtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1656,NaN,NaN,NaN,UOL46809,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdsvtitcqasqdignflnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgteftftisslqpediatfycqqydnvhpltfgggtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1657,NaN,NaN,NaN,UOL46808,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlssspgeratlscrasqsvsrylswyqqkpgqaprlliydasnratgipprfsgsgsgtdftltisslepedfavyychqrsnpltfgggtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1658,NaN,NaN,NaN,UOL46807,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygavsratgipdrfsgsgsgtdftltitrlepedyavyycqqmgtfgpgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1659,NaN,NaN,NaN,UOL46806,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkfgqaprlliygastrangiparfsgsgsgteftltisslqsedfavyycqqynnwppltfgqgtkveik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1660,NaN,NaN,NaN,UOL46805,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtltcrasqsirnylnwyqlkpgkapklliyaasilhsgvptrfsgsgsgtdftltisslqpadfatyycqqsyimppwtfgpgtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1661,NaN,NaN,NaN,UOL46804,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvssnylawyqqrpgqaprlliygasrraagipdrfsgggsgtdftltisrldpedyavyycqqygnspgtfgpgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1662,NaN,NaN,NaN,UOL46803,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasnlqsgvpsrfsgsgsgteftltisslqpadfatyycqqyydypwtfgqgtkleik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1663,NaN,NaN,NaN,UOL46802,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcrasqsissylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptwtfgqgtkvdik,"Seow,J. et al.; ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants; Cell Rep (2022) In press; 2022.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1664,NaN,NaN,7MW6_F,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mgwnwifililsvttgvhsevqlqqsgpelvkpgasvkisckasgysftgysmnwmkqspekslewigeinpstggttdnqkfkakatltvdkssstaymqlksltsedsavyycarsrgdywgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain F, Fab of antibody clone 2, heavy chain",NaN,2022-10-12,NaN,NaN
1665,NaN,NaN,7MW6_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mgwnwifililsvttgvhsevqlqqsgpelvkpgasvkisckasgysftgysmnwmkqspekslewigeinpstggttdnqkfkakatltvdkssstaymqlksltsedsavyycarsrgdywgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain H, Fab of antibody clone 2, heavy chain",NaN,2022-10-12,NaN,NaN
1666,NaN,NaN,7MW6_D,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),mgwnwifililsvttgvhsevqlqqsgpelvkpgasvkisckasgysftgysmnwmkqspekslewigeinpstggttdnqkfkakatltvdkssstaymqlksltsedsavyycarsrgdywgqgtsvtvssakttppsvyplapgsaaqtnsmvtlgclvkastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain D, Fab of antibody clone 2, heavy chain",NaN,2022-10-12,NaN,NaN
1667,NaN,NaN,7MW4_F,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),merhwiflfllsvtagvhsqvqlqqsaaelarpgasvkmsckasgytftsytmhwvkqrpgqglewigyinptsgyteynqnfkdkttltadkssstaymqlnsltsedsavyycareghrvgpaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain F, Fab of antibody clone 6, heavy chain",NaN,2022-10-12,NaN,NaN
1668,NaN,NaN,7MW4_D,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),merhwiflfllsvtagvhsqvqlqqsaaelarpgasvkmsckasgytftsytmhwvkqrpgqglewigyinptsgyteynqnfkdkttltadkssstaymqlnsltsedsavyycareghrvgpaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain D, Fab of antibody clone 6, heavy chain",NaN,2022-10-12,NaN,NaN
1669,NaN,NaN,7MW4_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),merhwiflfllsvtagvhsqvqlqqsaaelarpgasvkmsckasgytftsytmhwvkqrpgqglewigyinptsgyteynqnfkdkttltadkssstaymqlnsltsedsavyycareghrvgpaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain H, Fab of antibody clone 6, heavy chain",NaN,2022-10-12,NaN,NaN
1670,NaN,NaN,7MW3_D,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),merhwiflfllsvtagvhsqvqlqqsaaelarpgasvkmsckasgytftsytmhwvkqrpgqglewigyinptsgyteynqnfkdkttltadkssstaymqlnsltsedsavyycareghrvgpaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain D, Fab of antibody clone 6, heavy chain",NaN,2022-10-12,NaN,NaN
1671,NaN,NaN,7MW3_F,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),merhwiflfllsvtagvhsqvqlqqsaaelarpgasvkmsckasgytftsytmhwvkqrpgqglewigyinptsgyteynqnfkdkttltadkssstaymqlnsltsedsavyycareghrvgpaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain F, Fab of antibody clone 6, heavy chain",NaN,2022-10-12,NaN,NaN
1672,NaN,NaN,7MW3_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),merhwiflfllsvtagvhsqvqlqqsaaelarpgasvkmsckasgytftsytmhwvkqrpgqglewigyinptsgyteynqnfkdkttltadkssstaymqlnsltsedsavyycareghrvgpaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain H, Fab of antibody clone 6, heavy chain",NaN,2022-10-12,NaN,NaN
1673,NaN,NaN,7MW2_F,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),merhwiflfllsvtagvhsqvqlqqsaaelarpgasvkmsckasgytftsytmhwvkqrpgqglewigyinptsgyteynqnfkdkttltadkssstaymqlnsltsedsavyycareghrvgpaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain F, Fab of antibody clone 6, heavy chain",NaN,2022-10-12,NaN,NaN
1674,NaN,NaN,7MW2_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),merhwiflfllsvtagvhsqvqlqqsaaelarpgasvkmsckasgytftsytmhwvkqrpgqglewigyinptsgyteynqnfkdkttltadkssstaymqlnsltsedsavyycareghrvgpaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain H, Fab of antibody clone 6, heavy chain",NaN,2022-10-12,NaN,NaN
1675,NaN,NaN,7MW2_D,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),merhwiflfllsvtagvhsqvqlqqsaaelarpgasvkmsckasgytftsytmhwvkqrpgqglewigyinptsgyteynqnfkdkttltadkssstaymqlnsltsedsavyycareghrvgpaywgqgtlvtvsaastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvep,NaN,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,"Chain D, Fab of antibody clone 6, heavy chain",NaN,2022-10-12,NaN,NaN
1676,NaN,NaN,NaN,7MW6_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,mesdtlllwvlllwvpgstgdivltqspaslavslgqratiscrasesveyygtslmqwyqqkpgqppkvliyaasnvesgvparfsgsgsgtdfslnihpveeddiamyfcqqsrkvpwtfgggtkleikradaaptvsifppsseqltsggasvvcftvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgea,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,NaN,"Chain G, Fab of antibody clone 2, light chain",2022-10-12,NaN,NaN
1677,NaN,NaN,NaN,7MW6_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,mesdtlllwvlllwvpgstgdivltqspaslavslgqratiscrasesveyygtslmqwyqqkpgqppkvliyaasnvesgvparfsgsgsgtdfslnihpveeddiamyfcqqsrkvpwtfgggtkleikradaaptvsifppsseqltsggasvvcftvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgea,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,NaN,"Chain L, Fab of antibody clone 2, light chain",2022-10-12,NaN,NaN
1678,NaN,NaN,NaN,7MW6_E,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,mesdtlllwvlllwvpgstgdivltqspaslavslgqratiscrasesveyygtslmqwyqqkpgqppkvliyaasnvesgvparfsgsgsgtdfslnihpveeddiamyfcqqsrkvpwtfgggtkleikradaaptvsifppsseqltsggasvvcftvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgea,"Hu,Y. et al.; Development, structure and function of potent monospecific and bispecific monoclonal antibodies that neutralize SARS-CoV-2 and its mutant variant; Unpublished; 2022.",NaN,NaN,"Chain E, Fab of antibody clone 2, light chain",2022-10-12,NaN,NaN
1679,NaN,NaN,UGO91527,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardirdssgwanwfdpwgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1680,NaN,NaN,UGO91525,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsmssyywswirqppgkglewigyiynsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarlegegqlvdyygmdvwgqgttvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1681,NaN,NaN,UGO91523,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqsgrslrlscaasgftfssyamhwvrqapgkglewvavishdgsntyyedsvkgrftisrdnskntlhlqvnslrvedtavyycarakgevryfdwaeqggdywgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1682,NaN,NaN,UGO91521,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfstyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymglsslrsedtavyycarwvtaygdyvpfdpwgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1683,NaN,NaN,UGO91519,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycardivgateidywgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1684,NaN,NaN,UGO91517,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsryaiswvrqapgqglewmgriipifgianyaqkfqgrvtitadkststaymevsslrsedtavyycarktyyydssgypeafdiwgqgtmvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1685,NaN,NaN,UGO91515,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslhlqmnslraedtalyycanlltpprrysgydlredyfeywgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1686,NaN,NaN,UGO91513,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfspysmnwvrqapgkglewvssisvsniytyyadsvkgrftisrdnaknslylqmnslraedtaiyycardlkkggiqydafdiwgqgtvvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1687,NaN,NaN,UGO91511,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgiswvrqapgqglewmgriipilgtanhaqkfqgrvtitadkstgtvymelsslrsedtavyycardgdsgsyyetlgfdywgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1688,NaN,NaN,NaN,UGO91528,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgtivtltisgvqaedeadyycqsadssatyvvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1689,NaN,NaN,NaN,UGO91526,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvmviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1690,NaN,NaN,NaN,UGO91524,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdnsgdhgvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1691,NaN,NaN,NaN,UGO91522,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppwtfgqgtkveik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1692,NaN,NaN,NaN,UGO91520,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1693,NaN,NaN,NaN,UGO91518,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1694,NaN,NaN,NaN,UGO91516,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviydrnnrpsgipdrfsgsssgntasltitgaqaedeadyychsrdssgnplhvvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1695,NaN,NaN,NaN,UGO91514,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvndylawyqqkpgqaprlliydasnratgfparfsgsgsgtdftltisslepedfavyycqqrsnwpptfgqgtrleik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1696,NaN,NaN,NaN,UGO91512,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1697,NaN,NaN,ULE72511,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgesltisckasgyrftsnwitwvrqmpgkglewmgridpddpysnsspsfqghatlsldkaintaylhwsslkasdtamyycarvnrvgdgpdfwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1698,NaN,NaN,ULE72510,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfndygvswvrqapgqglewmggiiaifgtanyaqkfqgrvaitadeststaymelsglrsedtavyfcaslggdsyisgthydrsgydpwgqgtlvivss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1699,NaN,NaN,ULE72509,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewltlisydginkyygdsvkgrftisrdnskntlyiqmnslrpedtavyycarayggnyyygmdvwghgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1700,NaN,NaN,ULE72508,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvgsggglvqpggslrlscaasgftfstywmswvrqapgkglewvadikqdgsekyyvdsvkgrftisrdnaknslylqmnslrvedtalyycargglwgtfdywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1701,NaN,NaN,ULE72507,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsgasissssyywgwirqppgkglewigtmyyrgstdynpslksrvtisvdtsknqfslrlssvtaadtavyycarrvpgdyycldvwgkgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1702,NaN,NaN,ULE72506,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssypitwvrqapgqgfewmgkiipilgiadyaqsfqgrvtitadkstttaymelsslrsedtavyycarekgysssssatyyldfwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1703,NaN,NaN,ULE72505,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlrlwgagllkpsetlsltcavsggsfidyywtwirqppgkglewigeinhfggsgynpslksrvsisvdtsknqfslrlnsvtaadtaiyycarkpllhssvnpgafdiwgqgtmltvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1704,NaN,NaN,ULE72504,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssypmywvrqapgigleyvsgitdnggstyygdsvkgrftisrdnskntlnlqmnnlrtedtavyycvkgkiqlwlgadywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1705,NaN,NaN,ULE72503,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfssytiiwvrqapgqglewmgrvipvvhithyaqrfrgrvtisadkststaymelsslrsedtavyycarglwfgdsetvwfdpwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1706,NaN,NaN,ULE72502,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfstsvvqwvrqprgqrlewiggivvgrgntkyaqnfqervtitrdmststaymelsnlrsedtavyycaadpfadywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1707,NaN,NaN,ULE72490,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvefggglvqpgrslrlscatsgftfedfdmhwvrqapgkglewvsgstwnsgiigyadsvkgrfttsrdnaknslymqmnnlreedtalyycakdigrydhynifgrvggafdiwgqgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1708,NaN,NaN,ULE72489,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdgdkryspslknrltitedtsknqvvltmtnmdpvdtatyycahhtvptiydywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1709,NaN,NaN,ULE72488,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglilpggslrlscaasgvtvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarggwpsgdtfdiwgqgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1710,NaN,NaN,ULE72487,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsktqfslklssvtaadtavyycardrrgggwtasfdfwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1711,NaN,NaN,ULE72486,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftlssyamnwvrqapgkglewvsaisgsggstyyadsvkgrvtisrdnskntlylqmnslrvedtavyycakdafyygsgshfyyyyymdvwgkgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1712,NaN,NaN,ULE72485,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsdnymswvrqapgkglqwvsviysggntyyadfvkgrfnitrddsknmlylqmnslrredtavyycvrdrrivgyyfgldvwgqgttvtvfs,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1713,NaN,NaN,ULE72484,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaelkkpgssvrvsctasggdftyyplswmrqapgrglewlggiipgyggahvarrfqdrvtitadestttvnmelrslrsddsavyycareegsgwwkhdywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1714,NaN,NaN,ULE72483,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitleesgptlvtptqtltltcsfsgfsldtigvavawirqppgkalewlgtvfwdydkryspplssrltvikdtsqqyvvlrltdvgpgdtatyycarlliehdafdiwgqgavvivss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1715,NaN,NaN,ULE72482,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evhlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggntyyadsvkgrftisrdnskntlylqmnslraedtavyycardrriigyyfgmdvwgrgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1716,NaN,NaN,ULE72481,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfnsysmnwvrqapgkglewvsyistssstmyyadsvkgrftisrdnaknslylqmnslraedtavyycareggwysvgwvdpwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1717,NaN,NaN,ULE72480,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlsctasgitvstnymtwvrqapgkglewvsiiysggstyyadsvkgrftisrdnskntlylqmnslraddtavyyctrggwpsgdtfdiwglgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1718,NaN,NaN,ULE72470,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgitfkdygmhwvrqapgrglewvafisydgsvqhygdsvkgrftisrddlkstlflqmnslrgddtavyycvkgatkidywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1719,NaN,NaN,ULE72469,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansyiteyaasvkgrftisrddsknslylqmnslktedtavyycarvrggewvgdlgwyyyygmdvwgqgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1720,NaN,NaN,ULE72468,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscvdseftfityamswvrqapgkglewvstisgsgdstsyadsvkgrftisrdsskntlflqmhslraedtalyycaksativlmvsaiywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1721,NaN,NaN,ULE72467,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyswswirqspgtglewvgdiystgstnynpslksrltmsldtskshfslklssvaaadtavyycargageqrlvgglfgvshfyyymdvwgkgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1722,NaN,NaN,ULE72466,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqvsgpgllkpsetlsltcivsggsisshywswfrqppgkglewigyiyysgstnynpslksrvaisvdtsknhfslnltsvtaadtavyycargfdywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1723,NaN,NaN,ULE72465,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssygmhwvrqapgkglewvtliwfdgsnqyyadsvkgrftisrdnskntlylqmnslrgedtavyycaregavgatsgldywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1724,NaN,NaN,ULE72464,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggsfssyafswvrqapgqglewmggivgmfgttsysqkfqgrliitadeltstaymelsslrsedtavyfcarsggyrlwfgelwgpgtqvivss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1725,NaN,NaN,ULE72463,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsysinwvrqapgqglewmgwisayngstnyaqklqgrvtmttdtststaymelrslrsddtavyycardpasyydlwsgyvdyyyygmdvwgqgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1726,NaN,NaN,ULE72462,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyvltwvrqapgqglewmgwisayngstnyaqnlqgrvtmttdtststaymelrslrsddtavyycardpasyydfwsgyvdyyyygmdvwgqgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1727,NaN,NaN,NaN,ULE72521,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllfgngytylnwylqkpgqspqlliylgsnrasgvpdrfsvsgsgtdftliisrveaedvgvyfcmqalqtpwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1728,NaN,NaN,NaN,ULE72520,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgdratlscrasqsissflawyqqkpgqaprlliydasnratgvparfsgsgsgtdftltisslepedfavyycqrrsnwppftfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1729,NaN,NaN,NaN,ULE72519,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtatitcsadklgkkyvcwyqqkpgqspvlviyqnnrrpsgiperfsgsnsgntatltisgtqpmdeadyycqawdsstasfvfgtgtkvtvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1730,NaN,NaN,NaN,ULE72518,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeraslscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavywcqqfayslytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1731,NaN,NaN,NaN,ULE72517,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtvtcrasqsisdylnwyqqkpgkapklliyaasslqtgvpprfsgsgsgtdftltisslqpedfatyycqqsfsarvptfgggtkvesk,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1732,NaN,NaN,NaN,ULE72516,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtaprlliyrnsnrpsgvpdrfsgsksgtaaslaisglqaedeadyycqsydssltalvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1733,NaN,NaN,NaN,ULE72515,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeraalscrasqsvagtylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyatsprtfgqgtqleir,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1734,NaN,NaN,NaN,ULE72514,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcranqtissylnwyqqkpgkapkvlifaassleggvpsrfsgsgsgtdftltisslqpedfatyscqqsyntpwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1735,NaN,NaN,NaN,ULE72513,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnityylnwyqqkpgkapnlliytasslqsgvpsrfigsgsgtdftltisslqpedfatyccqqsystpptfgqgtkveir,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1736,NaN,NaN,NaN,ULE72512,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnignntvnwnhqvpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslnawvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1737,NaN,NaN,NaN,ULE72501,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtiscqtsqdisvslnwyqqkpgkppkvliydasnleagapsrfsgsgsgtdftftisslqpediatyycqhydnlprfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1738,NaN,NaN,NaN,ULE72500,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctatssdvgnynyvswyqhhpgkapklliyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnplvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1739,NaN,NaN,NaN,ULE72499,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypeitfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1740,NaN,NaN,NaN,ULE72497,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvtssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtrleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1741,NaN,NaN,NaN,ULE72496,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvrnynlvswyqqhpgkapklmifedskrpsgvsnrfsgsksgntasltiaglqpedeadyyccsyattwvfgggtkvtvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1742,NaN,NaN,NaN,ULE72495,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisdylawyqekpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlsgypytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1743,NaN,NaN,NaN,ULE72498,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlynsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqhystpgytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1744,NaN,NaN,NaN,ULE72494,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvvtqspvslpatpgepasiscrasqsllhrngkhylhwylqrpgqspqlliylgsnrasgvpdrfsgsgsgtvfslkisrveaedvgiyycmqalhfpytfgqgtkldik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1745,NaN,NaN,NaN,ULE72493,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssyvgsfdlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccpyadtwvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1746,NaN,NaN,NaN,ULE72492,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqtvssnflawyqqkpgqaprlliygasiratgipdrfsgsgsatdftltisrlepedfavyycqqygssrtfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1747,NaN,NaN,NaN,ULE72491,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypeitfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1748,NaN,NaN,NaN,ULE72479,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsydhvswfqqhagkgpnvvifdvnsrpsgvsnrfsgsksgntasltisglqaedeadyycfsytsggtrvfgsgttvtvv,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1749,NaN,NaN,NaN,ULE72478,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsnghnfldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1750,NaN,NaN,NaN,ULE72477,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkaprlmiydvsdrpsgvsnrfsgsksgntasltisglrtedeadyycssytststlvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1751,NaN,NaN,NaN,ULE72476,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqtisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1752,NaN,NaN,NaN,ULE72475,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvgsiylawyqqkpgqaprllifgassraigipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1753,NaN,NaN,NaN,ULE72474,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedtkrpsgiperfsgsssgtmatltisgaqvedeadyycysrdssgnplfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1754,NaN,NaN,NaN,ULE72473,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratfscrasqsvnnnylawyqqkpgqaprlltsgtftratgipdrfsgsgsgtdftltisrvesedfavyycqqyggspatfgqgtrleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1755,NaN,NaN,NaN,ULE72472,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyychhygssrltfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1756,NaN,NaN,NaN,ULE72471,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,elvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyycqqygnsrltfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1757,NaN,NaN,UKY18853,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcivsddsinsyywswirqppgrglewigyiyysgstnydpslksratisldtsknqlslkltsvtaadtavyycarsgsygdrtfdhwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1758,NaN,NaN,UKY18852,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgfntnyadsvkgrftisrdnskntlylqmnslraedtavyycakygwgllaaagdafdiwgqgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1759,NaN,NaN,UKY18851,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkisckpsgytftnyliqwvrqapgqslewmgwinagdgysknslsfrgrvtftrdtsastasmelsslnsedtavyycarggfnyghgldywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1760,NaN,NaN,UKY18850,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasryafttyaihwvrqapgqglewmgwintntgdpmyahgftgrfvfslatsvstayleisslkaedtavyycaredtfyfdywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1761,NaN,NaN,UKY18849,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngdtkysqkfqgrvtitrdtsastaymelrslrsedtavyycarpprgyydrsgyynvllyfqhwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1762,NaN,NaN,UKY18848,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftsydlhwvrqapgqrlewmgwinvgngntkysqkflgrvtftrdtsastvymelsslrsedtamyycarpprgyydrtgyynvvhyfqhwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1763,NaN,NaN,UKY18847,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsasywswirqppgkglewigeihhsgstnynpslesrvtisvdtsknqfslklssvtatdtavyycareysstvwdnwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1764,NaN,NaN,UKY18846,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqslsltcnvsggsissnnyywnwirqpagkglewigrgyssgstnynpslksrltisldtsknqfslklssvtaadtavyycarstyyydrsgystsdgmdvwgqgttvivss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1765,NaN,NaN,UKY18845,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgggvvqpgrslrlscavsgftfssygmhwvrqapgkglewvtfisydgsneyyadsvkgrftisrdsskntlylqmnslrpedtavyycakseysyaykvhfldywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1766,NaN,NaN,UKY18844,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsnysissgyywgwirqppgkglewigsifhsgstyynpslkgrvtisvdrsknqfslkltsvtaadtavylcakegargrgattsfyyyymdvwgkgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1767,NaN,NaN,UKY18843,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvdsggglvqpggslrvscaasgftvssnhmswvrqapgkglewvsliygdgsthyadsvkgrftmsrdkskntlylqmnslraedtavyycardvthafdlwgqgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1768,NaN,NaN,UKY18842,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evllvesggglvkpggslrlscaasgfsfssynmnwvrqapgkglewvssissssnyiyyadsvkgrftisrdnaknslylqmnslraedtavyycanmrtnydiftgyypdafdiwgqgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1769,NaN,NaN,UKY18841,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpgvvkpsetlsltcsvsggsisstnyywawirqppgkglewigsifytgstyynpslksrviisvdtsknqfslrltsvtaadtavyycarytsyydrsgfrrveyfqhwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1770,NaN,NaN,NaN,UKY18866,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtatitcsgdklgdkyacwfqqkpgqspvlviyhdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgsstavfgtgtkvtvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1771,NaN,NaN,NaN,UKY18865,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvliqsplslpvtlgqpasiscrssqslvygdgdtylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1772,NaN,NaN,NaN,UKY18864,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvfwyqqhsgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagvtnnlifgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1773,NaN,NaN,NaN,UKY18863,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,esvltqspgtlalspgeratlscrasqsvgsrylawyqqkpgqaprvliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspsfgqgtrleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1774,NaN,NaN,NaN,UKY18862,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpediatyycqqyvnlpltfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1775,NaN,NaN,NaN,UKY18861,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedvatyycqqydnlsltfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1776,NaN,NaN,NaN,UKY18860,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgrhnyvswyqqypgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssayvvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1777,NaN,NaN,NaN,UKY18859,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgervtlscrasqsvsnslawyqqkpgqaprllidgassratgipdrfsgsgsetdftltisrlepedfavyycqqygsspltfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1778,NaN,NaN,NaN,UKY18858,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnsvqwyqqrpgsapttviyednqrpswvpdrfsgsidsssnsasltisglkaedesdyycqsydssnhvlfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1779,NaN,NaN,NaN,UKY18857,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigaghdvhwyqqlpgtapklliygntnrpsgvpdrvsgsksgtsaslaisglqaedeadyycqsydislngwvlgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1780,NaN,NaN,NaN,UKY18856,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqiigmwlawyqqkpgkapklliykassleygvpsrfsgsgsgteftltisslqpddfatyycqqynsdlytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1781,NaN,NaN,NaN,UKY18855,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscsasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslesedfavyycqqyynwppwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1782,NaN,NaN,NaN,UKY18854,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqapsllisgsssratdipdrfsgsgsgtdftltisrlepedfavyfcqqygsspytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1783,NaN,NaN,UKB89181,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycatqggrfycsggscyryyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1784,NaN,NaN,UKB89180,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsvisgsdgstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfvvvvaarshddyyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1785,NaN,NaN,UKB89179,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarwagadgmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1786,NaN,NaN,UKB89178,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvrpggslrlscaasgftfssydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarvrptmtkgfdwyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1787,NaN,NaN,UKB89177,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlsvaggmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1788,NaN,NaN,UKB89176,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardydyvwgsypsaccywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1789,NaN,NaN,UKB89175,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmywvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaralygsgsystqagyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1790,NaN,NaN,UKB89174,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarellllgycsggscypvgpdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1791,NaN,NaN,UKB89173,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissayywgwirqppgkglewigsffhsgstyynpslksrvtitvdtskkqfslklssvtaadtavyycarddygdyavsywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1792,NaN,NaN,UKB89172,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvsshymswvrqapgkglewvsvlysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlhssgpfdafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1793,NaN,NaN,UKB89171,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarhegstsplmvknyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1794,NaN,NaN,UKB89170,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsnnqfslklssvtaadtavyfcardyggnqnyfgywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1795,NaN,NaN,UKB89169,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfgsygmhwvrqapgkglewvavisydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdldivlmvyaiprgyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1796,NaN,NaN,UKB89168,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqksqervtitrdlstrtaymelsslrsedtavyycaapycsggscfdafdmwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1797,NaN,NaN,UKB89167,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlresgpglakpsgtlsltcavsggsitsiywwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyfcasapgtpwfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1798,NaN,NaN,UKB89166,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmsslraedtavyycardlavygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1799,NaN,NaN,UKB89165,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgysftshamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycartsgwsgpsygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1800,NaN,NaN,UKB89164,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssyymnwvrqppgkglewvsviynggnayyadsvkgrftisrdnsrntlylqmnslraedtavyycargkwlrgafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1801,NaN,NaN,UKB89163,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfpfsnygmhwvrqapgkglewvavisydgssqyyadsvkgrftisrdnskntlylqmnslrgddtavyycakdrsvgattsqynyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1802,NaN,NaN,UKB89162,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqsspklgddafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1803,NaN,NaN,UKB89161,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgitftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggtchdgfdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1804,NaN,NaN,UKB89160,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkssetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrlgprgpfdnhgnhfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1805,NaN,NaN,UKB89159,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgrirsktdggtpdyaaplkgrftisrddskntlylqmnslktedtavyycttdsldvgggsyvnfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1806,NaN,NaN,UKB89158,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglecigsihysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhagpyssswianwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1807,NaN,NaN,UKB89157,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhaaprpgdswfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1808,NaN,NaN,UKB89156,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfgsygmhwvrqapgkglewvavisddgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfgstgttlgyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1809,NaN,NaN,UKB89155,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdkarnyydssgyehdafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1810,NaN,NaN,UKB89154,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycardltqdwyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1811,NaN,NaN,UKB89153,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgcirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhvgpysgydknnwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1812,NaN,NaN,UKB89152,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnilraedtavyycarsqstswhdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1813,NaN,NaN,UKB89151,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycatqlwlrsnfdswgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1814,NaN,NaN,UKB89150,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsgdsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknlfslklssvtaadtavyycarrgwlrgyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1815,NaN,NaN,UKB89149,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasrftfsnywmswvrqapgkglewvanikqdgsekycvdsvkgrftisrdnaknslylqmnslraedtavyycaralsmvrgviippyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1816,NaN,NaN,UKB89148,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargiaarpgdwhfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1817,NaN,NaN,UKB89147,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriqsktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdpnqqpprgyyfyygldvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1818,NaN,NaN,UKB89146,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpsltsrvtisvdtsknqfslklssvtaadtavyycarqfwtrppsvwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1819,NaN,NaN,UKB89145,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargtamaygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1820,NaN,NaN,UKB89144,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvetgggliqpggslriscaasgltvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnsrntlylqmnslraedtavyycardlitygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1821,NaN,NaN,UKB89143,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvscrasgytftsygitwvrqapgqglewmgwisvdngntkyaeklqgrvtmttdtststaymelrslgsddtavyycardggwtgimgainfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1822,NaN,NaN,UKB89142,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfsrsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstsaaymelsslrsedtavyycaapacsstrcydgfdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1823,NaN,NaN,UKB89141,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgahywswirqhpgkglewigyiyysggtyynpslkslvtisvdtsknhfslklssvtaadtavyycarttaprpgsswfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1824,NaN,NaN,UKB89140,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasglivssnymswvrqapgkglewvsvlysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarwgrvgatglafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1825,NaN,NaN,UKB89139,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsrnaiswvrqapgqglewmggiipifgtahyaqkfqgrvtitadeststaymelsslrsedtavyycarreysstdwfdpwgqgtrvtvs,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1826,NaN,NaN,UKB89138,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslraedtavyycarggavipvwyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1827,NaN,NaN,UKB89137,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvafisydgddkyyadsvkgrftisrdnskntlylqmnslraedtavyfcakavysyayavlyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1828,NaN,NaN,UKB89136,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglqwvaiisydesskyyadsvkgrftisrdnskntlylqmnslraedtamyycakdppqfavagtgyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1829,NaN,NaN,UKB89135,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysggtysnpslksrvtisvdtsknqlslklssvtaadtavyycarevapikqwlvsyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1830,NaN,NaN,UKB89134,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmkslraedtavyycardrfydysssgysldafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1831,NaN,NaN,UKB89133,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyytpslksrvtisvdtsknqfslklssvtaadtavyycarftrfaglyyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1832,NaN,NaN,UKB89132,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhmsgthssgwyerwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1833,NaN,NaN,UKB89131,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqvawlprddyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1834,NaN,NaN,UKB89130,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1835,NaN,NaN,UKB89129,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaraaydiltgyyrgmdvwgkgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1836,NaN,NaN,UKB89128,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmsslragdtavyycarghfygligymdvwgkgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1837,NaN,NaN,UKB89127,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaignagdtyypasvkgrftisrenarnslylqmnslragdtavyycarvrptmtkgfdwyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1838,NaN,NaN,UKB89126,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakdtyydifpdvfdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1839,NaN,NaN,UKB89125,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgdtnytqkfqervtitrdmststaymelsslrsedtavyycaapycsgsscldgfdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1840,NaN,NaN,UKB89124,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakapyaycsstscyadyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1841,NaN,NaN,UKB89123,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtgdtststvymelsslrsedtavyycarggivpaatllfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1842,NaN,NaN,UKB89122,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgshntnyaqkfqervtitrdmststaymelssltsedtavyycaaaiiasaapdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1843,NaN,NaN,UKB89121,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfnnyemnwvrqapgkglewvsyissggttmyyadsvkgrftisrdnaknslylemnslraedtalyycarvghpdtlfgveywgqgilvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1844,NaN,NaN,UKB89120,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifnnyemnwvrqapgkglewisyissggttvyyadsvkgrftisrdnaknslylqmsslraedtalyycvrvghpdtlfgvdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1845,NaN,NaN,UKB89119,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgggwydykgyyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1846,NaN,NaN,UKB89118,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgtqpipdygdffdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1847,NaN,NaN,UKB89117,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarwaqqlvpsenlkpyyyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1848,NaN,NaN,UKB89116,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarqpreyydfwsgyrrlfyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1849,NaN,NaN,UKB89115,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsggscydafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1850,NaN,NaN,UKB89114,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardgtshyydssgyygadrnwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1851,NaN,NaN,UKB89113,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsihysgstyynpslksrvtisvdtsknqfslklssmtaadtavyycarhtgyydssgyyrleyfqhwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1852,NaN,NaN,UKB89112,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewiayiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgynyglglgwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1853,NaN,NaN,UKB89111,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnglraedtavyycakvlgsycsggscyggsfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1854,NaN,NaN,UKB89110,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksgapaamrgyyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1855,NaN,NaN,UKB89109,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdafgdpqglygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1856,NaN,NaN,UKB89108,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgddygdlfyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1857,NaN,NaN,UKB89107,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkrpgssvkvsckasggtfsnygfswvrqapgqglewmggtsplfhtpnyvqkfqdrvtitadesttsvymelnsltsddtavyycacssgrwgvlgnyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1858,NaN,NaN,UKB89106,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssygiswvrqapgqglewmggiipifgtayyaqkfqgrvtitadeststaymelsslrsedtavyycassspllryfdwpheaifdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1859,NaN,NaN,UKB89105,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmtwvrqapgkglewvgriksktdggttdyaapvkgrftisrddsknmlylqmnslktedtavyycttdpgytyspaywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1860,NaN,NaN,UKB89104,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvssissnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvkdvtvdtamvtifdnwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1861,NaN,NaN,UKB89103,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvstigtsgdtyypgsvkgrftisrenaknslylqmnslragdtavyycargggdgynlglwyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1862,NaN,NaN,UKB89102,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfpssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcgggscydgfdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1863,NaN,NaN,UKB89101,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfpfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfqyvaathspyyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
1864,NaN,NaN,NaN,UKB89262,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgegtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1865,NaN,NaN,NaN,UKB89261,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyknfpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1866,NaN,NaN,NaN,UKB89260,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssqytfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1867,NaN,NaN,NaN,UKB89259,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlgtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1868,NaN,NaN,NaN,UKB89258,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltigrlepedfavyycqqygssppitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1869,NaN,NaN,NaN,UKB89257,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsglsnrfsgsksgntasltisglqaedeadyycssytsstnwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1870,NaN,NaN,NaN,UKB89256,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyraftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1871,NaN,NaN,NaN,UKB89255,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1872,NaN,NaN,NaN,UKB89254,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1873,NaN,NaN,NaN,UKB89253,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvaitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftisslqpediatyycqqydivgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1874,NaN,NaN,NaN,UKB89252,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1875,NaN,NaN,NaN,UKB89251,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditnslnwyqqkpgkapklliydasnletgvpssfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1876,NaN,NaN,NaN,UKB89250,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeaayycssytsssppvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1877,NaN,NaN,NaN,UKB89249,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1878,NaN,NaN,NaN,UKB89248,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgrynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1879,NaN,NaN,NaN,UKB89247,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqipgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydsslitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1880,NaN,NaN,NaN,UKB89246,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qavvtqepsltvspggtvtltcasstgavtsgyypnwfqqkpgqapraliysisnkhswtparfsgsllggkaaltlsgvqpedeaeyycllyfggaqyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1881,NaN,NaN,NaN,UKB89245,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapitviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssdlwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1882,NaN,NaN,NaN,UKB89244,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqfpgtapklliydndkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwetslsaevfgggtrltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1883,NaN,NaN,NaN,UKB89243,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1884,NaN,NaN,NaN,UKB89242,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1885,NaN,NaN,NaN,UKB89241,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrviitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltvsslqpedfatyycqqlnsypwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1886,NaN,NaN,NaN,UKB89240,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsvsvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1887,NaN,NaN,NaN,UKB89239,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteltltisslqpedfatyycqqlnsypltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1888,NaN,NaN,NaN,UKB89238,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqafsswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfptfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1889,NaN,NaN,NaN,UKB89237,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1890,NaN,NaN,NaN,UKB89236,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1891,NaN,NaN,NaN,UKB89235,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgthftlaisslqpedfatyycqqsystppitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1892,NaN,NaN,NaN,UKB89234,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1893,NaN,NaN,NaN,UKB89233,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidtssnsasltisglktedeadyycqsydnnnhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1894,NaN,NaN,NaN,UKB89232,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwhqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1895,NaN,NaN,NaN,UKB89231,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydstnhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1896,NaN,NaN,NaN,UKB89230,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidiysnsasltisglktedeadyycqsydssnhwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1897,NaN,NaN,NaN,UKB89229,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsrgvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1898,NaN,NaN,NaN,UKB89228,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqapmtlicdtsnkhswtparfsgsllgdkaaltlsgaqpedeaeyycllsysgapvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1899,NaN,NaN,NaN,UKB89227,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignyyvswyqqlprtapklliydnnerpsgipdrfsgsksgtsatlaitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1900,NaN,NaN,NaN,UKB89226,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnniggqsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1901,NaN,NaN,NaN,UKB89225,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqginsylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyscqhlltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1902,NaN,NaN,NaN,UKB89224,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywcqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddslsgwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1903,NaN,NaN,NaN,UKB89223,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqapslliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1904,NaN,NaN,NaN,UKB89222,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlaitglqtgdeadyycgtwdntlspgrgvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1905,NaN,NaN,NaN,UKB89221,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgqtariscggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsdsnsgntatltisrveagdeadyycqvwdsssdhhyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1906,NaN,NaN,NaN,UKB89220,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1907,NaN,NaN,NaN,UKB89219,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyshpgitfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1908,NaN,NaN,NaN,UKB89218,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsfasnsvqwyqqrpgsapttmiyednhrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydynnhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1909,NaN,NaN,NaN,UKB89217,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsknvhwyhqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1910,NaN,NaN,NaN,UKB89216,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvqwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsglvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1911,NaN,NaN,NaN,UKB89215,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvseaprqrvtiscsgsssnignnavnwfqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaawddslnawvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1912,NaN,NaN,NaN,UKB89214,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklliyevskrpsgvpdrfsgsksgntasltvsglraddeadyycssyagtvlfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1913,NaN,NaN,NaN,UKB89213,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1914,NaN,NaN,NaN,UKB89212,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvgfynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnyvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1915,NaN,NaN,NaN,UKB89211,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsnsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsksgntatltisrveagdeadyycqvwdsssdhpvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1916,NaN,NaN,NaN,UKB89210,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgidftltisslqpedfatyycqqsyniastfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1917,NaN,NaN,NaN,UKB89209,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqklgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1918,NaN,NaN,NaN,UKB89208,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlgtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1919,NaN,NaN,NaN,UKB89207,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitiscagtssdlggyyyvswyqhhpgkapklmiyevsnrpsgisnrfsgsksgntasltisglqaedeadyycssytssstlpvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1920,NaN,NaN,NaN,UKB89206,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspdtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftlaisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1921,NaN,NaN,NaN,UKB89205,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1922,NaN,NaN,NaN,UKB89204,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyscsfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1923,NaN,NaN,NaN,UKB89203,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1924,NaN,NaN,NaN,UKB89202,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscgasqsisstlawyqhkpgqaprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynnwprysfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1925,NaN,NaN,NaN,UKB89201,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqapslliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprysfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1926,NaN,NaN,NaN,UKB89200,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1927,NaN,NaN,NaN,UKB89199,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppctfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1928,NaN,NaN,NaN,UKB89198,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgytfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1929,NaN,NaN,NaN,UKB89197,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1930,NaN,NaN,NaN,UKB89196,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1931,NaN,NaN,NaN,UKB89195,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedgadyycqsydsslsgwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1932,NaN,NaN,NaN,UKB89194,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylywyqqkpgkapkvliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1933,NaN,NaN,NaN,UKB89193,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnlergvpsrfsgsgsgtdftftisslqaediatyycqqyddvpftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1934,NaN,NaN,NaN,UKB89192,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkvliydassleagvpsrfsgsgsgtdftftisslqpediatyycqqydnlpsfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1935,NaN,NaN,NaN,UKB89191,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgaqpedeadyycllsysgarevfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1936,NaN,NaN,NaN,UKB89190,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfaqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1937,NaN,NaN,NaN,UKB89189,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrtltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1938,NaN,NaN,NaN,UKB89188,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditdylnwyqqkpgqapklliydasnletgvpsrfsgsgsgtdftltisslqpediatyycqqyanllltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1939,NaN,NaN,NaN,UKB89187,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwsgitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1940,NaN,NaN,NaN,UKB89186,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcragqsissylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1941,NaN,NaN,NaN,UKB89185,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1942,NaN,NaN,NaN,UKB89184,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqrkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnppptfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1943,NaN,NaN,NaN,UKB89183,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1944,NaN,NaN,NaN,UKB89182,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylacyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgvtfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
1945,N3113.1,NaN,7VNE_V,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqapgkaqewigsmypsgrtyinpslkslvtisrdnskntlylqlnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain V, n3113.1",NaN,2022-10-12,NaN,NaN
1946,N3113.1,NaN,7VNE_U,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqapgkaqewigsmypsgrtyinpslkslvtisrdnskntlylqlnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain U, n3113.1",NaN,2022-10-12,NaN,NaN
1947,N3113.1,NaN,7VNE_W,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqapgkaqewigsmypsgrtyinpslkslvtisrdnskntlylqlnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain W, n3113.1",NaN,2022-10-12,NaN,NaN
1948,N3113,NaN,7VND_D,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain D, n3113",NaN,2022-10-12,NaN,NaN
1949,N3113,NaN,7VND_V,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain V, n3113",NaN,2022-10-12,NaN,NaN
1950,N3113,NaN,7VNC_V,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain V, n3113",NaN,2022-10-12,NaN,NaN
1951,N3113,NaN,7VNB_A,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain A, n3113",NaN,2022-10-12,NaN,NaN
1952,GAMMA-1,NaN,7NP1_K,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsggglvkpggslrlscaasgitvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargeggsivgvtsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,"Chain K, Immunoglobulin gamma-1 heavy chain",NaN,2022-10-12,NaN,NaN
1953,GAMMA-1,NaN,7NP1_J,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsggglvkpggslrlscaasgitvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargeggsivgvtsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,"Chain J, Immunoglobulin gamma-1 heavy chain",NaN,2022-10-12,NaN,NaN
1954,GAMMA-1,NaN,7NP1_I,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsggglvkpggslrlscaasgitvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargeggsivgvtsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,"Chain I, Immunoglobulin gamma-1 heavy chain",NaN,2022-10-12,NaN,NaN
1955,GAMMA-1,NaN,7NP1_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsggglvkpggslrlscaasgitvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycargeggsivgvtsdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,"Chain H, Immunoglobulin gamma-1 heavy chain",NaN,2022-10-12,NaN,NaN
1956,NaN,NaN,7BNV_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhpspyyygsgsysggfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,"Chain H, Heavy Chain",NaN,2022-10-12,NaN,NaN
1957,NaN,NaN,NaN,7NP1_O,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,asdiqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgseteftltisslhpddfatyycqqsystlpytfgqgtkveikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,NaN,"Chain O, Immunoblobulin light chain",2022-10-12,NaN,NaN
1958,NaN,NaN,NaN,7NP1_N,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,asdiqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgseteftltisslhpddfatyycqqsystlpytfgqgtkveikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,NaN,"Chain N, Immunoblobulin light chain",2022-10-12,NaN,NaN
1959,NaN,NaN,NaN,7NP1_M,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,asdiqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgseteftltisslhpddfatyycqqsystlpytfgqgtkveikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,NaN,"Chain M, Immunoblobulin light chain",2022-10-12,NaN,NaN
1960,NaN,NaN,NaN,7NP1_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,asdiqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgseteftltisslhpddfatyycqqsystlpytfgqgtkveikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,NaN,"Chain L, Immunoblobulin light chain",2022-10-12,NaN,NaN
1961,NaN,NaN,NaN,7BNV_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,asdivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqydnwplmhtfgqgtkleikrtaaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgec,"Bullen,G. et al.; Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses; Front Immunol 12, 678570 (2021); 2021.",10.3389/fimmu.2021.678570,NaN,"Chain L, Light Chain",2022-10-12,NaN,NaN
1962,NaN,NaN,7MZM_H,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkgpewvsyisggssftnyadsvqgrftiyrdnaknsmflrmnslraedtavyycarspptgdssdwydspaynnyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 215 heavy chain",NaN,2022-10-12,NaN,NaN
1963,NaN,NaN,7MZL_H,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcvvygetlsgyywtwirqspgkglewigeislrgtanynpslksrvtlsveasknqfslkmtsvtaadtavyycvggvvldnvvwfdpwgqgipvtvslastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 210 heavy chain",NaN,2022-10-12,NaN,NaN
1964,NaN,NaN,7MZK_H,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),lvqlvqsgaevkkpgasvkisckasgytftsyymhwvrqapgqglewmgiinpsgggtsyaqkfqgrvtmtrdtststvymeltslrsddtavyycakdrvtifwgngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 96 heavy chain",NaN,2022-10-12,NaN,NaN
1965,NaN,NaN,7MZK_N,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),lvqlvqsgaevkkpgasvkisckasgytftsyymhwvrqapgqglewmgiinpsgggtsyaqkfqgrvtmtrdtststvymeltslrsddtavyycakdrvtifwgngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain N, PDI 96 heavy chain",NaN,2022-10-12,NaN,NaN
1966,NaN,NaN,7MZK_F,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain F, WCSL 129 heavy chain",NaN,2022-10-12,NaN,NaN
1967,NaN,NaN,7MZK_C,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain C, WCSL 129 heavy chain",NaN,2022-10-12,NaN,NaN
1968,NaN,NaN,7MZJ_N,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),vvqlvesggglvkpggslrlscaasgftfsyawmswvrqapgkglewvgrikrksdggttdyaapvkgrftisrddskntlylqmsslktedtavyycttdlcrstscehdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain N, PDI 93 heavy chain",NaN,2022-10-12,NaN,NaN
1969,NaN,NaN,7MZJ_H,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),vvqlvesggglvkpggslrlscaasgftfsyawmswvrqapgkglewvgrikrksdggttdyaapvkgrftisrddskntlylqmsslktedtavyycttdlcrstscehdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 93 heavy chain",NaN,2022-10-12,NaN,NaN
1970,NaN,NaN,7MZJ_F,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain F, WCSL 129 heavy chain",NaN,2022-10-12,NaN,NaN
1971,NaN,NaN,7MZJ_C,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain C, WCSL 129 heavy chain",NaN,2022-10-12,NaN,NaN
1972,NaN,NaN,7MZI_H,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsrfamtwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakvgwgafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, WCSL 129 heavy chain",NaN,2022-10-12,NaN,NaN
1973,NaN,NaN,7MZH_B,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarsyydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain B, WCSL 119 heavy chain",NaN,2022-10-12,NaN,NaN
1974,NaN,NaN,7MZH_H,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgrinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarsyydywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, WCSL 119 heavy chain",NaN,2022-10-12,NaN,NaN
1975,NaN,NaN,7MZG_H,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsvfypggstynadsvkgrftisrdnskntlylqmnslraedtavyycardavyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 42 heavy chain",NaN,2022-10-12,NaN,NaN
1976,NaN,NaN,7MZF_H,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymswvrqapgkglewvsviysggttyyadsvkgrftisrdsskntlylqmnslraedtavyycardrgdylfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkth,NaN,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,"Chain H, PDI 37 heavy chain",NaN,2022-10-12,NaN,NaN
1977,NaN,NaN,NaN,7MZM_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,eivltqspvtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtsptvtfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain L, PDI 215 light chain",2022-10-12,NaN,NaN
1978,NaN,NaN,NaN,7MZK_D,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain D, WCSL 129 light chain",2022-10-12,NaN,NaN
1979,NaN,NaN,NaN,7MZK_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,divmtqspvslavslgeratikckssqsvlyssnnknylgwyqqkpgqplrlliywastresgvpdrfsgsgsgtdftltisslqaedvavyychqysttpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain L, PDI 96 light chain",2022-10-12,NaN,NaN
1980,NaN,NaN,NaN,7MZK_M,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,divmtqspvslavslgeratikckssqsvlyssnnknylgwyqqkpgqplrlliywastresgvpdrfsgsgsgtdftltisslqaedvavyychqysttpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain M, PDI 96 light chain",2022-10-12,NaN,NaN
1981,NaN,NaN,NaN,7MZK_E,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain E, WCSL 129 light chain",2022-10-12,NaN,NaN
1982,NaN,NaN,NaN,7MZJ_M,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtvtcrasqsirsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpaitfgqgtrvqikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain M, PDI 93 light chain",2022-10-12,NaN,NaN
1983,NaN,NaN,NaN,7MZJ_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtvtcrasqsirsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpaitfgqgtrvqikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain L, PDI 93 light chain",2022-10-12,NaN,NaN
1984,NaN,NaN,NaN,7MZJ_E,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain E, WCSL 129 light chain",2022-10-12,NaN,NaN
1985,NaN,NaN,NaN,7MZJ_D,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain D, WCSL 129 light chain",2022-10-12,NaN,NaN
1986,NaN,NaN,NaN,7MZI_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsasgtpgqsvsiscsgtysnigsnpvnwyqqvpgtapklliyandqrpsgvpdrfsgsksatsaflaigglqseddadyycstwddslpgplfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain L, WCSL 129 light chain",2022-10-12,NaN,NaN
1987,NaN,NaN,NaN,7MZH_C,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsvseaprqrvtiscsgsssnighnavhwyqqlpgkapklliyyddllpagvsdrfsgsksgtsaslaisglqsedeadyycaawddilngpvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain C, WCSL 119 light chain",2022-10-12,NaN,NaN
1988,NaN,NaN,NaN,7MZH_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,qsvltqppsvseaprqrvtiscsgsssnighnavhwyqqlpgkapklliyyddllpagvsdrfsgsksgtsaslaisglqsedeadyycaawddilngpvfgggtkltvlgqpkanptvtlfppsseelqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain L, WCSL 119 light chain",2022-10-12,NaN,NaN
1989,NaN,NaN,NaN,7MZG_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaiyycqesystpglftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain L, PDI 42 light chain",2022-10-12,NaN,NaN
1990,NaN,NaN,NaN,7MZF_L,"['COVID', 'SARS-COV-2', 'RBD']",Homo sapiens (human),NaN,diqmtqppsplfasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgseteftltisslqpddfatyycqqynsyfptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Wheatley,A.K. et al.; Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain; Cell Rep 37 (2), 109822 (2021); 2021.",10.1016/j.celrep.2021.109822,NaN,"Chain L, PDI 37 light chain",2022-10-12,NaN,NaN
1991,C5,NaN,7OAU_FFF,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain FFF, C5",NaN,2022-10-12,NaN,NaN
1992,C5,NaN,7OAU_BBB,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain BBB, C5",NaN,2022-10-12,NaN,NaN
1993,H3,NaN,7OAQ_FFF,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),maqvqlvesggglvktggslrlscaasgrtfstysmgwfrqapgkerefvagmrwtgsstfysdsvkgrftvsrnnakdtvylhmnslkpedtavyycaittivrayyteyteadfgswgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain FFF, H3",NaN,2022-10-12,NaN,NaN
1994,H3,NaN,7OAQ_AAA,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),qvqlvesggglvqpggslrlscaasgftndfysiawfrqapgkeregvswlsvsdntptyvdsvkdrftisrhnanntvylqmnmlkpedtaiyycaagrfagrdtwpssydywgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain AAA, H3",NaN,2022-10-12,NaN,NaN
1995,NaN,NaN,7OAN_H,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain H, immunoglobulin mu heavy chain",NaN,2022-10-12,NaN,NaN
1996,NaN,NaN,7OAN_G,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain G, immunoglobulin mu heavy chain",NaN,2022-10-12,NaN,NaN
1997,NaN,NaN,7OAN_F,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain F, immunoglobulin mu heavy chain",NaN,2022-10-12,NaN,NaN
1998,NB21,NaN,7MDW_A,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),qvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvss,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain A, nonobody Nb21",NaN,2022-10-12,NaN,NaN
1999,SR31,NaN,7D2Z_A,NaN,"['COVID', 'SARS-COV-2', 'RBD']",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvwqgemawyrqapgkerewvaaissmgyktyyadsvkgrftisrdnakntvylqmnslkpedtavyycavmvgfwyagqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Yao,H. et al.; A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2; PLoS Pathog 17 (3), e1009328 (2021); 2021.",10.1371/journal.ppat.1009328,"Chain A, SR31 against SARS-CoV-2 RBD, non neutralizing",NaN,2022-10-12,NaN,NaN
2000,C1A-B12,NaN,7KFV_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggatyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,NaN,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,"Chain H, Heavy chain of antibody C1A-B12 Fab",NaN,2022-10-12,NaN,NaN
2001,C1A-B12,NaN,7KFV_F,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggatyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,NaN,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,"Chain F, Heavy chain of antibody C1A-B12 Fab",NaN,2022-10-12,NaN,NaN
2002,C1A-B12,NaN,7KFV_C,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggatyyadsvkgrftisrdnskntlylqmnslraedtavyycargdvsgyrygldywgqgtlvtvsgastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdr,NaN,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,"Chain C, Heavy chain of antibody C1A-B12 Fab",NaN,2022-10-12,NaN,NaN
2003,NaN,C1A-B3,NaN,7KFV_L,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlisypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,NaN,"Chain L, light chain of antibody C1A-B3 Fab",2022-10-12,NaN,NaN
2004,NaN,C1A-B3,NaN,7KFV_G,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlisypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,NaN,"Chain G, light chain of antibody C1A-B3 Fab",2022-10-12,NaN,NaN
2005,NaN,C1A-B3,NaN,7KFV_D,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlisypgtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Clark,S.A. et al.; Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2; bioRxiv (2020); 2020.",10.1101/2020.11.13.381533,NaN,"Chain D, light chain of antibody C1A-B3 Fab",2022-10-12,NaN,NaN
2006,NaN,NaN,7K9Z_B,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasggtfstygiswvrqapgqglewmgwispnsggtdlaqkfqgrvtmtrdtststvymelsslrsedtavyycasdprddiaggywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.",NaN,"Chain B, Fab Heavy Chain",NaN,2022-10-12,NaN,NaN
2007,NaN,NaN,7K9Z_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmggiipmfgttnyaqkfqgrvtitadkststaymelsslrsedtavyycardrgdtidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Rujas,E. et al.; Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers; Biorxiv (2020); 2020.",NaN,"Chain H, Fab Heavy Chain",NaN,2022-10-12,NaN,NaN
2008,NaN,NaN,NaN,5ZXV_D,"['MERS', 'Spike protein']",Homo sapiens (human),NaN,svltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,NaN,"Chain D, light chain",2022-10-12,NaN,NaN
2009,NaN,NaN,NaN,5ZXV_L,"['MERS', 'Spike protein']",Homo sapiens (human),NaN,svltqspsasgtpgqrvtiscsgsssnignnyvywyqqlpgtapklliywndqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgavfgggtqltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Zhang,S. et al.; Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein; Cell Rep 24 (2), 441-452 (2018); 2018.",10.1016/j.celrep.2018.06.041,NaN,"Chain L, light chain",2022-10-12,NaN,NaN
2010,NaN,NaN,UIK23909,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyaihwvrqapgkglewvaiisydgsnkyyadsvkgrftisrdnsnntvylqinslrtedtavyycaksragsyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2011,NaN,NaN,UIK23908,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisctgsgysfttywigwvrqmpgkglewmgviypgdsdtryspsfqgqvtfsadksistaylqwsslkasdtaiyycarhgnryssgwyqptgvdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2012,NaN,NaN,UIK23907,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgasigsyywswirqppgkgleyigyiyysgstdynpslksrvtisidtsknlfslnltsvtaadtavyycargfdswgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2013,NaN,NaN,UIK23906,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggdvvqpgrslrlscaasgftfstyamhwvrqapgkglewvslisydginkyyagsvkgrfsisrdnskntlylqmnslrvedtavyycarslsggyyygmgvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2014,NaN,NaN,UIK23905,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwyhgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardretstnyvghyyngmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2015,NaN,NaN,UIK23904,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftgyyihwvrqapgqglewmgwvnpnsgatncaqkfqgrvtmtrdtsittvymelsrlkfddtavyycargvdfsifgaaisddwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2016,NaN,NaN,UIK23903,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsenlsltcnvagdsisgyywswirqtpgkglefigymyyggstiynpslrtrvtisidtsknqfslnlnsvtaadtaiyycargfdlwgrgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2017,NaN,NaN,UIK23902,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsgyamhwvrqapgkglewvavisydgdnkyyadsvrgrftisrdnskntlylqmnslrvedtavyycarsssgsyfaafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2018,NaN,NaN,UIK23901,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyfwtwirqppgkglewighifysgstyynpslksrvtisldtsknqfslklssvtaadtavyycarvvlaknyydrsgyfhgdwyfygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2019,NaN,NaN,UIK23900,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvssvsgsgdrtyyadsvkghfiisrdnskntlylqmnslraedtavyycatdsyyhdrdgfvnyafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2020,NaN,NaN,UIK23899,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfnfnnvwmswvrqapgkglewvgliksksdggtkdyaapvrgrftisrddprnnlylqmnslktedtavyycstapyyydysaypqihfeywgrgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2021,NaN,NaN,UIK23898,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglecvsviygggptyyadsvkgrftisrdnskntlylqmnslraedtavyycardkripyyfygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2022,NaN,NaN,UIK23897,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasrfpfstygmhwarrapgkglewvslisddgknkyyadsvkgrftisrdnyentlylemnslrpedtavyycakailrgvkyylygvdiwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2023,NaN,NaN,UIK23896,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpgvvkpsetlsltctvsgdsissyywswirqspgkglewigyiyssgstnynpslksrvamsvdtsknhfslkmtsvtaadtavyycargfdfwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2024,NaN,NaN,UIK23895,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsnrymswvrqtpgkglewvsiiysagstyyadsvkgrftisrdnskntlylqmnslrvedtavyycaragsplslrwrphidywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2025,NaN,NaN,UIK23894,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqvqqwgagllkpsetlsltcavyggsfsdyswtwirqspgkglewigeindsgitnydptlksriimsvdrsknqfslrltsvtaadtavyfcargstvlglsslryyssldvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2026,NaN,NaN,UIK23893,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsggevkkpgasvkvsckasgytftnyglswvrqapgqglewmgwisgnngntnyaqkfqgrvtmttdtststgymelrslrsddtavyycardqstvvtfgtfdywgqgtlltvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2027,NaN,NaN,UIK23892,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpggslrlscaasgftfssygmhwvrqapgkglewvafirydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaspsryydssgyylaeyfqhwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2028,NaN,NaN,UIK23891,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpgpvkpsgtlsltcavsgdsitntnwwswvrqspggglewigeihhsgttnyksslksrviisidksknqfslkmrsvtaadtalyycargrynwnggyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2029,NaN,NaN,UIK23890,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvnvsckasggtfssyaiswvrqapgqglewmggifplygttkyaqqfqgrvtfsadestrtaymdlrslrsedtavyycarsadgdyvvgyyhymdvwgkgttvivss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2030,NaN,NaN,UIK23889,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggtfssytfswvrqapgqglewmgvfipifgttsyaqkfqgrvtitadestytsymelssltsedtamyycasrlgcpngachepdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2031,NaN,NaN,UIK23888,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlsctasgftfntyaihwvrqapgkglesvalisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycargtggnyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2032,NaN,NaN,UIK23887,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmagimpifgrpnyaqkfqgrvtitadeststaymelsslrsedtavyycasrhsgyryshfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2033,NaN,NaN,UIK23886,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggwvqpggslrlscaasefsvstnymtwvrqapgkglewvsiiysdgrtfyadsvkgrftisrdnskntvylqmnnlrpedtavyfcararvtiivvvvdyffdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2034,NaN,NaN,UIK23885,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvkpggslrlscaasgftfynawmswvrqapgkglewvghikgntnggttdyaapvkgrftisrddskntlylqmnslrtedtgvyycttetllwfgespfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2035,NaN,NaN,UIK23884,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgvtvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrddsmntlylqmsnvraedtavyycardlyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2036,NaN,NaN,UIK23883,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfnsyaftwvrqapgqglewmgaiipilgianheqkfqdratitadkststaymelrslrsddtavyycasgvvvpatdyyyamdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2037,NaN,NaN,UIK23882,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgfifsssamswvrqapgkglewvsgisdsglrtyygdsvkgrftisrdnskntvsllmnslraedtavyycaygyspdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2038,NaN,NaN,UIK23881,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnnlrdedtamyycardlivygmdvwgqgtpvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2039,NaN,NaN,UIK23880,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymswvrqapgkglewvsiiyaggstfyadsvkgrftisrdnskntlylqmnslraedtavyyctrdlvyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2040,NaN,NaN,UIK23879,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglaqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfysdsvkgrftisrdgpkntlylhmhslraedtavyycardlvhygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2041,NaN,NaN,UIK23878,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwirqapgkglewvaviwsdginkyyvdsvkgrftisrdnskntlylqmnslraddtavyycarapqdpdsssyyyfyygldvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2042,NaN,NaN,UIK23877,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftayyihwvrqapgqglewmawinpmsgatnytqkfqgrvtmtrdtsittvymelsrlrsadtavyycarvspptifgvtvdhwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2043,NaN,NaN,UIK23876,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymnwirqapgkglewvssisttgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarddssgyyygsaldwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2044,NaN,NaN,UIK23875,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfytdsvkgrftisrdnskntlylqmnslraedtavyycardlvvlygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2045,NaN,NaN,UIK23874,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaapgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2046,NaN,NaN,UIK23873,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfnnyainwvrqapgqglewmgriipmlgvvnhaqkfqgrvtitadkststaymelsslrsedtavyycatrvsvttmgvnfdgmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2047,NaN,NaN,UIK23872,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymtwvrqapgkglewvsvlyaggssfyadsvkgrftisrdnskntlflqmnslraedtavyycardlvaygmdvwgqgttvsvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2048,NaN,NaN,UIK23871,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpessvkvsckvsggtfssygiswvrqapgqglewmgriipslgvvnyaqrfqgrvtftadkststaymdlsslksedtavyycakttvvtpglgkdafdvwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2049,NaN,NaN,UIK23870,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgyiftnfwiawvrqmpgkglewmgiiypddsdvrysppfqgqvtisadksintaylqwsslkasdtamyycarlsflpsgfshyyaldvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2050,NaN,NaN,UIK23869,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvalisydgsneyyadsvrgrftisrdnskntlylqmsslraedttmyycaranrgnyyygmdvwgpgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2051,NaN,NaN,UIK23868,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqleqsgaevkkpgssvkvsckasgssfssyaitwvrqapgqglewmggiipifgtanyaqifqgrvtltaeestgaaymelsslrsedtalyyctiigmfdssgsythywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2052,NaN,NaN,UIK23867,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifntyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskstlylqmnslriedtavyycarsrsgsyfsafdiwgqgtkvtvsp,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2053,NaN,NaN,UIK23866,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvrpgrslrlscaasgftfssygmhwvrqapgkglewvalisydginkyypdsvkgrftisrdnsnntlylqmnslraedtavyycanaktgnyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2054,NaN,NaN,UIK23865,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsistyywswirqppgkrlewigyiyysgstnynpslksrvtisvdtsknqfslklnsvtaadtaiyycargfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2055,NaN,NaN,UIK23864,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydgdkkyytdsvkgrftisrdnskntlflqmnslraedtavyycararegtyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2056,NaN,NaN,UIK23863,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarlsfgyssssnyyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2057,NaN,NaN,UIK23862,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscavsgftfrsyamswvrqapgkglewvstisgsggrtdyadsvkgrftisrdnskntlyvqmsslraedtavyycalpylgwlrsfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2058,NaN,NaN,UIK23861,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqisgpglekpsgtlsltctvsggsvsrsdfywgwvrqppgkglewigsihysgstyynpslksrvtisvdtsenqlslrlssvtaadtavyycarsggysygravwfdnwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2059,NaN,NaN,UIK23860,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsisaihwvrqapgkglewvavisydgfnkyyedsvkgrfiisrdnskntlylqmnslrvedtavyycakgggsyyhpfdnwgqgtlvsvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2060,NaN,NaN,UIK23859,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptvvkptqtltltctfsgfslsisgegvgwirqppgkalewlaliywnderrytpslksrlsitkdtsknqvvltmtnmdpvdtatyycahtyyydsrgyafdnwgqgtlvpvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2061,NaN,NaN,UIK23858,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavfggsfsayywnwirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargsreqwlvrrawyfdlwgrgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2062,NaN,NaN,UIK23857,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcavsggsisiyywswirqppgkglewigyishsgdtnynpslksrvtisvdtsknqfslrlssvtaadtalyycargdimwtqwltsggrfldywgqgalvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2063,NaN,NaN,UIK23856,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsisgyywswirqspgkglewmgylyysgsinynpslksrvtisidtsknqfslkmrsvtaadtavyycargfeswgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2064,NaN,NaN,UIK23855,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgntfidsymhwvrqapgqglewmglidpsgknryypqnfqgrltltrdaststtymqlsslrsqdtavyycarmteagswdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2065,NaN,NaN,UIK23854,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyaiywvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlslqlnslraedtavyycarmhsgsyigyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2066,NaN,NaN,UIK23853,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfitysfhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarqksqwellfrgdafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2067,NaN,NaN,UIK23852,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyaihwvrqapgkglewvaliaydgdkkyyadsvrgrftlsrdnskntlylemnslraedtavyycarpysgsyygafeiwgqgtmvtvsa,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2068,NaN,NaN,UIK23851,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnsnstlylqmnslraedtalyycarggyhyfrhfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2069,NaN,NaN,UIK23850,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),dvllvesggglvqpggslrlscsasgfpfitywmswvrqapgkglewvanikedgsekyyvdsvrgrftisrdnaenslslqmnslraddtavyycartggrgsldrgrfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2070,NaN,NaN,UIK23849,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscvvsgftfntyamhwvrqapgkglewvavisydgnnhysadsvrgrfsvsrdnskktlflqmnslraedtavyycarsyggnylgyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2071,NaN,NaN,UIK23848,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsmyysgstnynpslksrvtisldtsknqfslkltsvtaadtavyycarrrrgysyghptyhafdmwgqgtmvtvsa,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2072,NaN,NaN,UIK23847,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarhslrggtrggyyyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2073,NaN,NaN,UIK23846,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggavvqpgrslrlsceasgftfstyamhwvrqapgkglewvalvsydgsnkyyadsvkgrftisrdnskntlylqmdslraedsavyycaralsgsyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2074,NaN,NaN,UIK23845,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscavsgftfgsywmswvrqapgrglewvanirqdgsekyyvdsvkgrftisrdnaknsmylqmnslraedtavyycakenivavpaargydyyyymdvwgkgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2075,NaN,NaN,UIK23844,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlsceasgltfinawmswvrqapgkglewvgriksktdggttdfaapvkgrftisrddskntvflqmnslktedtavyycatdllfprdpgdnwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2076,NaN,NaN,UIK23843,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevqkpgeslkiscrasgytftdqwigwvrqmpgkglewvgviypgdsdtryspsfqgqvtisvdksistaylqwsslkasdtamyycarqsafwtgylyyyafdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2077,NaN,NaN,UIK23842,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaaseftfstytmhwvrqapgkglewvalisydgshkyyadsvkgrftisrdnskntlslqmnslraddtavyycararggnyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2078,NaN,NaN,UIK23841,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggmvqpgrslrlscaasgftfstyaihwvrqapgkglewvavvsydglnkyyadsvrgrftisrdnskntlylqmnnlraedtalyycarsasggywselpywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2079,NaN,NaN,UIK23840,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisrtnyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarlppwynsgwagldsltyqyymdvwgkgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2080,NaN,NaN,UIK23839,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlmesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglqwvavisydgnnkyyadsvkgrftisrdnskntlylqintlraedtavyycargyggnyhyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2081,NaN,NaN,UIK23838,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpseilsltctvsggsisshywswirqppgkglewigyisysgstnynpslksrvtisvdtsknqfslkltsvtaadtavyycargfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2082,NaN,NaN,UIK23837,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaelkkpgeslrisckgsgysftsywiiwvrqmpgkglewmgridpsdsytkyspsfqghvtissdksistaylqwnslktsdtavyycarqfatlenvigpaaldwfdpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2083,NaN,NaN,UIK23836,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmhlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqhlewigwivvgsgntnygqkfqervtitrdlststvymelislrsedtavyfcaapyctggscfdafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2084,NaN,NaN,UIK23835,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifstyamhwvrqapgkglewmavisydgsnkyyadsmkarfsisrdnskntlylhmnslrpedtavyycaraaggnyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2085,NaN,NaN,UIK23834,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvrvscraseyaftdyyihwvrqapgqtlewmgiinpsggsaryaqkfqgrvtmtrdtststvymevsslrfedtavyycardpsggssvttqnyfdswgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2086,NaN,NaN,UIK23833,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymnwvrqapgkglewvsvlysggstfyadsvkgrftisrdnskntlhlqmnslrvedtavyycardlvaygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2087,NaN,NaN,UIK23832,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnlgfswvrqapgqglewmggiipivalanyaekfqgrvtitadkststvymelsslrsedtavyycatkgdghnyfyyygvdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2088,NaN,NaN,UIK23831,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymnwvrqapgmglewvsviypggttyyadsvkgrftisrdnskntlflqmnslriddtalyycardlvyrgmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2089,NaN,NaN,UIK23830,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsvifpggstfsadsvkgrftisrdnsnntlylqmnslraedtavyycargegwdlpfdywgqgilvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2090,NaN,NaN,UIK23829,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvscktsgytftsydinwvrqatgqglewmgwmnpnsgnrgyaqmfqgrvtmtsnpsigtaymeltslrsedtavyycargtkfgsnwfwfdhwgqgtlltvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2091,NaN,NaN,UIK23828,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsiiypggstfyaesvkgrftisrdnskntlflqmnnlraedtaiyycardygdyyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2092,NaN,NaN,UIK23827,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltcsvsgdsitnimsywgwirqspgkalewigsaynsgnsyynpslksrvtisvdtsknqfslklrsvtaadtsvyfcarhryyydgspgyffdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2093,NaN,NaN,UIK23826,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyafswvrqapgqglewmggiipilhipnyaqkfqarltitadrststaymelsslksedtavyycagtaaehdylwgtyreiygldvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2094,NaN,NaN,UIK23825,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifisygiswlrqapgqglewmgwispynsntnyaqkfqgrvtmttdtststaymelrslrsddtavyycardgewggwfdpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2095,NaN,NaN,UIK23824,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscvasgltvssnymtwvrqapgkglewvsvlyvggstfyadsvkgrftisrdkskntlylqmnnlraedtavyycardryvlgmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2096,NaN,NaN,UIK23823,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgsyainwvrqapgqglewmgrifpmldkatyaqnfqgrvtftadkstntasmelsslssedtafyycargivgptpfyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2097,NaN,NaN,UIK23822,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssfvinwvrqapgqglewmggiipisatanyaqkfqgrvtitadestrtaymelsslrsedtavyycargsrkpfstdiyghvdyyyygmdvwgqgtavtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2098,NaN,NaN,UIK23821,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesaggvvqpgrslrlscaasgftfsdygmkwvrqapgkglewvaviwhdgsnkyyedsvkgrftisrdnsqntlylhmnslrvedtaiyfcargsgssdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2099,NaN,NaN,UIK23820,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsssamywvrqapgkglewvavisndgsnkyyadtvkgrftisrdiskntlyllmnslrvedtgiyycardslpgyngydapdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2100,NaN,NaN,UIK23819,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadkststasmelsslelsslrsedtavyycarthsydssgyyvdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2101,NaN,NaN,UIK23818,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvdsgggvvqpgrslrlscaasgfifssfamhwvrqtpgkglewvavisydginkyyadsvkgrftvsrdnskntlslqmnslrgedtavyycargqgayktafdswgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2102,NaN,NaN,UIK23817,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakssyggyvgyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2103,NaN,NaN,UIK23816,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgasissggyywswirqhpgkglewigyiyytgstyyspslkgrvtisvdtsknqfslklssltaadtavyycargsgpevvvirpyyldnwgpgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2104,NaN,NaN,UIK23815,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifskysmdwvrqapgkglewvsyidsggssryyadsvkgrftisrdnaknslylqmnslraedtavyycvrdardghsnndfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2105,NaN,NaN,UIK23814,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyamhwvrqapgkglewvavisydgsnkhyvdsvrgrftisrdnskntlylqmislitedtavyycardwsakmatignfdywgqgslvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2106,NaN,NaN,UIK23813,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfdssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdvstntaymelrslgsedtavyfcaaphcnrttcydafdlwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2107,NaN,NaN,UIK23812,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsistgayywswirqhpgkgleligyiyysettyynpslksrvtmsvdtsenqfslklnsvtaadtavyycarvvhcsgggcsrhnyfdpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2108,NaN,NaN,UIK23811,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssfaihwvrqapgkglewvtvisfdgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarglsgnyyyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2109,NaN,NaN,UIK23810,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssfaihwvrqapgkglewvavisydgsnkyyadsvkgrfsisrdnskntlylqmnslrsedtaiyycarplggnyggafdiwgqgalvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2110,NaN,NaN,UIK23809,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqleesgpglvkpsetlsltcsvsadsisnyywswirqppgkglewigyiyysgstsynpslksrvtmsvdtsknqfslklssvtaadtavyycargfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2111,NaN,NaN,UIK23808,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsiastyyywgwirqspgkglewianihyngstynkpslknrvtlsvdtsknqfslklssvtaadtavyycarygpyyydrsgsllsdpfdnwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2112,NaN,NaN,UIK23807,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgpglvkpsetlslsctvsggsissyfwswlrqppgkglewigyisyigstnhnpslksrvtmsvdtskkqfslrlssvtdadtavyycarrfphhydstglssdafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2113,NaN,NaN,UIK23806,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvnsgsyywswirqppgkglewigyiyytgstnynpslksrvtisvdtsknqfslklnsvtaadtavyycarvrfcsgsscrshnwfdpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2114,NaN,NaN,UIK23805,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvhpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgnnkysadsvkgrftisrdnskntlylqmnslrpedsavyycarglggnyyaadywgqgslvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2115,NaN,NaN,UIK23804,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydgynkyyadsvkgrftisrdnskntlylqmnslrvedtamyycaralggnyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2116,NaN,NaN,UIK23803,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvtvsckasgytftsyyihwvrqapgqglewmgiinpgagstsnaqkfqgrvtmtsdtststvymelsslrsedtavyycasgmdtlipaaqrafdiwgqgtvvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2117,NaN,NaN,UIK23802,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsissgsvfwtwirqhpgkglewighiyyrgttnynpslksrisisvdtsknqfslnltsvtaadtaiyycarkaggcggdcyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2118,NaN,NaN,UIK23801,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqperslrlscaasgftfsrdgmhwvrrapgkglewvavisydgsnkvyaesvkgrftvsrdsskntvylqmnslraedtavyycakdgpqafgtyfdywgqgtlvivss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2119,NaN,NaN,UIK23800,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaeviqpgaslkvsckasgytftayylfwvrqapgrglewmgwinpnnggtnyaqnfqgrvtmtrdtsmstaymelsrlssddtavyfcarwmvavagmgdrgynyhyymdvwgkgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2120,NaN,NaN,UIK23799,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqveesggglvkpggslrlscaasgfnfssygmnwvrqapgkglewvssisrssdfiyyadsvkgrftisrdnaknavflqmnrlrvedtavyycarnlkirssgdlfrgyyyhgmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2121,NaN,NaN,UIK23798,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvdsgggvvqpgrslrlscaasgftfssyamywvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpgsgnylgyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2122,NaN,NaN,UIK23797,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvlsgaevkkpgasvkvsckasgyiftgyyihwvrqapgqglewmgwinpmsgatnfarkfqgrvtltrdtsittaymelsrlrsddtavyycarvppfyengahfdnwgqgslvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2123,NaN,NaN,UIK23796,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargfwvpaaipgvwfdpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2124,NaN,NaN,UIK23795,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymrwvrqapgkglewvsliyaggstfyadsvkgrfiisrhnsknilylqmnslraedtavyfcardlyvfgmdvwgqgtavtvsa,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2125,NaN,NaN,UIK23794,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgsslrlscaasgfsfisygmhwlrqapgeglewvaiiwfdgrnkyyadsvkgrftisrdnsksmlylqmnslraedtavyycardlpaqkrgdafdiwglgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2126,NaN,NaN,UIK23793,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyythwvrqapgqglewmgwinpnsggtiyaqrfqgrvtmtrdtsistaymelsrlrsddtavyycarwvpprgygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2127,NaN,NaN,UIK23792,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmnwvrqapgkglewvaviwydgnnkyyadsvkgrftisrdnskttlylqmkslraedtavyycaralqyydiltgdysvvrsdafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2128,NaN,NaN,UIK23791,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycardrafgvvtvdfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2129,NaN,NaN,UIK23790,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggtlvkpggslrlscaasgftfsdyamswvrqapgrglewvsalsdsggstffadsvkgrftisrdnskntlylqmsslraedtakyycargevqpfllafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2130,NaN,NaN,UIK23789,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvsrnymswvrqapgkglewvsviyaggstfyadsvkgrftisrhnskntlylqmnslrvedtavyycvrdlvdygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2131,NaN,NaN,UIK23788,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmsvnwirqppgkalewlaridwdddkyystslmtrltiskdtsknqvvltmtnmdsvdtatyycarsvpttaldywgqgtlvivss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2132,NaN,NaN,UIK23787,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftdyymhwvrqapgqglewmgwinpksggtdfaqiflgrvtmtrdtsistaymelrglrsddtavyycargsyprdvvvvpaaapfnwldpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2133,NaN,NaN,UIK23786,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlshdgsesyyadsvkgrftisrdnsknslyvqmnslraedtavyycasacnsfncqlgdafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2134,NaN,NaN,UIK23785,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggrvvqpggslrlscaasgftfhdyamhwvrqapgkglewvslingdgrgryyadsvkgrftisrdnsknslylqmnslrtedtalyycakdmesnwnesdfvdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2135,NaN,NaN,UIK23784,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qahlvqsgpevkkpgasvkvsckasgyafttfaiswvrqapghglewmgrinpyngktyyaqkvqgrvtmttetststaymevrslrsddtavyycarqypmprgphynymdvwgkgtavtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2136,NaN,NaN,NaN,UIK24035,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapqlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystwtfgqgtkveir,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2137,NaN,NaN,NaN,UIK24034,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsniylawyqqkpgqaprlliygassraigipdrfsgsgsgtdftltisrlepedsavfycqqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2138,NaN,NaN,NaN,UIK24033,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpytfgpgtkvgik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2139,NaN,NaN,NaN,UIK24032,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystrtitfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2140,NaN,NaN,NaN,UIK24031,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprllvyaassraigipdrfigsgsgtdftltinrlepedfavyfchqygsspwtfgqgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2141,NaN,NaN,NaN,UIK24030,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntypwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2142,NaN,NaN,NaN,UIK24029,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrvsqsvssnylawfqqkpgqaprllifatssraigipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2143,NaN,NaN,NaN,UIK24028,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dfqmtqspsslsasvgdrvtitcrasqtittylnwylqkpgkapdlliyaastlqsgvpsrfsgsgsgtdftltidslqpedfatyycqqsyttpytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2144,NaN,NaN,NaN,UIK24027,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqninrylnwyqqkpgqapklliyaasgvqsgvpsrfsgsvsgtdftltisslqpedfatyhrqqsyitpftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2145,NaN,NaN,NaN,UIK24026,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2146,NaN,NaN,NaN,UIK24025,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasrsvpsdylawyqqkpgqaprlliydtssratgipdrfsggasgtaftltisrlepedfavyychqygtslrtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2147,NaN,NaN,NaN,UIK24024,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqnianwlawyqqkpgkapklliytasnlesgvpsrfsasgsgteftltisslqpddfatyycqqynsysrlvtfgggtkvesk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2148,NaN,NaN,NaN,UIK24023,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtftcrasqgissylawyqlkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlssypftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2149,NaN,NaN,NaN,UIK24022,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqsppflsasvgdrvtitcrasqgisrylawyqqkpgkapklliyaastlqsgvpprfsgtgsgteftltisslqpedfatyycqqlntyplafgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2150,NaN,NaN,NaN,UIK24021,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsastgdrvtitcrasqdissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqsedfatyhcqqyysyprtfgqrtkvevk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2151,NaN,NaN,NaN,UIK24020,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgignylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedlatyycqqvnsyppectfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2152,NaN,NaN,NaN,UIK24019,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkfgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwppytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2153,NaN,NaN,NaN,UIK24018,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdfftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2154,NaN,NaN,NaN,UIK24017,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdritltcrasqgisnylawyqqkpgkapklliyaastlqggvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2155,NaN,NaN,NaN,UIK24016,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspaflsasvgdrvritcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqltnyppdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2156,NaN,NaN,NaN,UIK24015,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsispwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisglqpddfatyycqqyngysntfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2157,NaN,NaN,NaN,UIK24014,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyppvfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2158,NaN,NaN,NaN,UIK24013,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydastlesgvpsrfsgsgsgteftltisslqpddfatyycqqyhsyspltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2159,NaN,NaN,NaN,UIK24012,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvggrvtitcrasqgissslawyqqkpgkapklliygastlrtgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdlytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2160,NaN,NaN,NaN,UIK24011,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsinswlawyqqkpgkapnlliydasnlesgvpsrfsgsgsgteftltisglqpddfatyycqqyhsyspltfgggtkvefk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2161,NaN,NaN,NaN,UIK24010,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqtvrnnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftitisrlepedfavyycqqygrahgafgpgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2162,NaN,NaN,NaN,UIK24009,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsinnylnwyqqqpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtysspftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2163,NaN,NaN,NaN,UIK24008,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqnrrnwpplltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2164,NaN,NaN,NaN,UIK24007,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnslnwyqqrpgrapkllihaasslqsgvpsrfsgsgsgtdftltiaglqpedfatyycqqsfttpftsgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2165,NaN,NaN,NaN,UIK24006,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsigsylnwyqqkpgkapkllisaasslqsgvpsrfsgsgsgteftltmsslqpedfatyycqqsysshtfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2166,NaN,NaN,NaN,UIK24005,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqtvssiylawfqqkpgqaprlliyaassraigipdrfsgsgsgtdftltisrlepedfavyyclqsgnspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2167,NaN,NaN,NaN,UIK24004,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgrapklliyaasslesgvpsrfsgsgsgtdftlsvsslqpedfatyycqqsyntpqtfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2168,NaN,NaN,NaN,UIK24003,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllingassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssqgtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2169,NaN,NaN,NaN,UIK24002,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssyltwyqhkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyycqqrtdwppevtfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2170,NaN,NaN,NaN,UIK24001,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqrpgqaprlliagtstratgipdrfsgsgsgtdftltisrlepedfavyycqqygasytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2171,NaN,NaN,NaN,UIK24000,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqsliswlawyqqkpgkapklliyatsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfpvtfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2172,NaN,NaN,NaN,UIK23999,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynnypytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2173,NaN,NaN,NaN,UIK23998,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtplslsvtpgqpvsisctssqsllhgggktslnwyhqkpgqppqlliygvsnrfsgvpdrfsgsgsgtdftlkisrvqaddvgvyycmqsislpwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2174,NaN,NaN,NaN,UIK23997,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsslylawsqqkpgqaprllvfgassraigipdrfsgsgsgtdftliisrlepedfavyychqygsspwtfgqgtkvevk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2175,NaN,NaN,NaN,UIK23996,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspdtlslspgeratlscrasqsigsrylawyqqkpgqaprllitaassratgipdrisgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleir,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2176,NaN,NaN,NaN,UIK23995,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrlpvafgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2177,NaN,NaN,NaN,UIK23994,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlngyplfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2178,NaN,NaN,NaN,UIK23993,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,ekvmtqspatlsmspgeratlscrasqsisnnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedsavyycqqynnwpftfgqgtklemk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2179,NaN,NaN,NaN,UIK23992,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dfvmtqsplslpvtpgepasiscrssqsllysngynyldwylqkpgqspqlliylgstrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2180,NaN,NaN,NaN,UIK23991,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmsqspsslsasvgdrvtitcrasqdiayslnwyqqipgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2181,NaN,NaN,NaN,UIK23990,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsinsylnwfqqkpgkapnlliyaasslqsgvpsrfsgggsgtdftltisrlqpedfatyycqqsystpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2182,NaN,NaN,NaN,UIK23989,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dtvmtqsplslpvtpgepapiscrssqsllhsngynyldwylqksgqtpqlliylgshrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmealqtplftfgpgtkvhik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2183,NaN,NaN,NaN,UIK23988,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylvwyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsygytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2184,NaN,NaN,NaN,UIK23987,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrtsqsvntklvwyqqkpgqaprlliygastratgvparfsgsgsgteftltisslqsedfavyycqqhndwprsfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2185,NaN,NaN,NaN,UIK23986,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsinsylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqtyntphtfgqgtkldik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2186,NaN,NaN,NaN,UIK23985,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprllisgassratgipdrfsgsgsgtdftltisrlepedfavyhcqqygtspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2187,NaN,NaN,NaN,UIK23984,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscranqsvssylawyrqkpgqaprllihdasnratgiparisgsgsgtdftltisslepedfavyycqqrsnwpgftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2188,NaN,NaN,NaN,UIK23983,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2189,NaN,NaN,NaN,UIK23982,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvnsiylawhqqkpgqaprlliygassraigipdrfsdsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2190,NaN,NaN,NaN,UIK23981,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,etvltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlviygpstratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2191,NaN,NaN,NaN,UIK23980,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqdgvpsrfsgsgsgteftltisslqpedfatyycqqlnnypftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2192,NaN,NaN,NaN,UIK23979,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisshlawyqqkpgkapkllifaastlqsgvpsrfsgsgsgtefsltisslqpadfatyfcqhlemfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2193,NaN,NaN,NaN,UIK23978,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqtplsspvtlgqpasiscrssqglvhsdgntylswlhqrpgqpprvliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqvtqfpfnfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2194,NaN,NaN,NaN,UIK23977,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,kiqmtqspsslsasvgdrviitcqasqdinkylhwyqqkpgeapklviydasnletgvpsrfsgsgsgtdftftisslqpedlaryycqqydnlpptfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2195,NaN,NaN,NaN,UIK23976,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqpprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2196,NaN,NaN,NaN,UIK23975,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlqisrveaedvgvyycmqttqfpdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2197,NaN,NaN,NaN,UIK23974,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtltcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqelnsypffgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2198,NaN,NaN,NaN,UIK23973,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2199,NaN,NaN,NaN,UIK23972,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqvisnslnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpptfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2200,NaN,NaN,NaN,UIK23971,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistwlawyqqkpgkvpkllihkasnlhsgvpsrfsgsgsgteftltinslqpedfatyycqqynsystwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2201,NaN,NaN,NaN,UIK23970,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2202,NaN,NaN,NaN,UIK23969,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2203,NaN,NaN,NaN,UIK23968,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrashsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltitslqsediavyycqqynnwppltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2204,NaN,NaN,NaN,UIK23967,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2205,NaN,NaN,NaN,UIK23966,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,yiqmtqspsslsasvgdrvtitcrasqnidtylnwyqqtpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyscqqsysspltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2206,NaN,NaN,NaN,UIK23965,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nivltqspaalsfspgeratlscrasqsvsiflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpitfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2207,NaN,NaN,NaN,UIK23964,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasglqsgvpsrfsgsgsgtdftltissllpedfatyycqqsyrtpfnfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2208,NaN,NaN,NaN,UIK23963,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygpssratgipdrfsgsgsgtdftltinrlepedfavyycqqydrspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2209,NaN,NaN,NaN,UIK23962,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsasssylawyqhkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyychqfgssfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2210,NaN,NaN,NaN,UIK23961,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssrylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltigrlepedfavyychqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2211,NaN,NaN,NaN,UIK23960,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvgsnylawyqqkpgqsprlliyatssraigfpdrfigsgsgtdftltisrlepedfavyychqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2212,NaN,NaN,NaN,UIK23959,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,evvltqspgtlslspgeratlscrasqglsssslawyqqrpgqaprlliygasnratgisdrfsgsgsgtdftlsvsrlepedfavyycqqysnspltfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2213,NaN,NaN,NaN,UIK23958,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtftcrasqaissklvwyqqkpgkapkvlisdasslqsgapsrfsgsgsgtdftltisslqpedfatyycqqakslpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2214,NaN,NaN,NaN,UIK23957,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrstqsfagsylawyqqkagqaprllihgassrapgipdrfsgsgsgtdftltisrlepedfavyycqqyggsqwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2215,NaN,NaN,NaN,UIK23956,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyycqlygssprytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2216,NaN,NaN,NaN,UIK23955,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratisckssqtvffisnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvaayycqqyystpptfgpgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2217,NaN,NaN,NaN,UIK23954,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllmygassratgipdrfsgsgsgtdftltigrlepedfavyycqqygssvvtfgggttveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2218,NaN,NaN,NaN,UIK23953,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqpprlliygastratgiparfsgsgsgteftltisslqsedfavyychqynnwppwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2219,NaN,NaN,NaN,UIK23952,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlcvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwppltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2220,NaN,NaN,NaN,UIK23951,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgrapklliyaastlqsgvpsrfsgsgsgtvftltisslqpedfatyycqqlnsdsstfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2221,NaN,NaN,NaN,UIK23950,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsvsvgdrvtitcrasqsisnylnwyqqkpgkapnllifaasslqrgvpsrfsgsgsgtdftltisslqpedfaayycqqsystpltfgqgtkvevn,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2222,NaN,NaN,NaN,UIK23949,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstflawyqqkagqaprlliygastrapgipdrfsgsgsgtdftltisrlepedfavyycqqfgssltfgggskveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2223,NaN,NaN,NaN,UIK23948,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsgtylawyqqkpgqaprlliygassrasgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2224,NaN,NaN,NaN,UIK23947,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqginsylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsysrdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2225,NaN,NaN,NaN,UIK23946,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgtapklliysasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysiprtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2226,NaN,NaN,NaN,UIK23945,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtplslpvtpgepasfscrssqslldsddgntyldwylqkpgqspqlliysvsyrasgvpdrvsgsgsgtdftlkisrveaedvgvyycmqrtefpwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2227,NaN,NaN,NaN,UIK23944,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvviqepsfsvspggtvtltcglssgsvssnyyptwykqtpgqapstliyttntrssgvpdrfsgsilgnkaaltitgaqaddeceyhcalymgsgiwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2228,NaN,NaN,NaN,UIK23943,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsespgqsitisctgtssdvgnynlvswyqhhpgkapklmiyevtkrpsgvsirfsgsksgntasltvsglqtedeadyyccsyagnstlvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2229,NaN,NaN,NaN,UIK23942,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsgspgqsvtisctgtssdigsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytsnntfvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2230,NaN,NaN,NaN,UIK23941,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlvihedfkrpsgiperfsgsssgtmatltirraqaedeadyycystdnsgnrvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2231,NaN,NaN,NaN,UIK23940,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,pyeltqppsvsvspgqtaritcsgdalprqfaywyqqkpgqapvlliykdterpsriperfsgsssgttftltisgvqaedeadyycqsaenggtypvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2232,NaN,NaN,NaN,UIK23939,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgttsdvggynyvswyqqhpgkapkvmiyevsnrpsgisnrfsgsksgntasltisglqaedeadyycssytssstlgvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2233,NaN,NaN,NaN,UIK23938,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasatpgqrvtiscsgsssnigsnpvnwyqqlpgtapklliynndqrpsrvpdrfsgsksgtsaslaisglqsedeadyycaawddslnglwvfgggtkmtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2234,NaN,NaN,NaN,UIK23937,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgrnsdigsntvnwyqqfpgtapklliysdnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddrlhgwvfgggtklavl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2235,NaN,NaN,NaN,UIK23936,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sfvltqppsvsvapgqtaritcggnniggktvhwyqqkpgqapvlvvhddsdrpsgiperfsgsnsgntatltisrvelgdeadyycqvwdssgghfyvfgagtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2236,NaN,NaN,NaN,UIK23935,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsmsaapgqkvtiscsgsssnignnyvswyqqvpgtapklliynsnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycaawdsslsayvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2237,NaN,NaN,NaN,UIK23934,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnfvywyqqfpgtapkvliyrnslrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsarwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2238,NaN,NaN,NaN,UIK23933,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevtkrpsgvpdrfsgsksgntasltvsglqaedeadyycnsyagnnnfvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2239,NaN,NaN,NaN,UIK23932,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnsvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2240,NaN,NaN,NaN,UIK23931,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgnssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2241,NaN,NaN,NaN,UIK23930,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqaasvsgtpgqsitisctgtisnigsynyvswyqqhpgkapklliyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssspwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2242,NaN,NaN,NaN,UIK23929,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggykyvswyqqhpgkapklmiyevsnwpsgvsnrfsgsksgntasltisglqaedeadyycssytssitlyvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2243,NaN,NaN,NaN,UIK23928,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrnyyanwyqqkpgqapvfvingknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhpwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2244,NaN,NaN,NaN,UIK23927,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapilviygqskrpsgipdrfsgstsgntasltitgaqaedeadyycssrdssgnhlvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2245,NaN,NaN,NaN,UIK23926,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgapgqrvtisctgsssnigagydvhwyqqlpgtppklliygndnrpsgvpdrfsgsksgtsaslaitglqvedeadyycqsydsslsgslfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2246,NaN,NaN,NaN,UIK23925,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigigyavhwyqqlpgtapkllifgtsrrpsgvpdrfsgsrsgtsaslaitglqaedeavyycqsydnsqtdsvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2247,NaN,NaN,NaN,UIK23924,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgppgqsvtisctgtssdvggyhyvswyqqhpgkapklmiygvtrrpsgvpdrfsgsksgntasltvsglqaddeadyycssyagsntvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2248,NaN,NaN,NaN,UIK23923,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdigsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsskdmifgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2249,NaN,NaN,NaN,UIK23922,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnpvswyqqlpgtapkllmydndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddtlnghfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2250,NaN,NaN,NaN,UIK23921,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2251,NaN,NaN,NaN,UIK23920,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvlmqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydnslsdvlfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2252,NaN,NaN,NaN,UIK23919,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssligsvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2253,NaN,NaN,NaN,UIK23918,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqhlpgiapklliygnnirpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2254,NaN,NaN,NaN,UIK23917,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsgapgqrvtisctgsssnigsgyvvhwyqhlpntapkllifgnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2255,NaN,NaN,NaN,UIK23916,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvgkrpsgvpdrfsgsksdntasltisglqaedeadyyccsyagspwvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2256,NaN,NaN,NaN,UIK23915,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsittsctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstsnyvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2257,NaN,NaN,NaN,UIK23914,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhhvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2258,NaN,NaN,NaN,UIK23913,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtstdvggydyvswyqqhpgkapkvmiygvsnrpsgvssrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2259,NaN,NaN,NaN,UIK23912,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagyvvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqsydsrlfvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2260,NaN,NaN,NaN,UIK23911,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sfeltqppsvsvspgqtarircsgnalprryaywyqqkpgqapvlviykdserpsgiperfssstsgttvtltisgvqaedeadyycqssdsngsymfgggtkltal,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2261,NaN,NaN,NaN,UIK23910,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvtnrppgvsnrfsgsksgntasltisglqaedeadyycssytststrvfgggtyltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2262,NaN,NaN,NaN,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-10-12,"Chain E, pYLQ7 T cell receptor beta chain",NaN
2263,NaN,NaN,NaN,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-10-12,NaN,"Chain D, pYLQ7 T cell receptor alpha chain"
2264,NaN,NaN,NaN,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-10-12,"Chain E, pRLQ3 T cell receptor beta chain",NaN
2265,NaN,NaN,NaN,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-10-12,NaN,"Chain D, pRLQ3 T cell receptor alpha chain"
2266,NaN,NaN,NaN,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-10-12,"Chain B, pYLQ7 T cell receptor beta chain",NaN
2267,NaN,NaN,NaN,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-10-12,NaN,"Chain A, pYLQ7 T cell receptor alpha chain"
2268,NaN,NaN,NaN,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-10-12,"Chain E, pRLQ3 T cell receptor beta chain",NaN
2269,NaN,NaN,NaN,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-10-12,NaN,"Chain D, pRLQ3 T cell receptor alpha chain"
2270,AB8,NaN,7MJI_E,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvsssgqaghhhhhhgdykddddkg,NaN,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,"Chain E, VH ab8",NaN,2022-10-12,NaN,NaN
2271,AB8,NaN,7MJH_F,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvsssgqaghhhhhhgdykddddkg,NaN,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,"Chain F, VH ab8",NaN,2022-10-12,NaN,NaN
2272,AB8,NaN,7MJH_E,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvsssgqaghhhhhhgdykddddkg,NaN,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,"Chain E, VH ab8",NaN,2022-10-12,NaN,NaN
2273,AB8,NaN,7MJH_D,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvsssgqaghhhhhhgdykddddkg,NaN,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,"Chain D, VH ab8",NaN,2022-10-12,NaN,NaN
2274,NaN,NaN,7LX5_A,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),qvqlqesggglvqpggslrlscaasgftfrrylmgwarqvpgkglewvsgiysdgstyyadsvkgrftisrdnakntvylqmnslkpedtavyycakdrmdgstwperdfgswgqgtqvtvss,NaN,"Pymm,P. et al.; Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice; Proc Natl Acad Sci U S A 118 (19) (2021); 2021.",10.1073/pnas.2101918118,"Chain A, WNb 10",NaN,2022-10-12,NaN,NaN
2275,NaN,NaN,7LX5_C,NaN,"['COVID', 'SARS-COV-2']",Vicugna pacos (alpaca),qvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvscisssggntkyadsvkgrftasrdnakntfylqmnslkpedtavyycaaiaatyysgsyyfqcphdgmdywgkgtqvtvss,NaN,"Pymm,P. et al.; Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice; Proc Natl Acad Sci U S A 118 (19) (2021); 2021.",10.1073/pnas.2101918118,"Chain C, WNb 2",NaN,2022-10-12,NaN,NaN
2276,NaN,NaN,7JWB_D,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfriysyysyigwvrrapgkgeelvariypssgytyyadsvkgrftisadtskntaylqmnslraedtavyycarwdfaspyypgssgldywgqgtlvtvssggggtggggsggggsggggsevqlvesggglvqpggslrlscaasgfriysyysyigwvrrapgkgeelvariypssgytyyadsvkgrftisadtskntaylqmnslraedtavyycarwdfaspyypgssgldywgqgtlvtvssggggsggggsggggsggggsevqlvesggglvqpggslrlscaasgfriysyysyigwvrrapgkgeelvariypssgytyyadsvkgrftisadtskntaylqmnslraedtavyycarwdfaspyypgssgldywgqgtlvtvss,NaN,"Bracken,C.J. et al.; Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike; bioRxiv (2020); 2020.",10.1101/2020.08.08.242511,"Chain D, autonomous human heavy chain variable domain",NaN,2022-10-12,NaN,NaN
2277,BD-629,NaN,7CH5_H,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlnlqmnslraedtavyycardygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdk,NaN,"Du,S. et al.; Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy; Cell 183 (4), 1013-1023 (2020); 2020.",10.1016/j.cell.2020.09.035,"Chain H, BD-629 Fab H",NaN,2022-10-12,NaN,NaN
2278,NaN,NaN,2DD8_H,NaN,['COVID'],Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvssastkgpsvfplapsskstsggtsalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsplfvhhhhhhgdykddddkg,NaN,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.",10.1074/jbc.M600697200,"Chain H, IGG Heavy Chain",NaN,2022-10-12,NaN,NaN
2279,NaN,NaN,2G75_C,NaN,['COVID'],Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvssastkgpsvfplapsskstsggtsalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsplfvhhhhhhgdykddddkg,NaN,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.",10.1074/jbc.M600697200,"Chain C, IGG Heavy Chain",NaN,2022-10-12,NaN,NaN
2280,NaN,NaN,2G75_A,NaN,['COVID'],Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvssastkgpsvfplapsskstsggtsalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdktsplfvhhhhhhgdykddddkg,NaN,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.",10.1074/jbc.M600697200,"Chain A, IGG Heavy Chain",NaN,2022-10-12,NaN,NaN
2281,NaN,NaN,NaN,2DD8_L,['COVID'],Homo sapiens (human),NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvlgqpkanptvtlfppsseefqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.",10.1074/jbc.M600697200,NaN,"Chain L, IGG Light Chain",2022-10-12,NaN,NaN
2282,NaN,NaN,NaN,2G75_D,['COVID'],Homo sapiens (human),NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvlgqpkanptvtlfppsseefqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.",10.1074/jbc.M600697200,NaN,"Chain D, IGG Light Chain",2022-10-12,NaN,NaN
2283,NaN,NaN,NaN,2G75_B,['COVID'],Homo sapiens (human),NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvlgqpkanptvtlfppsseefqankatlvclisdfypgavtvawkadgspvkagvettkpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Prabakaran,P. et al.; Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody; J. Biol. Chem. 281 (23), 15829-15836 (2006); 2006.",10.1074/jbc.M600697200,NaN,"Chain B, IGG Light Chain",2022-10-12,NaN,NaN
2284,NaN,NaN,QYU59156,NaN,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Mus musculus (house mouse),vqlqqsgpelkkpgetvkisckasgytftkyrmhwvkqapgkglkwmgwintntgestyaddfkgrfafsletsastaylqinnlknedtatyfcassmdywgqgttvtvss,NaN,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARSCoV-2 RBD-based antigen; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2285,NaN,NaN,QYU59154,NaN,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Mus musculus (house mouse),evklqesggglvkpggslklscaasgftfsnysmswvrqtpekrlewvatisngggyiyyldsvkgrftisrdnakntlylqmsslrsedtamyycgrprpekefiststamdhwgqgttvt,NaN,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARSCoV-2 RBD-based antigen; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2286,NaN,NaN,NaN,QYU59157,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Mus musculus (house mouse),NaN,divltqspaslavslgqratisyrasksvstsgysymhwnqqkpgqpprlliylvsnlesgvparfsgsgsgtdftlnihpveeedaatyycqhireltrseggpsw,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARSCoV-2 RBD-based antigen; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Mus musculus]",2022-10-12,NaN,NaN
2287,NaN,NaN,NaN,QYU59155,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Mus musculus (house mouse),NaN,evtmsckssqsllyssyqknylawyqqkpgqspklliywastresgvpdrftgsgsgtdftltissvkaedlavyycqqyysypftfgsgtkleik,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARSCoV-2 RBD-based antigen; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Mus musculus]",2022-10-12,NaN,NaN
2288,NaN,NaN,QYU59153,NaN,"['COVID', 'SARS-COV-2', 'Spike protein', 'RBD']",Mus musculus (house mouse),vqlqqsgpevvrpgvsvkisckgsgytftdyaihwvkqshakslewigvisshngnrgynqkfkgmatvtvdrssstaymelarltsedsaiyycaifdydfdywgqgttvmvss,NaN,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARS-CoV-2 RBD-based antigen; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2289,NaN,NaN,QXI90084,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgyslievsvhwvrqapgkglewmggfdpenaetiyaqkfqgrvtmtedtstdtaymelsslkyedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2290,NaN,NaN,QXI90082,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),mdctwrilllvaaatgthaqvhlvqsgaevkkpgasvkvsckvsgytlvevsvhwvrqapgkgfewmggfdpenaatiyaqkfqgrvtmtedtstdtaymelsslryedtavyfcatapavagplyyyyygmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2291,NaN,NaN,QXI90080,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslryedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2292,NaN,NaN,QXI90078,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaktiyaqkfqgrvtmtedtstdtaymelsslssedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2293,NaN,NaN,QXI90076,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapekglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2294,NaN,NaN,QXI90074,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyfcatapavagpfynfyygidvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2295,NaN,NaN,QXI90072,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),mefglswvflvallrgvqcqvqvvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycvretvdgmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2296,NaN,NaN,QXI90070,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),mefglswvflvallrgvqcqvqvvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycvretvdgmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2297,NaN,NaN,QXI90068,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),mefglswvflvallrgvqcqvqvvesgggvvqpgrslrlscaasgftfsgygmhwvrqapgkglewvaviwydgsnqyyadsvkgrftisrdnskntlylqmnslrvedtavyhcvretvdgmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
2298,NaN,NaN,NaN,QXI90085,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),NaN,mdmrllaqllgllmlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-10-12,NaN,NaN
2299,NaN,NaN,NaN,QXI90083,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),NaN,mdmrllaqllgllmlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-10-12,NaN,NaN
2300,NaN,NaN,NaN,QXI90081,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),NaN,mdmrllaqllgllmlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-10-12,NaN,NaN
2301,NaN,NaN,NaN,QXI90079,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),NaN,mvsplqligflllwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-10-12,NaN,NaN
2302,NaN,NaN,NaN,QXI90077,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),NaN,mdmrlrdqlmglimlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprliiykvsnrfcgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-10-12,NaN,NaN
2303,NaN,NaN,NaN,QXI90075,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),NaN,mvsplqligflllwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-10-12,NaN,NaN
2304,NaN,NaN,NaN,QXI90073,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),NaN,mdmrvpaqllgllllwfpgarcniqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-10-12,NaN,NaN
2305,NaN,NaN,NaN,QXI90071,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),NaN,mdmrvpaqllgllllwfpgarcniqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-10-12,NaN,NaN
2306,NaN,NaN,NaN,QXI90069,"['COVID', 'SARS-COV-2', 'Spike protein']",Mus musculus (house mouse),NaN,mdmrvpaqllgllllwfpgarcniqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-10-12,NaN,NaN
2307,NaN,NaN,QYT87288,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 440 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 440 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2308,NaN,NaN,QYT87225,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywiswvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgiiqpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 377 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 377 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2309,NaN,NaN,QYT87224,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgstasyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 376 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 376 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2310,NaN,NaN,QYT87223,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 375 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 375 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2311,NaN,NaN,QYT87222,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmggiipvlhtvdyaqrlqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 374 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 374 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2312,NaN,NaN,QYT87221,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 373 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 373 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2313,NaN,NaN,QYT87220,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgynftdyhiqwvrqapgqglewvgmiiprhggtayaqrfqgrvtitadeststaymelsslrsedtavyycaggsglttpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 372 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 372 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2314,NaN,NaN,QYT87219,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtlssyaiswvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistprsvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 371 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 371 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2315,NaN,NaN,QYT87218,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggegistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 370 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 370 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2316,NaN,NaN,QYT87217,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftnyginwvrqapgqglewmgwmnpysgntgyaqkfqgrvtitadeststaymelsslrsedtavyycavlsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 369 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 369 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2317,NaN,NaN,QYT87216,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfstywigwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 368 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 368 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2318,NaN,NaN,QYT87215,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdstarysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistlydvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 367 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 367 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2319,NaN,NaN,QYT87214,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgqinpsgdstryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 366 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 366 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2320,NaN,NaN,QYT87213,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfisyaiswvrqapgqglewmggiiptlgtynyaqkfqgrvtitadeststaymelsslrsedtavyycagswgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 365 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 365 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2321,NaN,NaN,QYT87212,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 364 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 364 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2322,NaN,NaN,QYT87211,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfisywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgilepmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 363 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 363 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2323,NaN,NaN,QYT87210,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycagsdgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 362 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 362 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2324,NaN,NaN,QYT87209,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgvintgggsvtyaqkfqgrvtitadeststaymelsslrsedtavyycaghwgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 361 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 361 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2325,NaN,NaN,QYT87208,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 360 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 360 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2326,NaN,NaN,QYT87207,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfitywigwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 359 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 359 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2327,NaN,NaN,QYT87206,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 358 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 358 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2328,NaN,NaN,QYT87205,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsglltpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 357 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 357 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2329,NaN,NaN,QYT87204,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnnglswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycrmgsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 356 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 356 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2330,NaN,NaN,QYT87203,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgwinpnsggtkyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpidvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 355 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 355 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2331,NaN,NaN,QYT87202,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 354 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 354 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2332,NaN,NaN,QYT87201,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfisywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycagsdgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 353 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 353 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2333,NaN,NaN,QYT87200,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgypftnygiswvrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycatlsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 352 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 352 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2334,NaN,NaN,QYT87199,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetnysqkfqgrvtitadeststaymelsslrsedtavyycaggsglftpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 351 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 351 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2335,NaN,NaN,QYT87198,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttnysqkfqgrvtitadeststaymelsslrsedtavyycaghwgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 350 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 350 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2336,NaN,NaN,QYT87197,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgiyvpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 349 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 349 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2337,NaN,NaN,QYT87196,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 348 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 348 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2338,NaN,NaN,QYT87195,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfsdyyihwvrqapgqglewmgwidpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 347 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 347 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2339,NaN,NaN,QYT87194,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgysftdyhihwvrqapgqglewmamivprggsttyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 346 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 346 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2340,NaN,NaN,QYT87193,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgyrftdyhlhwvrqapgqglewmggivpfsgttnfaqkfqgrvtitadeststaymelsslrsedtavyycaggsgettpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 345 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 345 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2341,NaN,NaN,QYT87192,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiiptlgtanyaqkfqgrvtitadeststaymelsslrsedtavyycagswgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 344 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 344 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2342,NaN,NaN,QYT87191,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfstywigwvrqapgqglewvgwinpnsgatkyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 343 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 343 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2343,NaN,NaN,QYT87190,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 342 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 342 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2344,NaN,NaN,QYT87189,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgissdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 341 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 341 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2345,NaN,NaN,QYT87188,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgvltpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 340 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 340 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2346,NaN,NaN,QYT87187,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsglytpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 339 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 339 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2347,NaN,NaN,QYT87186,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfstyafnwvrqapgqglewmgvintgggsvtyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpgavwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 338 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 338 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2348,NaN,NaN,QYT87185,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmgiiypgdgttrysqkfqgrvtitadeststaymelsslrsedtavyyclpgsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 337 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 337 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2349,NaN,NaN,QYT87184,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 336 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 336 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2350,NaN,NaN,QYT87183,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftnyginwmrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 335 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 335 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2351,NaN,NaN,QYT87182,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgminpgggntnyaekfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 334 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 334 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2352,NaN,NaN,QYT87181,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftghymhwvrqapgqglewmgiiypgdsearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 333 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 333 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2353,NaN,NaN,QYT87180,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftnyginwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycaavsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 332 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 332 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2354,NaN,NaN,QYT87179,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfstywigwvrqapgqglewmgwidpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 331 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 331 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2355,NaN,NaN,QYT87178,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgsvipvfgrpnyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 330 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 330 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2356,NaN,NaN,QYT87177,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnssinwvrqapgqglewmgrinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 329 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 329 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2357,NaN,NaN,QYT87176,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfnshaiswvrqapgqglewmgwinpnsgatnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpvgvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 328 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 328 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2358,NaN,NaN,QYT87175,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycagsggistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 327 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 327 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2359,NaN,NaN,QYT87174,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfsdyhvhwvrqapgqglewvgmiiprhggtayaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 326 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 326 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2360,NaN,NaN,QYT87173,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdyyihwvrqapgqglewmgwmnpnsgntgyaqnfqgrvtitadeststaymelsslrsedtavyycaggsgistawdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 325 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 325 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2361,NaN,NaN,QYT87172,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfitywiywvrqapgqglewmgiiypgdgearysqkfygrvtitadeststaymelsslrsedtavyycagsggistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 324 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 324 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2362,NaN,NaN,QYT87171,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 323 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 323 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2363,NaN,NaN,QYT87170,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftghymhwvrqapgqglewmgiiypgdsearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 322 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 322 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2364,NaN,NaN,QYT87169,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnhaiswvrqaygqglewmgiiypgdgttrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 321 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 321 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2365,NaN,NaN,QYT87168,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 320 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 320 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2366,NaN,NaN,QYT87167,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiidpsggstsyaqqfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 319 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 319 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2367,NaN,NaN,QYT87166,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 318 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 318 from patent US 11034762,NaN,2022-10-12,NaN,NaN
2368,NaN,NaN,NaN,QYT87289,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 441 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 441 from patent US 11034762,2022-10-12,NaN,NaN
2369,NaN,NaN,NaN,QYT87285,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqylstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 437 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 437 from patent US 11034762,2022-10-12,NaN,NaN
2370,NaN,NaN,NaN,QYT87284,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywsslresgvpdrfsgsgsgtdftltisslqaedvavyycqqyytapftfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 436 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 436 from patent US 11034762,2022-10-12,NaN,NaN
2371,NaN,NaN,NaN,QYT87283,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 435 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 435 from patent US 11034762,2022-10-12,NaN,NaN
2372,NaN,NaN,NaN,QYT87282,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasfresgvpdrfsgsgsgtdftltisslqaedvavyycqqylstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 434 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 434 from patent US 11034762,2022-10-12,NaN,NaN
2373,NaN,NaN,NaN,QYT87281,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 433 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 433 from patent US 11034762,2022-10-12,NaN,NaN
2374,NaN,NaN,NaN,QYT87280,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqhyyntpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 432 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 432 from patent US 11034762,2022-10-12,NaN,NaN
2375,NaN,NaN,NaN,QYT87279,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssrilsyspdnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqsyitpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 431 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 431 from patent US 11034762,2022-10-12,NaN,NaN
2376,NaN,NaN,NaN,QYT87278,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 430 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 430 from patent US 11034762,2022-10-12,NaN,NaN
2377,NaN,NaN,NaN,QYT87277,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywatnresgvpdrfsgsgsgtdftltisslqaedvavyychqyyntpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 429 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 429 from patent US 11034762,2022-10-12,NaN,NaN
2378,NaN,NaN,NaN,QYT87276,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyrsnnlhylawyqqkpgqppklliywastrssgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 428 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 428 from patent US 11034762,2022-10-12,NaN,NaN
2379,NaN,NaN,NaN,QYT87275,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinctssqsvlhssnnlnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 427 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 427 from patent US 11034762,2022-10-12,NaN,NaN
2380,NaN,NaN,NaN,QYT87274,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlhssnnlnyfawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 426 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 426 from patent US 11034762,2022-10-12,NaN,NaN
2381,NaN,NaN,NaN,QYT87273,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 425 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 425 from patent US 11034762,2022-10-12,NaN,NaN
2382,NaN,NaN,NaN,QYT87272,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckstqsvlyssinknyvawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 424 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 424 from patent US 11034762,2022-10-12,NaN,NaN
2383,NaN,NaN,NaN,QYT87271,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysstpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 423 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 423 from patent US 11034762,2022-10-12,NaN,NaN
2384,NaN,NaN,NaN,QYT87270,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 422 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 422 from patent US 11034762,2022-10-12,NaN,NaN
2385,NaN,NaN,NaN,QYT87269,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasfresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygtpftfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 421 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 421 from patent US 11034762,2022-10-12,NaN,NaN
2386,NaN,NaN,NaN,QYT87268,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 420 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 420 from patent US 11034762,2022-10-12,NaN,NaN
2387,NaN,NaN,NaN,QYT87267,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnhnylawyqqkpgqppklliywastrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 419 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 419 from patent US 11034762,2022-10-12,NaN,NaN
2388,NaN,NaN,NaN,QYT87266,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 418 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 418 from patent US 11034762,2022-10-12,NaN,NaN
2389,NaN,NaN,NaN,QYT87265,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 417 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 417 from patent US 11034762,2022-10-12,NaN,NaN
2390,NaN,NaN,NaN,QYT87264,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqtisyssdnknylawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 416 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 416 from patent US 11034762,2022-10-12,NaN,NaN
2391,NaN,NaN,NaN,QYT87263,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliyrastrasgvpdrfsgsgsgtdftltisslqaedvavyycqqyystvitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 415 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 415 from patent US 11034762,2022-10-12,NaN,NaN
2392,NaN,NaN,NaN,QYT87262,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 414 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 414 from patent US 11034762,2022-10-12,NaN,NaN
2393,NaN,NaN,NaN,QYT87261,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 413 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 413 from patent US 11034762,2022-10-12,NaN,NaN
2394,NaN,NaN,NaN,QYT87260,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratincrssqsvlyssnnknyfawyqqkpgqppklliywasirgsgvpdrfsgsgsgtdftltisslqaedvavyychqyyttpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 412 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 412 from patent US 11034762,2022-10-12,NaN,NaN
2395,NaN,NaN,NaN,QYT87259,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 411 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 411 from patent US 11034762,2022-10-12,NaN,NaN
2396,NaN,NaN,NaN,QYT87258,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasyresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 410 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 410 from patent US 11034762,2022-10-12,NaN,NaN
2397,NaN,NaN,NaN,QYT87257,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyykipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 409 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 409 from patent US 11034762,2022-10-12,NaN,NaN
2398,NaN,NaN,NaN,QYT87256,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlhsainknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 408 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 408 from patent US 11034762,2022-10-12,NaN,NaN
2399,NaN,NaN,NaN,QYT87255,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnhnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 407 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 407 from patent US 11034762,2022-10-12,NaN,NaN
2400,NaN,NaN,NaN,QYT87254,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpvtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 406 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 406 from patent US 11034762,2022-10-12,NaN,NaN
2401,NaN,NaN,NaN,QYT87253,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyslpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 405 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 405 from patent US 11034762,2022-10-12,NaN,NaN
2402,NaN,NaN,NaN,QYT87252,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 404 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 404 from patent US 11034762,2022-10-12,NaN,NaN
2403,NaN,NaN,NaN,QYT87251,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvfhssnnknhlawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 403 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 403 from patent US 11034762,2022-10-12,NaN,NaN
2404,NaN,NaN,NaN,QYT87250,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasmresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 402 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 402 from patent US 11034762,2022-10-12,NaN,NaN
2405,NaN,NaN,NaN,QYT87249,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastrefgvpdrfsgsgsgtdftltisslqaedvavyycqqyykipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 401 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 401 from patent US 11034762,2022-10-12,NaN,NaN
2406,NaN,NaN,NaN,QYT87248,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyatpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 400 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 400 from patent US 11034762,2022-10-12,NaN,NaN
2407,NaN,NaN,NaN,QYT87247,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhtipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 399 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 399 from patent US 11034762,2022-10-12,NaN,NaN
2408,NaN,NaN,NaN,QYT87246,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnninylawyqqkpgqppklliywastraagvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 398 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 398 from patent US 11034762,2022-10-12,NaN,NaN
2409,NaN,NaN,NaN,QYT87245,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqrvlyssnnlnylawyqqkpgqppklliywastrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 397 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 397 from patent US 11034762,2022-10-12,NaN,NaN
2410,NaN,NaN,NaN,QYT87244,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaytrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 396 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 396 from patent US 11034762,2022-10-12,NaN,NaN
2411,NaN,NaN,NaN,QYT87243,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasnrepgvpdrfsgsgsgtdftltisslqaedvavyfchqyystpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 395 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 395 from patent US 11034762,2022-10-12,NaN,NaN
2412,NaN,NaN,NaN,QYT87242,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasyresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygfpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 394 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 394 from patent US 11034762,2022-10-12,NaN,NaN
2413,NaN,NaN,NaN,QYT87241,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnlnylawyqqkpgqppklliywgstrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 393 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 393 from patent US 11034762,2022-10-12,NaN,NaN
2414,NaN,NaN,NaN,QYT87240,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratincrssqtvlyrsnnynylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 392 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 392 from patent US 11034762,2022-10-12,NaN,NaN
2415,NaN,NaN,NaN,QYT87239,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnknnylawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 391 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 391 from patent US 11034762,2022-10-12,NaN,NaN
2416,NaN,NaN,NaN,QYT87238,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyyyapwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 390 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 390 from patent US 11034762,2022-10-12,NaN,NaN
2417,NaN,NaN,NaN,QYT87237,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnninylawyqqkpgqppklliywastrasgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 389 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 389 from patent US 11034762,2022-10-12,NaN,NaN
2418,NaN,NaN,NaN,QYT87236,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 388 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 388 from patent US 11034762,2022-10-12,NaN,NaN
2419,NaN,NaN,NaN,QYT87235,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqnvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 387 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 387 from patent US 11034762,2022-10-12,NaN,NaN
2420,NaN,NaN,NaN,QYT87234,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastrdfgvpdrfsgsgsgtdftltisslqaedvavyycqqyyalpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 386 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 386 from patent US 11034762,2022-10-12,NaN,NaN
2421,NaN,NaN,NaN,QYT87233,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratirctsslslqdrsnnknyltwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqhysapltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 385 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 385 from patent US 11034762,2022-10-12,NaN,NaN
2422,NaN,NaN,NaN,QYT87232,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqnvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 384 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 384 from patent US 11034762,2022-10-12,NaN,NaN
2423,NaN,NaN,NaN,QYT87231,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaniresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 383 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 383 from patent US 11034762,2022-10-12,NaN,NaN
2424,NaN,NaN,NaN,QYT87230,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlytsnnnnylawyqqkpgqppklliywgstrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 382 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 382 from patent US 11034762,2022-10-12,NaN,NaN
2425,NaN,NaN,NaN,QYT87229,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlytsnnnnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 381 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 381 from patent US 11034762,2022-10-12,NaN,NaN
2426,NaN,NaN,NaN,QYT87228,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 380 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 380 from patent US 11034762,2022-10-12,NaN,NaN
2427,NaN,NaN,NaN,QYT87227,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 379 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 379 from patent US 11034762,2022-10-12,NaN,NaN
2428,NaN,NaN,NaN,QYT87226,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 378 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 378 from patent US 11034762,2022-10-12,NaN,NaN
2429,NaN,NaN,QYS33726,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewmgiinprggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctreakpqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 208 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 208 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2430,NaN,NaN,QYS33717,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 199 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 199 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2431,NaN,NaN,QYS33686,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpngggtyyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 168 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 168 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2432,NaN,NaN,QYS33685,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiintsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 167 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 167 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2433,NaN,NaN,QYS33684,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregppqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 166 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 166 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2434,NaN,NaN,QYS33683,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfteyemhwvrqapgqglewmgiinpsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqvlrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 165 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 165 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2435,NaN,NaN,QYS33682,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgmvdpnsgntyyaqkfqgrftmtrdtststvymelsslrsedtavyyctregipqllgtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 164 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 164 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2436,NaN,NaN,QYS33681,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfsdyymhwvrqapgqglewmgiidpsggsasyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 163 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 163 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2437,NaN,NaN,QYS33680,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgysftsyeihwvrqapgqglewmgiinpsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqvlrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 162 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 162 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2438,NaN,NaN,QYS33679,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgvinpsggytsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrhldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 161 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 161 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2439,NaN,NaN,QYS33678,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiintsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 160 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 160 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2440,NaN,NaN,QYS33677,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgminpsggytnyaqefqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 159 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 159 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2441,NaN,NaN,QYS33676,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpdggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 158 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 158 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2442,NaN,NaN,QYS33675,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgydfinyyihwvrqapgqglewmgiidpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 157 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 157 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2443,NaN,NaN,QYS33674,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfasydvnwvrqapgqglewmgiinprsgdanyaqkfqgrvtmtrdtststvymelsslrsedtavyyctrerhpqllmpldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 156 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 156 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2444,NaN,NaN,QYS33673,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsysmhwvrqapgqglewmgaiypgnsdttyaqkfqgrvtmtrdtststvymelsslrsedtavyyctldgipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 155 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 155 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2445,NaN,NaN,QYS33672,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipwwlrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 154 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 154 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2446,NaN,NaN,QYS33671,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfgnyainwvrqapgqglewmgaiypgnsdttynqkfqgrvtmtrdtststvymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 153 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 153 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2447,NaN,NaN,QYS33670,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyrftsyevnwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllwaldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 152 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 152 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2448,NaN,NaN,QYS33669,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 151 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 151 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2449,NaN,NaN,QYS33668,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsagstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 150 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 150 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2450,NaN,NaN,QYS33667,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgdiwrlhwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 149 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 149 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2451,NaN,NaN,QYS33666,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgntftgyymhwvrqapgqglewmgaiypggsdtsynqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqlawtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 148 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 148 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2452,NaN,NaN,QYS33665,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgvvnpsggytsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrsqdywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 147 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 147 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2453,NaN,NaN,QYS33664,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftshdinwvrqapgqglewmgminpsggytsyaqnfqgrvtmtrdtststvymelsslrsedtavyyctregipallrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 146 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 146 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2454,NaN,NaN,QYS33663,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyeinwvrqapgqglewmgvinpsgghtnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqlagtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 145 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 145 from patent US 11028167,NaN,2022-10-12,NaN,NaN
2455,NaN,NaN,NaN,QYS33727,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgidtylnwyqqkpgkapklliykasslesgvpsrfsgsgsgteftltinslqpediatyycqqydnlpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 209 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 209 from patent US 11028167,2022-10-12,NaN,NaN
2456,NaN,NaN,NaN,QYS33718,"['COVID', 'SARS-COV-2']",Unknown.,NaN,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleik,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 200 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 200 from patent US 11028167,2022-10-12,NaN,NaN
2457,NaN,NaN,NaN,QYS33710,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtysapytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 192 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 192 from patent US 11028167,2022-10-12,NaN,NaN
2458,NaN,NaN,NaN,QYS33709,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnplhfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 191 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 191 from patent US 11028167,2022-10-12,NaN,NaN
2459,NaN,NaN,NaN,QYS33708,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyhtsnletgvpsrfsgsgsgtdftltisslqpedfatyycqqsysfpattfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 190 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 190 from patent US 11028167,2022-10-12,NaN,NaN
2460,NaN,NaN,NaN,QYS33707,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 189 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 189 from patent US 11028167,2022-10-12,NaN,NaN
2461,NaN,NaN,NaN,QYS33706,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgyttprtfgggtkggdqt,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 188 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 188 from patent US 11028167,2022-10-12,NaN,NaN
2462,NaN,NaN,NaN,QYS33705,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqvgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlavtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 187 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 187 from patent US 11028167,2022-10-12,NaN,NaN
2463,NaN,NaN,NaN,QYS33704,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 186 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 186 from patent US 11028167,2022-10-12,NaN,NaN
2464,NaN,NaN,NaN,QYS33703,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisgylswyqqkpgkapklliyaasslqsgvpsrfsgsgswtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 185 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 185 from patent US 11028167,2022-10-12,NaN,NaN
2465,NaN,NaN,NaN,QYS33702,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 184 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 184 from patent US 11028167,2022-10-12,NaN,NaN
2466,NaN,NaN,NaN,QYS33701,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsiyrwlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyycqqsygnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 183 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 183 from patent US 11028167,2022-10-12,NaN,NaN
2467,NaN,NaN,NaN,QYS33700,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpqytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 182 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 182 from patent US 11028167,2022-10-12,NaN,NaN
2468,NaN,NaN,NaN,QYS33699,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqdisdslawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysrlawtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 181 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 181 from patent US 11028167,2022-10-12,NaN,NaN
2469,NaN,NaN,NaN,QYS33698,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasrlesgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 180 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 180 from patent US 11028167,2022-10-12,NaN,NaN
2470,NaN,NaN,NaN,QYS33697,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygvsslhsgvpsrfsgsgsgtdftltisslqpedfatyyclqyvsypwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 179 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 179 from patent US 11028167,2022-10-12,NaN,NaN
2471,NaN,NaN,NaN,QYS33696,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpewtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 178 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 178 from patent US 11028167,2022-10-12,NaN,NaN
2472,NaN,NaN,NaN,QYS33695,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqeisgylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyvsypwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 177 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 177 from patent US 11028167,2022-10-12,NaN,NaN
2473,NaN,NaN,NaN,QYS33694,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 176 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 176 from patent US 11028167,2022-10-12,NaN,NaN
2474,NaN,NaN,NaN,QYS33693,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsirtylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpsytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 175 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 175 from patent US 11028167,2022-10-12,NaN,NaN
2475,NaN,NaN,NaN,QYS33692,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpsytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 174 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 174 from patent US 11028167,2022-10-12,NaN,NaN
2476,NaN,NaN,NaN,QYS33691,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqeissylswyqqkpgkapklliyaasslqsgvssrfsgsgsgtdftltisslqpedfatyycqqynsypltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 173 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 173 from patent US 11028167,2022-10-12,NaN,NaN
2477,NaN,NaN,NaN,QYS33690,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpediatyycqqfgsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 172 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 172 from patent US 11028167,2022-10-12,NaN,NaN
2478,NaN,NaN,NaN,QYS33689,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 171 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 171 from patent US 11028167,2022-10-12,NaN,NaN
2479,NaN,NaN,NaN,QYS33688,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 170 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 170 from patent US 11028167,2022-10-12,NaN,NaN
2480,NaN,NaN,NaN,QYS33687,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisgylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgyttprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 169 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 169 from patent US 11028167,2022-10-12,NaN,NaN
2481,NaN,NaN,QYS31785,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 280 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 280 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2482,NaN,NaN,QYS31737,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggsfsrfpiswvrqapgqglewmggiipifgtanyaqrfqgrvtitadeststaymelsslrsedtavyycaletvmgglqvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 232 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 232 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2483,NaN,NaN,QYS31736,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftafyihwvrqapgqglewmggiipisgtanyaqkfqgratitadeststaymelsslrsedtavyycarevvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 231 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 231 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2484,NaN,NaN,QYS31735,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswmrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsnlrsedtavyycardtywggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 230 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 230 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2485,NaN,NaN,QYS31734,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssfaiiwvrqapgqglewmalinpssgttsyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 229 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 229 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2486,NaN,NaN,QYS31733,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgntfsmfainwvrqapgqglewvgvinpigstttyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 228 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 228 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2487,NaN,NaN,QYS31732,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 227 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 227 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2488,NaN,NaN,QYS31731,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsyymhwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycavetvmggmqmwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 226 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 226 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2489,NaN,NaN,QYS31730,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfssfyihwvrqapgqglewmggiipifgeaeyahkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 225 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 225 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2490,NaN,NaN,QYS31729,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfsdfylhwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 224 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 224 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2491,NaN,NaN,QYS31728,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsyyvhwvrqapgqglewmggilpilgtphyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmtawgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 223 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 223 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2492,NaN,NaN,QYS31727,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycavetvmggftvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 222 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 222 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2493,NaN,NaN,QYS31726,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgiinpsggstsyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmgvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 221 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 221 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2494,NaN,NaN,QYS31725,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtakyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 220 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 220 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2495,NaN,NaN,QYS31724,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftgfymqwvrqapgqglewmggitpilgtanyaqkfqgrvtitadeststaymelsslrsedtavyycareivmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 219 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 219 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2496,NaN,NaN,QYS31723,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinyeihwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 218 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 218 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2497,NaN,NaN,QYS31722,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfnafyihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 217 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 217 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2498,NaN,NaN,QYS31721,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfsdfdinwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycgmdtvmggmtswgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 216 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 216 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2499,NaN,NaN,QYS31720,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdfhmhwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 215 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 215 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2500,NaN,NaN,QYS31719,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsydinwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycardtffggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 214 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 214 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2501,NaN,NaN,QYS31718,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 213 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 213 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2502,NaN,NaN,QYS31717,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgymftefymhwvrqapgqglewmggiipvsgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 212 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 212 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2503,NaN,NaN,QYS31716,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfssyyihwvrqapgqglewmggiipifgeaeyahkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 211 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 211 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2504,NaN,NaN,QYS31715,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgstfsmfainwvrqapgqglewvgvinprgssttyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 210 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 210 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2505,NaN,NaN,QYS31714,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgyaftsyymhwvrqapgqglewmgvidpsegstsnarkfqgrvtitadeststaymelsslrsedtavyycvsdtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 209 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 209 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2506,NaN,NaN,QYS31713,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfgnypitwvrqapgqglewmgiiypgdsdaryrpsfqgrvtitadeststaymelsslrsedtavyycardfsmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 208 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 208 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2507,NaN,NaN,QYS31712,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnfaltwvrqapgqglewmglinpsggstsyaqrfqgrvtitadeststaymelsslrsedtavyycardsvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 207 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 207 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2508,NaN,NaN,QYS31711,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgypfssyeinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycadetvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 206 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 206 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2509,NaN,NaN,QYS31710,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdfyihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 205 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 205 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2510,NaN,NaN,QYS31709,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnytitwvrqapgqglewlgwisayngntdyaqklqgrvtitadeststaymelsslrsedtavyycardalmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 204 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 204 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2511,NaN,NaN,QYS31708,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsfdihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycayetvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 203 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 203 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2512,NaN,NaN,QYS31707,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnfaitwvrqapgqglewmgvinpgggsttyaqtfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 202 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 202 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2513,NaN,NaN,QYS31706,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfsayymhwvrqapgqglewmggitplfgtpsyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggvgvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 201 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 201 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2514,NaN,NaN,QYS31705,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgynfinyylhwvrqapgqglewmggitpifgianyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 200 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 200 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2515,NaN,NaN,QYS31704,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfnrfamtwvrqapgqglewmgtinpsggstiytqrfqgrvtitadeststaymelsslrsedtavyycghdtvmggmgewgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 199 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 199 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2516,NaN,NaN,QYS31703,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfttydinwvrqapgqglewmgiidpiggttnyaqkfqgrvtitadeststaymelsslrsedtavyycardtvgfgmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 198 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 198 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2517,NaN,NaN,QYS31702,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsrydinwvrqapgqglewmgiinpsggsttyaqkfqgrvtitadeststaymelsslrsedtavyycahdtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 197 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 197 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2518,NaN,NaN,QYS31701,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfssfhinwvrqapgqglewmggitpifgianyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 196 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 196 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2519,NaN,NaN,QYS31700,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfnnydlhwvrqapgqglewmggiipifdtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmvkwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 195 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 195 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2520,NaN,NaN,QYS31699,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsyymhwvrqapgqglewmglidpsggttsyaqkfqgrvtitadeststaymelsslrsedtavyycvwdtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 194 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 194 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2521,NaN,NaN,QYS31698,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfttydinwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycardtywggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 193 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 193 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2522,NaN,NaN,QYS31697,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgctftrftmhwvrqapgqglewmggitpifgitnyaqkfqgrvtitadeststaymelsslrsedtavyycahdtvmggmeewgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 192 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 192 from patent US 11028150,NaN,2022-10-12,NaN,NaN
2523,NaN,NaN,NaN,QYS31786,"['COVID', 'SARS-COV-2']",Unknown.,NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvl,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 281 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 281 from patent US 11028150,2022-10-12,NaN,NaN
2524,NaN,NaN,NaN,QYS31778,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 273 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 273 from patent US 11028150,2022-10-12,NaN,NaN
2525,NaN,NaN,NaN,QYS31777,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 272 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 272 from patent US 11028150,2022-10-12,NaN,NaN
2526,NaN,NaN,NaN,QYS31776,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 271 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 271 from patent US 11028150,2022-10-12,NaN,NaN
2527,NaN,NaN,NaN,QYS31775,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssshyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 270 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 270 from patent US 11028150,2022-10-12,NaN,NaN
2528,NaN,NaN,NaN,QYS31774,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwvsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 269 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 269 from patent US 11028150,2022-10-12,NaN,NaN
2529,NaN,NaN,NaN,QYS31773,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdshsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 268 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 268 from patent US 11028150,2022-10-12,NaN,NaN
2530,NaN,NaN,NaN,QYS31772,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 267 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 267 from patent US 11028150,2022-10-12,NaN,NaN
2531,NaN,NaN,NaN,QYS31771,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 266 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 266 from patent US 11028150,2022-10-12,NaN,NaN
2532,NaN,NaN,NaN,QYS31770,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 265 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 265 from patent US 11028150,2022-10-12,NaN,NaN
2533,NaN,NaN,NaN,QYS31769,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 264 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 264 from patent US 11028150,2022-10-12,NaN,NaN
2534,NaN,NaN,NaN,QYS31768,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 263 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 263 from patent US 11028150,2022-10-12,NaN,NaN
2535,NaN,NaN,NaN,QYS31767,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 262 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 262 from patent US 11028150,2022-10-12,NaN,NaN
2536,NaN,NaN,NaN,QYS31766,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 261 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 261 from patent US 11028150,2022-10-12,NaN,NaN
2537,NaN,NaN,NaN,QYS31765,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqswdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 260 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 260 from patent US 11028150,2022-10-12,NaN,NaN
2538,NaN,NaN,NaN,QYS31764,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 259 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 259 from patent US 11028150,2022-10-12,NaN,NaN
2539,NaN,NaN,NaN,QYS31763,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdgssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 258 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 258 from patent US 11028150,2022-10-12,NaN,NaN
2540,NaN,NaN,NaN,QYS31762,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsshdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 257 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 257 from patent US 11028150,2022-10-12,NaN,NaN
2541,NaN,NaN,NaN,QYS31761,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 256 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 256 from patent US 11028150,2022-10-12,NaN,NaN
2542,NaN,NaN,NaN,QYS31760,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 255 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 255 from patent US 11028150,2022-10-12,NaN,NaN
2543,NaN,NaN,NaN,QYS31759,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsrsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 254 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 254 from patent US 11028150,2022-10-12,NaN,NaN
2544,NaN,NaN,NaN,QYS31758,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 253 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 253 from patent US 11028150,2022-10-12,NaN,NaN
2545,NaN,NaN,NaN,QYS31757,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 252 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 252 from patent US 11028150,2022-10-12,NaN,NaN
2546,NaN,NaN,NaN,QYS31756,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdrssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 251 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 251 from patent US 11028150,2022-10-12,NaN,NaN
2547,NaN,NaN,NaN,QYS31755,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssslyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 250 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 250 from patent US 11028150,2022-10-12,NaN,NaN
2548,NaN,NaN,NaN,QYS31754,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwddssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 249 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 249 from patent US 11028150,2022-10-12,NaN,NaN
2549,NaN,NaN,NaN,QYS31753,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwasssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 248 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 248 from patent US 11028150,2022-10-12,NaN,NaN
2550,NaN,NaN,NaN,QYS31752,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssndyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 247 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 247 from patent US 11028150,2022-10-12,NaN,NaN
2551,NaN,NaN,NaN,QYS31751,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssshyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 246 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 246 from patent US 11028150,2022-10-12,NaN,NaN
2552,NaN,NaN,NaN,QYS31750,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsrsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 245 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 245 from patent US 11028150,2022-10-12,NaN,NaN
2553,NaN,NaN,NaN,QYS31749,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 244 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 244 from patent US 11028150,2022-10-12,NaN,NaN
2554,NaN,NaN,NaN,QYS31748,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 243 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 243 from patent US 11028150,2022-10-12,NaN,NaN
2555,NaN,NaN,NaN,QYS31747,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveavdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 242 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 242 from patent US 11028150,2022-10-12,NaN,NaN
2556,NaN,NaN,NaN,QYS31746,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnkigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 241 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 241 from patent US 11028150,2022-10-12,NaN,NaN
2557,NaN,NaN,NaN,QYS31745,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqstdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 240 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 240 from patent US 11028150,2022-10-12,NaN,NaN
2558,NaN,NaN,NaN,QYS31744,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssslyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 239 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 239 from patent US 11028150,2022-10-12,NaN,NaN
2559,NaN,NaN,NaN,QYS31743,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 238 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 238 from patent US 11028150,2022-10-12,NaN,NaN
2560,NaN,NaN,NaN,QYS31742,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqswdssgdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 237 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 237 from patent US 11028150,2022-10-12,NaN,NaN
2561,NaN,NaN,NaN,QYS31741,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrieagdeadyycqvwdssgdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 236 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 236 from patent US 11028150,2022-10-12,NaN,NaN
2562,NaN,NaN,NaN,QYS31740,"['COVID', 'SARS-COV-2']",Unknown.,NaN,syvltqppsvsvapgktaaritcggnnigsksvhwyqqkpgqapvlviykdgerpsgiperfsgsnsrntatltisrveagdeadyycqvwdssslyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 235 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 235 from patent US 11028150,2022-10-12,NaN,NaN
2563,NaN,NaN,NaN,QYS31739,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 234 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 234 from patent US 11028150,2022-10-12,NaN,NaN
2564,NaN,NaN,NaN,QYS31738,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssndyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 233 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 233 from patent US 11028150,2022-10-12,NaN,NaN
2565,NaN,NaN,QYS20240,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 497 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 497 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2566,NaN,NaN,QYS20171,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 428 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 428 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2567,NaN,NaN,QYS20170,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsavsssggspyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 427 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 427 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2568,NaN,NaN,QYS20169,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsvisasggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 426 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 426 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2569,NaN,NaN,QYS20168,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfstyamhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 425 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 425 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2570,NaN,NaN,QYS20167,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfafssyalhwvrqapgkglewvsaisgsggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 424 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 424 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2571,NaN,NaN,QYS20166,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfafsnygmhwirqapgkglewvsgidgsggtahyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 423 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 423 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2572,NaN,NaN,QYS20165,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 422 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 422 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2573,NaN,NaN,QYS20164,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisgsgdntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 421 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 421 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2574,NaN,NaN,QYS20163,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 420 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 420 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2575,NaN,NaN,QYS20162,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfpfslygmhwvrqapgkglewvavitsdgrskfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 419 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 419 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2576,NaN,NaN,QYS20161,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgitfnnyamtwvrqapgkglewvsgisgsggstyyadsvkgrftisrdnsrntlylqmnslraedtavyycvtqrdnpvdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 418 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 418 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2577,NaN,NaN,QYS20160,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfrfddfgmhwyrqapgkglewvsatsgggsityyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 417 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 417 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2578,NaN,NaN,QYS20159,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfkfntyamhwvrqapgkglewvsaisitggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 416 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 416 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2579,NaN,NaN,QYS20158,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsgvsasgggpyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 415 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 415 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2580,NaN,NaN,QYS20157,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfsfrsygmhwvrqapgkglewvavissdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnfdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 414 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 414 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2581,NaN,NaN,QYS20156,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 413 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 413 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2582,NaN,NaN,QYS20155,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfifndygmhwvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 412 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 412 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2583,NaN,NaN,QYS20154,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 411 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 411 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2584,NaN,NaN,QYS20153,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsvitgdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 410 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 410 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2585,NaN,NaN,QYS20152,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisrsgdsayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 409 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 409 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2586,NaN,NaN,QYS20151,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 408 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 408 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2587,NaN,NaN,QYS20150,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfrfntyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 407 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 407 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2588,NaN,NaN,QYS20149,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 406 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 406 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2589,NaN,NaN,QYS20148,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsgvsasgggpyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 405 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 405 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2590,NaN,NaN,QYS20147,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfsnyamhwvrqapgkglewvsgissggsgthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 404 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 404 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2591,NaN,NaN,QYS20146,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfafsnygmhwirqapgkglewvsgidgsggtahyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 403 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 403 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2592,NaN,NaN,QYS20145,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfsfsrygmhwvrqapgkglewvsgisadggtayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 402 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 402 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2593,NaN,NaN,QYS20144,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygvhwvrqapgkglewvavishdgkkkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnvdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 401 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 401 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2594,NaN,NaN,QYS20143,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsgisgggagtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtyrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 400 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 400 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2595,NaN,NaN,QYS20142,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsgisgsgdrtyyadsvkgrftisrdnskntlylqmnslraedtavyycsmqrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 399 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 399 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2596,NaN,NaN,QYS20141,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfhdyamhwvrqapgkglewvavtsydgntkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 398 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 398 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2597,NaN,NaN,QYS20140,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfgtsavswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 397 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 397 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2598,NaN,NaN,QYS20139,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsaysgsggytyfadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 396 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 396 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2599,NaN,NaN,QYS20138,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavvsrsggstfyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 395 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 395 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2600,NaN,NaN,QYS20137,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvaaisgsggsthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 394 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 394 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2601,NaN,NaN,QYS20136,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisassagayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 393 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 393 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2602,NaN,NaN,QYS20135,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsringdgsttgyadsvkgrftisrdnskntlylqmnslraedtavyycvttgdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 392 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 392 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2603,NaN,NaN,QYS20134,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfsshtiawvrqapgkglewlshisssgsttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdmsphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 391 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 391 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2604,NaN,NaN,QYS20133,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvaaigasgestyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfplwfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 390 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 390 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2605,NaN,NaN,QYS20132,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfstygmhwvrqapgkglewvstisgngvstsyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 389 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 389 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2606,NaN,NaN,QYS20131,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 388 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 388 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2607,NaN,NaN,QYS20130,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftftsygmhwvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 387 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 387 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2608,NaN,NaN,QYS20129,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfiftnyalhwvrqapgkglewvsaisgsggsthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 386 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 386 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2609,NaN,NaN,QYS20128,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfstyamhwvrqapgkglewvavisydgnyqyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 385 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 385 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2610,NaN,NaN,QYS20127,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfifssyamnwvrqapgkglewvsgisgsgggayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 384 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 384 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2611,NaN,NaN,QYS20126,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfnnyalhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 383 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 383 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2612,NaN,NaN,QYS20125,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsavsssggspyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 382 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 382 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2613,NaN,NaN,QYS20124,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 381 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 381 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2614,NaN,NaN,QYS20123,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 380 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 380 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2615,NaN,NaN,QYS20122,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfrsyamhwvrqapgkglewvavissdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 379 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 379 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2616,NaN,NaN,QYS20121,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaigagggtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 378 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 378 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2617,NaN,NaN,QYS20120,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsavgdsgrstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 377 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 377 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2618,NaN,NaN,QYS20119,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 376 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 376 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2619,NaN,NaN,QYS20118,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfifssfgmhwvrqapgkglewvsaisdsgdatqyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 375 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 375 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2620,NaN,NaN,QYS20117,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvsavsttggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 374 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 374 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2621,NaN,NaN,QYS20116,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsaigtggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 373 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 373 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2622,NaN,NaN,QYS20115,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfrsyamhwvrqapgkglewvavishdasnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 372 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 372 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2623,NaN,NaN,QYS20114,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfrfsdhpmhwvrqapgkglewvavitgsgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 371 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 371 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2624,NaN,NaN,QYS20113,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvsvisgsgrntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 370 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 370 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2625,NaN,NaN,QYS20112,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfsnyamhwvrqapgkglewvsaigagggtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 369 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 369 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2626,NaN,NaN,QYS20111,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfsdyalhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 368 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 368 from patent US 11053304,NaN,2022-10-12,NaN,NaN
2627,NaN,NaN,NaN,QYS20241,"['COVID', 'SARS-COV-2']",Unknown.,NaN,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 498 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 498 from patent US 11053304,2022-10-12,NaN,NaN
2628,NaN,NaN,NaN,QYS20233,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 490 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 490 from patent US 11053304,2022-10-12,NaN,NaN
2629,NaN,NaN,NaN,QYS20232,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvhsdgdnylnwylqkpgqspqlliysgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 489 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 489 from patent US 11053304,2022-10-12,NaN,NaN
2630,NaN,NaN,NaN,QYS20231,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssrsllhtnglnyidwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyctqalqtpisfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 488 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 488 from patent US 11053304,2022-10-12,NaN,NaN
2631,NaN,NaN,NaN,QYS20230,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalrtptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 487 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 487 from patent US 11053304,2022-10-12,NaN,NaN
2632,NaN,NaN,NaN,QYS20229,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhrngynyvdwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlrisrveaedvgvyycmqarqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 486 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 486 from patent US 11053304,2022-10-12,NaN,NaN
2633,NaN,NaN,NaN,QYS20228,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsdrapgvpdrfsgsgsgtdftlkisrveaedvgvyycaqglqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 485 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 485 from patent US 11053304,2022-10-12,NaN,NaN
2634,NaN,NaN,NaN,QYS20227,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqllislgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 484 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 484 from patent US 11053304,2022-10-12,NaN,NaN
2635,NaN,NaN,NaN,QYS20226,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 483 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 483 from patent US 11053304,2022-10-12,NaN,NaN
2636,NaN,NaN,NaN,QYS20225,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssesllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyciqalqtpftfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 482 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 482 from patent US 11053304,2022-10-12,NaN,NaN
2637,NaN,NaN,NaN,QYS20224,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylssnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqspytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 481 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 481 from patent US 11053304,2022-10-12,NaN,NaN
2638,NaN,NaN,NaN,QYS20223,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqvpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 480 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 480 from patent US 11053304,2022-10-12,NaN,NaN
2639,NaN,NaN,NaN,QYS20222,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlhtpgtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 479 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 479 from patent US 11053304,2022-10-12,NaN,NaN
2640,NaN,NaN,NaN,QYS20221,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqaysfpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 478 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 478 from patent US 11053304,2022-10-12,NaN,NaN
2641,NaN,NaN,NaN,QYS20220,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkitrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 477 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 477 from patent US 11053304,2022-10-12,NaN,NaN
2642,NaN,NaN,NaN,QYS20219,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 476 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 476 from patent US 11053304,2022-10-12,NaN,NaN
2643,NaN,NaN,NaN,QYS20218,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsirasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsqqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 475 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 475 from patent US 11053304,2022-10-12,NaN,NaN
2644,NaN,NaN,NaN,QYS20217,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpgtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 474 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 474 from patent US 11053304,2022-10-12,NaN,NaN
2645,NaN,NaN,NaN,QYS20216,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 473 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 473 from patent US 11053304,2022-10-12,NaN,NaN
2646,NaN,NaN,NaN,QYS20215,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssksllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaaqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 472 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 472 from patent US 11053304,2022-10-12,NaN,NaN
2647,NaN,NaN,NaN,QYS20214,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyclqtlqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 471 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 471 from patent US 11053304,2022-10-12,NaN,NaN
2648,NaN,NaN,NaN,QYS20213,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgtnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtppkfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 470 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 470 from patent US 11053304,2022-10-12,NaN,NaN
2649,NaN,NaN,NaN,QYS20212,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrsshsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqlphtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 469 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 469 from patent US 11053304,2022-10-12,NaN,NaN
2650,NaN,NaN,NaN,QYS20211,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylaanrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 468 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 468 from patent US 11053304,2022-10-12,NaN,NaN
2651,NaN,NaN,NaN,QYS20210,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliyfgsnrasgvpdrfsgsgsgtdftlkisrvetedvgvyycmqalqtpaltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 467 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 467 from patent US 11053304,2022-10-12,NaN,NaN
2652,NaN,NaN,NaN,QYS20209,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliyqgsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 466 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 466 from patent US 11053304,2022-10-12,NaN,NaN
2653,NaN,NaN,NaN,QYS20208,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaqqtpitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 465 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 465 from patent US 11053304,2022-10-12,NaN,NaN
2654,NaN,NaN,NaN,QYS20207,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllqsngdnyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglhwpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 464 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 464 from patent US 11053304,2022-10-12,NaN,NaN
2655,NaN,NaN,NaN,QYS20206,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 463 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 463 from patent US 11053304,2022-10-12,NaN,NaN
2656,NaN,NaN,NaN,QYS20205,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 462 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 462 from patent US 11053304,2022-10-12,NaN,NaN
2657,NaN,NaN,NaN,QYS20204,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsvqtpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 461 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 461 from patent US 11053304,2022-10-12,NaN,NaN
2658,NaN,NaN,NaN,QYS20203,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsvrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqgynmpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 460 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 460 from patent US 11053304,2022-10-12,NaN,NaN
2659,NaN,NaN,NaN,QYS20202,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgletpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 459 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 459 from patent US 11053304,2022-10-12,NaN,NaN
2660,NaN,NaN,NaN,QYS20201,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasisckssqsllhingfnyldwflqkpgqspqlliylgsnrapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqslqnprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 458 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 458 from patent US 11053304,2022-10-12,NaN,NaN
2661,NaN,NaN,NaN,QYS20200,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 457 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 457 from patent US 11053304,2022-10-12,NaN,NaN
2662,NaN,NaN,NaN,QYS20199,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhingynyldwflqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqnprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 456 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 456 from patent US 11053304,2022-10-12,NaN,NaN
2663,NaN,NaN,NaN,QYS20197,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngnnyldwylqkpgqspqlliyggsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsytppptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 454 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 454 from patent US 11053304,2022-10-12,NaN,NaN
2664,NaN,NaN,NaN,QYS20196,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsyitpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 453 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 453 from patent US 11053304,2022-10-12,NaN,NaN
2665,NaN,NaN,NaN,QYS20195,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslldsngfnyldwylqkpgqspqlliylgssrapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsyntpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 452 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 452 from patent US 11053304,2022-10-12,NaN,NaN
2666,NaN,NaN,NaN,QYS20194,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqtpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 451 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 451 from patent US 11053304,2022-10-12,NaN,NaN
2667,NaN,NaN,NaN,QYS20193,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvysdgytylnwylqkpgqspqlliyqvsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpaltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 450 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 450 from patent US 11053304,2022-10-12,NaN,NaN
2668,NaN,NaN,NaN,QYS20192,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvhsdgytylnwylqkpgqspqlliyvgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqasqwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 449 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 449 from patent US 11053304,2022-10-12,NaN,NaN
2669,NaN,NaN,NaN,QYS20191,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllqsngynyldwylqkpgqspqlliylgynrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqapltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 448 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 448 from patent US 11053304,2022-10-12,NaN,NaN
2670,NaN,NaN,NaN,QYS20190,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrpsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlqtpfsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 447 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 447 from patent US 11053304,2022-10-12,NaN,NaN
2671,NaN,NaN,NaN,QYS20189,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaiqnrrtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 446 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 446 from patent US 11053304,2022-10-12,NaN,NaN
2672,NaN,NaN,NaN,QYS20188,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllqsngynymdwylqkpgqspqlliyltsnraagvpdrfsgsgsgtdftlkisrveaedvgvyycqqsygppltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 445 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 445 from patent US 11053304,2022-10-12,NaN,NaN
2673,NaN,NaN,NaN,QYS20187,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscssrqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycvqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 444 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 444 from patent US 11053304,2022-10-12,NaN,NaN
2674,NaN,NaN,NaN,QYS20186,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvhsdgdnylnwylqkpgqspqlliysgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 443 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 443 from patent US 11053304,2022-10-12,NaN,NaN
2675,NaN,NaN,NaN,QYS20185,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 442 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 442 from patent US 11053304,2022-10-12,NaN,NaN
2676,NaN,NaN,NaN,QYS20184,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynrlawylqkpgqspqlliylgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 441 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 441 from patent US 11053304,2022-10-12,NaN,NaN
2677,NaN,NaN,NaN,QYS20183,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngnnymdwylqkpgqspqlliylasqrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 440 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 440 from patent US 11053304,2022-10-12,NaN,NaN
2678,NaN,NaN,NaN,QYS20182,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliygastratgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlqtprfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 439 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 439 from patent US 11053304,2022-10-12,NaN,NaN
2679,NaN,NaN,NaN,QYS20181,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 438 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 438 from patent US 11053304,2022-10-12,NaN,NaN
2680,NaN,NaN,NaN,QYS20180,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngyndldwylqkpgqspqlliyggsngasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 437 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 437 from patent US 11053304,2022-10-12,NaN,NaN
2681,NaN,NaN,NaN,QYS20179,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrpsqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalhipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 436 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 436 from patent US 11053304,2022-10-12,NaN,NaN
2682,NaN,NaN,NaN,QYS20178,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsdrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlhtpgtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 435 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 435 from patent US 11053304,2022-10-12,NaN,NaN
2683,NaN,NaN,NaN,QYS20177,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngyiyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlrtpitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 434 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 434 from patent US 11053304,2022-10-12,NaN,NaN
2684,NaN,NaN,NaN,QYS20176,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrmeaedvgvyycmqtlqmpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 433 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 433 from patent US 11053304,2022-10-12,NaN,NaN
2685,NaN,NaN,NaN,QYS20175,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhrngynyldwylqkpgqspqlliygastratgvpdrfsgsgsgtdftlkisrveaedvgvyyctqslqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 432 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 432 from patent US 11053304,2022-10-12,NaN,NaN
2686,NaN,NaN,NaN,QYS20174,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrpsqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaahwpitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 431 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 431 from patent US 11053304,2022-10-12,NaN,NaN
2687,NaN,NaN,NaN,QYS20173,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 430 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 430 from patent US 11053304,2022-10-12,NaN,NaN
2688,NaN,NaN,NaN,QYS20172,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 429 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 429 from patent US 11053304,2022-10-12,NaN,NaN
2689,NaN,NaN,QYR87209,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftsypihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgsydtdafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 436 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 436 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2690,NaN,NaN,QYR87201,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 427 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 427 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2691,NaN,NaN,QYR87193,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 419 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 419 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2692,NaN,NaN,QYR87185,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 411 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 411 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2693,NaN,NaN,QYR87177,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 403 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 403 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2694,NaN,NaN,QYR87169,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 395 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 395 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2695,NaN,NaN,QYR87138,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvyvsckasgytftsygiswvrqapgqglewmggiipmfgttnyaqkfqgrvtitadkststaymelsslrsedtavyycardrgdtidywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 364 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 364 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2696,NaN,NaN,QYR87137,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyeinwvrqapgqglewmgiinpsdgsstyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgysydhdqiyyyygmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 363 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 363 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2697,NaN,NaN,QYR87136,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgwmnsnsgstgyaqkfqgrvtmtrdtststvymelsslrsedtavyycargwmaydafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 362 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 362 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2698,NaN,NaN,QYR87135,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgiidpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycatvtpgygmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 361 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 361 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2699,NaN,NaN,QYR87134,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftryyihwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycakgaphdyiwgsyrpdafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 360 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 360 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2700,NaN,NaN,QYR87133,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftryyihwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycakgaphdyiwgsyrpdafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 359 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 359 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2701,NaN,NaN,QYR87132,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisarngntnyaqkfqgrvtmtrdtststvymelsslrsedtavyycttdpvlewfgysiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 358 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 358 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2702,NaN,NaN,QYR87131,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftgsyaiswvrqapgqglewmgwinpktgdtnyaqefqgrvtmtrdtststvymelsslrsedtavyycargssgyyfgwgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 357 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 357 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2703,NaN,NaN,QYR87130,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftgnyihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycakdvqnyygsgssfdywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 356 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 356 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2704,NaN,NaN,QYR87129,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardsgvdtatlryyyygmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 355 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 355 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2705,NaN,NaN,QYR87128,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardsgvdtatlryyyygmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 354 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 354 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2706,NaN,NaN,QYR87127,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardlmdivvvpwlggmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 353 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 353 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2707,NaN,NaN,QYR87126,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycaktryggnsrsryyyygmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 352 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 352 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2708,NaN,NaN,QYR87125,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftdyymqwvrqapgqglewmgwidphsgatnyahsfqgrvtmtrdtststvymelsslrsedtavyycarleggsywtgyfdlwgrgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 351 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 351 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2709,NaN,NaN,QYR87124,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdyyiqwvrqapgqglewmgwinpnsggpnyaqkfqgrvtitadeststaymelsslrsedtavyycarvdygdygrledywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 350 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 350 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2710,NaN,NaN,QYR87123,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftdyhmhwvrqapgqglewmgwmnpnsgntsyaqkfqgrvtmtrdtststvymelsslrsedtavyycagmgmgrdgynsrafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 349 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 349 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2711,NaN,NaN,QYR87122,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinydinwvrqapgqglewmgvinpsagstsyahkfqgrvtmtrdtststvymelsslrsedtavyycasahssswysdwfdpwgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 348 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 348 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2712,NaN,NaN,QYR87121,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftsypihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgsydtdafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 347 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 347 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2713,NaN,NaN,QYR87120,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasggtftsyhmhwvrqapgqglewmgwmnpnsgntgyalkfqgrvtmtrdtststvymelsslrsedtavyycasferfgelvpetfdywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 346 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 346 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2714,NaN,NaN,QYR87119,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasggtfssyaiswvrqapgqglewmgivnpssgsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycarvrgsaaiammdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 345 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 345 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2715,NaN,NaN,QYR87118,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasggtfrstaiswvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycaragyssssgyyyygmdvwgkgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 344 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 344 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2716,NaN,NaN,QYR87117,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqllesggglvqpggslrlscaasgftfsgsamhwvrqapgkgleyvsaisrnggttyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgtlitttldywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 343 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 343 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2717,NaN,NaN,QYR87116,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqllesggglvqpggslrlscaasgfsfsnydmhwvrqapgkglewvavisydggfklyadsvkgrftisrdnaknslylrmnslrsedtavyycargqvrgsgpqvvvmdvwgkgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 342 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 342 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2718,NaN,NaN,QYR87115,NaN,"['COVID', 'SARS-COV-2']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgdtfsnygiswvrqapgqglewmgwmnpnsggtnyaqkfqgrvtmtrdtststvymelsslrsedtavyycaigttvvtpfgywgqgtlvnvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 341 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 341 from patent US 11021532,NaN,2022-10-12,NaN,NaN
2719,NaN,NaN,NaN,QYR87210,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqdisnylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpstfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 437 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 437 from patent US 11021532,2022-10-12,NaN,NaN
2720,NaN,NaN,NaN,QYR87202,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 428 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 428 from patent US 11021532,2022-10-12,NaN,NaN
2721,NaN,NaN,NaN,QYR87194,"['COVID', 'SARS-COV-2']",Unknown.,NaN,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 420 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 420 from patent US 11021532,2022-10-12,NaN,NaN
2722,NaN,NaN,NaN,QYR87186,"['COVID', 'SARS-COV-2']",Unknown.,NaN,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleik,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 412 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 412 from patent US 11021532,2022-10-12,NaN,NaN
2723,NaN,NaN,NaN,QYR87178,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 404 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 404 from patent US 11021532,2022-10-12,NaN,NaN
2724,NaN,NaN,NaN,QYR87170,"['COVID', 'SARS-COV-2']",Unknown.,NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvl,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 396 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 396 from patent US 11021532,2022-10-12,NaN,NaN
2725,NaN,NaN,NaN,QYR87162,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgngfpltfgpgtkvdikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 388 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 388 from patent US 11021532,2022-10-12,NaN,NaN
2726,NaN,NaN,NaN,QYR87161,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrvsqgissylnwyqqkpgkapklliyaasilqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpftfgpgtkvdikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 387 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 387 from patent US 11021532,2022-10-12,NaN,NaN
2727,NaN,NaN,NaN,QYR87160,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqsiynylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpedfatyycqqaisfpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 386 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 386 from patent US 11021532,2022-10-12,NaN,NaN
2728,NaN,NaN,NaN,QYR87159,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqtiysylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpedfatyycqqaisfpltfgggtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 385 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 385 from patent US 11021532,2022-10-12,NaN,NaN
2729,NaN,NaN,NaN,QYR87158,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasenidswlawyqqkpgkapklliyeastlesgvpsrfsgsgsgtdftltisslqpedfatyychqylsspetfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 384 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 384 from patent US 11021532,2022-10-12,NaN,NaN
2730,NaN,NaN,NaN,QYR87157,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasenidswlawyqqkpgkapklliyeastlesgvpsrfsgsgsgtdftltisslqpedfatyychqylsspetfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 383 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 383 from patent US 11021532,2022-10-12,NaN,NaN
2731,NaN,NaN,NaN,QYR87156,"['COVID', 'SARS-COV-2']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvfsssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 382 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 382 from patent US 11021532,2022-10-12,NaN,NaN
2732,NaN,NaN,NaN,QYR87155,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasrlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 381 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 381 from patent US 11021532,2022-10-12,NaN,NaN
2733,NaN,NaN,NaN,QYR87154,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgirnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysppltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 380 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 380 from patent US 11021532,2022-10-12,NaN,NaN
2734,NaN,NaN,NaN,QYR87153,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliygastlsdgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpysfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 379 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 379 from patent US 11021532,2022-10-12,NaN,NaN
2735,NaN,NaN,NaN,QYR87152,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliygastlsdgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpysfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 378 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 378 from patent US 11021532,2022-10-12,NaN,NaN
2736,NaN,NaN,NaN,QYR87151,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqaitnylawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyysypptfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 377 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 377 from patent US 11021532,2022-10-12,NaN,NaN
2737,NaN,NaN,NaN,QYR87150,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqhissylnwyqqkpgkapklliyaasalqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgygtpytfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 376 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 376 from patent US 11021532,2022-10-12,NaN,NaN
2738,NaN,NaN,NaN,QYR87149,"['COVID', 'SARS-COV-2']",Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvssnylawyqqkpgqaprlliyavssratgiparfsgsgsgteftltisslqsedfavyycqqygsspltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 375 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 375 from patent US 11021532,2022-10-12,NaN,NaN
2739,NaN,NaN,NaN,QYR87148,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsiyswlawyqqkpgkapklliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypytfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 374 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 374 from patent US 11021532,2022-10-12,NaN,NaN
2740,NaN,NaN,NaN,QYR87147,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysmpltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 373 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 373 from patent US 11021532,2022-10-12,NaN,NaN
2741,NaN,NaN,NaN,QYR87146,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 372 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 372 from patent US 11021532,2022-10-12,NaN,NaN
2742,NaN,NaN,NaN,QYR87145,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqdisnylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpstfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 371 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 371 from patent US 11021532,2022-10-12,NaN,NaN
2743,NaN,NaN,NaN,QYR87144,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgirndlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 370 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 370 from patent US 11021532,2022-10-12,NaN,NaN
2744,NaN,NaN,NaN,QYR87143,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqdirnelgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 369 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 369 from patent US 11021532,2022-10-12,NaN,NaN
2745,NaN,NaN,NaN,QYR87142,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqydtfpltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 368 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 368 from patent US 11021532,2022-10-12,NaN,NaN
2746,NaN,NaN,NaN,QYR87141,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsigyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 367 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 367 from patent US 11021532,2022-10-12,NaN,NaN
2747,NaN,NaN,NaN,QYR87140,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgirndlgwyqqkpgkapklliydasrlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyystppltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 366 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 366 from patent US 11021532,2022-10-12,NaN,NaN
2748,NaN,NaN,NaN,QYR87139,"['COVID', 'SARS-COV-2']",Unknown.,NaN,eivmtqspatlsvspgeratlscrasesvssrylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqgyknpptfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 365 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 365 from patent US 11021532,2022-10-12,NaN,NaN
2749,NaN,NaN,QYR85030,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 102 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 102 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2750,NaN,NaN,QYR85011,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfsfssygmswvrqapgkglewvsamnrdgsyiyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyvgywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 83 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 83 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2751,NaN,NaN,QYR85010,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 82 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 82 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2752,NaN,NaN,QYR85009,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvaiiyeggsphyadsvkgrftisrdnskntlylqmnslraedtavyycardrsgyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 81 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 81 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2753,NaN,NaN,QYR85008,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfsdhymswvrqapgkglewvsaistsgdstfyadsvkgrftisrdnskntlylqmnnlraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 80 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 80 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2754,NaN,NaN,QYR85007,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfsfssygmswvrqapgkglewvsamnrdgsyiyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyvgywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 79 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 79 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2755,NaN,NaN,QYR85006,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsaisgtgdtteyadsvkgrftisrdnskntlylqmnslraedtavyycardrslmldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 78 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 78 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2756,NaN,NaN,QYR85005,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfsnhymswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 77 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 77 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2757,NaN,NaN,QYR85004,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftftnyamtwvrqapgkglewvstmsniggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycardrrvyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 76 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 76 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2758,NaN,NaN,QYR85003,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfashamswvrqapgkglewvsgissdgsittyadsvkgrftisrdnskntlylqmnslraedtavyycardrgwyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 75 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 75 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2759,NaN,NaN,QYR85002,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasglsvtsnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 74 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 74 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2760,NaN,NaN,QYR85001,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsvvypggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 73 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 73 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2761,NaN,NaN,QYR85000,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgfrfsdaaihwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsygidywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 72 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 72 from patent US 11021531,NaN,2022-10-12,NaN,NaN
2762,NaN,NaN,NaN,QYR85031,"['COVID', 'SARS-COV-2']",Unknown.,NaN,ettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 103 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 103 from patent US 11021531,2022-10-12,NaN,NaN
2763,NaN,NaN,NaN,QYR85023,"['COVID', 'SARS-COV-2']",Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 95 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 95 from patent US 11021531,2022-10-12,NaN,NaN
2764,NaN,NaN,NaN,QYR85022,"['COVID', 'SARS-COV-2']",Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvsssylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqasstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 94 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 94 from patent US 11021531,2022-10-12,NaN,NaN
2765,NaN,NaN,NaN,QYR85021,"['COVID', 'SARS-COV-2']",Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvsnnlawyqqkpgqaprlliydastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 93 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 93 from patent US 11021531,2022-10-12,NaN,NaN
2766,NaN,NaN,NaN,QYR85020,"['COVID', 'SARS-COV-2']",Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqfgtsppglsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 92 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 92 from patent US 11021531,2022-10-12,NaN,NaN
2767,NaN,NaN,NaN,QYR85019,"['COVID', 'SARS-COV-2']",Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 91 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 91 from patent US 11021531,2022-10-12,NaN,NaN
2768,NaN,NaN,NaN,QYR85018,"['COVID', 'SARS-COV-2']",Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 90 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 90 from patent US 11021531,2022-10-12,NaN,NaN
2769,NaN,NaN,NaN,QYR85017,"['COVID', 'SARS-COV-2']",Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsigtylswyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqslslpvtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 89 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 89 from patent US 11021531,2022-10-12,NaN,NaN
2770,NaN,NaN,NaN,QYR85016,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqsedfavyycqqygsspltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 88 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 88 from patent US 11021531,2022-10-12,NaN,NaN
2771,NaN,NaN,NaN,QYR85015,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 87 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 87 from patent US 11021531,2022-10-12,NaN,NaN
2772,NaN,NaN,NaN,QYR85014,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 86 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 86 from patent US 11021531,2022-10-12,NaN,NaN
2773,NaN,NaN,NaN,QYR85013,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 85 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 85 from patent US 11021531,2022-10-12,NaN,NaN
2774,NaN,NaN,NaN,QYR85012,"['COVID', 'SARS-COV-2']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 84 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 84 from patent US 11021531,2022-10-12,NaN,NaN
2775,NaN,NaN,QXE98516,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitertygldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2776,NaN,NaN,QXE98515,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2777,NaN,NaN,QXE98514,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2778,NaN,NaN,QXE98513,NaN,['COVID'],Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvsdtpfywgwirqppgkglewigsmyytgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpssifrgtvftpyyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2779,NaN,NaN,QXE98512,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvnpggslrlscagsgftfsdyymgwirqapgkglevvsyisttgsyikdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgsfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2780,NaN,NaN,QXE98511,NaN,['COVID'],Homo sapiens (human),qvqlvesggglsqpggslrlscatsgfavrnncmnwvrqapgkglewvslicgdgityhsdsvkgrfiisrddsenalhlqmnslrvedtavyycvkasppggntgwpffhywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2781,NaN,NaN,QXE98510,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymiwirqapgkglewlsyishtastiyyadsvkgrftisrdnaknslflqmnsltaedtavyycardrgsgvidpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2782,NaN,NaN,QXE98509,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevrepgssvklscktsggpfsthafswvrqapgqrpewmggimpvfgeskdtqkfkgrvtftadasttttymelrslksddtaiyycvrdsdpytatsshnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2783,NaN,NaN,QXE98508,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewlggiiplfgtsesaqrfqarvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2784,NaN,NaN,QXE98507,NaN,['COVID'],Homo sapiens (human),evqlvqwgagllkpsetlslrcavyggsfngfywtwirqapgqglewiaeinhsgttnynpslksrvtisidtskkqfslslksvtaadtamyfcargtispivgvptpvvprrgrswfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2785,NaN,NaN,QXE98506,NaN,['COVID'],Homo sapiens (human),qvqlvesgggvvqpgtslrlscaatgftfttypmhwvrqapgkglewvavisydgmnqyyadflkgrftisrdnskntlylqmnslraddtavyycarayggnyqnhfdhwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2786,NaN,NaN,QXE98505,NaN,['COVID'],Homo sapiens (human),qvqlvqsgggvvqpggslrlscadsgnafianpmhwvrqapgkglewlalistdgnnrhyadsvkgrftfsrdnsknslylqmdslrpedtgvyycaresrssgragcfdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2787,NaN,NaN,QXE98504,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfsryamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlflqmsnvrpedtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2788,NaN,NaN,QXE98503,NaN,['COVID'],Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsissnnlywgwirqppgkglewigsiyysgstyynpslksrviipvdtskdqfslrlssvtaadtavyycarhsqkdivlipaaqspifdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2789,NaN,NaN,QXE98502,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfsshaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftvdestntaymeltslksedtaiyycvrdpdpytatvrhnhywhgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2790,NaN,NaN,QXE98501,NaN,['COVID'],Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsinsqywnwirqspgkglewigyvyysgstnynpslksrvtmsvdtsknhfslnlrsvtaadtavyycarglvvryfdgfpsgpiigafdiwnqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2791,NaN,NaN,QXE98500,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkisckisgdtfstnaiswlrqapgrepewmggivplvgpasyaqrpqgrltitadeftntaylelnslrsedtatyycardsdpytatrrhnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2792,NaN,NaN,QXE98499,NaN,['COVID'],Homo sapiens (human),qvqlqqwgagllkpsetlsltcgvyggsfsgyfwswirqspgkglewigeinhsrsmsynpslksritmsvdtsknqfslnlnsvtaadtavyfcargkahrndfwsgyyphwfdpwgqgilvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2793,NaN,NaN,QXE98498,NaN,['COVID'],Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgfywtwirqppgkglewigeinhsgssnydlslksrvtmsvdtsknqfslklssvtaadtavyycargmispriprttrqrwfdtwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2794,NaN,NaN,QXE98497,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalsrvgyvrkfqarltisadeltttaymdlssltsedtavyycardpsflntgnhfwydfdlwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2795,NaN,NaN,QXE98496,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewlggilplfgtsesaqrfqarvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2796,NaN,NaN,QXE98495,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkmpgssvkvsckvsggrfsdyaiswlrqapleglewmggivphlnrkgysqkfqdrltftaddststaymelsgltsedtavyycardptflntgnhfwyavdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2797,NaN,NaN,QXE98494,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmlsdyaiswvrqapgqrlewmggimpafgspgyaqifrgratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2798,NaN,NaN,QXE98493,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvqpgrslrlscaaseftfstyamhwvrqapgkglewvalisydginkyyadsvkgrfaisrdnskntlylqvnslraddtavyycvrpysgsytnwfdlwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2799,NaN,NaN,QXE98492,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscvasgftfsdfymswirqapgkglewvsyisgsgdtiyyadsvkgrftvsrdnaknslflqmsslgaedtamyycarematsfgyyfvldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2800,NaN,NaN,QXE98491,NaN,['COVID'],Homo sapiens (human),evqllesgggvvqpgtslrlscavsgfmfknyaihwvrqapgkglewvavisfdgsdisytesvqgrftisrdnsenmlylqmnslraedtamyycarepdgigaagisgywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2801,NaN,NaN,QXE98490,NaN,['COVID'],Homo sapiens (human),evqllesgaevkkpgssvkvscktsggtfsthaiswvrqapgqgpewmggiiplfgtsehaqrfqarvkftadeststaymelssltpedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2802,NaN,NaN,QXE98489,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2803,NaN,NaN,QXE98488,NaN,['COVID'],Homo sapiens (human),qvqlvesggevkkpgasvkvsckasgytlssypiswvrqapghglewmgwintyngrtnyeqmlqgrvtmttdtststaymelrslrsddtavyycarvvfrhgqyddssgrlafdiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2804,NaN,NaN,QXE98487,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpggslrlsceasgfnfnsysmswvrqapgkglewlsyissrsstikyassvqgrftvsrdnakksvylqmnslrdedtavyfcareldsetyynynsldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2805,NaN,NaN,QXE98486,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkgpgasvkvsckvsgysfityditwvrqapgqglewmgwistksgdtryaqnvqgrvtmttdtstntaymelrnlksddtalyycarttprgweqwpvleywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2806,NaN,NaN,QXE98485,NaN,['COVID'],Homo sapiens (human),qvqlqesgrglvkpsetlsltctvsggsitssryywgwirqppgrnlewigsihysgttsynpslwsrvaisvdtaqnqfslrlnsvtaadtavyycaapapsnheswsgtdwfdpwgqgilvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2807,NaN,NaN,QXE98484,NaN,['COVID'],Homo sapiens (human),evqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2808,NaN,NaN,QXE98483,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevrepgssvklscktsggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslksddtaiyycvrdsdpytatvrsnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2809,NaN,NaN,QXE98482,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvqpgrslrlsceasgftfadypmhwvrqapgkglewvavisshgrsqgyaasvkgrftfsrdnsqsslflqlnslrvedtavyfcareaqssgragcldawgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2810,NaN,NaN,QXE98481,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpggslrlscgasgftfsdyamswvrqapgkglewvstisgsgdktyyadslkgrftnsrdnskstlylqmtslraedtavyfcakdrycsggscfydafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2811,NaN,NaN,QXE98480,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfsgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2812,NaN,NaN,QXE98479,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggpfssfaiswvrqapgqglewlggimtvfgpahyaqksrdrisitadeststsylelssltsddtavyycaaeersgtnhnyygldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2813,NaN,NaN,QXE98478,NaN,['COVID'],Homo sapiens (human),qvqlvqsggdsvnpggslrlscagsgfsvrdvwmswvrqapgkglewigrikseadggssdyraslkdrfsiwrdaskntlylqvnglqtedtaiyfcswndvgwaftfwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2814,NaN,NaN,QXE98477,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgdkkyypdsvrgrftisrdnskntlhlqmnslrledtavyycarsyggsystvgywgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2815,NaN,NaN,QXE98476,NaN,['COVID'],Homo sapiens (human),qvqlqqwgagllkpsetlsltcavnggsfnnyywswirqppgkgpewigevvhsgsttynpslksrvtisidmsknqfalklnsvtaadtavyycargftftysdfltgqrtfeywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2816,NaN,NaN,QXE98475,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvqpggslrlscvasgfpfgryamhwvrqapgqglewltlisfdssnieysdsvqgrftisrdnsrntlflqmtslrpedtavyfcardlppldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2817,NaN,NaN,QXE98474,NaN,['COVID'],Homo sapiens (human),evqlvesgptlvkptqtltltctfsgfslntrelgvgwirqppgkalewlaliywdddkryspslksrlsitkdtsknqvvltltnmdpgdtatyycahtselpprrpyaafdfwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2818,NaN,NaN,QXE98473,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvkpggslrvscvgsgftfsdhymswirqapgkgleiisyistdgsyindadsvkgrfinsrdnaknsvylqlnslraedtavyycarmgpsgsgsldywgqgslvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2819,NaN,NaN,QXE98472,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2820,NaN,NaN,QXE98471,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewmggiiplfgtsesaqrfqarvrftadeststaymelssltsedtavyycvrdsdpytatsrnnhywydmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2821,NaN,NaN,QXE98470,NaN,['COVID'],Homo sapiens (human),evqlvqsggglvqpggslrlscaasgftfssysmswvrqapgkglewvsyitrssdniyyaesvkgrftisrdsaknslylhmnslrdedtavyycardpgleysgnyfsyyyyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2822,NaN,NaN,QXE98469,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvtdnymswvrqapgkglewvsvlysggstyyadavqgrfsisrdnsknalylqmnslraedtavyycargfgngwsyyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2823,NaN,NaN,QXE98468,NaN,['COVID'],Homo sapiens (human),evqllesggglvkpggslrlsceasgftfsnynmnwvrqapgkglewvssisgsssyisyadsvkgrftisrdnaknslylqmnslrvedtavyycaradrdydfwsdpplidhwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2824,NaN,NaN,QXE98467,NaN,['COVID'],Homo sapiens (human),qvqlvesgaevkrpgasvkvsckasgyafsdyymhwvrqapgqgpewmgwinpnsgdtgypqkfrgwvtmtrdtsvstaymelkrlksddtavyycasgpnyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2825,NaN,NaN,QXE98466,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtlshyaiswvrqapgqglewmggimpvsgtvgyaqkfqgrvkftadeyastaymeltnlrsedsavyfcardpsivdsgphhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2826,NaN,NaN,QXE98465,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2827,NaN,NaN,QXE98464,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssmrvscrvsggtfithamswvrqapgqgpewmggivplfgrasyaqpsqtrvqitadeststvylevpsltsedtavyycvrdsepytatrsqnhywydmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2828,NaN,NaN,QXE98463,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2829,NaN,NaN,QXE98462,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrlewmggilpafaasgspgyapifrgratfsadvststayleltnlkpedtavyycardpsilntgnhhwydldlwgqgtevtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2830,NaN,NaN,QXE98461,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfskfamhwvrqapgkglewvaiisydgshknyadsvkgrftisrdnskntvylqvdslraedtavyycallygsgsyynfvffgwkdgsdawgpgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2831,NaN,NaN,QXE98460,NaN,['COVID'],Homo sapiens (human),evqllesgghvvlpgkslrlscagsgfgfplyamqwvrrapgkglewvalvsydssniryadsvkgrftisrdnsqntlylqmdslrpedtamyycardnalqdgrpgyfdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2832,NaN,NaN,QXE98459,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgfifsdyymswirqapgkglewvsyitgsgrtihyadsvkgrftisrdnaknsvylqmnslraedtavyycarghrflefplnyfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2833,NaN,NaN,QXE98458,NaN,['COVID'],Homo sapiens (human),evqlvesgghvvlpgkslrlscagsgfgfplyamqwvrrapgkglewvalvsydssniryadsvkgrftisrdnsqntlylqmdslrpedtamyycardnalqdgrpgyfdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2834,NaN,NaN,QXE98457,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaelkkpgssvkvsckasggtfynsafswlrhapgqgpewmggitpslgrvgyserflarltitadeststvymeltslasedtavyycardasivgtgnhlwygldfwghgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2835,NaN,NaN,QXE98456,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtladyaiswvrqapgqglewmggikplhgaagysqhfrgrlsitadesastaymeltglrsedtamyycardpsilntgnhhwydldlwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2836,NaN,NaN,QXE98455,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpggslrlscsaseftlrshamhwvrqapgkgleyvsgistdgsgrfyadsvkgrftisrdnsknklflqmsslrpedtavyycvrdwgssthydvfdlwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2837,NaN,NaN,QXE98454,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsgatyknsafswarqapgqgfqwmggiiplfgvphyvqmfqgrvtitadestsavymelsgltsddtavyycareeysgtvhnffgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2838,NaN,NaN,QXE98453,NaN,['COVID'],Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtlsdyaiswvrqapgqglewmggimpifgspgyaeifqgrvtitadeskstvymeltslrsedtavyycardpsildtgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2839,NaN,NaN,QXE98452,NaN,['COVID'],Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgfifsghwmswvrqapgkglewvanikqdgrekhyvdsvkgrftisrdnaknsvslqmnslraedtavyycvrqnvaiqyyyyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2840,NaN,NaN,QXE98451,NaN,['COVID'],Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfnsyalfwvrqapgkglewvavvsydgnnkyyadsvkgrftisrdnskntlylqmnslktedtsvyycarprsgsyrqaidywglgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2841,NaN,NaN,QXE98450,NaN,['COVID'],Homo sapiens (human),evqlvesgaevknpgssvkisckssggtlgdyaiswvrqapglglewlggimplhgttgysqrfrprltitadesartaymeltalssedsaiyycardpsilntgnhhwydldlwgqgtevtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2842,NaN,NaN,QXE98449,NaN,['COVID'],Homo sapiens (human),qvqlvqsggglvqpgeslrlscaasgfnfspygmnwvrqapgkglewiayiisgsgtiyyadsvkgrftisrdnaqsslylqmnslraedtavyycarglldylhdafdiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2843,NaN,NaN,QXE98448,NaN,['COVID'],Homo sapiens (human),evqlvesgpglvkpsetlslactvsggsisnyywnwvrqppgkglewigniyysgsttfnpslksrvtisvdtsrnqfslklssvtaadtavyycarqssswynpyyfdqwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2844,NaN,NaN,QXE98447,NaN,['COVID'],Homo sapiens (human),evqllesgaevkkpgssvkvscktsggtfnsytiswvrqapgqglewmggiipildtphyaqkfrgrvtitadkststafmdlssltsedtavyycairrdysdyrdfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2845,NaN,NaN,QXE98446,NaN,['COVID'],Homo sapiens (human),qvqllesggglvqpgrslrlsctasgfrfgdytmtwfrqapgkglewvgfirsiayggttehaasvegrfiisrddsksiaylqmnslkaedtgvyfctrgsgmfygsssgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2846,NaN,NaN,QXE98445,NaN,['COVID'],Homo sapiens (human),evqlqesgpglvkpsetlsltcavsggsvssdtdywgwirqppgkglewigsihdsertyydpslksrvtisvdtsknqfslrlssvtaadtalyfcasrhldllpigsfdvwgrgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2847,NaN,NaN,QXE98444,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpgeslrlscaasgfnfspygmnwvrqapgkglewiayiisgsgtiyyadsvkgrftisrdnaqsslylqmnslraedtavyycarglldylhdafdiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2848,NaN,NaN,QXE98443,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqvpgrglewvsgiswnsgtinyadsvmgrftisrdnaknslylqmnslraedtalyycakdgrycsgiscrtgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2849,NaN,NaN,QXE98442,NaN,['COVID'],Homo sapiens (human),evqllesgpglvkpsqtlsltctvsngfissgeyywswirqspgkglewigyishsgstyynrslksrvtisldtsrnqfslnlssvtaadtavyycardlakwsygyyysgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2850,NaN,NaN,QXE98441,NaN,['COVID'],Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgysstnygfswvrqapgqglewmgwisvhsgnanfaqkfqgritmttdtstttaymelrnlrsddtatyycatsassysryyfgldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2851,NaN,NaN,QXE98440,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsnynmvwvrqapgkglewisyissssstiyyadsvkgrfiisrdnaknslhlqmnslrdedtavyycvrdycnsvscytyyyigmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2852,NaN,NaN,QXE98439,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggsftsyvlswvrqapgqglewmgrivpnlgvanyaqkfqdrvtitadkstttaylelrslrsedtavyycardlyydnggynyldywgpgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2853,NaN,NaN,QXE98438,NaN,['COVID'],Homo sapiens (human),evqlvesgaevrkpgssvkvsckatggtfssygitwvrqapgqglewmgriiptlgrtnyaqkfqgrvtitadkststahmelsslrsedtavyycardlstlqpdaivnfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2854,NaN,NaN,QXE98437,NaN,['COVID'],Homo sapiens (human),evqllesgggvvnpggsmrlscagsgftfsdhymgwirqapgkglevisyisssgsfirdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgtfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2855,NaN,NaN,QXE98436,NaN,['COVID'],Homo sapiens (human),evqllesgaevkkpgssvkvsckasggtfssdaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadestntaymelsslrsedtavyycardgpydsggyhlnhwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2856,NaN,NaN,QXE98435,NaN,['COVID'],Homo sapiens (human),evqlvesgaevkkpgasvilsckasgytvtnyyihwvrqapgqglewmgwidpdsgvtnfaekfqgrvtmtrdtsistaymelrwlesddtavyycakdlitvirglgggmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2857,NaN,NaN,QXE98434,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewlgvihpsggsttfaqkfqgrvtmtrdtststvymelgslrsddtavyycarvlagsshewqlthdafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2858,NaN,NaN,QXE98433,NaN,['COVID'],Homo sapiens (human),qvqlqqwgagvlkpsetlsltcavyggsfrgffwswirqppgkglewigqithsgstnynsslksrltisvdtsknqfslnlssvtaadtaiyycargqggydlrrvgygltswfdpwgqgilvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2859,NaN,NaN,QXE98432,NaN,['COVID'],Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2860,NaN,NaN,QXE98431,NaN,['COVID'],Homo sapiens (human),qvqlvqsgggvvqpgkslrlscvasgfsfgtygmhwvrqapgkgpewlavmwydgitqyyadsvkgrftisrdnsketlylqmnsltaddtgvyycvkdqssgdrllylgyfdlwgpgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2861,NaN,NaN,QXE98430,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvqpgkslrlscvpsgfsfgtygmhwvrqapgkgpewlavmwydgitqyyadsvkgrftisrdnsketlylqmnsltaddtgiyycvkdqssgdrllylgyfdlwgpgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2862,NaN,NaN,QXE98429,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgasvkvscktsgytftghyihwvrqapgqglewmgwinpasgdtnyaqkfqgrvtktrdtsittaymelnrlrsddtavyycarggplpwsdldivgtfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2863,NaN,NaN,QXE98428,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyyvhwvrqvpgqglewmgwispdsgdtiraqnfqgrvtmtrdtsmntaymevnrlrtddtaiyycardlisvirglgggmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2864,NaN,NaN,QXE98427,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsnyamtwvrqapgkglkwvsginpsgdatfytdsvkgqftisrdnsknilylqmnrlraddtaiyycakglsfygsgsdafdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2865,NaN,NaN,QXE98426,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssmkvsckasgvnfrsysfswvrqapgqglewmggvipyfptanyadkfrdrvtitadestgtvyldmsslrsedtavyfcaseyfdgrsyhsfcgldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2866,NaN,NaN,QXE98425,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgeslkisckasgysftnywvgwvrqmpakglewmgiiwpddsdtryrpsfqgqvtisvdksistaylhwnslkasdngmyfcaraplascsggrcptynrfdlwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2867,NaN,NaN,QXE98424,NaN,['COVID'],Homo sapiens (human),qvqlvesgpglvrpsgtlsvtcavsgdsissdywctwvrqspgkglewigkishsgslnynpslksrvtmsvdksknhfslklasvtaadtavyycarvrigashhnfwsgyytdafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2868,NaN,NaN,QXE98423,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvgsgrvywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2869,NaN,NaN,QXE98422,NaN,['COVID'],Homo sapiens (human),qvqlvesgaevkkpgssvrvsckasggtfrksaiswvrqapgqgfewmggiiptldrrgfaqkfqdrltmtadeftstaymdlsdlrsddtavyycardasfpntgnhfwydfdlwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2870,NaN,NaN,QXE98421,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvscrvsggrfsdyafswlrqapvkglewmggiiprldrkgyshifqdrltftadeststtymelsgltsddtavyycardptflnsgnhfwydvdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2871,NaN,NaN,QXE98420,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvevsckvsggtfrdyaiswvrqapgqrlewmggimpglgspayaqifgdrvtisadtststaylqvtnlrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2872,NaN,NaN,QXE98419,NaN,['COVID'],Homo sapiens (human),evqllesgggvvqpgrslrlscvtsgfdfrpyamqwvrqapgkglewvavishdgvhtgyadslkgrftisrdnskntlylqvdslrpddsalyycardnalqnaqigyldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2873,NaN,NaN,QXE98418,NaN,['COVID'],Homo sapiens (human),qvqlqesgpgllkpsetlsltctvsnspissnywswirqpagkglewigriditgntnynpslksrvimsvdtsksqfslkmtsvtaadtavyycarsfisfdssghpyyyyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2874,NaN,NaN,QXE98417,NaN,['COVID'],Homo sapiens (human),qvqlqqwgagllkpsetlslicdvyggsfngfywswirqppgkglewigeishdgstnyspslksrvsisidtskkqfslklrsvtaadtamyycargmtspvvhlyssgrpsrwfdfwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2875,NaN,NaN,QXE98416,NaN,['COVID'],Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfsnyamnwvrqapgqgpewmgwidtntgnptyaqgfigrfvfsldtsvntaylligsleaedtavyycareehydfssgyfrpaywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2876,NaN,NaN,QXE98415,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2877,NaN,NaN,QXE98414,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggifsthaiswvrqapgqrpewmggiipifgeskdtrkfqgrvtftadestttaymelrslksddtaiyycvldsdpytatfshnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2878,NaN,NaN,QXE98413,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvqpgrslrlscvtsgfdfrpyamqwvrqapgkglewvavishdgvhtgyadslkgrftisrdnskntlylqvdslrpddsalyycardnalqnaqigyldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2879,NaN,NaN,QXE98412,NaN,['COVID'],Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2880,NaN,NaN,QXE98411,NaN,['COVID'],Homo sapiens (human),qvqlvesggsvvqpgtslklscagsagltitryamhwvrqapgkglewvalvshdgihigysdsvrgrftisrdnsrntlylqmdglrpedtavyycvrddvlqhsrpsgpgyfvswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2881,NaN,NaN,QXE98410,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmisdyaiswvrqapgqrlewmggimpafgspgyaqifrgratisadvstntayleltslnpddtavyycardpsilntgnhhwydldmwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2882,NaN,NaN,QXE98409,NaN,['COVID'],Homo sapiens (human),qvtlkesggglvqpggslrlscaasgftvnsygmswvrqapgkglewvsgfksrsdrpdyaesvkgrftisrdtskntvylemiglraedtatyycvrmdwmewmkyyfdswgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2883,NaN,NaN,QXE98408,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrpewmggimpglgspayaqifrgratisadlststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2884,NaN,NaN,QXE98407,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrlewmggimpglgspayaqifrdratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2885,NaN,NaN,QXE98406,NaN,['COVID'],Homo sapiens (human),qvqlvqsgdemkkpgssvkvsckasgdtfsthaiswvrqapgqgpewmggiiplfgtasyaqtsqsrvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2886,NaN,NaN,QXE98405,NaN,['COVID'],Homo sapiens (human),evqllesgpgllkpsetlsltctvsgdsvssgnfywswvrrppgkalewiayshytggtnsdpsfmgrvtmsidpsrnqfslrltsvaaadtavyycarttspltysghwplfdywgqgslvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2887,NaN,NaN,QXE98404,NaN,['COVID'],Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsgidggggssyyadsvrgrftvsrdnsknmlhlqmnslraddtavyfcakgdwiryfdwslpisffdywgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2888,NaN,NaN,QXE98403,NaN,['COVID'],Homo sapiens (human),qvqlvqsgadvkkpgasvkvsckasgytftsyymhwvrqapgqglewlgvihpsggsttfaqkfqgrvtmtrdtststvymelsslrsedtavyycarvlagsshewqlthdafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2889,NaN,NaN,QXE98402,NaN,['COVID'],Homo sapiens (human),evqllesggglvqpggslrlscaasgfifknepmnwirqfpgkglewisnirdngndvyyadsvkgrftvsrdnaknslylqmnslrdddtalyycvrdtdwafdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2890,NaN,NaN,QXE98401,NaN,['COVID'],Homo sapiens (human),qvqlvesgaevkkpgssvkisckisgdtfstnaiswlrqapgrepewmggivplvgpasyaqrpqgrltitadeftntaylelnslrsedtatyycardsdpytatrrhnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2891,NaN,NaN,QXE98400,NaN,['COVID'],Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsmnhyywswirqppgkglegigytyysgstnynpslksrvtisvdasknqfslrlssvtaadtavyycargsqidlrgglgatffdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2892,NaN,NaN,QXE98399,NaN,['COVID'],Homo sapiens (human),evqlvesggsvvqpgtslklscagsagltitryamhwvrqapgkglewvalvshdgihigysdsvrgrftisrdnsrntlylqmdglrpedtavyycvrddvlqhsrpsgpgyfvswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2893,NaN,NaN,QXE98398,NaN,['COVID'],Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsitsrdwwswvrqppgkglewigevyhsgstsynpslksrvtisvdksknefslklssvtaadtavyycaragnivvmpaaqyyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2894,NaN,NaN,QXE98397,NaN,['COVID'],Homo sapiens (human),evqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalskvgyagkfqarltfsadelkttvymdlssltsedtavyycardpsflnagnhfyydfdvwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2895,NaN,NaN,QXE98396,NaN,['COVID'],Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsafamhwvrqapgkglewvtiisydgsneyyadsvqgrfsisrdnskntlflqmsslrtedtaiyycaraggylsafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2896,NaN,NaN,QXE98395,NaN,['COVID'],Homo sapiens (human),evqlvesgpglvkpsatlsltctvsggsinnyywtwvrqsagkglewigrintsgstnynaslksrvtmsidtsknefslrlssvtaadtavyycarefgvrfldrslfgamdvwghgatvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2897,NaN,NaN,QXE98394,NaN,['COVID'],Homo sapiens (human),evqlvqsgaevkkpgssmrvscrvsggtfithamswvrqapgqgpewmggivplfgrasyaqpsqtrvqitadeststvylevpsltsedtavyycvrdsepytatrsqnhywydmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2898,NaN,NaN,QXE98393,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtlsdyaiswvrqapgqglewmggimpvfgspgyaeifqgrltitadesrstaymeltslrsedtavyycardpsilntgphhwydldiwgpgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2899,NaN,NaN,QXE98392,NaN,['COVID'],Homo sapiens (human),qvqlvqsgpevkkpgssvrvsckvsggpfssygvswarqapekglewmggvlpifgtvgyvhkfqgrvtitadeststvymalsslrsedtavyycvldttmshphnwygmdvwghgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2900,NaN,NaN,QXE98391,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftndgfvwvrqapgqvpewmgwisvhtgdtiyaqrfqgrvtmttdtstrtsymelmslrsddtavyycardygdgppdhwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2901,NaN,NaN,QXE98390,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggslrdyaiswvrqapgqgpewmggimpifgtagyaqkfqgrvkftadesattaymeltglrsedsavyfcardpsilntgnhhwydldiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2902,NaN,NaN,QXE98389,NaN,['COVID'],Homo sapiens (human),qvqlqqwgagllkpsetlsltcgvygvsfsdyywswirqppgkglewigeinhsgitnynpslksrvtisvdtsknqfslklssvtaadtavyycarglisytlwlresyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2903,NaN,NaN,QXE98388,NaN,['COVID'],Homo sapiens (human),evqlvqsgaevkkpgasvkisckasgyafrnnyinwirqapgqglewmgiinpsagtstyaqkfqgrvtmtrdtstntvymeitslrsedtatyfcarearrqvtqwfgefwgpynwfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2904,NaN,NaN,QXE98387,NaN,['COVID'],Homo sapiens (human),qvqlqesgpglvrpsetlsltctvsrgsisssywswirqppgkglewigfmyysgstnynpslksrvtisldtsknqfslklssvtaadtavyycakaqgiyyrgwsywfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2905,NaN,NaN,QXE98386,NaN,['COVID'],Homo sapiens (human),qvqlqqsggglvqpggslrlsceasgfnfnsysmswvrqapgkglewlsyissrsstikyassvqgrftvsrdnakksvflqmnslrdedtavyycareldsetyynynsldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2906,NaN,NaN,QXE98385,NaN,['COVID'],Homo sapiens (human),qvqlvqsggglvqpggslrlscsasgftfntytmhwvrqapgkgleyvsaissngvvtyyadsvkgrftisrdnskntlylqmsslraedtavyycvkalyssswcpfdywgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2907,NaN,NaN,QXE98384,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpgrslrlscaasgfilddyavhwvrlapgkglewvsgitwnsgylgyadsvkgrftisrdnaknslylqmnslrpedtalyycaklgtdhpigvdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2908,NaN,NaN,QXE98383,NaN,['COVID'],Homo sapiens (human),evqllesggglvqpggslrlscaasgfpfstdamnwvrqapgeglewvstisdtgrdtyyaasvkgrftisrdnskntvylqmnslraedtavyycantnfldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2909,NaN,NaN,QXE98382,NaN,['COVID'],Homo sapiens (human),qvqlqesggglvqpggslrlsceasgfsfsdfvmhwvrqvpgkglewvsrishdgsitsyvdsvkgrftvsrdngkktlylqmnsprtedtavyycardlawtffdywghgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2910,NaN,NaN,QXE98381,NaN,['COVID'],Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2911,NaN,NaN,QXE98380,NaN,['COVID'],Homo sapiens (human),evqlvesgpglvkpsgtlsltcavtgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2912,NaN,NaN,QXE98379,NaN,['COVID'],Homo sapiens (human),evqlvesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2913,NaN,NaN,QXE98378,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevrkpgssvklscrasggtfhtytvnwvrqapgqglewlggiipifgtptyaqrfqgkvsitadsstntvfmeltsltsedtavyyctretgtdefdfwgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2914,NaN,NaN,QXE98377,NaN,['COVID'],Homo sapiens (human),evqlqesgpgllkpsetlsltctvsgspiasnywswvrqpagkglewigridtspttdynpslksrvimsvdtstsqfslkmssvtaadtavyyctrsfisfdssghpyyyyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2915,NaN,NaN,QXE98376,NaN,['COVID'],Homo sapiens (human),evqllesggglvqpggslrlscaasgfpfstdamnwvrqapgeglewvstisdsgrdtyyaasvrgrftisrdnskntvylqmnslrvedtavyycantnfldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2916,NaN,NaN,QXE98375,NaN,['COVID'],Homo sapiens (human),evqlvesgptlvkptqtltltctfsgfslttrrqgvgwlrrppgkalewlaliywdddkryspslksrltitkdtsknhvvlsltnvgpadtatyycahtselpprrpyaafdfwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2917,NaN,NaN,QXE98374,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifknepmnwirqfpgkglewisnirdngndvyyadsvkgrftvsrdnaknslylqmnslrdddtalyycvrdtdwafdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2918,NaN,NaN,QXE98373,NaN,['COVID'],Homo sapiens (human),evqlvqsgaemkkpgeslkisckgsgysfpnywigwvrqmpgkglewmaimwpsdsdtryspsfqgqvtisadtststvylqwgslkasdtamyycvrqrycsggscflfedafeiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2919,NaN,NaN,QXE98372,NaN,['COVID'],Homo sapiens (human),qvqlvqsggglvqpggslrlscsasgftfntyamhwvrqapgkrleyvssitrdgagkfyadsvkgrftisrdnskntlyqqmsslrpedtavyycvregqqwlglyfdhwgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2920,NaN,NaN,QXE98371,NaN,['COVID'],Homo sapiens (human),qvqlvqsggnvvqpggslrlscvgsefsitffamqwvrrtpgkglewvalvshdgsnirysdsvkgrfiisrdnakntlylqldsltpedtgiyycardhalqngrpgyfdswgqgsqvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2921,NaN,NaN,QXE98370,NaN,['COVID'],Homo sapiens (human),qvqlvqsgggvvnpggsmrlscagsgftfsdhymgwirqapgkglevisyisssgsfirdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgtfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2922,NaN,NaN,QXE98369,NaN,['COVID'],Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfrgfywtwirqppgkglewigevshsgetnynpslksrvtisvdtsknqfslnlisvtaadtsvyycargytapiirevpitfrprwfdpwgqgtpvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2923,NaN,NaN,QXE98368,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmswvrqapgkglewvsghdggtthyadsvkgrftisrddsmntlslqmnslraedtavyycakerdlpgrggyfdhwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2924,NaN,NaN,QXE98367,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfsnyamywvrqapgkrpeyvsgissnggityyadsvegrftvsrdnskkslylqmsslrpedtavyycvkdlgatvtydvfdvwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2925,NaN,NaN,QXE98366,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqsfggrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2926,NaN,NaN,QXE98365,NaN,['COVID'],Homo sapiens (human),qvqlvqsgdemkkpgssvkvsckasgdtfsthaiswvrqapgqgpewmggiiplfgtasyaqtsqsrvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2927,NaN,NaN,QXE98364,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpggslrlscltsgfsfssywmiwvrqapgkglewvaniepdgneeyyvdsvkgrftisrdnaknslylqmnslraedtavyycargpirhfgldafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2928,NaN,NaN,QXE98363,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqifrgrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2929,NaN,NaN,QXE98362,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqsfggrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2930,NaN,NaN,QXE98361,NaN,['COVID'],Homo sapiens (human),qvtlkesgaevkkpgssvkvscktsggtfsthaiswvrqapgqgpewmggiiplfgtsqhaqrfqarvkftadestntaymelssltpedtavyycvrdsdpytatsrnnhywygmdvwghgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2931,NaN,NaN,QXE98360,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfrdyaiswlrqapgqrlewmggimpafgapgyaqifrgratisadvstttayleltslmpddtavyycardpsilntgnhhwydldlwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2932,NaN,NaN,QXE98359,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvqpgrslrlscvasgftlapygmqwvrqapgkglewvaflshdgshlgyvdsvkgrftisrdnskntlylemnslraedtatyycardnvvqqnadnvgyfdfwgqgslvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2933,NaN,NaN,QXE98358,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggmfsdyaiswvrqapgqrlewmggimpglgspayaqifrgrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2934,NaN,NaN,QXE98357,NaN,['COVID'],Homo sapiens (human),qvqlvqsggglvqpggslrvscsasgftfssfamhwvrqapgkgleyvagisdnghttmyadsvkgrftisrdnskntlylqlsslrpedtavyfcvkdnvilpgaivrpqfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2935,NaN,NaN,QXE98356,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggiipifgeskdtqkfqgrvtftadestttaymelrslrsddtaiyycvrdsdpytttfshnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2936,NaN,NaN,QXE98355,NaN,['COVID'],Homo sapiens (human),evqllesgggvvqpgtslrlscvasgftfstfamhwvrqapgkglewvalisfdstniryansvrgrftisrdnskntlylevdslriedtgvyycardlppldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2937,NaN,NaN,QXE98354,NaN,['COVID'],Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvaviysdgrneyyadsvkgrftisrdnskntlhlqmnslgaadtavyycardpgpitffdwspdksrksyydyngmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2938,NaN,NaN,QXE98353,NaN,['COVID'],Homo sapiens (human),qvqlvesggdlvkpgrslrlsctasgftigdyamtwfrqapgkglecvavirsrafggtteyaasvkgrfivsrddsnsvaflqmnslktedtavyycsrdlrrgyydsnghqqfdlwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2939,NaN,NaN,QXE98352,NaN,['COVID'],Homo sapiens (human),evqlqqsgaevkkpgssvkvsckasggtssthaiswvrqapgqglewmggiipifgttnyaqkfqdrvtitadeststaymelsslrsedtavyfcvrdgaydssgyystqwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2940,NaN,NaN,QXE98351,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalsrvgyarkfqarltisadeltttaymdlssltsedtavyycardpsflntgnhfwydfdmwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2941,NaN,NaN,QXE98350,NaN,['COVID'],Homo sapiens (human),qvqlvqsgpglvrpsgtlsltcavsgdsisgdywctwvrqtpgkglewigkishsgsinynpslksritmsvdksknqfslklnsvtaadtamyycarvrvgashhnfwsgyytdafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2942,NaN,NaN,QXE98349,NaN,['COVID'],Homo sapiens (human),qvqlvqsgpelkkpgssvrvsckasggsissyaiswvrqapgqrlewmggvlpmmgrespvqkfkdrvtiaadeststaymelrslsaedtavyycvvdttmadphnwygldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2943,NaN,NaN,QXE98348,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtladyaiswvrqapgqglewmggikplhgaagysqlfrgrlsitadesastaymeltgltsddtamyycardpsilntgnhhwydldlwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2944,NaN,NaN,QXE98347,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfslfhvhwvrqapgqglewmgwinphngdttfaerfqgrvaltrdtsintaymelsrltsddtavyfcardfgvryddsrqlmkycdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2945,NaN,NaN,QXE98346,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvtvsckvsggrfsdyaiswlrqapveglewmggiiphlnkkgysqkfqdritftadeststaymelsgltsedtaiyycardptflntgnhfwyavdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2946,NaN,NaN,QXE98345,NaN,['COVID'],Homo sapiens (human),evqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2947,NaN,NaN,QXE98344,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtssthaiswvrqapgqglewmggiipifgttnyaqkfqdrvtitadeststaymelsslrsedtavyfcvrdgaydssgyystqwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2948,NaN,NaN,QXE98343,NaN,['COVID'],Homo sapiens (human),pgpactvwaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspgyaqifrgratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtqvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2949,NaN,NaN,QXE98342,NaN,['COVID'],Homo sapiens (human),qvqlvqsgggvvnpggslrlscvgsgftfsdyymgwirqapgkglevisyisstgsyirdadsvkgrftisrdnaensvylqmnslrgedtavyycarmgpygsgsfdywglgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2950,NaN,NaN,QXE98341,NaN,['COVID'],Homo sapiens (human),evqlvesgpelkkpgssvrvsckasggsfsnfavswvrqapgqrlewmggviprfgrseyvqkfqgrvtitvdeaastaymelsslrsedtaiyycvldttsanphnwygmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2951,NaN,NaN,QXE98340,NaN,['COVID'],Homo sapiens (human),qvqlvqwgagllkpsetlsltcavyggsfsgfhwswirqppgkglewigeinhsgstkynpslksrvtisvdtsknqfslrlrsvtaadtaiyycargslsreydfltapqngpwfdswgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2952,NaN,NaN,QXE98339,NaN,['COVID'],Homo sapiens (human),evqlqesgpglvkpsgtlsltcgvsgvsisssswwswvrqppgrglewigeispsgstsynpsfrsrltmsvdksrnqlslklssvtaadtavyycartqsndfwsgyytaafdlwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2953,NaN,NaN,QXE98338,NaN,['COVID'],Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssdwcswvrqppgkgpewiaeishsgstnynpslksrvtmsvdrsknqfslnlnsvtaadtavyycaarirgathydfwsgfwagpfdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2954,NaN,NaN,QXE98337,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaemrkpgssvkvsckasggtfsrycfswvrqapgqrlewmggimsilgahyaqkfqgrvtftadestntaymelisltsedtavyycareepsgtyhnyygldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2955,NaN,NaN,QXE98336,NaN,['COVID'],Homo sapiens (human),evqlvesggglsqpggslrlscaasgftvrtycmnwvrqapgkglewvslvcgdnidyypdsvkgrfsisrddskntlllhmdslrvedtavyycaratppgggtgwpyfdfwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2956,NaN,NaN,QXE98335,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslksddtaiyycvrdsdpytatvrnnhywyaldvwgpgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2957,NaN,NaN,QXE98334,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfstsamswvrqapgkglewvsrigggggrtkyadsvkgrftisrdnskntlylqmnslraddtavyycakcdlvryfdwlgeennwfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2958,NaN,NaN,QXE98333,NaN,['COVID'],Homo sapiens (human),evqlvesgpglvkpsetlsltctvsgasvtagssywgwirqppgkglewigymfssgntkynpslksrvtisadtsknqfslrlssvtaadtavyfcarvgwvryfdwskpyyyfdlwgrgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2959,NaN,NaN,QXE98332,NaN,['COVID'],Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgfhwswirqppgkglewigevnhsgstkynpslksrvtvsvdtsknqfslrlssvtaadtaiyycargslsreydfltapqngpwfdswgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2960,NaN,NaN,QXE98331,NaN,['COVID'],Homo sapiens (human),qvqlqqwgagllkpsetlslscavyggsfsgfywswirqppgkglewigeinhsgsanynpslmsrvtismdtskkqfslqlrsvtaadtavyycargqespivgvtgrwfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2961,NaN,NaN,QXE98330,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2962,NaN,NaN,QXE98329,NaN,['COVID'],Homo sapiens (human),evqlvesgaevrtpgssvklsckasggtfsthafswvrqapgqrpewmggiipifgeskdtqkfqgrvtftadestttvymelrslksddtaiyycvrdsdpytatyrnnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2963,NaN,NaN,QXE98328,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2964,NaN,NaN,QXE98327,NaN,['COVID'],Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsgypmhwvrqapgkglewvalisfdgdskyytdsvkarfaisrdnskntlflqmnslrvadtalyycarakggsysnafdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2965,NaN,NaN,QXE98326,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckisggtfknsafswarqvpgqgfqwmggiipmfgvphsvqmfqgrvtltadestsavymelsgltsddtavyycareeysgtvhnffgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2966,NaN,NaN,QXE98325,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslrsddtaiyycvrdsdpytatvtsnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2967,NaN,NaN,QXE98324,NaN,['COVID'],Homo sapiens (human),qvqlvqsgggvvqpgrslklscvvsgfsfshygmnwvrqapgkglewvavmsydgsdkyyadsvkgrftisrdiskntlylemnslrtedtavyycakkgspycgvdcykgyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2968,NaN,NaN,QXE98323,NaN,['COVID'],Homo sapiens (human),evqlvesggglsqpggslrlscaasgfvvknncmnwvrqapgkglewvalicadgityhsdsvtgrftiyrdesdntlhlqmdslriedtavyycvrasppggntgwpffedwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2969,NaN,NaN,QXE98322,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfssydinwvrqatgqglewmgwmspntgdtgyahkfqgrvrmtsntsistaymelnsltsedtavyycarrgnnfgyyyyytvdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2970,NaN,NaN,QXE98321,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgssmklsckasginfrsysfswvrqapgqglewmggvipyfptanyaekfrgrvtatadestgtvylemsslrsedtavyycaseyfdgrsyhsfcgldvwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2971,NaN,NaN,QXE98320,NaN,['COVID'],Homo sapiens (human),evqllesggglsrpggslrlscaasgfiasrncmqwvrqapgkglewvsiicgdeityirdsvkgrftisrddskntlhlemnslraddtavyycaratppggttgwpyidlwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2972,NaN,NaN,QXE98319,NaN,['COVID'],Homo sapiens (human),qvqlvqsgaevkkpgasvkvscrasgytfsgydinwvrqatgqglewmgwmnpnsgdtgyahkfqgrvtmtrnssistaymelssltsedtavyfcarekksfgpqyyygsgedwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2973,NaN,NaN,QXE98318,NaN,['COVID'],Homo sapiens (human),evqlvesggglvqpgrslrlscsasgfsfgdyamswfrqapgkglqwvgliktraygaatdyaasvqgrfiisrddsksiaylqmnslktedtavyfcaregtslgyyyyyamdvwghgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2974,NaN,NaN,QXE98317,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymnwvrqapgkglewvssissssymyyadsmkgrftisrdnaqnslylqmsslraedtavyycardfpgdtavagtgfnywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2975,NaN,NaN,QXE98316,NaN,['COVID'],Homo sapiens (human),qvqlqesgpglvrpsetlsltctvsgdsvsssdyhwgwirqppgkglewigsiyyggrshfnpslksrvaifvdtsnnqfslrlnsvtasdtavyfcagrhqellpmgsfdmwaqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2976,NaN,NaN,QXE98315,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2977,NaN,NaN,QXE98314,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
2978,NaN,NaN,NaN,QXE98313,['COVID'],Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsggssnigsnsvnwyqqlpgtapklliysnsqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslntfryvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2979,NaN,NaN,NaN,QXE98312,['COVID'],Homo sapiens (human),NaN,qsvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrnsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlytfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2980,NaN,NaN,NaN,QXE98311,['COVID'],Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasenilhylawyqqkpgqaprlviydasrratgipgrfsgsgagtdftltinslepedfavyycqqranwpqnfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2981,NaN,NaN,NaN,QXE98310,['COVID'],Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvtsnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygraplytfglgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2982,NaN,NaN,NaN,QXE98309,['COVID'],Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqtvtrsqlawyqhkpgqpprlliydssnratgtpdrfsasgsgteftltitrlepedsavyyclqyssattfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2983,NaN,NaN,NaN,QXE98308,['COVID'],Homo sapiens (human),NaN,ettltqspailsvspgegatlscrasqsvrsnlawfqqrpgqvprlliydasnratgvparfsgsgfgteftltisslqsedfavyycqqynnwppltfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2984,NaN,NaN,NaN,QXE98307,['COVID'],Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsishylnwyqqkpgkapklliyaasnlqsgvpsrfsgngsgtdftltisslqpedfatyfcqqsystpltfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2985,NaN,NaN,NaN,QXE98306,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqvlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgidftlkisrveaedigvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2986,NaN,NaN,NaN,QXE98305,['COVID'],Homo sapiens (human),NaN,divltqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2987,NaN,NaN,NaN,QXE98304,['COVID'],Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnigndyvswyqqlpgtapklliyenykrpsgipdrfsgsksgtsatlditglqtgdeadyycgtwdsslsvdnyvfgtgtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2988,NaN,NaN,NaN,QXE98303,['COVID'],Homo sapiens (human),NaN,divltqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyytmwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2989,NaN,NaN,NaN,QXE98302,['COVID'],Homo sapiens (human),NaN,dirltqspsslsasvgdrvtitcrasqdisswlawyqqksgkapksliyaasslqngvpsrfsgsrsgtdftltisslqpedlgtyycqqydsypvtfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2990,NaN,NaN,NaN,QXE98301,['COVID'],Homo sapiens (human),NaN,dirvtqspatlslspgeratlscraseniahylawyqqkpgqaprlviydassratgipgrfsgsgagtdftltinslepedfavyycqqrsnwpqnfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2991,NaN,NaN,NaN,QXE98300,['COVID'],Homo sapiens (human),NaN,qsvltqppsvsatpgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsrlsavvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2992,NaN,NaN,NaN,QXE98299,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqaasiscrssqavvhsdgntylnwfqqrpgqpprrliykvsnrdsgvpdrfsgsgsgtvftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2993,NaN,NaN,NaN,QXE98298,['COVID'],Homo sapiens (human),NaN,ettltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydafnratgvparfsgsgsgtdftltisslepedfavyycqqrtstltfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2994,NaN,NaN,NaN,QXE98297,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqiamhsdgntylswfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaedigtfycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2995,NaN,NaN,NaN,QXE98296,['COVID'],Homo sapiens (human),NaN,divltqspgtlslspgervtlscrasqsissnylawyqqkpgqaprllisdassratgipdrfsgsgsgadftliisrlepedfavyfchqyggspttfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2996,NaN,NaN,NaN,QXE98295,['COVID'],Homo sapiens (human),NaN,qpgltqpasvsgspgqsitisctgtsgdvgsdnlvswyqrhpgkapklmiyegskrpsgvshrfsgsnsgntasltisglqaeddadyyccsyagddtvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2997,NaN,NaN,NaN,QXE98294,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqpasisctssqtvvhtdrntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2998,NaN,NaN,NaN,QXE98293,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
2999,NaN,NaN,NaN,QXE98292,['COVID'],Homo sapiens (human),NaN,dirltqsplslsvtlgqaasisctcsqsavhsdgttyfnwfhqrpgqsprrliykvsnrdsgvpdrfigsgsgthftlkisrveaedvgvyycmqttdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3000,NaN,NaN,NaN,QXE98291,['COVID'],Homo sapiens (human),NaN,divmtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3001,NaN,NaN,NaN,QXE98290,['COVID'],Homo sapiens (human),NaN,eivmtqspgtlssspgeratlscrasqsvssrylawyqqkpgqaprlliygtsnratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3002,NaN,NaN,NaN,QXE98289,['COVID'],Homo sapiens (human),NaN,eivmtqtpsslsasvgdrvtitcrasqsisnyvnwyqqkpgrapnlliyaasslqsgvssrfsgsgsgtdftltisslqpedfatyycqqtystppegptfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3003,NaN,NaN,NaN,QXE98288,['COVID'],Homo sapiens (human),NaN,givltqspdslavsvgeratinckssqtvlyssknkhylawyqqkpgqppklltsspstrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3004,NaN,NaN,NaN,QXE98287,['COVID'],Homo sapiens (human),NaN,diqmtqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3005,NaN,NaN,NaN,QXE98286,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3006,NaN,NaN,NaN,QXE98285,['COVID'],Homo sapiens (human),NaN,eivmtqspsslsasvgdsvtitcrasqsisnylnwyqdkpgkapelliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysdswtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3007,NaN,NaN,NaN,QXE98284,['COVID'],Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtiscrasqgistflawfqqrpgkapksliyaasklqsgvpsrfsgsdsgpdftltidnlrpedsatyyckqynsypytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3008,NaN,NaN,NaN,QXE98283,['COVID'],Homo sapiens (human),NaN,diqvtqspatlsvspgervtlscrasqsisntlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyychqynkwppitfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3009,NaN,NaN,NaN,QXE98282,['COVID'],Homo sapiens (human),NaN,eivmtqspaslsasvgdrvtitcragqsistnlcwyqqrqgkapklliyaasslrsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3010,NaN,NaN,NaN,QXE98281,['COVID'],Homo sapiens (human),NaN,ettltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3011,NaN,NaN,NaN,QXE98280,['COVID'],Homo sapiens (human),NaN,ettltqsplslavtlgqpasiscrsslglvhtngntylnwfqqrpgqsprrliyrvsnrdsgvpdrfsgsgsvtdftltisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3012,NaN,NaN,NaN,QXE98279,['COVID'],Homo sapiens (human),NaN,dirltqspsslsasvgdrvtitcrasqaiagwlawyqqkpgrapksliyrasslqsgvpsrfsgsgsgtdfsltisnlqpedsatyycqhydsyptafgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3013,NaN,NaN,NaN,QXE98278,['COVID'],Homo sapiens (human),NaN,ettltqspsslsasvgdrvnitcrasqsistyltwyqqkpgkapklliygasslhsgvpsrftgvgsgteftlsisslqpedfatyycqqsyntfftfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3014,NaN,NaN,NaN,QXE98277,['COVID'],Homo sapiens (human),NaN,qpvltqppsasgtpgqrvtiscsggssnigsnsvnwyqqlpgtapklliysnsqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslntfryvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3015,NaN,NaN,NaN,QXE98276,['COVID'],Homo sapiens (human),NaN,ettltqsplflpvtlgqpasiscrssqrlvhtngntylnwfqqrpghsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgtewprtfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3016,NaN,NaN,NaN,QXE98275,['COVID'],Homo sapiens (human),NaN,qsvltqppsvsgspgqsvsiscsgtssdfgnynriswyqqtpgtapkviiyevnsrpsgvpdrfsgsksgntasltitglqaedeadyyccsyrsdntyifgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3017,NaN,NaN,NaN,QXE98274,['COVID'],Homo sapiens (human),NaN,qsaliqprsvsgspgqsvtisctgtssdvggsnyvswyqqhpgkapkllvydvtkrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagtyifgtgtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3018,NaN,NaN,NaN,QXE98273,['COVID'],Homo sapiens (human),NaN,qsaliqpasvsgspgqsitisctgtssdvgrynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaayycssyisdiklvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3019,NaN,NaN,NaN,QXE98272,['COVID'],Homo sapiens (human),NaN,dirmtqspsslsasvgdrvtitcrasqgfgnkvawyqqkpgtapklliyetstlqsgvpsrfsgsgsgtefaftisslqpedgatyycqkynrapwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3020,NaN,NaN,NaN,QXE98271,['COVID'],Homo sapiens (human),NaN,syeltqppsvsgaprqkvtiscsgssaniasngvnwyqqlpgkapklliyyddlvssgvsdrfsgsksgtsaslaisglqsedeadyycatwddilngpvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3021,NaN,NaN,NaN,QXE98270,['COVID'],Homo sapiens (human),NaN,divmtqspgtlslspgeraalscrasqivtrsqlawyqhkpgqpprlliydsssratgtpdrfsgsgsgtdftltisrlepedsavyychqysgsatfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3022,NaN,NaN,NaN,QXE98269,['COVID'],Homo sapiens (human),NaN,dirltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3023,NaN,NaN,NaN,QXE98268,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqivvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3024,NaN,NaN,NaN,QXE98267,['COVID'],Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcrasqsisyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfiltisslqpediatyycqhsyssppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3025,NaN,NaN,NaN,QXE98266,['COVID'],Homo sapiens (human),NaN,divltqtpsslsasvgdrvtitcrasqtiatylswyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltigslqpedfatyycqqsysipwtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3026,NaN,NaN,NaN,QXE98265,['COVID'],Homo sapiens (human),NaN,ettltqspatlslspgegatlscrasqsvssslawyqqkpgqaprlliydasnratgiparfsgsgsgtdytltisslepedfavyychqrsnwpytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3027,NaN,NaN,NaN,QXE98264,['COVID'],Homo sapiens (human),NaN,syvltqppsvsvspgqtaritcsadglpkqysywyqqkpgqapvmviykdterpsgiperfsgsssgttatltisgvqaedeadyycqsadsndsspvfgggtqltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3028,NaN,NaN,NaN,QXE98263,['COVID'],Homo sapiens (human),NaN,dirmtqsplslpvtlgqpasiscrssqfvvhtdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqatewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3029,NaN,NaN,NaN,QXE98262,['COVID'],Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3030,NaN,NaN,NaN,QXE98261,['COVID'],Homo sapiens (human),NaN,ettltqsplslsvtlgqsasiscrasqtvvhsvdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedigiyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3031,NaN,NaN,NaN,QXE98260,['COVID'],Homo sapiens (human),NaN,diqltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3032,NaN,NaN,NaN,QXE98259,['COVID'],Homo sapiens (human),NaN,diqmtqsplslpvglgqsasiscrssqwvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3033,NaN,NaN,NaN,QXE98258,['COVID'],Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgttsdvggydyvswyqqrpgkapkliiydvinrpsgvsnrfsgsksgntasltisglqaddetdyycssytsggtlvfgtgtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3034,NaN,NaN,NaN,QXE98257,['COVID'],Homo sapiens (human),NaN,dirltqspatlslspgeratlscrasqsindylgwyqhrpgqaprllihdastrapgipvrfsgsgsgtdftltisslepedsavyycqqrfswynfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3035,NaN,NaN,NaN,QXE98256,['COVID'],Homo sapiens (human),NaN,qsvltqpasvsgspgqsitiscavtssdvgsynlvswhqqhpgkapklmiyevnkrpsgvsnrfsgsksgntasltisglqaedeavyyccsyggrstsvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3036,NaN,NaN,NaN,QXE98255,['COVID'],Homo sapiens (human),NaN,ettltqspatlslspgeratlscrasqsindylgwyqhrpgqaprllihdastrapgipvrfsgsgsgtdftltisslepedsavyycqqrfswynfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3037,NaN,NaN,NaN,QXE98254,['COVID'],Homo sapiens (human),NaN,ettltqsplflpvtlgqpasisctssvhvvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtyftlkisrveaedvgvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3038,NaN,NaN,NaN,QXE98253,['COVID'],Homo sapiens (human),NaN,dirltqsplslpvtlgqaasiscksshfivhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftleisgveaedvgvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3039,NaN,NaN,NaN,QXE98252,['COVID'],Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsiniylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystplitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3040,NaN,NaN,NaN,QXE98251,['COVID'],Homo sapiens (human),NaN,divmtqsplslpvsrgqsasiscrsshsvvhsdgktyvnwfhqrpgqaprrliyqvskrdsgvpdrfsgsgsgfdftlkisrveaedvgvyfcmqgtdwprsfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3041,NaN,NaN,NaN,QXE98250,['COVID'],Homo sapiens (human),NaN,eivmtqsplslpvslgqpasiscrssqsvihtdgntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsvtdftlkisrveaedvgvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3042,NaN,NaN,NaN,QXE98249,['COVID'],Homo sapiens (human),NaN,ettltqspgtlsvspgeratlscrasqsvisnlawyqqkpgqaprlliygastratgvparfsgsgsgteftltiaslqsedfavyycqqyhhwppytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3043,NaN,NaN,NaN,QXE98248,['COVID'],Homo sapiens (human),NaN,dirmtqspstlsasvgdrvtitcrasqtigswlawyqqkpgkapnlliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynslytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3044,NaN,NaN,NaN,QXE98247,['COVID'],Homo sapiens (human),NaN,ettltqsplslsvtlgqaasiscrpnlglmhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfagsgsgthftleisgveaddvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3045,NaN,NaN,NaN,QXE98246,['COVID'],Homo sapiens (human),NaN,divltqspatlsvspgeritlscrashsvssnlawyqqkpgqvprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3046,NaN,NaN,NaN,QXE98245,['COVID'],Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiannyvqwlqqrpgsspttiiyednqrpsgvpdrfsgsidassnsasltisglktedeadyycqsydsssqvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3047,NaN,NaN,NaN,QXE98244,['COVID'],Homo sapiens (human),NaN,qpvltqspsasaslggsvkltctltsghstyaiawhqqqpekgprflmklnsdgshnkgdgipdrfsgsssgaeryltisslqsedeadyychtwgtdiqvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3048,NaN,NaN,NaN,QXE98243,['COVID'],Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvgtylawyqqkhgqaprllisdvskratgiparfsgsgsgtdftltitslepedfavyycqqrtnwpgatfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3049,NaN,NaN,NaN,QXE98242,['COVID'],Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqktgkapelliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyrfpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3050,NaN,NaN,NaN,QXE98241,['COVID'],Homo sapiens (human),NaN,eivltqspatlsvspgeritlscrashsvssnlawyqqkpgqvprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3051,NaN,NaN,NaN,QXE98240,['COVID'],Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcrasrsissylnwyqqkpgkapnlliydastlqsgvpsrfsgsgsgtdfsltisslqpedfatyyclhtyttprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3052,NaN,NaN,NaN,QXE98239,['COVID'],Homo sapiens (human),NaN,qpvltqppsasgtpgqrvtiscsgsysnigtnpanwyqqlpgtapklliynndqrpsgvpdrfsgsksgtsaslaisglqsedetdyycatwddslngvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3053,NaN,NaN,NaN,QXE98238,['COVID'],Homo sapiens (human),NaN,dirmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgvtfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3054,NaN,NaN,NaN,QXE98237,['COVID'],Homo sapiens (human),NaN,diqltqspsamsasvgdrvtitcrasqgindnlawfqqkpgkvpkrliyaasnlqngvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3055,NaN,NaN,NaN,QXE98236,['COVID'],Homo sapiens (human),NaN,qpvltqsssasaslgssvkltctlrsghssyiiawhqqqpgkaprflmkvghsgsynkgsgvpdrfsgsrsgadhyltisnlqpddeadyyceawdnnnlgvfsggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3056,NaN,NaN,NaN,QXE98235,['COVID'],Homo sapiens (human),NaN,qpvltqsssasaslgssvkltctlssghssyilawhqqqpgkaprflmkfevggrynkgsgvpdrfsgsssgadryltisnlqsedeadyycetwdsnlkgvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3057,NaN,NaN,NaN,QXE98234,['COVID'],Homo sapiens (human),NaN,divmtqtpgtlsvspgeratlscrasqiinrsqlgwyqhkpgqpprllifdsskratgtpdrfsasgsetdftltisgvepedsgvyyclqyslattfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3058,NaN,NaN,NaN,QXE98233,['COVID'],Homo sapiens (human),NaN,diqltqspatlslspgeratlscranqsvsnflawyqqkpgqaprhliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3059,NaN,NaN,NaN,QXE98232,['COVID'],Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvstylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyyclqrsdwhpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3060,NaN,NaN,NaN,QXE98231,['COVID'],Homo sapiens (human),NaN,dirvtqspdslavslgeratincrtsqsvlyssnnknylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3061,NaN,NaN,NaN,QXE98230,['COVID'],Homo sapiens (human),NaN,qsvliqpasvsgspgqsitisctgsssdvgsynlvswyqqhpgkapklmiyegykrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagssavvvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3062,NaN,NaN,NaN,QXE98229,['COVID'],Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtmatltisgaqvedeadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3063,NaN,NaN,NaN,QXE98228,['COVID'],Homo sapiens (human),NaN,divltqspatlslspgeratlscrasqsvsiylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltinnlepedfaiyycqqrakwpprvifgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3064,NaN,NaN,NaN,QXE98227,['COVID'],Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvsiylawyqqkpgqaprlliydasnratgvparfsgsgsgtdftltinnlepedfaiyycqqrakwpprvtfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3065,NaN,NaN,NaN,QXE98226,['COVID'],Homo sapiens (human),NaN,diqvtqspsslsasvgdrvtitcrasqsissslnwyqqkpgkaptlliytasnlqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystpgfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3066,NaN,NaN,NaN,QXE98225,['COVID'],Homo sapiens (human),NaN,diqvtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydaskratgiparfsgsgsgtdftltisslepedfavyycqqrsdwhpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3067,NaN,NaN,NaN,QXE98224,['COVID'],Homo sapiens (human),NaN,diqltqspstlsasvgdsvtitcrasqsisswlawyqqkpgkapklliykassletgvpsrfsgsgsgteftltisslqpddfatyycqqyksplsfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3068,NaN,NaN,NaN,QXE98223,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqglvhtngnlylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3069,NaN,NaN,NaN,QXE98222,['COVID'],Homo sapiens (human),NaN,qpvltqppsvsaapgqkvtiscsgsssniennyvswyqqlpgaapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdfslsagvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3070,NaN,NaN,NaN,QXE98221,['COVID'],Homo sapiens (human),NaN,divvtqspgtlslspgeraalscrasqsvgnnylawyqqkpgqaprlliygatsratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspvytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3071,NaN,NaN,NaN,QXE98220,['COVID'],Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3072,NaN,NaN,NaN,QXE98219,['COVID'],Homo sapiens (human),NaN,ettltqspvtlpvtlgqpasisctssrwlvhtngntylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlqisrveaedvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3073,NaN,NaN,NaN,QXE98218,['COVID'],Homo sapiens (human),NaN,divmtqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkinrveaedvgiyycmqttdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3074,NaN,NaN,NaN,QXE98217,['COVID'],Homo sapiens (human),NaN,dirmtqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3075,NaN,NaN,NaN,QXE98216,['COVID'],Homo sapiens (human),NaN,ettltqspatlsvspgetatlscrasqsvgrfmgwyqqkpgqaprllifdasnrvtgvpdrfrgsgsgtdfiltinslepedsasyycqrrgdgynfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3076,NaN,NaN,NaN,QXE98215,['COVID'],Homo sapiens (human),NaN,eivltqspgtlslspgdrvtlfcrasqniannhlawyqqkpgqaprvliygasttatdipdrfsgrvsgtdftltisrldpedfavyychqygsspwtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3077,NaN,NaN,NaN,QXE98214,['COVID'],Homo sapiens (human),NaN,qpvltqpasvsgspgqsstlscsgtssdvgsydlvswyqqhpgkapklmiyegtkrpsgvsdrfsgstsgntasltisglqaedeanyyccsyagsgtwifgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3078,NaN,NaN,NaN,QXE98213,['COVID'],Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcraghtistylnwyqqkpgkapkilisgasslqsgvpsrfsgsgsgtdftltigslqpedfatyycqqsystpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3079,NaN,NaN,NaN,QXE98212,['COVID'],Homo sapiens (human),NaN,dirvtqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3080,NaN,NaN,NaN,QXE98211,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqglvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3081,NaN,NaN,NaN,QXE98210,['COVID'],Homo sapiens (human),NaN,eivmtqspatlsvspgetatlscrasqsvgrfmgwyqqkpgqaprllifdasnrvtgvpdrfrgsgsgtdfiltinslepedsasyycqrrgdgynfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3082,NaN,NaN,NaN,QXE98209,['COVID'],Homo sapiens (human),NaN,qpvltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedqadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3083,NaN,NaN,NaN,QXE98208,['COVID'],Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvstflgwyqqrpgqpprlliydasyrapdipvrfsgsgsgtdftltinslepedsavyycqqrsdgynfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3084,NaN,NaN,NaN,QXE98207,['COVID'],Homo sapiens (human),NaN,diqvtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3085,NaN,NaN,NaN,QXE98206,['COVID'],Homo sapiens (human),NaN,ettltqspvtlsvspgeratlscrasqsvisnlawyqqkpgqaprllifgastratgvparfsgsgsgteftltisslqsedfavyycqqynnwpsltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3086,NaN,NaN,NaN,QXE98205,['COVID'],Homo sapiens (human),NaN,divltqsplslpvglgqsasiscrssqrvvhtdgntylhwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3087,NaN,NaN,NaN,QXE98204,['COVID'],Homo sapiens (human),NaN,diqltqsplslpvglgqsasiscrssqrvvhtdgntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqstdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3088,NaN,NaN,NaN,QXE98203,['COVID'],Homo sapiens (human),NaN,divmtqtplslpvtlgqpasiscrasqtvvhtngntylnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlsisrveaedigvyycmqgtdwprtfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3089,NaN,NaN,NaN,QXE98202,['COVID'],Homo sapiens (human),NaN,diqltqspatlsvspgeratlscrasqsvtkhlawyqqkpgqaprlliygastratgvparfsgsgsdtefsltisslqsedfavyycqqyyswppltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3090,NaN,NaN,NaN,QXE98201,['COVID'],Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtnsdisnsysvswyqqypgkapklvifdvinrpsgvsnrfsgsksgntasltisglqaddeadyyccsytrtntpvlfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3091,NaN,NaN,NaN,QXE98200,['COVID'],Homo sapiens (human),NaN,dirmtqspdslavslgeratincrtsqsvlyssnnknylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3092,NaN,NaN,NaN,QXE98199,['COVID'],Homo sapiens (human),NaN,qsaliqprsvsgspgqsvtisctgssstfgtdnhiswyqqlpgkvpkliihavsqrpsvvpdrfsgsrsgntasltisglqaedeadyyccsspgtitwvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3093,NaN,NaN,NaN,QXE98198,['COVID'],Homo sapiens (human),NaN,dirltqtplslpvtlgqpasiscrssqiamhsdgntylswfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaedigtfycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3094,NaN,NaN,NaN,QXE98197,['COVID'],Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapkltvydvrnrpsgvsnrfsgsksgntasltisglqaedeahyycssytstntvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3095,NaN,NaN,NaN,QXE98196,['COVID'],Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvstflgwyqqrpgqpprlliydasyrapdipvrfsgsgsgtdftltinslepedsavyycqqrsdgynfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3096,NaN,NaN,NaN,QXE98195,['COVID'],Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcrasqdisnylawyqqkpgkapklliyaastlqsgvplrfsgsgsgtdftltisslqpedfatyyclqlhnyssfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3097,NaN,NaN,NaN,QXE98194,['COVID'],Homo sapiens (human),NaN,dirltqsplslpvtlgqpasisctssqdvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedagiyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3098,NaN,NaN,NaN,QXE98193,['COVID'],Homo sapiens (human),NaN,dirltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapnlliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsgwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3099,NaN,NaN,NaN,QXE98192,['COVID'],Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvgsfnyvswyqqhpgkapklviydvynrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3100,NaN,NaN,NaN,QXE98191,['COVID'],Homo sapiens (human),NaN,diqmtqsplslsvtlgqsasiscrasqtvvhsvdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedigiyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3101,NaN,NaN,NaN,QXE98190,['COVID'],Homo sapiens (human),NaN,divmtqsplslpvslgqpasiscrssqsvvhtdgntylnwyqqrpgqsprrliykvsnrdsgvpdrfsgsgsvtdftlkisrveaedvavyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3102,NaN,NaN,NaN,QXE98189,['COVID'],Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrsshslvhtngntylnwfqqrpgqpprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaddvgiyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3103,NaN,NaN,NaN,QXE98188,['COVID'],Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlfssnnknylawyqqkpglppklliywastrksgvsdrfsgsgsgtdftltisslqaedvavyycqqyyttplftfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3104,NaN,NaN,NaN,QXE98187,['COVID'],Homo sapiens (human),NaN,eivmtqtplslpvtlgqpasiscrssqfvshtdgntylnwfqqrpgqsprrliykvskrdsgvpdrfsgsgsgtdftltisrveaedvgvyycmqatewprtfgqgtkveyq,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3105,NaN,NaN,NaN,QXE98186,['COVID'],Homo sapiens (human),NaN,dirvtqspdslavslgeratinckssqsvlyssnnknylawyqqkigqppklliywasiresgvpdrftgsgsgtdftltisslqaedvavyycqqyystpptfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3106,NaN,NaN,NaN,QXE98185,['COVID'],Homo sapiens (human),NaN,divltqsplslsvtpgqpasiscrssqslqhtdgktylywylqkpgqspqlliyelfnrfsgvperfsgsgsgtdftlkisrveaedvgiyycmqsiqtpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3107,NaN,NaN,NaN,QXE98184,['COVID'],Homo sapiens (human),NaN,qsvvtqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydsdkrpsgiperfsgsksatsatlgitglqtgdeadyycetwddslsavvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3108,NaN,NaN,NaN,QXE98183,['COVID'],Homo sapiens (human),NaN,eivltqspsslsasvgdrvtiscrasqgistflawfqqrpgkapksliyaasklqsgvpsrfsgsdsgpdftltidnlqpedsatyyckqynsypytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3109,NaN,NaN,NaN,QXE98182,['COVID'],Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratniparfsgsgsgteftltisslqsedfavyycqqynlwpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3110,NaN,NaN,NaN,QXE98181,['COVID'],Homo sapiens (human),NaN,divmtqsplalsvtpgqpasisckssqsllhsdgktyfywylqkpgqsphlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqvpitfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3111,NaN,NaN,NaN,QXE98180,['COVID'],Homo sapiens (human),NaN,eivmtqsplslpvtlgqsasiscrssqglvhsdgniylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvglyycmqathwprafgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3112,NaN,NaN,NaN,QXE98179,['COVID'],Homo sapiens (human),NaN,qsvltqpsslsaspgasasltctlhsgfnvgdhtinwyqqrpgsppryllkyksdsdkeqgsgvpirfsgskdasanagfllisglrsedeadyycmiwhdnavvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3113,NaN,NaN,NaN,QXE98178,['COVID'],Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3114,NaN,NaN,NaN,QXE98177,['COVID'],Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3115,NaN,NaN,NaN,QXE98176,['COVID'],Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3116,NaN,NaN,NaN,QXE98175,['COVID'],Homo sapiens (human),NaN,dirltqspatlslspgeratlscrasqsvssslawyqqkpgqaprlliyeasnratgvparfsgsgsgtdftlaisslepedfavyycqhrsnwpprytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3117,NaN,NaN,NaN,QXE98174,['COVID'],Homo sapiens (human),NaN,eivmtqspgtlslspgervtlscratqsvsnnhlawyqqkpgqaprlliygasttatdipdrfsgrvagtdftltisrldpedfavyychqygsspwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3118,NaN,NaN,NaN,QXE98173,['COVID'],Homo sapiens (human),NaN,divltqsplslpvtlgqsasiscrssqglvhsdgniylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvglyycmqathwprafgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3119,NaN,NaN,NaN,QXE98172,['COVID'],Homo sapiens (human),NaN,qsvltqppsvsgvprqkvtiscsgstaniasngvnwyqlvpgkaprllisyddlvpsgvsarfsgsksgtsaslaisglqaedeadyycatwddilngpvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3120,NaN,NaN,NaN,QXE98171,['COVID'],Homo sapiens (human),NaN,qpvltqprsvsgspgqsvtisctgssstfgtdnhiswyqqlpgkvpkliihavsqrpsvvpdrfsgsrsgntasltisglqaedeadyyccsspgtitwvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3121,NaN,NaN,NaN,QXE98170,['COVID'],Homo sapiens (human),NaN,eivltqspstlsasvgdrvtitcrasqnvnnwlawyqqkpgkapklliyeastlksgvpsrfsgsgsgteftltisslqpddfatyycqqynsqytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3122,NaN,NaN,NaN,QXE98169,['COVID'],Homo sapiens (human),NaN,dirvtqspsslsasvgdrvtitcrasqtinnylnwyqqkpgkapnlliyaastlqngvpsrfsgsgsgtdftltissvqpedfatyycqqtyitptwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3123,NaN,NaN,NaN,QXE98168,['COVID'],Homo sapiens (human),NaN,diqltqspatlslspgeratlscraspsvftflawyqqrpgqpprllihdvsnrapgiparfsgsgsgtdftliisslepddsavyfcqqrsdgynfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3124,NaN,NaN,NaN,QXE98167,['COVID'],Homo sapiens (human),NaN,eivltqspgtlsvspgeratlscrasqiinrsqlgwyqhkpgqaprllifdsskratgtpdrfsasgsetdftltisgvepedsgvyyclqyslattfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3125,NaN,NaN,NaN,QXE98166,['COVID'],Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvgnynvvswyqqhpgkapqlfiyedtkrpsgvsdrfsgsksgitasltisrlqpedeadyyccsyavsgtvlfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3126,NaN,NaN,NaN,QXE98165,['COVID'],Homo sapiens (human),NaN,dirltqspdslalslgeratinckssqsvlfssnnnnylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyltpwtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3127,NaN,NaN,NaN,QXE98164,['COVID'],Homo sapiens (human),NaN,dirvtqspsslsatvgdrvtitcrasqtitkylnwyqqkpgkapklllygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyitpgtfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3128,NaN,NaN,NaN,QXE98163,['COVID'],Homo sapiens (human),NaN,dirltqsplslpvdlgqsasiscrssqtvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3129,NaN,NaN,NaN,QXE98162,['COVID'],Homo sapiens (human),NaN,diqmtqsplslpvtlgqpasiscrasqtvvhtngntylnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlsisrveaedigvyycmqgtdwprtfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3130,NaN,NaN,NaN,QXE98161,['COVID'],Homo sapiens (human),NaN,qpgltqpasvsgspgqsitisctrtsgdvgdynsvswyvswyqqhpgrapklmlydvsnrpsgvsnrfsgsklgdtasltiselqaedeadyycstytststifgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3131,NaN,NaN,NaN,QXE98160,['COVID'],Homo sapiens (human),NaN,diqmtqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3132,NaN,NaN,NaN,QXE98159,['COVID'],Homo sapiens (human),NaN,divmtqsplslpvdlgqsasiscrssqtavhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrinrveaedvgvyycmqatdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3133,NaN,NaN,NaN,QXE98158,['COVID'],Homo sapiens (human),NaN,eivmtqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3134,NaN,NaN,NaN,QXE98157,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3135,NaN,NaN,NaN,QXE98156,['COVID'],Homo sapiens (human),NaN,cirltqspatlslspgeratlscrasqsvtsylawyqqrpgqaprlliydtsnrvtgvpvrfsgsgygtdftltisslepedfavyycqqrgngytfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3136,NaN,NaN,NaN,QXE98155,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3137,NaN,NaN,NaN,QXE98154,['COVID'],Homo sapiens (human),NaN,ettltqspasvsasvgdrvtiscrasqgigrwlawyqqkpgrapkllifsasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaesfpftfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3138,NaN,NaN,NaN,QXE98153,['COVID'],Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqrlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3139,NaN,NaN,NaN,QXE98152,['COVID'],Homo sapiens (human),NaN,dirmtqspfslsasvgdrvtitcrasqgfgnrlawyqqkpgrapklliydastlqsgvpsrfsgsgsetdfaltisslqpedvatyycqkhdrdpwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3140,NaN,NaN,NaN,QXE98151,['COVID'],Homo sapiens (human),NaN,qpgltqepsltvspggtvtltcgssagavtsghypywfqqkpgqaprtliydtnnkyswtparfsgsllggkaaltlsgaqpedeaeyfcflsyrgappvfgggthltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3141,NaN,NaN,NaN,QXE98150,['COVID'],Homo sapiens (human),NaN,dirltqspatlslspgeratlscrasqsigyylawfqqkpgqaprlliydaskratgiparfsgsgsgtdftltisslepedfavyycqhrtnwpytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3142,NaN,NaN,NaN,QXE98149,['COVID'],Homo sapiens (human),NaN,divltqtpatlslspgeratlscrasqsvsnflawyqqkpgqpprlliydasnrasgiaarfsgrgsgtdftltisslepedfavyycqqrrnwppmytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3143,NaN,NaN,NaN,QXE98148,['COVID'],Homo sapiens (human),NaN,diqltqsplslpvtlgqpasisctssqnvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedvgiyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3144,NaN,NaN,NaN,QXE98147,['COVID'],Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvgnnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspvytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3145,NaN,NaN,NaN,QXE98146,['COVID'],Homo sapiens (human),NaN,eivmtqtplslpvtlgqpasiscrsshglvhtngntylnwfhqrpgqpprrliyqvshrdsgvpdrfsgsgsgtdftlkisrveaddvgvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3146,NaN,NaN,NaN,QXE98145,['COVID'],Homo sapiens (human),NaN,diqmtqsplslpvtlgqaasiscrssqpiphtdgntylnwfhqrpgqsprrlihkvsnrdsgvpdrfsgsgsgldftleisgveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3147,NaN,NaN,NaN,QXE98144,['COVID'],Homo sapiens (human),NaN,nfmltqphsvsespgkaviisctrssgniasnfvqwyqqrpgssptpviyedklrpsgvpdrfsgsidrssnsasltisglktedeadyycqsydsgnlvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3148,NaN,NaN,NaN,QXE98143,['COVID'],Homo sapiens (human),NaN,ettltqsplslsvtlgqaasisctcsqsavhsdgntyfnwfhqrpgqsprrliykvsnrdsgvperfsgsgsgthftliisrveaedvgvyycmqttdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3149,NaN,NaN,NaN,QXE98142,['COVID'],Homo sapiens (human),NaN,eivltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3150,NaN,NaN,NaN,QXE98141,['COVID'],Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqpprlliydasnrasgiaarfsgrgsgtdftltisslepedfavyycqqrrnwppmytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3151,NaN,NaN,NaN,QXE98140,['COVID'],Homo sapiens (human),NaN,divmtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3152,NaN,NaN,NaN,QXE98139,['COVID'],Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqtvtrsqlawyqhkpgqpprlliydsskratgspdrfsasgsgtdftltisglepedtgiyyclqysdattfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3153,NaN,NaN,NaN,QXE98138,['COVID'],Homo sapiens (human),NaN,divmtqtplslavtlgqpasiscrsshglvhtngntylnwfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaddvgvyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3154,NaN,NaN,NaN,QXE98137,['COVID'],Homo sapiens (human),NaN,qpvltqppsvsaapgqkvtiscsgsssnigdnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycetwdtslsvvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3155,NaN,NaN,NaN,QXE98136,['COVID'],Homo sapiens (human),NaN,eivltqspgtlslspgeraslscrasqsvsssylawyqhrpgqaprlliydassratgipdrfsgsgsgtdftltisrlesedfavyycqqygnsprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3156,NaN,NaN,NaN,QXE98135,['COVID'],Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsigssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsaplytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3157,NaN,NaN,NaN,QXE98134,['COVID'],Homo sapiens (human),NaN,dirltqsplslpvtlgqpasiscrssqslvhsngntylnwfqqrpgqsprrliyevsnrdsgvpdrftgsgsgtdftlkisrveaedvgvyycmqgthwprsfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3158,NaN,NaN,NaN,QXE98133,['COVID'],Homo sapiens (human),NaN,diqvtqspatvsvspgegaslscrasqsvrsnlawfqqkpgqaprllisdastrasgvparftgsgfgteftltisslqsedfaiyycqqyntwppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3159,NaN,NaN,NaN,QXE98132,['COVID'],Homo sapiens (human),NaN,diqltqsplslpvtlgqpasiscrssqhlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgidftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3160,NaN,NaN,NaN,QXE98131,['COVID'],Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpetapklliyangnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgvlfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3161,NaN,NaN,NaN,QXE98130,['COVID'],Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagyyvhwyqqlpgtapklliydnnnrpsgvpdrfsgsrsgtsaslaitglqaedegdyfcqsydsslsasfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3162,NaN,NaN,NaN,QXE98129,['COVID'],Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnlgnnyvswyqqlpgtapklliydnhkrpsgipdrfsgsksgtsatlgitglqtgdeadyycetwdsslsvvvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3163,NaN,NaN,NaN,QXE98128,['COVID'],Homo sapiens (human),NaN,qpvltqpasvsgspgqsvtisctgtssdvgsysdvgnyvswyqhhpgkapklmiyevrtrpswvstrfsgsksgttasltisglqaedeadyyccsyagaspfvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3164,NaN,NaN,NaN,QXE98127,['COVID'],Homo sapiens (human),NaN,etgltqipfslpvtfgqpasiscrfsqrlvhtdgntnlnwflqrpgqfprgliykvfnrdsgvpdrfrgsgsgidftlkisrvevedvgiyygmqgtewlgtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3165,NaN,NaN,NaN,QXE98126,['COVID'],Homo sapiens (human),NaN,eivltqsplslpvtlgqpasiscrsslrlvhtdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3166,NaN,NaN,NaN,QXE98125,['COVID'],Homo sapiens (human),NaN,dirltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3167,NaN,NaN,NaN,QXE98124,['COVID'],Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlyssnnenclawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqycstppytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3168,NaN,NaN,NaN,QXE98123,['COVID'],Homo sapiens (human),NaN,dirmtqsplslpvtrgqpasiscrsshnvvhsdgktylnwfhqrpgqaprrliyqvskrdsgvpdrfsgsgsgsdftltisrveaedvgvyycmqgtdwprsfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3169,NaN,NaN,NaN,QXE98122,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqglvhsngntyvnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3170,NaN,NaN,NaN,QXE98121,['COVID'],Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcqasqdirkclnwyqhipgkapkllihdasslesgvpsrfsgsgsgtdfsftinslhpediatyycqqfedlpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3171,NaN,NaN,NaN,QXE98120,['COVID'],Homo sapiens (human),NaN,divltqtpatlsvspgegatlscrasqsvrsnlawfqqrpgqvprlliydastratgvparftgsgsgtyftltisslqsedfavyycqqynswppltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3172,NaN,NaN,NaN,QXE98119,['COVID'],Homo sapiens (human),NaN,dirltqspsslsasvgdrvtiacrasqsvsnylnwyqqkpgkapklliyaasslqngvpsrfggsgsgtdftltisslqpedfatyycqqcysypptfghgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3173,NaN,NaN,NaN,QXE98118,['COVID'],Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqglahsngntylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3174,NaN,NaN,NaN,QXE98117,['COVID'],Homo sapiens (human),NaN,eivltqspatlsvspgdgaslscrasqsvgsnlawyqqkpgqaprllisdasaratgvparftgsgsgtdftltisslqsedfavyychqyntwppltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3175,NaN,NaN,NaN,QXE98116,['COVID'],Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcrasqsisnylywyqqkpgkapklliyvasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpynfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3176,NaN,NaN,NaN,QXE98115,['COVID'],Homo sapiens (human),NaN,divltqtpsslsasvgdrvtitcrasqtisyylnwyqqkvgkapqllvyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysvpltlgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3177,NaN,NaN,NaN,QXE98114,['COVID'],Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqvpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlyvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3178,NaN,NaN,NaN,QXE98113,['COVID'],Homo sapiens (human),NaN,eivmtqspsslsasigdrvtiscrasqnigsylnwyqqrpgkapnllifvasslqsgvpsrfsgsgsgtdftltisslqaedfatyycqqsyttpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3179,NaN,NaN,NaN,QXE98112,['COVID'],Homo sapiens (human),NaN,eivltqspatlslspgeratlscraseniahylawyqqkpgqaprlviydassratgipgrfsgsgagtdftltinslepedfavyycqqrsnwpqnfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3180,NaN,NaN,NaN,QXE98111,['COVID'],Homo sapiens (human),NaN,qpvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlyvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3181,NaN,NaN,QXE98038,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvss,NaN,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3182,NaN,NaN,QXE98037,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvss,NaN,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3183,NaN,NaN,QXE98036,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyafhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraddtavyycardlaiavagtwhyyngmdvwgqgttvtvss,NaN,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3184,NaN,NaN,QXE98035,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftlssygmhwvrqapgkglewvavisydgsnkyyvdsvkgrftisrdnskntlylqmnslraedtavyycargwaywellpdyyygmdvwgqgttvtvss,NaN,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3185,NaN,NaN,NaN,QXE98042,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveir,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3186,NaN,NaN,NaN,QXE98041,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveik,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3187,NaN,NaN,NaN,QXE98040,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrviitcrasqgisswlawyqqkpgkapkvliydasslqsgvpsrfsgsgygtdftltisslqpedsatyycqqaksfpitfgqgtrleik,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3188,NaN,NaN,NaN,QXE98039,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqepsfsvspggtvtltcglssgsvstayfpswyqqtpgqaprtliygtntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgrgivvfgggtkltvl,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
3189,NaN,NaN,QQP23469,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgfdfsrfamhwvrqapgkgleyvsainlhgdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3190,NaN,NaN,QQP23468,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3191,NaN,NaN,QQP23467,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3192,NaN,NaN,QQP23466,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3193,NaN,NaN,QQP23465,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgfdfsrfamhwvrqapgkgleyvsainlwgdstyytdsvrgrftisrdnskntlylqmrsvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3194,NaN,NaN,QQP23464,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlhgdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3195,NaN,NaN,QQP23463,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3196,NaN,NaN,QQP23462,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3197,NaN,NaN,QQP23461,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3198,NaN,NaN,QQP23460,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3199,NaN,NaN,QQP23459,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3200,NaN,NaN,QQP23458,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3201,NaN,NaN,QQP23457,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3202,NaN,NaN,QQP23456,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3203,NaN,NaN,QQP23455,NaN,['COVID'],Homo sapiens (human),evqlvesggdlvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtasagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3204,NaN,NaN,QQP23454,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3205,NaN,NaN,QQP23453,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslgaddtavyycardfsghtawagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3206,NaN,NaN,QQP23452,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymnwvrqapgkglewvssisedgynpyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3207,NaN,NaN,QQP23451,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3208,NaN,NaN,QQP23450,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3209,NaN,NaN,QQP23449,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnnlrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3210,NaN,NaN,QQP23448,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlwgdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3211,NaN,NaN,QQP23447,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3212,NaN,NaN,QQP23446,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyttyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtasagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3213,NaN,NaN,QQP23445,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsayymnwvrqapgkglewvssissdgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3214,NaN,NaN,QQP23444,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitertygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3215,NaN,NaN,QQP23443,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgfplrgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3216,NaN,NaN,QQP23442,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysdgdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3217,NaN,NaN,QQP23441,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3218,NaN,NaN,QQP23440,NaN,['COVID'],Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfsgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3219,NaN,NaN,QQP23439,NaN,['COVID'],Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3220,NaN,NaN,QQP23438,NaN,['COVID'],Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3221,NaN,NaN,QXD47405,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 828 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 828 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3222,NaN,NaN,QXD47403,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 824 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 824 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3223,NaN,NaN,QXD47397,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 810 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 810 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3224,NaN,NaN,QXD47396,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 808 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 808 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3225,NaN,NaN,QXD47394,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 804 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 804 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3226,NaN,NaN,QXD47390,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 796 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 796 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3227,NaN,NaN,QXD47389,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 794 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 794 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3228,NaN,NaN,QXD47387,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 790 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 790 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3229,NaN,NaN,QXD47382,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 780 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 780 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3230,NaN,NaN,QXD47381,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 778 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 778 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3231,NaN,NaN,QXD47379,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 774 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 774 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3232,NaN,NaN,QXD47374,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 764 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 764 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3233,NaN,NaN,QXD47373,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 762 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 762 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3234,NaN,NaN,QXD47372,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 759 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 759 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3235,NaN,NaN,QXD47371,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 757 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 757 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3236,NaN,NaN,QXD47369,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 753 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 753 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3237,NaN,NaN,QXD47368,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 751 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 751 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3238,NaN,NaN,QXD47366,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 747 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 747 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3239,NaN,NaN,QXD47361,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 737 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 737 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3240,NaN,NaN,QXD47360,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 735 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 735 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3241,NaN,NaN,QXD47358,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 731 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 731 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3242,NaN,NaN,QXD47354,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 723 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 723 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3243,NaN,NaN,QXD47353,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 721 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 721 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3244,NaN,NaN,QXD47351,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 717 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 717 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3245,NaN,NaN,QXD47347,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 708 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 708 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3246,NaN,NaN,QXD47346,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 706 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 706 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3247,NaN,NaN,QXD47345,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 704 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 704 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3248,NaN,NaN,QXD47344,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 702 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 702 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3249,NaN,NaN,QXD47343,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 700 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 700 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3250,NaN,NaN,QXD47342,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 698 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 698 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3251,NaN,NaN,QXD47341,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 696 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 696 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3252,NaN,NaN,QXD47339,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 692 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 692 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3253,NaN,NaN,QXD47332,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 678 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 678 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3254,NaN,NaN,QXD47330,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 674 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 674 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3255,NaN,NaN,QXD47323,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 658 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 658 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3256,NaN,NaN,QXD47321,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 654 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 654 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3257,NaN,NaN,QXD47315,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 640 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 640 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3258,NaN,NaN,QXD47313,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 636 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 636 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3259,NaN,NaN,QXD47308,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 624 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 624 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3260,NaN,NaN,QXD47306,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 620 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 620 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3261,NaN,NaN,QXD47300,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 608 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 608 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3262,NaN,NaN,QXD47298,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 604 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 604 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3263,NaN,NaN,QXD47293,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 594 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 594 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3264,NaN,NaN,QXD47292,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 592 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 592 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3265,NaN,NaN,QXD47290,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 588 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 588 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3266,NaN,NaN,QXD47284,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 574 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 574 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3267,NaN,NaN,QXD47283,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 572 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 572 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3268,NaN,NaN,QXD47282,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 570 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 570 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3269,NaN,NaN,QXD47281,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 568 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 568 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3270,NaN,NaN,QXD47280,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 566 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 566 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3271,NaN,NaN,QXD47278,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 562 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 562 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3272,NaN,NaN,QXD47271,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 548 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 548 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3273,NaN,NaN,QXD47270,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 546 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 546 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3274,NaN,NaN,QXD47269,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 544 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 544 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3275,NaN,NaN,QXD47268,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 542 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 542 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3276,NaN,NaN,QXD47267,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 540 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 540 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3277,NaN,NaN,QXD47265,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 536 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 536 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3278,NaN,NaN,QXD47260,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 524 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 524 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3279,NaN,NaN,QXD47258,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 520 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 520 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3280,NaN,NaN,QXD47253,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 510 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 510 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3281,NaN,NaN,QXD47251,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 506 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 506 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3282,NaN,NaN,QXD47246,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 495 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 495 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3283,NaN,NaN,QXD47244,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 491 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 491 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3284,NaN,NaN,QXD47239,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 480 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 480 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3285,NaN,NaN,QXD47237,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 476 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 476 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3286,NaN,NaN,QXD47233,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 468 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 468 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3287,NaN,NaN,QXD47231,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 464 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 464 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3288,NaN,NaN,QXD47225,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 451 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 451 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3289,NaN,NaN,QXD47223,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 447 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 447 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3290,NaN,NaN,QXD47216,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 432 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 432 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3291,NaN,NaN,QXD47215,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 430 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 430 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3292,NaN,NaN,QXD47214,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 428 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 428 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3293,NaN,NaN,QXD47213,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 426 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 426 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3294,NaN,NaN,QXD47212,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 424 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 424 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3295,NaN,NaN,QXD47210,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 420 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 420 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3296,NaN,NaN,QXD47205,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 409 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 409 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3297,NaN,NaN,QXD47203,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 405 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 405 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3298,NaN,NaN,QXD47199,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 396 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 396 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3299,NaN,NaN,QXD47197,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 392 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 392 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3300,NaN,NaN,QXD47192,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 381 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 381 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3301,NaN,NaN,QXD47190,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 377 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 377 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3302,NaN,NaN,QXD47186,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 366 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 366 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3303,NaN,NaN,QXD47185,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 364 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 364 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3304,NaN,NaN,QXD47184,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 362 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 362 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3305,NaN,NaN,QXD47183,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 360 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 360 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3306,NaN,NaN,QXD47182,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 358 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 358 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3307,NaN,NaN,QXD47181,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 356 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 356 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3308,NaN,NaN,QXD47180,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 354 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 354 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3309,NaN,NaN,QXD47179,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 352 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 352 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3310,NaN,NaN,QXD47178,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 350 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 350 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3311,NaN,NaN,QXD47177,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 348 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 348 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3312,NaN,NaN,QXD47176,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 346 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 346 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3313,NaN,NaN,QXD47174,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 342 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 342 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3314,NaN,NaN,QXD47170,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 333 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 333 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3315,NaN,NaN,QXD47168,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 329 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 329 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3316,NaN,NaN,QXD47162,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 316 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 316 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3317,NaN,NaN,QXD47160,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 312 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 312 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3318,NaN,NaN,QXD47155,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 302 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 302 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3319,NaN,NaN,QXD47153,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 298 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 298 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3320,NaN,NaN,QXD47147,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 284 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 284 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3321,NaN,NaN,QXD47145,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 280 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 280 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3322,NaN,NaN,QXD47139,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 268 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 268 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3323,NaN,NaN,QXD47137,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 264 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 264 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3324,NaN,NaN,QXD47131,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 252 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 252 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3325,NaN,NaN,QXD47129,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 248 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 248 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3326,NaN,NaN,QXD47124,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 238 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 238 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3327,NaN,NaN,QXD47122,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 234 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 234 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3328,NaN,NaN,QXD47115,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 220 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 220 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3329,NaN,NaN,QXD47113,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 216 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 216 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3330,NaN,NaN,QXD47106,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 202 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 202 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3331,NaN,NaN,QXD47104,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 198 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 198 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3332,NaN,NaN,QXD47099,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 185 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 185 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3333,NaN,NaN,QXD47098,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 183 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 183 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3334,NaN,NaN,QXD47096,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 179 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 179 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3335,NaN,NaN,QXD47090,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 167 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 167 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3336,NaN,NaN,QXD47089,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 165 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 165 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3337,NaN,NaN,QXD47088,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 163 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 163 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3338,NaN,NaN,QXD47087,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 161 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 161 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3339,NaN,NaN,QXD47086,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 159 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 159 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3340,NaN,NaN,QXD47085,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 157 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 157 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3341,NaN,NaN,QXD47083,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 153 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 153 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3342,NaN,NaN,QXD47076,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 137 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 137 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3343,NaN,NaN,QXD47074,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 133 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 133 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3344,NaN,NaN,QXD47067,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 119 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 119 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3345,NaN,NaN,QXD47065,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 115 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 115 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3346,NaN,NaN,QXD47058,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 99 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 99 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3347,NaN,NaN,QXD47056,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 95 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 95 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3348,NaN,NaN,QXD47050,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 83 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 83 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3349,NaN,NaN,QXD47048,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 79 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 79 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3350,NaN,NaN,QXD47041,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 65 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 65 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3351,NaN,NaN,QXD47040,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 63 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 63 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3352,NaN,NaN,QXD47038,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 59 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 59 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3353,NaN,NaN,QXD47032,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 44 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 44 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3354,NaN,NaN,QXD47031,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 42 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 42 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3355,NaN,NaN,QXD47029,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 38 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 38 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3356,NaN,NaN,QXD47022,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 22 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 22 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3357,NaN,NaN,QXD47020,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 18 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 18 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3358,NaN,NaN,QXD47013,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 2 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 2 from patent US 10975139,NaN,2022-10-12,NaN,NaN
3359,NaN,NaN,NaN,QXD47404,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 826 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 826 from patent US 10975139,2022-10-12,NaN,NaN
3360,NaN,NaN,NaN,QXD47401,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 818 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 818 from patent US 10975139,2022-10-12,NaN,NaN
3361,NaN,NaN,NaN,QXD47395,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 806 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 806 from patent US 10975139,2022-10-12,NaN,NaN
3362,NaN,NaN,NaN,QXD47392,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 800 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 800 from patent US 10975139,2022-10-12,NaN,NaN
3363,NaN,NaN,NaN,QXD47388,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 792 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 792 from patent US 10975139,2022-10-12,NaN,NaN
3364,NaN,NaN,NaN,QXD47385,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 786 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 786 from patent US 10975139,2022-10-12,NaN,NaN
3365,NaN,NaN,NaN,QXD47380,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 776 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 776 from patent US 10975139,2022-10-12,NaN,NaN
3366,NaN,NaN,NaN,QXD47377,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 770 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 770 from patent US 10975139,2022-10-12,NaN,NaN
3367,NaN,NaN,NaN,QXD47367,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 749 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 749 from patent US 10975139,2022-10-12,NaN,NaN
3368,NaN,NaN,NaN,QXD47363,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 741 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 741 from patent US 10975139,2022-10-12,NaN,NaN
3369,NaN,NaN,NaN,QXD47359,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 733 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 733 from patent US 10975139,2022-10-12,NaN,NaN
3370,NaN,NaN,NaN,QXD47356,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 727 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 727 from patent US 10975139,2022-10-12,NaN,NaN
3371,NaN,NaN,NaN,QXD47352,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 719 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 719 from patent US 10975139,2022-10-12,NaN,NaN
3372,NaN,NaN,NaN,QXD47349,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 713 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 713 from patent US 10975139,2022-10-12,NaN,NaN
3373,NaN,NaN,NaN,QXD47340,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 694 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 694 from patent US 10975139,2022-10-12,NaN,NaN
3374,NaN,NaN,NaN,QXD47336,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 686 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 686 from patent US 10975139,2022-10-12,NaN,NaN
3375,NaN,NaN,NaN,QXD47331,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 676 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 676 from patent US 10975139,2022-10-12,NaN,NaN
3376,NaN,NaN,NaN,QXD47327,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 666 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 666 from patent US 10975139,2022-10-12,NaN,NaN
3377,NaN,NaN,NaN,QXD47322,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 656 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 656 from patent US 10975139,2022-10-12,NaN,NaN
3378,NaN,NaN,NaN,QXD47318,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 646 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 646 from patent US 10975139,2022-10-12,NaN,NaN
3379,NaN,NaN,NaN,QXD47314,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 638 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 638 from patent US 10975139,2022-10-12,NaN,NaN
3380,NaN,NaN,NaN,QXD47311,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 630 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 630 from patent US 10975139,2022-10-12,NaN,NaN
3381,NaN,NaN,NaN,QXD47307,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 622 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 622 from patent US 10975139,2022-10-12,NaN,NaN
3382,NaN,NaN,NaN,QXD47303,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 614 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 614 from patent US 10975139,2022-10-12,NaN,NaN
3383,NaN,NaN,NaN,QXD47299,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 606 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 606 from patent US 10975139,2022-10-12,NaN,NaN
3384,NaN,NaN,NaN,QXD47296,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 600 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 600 from patent US 10975139,2022-10-12,NaN,NaN
3385,NaN,NaN,NaN,QXD47291,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 590 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 590 from patent US 10975139,2022-10-12,NaN,NaN
3386,NaN,NaN,NaN,QXD47287,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 580 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 580 from patent US 10975139,2022-10-12,NaN,NaN
3387,NaN,NaN,NaN,QXD47279,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 564 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 564 from patent US 10975139,2022-10-12,NaN,NaN
3388,NaN,NaN,NaN,QXD47275,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 556 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 556 from patent US 10975139,2022-10-12,NaN,NaN
3389,NaN,NaN,NaN,QXD47266,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 538 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 538 from patent US 10975139,2022-10-12,NaN,NaN
3390,NaN,NaN,NaN,QXD47262,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 530 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 530 from patent US 10975139,2022-10-12,NaN,NaN
3391,NaN,NaN,NaN,QXD47259,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 522 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 522 from patent US 10975139,2022-10-12,NaN,NaN
3392,NaN,NaN,NaN,QXD47255,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 514 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 514 from patent US 10975139,2022-10-12,NaN,NaN
3393,NaN,NaN,NaN,QXD47252,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 508 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 508 from patent US 10975139,2022-10-12,NaN,NaN
3394,NaN,NaN,NaN,QXD47250,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 503 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 503 from patent US 10975139,2022-10-12,NaN,NaN
3395,NaN,NaN,NaN,QXD47245,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 493 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 493 from patent US 10975139,2022-10-12,NaN,NaN
3396,NaN,NaN,NaN,QXD47242,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 487 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 487 from patent US 10975139,2022-10-12,NaN,NaN
3397,NaN,NaN,NaN,QXD47238,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 478 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 478 from patent US 10975139,2022-10-12,NaN,NaN
3398,NaN,NaN,NaN,QXD47235,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 472 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 472 from patent US 10975139,2022-10-12,NaN,NaN
3399,NaN,NaN,NaN,QXD47232,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 466 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 466 from patent US 10975139,2022-10-12,NaN,NaN
3400,NaN,NaN,NaN,QXD47228,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 457 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 457 from patent US 10975139,2022-10-12,NaN,NaN
3401,NaN,NaN,NaN,QXD47224,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 449 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 449 from patent US 10975139,2022-10-12,NaN,NaN
3402,NaN,NaN,NaN,QXD47220,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 440 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 440 from patent US 10975139,2022-10-12,NaN,NaN
3403,NaN,NaN,NaN,QXD47211,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 422 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 422 from patent US 10975139,2022-10-12,NaN,NaN
3404,NaN,NaN,NaN,QXD47208,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 416 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 416 from patent US 10975139,2022-10-12,NaN,NaN
3405,NaN,NaN,NaN,QXD47204,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 407 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 407 from patent US 10975139,2022-10-12,NaN,NaN
3406,NaN,NaN,NaN,QXD47201,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 401 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 401 from patent US 10975139,2022-10-12,NaN,NaN
3407,NaN,NaN,NaN,QXD47198,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 394 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 394 from patent US 10975139,2022-10-12,NaN,NaN
3408,NaN,NaN,NaN,QXD47195,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 387 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 387 from patent US 10975139,2022-10-12,NaN,NaN
3409,NaN,NaN,NaN,QXD47191,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 379 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 379 from patent US 10975139,2022-10-12,NaN,NaN
3410,NaN,NaN,NaN,QXD47188,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 372 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 372 from patent US 10975139,2022-10-12,NaN,NaN
3411,NaN,NaN,NaN,QXD47175,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 344 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 344 from patent US 10975139,2022-10-12,NaN,NaN
3412,NaN,NaN,NaN,QXD47172,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 338 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 338 from patent US 10975139,2022-10-12,NaN,NaN
3413,NaN,NaN,NaN,QXD47169,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 331 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 331 from patent US 10975139,2022-10-12,NaN,NaN
3414,NaN,NaN,NaN,QXD47165,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 323 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 323 from patent US 10975139,2022-10-12,NaN,NaN
3415,NaN,NaN,NaN,QXD47161,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 314 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 314 from patent US 10975139,2022-10-12,NaN,NaN
3416,NaN,NaN,NaN,QXD47157,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 306 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 306 from patent US 10975139,2022-10-12,NaN,NaN
3417,NaN,NaN,NaN,QXD47154,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 300 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 300 from patent US 10975139,2022-10-12,NaN,NaN
3418,NaN,NaN,NaN,QXD47150,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 290 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 290 from patent US 10975139,2022-10-12,NaN,NaN
3419,NaN,NaN,NaN,QXD47146,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 282 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 282 from patent US 10975139,2022-10-12,NaN,NaN
3420,NaN,NaN,NaN,QXD47143,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 276 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 276 from patent US 10975139,2022-10-12,NaN,NaN
3421,NaN,NaN,NaN,QXD47138,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 266 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 266 from patent US 10975139,2022-10-12,NaN,NaN
3422,NaN,NaN,NaN,QXD47135,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 260 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 260 from patent US 10975139,2022-10-12,NaN,NaN
3423,NaN,NaN,NaN,QXD47130,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 250 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 250 from patent US 10975139,2022-10-12,NaN,NaN
3424,NaN,NaN,NaN,QXD47126,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 242 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 242 from patent US 10975139,2022-10-12,NaN,NaN
3425,NaN,NaN,NaN,QXD47123,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 236 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 236 from patent US 10975139,2022-10-12,NaN,NaN
3426,NaN,NaN,NaN,QXD47119,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 228 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 228 from patent US 10975139,2022-10-12,NaN,NaN
3427,NaN,NaN,NaN,QXD47114,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 218 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 218 from patent US 10975139,2022-10-12,NaN,NaN
3428,NaN,NaN,NaN,QXD47110,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 210 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 210 from patent US 10975139,2022-10-12,NaN,NaN
3429,NaN,NaN,NaN,QXD47105,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 200 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 200 from patent US 10975139,2022-10-12,NaN,NaN
3430,NaN,NaN,NaN,QXD47102,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 191 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 191 from patent US 10975139,2022-10-12,NaN,NaN
3431,NaN,NaN,NaN,QXD47097,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 181 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 181 from patent US 10975139,2022-10-12,NaN,NaN
3432,NaN,NaN,NaN,QXD47094,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 175 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 175 from patent US 10975139,2022-10-12,NaN,NaN
3433,NaN,NaN,NaN,QXD47084,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 155 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 155 from patent US 10975139,2022-10-12,NaN,NaN
3434,NaN,NaN,NaN,QXD47080,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 145 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 145 from patent US 10975139,2022-10-12,NaN,NaN
3435,NaN,NaN,NaN,QXD47075,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 135 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 135 from patent US 10975139,2022-10-12,NaN,NaN
3436,NaN,NaN,NaN,QXD47071,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 127 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 127 from patent US 10975139,2022-10-12,NaN,NaN
3437,NaN,NaN,NaN,QXD47066,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 117 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 117 from patent US 10975139,2022-10-12,NaN,NaN
3438,NaN,NaN,NaN,QXD47062,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 107 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 107 from patent US 10975139,2022-10-12,NaN,NaN
3439,NaN,NaN,NaN,QXD47057,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 97 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 97 from patent US 10975139,2022-10-12,NaN,NaN
3440,NaN,NaN,NaN,QXD47053,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 89 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 89 from patent US 10975139,2022-10-12,NaN,NaN
3441,NaN,NaN,NaN,QXD47049,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 81 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 81 from patent US 10975139,2022-10-12,NaN,NaN
3442,NaN,NaN,NaN,QXD47045,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 73 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 73 from patent US 10975139,2022-10-12,NaN,NaN
3443,NaN,NaN,NaN,QXD47039,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 61 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 61 from patent US 10975139,2022-10-12,NaN,NaN
3444,NaN,NaN,NaN,QXD47035,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 51 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 51 from patent US 10975139,2022-10-12,NaN,NaN
3445,NaN,NaN,NaN,QXD47030,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 40 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 40 from patent US 10975139,2022-10-12,NaN,NaN
3446,NaN,NaN,NaN,QXD47026,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 30 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 30 from patent US 10975139,2022-10-12,NaN,NaN
3447,NaN,NaN,NaN,QXD47021,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 20 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 20 from patent US 10975139,2022-10-12,NaN,NaN
3448,NaN,NaN,NaN,QXD47017,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 10 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 10 from patent US 10975139,2022-10-12,NaN,NaN
3449,NaN,NaN,QXC72641,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 828 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 828 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3450,NaN,NaN,QXC72639,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 824 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 824 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3451,NaN,NaN,QXC72633,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 810 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 810 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3452,NaN,NaN,QXC72632,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 808 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 808 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3453,NaN,NaN,QXC72630,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 804 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 804 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3454,NaN,NaN,QXC72626,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 796 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 796 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3455,NaN,NaN,QXC72625,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 794 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 794 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3456,NaN,NaN,QXC72623,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 790 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 790 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3457,NaN,NaN,QXC72618,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 780 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 780 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3458,NaN,NaN,QXC72617,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 778 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 778 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3459,NaN,NaN,QXC72615,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 774 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 774 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3460,NaN,NaN,QXC72610,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 764 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 764 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3461,NaN,NaN,QXC72609,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 762 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 762 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3462,NaN,NaN,QXC72608,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 759 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 759 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3463,NaN,NaN,QXC72607,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 757 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 757 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3464,NaN,NaN,QXC72605,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 753 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 753 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3465,NaN,NaN,QXC72604,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 751 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 751 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3466,NaN,NaN,QXC72602,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 747 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 747 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3467,NaN,NaN,QXC72597,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 737 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 737 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3468,NaN,NaN,QXC72596,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 735 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 735 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3469,NaN,NaN,QXC72594,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 731 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 731 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3470,NaN,NaN,QXC72590,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 723 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 723 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3471,NaN,NaN,QXC72589,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 721 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 721 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3472,NaN,NaN,QXC72587,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 717 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 717 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3473,NaN,NaN,QXC72583,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 708 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 708 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3474,NaN,NaN,QXC72582,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 706 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 706 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3475,NaN,NaN,QXC72581,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 704 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 704 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3476,NaN,NaN,QXC72580,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 702 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 702 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3477,NaN,NaN,QXC72579,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 700 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 700 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3478,NaN,NaN,QXC72578,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 698 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 698 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3479,NaN,NaN,QXC72577,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 696 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 696 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3480,NaN,NaN,QXC72575,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 692 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 692 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3481,NaN,NaN,QXC72568,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 678 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 678 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3482,NaN,NaN,QXC72566,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 674 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 674 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3483,NaN,NaN,QXC72559,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 658 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 658 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3484,NaN,NaN,QXC72557,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 654 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 654 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3485,NaN,NaN,QXC72551,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 640 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 640 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3486,NaN,NaN,QXC72549,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 636 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 636 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3487,NaN,NaN,QXC72544,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 624 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 624 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3488,NaN,NaN,QXC72542,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 620 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 620 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3489,NaN,NaN,QXC72536,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 608 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 608 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3490,NaN,NaN,QXC72534,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 604 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 604 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3491,NaN,NaN,QXC72529,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 594 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 594 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3492,NaN,NaN,QXC72528,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 592 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 592 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3493,NaN,NaN,QXC72526,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 588 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 588 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3494,NaN,NaN,QXC72520,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 574 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 574 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3495,NaN,NaN,QXC72519,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 572 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 572 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3496,NaN,NaN,QXC72518,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 570 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 570 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3497,NaN,NaN,QXC72517,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 568 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 568 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3498,NaN,NaN,QXC72516,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 566 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 566 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3499,NaN,NaN,QXC72514,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 562 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 562 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3500,NaN,NaN,QXC72507,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 548 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 548 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3501,NaN,NaN,QXC72506,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 546 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 546 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3502,NaN,NaN,QXC72505,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 544 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 544 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3503,NaN,NaN,QXC72504,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 542 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 542 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3504,NaN,NaN,QXC72503,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 540 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 540 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3505,NaN,NaN,QXC72501,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 536 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 536 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3506,NaN,NaN,QXC72496,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 524 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 524 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3507,NaN,NaN,QXC72494,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 520 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 520 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3508,NaN,NaN,QXC72489,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 510 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 510 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3509,NaN,NaN,QXC72487,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 506 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 506 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3510,NaN,NaN,QXC72482,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 495 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 495 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3511,NaN,NaN,QXC72480,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 491 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 491 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3512,NaN,NaN,QXC72475,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 480 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 480 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3513,NaN,NaN,QXC72473,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 476 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 476 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3514,NaN,NaN,QXC72469,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 468 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 468 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3515,NaN,NaN,QXC72467,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 464 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 464 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3516,NaN,NaN,QXC72461,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 451 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 451 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3517,NaN,NaN,QXC72459,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 447 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 447 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3518,NaN,NaN,QXC72452,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 432 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 432 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3519,NaN,NaN,QXC72451,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 430 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 430 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3520,NaN,NaN,QXC72450,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 428 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 428 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3521,NaN,NaN,QXC72449,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 426 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 426 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3522,NaN,NaN,QXC72448,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 424 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 424 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3523,NaN,NaN,QXC72446,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 420 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 420 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3524,NaN,NaN,QXC72441,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 409 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 409 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3525,NaN,NaN,QXC72439,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 405 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 405 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3526,NaN,NaN,QXC72435,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 396 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 396 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3527,NaN,NaN,QXC72433,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 392 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 392 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3528,NaN,NaN,QXC72428,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 381 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 381 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3529,NaN,NaN,QXC72426,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 377 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 377 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3530,NaN,NaN,QXC72422,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 366 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 366 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3531,NaN,NaN,QXC72421,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 364 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 364 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3532,NaN,NaN,QXC72420,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 362 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 362 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3533,NaN,NaN,QXC72419,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 360 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 360 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3534,NaN,NaN,QXC72418,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 358 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 358 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3535,NaN,NaN,QXC72417,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 356 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 356 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3536,NaN,NaN,QXC72416,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 354 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 354 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3537,NaN,NaN,QXC72415,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 352 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 352 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3538,NaN,NaN,QXC72414,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 350 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 350 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3539,NaN,NaN,QXC72413,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 348 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 348 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3540,NaN,NaN,QXC72412,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 346 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 346 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3541,NaN,NaN,QXC72410,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 342 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 342 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3542,NaN,NaN,QXC72406,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 333 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 333 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3543,NaN,NaN,QXC72404,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 329 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 329 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3544,NaN,NaN,QXC72398,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 316 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 316 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3545,NaN,NaN,QXC72396,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 312 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 312 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3546,NaN,NaN,QXC72391,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 302 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 302 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3547,NaN,NaN,QXC72389,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 298 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 298 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3548,NaN,NaN,QXC72383,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 284 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 284 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3549,NaN,NaN,QXC72381,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 280 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 280 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3550,NaN,NaN,QXC72375,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 268 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 268 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3551,NaN,NaN,QXC72373,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 264 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 264 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3552,NaN,NaN,QXC72367,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 252 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 252 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3553,NaN,NaN,QXC72365,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 248 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 248 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3554,NaN,NaN,QXC72360,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 238 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 238 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3555,NaN,NaN,QXC72358,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 234 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 234 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3556,NaN,NaN,QXC72351,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 220 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 220 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3557,NaN,NaN,QXC72349,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 216 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 216 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3558,NaN,NaN,QXC72342,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 202 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 202 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3559,NaN,NaN,QXC72340,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 198 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 198 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3560,NaN,NaN,QXC72335,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 185 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 185 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3561,NaN,NaN,QXC72334,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 183 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 183 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3562,NaN,NaN,QXC72332,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 179 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 179 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3563,NaN,NaN,QXC72326,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 167 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 167 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3564,NaN,NaN,QXC72325,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 165 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 165 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3565,NaN,NaN,QXC72324,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 163 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 163 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3566,NaN,NaN,QXC72323,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 161 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 161 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3567,NaN,NaN,QXC72322,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 159 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 159 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3568,NaN,NaN,QXC72321,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 157 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 157 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3569,NaN,NaN,QXC72319,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 153 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 153 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3570,NaN,NaN,QXC72312,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 137 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 137 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3571,NaN,NaN,QXC72310,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 133 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 133 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3572,NaN,NaN,QXC72303,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 119 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 119 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3573,NaN,NaN,QXC72301,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 115 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 115 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3574,NaN,NaN,QXC72294,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 99 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 99 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3575,NaN,NaN,QXC72292,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 95 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 95 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3576,NaN,NaN,QXC72286,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 83 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 83 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3577,NaN,NaN,QXC72284,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 79 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 79 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3578,NaN,NaN,QXC72277,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 65 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 65 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3579,NaN,NaN,QXC72276,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 63 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 63 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3580,NaN,NaN,QXC72274,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 59 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 59 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3581,NaN,NaN,QXC72268,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 44 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 44 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3582,NaN,NaN,QXC72267,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 42 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 42 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3583,NaN,NaN,QXC72265,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 38 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 38 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3584,NaN,NaN,QXC72258,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 22 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 22 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3585,NaN,NaN,QXC72256,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 18 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 18 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3586,NaN,NaN,QXC72249,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 2 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 2 from patent US 10954289,NaN,2022-10-12,NaN,NaN
3587,NaN,NaN,QPY34286,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 828 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 828 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3588,NaN,NaN,QPY34284,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 824 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 824 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3589,NaN,NaN,QPY34278,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 810 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 810 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3590,NaN,NaN,QPY34277,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 808 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 808 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3591,NaN,NaN,QPY34275,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 804 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 804 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3592,NaN,NaN,QPY34271,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 796 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 796 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3593,NaN,NaN,QPY34270,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 794 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 794 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3594,NaN,NaN,QPY34268,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 790 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 790 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3595,NaN,NaN,QPY34263,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 780 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 780 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3596,NaN,NaN,QPY34262,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 778 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 778 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3597,NaN,NaN,QPY34260,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 774 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 774 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3598,NaN,NaN,QPY34255,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 764 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 764 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3599,NaN,NaN,QPY34254,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 762 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 762 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3600,NaN,NaN,QPY34253,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 759 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 759 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3601,NaN,NaN,QPY34252,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 757 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 757 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3602,NaN,NaN,QPY34250,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 753 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 753 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3603,NaN,NaN,QPY34249,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 751 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 751 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3604,NaN,NaN,QPY34247,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 747 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 747 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3605,NaN,NaN,QPY34242,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 737 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 737 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3606,NaN,NaN,QPY34241,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 735 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 735 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3607,NaN,NaN,QPY34239,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 731 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 731 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3608,NaN,NaN,QPY34235,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 723 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 723 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3609,NaN,NaN,QPY34234,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 721 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 721 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3610,NaN,NaN,QPY34232,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 717 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 717 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3611,NaN,NaN,QPY34228,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 708 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 708 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3612,NaN,NaN,QPY34227,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 706 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 706 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3613,NaN,NaN,QPY34226,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 704 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 704 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3614,NaN,NaN,QPY34225,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 702 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 702 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3615,NaN,NaN,QPY34224,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 700 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 700 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3616,NaN,NaN,QPY34223,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 698 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 698 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3617,NaN,NaN,QPY34222,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 696 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 696 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3618,NaN,NaN,QPY34220,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 692 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 692 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3619,NaN,NaN,QPY34213,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 678 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 678 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3620,NaN,NaN,QPY34211,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 674 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 674 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3621,NaN,NaN,QPY34204,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 658 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 658 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3622,NaN,NaN,QPY34202,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 654 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 654 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3623,NaN,NaN,QPY34196,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 640 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 640 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3624,NaN,NaN,QPY34194,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 636 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 636 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3625,NaN,NaN,QPY34189,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 624 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 624 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3626,NaN,NaN,QPY34187,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 620 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 620 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3627,NaN,NaN,QPY34181,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 608 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 608 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3628,NaN,NaN,QPY34179,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 604 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 604 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3629,NaN,NaN,QPY34174,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 594 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 594 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3630,NaN,NaN,QPY34173,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 592 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 592 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3631,NaN,NaN,QPY34171,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 588 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 588 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3632,NaN,NaN,QPY34165,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 574 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 574 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3633,NaN,NaN,QPY34164,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 572 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 572 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3634,NaN,NaN,QPY34163,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 570 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 570 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3635,NaN,NaN,QPY34162,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 568 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 568 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3636,NaN,NaN,QPY34161,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 566 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 566 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3637,NaN,NaN,QPY34159,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 562 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 562 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3638,NaN,NaN,QPY34152,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 548 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 548 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3639,NaN,NaN,QPY34151,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 546 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 546 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3640,NaN,NaN,QPY34150,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 544 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 544 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3641,NaN,NaN,QPY34149,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 542 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 542 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3642,NaN,NaN,QPY34148,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 540 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 540 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3643,NaN,NaN,QPY34146,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 536 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 536 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3644,NaN,NaN,QPY34141,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 524 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 524 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3645,NaN,NaN,QPY34139,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 520 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 520 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3646,NaN,NaN,QPY34134,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 510 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 510 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3647,NaN,NaN,QPY34132,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 506 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 506 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3648,NaN,NaN,QPY34127,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 495 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 495 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3649,NaN,NaN,QPY34125,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 491 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 491 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3650,NaN,NaN,QPY34120,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 480 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 480 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3651,NaN,NaN,QPY34118,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 476 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 476 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3652,NaN,NaN,QPY34114,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 468 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 468 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3653,NaN,NaN,QPY34112,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 464 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 464 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3654,NaN,NaN,QPY34106,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 451 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 451 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3655,NaN,NaN,QPY34104,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 447 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 447 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3656,NaN,NaN,QPY34097,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 432 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 432 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3657,NaN,NaN,QPY34096,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 430 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 430 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3658,NaN,NaN,QPY34095,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 428 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 428 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3659,NaN,NaN,QPY34094,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 426 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 426 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3660,NaN,NaN,QPY34093,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 424 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 424 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3661,NaN,NaN,QPY34091,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 420 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 420 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3662,NaN,NaN,QPY34086,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 409 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 409 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3663,NaN,NaN,QPY34084,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 405 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 405 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3664,NaN,NaN,QPY34080,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 396 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 396 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3665,NaN,NaN,QPY34078,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 392 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 392 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3666,NaN,NaN,QPY34073,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 381 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 381 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3667,NaN,NaN,QPY34071,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 377 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 377 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3668,NaN,NaN,QPY34067,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 366 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 366 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3669,NaN,NaN,QPY34066,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 364 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 364 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3670,NaN,NaN,QPY34065,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 362 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 362 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3671,NaN,NaN,QPY34064,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 360 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 360 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3672,NaN,NaN,QPY34063,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 358 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 358 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3673,NaN,NaN,QPY34062,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 356 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 356 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3674,NaN,NaN,QPY34061,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 354 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 354 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3675,NaN,NaN,QPY34060,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 352 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 352 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3676,NaN,NaN,QPY34059,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 350 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 350 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3677,NaN,NaN,QPY34058,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 348 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 348 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3678,NaN,NaN,QPY34057,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 346 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 346 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3679,NaN,NaN,QPY34055,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 342 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 342 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3680,NaN,NaN,QPY34051,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 333 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 333 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3681,NaN,NaN,QPY34049,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 329 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 329 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3682,NaN,NaN,QPY34043,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 316 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 316 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3683,NaN,NaN,QPY34041,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 312 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 312 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3684,NaN,NaN,QPY34036,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 302 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 302 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3685,NaN,NaN,QPY34034,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 298 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 298 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3686,NaN,NaN,QPY34028,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 284 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 284 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3687,NaN,NaN,QPY34026,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 280 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 280 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3688,NaN,NaN,QPY34020,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 268 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 268 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3689,NaN,NaN,QPY34018,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 264 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 264 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3690,NaN,NaN,QPY34012,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 252 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 252 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3691,NaN,NaN,QPY34010,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 248 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 248 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3692,NaN,NaN,QPY34005,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 238 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 238 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3693,NaN,NaN,QPY34003,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 234 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 234 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3694,NaN,NaN,QPY33996,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 220 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 220 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3695,NaN,NaN,QPY33994,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 216 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 216 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3696,NaN,NaN,QPY33987,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 202 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 202 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3697,NaN,NaN,QPY33985,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 198 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 198 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3698,NaN,NaN,QPY33980,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 185 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 185 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3699,NaN,NaN,QPY33979,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 183 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 183 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3700,NaN,NaN,QPY33977,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 179 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 179 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3701,NaN,NaN,QPY33971,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 167 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 167 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3702,NaN,NaN,QPY33970,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 165 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 165 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3703,NaN,NaN,QPY33969,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 163 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 163 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3704,NaN,NaN,QPY33968,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 161 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 161 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3705,NaN,NaN,QPY33967,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 159 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 159 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3706,NaN,NaN,QPY33966,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 157 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 157 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3707,NaN,NaN,QPY33964,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 153 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 153 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3708,NaN,NaN,QPY33957,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 137 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 137 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3709,NaN,NaN,QPY33955,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 133 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 133 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3710,NaN,NaN,QPY33948,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 119 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 119 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3711,NaN,NaN,QPY33946,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 115 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 115 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3712,NaN,NaN,QPY33939,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 99 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 99 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3713,NaN,NaN,QPY33937,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 95 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 95 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3714,NaN,NaN,QPY33931,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 83 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 83 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3715,NaN,NaN,QPY33929,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 79 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 79 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3716,NaN,NaN,QPY33922,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 65 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 65 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3717,NaN,NaN,QPY33921,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 63 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 63 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3718,NaN,NaN,QPY33919,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 59 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 59 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3719,NaN,NaN,QPY33913,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 44 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 44 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3720,NaN,NaN,QPY33912,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 42 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 42 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3721,NaN,NaN,QPY33910,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 38 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 38 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3722,NaN,NaN,QPY33903,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 22 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 22 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3723,NaN,NaN,QPY33901,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 18 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 18 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3724,NaN,NaN,QPY33894,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 2 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 2 from patent US 10787501,NaN,2022-10-12,NaN,NaN
3725,NaN,NaN,NaN,QXC72640,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 826 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 826 from patent US 10954289,2022-10-12,NaN,NaN
3726,NaN,NaN,NaN,QXC72637,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 818 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 818 from patent US 10954289,2022-10-12,NaN,NaN
3727,NaN,NaN,NaN,QXC72631,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 806 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 806 from patent US 10954289,2022-10-12,NaN,NaN
3728,NaN,NaN,NaN,QXC72628,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 800 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 800 from patent US 10954289,2022-10-12,NaN,NaN
3729,NaN,NaN,NaN,QXC72624,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 792 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 792 from patent US 10954289,2022-10-12,NaN,NaN
3730,NaN,NaN,NaN,QXC72621,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 786 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 786 from patent US 10954289,2022-10-12,NaN,NaN
3731,NaN,NaN,NaN,QXC72616,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 776 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 776 from patent US 10954289,2022-10-12,NaN,NaN
3732,NaN,NaN,NaN,QXC72613,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 770 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 770 from patent US 10954289,2022-10-12,NaN,NaN
3733,NaN,NaN,NaN,QXC72603,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 749 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 749 from patent US 10954289,2022-10-12,NaN,NaN
3734,NaN,NaN,NaN,QXC72599,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 741 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 741 from patent US 10954289,2022-10-12,NaN,NaN
3735,NaN,NaN,NaN,QXC72595,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 733 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 733 from patent US 10954289,2022-10-12,NaN,NaN
3736,NaN,NaN,NaN,QXC72592,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 727 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 727 from patent US 10954289,2022-10-12,NaN,NaN
3737,NaN,NaN,NaN,QXC72588,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 719 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 719 from patent US 10954289,2022-10-12,NaN,NaN
3738,NaN,NaN,NaN,QXC72585,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 713 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 713 from patent US 10954289,2022-10-12,NaN,NaN
3739,NaN,NaN,NaN,QXC72576,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 694 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 694 from patent US 10954289,2022-10-12,NaN,NaN
3740,NaN,NaN,NaN,QXC72572,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 686 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 686 from patent US 10954289,2022-10-12,NaN,NaN
3741,NaN,NaN,NaN,QXC72567,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 676 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 676 from patent US 10954289,2022-10-12,NaN,NaN
3742,NaN,NaN,NaN,QXC72563,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 666 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 666 from patent US 10954289,2022-10-12,NaN,NaN
3743,NaN,NaN,NaN,QXC72558,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 656 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 656 from patent US 10954289,2022-10-12,NaN,NaN
3744,NaN,NaN,NaN,QXC72554,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 646 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 646 from patent US 10954289,2022-10-12,NaN,NaN
3745,NaN,NaN,NaN,QXC72550,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 638 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 638 from patent US 10954289,2022-10-12,NaN,NaN
3746,NaN,NaN,NaN,QXC72547,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 630 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 630 from patent US 10954289,2022-10-12,NaN,NaN
3747,NaN,NaN,NaN,QXC72543,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 622 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 622 from patent US 10954289,2022-10-12,NaN,NaN
3748,NaN,NaN,NaN,QXC72539,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 614 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 614 from patent US 10954289,2022-10-12,NaN,NaN
3749,NaN,NaN,NaN,QXC72535,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 606 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 606 from patent US 10954289,2022-10-12,NaN,NaN
3750,NaN,NaN,NaN,QXC72532,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 600 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 600 from patent US 10954289,2022-10-12,NaN,NaN
3751,NaN,NaN,NaN,QXC72527,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 590 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 590 from patent US 10954289,2022-10-12,NaN,NaN
3752,NaN,NaN,NaN,QXC72523,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 580 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 580 from patent US 10954289,2022-10-12,NaN,NaN
3753,NaN,NaN,NaN,QXC72515,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 564 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 564 from patent US 10954289,2022-10-12,NaN,NaN
3754,NaN,NaN,NaN,QXC72511,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 556 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 556 from patent US 10954289,2022-10-12,NaN,NaN
3755,NaN,NaN,NaN,QXC72502,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 538 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 538 from patent US 10954289,2022-10-12,NaN,NaN
3756,NaN,NaN,NaN,QXC72498,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 530 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 530 from patent US 10954289,2022-10-12,NaN,NaN
3757,NaN,NaN,NaN,QXC72495,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 522 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 522 from patent US 10954289,2022-10-12,NaN,NaN
3758,NaN,NaN,NaN,QXC72491,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 514 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 514 from patent US 10954289,2022-10-12,NaN,NaN
3759,NaN,NaN,NaN,QXC72488,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 508 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 508 from patent US 10954289,2022-10-12,NaN,NaN
3760,NaN,NaN,NaN,QXC72486,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 503 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 503 from patent US 10954289,2022-10-12,NaN,NaN
3761,NaN,NaN,NaN,QXC72481,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 493 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 493 from patent US 10954289,2022-10-12,NaN,NaN
3762,NaN,NaN,NaN,QXC72478,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 487 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 487 from patent US 10954289,2022-10-12,NaN,NaN
3763,NaN,NaN,NaN,QXC72474,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 478 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 478 from patent US 10954289,2022-10-12,NaN,NaN
3764,NaN,NaN,NaN,QXC72471,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 472 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 472 from patent US 10954289,2022-10-12,NaN,NaN
3765,NaN,NaN,NaN,QXC72468,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 466 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 466 from patent US 10954289,2022-10-12,NaN,NaN
3766,NaN,NaN,NaN,QXC72464,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 457 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 457 from patent US 10954289,2022-10-12,NaN,NaN
3767,NaN,NaN,NaN,QXC72460,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 449 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 449 from patent US 10954289,2022-10-12,NaN,NaN
3768,NaN,NaN,NaN,QXC72456,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 440 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 440 from patent US 10954289,2022-10-12,NaN,NaN
3769,NaN,NaN,NaN,QXC72447,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 422 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 422 from patent US 10954289,2022-10-12,NaN,NaN
3770,NaN,NaN,NaN,QXC72444,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 416 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 416 from patent US 10954289,2022-10-12,NaN,NaN
3771,NaN,NaN,NaN,QXC72440,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 407 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 407 from patent US 10954289,2022-10-12,NaN,NaN
3772,NaN,NaN,NaN,QXC72437,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 401 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 401 from patent US 10954289,2022-10-12,NaN,NaN
3773,NaN,NaN,NaN,QXC72434,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 394 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 394 from patent US 10954289,2022-10-12,NaN,NaN
3774,NaN,NaN,NaN,QXC72431,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 387 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 387 from patent US 10954289,2022-10-12,NaN,NaN
3775,NaN,NaN,NaN,QXC72427,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 379 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 379 from patent US 10954289,2022-10-12,NaN,NaN
3776,NaN,NaN,NaN,QXC72424,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 372 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 372 from patent US 10954289,2022-10-12,NaN,NaN
3777,NaN,NaN,NaN,QXC72411,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 344 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 344 from patent US 10954289,2022-10-12,NaN,NaN
3778,NaN,NaN,NaN,QXC72408,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 338 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 338 from patent US 10954289,2022-10-12,NaN,NaN
3779,NaN,NaN,NaN,QXC72405,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 331 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 331 from patent US 10954289,2022-10-12,NaN,NaN
3780,NaN,NaN,NaN,QXC72401,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 323 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 323 from patent US 10954289,2022-10-12,NaN,NaN
3781,NaN,NaN,NaN,QXC72397,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 314 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 314 from patent US 10954289,2022-10-12,NaN,NaN
3782,NaN,NaN,NaN,QXC72393,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 306 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 306 from patent US 10954289,2022-10-12,NaN,NaN
3783,NaN,NaN,NaN,QXC72390,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 300 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 300 from patent US 10954289,2022-10-12,NaN,NaN
3784,NaN,NaN,NaN,QXC72386,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 290 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 290 from patent US 10954289,2022-10-12,NaN,NaN
3785,NaN,NaN,NaN,QXC72382,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 282 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 282 from patent US 10954289,2022-10-12,NaN,NaN
3786,NaN,NaN,NaN,QXC72379,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 276 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 276 from patent US 10954289,2022-10-12,NaN,NaN
3787,NaN,NaN,NaN,QXC72374,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 266 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 266 from patent US 10954289,2022-10-12,NaN,NaN
3788,NaN,NaN,NaN,QXC72371,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 260 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 260 from patent US 10954289,2022-10-12,NaN,NaN
3789,NaN,NaN,NaN,QXC72366,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 250 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 250 from patent US 10954289,2022-10-12,NaN,NaN
3790,NaN,NaN,NaN,QXC72362,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 242 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 242 from patent US 10954289,2022-10-12,NaN,NaN
3791,NaN,NaN,NaN,QXC72359,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 236 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 236 from patent US 10954289,2022-10-12,NaN,NaN
3792,NaN,NaN,NaN,QXC72355,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 228 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 228 from patent US 10954289,2022-10-12,NaN,NaN
3793,NaN,NaN,NaN,QXC72350,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 218 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 218 from patent US 10954289,2022-10-12,NaN,NaN
3794,NaN,NaN,NaN,QXC72346,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 210 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 210 from patent US 10954289,2022-10-12,NaN,NaN
3795,NaN,NaN,NaN,QXC72341,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 200 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 200 from patent US 10954289,2022-10-12,NaN,NaN
3796,NaN,NaN,NaN,QXC72338,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 191 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 191 from patent US 10954289,2022-10-12,NaN,NaN
3797,NaN,NaN,NaN,QXC72333,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 181 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 181 from patent US 10954289,2022-10-12,NaN,NaN
3798,NaN,NaN,NaN,QXC72330,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 175 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 175 from patent US 10954289,2022-10-12,NaN,NaN
3799,NaN,NaN,NaN,QXC72320,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 155 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 155 from patent US 10954289,2022-10-12,NaN,NaN
3800,NaN,NaN,NaN,QXC72316,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 145 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 145 from patent US 10954289,2022-10-12,NaN,NaN
3801,NaN,NaN,NaN,QXC72311,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 135 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 135 from patent US 10954289,2022-10-12,NaN,NaN
3802,NaN,NaN,NaN,QXC72307,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 127 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 127 from patent US 10954289,2022-10-12,NaN,NaN
3803,NaN,NaN,NaN,QXC72302,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 117 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 117 from patent US 10954289,2022-10-12,NaN,NaN
3804,NaN,NaN,NaN,QXC72298,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 107 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 107 from patent US 10954289,2022-10-12,NaN,NaN
3805,NaN,NaN,NaN,QXC72293,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 97 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 97 from patent US 10954289,2022-10-12,NaN,NaN
3806,NaN,NaN,NaN,QXC72289,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 89 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 89 from patent US 10954289,2022-10-12,NaN,NaN
3807,NaN,NaN,NaN,QXC72285,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 81 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 81 from patent US 10954289,2022-10-12,NaN,NaN
3808,NaN,NaN,NaN,QXC72281,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 73 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 73 from patent US 10954289,2022-10-12,NaN,NaN
3809,NaN,NaN,NaN,QXC72275,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 61 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 61 from patent US 10954289,2022-10-12,NaN,NaN
3810,NaN,NaN,NaN,QXC72271,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 51 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 51 from patent US 10954289,2022-10-12,NaN,NaN
3811,NaN,NaN,NaN,QXC72266,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 40 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 40 from patent US 10954289,2022-10-12,NaN,NaN
3812,NaN,NaN,NaN,QXC72262,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 30 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 30 from patent US 10954289,2022-10-12,NaN,NaN
3813,NaN,NaN,NaN,QXC72257,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 20 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 20 from patent US 10954289,2022-10-12,NaN,NaN
3814,NaN,NaN,NaN,QXC72253,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 10 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 10 from patent US 10954289,2022-10-12,NaN,NaN
3815,NaN,NaN,NaN,QPY34285,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 826 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 826 from patent US 10787501,2022-10-12,NaN,NaN
3816,NaN,NaN,NaN,QPY34282,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 818 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 818 from patent US 10787501,2022-10-12,NaN,NaN
3817,NaN,NaN,NaN,QPY34276,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 806 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 806 from patent US 10787501,2022-10-12,NaN,NaN
3818,NaN,NaN,NaN,QPY34273,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 800 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 800 from patent US 10787501,2022-10-12,NaN,NaN
3819,NaN,NaN,NaN,QPY34269,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 792 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 792 from patent US 10787501,2022-10-12,NaN,NaN
3820,NaN,NaN,NaN,QPY34266,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 786 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 786 from patent US 10787501,2022-10-12,NaN,NaN
3821,NaN,NaN,NaN,QPY34261,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 776 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 776 from patent US 10787501,2022-10-12,NaN,NaN
3822,NaN,NaN,NaN,QPY34258,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 770 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 770 from patent US 10787501,2022-10-12,NaN,NaN
3823,NaN,NaN,NaN,QPY34248,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 749 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 749 from patent US 10787501,2022-10-12,NaN,NaN
3824,NaN,NaN,NaN,QPY34244,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 741 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 741 from patent US 10787501,2022-10-12,NaN,NaN
3825,NaN,NaN,NaN,QPY34240,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 733 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 733 from patent US 10787501,2022-10-12,NaN,NaN
3826,NaN,NaN,NaN,QPY34237,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 727 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 727 from patent US 10787501,2022-10-12,NaN,NaN
3827,NaN,NaN,NaN,QPY34233,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 719 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 719 from patent US 10787501,2022-10-12,NaN,NaN
3828,NaN,NaN,NaN,QPY34230,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 713 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 713 from patent US 10787501,2022-10-12,NaN,NaN
3829,NaN,NaN,NaN,QPY34221,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 694 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 694 from patent US 10787501,2022-10-12,NaN,NaN
3830,NaN,NaN,NaN,QPY34217,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 686 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 686 from patent US 10787501,2022-10-12,NaN,NaN
3831,NaN,NaN,NaN,QPY34212,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 676 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 676 from patent US 10787501,2022-10-12,NaN,NaN
3832,NaN,NaN,NaN,QPY34208,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 666 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 666 from patent US 10787501,2022-10-12,NaN,NaN
3833,NaN,NaN,NaN,QPY34203,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 656 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 656 from patent US 10787501,2022-10-12,NaN,NaN
3834,NaN,NaN,NaN,QPY34199,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 646 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 646 from patent US 10787501,2022-10-12,NaN,NaN
3835,NaN,NaN,NaN,QPY34195,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 638 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 638 from patent US 10787501,2022-10-12,NaN,NaN
3836,NaN,NaN,NaN,QPY34192,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 630 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 630 from patent US 10787501,2022-10-12,NaN,NaN
3837,NaN,NaN,NaN,QPY34188,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 622 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 622 from patent US 10787501,2022-10-12,NaN,NaN
3838,NaN,NaN,NaN,QPY34184,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 614 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 614 from patent US 10787501,2022-10-12,NaN,NaN
3839,NaN,NaN,NaN,QPY34180,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 606 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 606 from patent US 10787501,2022-10-12,NaN,NaN
3840,NaN,NaN,NaN,QPY34177,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 600 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 600 from patent US 10787501,2022-10-12,NaN,NaN
3841,NaN,NaN,NaN,QPY34172,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 590 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 590 from patent US 10787501,2022-10-12,NaN,NaN
3842,NaN,NaN,NaN,QPY34168,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 580 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 580 from patent US 10787501,2022-10-12,NaN,NaN
3843,NaN,NaN,NaN,QPY34160,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 564 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 564 from patent US 10787501,2022-10-12,NaN,NaN
3844,NaN,NaN,NaN,QPY34156,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 556 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 556 from patent US 10787501,2022-10-12,NaN,NaN
3845,NaN,NaN,NaN,QPY34147,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 538 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 538 from patent US 10787501,2022-10-12,NaN,NaN
3846,NaN,NaN,NaN,QPY34143,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 530 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 530 from patent US 10787501,2022-10-12,NaN,NaN
3847,NaN,NaN,NaN,QPY34140,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 522 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 522 from patent US 10787501,2022-10-12,NaN,NaN
3848,NaN,NaN,NaN,QPY34136,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 514 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 514 from patent US 10787501,2022-10-12,NaN,NaN
3849,NaN,NaN,NaN,QPY34133,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 508 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 508 from patent US 10787501,2022-10-12,NaN,NaN
3850,NaN,NaN,NaN,QPY34131,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 503 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 503 from patent US 10787501,2022-10-12,NaN,NaN
3851,NaN,NaN,NaN,QPY34126,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 493 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 493 from patent US 10787501,2022-10-12,NaN,NaN
3852,NaN,NaN,NaN,QPY34123,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 487 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 487 from patent US 10787501,2022-10-12,NaN,NaN
3853,NaN,NaN,NaN,QPY34119,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 478 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 478 from patent US 10787501,2022-10-12,NaN,NaN
3854,NaN,NaN,NaN,QPY34116,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 472 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 472 from patent US 10787501,2022-10-12,NaN,NaN
3855,NaN,NaN,NaN,QPY34113,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 466 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 466 from patent US 10787501,2022-10-12,NaN,NaN
3856,NaN,NaN,NaN,QPY34109,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 457 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 457 from patent US 10787501,2022-10-12,NaN,NaN
3857,NaN,NaN,NaN,QPY34105,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 449 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 449 from patent US 10787501,2022-10-12,NaN,NaN
3858,NaN,NaN,NaN,QPY34101,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 440 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 440 from patent US 10787501,2022-10-12,NaN,NaN
3859,NaN,NaN,NaN,QPY34092,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 422 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 422 from patent US 10787501,2022-10-12,NaN,NaN
3860,NaN,NaN,NaN,QPY34089,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 416 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 416 from patent US 10787501,2022-10-12,NaN,NaN
3861,NaN,NaN,NaN,QPY34085,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 407 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 407 from patent US 10787501,2022-10-12,NaN,NaN
3862,NaN,NaN,NaN,QPY34082,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 401 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 401 from patent US 10787501,2022-10-12,NaN,NaN
3863,NaN,NaN,NaN,QPY34079,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 394 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 394 from patent US 10787501,2022-10-12,NaN,NaN
3864,NaN,NaN,NaN,QPY34076,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 387 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 387 from patent US 10787501,2022-10-12,NaN,NaN
3865,NaN,NaN,NaN,QPY34072,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 379 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 379 from patent US 10787501,2022-10-12,NaN,NaN
3866,NaN,NaN,NaN,QPY34069,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 372 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 372 from patent US 10787501,2022-10-12,NaN,NaN
3867,NaN,NaN,NaN,QPY34056,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 344 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 344 from patent US 10787501,2022-10-12,NaN,NaN
3868,NaN,NaN,NaN,QPY34053,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 338 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 338 from patent US 10787501,2022-10-12,NaN,NaN
3869,NaN,NaN,NaN,QPY34050,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 331 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 331 from patent US 10787501,2022-10-12,NaN,NaN
3870,NaN,NaN,NaN,QPY34046,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 323 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 323 from patent US 10787501,2022-10-12,NaN,NaN
3871,NaN,NaN,NaN,QPY34042,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 314 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 314 from patent US 10787501,2022-10-12,NaN,NaN
3872,NaN,NaN,NaN,QPY34038,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 306 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 306 from patent US 10787501,2022-10-12,NaN,NaN
3873,NaN,NaN,NaN,QPY34035,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 300 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 300 from patent US 10787501,2022-10-12,NaN,NaN
3874,NaN,NaN,NaN,QPY34031,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 290 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 290 from patent US 10787501,2022-10-12,NaN,NaN
3875,NaN,NaN,NaN,QPY34027,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 282 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 282 from patent US 10787501,2022-10-12,NaN,NaN
3876,NaN,NaN,NaN,QPY34024,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 276 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 276 from patent US 10787501,2022-10-12,NaN,NaN
3877,NaN,NaN,NaN,QPY34019,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 266 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 266 from patent US 10787501,2022-10-12,NaN,NaN
3878,NaN,NaN,NaN,QPY34016,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 260 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 260 from patent US 10787501,2022-10-12,NaN,NaN
3879,NaN,NaN,NaN,QPY34011,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 250 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 250 from patent US 10787501,2022-10-12,NaN,NaN
3880,NaN,NaN,NaN,QPY34007,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 242 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 242 from patent US 10787501,2022-10-12,NaN,NaN
3881,NaN,NaN,NaN,QPY34004,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 236 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 236 from patent US 10787501,2022-10-12,NaN,NaN
3882,NaN,NaN,NaN,QPY34000,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 228 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 228 from patent US 10787501,2022-10-12,NaN,NaN
3883,NaN,NaN,NaN,QPY33995,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 218 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 218 from patent US 10787501,2022-10-12,NaN,NaN
3884,NaN,NaN,NaN,QPY33991,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 210 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 210 from patent US 10787501,2022-10-12,NaN,NaN
3885,NaN,NaN,NaN,QPY33986,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 200 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 200 from patent US 10787501,2022-10-12,NaN,NaN
3886,NaN,NaN,NaN,QPY33983,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 191 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 191 from patent US 10787501,2022-10-12,NaN,NaN
3887,NaN,NaN,NaN,QPY33978,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 181 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 181 from patent US 10787501,2022-10-12,NaN,NaN
3888,NaN,NaN,NaN,QPY33975,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 175 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 175 from patent US 10787501,2022-10-12,NaN,NaN
3889,NaN,NaN,NaN,QPY33965,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 155 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 155 from patent US 10787501,2022-10-12,NaN,NaN
3890,NaN,NaN,NaN,QPY33961,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 145 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 145 from patent US 10787501,2022-10-12,NaN,NaN
3891,NaN,NaN,NaN,QPY33956,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 135 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 135 from patent US 10787501,2022-10-12,NaN,NaN
3892,NaN,NaN,NaN,QPY33952,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 127 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 127 from patent US 10787501,2022-10-12,NaN,NaN
3893,NaN,NaN,NaN,QPY33947,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 117 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 117 from patent US 10787501,2022-10-12,NaN,NaN
3894,NaN,NaN,NaN,QPY33943,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 107 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 107 from patent US 10787501,2022-10-12,NaN,NaN
3895,NaN,NaN,NaN,QPY33938,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 97 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 97 from patent US 10787501,2022-10-12,NaN,NaN
3896,NaN,NaN,NaN,QPY33934,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 89 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 89 from patent US 10787501,2022-10-12,NaN,NaN
3897,NaN,NaN,NaN,QPY33930,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 81 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 81 from patent US 10787501,2022-10-12,NaN,NaN
3898,NaN,NaN,NaN,QPY33926,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 73 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 73 from patent US 10787501,2022-10-12,NaN,NaN
3899,NaN,NaN,NaN,QPY33920,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 61 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 61 from patent US 10787501,2022-10-12,NaN,NaN
3900,NaN,NaN,NaN,QPY33916,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 51 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 51 from patent US 10787501,2022-10-12,NaN,NaN
3901,NaN,NaN,NaN,QPY33911,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 40 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 40 from patent US 10787501,2022-10-12,NaN,NaN
3902,NaN,NaN,NaN,QPY33907,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 30 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 30 from patent US 10787501,2022-10-12,NaN,NaN
3903,NaN,NaN,NaN,QPY33902,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 20 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 20 from patent US 10787501,2022-10-12,NaN,NaN
3904,NaN,NaN,NaN,QPY33898,"['COVID', 'SARS-COV-2', 'Spike protein']",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 10 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 10 from patent US 10787501,2022-10-12,NaN,NaN
3905,NaN,NaN,QUX33762,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvassgnrreidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3906,NaN,NaN,QUX33761,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqdntamsyyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3907,NaN,NaN,QUX33760,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrtgtteyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3908,NaN,NaN,QUX33759,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrtgtteyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3909,NaN,NaN,QUX33758,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),ecrllesggglvqpggslrlscaasgftfsiypmtwvrqapgkglewvsaitagggstyytdsvkgrftisrdnskntlylqmnslraedtaiyycakngdcdstscppdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3910,NaN,NaN,QUX33757,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),eaqllesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardivvatartagdyyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3911,NaN,NaN,QUX33756,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qcrlvesggglvkpggslrlscaasgftfsdfymswirqapgkglewisyisrsggtiyyadsvkgrftisrdnaknslylqmnslraedtavyycargvsgydygsrfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3912,NaN,NaN,QUX33755,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqexgpglvkpsqtlsltctvxggsissgdxywswxrqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslkxssvtaadtavyycarvdcggdcypdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3913,NaN,NaN,QUX33754,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggdlvkpggslrlscaasgfrfsntwmnwvrqapgrglewvgriktlgeggitdyaapvkgrftisrddskqtlylqmnslkiedtavyycttdlptafdsyygmaawgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3914,NaN,NaN,QUX33753,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvkpggslrlscaasgftftnarmtwvrqapgkglewvgriktktqggtidygapvrgrftisrddlkntldlqmnslktedtavyycaaiddgldhwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3915,NaN,NaN,QUX33752,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdfyanyspsfqghvtisadksistaylqwsslkasdtamyycarqtgycsstscyaggpfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3916,NaN,NaN,QUX33751,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgsglvkpsqtlsltcavsggsissggyswswirqppgkglewigyiyhsgstyynpslksrvtisvdrsknqfslklssvtaadtavyycarspydssgaidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3917,NaN,NaN,QUX33750,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarhtdcsggscylggafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3918,NaN,NaN,QUX33749,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyyccffdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3919,NaN,NaN,QUX33748,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsvisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgggetyvryyfdfwgqgglvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3920,NaN,NaN,QUX33747,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdmtpyydilteaygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3921,NaN,NaN,QUX33746,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftftnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylemnslktedtavyycttrrycsstrcylgewsyfdcwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3922,NaN,NaN,QUX33745,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycasgwylswfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3923,NaN,NaN,QUX33744,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvsdyglfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3924,NaN,NaN,QUX33743,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgpyydssgyfdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3925,NaN,NaN,QUX33742,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarggdlfgellgatgyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3926,NaN,NaN,QUX33741,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycatcsggschpyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3927,NaN,NaN,QUX33740,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardfsrggydspsgyyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3928,NaN,NaN,QUX33739,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvefggglvqpgrslrlscaafgftfddyamhwvrqapgkglewvsgiswnsgsigyadfvkgrftisrdnaknslylqmnslraedtalyycaksriaaavfyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3929,NaN,NaN,QUX33738,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssytmnwvrqapgkglewvsyitsdsstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarnkamddywgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3930,NaN,NaN,QUX33737,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscavsgftfssswmfwvrqapgkglvwvsrisadgytatyaesvegrftisrdnakntlylqmnslraedtalyycarglthdywgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3931,NaN,NaN,QUX33736,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardldivvvpaadlnyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3932,NaN,NaN,QUX33735,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdlgrfrayyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3933,NaN,NaN,QUX33734,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdlgrfrayyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3934,NaN,NaN,QUX33733,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaktmmgyyyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3935,NaN,NaN,QUX33732,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyalswvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarangdydlpyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3936,NaN,NaN,QUX33731,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycatdadniatgfwsgyyseyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3937,NaN,NaN,QUX33730,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycareardpfyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3938,NaN,NaN,QUX33729,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsshwmhwvrqapgkglvwvsriigdgseityadsvkgrftisrdnvkntlyleinslraedtavyyclrghvsgstrhfdywgqgtlltvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3939,NaN,NaN,QUX33728,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssssytnyadsvkgrftisrdnaknslylqmnslraedtavyycardlfpeyssswyrplyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3940,NaN,NaN,QUX33727,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdrssswhyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3941,NaN,NaN,QTI96706,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssytiyyadsvkgrftisrdnaknslylqmnslrdedtavyycardpsdssswypiywyfdlwgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3942,NaN,NaN,QTI96705,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarspyydfwsgyhyyfdywgqgtlvavss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3943,NaN,NaN,QTI96704,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyysgstkynpslnrrvtmsvdtsknqfslklnsvtaadtavyycaryivptspppyyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3944,NaN,NaN,QTI96703,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyysgstkynpslnrrvtmsvdtsknqfslklnsvtaadtavyycaryivptspppyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3945,NaN,NaN,QTI96702,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaralssyydfwsaplswdrdnyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3946,NaN,NaN,QTI96701,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctasggsiasnsyywgwirqspgkgldwigsiyysgitysnsslksrvtisvdtsknqfslklssvtaadtavyhcaryssgwahddgfdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3947,NaN,NaN,QTI96700,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevrkpgasvkvsckasgytfsnyaiiwvrqapgqglewmgwisayngktdyseklqdrvtmttdtstntaymelknlrsddtavyycardmffrewfgelihyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3948,NaN,NaN,QTI96699,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsinngdyywswirqhpgkglewigyiyysgntyynpslksrvtisldtsknqfslklssvtaadtalyycargplgyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3949,NaN,NaN,QTI96698,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnyaihwvrqapgkglewvafisydgsikyytdsvkgrftisrdsskntlflqmnnlrpedtavyyctrgavagnnafdvwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3950,NaN,NaN,QTI96697,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckisgyrltelsihwvrqapakglewmggfdpddgetmysqrfqgrvtmtedtstdtaymelrnlnsedtaiyyctagfmaqgliitsifdfwgqgtqvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3951,NaN,NaN,QTI96696,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgaevkkpgasvkvsckisgyrltelsihwvrqapakglewmggfdpddgetmysqrfqgrvtmtedtstdtaymelrnlnsedtaiyycttgfmaqgliitsifdfwgqgtqvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3952,NaN,NaN,QTI96695,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyidnsgstyynpslksrvtisvdtsknqfslnlrsvtaadaavyycarerdlaaagidswgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3953,NaN,NaN,QTI96694,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltctvsggsvnsdsyywswirqppgkglewigyiyysgstncnpslksrltisadtsknqfslklnsvtaadtavyycarveapeggsdywgqgtlvtvsp,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3954,NaN,NaN,QTI96693,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsdtlsltctvsggsissssyywgwirqppgkglewigsisysgstyynpslksrvtisgdtsknqlslklssvtaadtavyycarhtyyydssgylalapdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3955,NaN,NaN,QTI96692,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarsreskdwsygggfyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3956,NaN,NaN,QTI96691,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggnlvqpggslrlscvvsgftfssysmnwvrqapgkglewvsvisgsgdttyyadsvkgrftisrdnskntlylqmnslraedtaiyycakdcdyeiltgyhsncfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3957,NaN,NaN,QTI96690,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsrggsyhdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3958,NaN,NaN,QTI96689,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsfggnyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3959,NaN,NaN,QTI96688,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcivsggsissssyywgwirqppgkglewigiiyfsgspyynpslksrvtisvdtsknqfslrlssvtaadtalyycarhnyltryyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3960,NaN,NaN,QTI96687,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfdnyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdwggvyygsgtyytnwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3961,NaN,NaN,QTI96686,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsggsissstyywgwirqppgkglewigslyysgstyynpslksrvsisvdtsknqfslklssvtaadtavyycatlyyvwgsyrglegnfdnwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3962,NaN,NaN,QTI96685,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpgvllwfgellspwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3963,NaN,NaN,QTI96684,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarawgsyysafdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3964,NaN,NaN,QTI96683,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvgvyydfwsgyyggdnggfwldywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3965,NaN,NaN,QTI96682,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckisgytlielsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtgymelsslrsedtavyycvtgppysgsywfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3966,NaN,NaN,QTI96681,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlqesgpglvkpsqtlsltctvsgdsisrgsyywswirqpagkglewigriytsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycaregsfwywfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3967,NaN,NaN,QTI96680,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardysycsstscytsifdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3968,NaN,NaN,QTI96679,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsayywswirqspgkglewigeinhsgstnyspslksrvtisldtsknqlslkvtsvtaadtgvyfcardsrtsgwhkiyyyyamdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3969,NaN,NaN,QTI96678,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltcavsgasisssgyywgwirqppgkglewignifyigsthynpslksrvtisldtsknqlslklrsvtaadtavyycarptndyggfyfdywgqgilvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3970,NaN,NaN,QTI96677,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaaafsnyeyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3971,NaN,NaN,QTI96676,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardskeyyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3972,NaN,NaN,QTI96675,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvkpggslrlscvvsgftfsnysmnwvrqapgkglewvssissvssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvlrryydfwsgyypdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3973,NaN,NaN,QTI96674,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyfsgatkynpslnrrvtmsvdtsknqfslklqsvtaadtavyycaryivptspppyyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3974,NaN,NaN,QTI96673,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsisssdyywgwirqppgkglewigsmyysgstyynpslnsrvtisvdtsknqfslnlnsvtaadtavyycarargycsivgcytslyyfdylgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3975,NaN,NaN,QTI96672,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrfaisrdnaknslylqmnslraedtalyycardivpyssswlyyygmdvwgqgttvsvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3976,NaN,NaN,QTI96671,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisnyywswirqppgkglewigyifysgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycardrgyssgwpdafdmwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3977,NaN,NaN,QTI96670,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisssywswirqtpgkglewigyidysgstnynpslksritmsvdtsknqfslklssvtaadtavyycarspnfdwllntggyygldvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3978,NaN,NaN,QTI96669,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrsvrlscaasgftfsscamywvrqapgkglewvavisydvinkyyedsvkgrftisrdnskntlylqmnslraedtavyycasqppairafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3979,NaN,NaN,QTI96668,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgggvvqpgrslrlscassgftfstyamhwvrqapgkglewvafisydgskkyyadslkgrftisrdnskntlylqtnslraedtavyycakvrrwlqfpetdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3980,NaN,NaN,QTI96667,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvrvsckasggpfsnyaifwvrqapgqglewmggiipvfgttnyaqkfqgrvtitadeststaymemsslrsedtavfycaglvastpwpdfwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3981,NaN,NaN,QTI96666,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglelvsyisssgsiiyyadsvkgrftisrdnaknslslqmnslraedtavyycardaniwfgelrglstgymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3982,NaN,NaN,QTI96665,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycardshiyrhdswetaitifgvviidafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3983,NaN,NaN,QTI96664,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakrenrllwfgelllghdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3984,NaN,NaN,QTI96663,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrsltlscaasgftfssygvhwvrqapgkglewvslisyegsitqyadpvrgrftisrdnskntlylqmnslktedtavyycargavagndafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3985,NaN,NaN,QTI96662,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisgnsgntkyaqkvqgrvtmttdtststaymelrslrsddtamyycardiiellwfgdyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3986,NaN,NaN,QTI96661,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaakmglwfgelwwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3987,NaN,NaN,QTI96660,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadrsintaflqwsslkasdtamyycarqrfsgslyfyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3988,NaN,NaN,QSI99137,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3989,NaN,NaN,QSI99136,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaslqwsslkasdtamyycarqkrdgttwafdywgqgtlvtass,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3990,NaN,NaN,QSI99135,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglewigyiyysgstnykyslksrvtisvdtsknqfslklssvtaadtavyycarekggtewefndafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3991,NaN,NaN,QSI99134,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvstnymswvrqapgkglewvsviysggstyyvdsvkgrftisrdnskntlylqmnslraedtavyycastnsgsyshvfdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3992,NaN,NaN,QSI99133,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglgqpggslrlscaasgftfsnyamswvrqapgkglewvsvisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakagavgyydsngyyydvdyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3993,NaN,NaN,QSI99132,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrltitaddststaymelsslksedtavyycarfraydssgygpdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3994,NaN,NaN,QSI99131,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslklscaasgftfnsyamtwvrqapgkglewlstisgsggrtyyadsvkgrfaisrdnskntvflqmstlraedtavyfcardfyglesfypgidswgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3995,NaN,NaN,QSI99130,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhiaglewlfraaavlnwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3996,NaN,NaN,QSI99129,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycagtyydfwsgstnyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3997,NaN,NaN,QSI99128,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctrvhhcsggscygyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3998,NaN,NaN,QSI99127,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqpagkglewigriytsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycaredsygsgstgafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
3999,NaN,NaN,QSI99126,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlsgifgvviipgffdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4000,NaN,NaN,QSI99125,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardptavtgpfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4001,NaN,NaN,QSI99124,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvprppwddfwsgylyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4002,NaN,NaN,QSI99123,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpseslslaffvyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargggysygaidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4003,NaN,NaN,QSI99122,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgynfisygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4004,NaN,NaN,QSI99121,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgptvttvtnwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4005,NaN,NaN,QSI99120,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilditnyaqkfqgrvtitadkststaymelsslrsedtavyycarglwrssiaglhvpygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4006,NaN,NaN,QSI99119,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgynfisygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4007,NaN,NaN,QSI99118,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgnslrlscvasgfkfsssamhwvrqapgkglewvaiiwfhgntkfygdfvkgrftvsrdnsnntlhlqmnslraedtavyhcarassdyggafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4008,NaN,NaN,QSI99117,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraltgnyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4009,NaN,NaN,QSI99116,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggiipifgtanyaqnfqgrvtitadeststaymelsslrsedtavyycarvsyydssgyytdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4010,NaN,NaN,QSI99115,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtftsyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgyyqdlwgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4011,NaN,NaN,QSI99114,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydginkyyadsvkgrftisrdsskntlylqmnslraedtavyycarggvgyqllfgndwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4012,NaN,NaN,QSI99113,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraedtavyycakdptifgvvlqiprfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4013,NaN,NaN,QSI99112,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpelvkpsetlsltcsvsggsissyywswirqppgkglewigyiyysgstnynpslsgstnynpslksrvtvsvdtsknqfslkvssvtaadtavyycargfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4014,NaN,NaN,QSI99111,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigniyysgityynpslksrvtisvdtsknqfslklssvtaadtavyycarqlwgyydssgyyafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4015,NaN,NaN,QSI99110,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggtfsnyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtftadeststaymelsslrsedtavfycvsriaaaadfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4016,NaN,NaN,QSI99109,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrlydyvwgsyrfghtwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4017,NaN,NaN,QSI99108,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntldlqmnslraedtavyycarayggnyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4018,NaN,NaN,QSI99107,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfisygiswvrqapgqglewmgwisgyngntnyaqkfqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4019,NaN,NaN,QSI99106,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaraysydssgyspdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4020,NaN,NaN,QSI99105,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardrrgsgwswdyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4021,NaN,NaN,QSI99104,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtstnqfslklssvtaadtavyycarrvhydiltgfyggalitrafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4022,NaN,NaN,QSI99103,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyissrssytnyadsvkgrftisrdnaknslylqmnslraedtavyycargydssgyhyslwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4023,NaN,NaN,QSI99102,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvsgissnggstyyadsvkgritisrdnskktlylqmsslraedtavyycvksssrgyywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4024,NaN,NaN,QSI99101,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasarfitmvrgviniyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4025,NaN,NaN,QSI99100,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvscrasgytftnfgiswvrqapglglewmgwistyngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarasgpyllglywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4026,NaN,NaN,QSI99099,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycatnsnypywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4027,NaN,NaN,QSI99098,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsncwmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarmgntawyfdlwgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4028,NaN,NaN,QSI99097,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasrftfstyamhwvrqapgkglewvtvisydgdnkyyadsvkgrftisrdnskntlylqmnslrtedtavyyctragsgsylsyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4029,NaN,NaN,QSI99096,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarissydssgysmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4030,NaN,NaN,QSI99095,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctmvwqqlhdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4031,NaN,NaN,QSI99094,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadestntaymelssltsedtavyycakigdydssgyyfdywaqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4032,NaN,NaN,QSI99093,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarayggsyfygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4033,NaN,NaN,QSI99092,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsvssnayywgwirqppgkglewigsvnyrgstyyiptlksritisvntsknqfslkltsvtaadtavyycarrgvalvtityfdfwgqgalvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4034,NaN,NaN,QSI99091,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglefigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycatqevvlvrpynyngmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4035,NaN,NaN,QSI99090,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaaagfifssyamnwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlnlqmnslraedtavyycargngyiiidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4036,NaN,NaN,QSI99089,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgkidpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarqfggellgwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4037,NaN,NaN,QSI99088,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisstsnyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvspnydfwsgyypdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4038,NaN,NaN,QSI99087,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnsfamhwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsggyscfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4039,NaN,NaN,QSI99086,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtalyycaseivsfigssedywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4040,NaN,NaN,QSI99085,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckafgytftknginwvrqapgqglewmgwispnngytnfaqkfqgratmtsdtststaymelrslrsddtavyycarvrvdydssgydayyyhldvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4041,NaN,NaN,QSI99084,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmardtsistaymelsrlrsddtavyycardqvspycggdcpdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4042,NaN,NaN,QSI99083,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydginkyyadsvkgrftisrdnskntlylqmnslrvedtavyycarpgggsyygpfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4043,NaN,NaN,QSI99082,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgyyqdlwgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4044,NaN,NaN,QSI99081,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvstistnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvlgycsstscqhfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4045,NaN,NaN,QSI99080,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssfafiwvrqapgqglewmggiipifgtakytqkfqgrvtitadeststaymelsslrsedtavyycarvsyydssgfytdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4046,NaN,NaN,QSI99079,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggifssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasysgfddyghyrnywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4047,NaN,NaN,QSI99078,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssfalhwvrqapgkglewvavvsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaayycarsmggnyadyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4048,NaN,NaN,QSI99077,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylemnslraedtavyycastsdsgsyyihwyfdlwgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4049,NaN,NaN,QSI99076,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygihwvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylhmnslraedtavyycarpnsgsyhsyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4050,NaN,NaN,QSI99075,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssrsyiyyadsvkgrftisrdnaknslylqmnslraedtavyycasnpaadpntyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4051,NaN,NaN,QSI99074,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsissstwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycarsasnyfgyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4052,NaN,NaN,QSI99073,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymtwvrqapgkglewvsiiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaagyydsinwgqgtlvtvps,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4053,NaN,NaN,QSI99072,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscgasgfifssyamhwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpysgtyfsafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4054,NaN,NaN,QSI99071,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgnsftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhrnydiltgyryyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4055,NaN,NaN,QSI99070,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsiyaihwvrqapgkglewvavisydginkyyadavkgrftisrdnskntlflqmnslrtedtavyycaramggnyfhafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4056,NaN,NaN,QSI99069,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnnaqkfqgrvtltadestsaaymelsslrsedtavyycariepyastgytfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4057,NaN,NaN,QSI99068,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycvrvalydssgyspdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4058,NaN,NaN,QSI99067,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissstyywgwirqppgkglewigniyytgstyynpslksrvtisvdtsknhfslrlssvtaadtavyycarhnrfwsedtpfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4059,NaN,NaN,QSI99066,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglaqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggntyyadslkgrftisrdnskstlylqmnslraedtavyycakgpmwqwlvrlslvgdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4060,NaN,NaN,QSI99065,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycarpysgsyyayfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4061,NaN,NaN,QSI99036,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssdnyywswirqppgkglewigyiyysgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycargfvatyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4062,NaN,NaN,QSI99035,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfsvssnymnwvrqaprkglewvsviysggstyyadsvkgrftisrdnskntlylqmntlraedtavyycargygdsqrwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4063,NaN,NaN,QSI99034,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpgqvkpsetlsltctvsgysissgyfwgwvrqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycardhgsydfwsgysrdafdiwgqgtmvtfss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4064,NaN,NaN,QSI99033,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvscktsgyiftdyfmhwvrqapgqglewmgwinpnsgganyaqkfqgrvtmtrdtsittvymelsrlriddtamyycareaslnrsryyssggtvyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4065,NaN,NaN,QSI99032,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarvglsswyfeywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4066,NaN,NaN,QSI99031,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsirsyshywgwirqppgkglewigtiyysgstyynpslksritisvdtsksqfslklssvtaadtavyfcastiptyddiltgyqfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4067,NaN,NaN,QSI99030,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyaiywvrqapgkglewvavisydgsnkyyadsvrgrftisrdnskntlylqmnslraedtavyycarggggyntffdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4068,NaN,NaN,QSI99029,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyfcakdgavatgpgyfyfymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4069,NaN,NaN,QSI99028,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgfpfrnyamhwvrqapgkglehisvissrgdttyyansvkgrftisrdnsqntlylqmdslraddmavyycarvqsgfsygygfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4070,NaN,NaN,QSI99027,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisadtsknqfslklssvtaadtavyycarapgatyssgwyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4071,NaN,NaN,QSI99026,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgytftrywigwvrqmpgkglewmgiiypgdsdtryspsfqghvtisadksistaylqwnslkasdtamyycarlpqycsngvcqrwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4072,NaN,NaN,QSI99025,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgggvvqpgrslrlscaasgftfssyaihwvrqapgkglewvavisydginkyyadsvkgrftssrdnskntlylqmnslraedtavyfcarmysgsylgyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4073,NaN,NaN,QSI99024,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsgdsissyywswirqppgkglewigyiyytgstnynpslksrvtisvdtsknqfslklssvtaadtavyycanlgynsgwyggyfeywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4074,NaN,NaN,QSI99023,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfifsrysmnwvrqapgkglewvssissstsfiyyadsvrgrftisrdnaknslylqmnslraedtavyycarwiggdssgyypdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4075,NaN,NaN,QSI99022,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgpglvkpsetlsltctvsgdsisnyywswirqppekglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtamyycardfslwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4076,NaN,NaN,QSI99021,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscavsgftfsnygmhwvrqapgkglewvavilydgsnryyadsvkgrftvsrdnskntlylqmnslraedtavyycakgggpycgggscwahyfdywgqgtlvsvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4077,NaN,NaN,QSI99020,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvaggsissgtyywswirqpagkglewigriytsgsanynpslksrvtisvdtsknqfslrlssvtaedtavyycareysssyyyfyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4078,NaN,NaN,QSI99019,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsissgnyywswirqpagkglewigriytsgstnynpslksrvtisvdtsknqfslklssvtaadtalyycardayydflsgyiptynwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4079,NaN,NaN,QSI99018,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpgrslrlsctasgftfgdyamiwfrqapgkglewvgfirskayggtteyaasmkgrftisrddsksiaylqmnslktedtavyyctrdldyydssgyyptyidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4080,NaN,NaN,QSI99017,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsyyalswvrqapgkglewvsatygsgsntyyadsvkgrftisrdnskntlylqmsnlraddtavyycakdqrnaydsfdfwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4081,NaN,NaN,QSI99016,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiyaihwvrqapgqglewvavisydgsnkyyadsvrgrftisrdnskntlylqmntlraedtavyycargptysymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4082,NaN,NaN,QSI99015,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdksknmvylqmnslraedtalyycakdleyytsgsyslfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4083,NaN,NaN,QSI99014,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcgfyggslnnyfwswirqppgkglewigdinhsgstnynpslksrvtvsvdtsknqfslnlnsvtaadtavyycarglflvyygsglggfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4084,NaN,NaN,QSI99013,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssygmswvrqapgkglewvsginnhggstyygdsvkgrftisrdnskntlylqmnslraedtavyycaksdtamvpynwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4085,NaN,NaN,QSI99012,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqgsgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarhptfsgyeyyfdhwgqgtlitvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4086,NaN,NaN,QSI99011,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlsceasgftfssyalswvrqapgkglewvsaisgsggsiyyadsvkgrftisrdnskstlylqmnslkaedtavyycakddstsayyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4087,NaN,NaN,QSI99010,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyigssgssihyadsvkgrftisrdnaknslylqmnslraedtavyycardgsygdyvrgywgqgalvivss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4088,NaN,NaN,QSI99009,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpevkkpgtsvkvpckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapscsggrcydgfdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4089,NaN,NaN,NaN,QUX33798,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qavvtqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4090,NaN,NaN,NaN,QUX33797,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4091,NaN,NaN,NaN,QUX33796,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigshpvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslsgrvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4092,NaN,NaN,NaN,QUX33795,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqepsltvspggtvtltcgsstgavtsghwpywfqqkpgqtprtliydtsnkqswtparfsgsllggkaaltlsgaqpedeaeyyclllysdgrvfgggtkltvq,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4093,NaN,NaN,NaN,QUX33794,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4094,NaN,NaN,NaN,QUX33793,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qlvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4095,NaN,NaN,NaN,QUX33792,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4096,NaN,NaN,NaN,QUX33791,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4097,NaN,NaN,NaN,QUX33790,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtsvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4098,NaN,NaN,NaN,QUX33789,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqepsltvspggtvtltcasstgvvtsghypywfqqkpgqaprtliydtnnkyswtparfsgsllggkaaltlsgaqpedeadyyclitysgrevfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4099,NaN,NaN,NaN,QUX33788,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyravvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4100,NaN,NaN,NaN,QUX33787,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qlvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4101,NaN,NaN,NaN,QUX33786,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qlvltqepslavspggtvtltcasstgtvtsgsypnwfqqkpgqppraliydtsnkhswtparfsgfllggkatlalsgaqpedeaeyycllynggvwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4102,NaN,NaN,NaN,QUX33785,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvrtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4103,NaN,NaN,NaN,QUX33784,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwppatfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4104,NaN,NaN,NaN,QUX33783,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvssnflawyqrkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4105,NaN,NaN,NaN,QUX33782,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtplflvatatgvhseivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4106,NaN,NaN,NaN,QUX33781,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4107,NaN,NaN,NaN,QUX33780,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsvsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsywtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4108,NaN,NaN,NaN,QUX33779,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystlaltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4109,NaN,NaN,NaN,QUX33778,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvwtfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4110,NaN,NaN,NaN,QUX33777,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4111,NaN,NaN,NaN,QUX33776,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlfsfnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqynstpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4112,NaN,NaN,NaN,QUX33775,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvaayycqqyystpptfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4113,NaN,NaN,NaN,QUX33774,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppkitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4114,NaN,NaN,NaN,QUX33773,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqatqfpftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4115,NaN,NaN,NaN,QUX33772,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpmtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4116,NaN,NaN,NaN,QUX33771,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppntfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4117,NaN,NaN,NaN,QUX33770,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrlmykvskrdsgvpdrfsgsgsgtdftlkisrveaedagiyycmqgthwppytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4118,NaN,NaN,NaN,QUX33769,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4119,NaN,NaN,NaN,QUX33768,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4120,NaN,NaN,NaN,QUX33767,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqtvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyntpptfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4121,NaN,NaN,NaN,QUX33766,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eilmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppgrtfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4122,NaN,NaN,NaN,QUX33765,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4123,NaN,NaN,NaN,QUX33764,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4124,NaN,NaN,NaN,QUX33763,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltvsslepedfavyycqqrsnwppitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4125,NaN,NaN,NaN,QTI96751,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssspyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4126,NaN,NaN,NaN,QTI96750,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsrsgtsatlgitglqtgdeadyycgtwdsslsawvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4127,NaN,NaN,NaN,QTI96749,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssniesntvqwyqqlpgtapkliihnnskrpsgvpdrfsasksgtsaslaisglqsqddgdyycaawddslnawvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4128,NaN,NaN,NaN,QTI96748,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsvapgktasiicggnnignknvhwyqqkpgqapvlvisydsgrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdlmvfgggtkltal,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4129,NaN,NaN,NaN,QTI96747,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4130,NaN,NaN,NaN,QTI96746,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsylsgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4131,NaN,NaN,NaN,QTI96745,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsnsvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4132,NaN,NaN,NaN,QTI96744,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsvspgqtasitcsgdklgnryacwyqqkpgqspvlviyqnnkrpsgiperfsgsnsgnsatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4133,NaN,NaN,NaN,QTI96743,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstlvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4134,NaN,NaN,NaN,QTI96742,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqprsvsgspglsvtisctgsssdvggynyvswyqqhpgkapklmiydvsrrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytyvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4135,NaN,NaN,NaN,QTI96741,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsvspgqtasitcsgdklgdkyaswyqqksgqspvlviyqdsrrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdsstvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4136,NaN,NaN,NaN,QTI96740,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnawvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4137,NaN,NaN,NaN,QTI96739,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasatpgqrvtiscsgsssnigsnyvywyqqfpgtapklliygnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddspsvhwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4138,NaN,NaN,NaN,QTI96738,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsvapgktaritcggnnigtksvhwyqqkpgqapvlviyydtdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggakltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4139,NaN,NaN,NaN,QTI96737,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4140,NaN,NaN,NaN,QTI96736,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsmsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydngkrpsgipdrfsasksgtsatlgitglqtgdeadyycgtwdsslstwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4141,NaN,NaN,NaN,QTI96735,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycsssassttlhgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4142,NaN,NaN,NaN,QTI96734,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsmsvspgqtasitcsgdklgnkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsestatltisgtlamdeadyycqawdsstegvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4143,NaN,NaN,NaN,QTI96733,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsvspgqtasiicsgdklgdkyacwyqqkpgqspllviyedtkrpsgiperfsgsnsgntatltisgtqamdeadyfcqawdsstavvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4144,NaN,NaN,NaN,QTI96732,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgfvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4145,NaN,NaN,NaN,QTI96731,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtnsdvgaynyvswyqqhpgkapklmiyevsnrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-10-12,NaN,NaN
4146,NaN,NaN,NaN,QTI96730,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslesedfvvyycqqrsnwpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4147,NaN,NaN,NaN,QTI96729,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspssvsasvgdrvtitcrasqdisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfppptfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4148,NaN,NaN,NaN,QTI96728,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpgtlslspgeratlscrasqsvsnnylawyhqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygnswtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4149,NaN,NaN,NaN,QTI96727,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcrasqsinnylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqssstpsitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4150,NaN,NaN,NaN,QTI96726,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4151,NaN,NaN,NaN,QTI96725,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpftfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4152,NaN,NaN,NaN,QTI96724,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqsplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsasgagtdftlkisrveaedvgvyycmqatqfpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4153,NaN,NaN,NaN,QTI96723,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrviitcrasqsiagylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysipytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4154,NaN,NaN,NaN,QTI96722,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapnlliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4155,NaN,NaN,NaN,QTI96721,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspmytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4156,NaN,NaN,NaN,QTI96720,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4157,NaN,NaN,NaN,QTI96719,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspmytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4158,NaN,NaN,NaN,QTI96718,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpqtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4159,NaN,NaN,NaN,QTI96717,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4160,NaN,NaN,NaN,QTI96716,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratglparfsgsgsgteftltisslqsedfavyycqqyynwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4161,NaN,NaN,NaN,QTI96715,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcqasqdisnflnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdfsftisslqpediatyycqqydnlpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4162,NaN,NaN,NaN,QTI96714,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpsslstsvgdrvtitcrtsqsigsflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltinslqpedfatyycqqsystpytfgqgtkmeik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4163,NaN,NaN,NaN,QTI96713,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqaprlliydasiratgiparfsgsgsgtdftltisslepedfavyycqyrsnwpprltfgggtrveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4164,NaN,NaN,NaN,QTI96712,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssnlawyqqkagqaprlliygastratgiparfsgsgsgteftltisslqsedfaiyycqqynnwpprtfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4165,NaN,NaN,NaN,QTI96711,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4166,NaN,NaN,NaN,QTI96710,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4167,NaN,NaN,NaN,QTI96709,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqsplslpvtlgqpasiscrssqslvysdgntyliwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlnisrveaedvgvyycmqgthwpltfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4168,NaN,NaN,NaN,QTI96708,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4169,NaN,NaN,NaN,QTI96707,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-10-12,NaN,NaN
4170,NaN,NaN,NaN,QSI99210,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4171,NaN,NaN,NaN,QSI99209,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4172,NaN,NaN,NaN,QSI99208,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqpssvsvfpgqtaritcsgdvlekkyarwfqqkpgqapllviykdserpsgiperffgsssgttvtltisgaqvedeadyycysaadnnrgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4173,NaN,NaN,NaN,QSI99207,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4174,NaN,NaN,NaN,QSI99206,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqplsvsvalgqtaritcggnnigsknvhwyqqkpgqapvlviyrdsnrpsgiperfsgsnsgntatltisraqagdeadyfcqvwdsstvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4175,NaN,NaN,NaN,QSI99205,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigtnyvywyqqlpgtapklliyrntqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaswddshvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4176,NaN,NaN,NaN,QSI99204,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4177,NaN,NaN,NaN,QSI99203,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsaevfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4178,NaN,NaN,NaN,QSI99202,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapqlliydnnkrpsripdrfsgsksgtsatlgitglqtgdeavyycgtwdsslsavvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4179,NaN,NaN,NaN,QSI99201,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedesdyycssyttsstlyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4180,NaN,NaN,NaN,QSI99200,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeaayyccsyvgsstyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4181,NaN,NaN,NaN,QSI99199,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeahyycgtwdsslsagvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4182,NaN,NaN,NaN,QSI99198,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytnsrtldvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4183,NaN,NaN,NaN,QSI99197,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstllfgggtklrs,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4184,NaN,NaN,NaN,QSI99196,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4185,NaN,NaN,NaN,QSI99195,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqatdeadyycqawdsstgvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4186,NaN,NaN,NaN,QSI99194,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyswvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4187,NaN,NaN,NaN,QSI99193,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtitctgsssnigsgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeahyycqsydssvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4188,NaN,NaN,NaN,QSI99192,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitlsctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistlvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4189,NaN,NaN,NaN,QSI99191,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qlvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmkfnsdgthskgdgipdrfsgsssgaersltisslqsedeadyycqtwgtggvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4190,NaN,NaN,NaN,QSI99190,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyccystdssdnhrrvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4191,NaN,NaN,NaN,QSI99189,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigrntvnwfqqlpgtapklliysnyqrpsgvpdrlsgsksgtsaslairglqsedeadyycaawddslhgwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4192,NaN,NaN,NaN,QSI99188,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvapgqtaritcggnnigskgvhwyqqkpgqapvlvvfddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4193,NaN,NaN,NaN,QSI99187,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltlsglqaedeadyycssytssstlyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4194,NaN,NaN,NaN,QSI99186,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4195,NaN,NaN,NaN,QSI99185,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyyccshagsstsyifgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4196,NaN,NaN,NaN,QSI99184,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4197,NaN,NaN,NaN,QSI99183,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvapgqtaritcggnnigskgvhwyqqkpgqapvlvvfddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4198,NaN,NaN,NaN,QSI99182,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4199,NaN,NaN,NaN,QSI99181,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysaprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4200,NaN,NaN,NaN,QSI99180,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqydnlltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4201,NaN,NaN,NaN,QSI99179,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4202,NaN,NaN,NaN,QSI99178,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgkratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqxygsspntfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4203,NaN,NaN,NaN,QSI99177,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4204,NaN,NaN,NaN,QSI99176,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwvtfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4205,NaN,NaN,NaN,QSI99175,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyslltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4206,NaN,NaN,NaN,QSI99174,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsappgftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4207,NaN,NaN,NaN,QSI99173,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4208,NaN,NaN,NaN,QSI99172,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvslgeratlscrasqsvtsslawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqynnwppwtfgqgtkvevt,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4209,NaN,NaN,NaN,QSI99171,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4210,NaN,NaN,NaN,QSI99170,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltinslepedfavyycqqrsnwppeytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4211,NaN,NaN,NaN,QSI99169,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4212,NaN,NaN,NaN,QSI99168,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpptfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4213,NaN,NaN,NaN,QSI99167,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4214,NaN,NaN,NaN,QSI99166,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsissylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpplltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4215,NaN,NaN,NaN,QSI99165,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4216,NaN,NaN,NaN,QSI99164,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissalawyqqkpgkapklliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqfnnypltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4217,NaN,NaN,NaN,QSI99163,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppkltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4218,NaN,NaN,NaN,QSI99162,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4219,NaN,NaN,NaN,QSI99161,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlhtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4220,NaN,NaN,NaN,QSI99160,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4221,NaN,NaN,NaN,QSI99159,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsyrpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4222,NaN,NaN,NaN,QSI99158,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyychhygsspplftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4223,NaN,NaN,NaN,QSI99157,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprvtfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4224,NaN,NaN,NaN,QSI99156,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4225,NaN,NaN,NaN,QSI99155,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4226,NaN,NaN,NaN,QSI99154,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsapftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4227,NaN,NaN,NaN,QSI99153,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprllifgastratgiparfsgsgsgteftltisslqsedfavyychqyynwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4228,NaN,NaN,NaN,QSI99152,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssklawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4229,NaN,NaN,NaN,QSI99151,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4230,NaN,NaN,NaN,QSI99150,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppeytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4231,NaN,NaN,NaN,QSI99149,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpatlslspgeratlscrasqsvsrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrynwppeltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4232,NaN,NaN,NaN,QSI99148,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvtnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpntfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4233,NaN,NaN,NaN,QSI99147,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscgasqsvsssylawyqqkpglaprlviydassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4234,NaN,NaN,NaN,QSI99146,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssqlawyqqkpgqaprllisdasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4235,NaN,NaN,NaN,QSI99145,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsistwlawyqqkpgkapklliykasnlesgvpsrfsgsgsgteftltisslqpddfatyycqqyytyswtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4236,NaN,NaN,NaN,QSI99144,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqlqpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiptfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4237,NaN,NaN,NaN,QSI99143,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4238,NaN,NaN,NaN,QSI99142,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqrkpgqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavfycqqygsspwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4239,NaN,NaN,NaN,QSI99141,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppritfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4240,NaN,NaN,NaN,QSI99140,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwppgitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4241,NaN,NaN,NaN,QSI99139,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4242,NaN,NaN,NaN,QSI99138,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwlaltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4243,NaN,NaN,NaN,QSI99064,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasigdrvtitcrasqsinnylnwyqqkpgkapelliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyspytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4244,NaN,NaN,NaN,QSI99063,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,digmtqspstlsasvgdrvtitcrasqsisswlawyqhkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysftfgpgtkvdpk,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4245,NaN,NaN,NaN,QSI99062,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqynsyprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4246,NaN,NaN,NaN,QSI99061,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcqasqdisnflnwyqqkpgkapklliydasnletrvpsrfsgsgsgtdftftisslqpediatyycqhyttfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4247,NaN,NaN,NaN,QSI99060,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyfcqqyystpltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4248,NaN,NaN,NaN,QSI99059,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqsplslpvtpgepasiscrssqsllhingynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4249,NaN,NaN,NaN,QSI99058,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4250,NaN,NaN,NaN,QSI99057,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpytfgqgtnleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4251,NaN,NaN,NaN,QSI99056,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwppitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4252,NaN,NaN,NaN,QSI99055,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdfiltirrlepedfavyycqqygsslytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4253,NaN,NaN,NaN,QSI99054,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspvslsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4254,NaN,NaN,NaN,QSI99053,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliystssravgipdrfsgggsgtdftltisrlepedfavyychqygsspwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4255,NaN,NaN,NaN,QSI99052,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslstsvgdrvtitcqasqdiskylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpttfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4256,NaN,NaN,NaN,QSI99051,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliyvasnletgvpsrfsgsgfgtdftftisslqpediatyycqqfdnlpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4257,NaN,NaN,NaN,QSI99050,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdisnylncyqqkpgkapkfliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqynnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekh,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4258,NaN,NaN,NaN,QSI99049,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpaqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslss,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4259,NaN,NaN,NaN,QSI99048,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqdissalawyqqkpgktpkiliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqfnnypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlska,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4260,NaN,NaN,NaN,QSI99047,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eixltqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgtparfsgsgsgteftltisslqsedfavyycqqynywppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdsty,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4261,NaN,NaN,NaN,QSI99046,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvnnylawyqqkpgqaprlliydashratdiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4262,NaN,NaN,NaN,QSI99045,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqspklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyynsytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsst,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4263,NaN,NaN,NaN,QSI99044,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspstlsasvgdrvtitcrasqtisswlawyqqkpgkapnlliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4264,NaN,NaN,NaN,QSI99043,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvtextartap,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4265,NaN,NaN,NaN,QSI99042,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgsssdvggydfvswyqqhpgkapkvviydvtnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4266,NaN,NaN,NaN,QSI99041,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsvspgqtasitcsgdklgdkyvcwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdsstgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4267,NaN,NaN,NaN,QSI99040,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstsyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4268,NaN,NaN,NaN,QSI99039,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsgapgqrvtisctgsgsnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaddeadyycqsydsslsgpvvigggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltp,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4269,NaN,NaN,NaN,QSI99038,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qlvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvvlfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwksh,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4270,NaN,NaN,NaN,QSI99037,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynvvswyqqhpgkapqlmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstswvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwks,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4271,NaN,NaN,QTX15864,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqptgqdlewvsaigtagdtyypdsvkgrftisrenaknssylqmnslragdtavyycarasfdssgylnyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4272,NaN,NaN,QTX15863,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsnnqfslklssvtaadtavyycarhvqwlvlyyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4273,NaN,NaN,QTX15862,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycartrggsyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4274,NaN,NaN,QTX15861,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaemkepgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqdrvtitadeststaylelsslrsedtavyycaresttifgvviltsygmdvwgqgttitiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4275,NaN,NaN,QTX15860,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgggliqpggslrlscaasvfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrddskntlylqmnslraedtavyycarsrggpldywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4276,NaN,NaN,QTX15859,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkepgasvkvsckasgytftsygiswvrqapgqglewmgwisaydgntnyaqklqgrvtmttdtststaymelrslrsddtavyycaregsdyydssgfhdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4277,NaN,NaN,QTX15858,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkgltwighisysgstyynpslksrltisvdtsknqfslklssvtaadtavyycarqlwlrapfdywgqgalvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4278,NaN,NaN,QTX15857,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvqpgrslrltcaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslrpedtalyycakddssswyfysraklgqyyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4279,NaN,NaN,QTX15856,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgsglvkpsqtlsltcavsggsidsggdswswirqppgkglewigyiyhsgstyynpslksrvtisvdrsnnqfslklssvtaadtavyycarhsgydlggafdiwgqgtmvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4280,NaN,NaN,QTX15855,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewlggfdpedaetiyaqkfqgrvtmtedtstdtaymglssltsedtavyycatgvavagtqknysyyygldvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4281,NaN,NaN,QTX15854,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvasgggvvqpgrslrlscaasgfiitsygmhwvrqapgkglewvaaiwydgsnkyyadsvkgrftisrdnskntlylqmnspraedtavyycarddptpdgdafdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4282,NaN,NaN,QTX15853,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvkpggslrlscaasgftfstysmnwvrqapgkglewvssisssstdihyadsmkgrftisrdnaknslylqmnslraedtavyycardfhrgwydhsayifdfwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4283,NaN,NaN,QTX15852,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsviswhsgsidyadsvkgrftisrdnaknslylqmnslraedtalyhcakgtgysygyavdggfdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4284,NaN,NaN,QTX15851,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyisssgstkyygdsvkgrftisrdnaknslylqlnslrdedtavyycartiysydssgyygteryfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4285,NaN,NaN,QTX15850,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysftnswiawvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdsamyycarlgswyvyyyyyaldvwgqgplvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4286,NaN,NaN,QTX15849,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgfyihwvrqapgqglewmgwinpnsggsncaqkfqgrvtmtrdtsistaymevsrlrsddtavyycarysnyyyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4287,NaN,NaN,QTX15848,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavygesfsgyywswirqppgkglewigeiihsgstnynpplksrvtisvdtsksqfslklssvtaadtavyycaremsvavvdhwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4288,NaN,NaN,QTX15847,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgtevkkpgasvkvsctasgytftvcyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvarhyydrsgnlhsadyfqhwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4289,NaN,NaN,QTX15846,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsggtdyvqkfqgrvtmtrdtsistaymelsrlrsddtavyycaslsaagplndvfdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4290,NaN,NaN,QTX15845,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitspgsaiyyadsvkgrftisrdnaknslylqmnslraedtalyyctrdgvipprfdywgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4291,NaN,NaN,QTX15844,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymnwvrqapgkglewvsliysggttyyadavkgrftisrdnskntlylqmnslraedtavyycargfgdrrldywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4292,NaN,NaN,QTX15843,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygihwvrqapgkglewvavisydgstkyyadsvkgrftisrdnskntlylqmnslraedtavyfcakdrgtliegmdvwgkgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4293,NaN,NaN,QTX15842,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesgggvvqpggslrlscaasglifshygmhwvrqapgkglewvafirndgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggyyyessgwfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4294,NaN,NaN,QTX15841,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsshamnwvrqapgkglewvsgisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaksmfgydssgyfygedfdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4295,NaN,NaN,QTX15840,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggstsssfhywgwirqppgkglewigniyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlgsgsyytadywgqgtrvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4296,NaN,NaN,QTX15839,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfisyamhwvrqapgkglewvavisydgnnkyysdsvkgrftisrdnskntlhlqmnslraedtavyycakdlsggysywdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4297,NaN,NaN,QTX15838,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtftsydvnwvrqatgqglewmgwmdpnsgntgyaqnfqgrvtmtrstsigtaymelsslrsedtavyycarskergyynrtgyyypgdwfdpwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4298,NaN,NaN,QTX15837,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisnnyaywgwirqppgkglewignlyysgstyynpslksrvtisvdtsenqfslrlssvtaadtavyycarlpygydyveafdiwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4299,NaN,NaN,QTX15836,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssnamhwvrqapgkglewvafisydgsnqystdpvkgrftfardnskdtlylqmnslrgddtavyycaksrggnyfdafdmwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4300,NaN,NaN,QTX15835,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvetgggliqpggslrlscaasgftvtanymswvrqapgkglewvstiysggstfyadsvkgrftisrdnsrntlylqmnslraedtavyycarergakafdpwgqgalvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4301,NaN,NaN,QTX15834,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsgygmhwvrqapgrglewvavisydgsnkyyadsvkgrftisrdnskntvylqmnslraedtavyycakpysgsywsyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4302,NaN,NaN,QTX15833,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissygkywswirqhpgkglewigyiyysgstqynpslksrvtisvdtsknqfslklnsvtaadtavyycardsaaghfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4303,NaN,NaN,QTX15832,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgnthyaqkfqervtitrdmststaymelsslrsedtavyycaapyctttrchdgfdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4304,NaN,NaN,QTX15831,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsdkyyadsvkgrltifrdnskntlylqmnslraedtavyycaregadrsgwwgsfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4305,NaN,NaN,QTX15830,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgitvnsnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardrfgrindywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4306,NaN,NaN,QTX15829,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckafgysftsfnlnwvrqapgqglewmgwisayngntsyaqkfqgrvtmttdtstttvymelrslrsddtavyycaralenyydrngnyyvgafdywgqgslvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4307,NaN,NaN,QTX15828,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsrtscqdgfdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4308,NaN,NaN,QTX15827,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsiywmhwvrqapgkglvwvsrinsdgsstsnadsvkgrftisrdnakntlylqmnslraedtavyycardhvvaatpgmdvwgqgttitvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4309,NaN,NaN,QTX15826,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfvaedgetiyaqkfqgrvsmtedtstdtaymelsslrsedtavyycatdrarldyfasgsyyghfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4310,NaN,NaN,QTX15825,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfmfssynmnwvrqapgkglewvssisssssyiyyedsvkgrftisrdnaknslylqmislsaedtavyycarmayfdssgyypnafdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4311,NaN,NaN,QTX15824,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifssydmhwvrqatgkglewvsgignagdthypgavkgrftisrenaknslylqmnslragdtavyycarahrgyydrsgyyhnpdafdiwgqgttvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4312,NaN,NaN,QTX15823,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgysftsygiswvrqapgqglewmgwisafnnnanyvqkfqgrvtmttdtststaylelrslrsddaavyycardddnydttgyylywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4313,NaN,NaN,QTX15822,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsgdtfrsysiswvrqapgqglewmgriipilgipnyaqkfqgrvtitadkstntaymelsslrsedtavyycarespycssttclsdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4314,NaN,NaN,QTX15821,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisstsyywgwirqppgkglewigsmyysgntyynpplqsrvtisvdtsknqvslslssvtaadtalyycarhpdicdfwsgypgwfdpwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4315,NaN,NaN,QTX15820,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgkslrlscaasgltfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakegwgysygsyyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4316,NaN,NaN,QTX15819,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycastprgdsygggaywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4317,NaN,NaN,QTX15818,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggalvqpggslrlsceasefivsrnymnwvrqapgkglewvsviysggstfyadsvkgrfiisrdnskntlylqmnslraedtavyycarelvgyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4318,NaN,NaN,QTX15817,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyytdsvkgrftisrdnskntlylqmnslrpedravyycakdaadsritmfgvviishfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4319,NaN,NaN,QTX15816,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewassissnssciyyadsvkgrftisrdnaknslylqmnslraedtavyycasgehnyyyyygmdvwgqgttvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4320,NaN,NaN,QTX15815,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqqsgaevkkpgasvkdsckasgytftsygiswvrqapgqglewvgwisayngntnyglklqgrvtmttdtststaymelrslrsddtavyycarahpfydsggysdywgqgslvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4321,NaN,NaN,QTX15814,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrltcaasgfifssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyyctkadyydfwsgyqktyyyymdvwgkgttvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4322,NaN,NaN,QTX15813,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgltvsanymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyycarniyddafdvwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4323,NaN,NaN,QTX15812,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfsfssysmnwvrqapgkglewvssissnsnyiyyadsmkgrftisrdnaknslylqmnslraedtavyycasnrspydssnyyfdywgqgtrvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4324,NaN,NaN,QTX15811,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnggiidyadsvkgrftisrdnaknslylhmrslraedtafyycakdigpfeaarpggnyyyyamdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4325,NaN,NaN,QTX15810,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvtsnnyywgwirqppgeglewigsiyytgstfynpslksrvtisvdasknqfslklssvtaadtavyyctrqlvlvrgyfdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4326,NaN,NaN,QTX15809,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgpglvkpsqtlsltctvsggsissgsyfwswirqpagkglewigriftsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycargpdivvvpaadprnwfdpwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4327,NaN,NaN,QTX15808,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvetgggliqpggslrlscatsgftvssnymtwvrqapgkglewvstiysggstyyadsvkgrfsisrdsskntlylqmnslraedtavyycargpyphfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4328,NaN,NaN,QTX15807,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiayadsvkgrftisrdnaknslylqmnslraedtalyycakdiksfgifgvvtafdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4329,NaN,NaN,QTX15806,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslrvedtavyycakkgysygyfdyyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4330,NaN,NaN,QTX15805,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaresygmdvwgqgttitvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4331,NaN,NaN,QTX15804,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfifddyaihwvrqgpgkglewvsgiswnsgsigygdsvkgrftisrdnaknslylqmnslraedtafyycakggrraamllnyfdywgqgtlvtvsa,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4332,NaN,NaN,QTX15803,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvrgrftisrdnaknslflqmnslraedtalyycardpfsrwerpegwfdpwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4333,NaN,NaN,QTX15802,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgrifpilgianyaqkfqnrvtitadrststafmelsslrsedtavyycardqdsgyiwwfdpwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4334,NaN,NaN,QTX15801,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslrvedtavyycakkgysygyfdyyfdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4335,NaN,NaN,QTX15800,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlteismhwvrqapgkglewmggfdpeegetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatsevvvpgairhkaayyynymdvwgkgttvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4336,NaN,NaN,QTX15799,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstnamhwvrqapgkglewvalisydgsnkyyavsakgrfiisrdnskntlhlqmsslraedtavyycvkglggnyyyfgfwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4337,NaN,NaN,QTX15798,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakmvgqycsggncylgyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4338,NaN,NaN,QTX15797,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyissttsytnyadsakgrftisrdnaknslylqmnslraedtavyycardvayyydsgsyyyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4339,NaN,NaN,QTX15796,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakmmgqycsggdcysgyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4340,NaN,NaN,QTX15795,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsfiypggstyyvdsvkgrftisrdnskntlylqmnslraedtavyycarsygdyyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4341,NaN,NaN,QTX15794,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlslsctvsggsispyywswirqlpgkglewigyiyytgstnynpslkgrvtmsadmsknqfslnlssvtaadtamyycargydfwsrgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4342,NaN,NaN,QTX15793,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgitwnsgtigyadsvkgrftiskdnaknslylqmnrlraedtafyycakdltgwgltfggvitnwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4343,NaN,NaN,QTX15792,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslksedtavyycateehpfagraklhhldywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4344,NaN,NaN,QTX15791,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftiyymhwvrqapgqglewmgiinpgggsrsyaqrfqgrvtmtrdtststvymelsslrsedtavyycargrycsssscyigldywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4345,NaN,NaN,QTX15790,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqprgslrlscaasgftfstywmtwvrqapgkglewvanigqdgseryfvdsvkgrftisrdnannslylqmnslraedsavyycardytddygdyggyfdlwgrgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4346,NaN,NaN,QTX15789,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgdsissshwwswvrqppgkglewigeiyhsgstnynpslksrvtisveksknqfslklssvtaadtavyycarrrlgpssnnsgyfywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4347,NaN,NaN,QTX15788,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifsnyrmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardsvpryyyhyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4348,NaN,NaN,QTX15787,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfniyvmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslraedtavyycakgrsgsyfnpldywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4349,NaN,NaN,QTX15786,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgtnkyyadsvngrftisrdnskntlylqmdslragdtavyycarpnsgsyssyldywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4350,NaN,NaN,QTX15785,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvhpggslrlscaasgftfssywmswvrqapgkglewvanikedgrekyyvdyvkgrftisrdnaknslylqmnslraedtavyycardsvhyyydssgyhysygmdvwgqgttvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4351,NaN,NaN,QTX15784,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcaahggsfsgynwswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqlslklssvtaadtavyycarggtigttgiydiltgydpffdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4352,NaN,NaN,QTX15783,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakgnwndvlshyyyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4353,NaN,NaN,QTX15782,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlsctgsgftfgdyamswfrqapgkglewvgfirsedhggtteyaasvkgrftisrddsksiaylqmnslktedtavyycsrpltyyydssgyyypyyfdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4354,NaN,NaN,QTX15781,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgwggynthfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4355,NaN,NaN,QTX15780,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftiywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrtltttygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4356,NaN,NaN,QTX15779,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakshsgsyfssgdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4357,NaN,NaN,QTX15778,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarenydfwsgyfngwfdpwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4358,NaN,NaN,QTX15777,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmtwvrqapgkglewvgriksktdggttdyaapvkgrftisrhdskntlylqmnslktedtavyycttasnpdywgqgtrvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4359,NaN,NaN,QTX15776,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardtrgrgghdafdiwgqgtmvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4360,NaN,NaN,QTX15775,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygthwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpdsgsywgafdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4361,NaN,NaN,QTX15774,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdladgetiyaqefqgrvtmtedtstdtaymalsslrsedtavyycatgpltiavagqwfdpwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4362,NaN,NaN,QTX15773,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftiprdnskntlylqmnslraedtavyycakggsgyryyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4363,NaN,NaN,QTX15772,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksafgsyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4364,NaN,NaN,QTX15771,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqvgatsgidywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4365,NaN,NaN,QTX15770,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycashpyydssgyypnygmdawgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4366,NaN,NaN,QTX15769,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnrlrdedtavyycardrcgdcygpyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4367,NaN,NaN,QTX15768,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardldivvvpaarsyyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4368,NaN,NaN,QTX15767,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdptivvvavnptfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4369,NaN,NaN,QTX15766,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstyygdsvkgrftisrdnskntlylqmnslraedtavyycardfregafdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4370,NaN,NaN,QTX15765,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssywmhwvrqapgkglvwvsriniygsstsyadsvkgrftisrdnakntlylqmnslraedtavyycardlhydssgwdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4371,NaN,NaN,QTX15764,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsgtlsltcavsggfisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycasrycsggscgyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4372,NaN,NaN,QTX15763,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslraedtavyycaraqyssgwylrfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4373,NaN,NaN,QTX15762,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargaasvlrflewlldywgqgalvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4374,NaN,NaN,QTX15761,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevknpgasvkvsctasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycalvgatdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4375,NaN,NaN,QTX15760,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycakafkgnyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4376,NaN,NaN,QTX15759,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardrppivvvttyyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4377,NaN,NaN,QTX15758,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgpglvkssqtlpltctvsgasinsnnyywnwirqpagkglewigrihssgntnyspslrsrltisvdtsknqfsleltsvtaadtavyycarddwttaldcwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4378,NaN,NaN,NaN,QTX15757,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsygipdwtfgpgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4379,NaN,NaN,NaN,QTX15756,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynsvswyqhhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagrytlvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4380,NaN,NaN,NaN,QTX15755,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftptisslqpedfatyycqqsystppytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4381,NaN,NaN,NaN,QTX15754,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsirswlawyqqkpgkapkvliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynyysvtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4382,NaN,NaN,NaN,QTX15753,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsygipxwtfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4383,NaN,NaN,NaN,QTX15752,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapkvliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyvtfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4384,NaN,NaN,NaN,QTX15751,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgisgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsskyvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4385,NaN,NaN,NaN,QTX15750,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvnnylawyqqepgqaprlliydasnratgiparfsgsgsgtdftltisslepedlavyycqqcsnwppsltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4386,NaN,NaN,NaN,QTX15749,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmisevskrpsgvpdrfsgsksgntasltvsglqaedeadyycnsyagsnnwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4387,NaN,NaN,NaN,QTX15748,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqatqfpitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4388,NaN,NaN,NaN,QTX15747,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qlvltqppsvsvapgqtaritcggnsigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsksgntatltisrveagdeadyycqvwhissdhlwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4389,NaN,NaN,NaN,QTX15746,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysftfgpgtkkdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4390,NaN,NaN,NaN,QTX15745,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsytvnwyqhlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4391,NaN,NaN,NaN,QTX15744,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspatlslspgeratlscrasqsvssylawyqhkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwptfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4392,NaN,NaN,NaN,QTX15743,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvsrnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynngrgtfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4393,NaN,NaN,NaN,QTX15742,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqtplslpvtpgepasiscrsgqslldsddgntyldwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqriefpwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4394,NaN,NaN,NaN,QTX15741,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklmiydvtnrpsgvsnrfsgsksgntasltisglqaedeatyycnsytssstyvlfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4395,NaN,NaN,NaN,QTX15740,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnflnwyqekpgkapkllisdasnletgvpsrfsgsgsgtdftftitslqpediatyycqqydnllitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4396,NaN,NaN,NaN,QTX15739,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qlvltqpptvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperisgsssgtmatltisgaqvedgadyycysidssgnhyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4397,NaN,NaN,NaN,QTX15738,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdiskylnwyqrkpgtaptlliydasnletgvpsrfsgsgsgtdftftisslqpedigtyycqqydnlptfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4398,NaN,NaN,NaN,QTX15737,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqfgewftfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4399,NaN,NaN,NaN,QTX15736,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qlvltqppsvseaprqrvtiscsgsssnignnpvnwyqqlpgkapkpliyyddllpsgvsdrfsgsrsatsaslaisglqsedeadyyctawdgslngyvfgsgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4400,NaN,NaN,NaN,QTX15735,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqksgqaprlliygassratgipdrfsgsgsgtdftltisrlqpedfavyycqqygsspmytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4401,NaN,NaN,NaN,QTX15734,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysipptfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4402,NaN,NaN,NaN,QTX15733,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgteftftitslqpediatyycqqydtlpptfgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4403,NaN,NaN,NaN,QTX15732,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgggsgtdftltisslepedfavyycqqrsnwrtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4404,NaN,NaN,NaN,QTX15731,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspatlslspgeratlscrasqsvssslawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslgpedfavyycqqrsnwpptwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4405,NaN,NaN,NaN,QTX15730,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,airmtqspsslsasvgdgvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgggsgteftltisslqpedfatyyclqhnsypltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4406,NaN,NaN,NaN,QTX15729,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4407,NaN,NaN,NaN,QTX15728,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcqasqdirnylnwyqqtpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyychqydnlpqsfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4408,NaN,NaN,NaN,QTX15727,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlhssnnknyvawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyhcqqyystpltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4409,NaN,NaN,NaN,QTX15726,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgagtyftftisslqpediatyycqqydnlpplftfgpgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4410,NaN,NaN,NaN,QTX15725,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsllftfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4411,NaN,NaN,NaN,QTX15724,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,airmtqspdslavslgeratinckssqsvlhnsknksylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyggrwtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4412,NaN,NaN,NaN,QTX15723,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpedvatyycqqydnlpgtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4413,NaN,NaN,NaN,QTX15722,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspgtlslspgeratlscrashnissthlvwyqqkpgqaprlliygasnratgipdrfsgggsgtdftltisrlepedfavyfcqqfgsspqtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4414,NaN,NaN,NaN,QTX15721,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrasqsvssshlawyqqksgqaprlfiygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppwtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4415,NaN,NaN,NaN,QTX15720,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspeqtasitcsgdklgdkyacwyqqkagqspvlviyedgkrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdrttavfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4416,NaN,NaN,NaN,QTX15719,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgirsylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlntyaltfgggtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4417,NaN,NaN,NaN,QTX15718,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlsvspgervtlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhyynwppwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4418,NaN,NaN,NaN,QTX15717,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqpasvsgspgqsitisctgtssdvgvydyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvlyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4419,NaN,NaN,NaN,QTX15716,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsisrwlawyqqipgkapnlliyqtsslqsgvpsrfsgsgsgteftltisslqpddfatyycqqyysypltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4420,NaN,NaN,NaN,QTX15715,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqfpgtapklliydntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydssridvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4421,NaN,NaN,NaN,QTX15714,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qavvtqppsvsgapgqrvtisctgsssnigagydihwyqqlpgtapklliynnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4422,NaN,NaN,NaN,QTX15713,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyhqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4423,NaN,NaN,NaN,QTX15712,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qlvltqspsasaslgasvkltctlssghssnaiawhqqqpekgprylmklnidgshrkgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgpnwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4424,NaN,NaN,NaN,QTX15711,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgygsgteftltisslqpedfatyycqhlnsyprytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4425,NaN,NaN,NaN,QTX15710,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsafvgdrvtiicrasqsisswlawyqqkpgkapklliykasslesgvpstfsgsgsgteftltisslqpddfatyfcqqynsypytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4426,NaN,NaN,NaN,QTX15709,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslavtpgepasiscrssqsllhsdgynyldwylqkpgqspqlltylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtsitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4427,NaN,NaN,NaN,QTX15708,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgitnslawyqqqpgkapklllyaasrlasgvpsrfsgsgsgtdytltisslqpedfatyycqqyysapptfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4428,NaN,NaN,NaN,QTX15707,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4429,NaN,NaN,NaN,QTX15706,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcrasqgvssylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppgtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4430,NaN,NaN,NaN,QTX15705,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqhhdslpltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4431,NaN,NaN,NaN,QTX15704,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qtvvtqapsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysdnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnvvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4432,NaN,NaN,NaN,QTX15703,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qavvtqprsvsgspgqsvtisctgtssdvgaynfvswyqqhpgkapklmtydvtkrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsfyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4433,NaN,NaN,NaN,QTX15702,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgegatlscrasqsvgrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppftfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4434,NaN,NaN,NaN,QTX15701,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqsediatyycqqydnlpitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4435,NaN,NaN,NaN,QTX15700,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqpwrltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4436,NaN,NaN,NaN,QTX15699,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqtplslsvtpgqpasisckssqsllhsdgktylywylqrpgqppqlliyevsdrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpvtfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4437,NaN,NaN,NaN,QTX15698,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsisstylawyqqkpgqaprllihgassratgisdrisgsgsgtdfiltisrlepedfavyycqqygsspgtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4438,NaN,NaN,NaN,QTX15697,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspatlsvslgeratlscrasqsvssnlawyqqkpgraprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppsitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4439,NaN,NaN,NaN,QTX15696,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspssvsasvgdrvtitcrasqgissglawyrqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpytfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4440,NaN,NaN,NaN,QTX15695,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qtvvtqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifgnsnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssligsvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4441,NaN,NaN,NaN,QTX15694,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqrpgqppqlliyevsdrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpvtfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4442,NaN,NaN,NaN,QTX15693,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgqapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpadfatyycqqsysifrtsgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4443,NaN,NaN,NaN,QTX15692,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgegatlscrasqsvssylawyqrkpgqaprlliydssnratgiparfsgsgsgtdftltisslepedfavyycqersswppafgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4444,NaN,NaN,NaN,QTX15691,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspsslsasegdrvtitcqasqdinnylnwyqqkpgkapklliydasnleagvpsrfsgsgsgtdftftisslqpediatyycqqydnlppafgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4445,NaN,NaN,NaN,QTX15690,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwprtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4446,NaN,NaN,NaN,QTX15689,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsrtdftftisslqpddiatyycqqydkppvtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4447,NaN,NaN,NaN,QTX15688,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlssspgeratlscrasqgvsssylawyqqklgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhsrtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4448,NaN,NaN,NaN,QTX15687,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4449,NaN,NaN,NaN,QTX15686,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnniggksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4450,NaN,NaN,NaN,QTX15685,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkfliydasnletgvpsrfsgsgsgtdftftisslqpedfatyfcqqyddlpytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4451,NaN,NaN,NaN,QTX15684,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftistlqpediatyycqqydnllsltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4452,NaN,NaN,NaN,QTX15683,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsastgdrvtitcrasqgirtylvwyqqkpgqapnlliyaasslqsgvpsrfsgsgsgtdftltisglqsedfatyycqqyysypltfgggtkvevk,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4453,NaN,NaN,NaN,QTX15682,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsissnlawhqqkpgqaprllisdastratgiparfsgsgsgteftltidslqsediavyycqqynnwpptitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4454,NaN,NaN,NaN,QTX15681,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,slsqlvltqgrlgpgqtaritcegnniggksvlwyqqkpgqapvlvvyddsdrpsgiperfsasnsgntatltisrveagdeadyycqvwdtssdhagvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4455,NaN,NaN,NaN,QTX15680,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,airmtqspstvsasvgdrvtitcrasqsistwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisrlqpddfatyycqqynsylfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4456,NaN,NaN,NaN,QTX15679,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftlttsslqpddfatyycqqystyspltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4457,NaN,NaN,NaN,QTX15678,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,airmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsylktfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4458,NaN,NaN,NaN,QTX15677,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqppsvsgapgqrvtisctgsssnigadydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqssdsslsgsrvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4459,NaN,NaN,NaN,QTX15676,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4460,NaN,NaN,NaN,QTX15675,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnryplytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4461,NaN,NaN,NaN,QTX15674,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysppptfgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4462,NaN,NaN,NaN,QTX15673,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapelpiyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpwtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4463,NaN,NaN,NaN,QTX15672,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nivmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4464,NaN,NaN,NaN,QTX15671,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystprtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4465,NaN,NaN,NaN,QTX15670,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4466,NaN,NaN,NaN,QTX15669,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4467,NaN,NaN,NaN,QTX15668,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssftfgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4468,NaN,NaN,NaN,QTX15667,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliymgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqspynlgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4469,NaN,NaN,NaN,QTX15666,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4470,NaN,NaN,NaN,QTX15665,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsaphtfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4471,NaN,NaN,NaN,QTX15664,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedegdyycystdssgnkrvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4472,NaN,NaN,NaN,QTX15663,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlarfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4473,NaN,NaN,NaN,QTX15662,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4474,NaN,NaN,NaN,QTX15661,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyhvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4475,NaN,NaN,NaN,QTX15660,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytfgyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4476,NaN,NaN,NaN,QTX15659,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsytltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4477,NaN,NaN,NaN,QTX15658,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4478,NaN,NaN,NaN,QTX15657,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4479,NaN,NaN,NaN,QTX15656,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssqytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4480,NaN,NaN,NaN,QTX15655,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4481,NaN,NaN,NaN,QTX15654,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwptfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4482,NaN,NaN,NaN,QTX15653,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsissylnwyqqepgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpftfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4483,NaN,NaN,NaN,QTX15652,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltissmqsedfavyycqqynnwppgdtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4484,NaN,NaN,NaN,QTX15651,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygssrntfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4485,NaN,NaN,QRG26522,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgnnkyyadsvkgrftissdnskntlylqmnslraedtavyycakdlaawgpycsstncytggmdvwgqgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4486,NaN,NaN,QRG26521,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyyctteepgagslyyyyymdvwgkgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4487,NaN,NaN,QRG26520,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedggtiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatglqaarrdyyyygmdvwgqgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4488,NaN,NaN,QRG26519,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdpyypgsvkgrftisrenaknslylqmnslragdtavyycargggryydfwsgyygdyyhyymdvwgkgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4489,NaN,NaN,QRG26518,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifdttnyaqkfqgrvtitadeststaymelsslrsedtavyycarvgdydssgyysdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4490,NaN,NaN,QRG26517,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitsssgyrnyadsvkgrftisrdnaknslylqmsslraedtavyycardsaldergyssgwhpphwgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4491,NaN,NaN,QRG26516,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskttlylqmnslktedtavyycsrsillyyyastgyhheldywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4492,NaN,NaN,QRG26515,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftlssyamywvrqapgkglewvavisydgtnkyyadsvkgrftisrdnskntlflqmnslraedtavyycarpysgsyreyfqhwgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4493,NaN,NaN,QRG26514,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyaihwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarglggnyyavdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4494,NaN,NaN,QRG26513,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmntlraedtavyycarsstyytgfdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4495,NaN,NaN,QRG26512,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvsaissnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvkdwavliqmpfdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4496,NaN,NaN,QRG26511,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlsctasgftlraydmiwvrqapgkglewvsysgrshsayyadsvkgrftisrddaenslylhmntlragdtalyycardrtycssgscyaydffygmdvwgqgttvtiss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4497,NaN,NaN,QRG26510,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregivgattgfdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4498,NaN,NaN,QRG26509,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdqsegygenymdvwgkgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4499,NaN,NaN,QRG26508,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargksptvvtpwfdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4500,NaN,NaN,NaN,QRG26537,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddgdrpsgiperfsgsnsgntatlaisrveagdeadyycqvwdssshwvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4501,NaN,NaN,NaN,QRG26536,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwprtfgqgtkvdik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4502,NaN,NaN,NaN,QRG26535,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprllifdasiratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgqgtkleik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4503,NaN,NaN,NaN,QRG26534,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqspqlliyevssrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgihlqvgitfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4504,NaN,NaN,NaN,QRG26533,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppavtfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4505,NaN,NaN,NaN,QRG26532,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspstlsasvgdrvtiscrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsrsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4506,NaN,NaN,NaN,QRG26531,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytiistlgvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4507,NaN,NaN,NaN,QRG26530,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpitfgqgtrleik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4508,NaN,NaN,NaN,QRG26529,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqqgtfgqgtkleik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4509,NaN,NaN,NaN,QRG26528,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydgsnhqvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4510,NaN,NaN,NaN,QRG26527,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qavvtpepsltvspggtvtltcgssigavtgghfpywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgaqpededeyycllsnsgarpvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4511,NaN,NaN,NaN,QRG26526,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgrssnigdnyvswyqhlpgaapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtsdsslsaggvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4512,NaN,NaN,NaN,QRG26525,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnpsfgtgtkvtvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4513,NaN,NaN,NaN,QRG26524,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqaaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttatltisgvqaedeadyycqsadssdtwvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4514,NaN,NaN,NaN,QRG26523,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalwvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4515,NaN,NaN,QQY97159,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsirsdfwswirqfpgkglewigyiyysgstnynpslesrvtisvdtsknefslklnyvtaadtaiyycaretrwnwldswgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4516,NaN,NaN,QQY97158,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscvapgftlggygmhwvrqapgkglewvglisydgsvqkygssvkgrftiskdnskntlylemnslraddtavyfcvkgaslgdnwgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4517,NaN,NaN,QQY97157,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyvmtwarqapgkglewvsaisgtgytyyadsvkgrftvsrdnskntlflqmsslraedtavyycaitmapvvwgqgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4518,NaN,NaN,QQY97156,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpgrslrlscvasgftfsnygmhwvrqapgkglewvavmsydgsvtyygdsvrgrftisrdnskntlylqmsslrtddtgvyycakgqplddiwglgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4519,NaN,NaN,NaN,QQY97164,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgerasinckssqtisyisnnknylawyqqkpgqpprlliywastresgvpdrfsgggfgtdftltisslqaedvavyycqqyfntpwtfgqgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4520,NaN,NaN,NaN,QQY97163,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqsplslpvtlgqpasiscrssqslvysdgdtymswfhqrpgqsprrliykvsnrdfgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpytfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4521,NaN,NaN,NaN,QQY97162,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqsplslpvtlgqpasiscrssqslvysdgdtymswfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpytfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4522,NaN,NaN,NaN,QQY97161,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkryaywyqqksgqapilviyedkkrpsgiperlsgsksgtvatltisgaqvedeadyycystdssgnhavfgggtqltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4523,NaN,NaN,NaN,QQY97160,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqsplslpvslgqsasiscrssqslvhtdgitylswfqqrpgqsprrllykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyyclqgtywpwtfgqgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4524,NaN,NaN,QRW39016,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfsfssywmswvrqapgkglewvgnikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardlgvlwfgdpywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4525,NaN,NaN,QRW39015,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsistaylqisslkaedtavyycarvgpssswpswgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4526,NaN,NaN,QRW39014,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggwysskwyyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4527,NaN,NaN,QRW39013,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvhlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifdianyaqkfqgrvtmtadkstttaymeltslrsedtamyycarteysydsgssraysmdvwgkgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4528,NaN,NaN,QRW39012,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsavgtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycargfdtttgfyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4529,NaN,NaN,QRW39011,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakaagggysyiywggdywgqgtlvtsph,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4530,NaN,NaN,QRW39010,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnyywgwirqppgrglewigsiyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycariprhlgqdhyyyvmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4531,NaN,NaN,QRW39009,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkplewlaliywdddkryspslksrltitkdtsknqvvlrmtnmdpvdtatyycahspdhryfdvltgyfnserfyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4532,NaN,NaN,QRW39008,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsfstyywswirqppgkglewighisysgsthynpslkgrvtisldtsknqfslnlssvtaadtavyycarggyyygpprdfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4533,NaN,NaN,QRW39007,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardlgvlwfgdllfssqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4534,NaN,NaN,QRW39006,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwddakyystsletrltiskdtsnnqvvltltnmdpvdtatyycarevagavhldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4535,NaN,NaN,QRW39005,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssssytnyadsvkgrftisrdnaknslylqmnslraedtavyfcardgsavagpmsyfdywgqgtpvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4536,NaN,NaN,QRW39004,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasghtftsylihwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardppsgnydnidewtrsenhynygmdawgqgttvtvlt,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4537,NaN,NaN,QRW39003,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4538,NaN,NaN,QRW39002,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglewigyiyysgstnynpsltsrvtlsvdtsknqfslklssvtaadtavyycareyfvslpaaqtlyyygidvwgqwttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4539,NaN,NaN,QRW39001,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsgisdsggspyyadsvkgrftisrdnskntlylqmnslrvedtavyycaesssltgnfnywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4540,NaN,NaN,QRW39000,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvrlvesgggvvqpgrslrlscaasgftfssfgmhwvrqapgkglewvallsydgtnkyyadsvkgrftisrdnskstlflqmhslraedtavyfcakgggyisawstryyamdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4541,NaN,NaN,QRW38999,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyqsgstyynlslksrvtilvdtsknqlslklssvtaadtavyycarvgvatilgvdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4542,NaN,NaN,QRW38998,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqhpgkglewigyifysgstyynpslksrviisvdtsknqfslklssvtaadtavyycarvsrytmvrgvifdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4543,NaN,NaN,QRW38997,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlmesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgtnekyadsvkgrftisrdnskntlylqvnslraedtavyycakngysyayprqyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4544,NaN,NaN,QRW38996,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaaseiivssnymswvrqapgmglewvsvvysggstfyadsvkgrftisrhnskntlylqmnslrtedtavyycareapnsrgsgtnfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4545,NaN,NaN,QRW38995,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsrydmhwvrqttgkslewvsaigtagdtyypdsvkgrfiisrenansslylqmnslragdtavyycargsdtvttafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4546,NaN,NaN,QRW38994,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasrgtfssyaiswvrqapgqglewmggiipifttpnyaqnfqgrvtitadkststaymelnsltsedtavyycavlplhssynwyyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4547,NaN,NaN,QRW38993,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsifamswvrqapgkglewvsgingsgdntyyadsvkgrftisrdnsrntlylqmnslrpedtavyycakqtdygvgwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4548,NaN,NaN,QRW38992,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckrsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasqaaagyyyymdvwgkgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4549,NaN,NaN,QRW38991,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstyynpslksrvtisvdksknqfslklssvtaadtavyycarvqglidywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4550,NaN,NaN,QRW38990,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgplgmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4551,NaN,NaN,QRW38989,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgkslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgnigyadsvkgrftisrdnandslflqmnslraedtalyycakdirsgdyvgvfdywgqgalvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4552,NaN,NaN,QRW38988,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrvscaasgfavsnnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmkslraedtavyycardlvvagidywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4553,NaN,NaN,QRW38987,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggdlvqpggslrlscaasgitvssnymnwvrqapgkglewisviysggstyyadsvkgrftisrdnskntlflqmnslraedtavyycardldiagafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4554,NaN,NaN,QRW38986,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaaagftfstydmhwvrqvtgkglewvsalgtsgdtyyadsvkgrftisrenaknslylqmnslragdtavyycvrgdhssgwygtyyyymdvwgkgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4555,NaN,NaN,QRW38985,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygitwvrqapgqglewmgwisvyngnthyaqklqgrvtmttgtststaymelrslrsddtavyycavldycsggssssgyynygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4556,NaN,NaN,QRW38984,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqnlqgrvtmttdtststaymelrslrsddtavyycaregagliiaydywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4557,NaN,NaN,QRW38983,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvtviwydgsnkyyadsvkgrftisrdnskntvylqmnslraedtavyycakggnygdylrgfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4558,NaN,NaN,QRW38982,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryrpsfqgqvtisadksistaylqwsslkasdtamyycalavgrgiptsyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4559,NaN,NaN,QRW38981,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgasissyfwswirqppgkgldwigyiyyngstnynpslksrvtisvdtsknqfslklssvtaadtavyfcastywdssgyyygvdywghgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4560,NaN,NaN,QRW38980,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarekirsiaaagtvyyygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4561,NaN,NaN,QRW38979,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdasekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaglfwyggyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4562,NaN,NaN,QRW38978,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgsstyyadsvkgrftisrdtskntlylqmnslraedtavyycarglqyyydtsgyykdsyyygvdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4563,NaN,NaN,QRW38977,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgasvkvsckasgytftsyyvhwvrqapghglewmaiinpdagstsfaqrfqgrltmttdtststvymglnslrsedtavyycargglvpavmpaldywgqgalvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4564,NaN,NaN,QRW38976,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqliqsgaevkkpgasvkvscttsgytftsyflhwvrqapgqglewmgiinpsdgtttyaqkfqgrvtmtrdtstgtvsmelsslryedtavyycardgalysnsptefdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4565,NaN,NaN,QRW38975,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsintaymelsrltsddtavyycardslfsrvdwyfdlwgrgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4566,NaN,NaN,QRW38974,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvllqesgpglvkpsqtlsltctvsggsisngsyywswirqhpgkglewigyiyysgstyynpslrsrvtisldtsmnqfslklssvtaadtavyycariyrgtmvvvfsdlhwyfdlwgrgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4567,NaN,NaN,QRW38973,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevrkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpeansttyaqkfqgrvtmtsdtststvyldlsslrsedtavyycartgflipskgggmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4568,NaN,NaN,QRW38972,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgselkkpgasvkvsckasgysftdyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqistlkaedtavyycastvgrgsgtyyygnyysysmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4569,NaN,NaN,QRW38971,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgysfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksittaylqwsslkasdtaiyycarlpphfgsgsyygnafdiwglgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4570,NaN,NaN,QRW38970,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslmtrltiskdtsknqvvltmtnmdpvdtatyycariqrgiaadywgqgilvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4571,NaN,NaN,QRW38969,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaaskftfsnyamnwvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakgellwfgellenwfdpwgqgtrvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4572,NaN,NaN,QRW38968,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycatgrytygygyyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4573,NaN,NaN,QRW38967,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywddddryspslksrltitkdtsknqvvltmtnmdpvdtatyycahslpskysysygsfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4574,NaN,NaN,QRW38966,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsiifsggttyyadsvkgrftisrdnsrntlylqmsslraedtavyycaetgwdgmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4575,NaN,NaN,QRW38965,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkgldwigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardyggnsnyfhywgqgtlvtvsp,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4576,NaN,NaN,QRW38964,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvatisydgsdkfyadsvkgrftisrdnsrntlyvqmnslrpedtalyycakggwygdirvdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4577,NaN,NaN,QRW38963,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),dvqlvesggglvqpggslrlscaasefivssnymswvrqapgrglewisviysggstfyadsvkgrftisrdsskntlylqmnslraedtavyycardlplhgdyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4578,NaN,NaN,QRW38962,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkgldwvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarelgpvggtdqwgqgtlvsvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4579,NaN,NaN,QRW38961,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkasetlsltctvsggsissssyywgwirqppgkglewigsihdsgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycaryygpgtyydafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4580,NaN,NaN,QRW38960,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsfysihwvrqapgkglewvavisydgsykfyadsvkgrftisrdnskdtvylqmnslraedtavyycardwvhygsgsyppdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4581,NaN,NaN,QRW38959,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgdsfpsywiewvrqmpgkglewmgliypgdsdtryspsfqgqvtisadksistaylqlsslkasdtamyfcarhpvlrgnidywgqgtlvivss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4582,NaN,NaN,QRW38958,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasglivsrnymnwvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlenggldvwgqgttvtvfs,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4583,NaN,NaN,QRW38957,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggflqpggslrlscaasgftfssddmhwvrqvtgkglewvsaigtsgdtyysgsvkgrftisrenaknslylqmnslrvgdtavyycargslrggilsgyafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4584,NaN,NaN,QRW38956,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymiwirqapgkglewvsyisssgatiyyadsvkgrftisrdnaknslylqmtslraedtavyycaspllshnygsgsyynvywyfelwgrgtlvsvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4585,NaN,NaN,QRW38955,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsiityywswirqppgkglewigyidysgstnynpslksrvtisvdtsknqfslelssvtaadtavyycartlgayydiltgfrtpggwfapwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4586,NaN,NaN,QRW38954,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisasgdstyyadfvkgrftisrdnskntvylqmnslraedtaiyycakepsfglwfgelsgwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4587,NaN,NaN,QRW38953,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4588,NaN,NaN,QRW38952,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgtevkkpgasvkvsckastytftnfglswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvqefwldpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4589,NaN,NaN,QRW38951,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaviywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahttwyyygsgwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4590,NaN,NaN,QRW38950,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfstywigwvrqmpgkglewmgiiypydsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycarqesgwsfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4591,NaN,NaN,QRW38949,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycaritphlvydywsqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4592,NaN,NaN,QRW38948,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqivqsgaevkkpgasvkvsckasgytftsyaihwvrqapgqrlewmgwintgngntkysqnfqdrvtitrdtsattaymelssltpedtavyycaragwelnywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4593,NaN,NaN,QRW38947,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasrftfsnyamtwvrqapgkglewvsaisgsagsiyyadsvkgrftisrdnskntlylqmnslraddtavyfcakgqrgspdffdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4594,NaN,NaN,QRW38946,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4595,NaN,NaN,QRW38945,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftrywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarieyyndssgyyqfwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4596,NaN,NaN,QRW38944,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfsfsnawmswvrqapgkglewvgrikfttdggtsdyaapvrgrftisrddskntlylqmnslrtedtavyycsttndygdysanywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4597,NaN,NaN,QRW38943,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfstyamhwvrqapgkglvwvafisydesnkyytdsvkgrftvsrdnskntlylqmnslraedtavyycagggvlvtsdpdafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4598,NaN,NaN,QRW38942,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissfywswirqpagkglewigrmsasgstnynpslksrvtmsvdtsenqislklgsvtaadtavyycageqhivttiidywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4599,NaN,NaN,QRW38941,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggdvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycakdptslycsggscynnwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4600,NaN,NaN,QRW38940,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggdlvqpggslrlscaasgftvssnymtwvrqapgkglewvsliysggstfyadsvkgrftisrlsskntlylqmnslrvedtavyycargpypssswawgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4601,NaN,NaN,QRW38939,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasmtvsckasgytfstyyihwvrqapgqglewmgiinpsagstsyaqkfqgrvtmttdtststvymelsslrsedtavyycardysritmirgagdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4602,NaN,NaN,QRW38938,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvavisydgsskyyadsvkgrstisrdnskntlylqmnslraedtavyycakrggtycsggicyggyfdywgqgmlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4603,NaN,NaN,QRW38937,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfstyamhwvrqapgkglvwvafisydesnkyytdsvkgrftvsrdnskntlylqmnslraedtavyycagggvlvtsdpdafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4604,NaN,NaN,QRW38936,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycareeaagtkldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4605,NaN,NaN,QRW38935,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslntsgmcvswirqppgkalewlaridwddekyystslqtrltiskdtsknqvvltmtnmdpvdtatyycarmipipaldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4606,NaN,NaN,QRW38934,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslntsgmsvswirqppgkalewlaridwdddkyystslktrlsiskdtsknqvvltmtnvdpvdtatyyctrtatvvkdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4607,NaN,NaN,QRW38933,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssfamswvrqapgkglewvsvisssgdytsyadsvkgrftisrdnskntlylqmnslraedtavyycakdvgsrliydvfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4608,NaN,NaN,QRW38932,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),rgpgngvwaevkkpgssvkvscktsggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasfgslwdlrdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4609,NaN,NaN,QRW38931,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlslictvsggsitsyywtwirqppgkglewigyiyyngssnynpslesrvtisvdasknqfslklssvtaadtavyycatdyydssgyrygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4610,NaN,NaN,QRW38930,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfnsygiswvrqapgqglewmgwissyngntnyaqklqgrvtmttdtststaymelrsltsddtavyycatddpdivlvpaamsldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4611,NaN,NaN,QRW38929,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsnntlylqmnslraedtavyycardygdyyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4612,NaN,NaN,QRW38928,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaliwydgsnkyyadsvkgrftisrdnskntmylqmnslraedtavyycakdgsgsyynsgaldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4613,NaN,NaN,QRW38927,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscagsgftfshygmhwvrqapgkglewvavilydgsnnyyadsvkgrftvsrdnskntlylqmnslrtedtavyycgkgagpycgggscyptkvdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4614,NaN,NaN,QRW38926,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggalvqpggslrlscaasgftfssydmhwvrqatakglewvstigtagdtyypgsvkgrftisrenaknslylqmnnlragdtavyycarvgydssgyywyldlwgrgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4615,NaN,NaN,QRW38925,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvnwirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycartrlgitafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4616,NaN,NaN,QRW38924,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvnsnymswvrqapgkglewvsviyngvttyyadsvkgrftisrdiskntvylqmnslraedtavyycaragwlrgrfdpwgqgtlvivss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4617,NaN,NaN,QRW38923,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslqisckgsgysfisnwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylrwsslkasdtamyycarigdwigfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4618,NaN,NaN,QRW38922,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardleergamdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4619,NaN,NaN,QRW38921,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfstywigwvrqmpgkglewmgiiypydsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycarqesgwsfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4620,NaN,NaN,QRW38920,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslriscaasgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmntlrvedtavyycardavgsyyygmevwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4621,NaN,NaN,QRW38919,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvrptqtltltctfagfslrthgmcvswirqppgkalewlaridwdgdkyystslktrltiskdtskdqvvltmtnmdpvdtatyycarflvggfkawfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4622,NaN,NaN,QRW38918,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysgdntyyadsvkgrftisrdnskntlylqmnslraedtavyycakmlwlrgwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4623,NaN,NaN,QRW38917,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgdtfsshyihwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtsdtststvylelsslrsedtavyycardqafivatlgpdywgqgilvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4624,NaN,NaN,QRW38916,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfddyamnwvrqapgkglewvslisgdgdspsysgsvkgrftisrdnsknslylqmislrtedtalyycarespkltgyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4625,NaN,NaN,QRW38915,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaaagftfsnydmhwvrqatgkglewvsvigtagdtyypdsvkgrftisrenaknslylqmnslragdtavyycarayydtsgyynyfdhwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4626,NaN,NaN,QRW38914,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymnwvrqapgkglewvsviysgdnthyadsvkgrftisrdnskntlylqmnslraedtavyycargygsgsygwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4627,NaN,NaN,QRW38913,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvaviwydgsdkyyadsvkgrftisrdnskntlylqmsslgvedtavyycakggfgyasgwyyldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4628,NaN,NaN,QRW38912,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgiivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareglvgttltfdywgqgslvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4629,NaN,NaN,QRW38911,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasagtfssyavswvrqapgqglewmgriipivsitkyaqkfqgrvtmtadkststaymelsslrsedtavyycargrytygtegyfdnwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4630,NaN,NaN,QRW38910,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareglgmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4631,NaN,NaN,QRW38909,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsnntlylqmnslraedtavyycardpmrpgmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4632,NaN,NaN,QRW38908,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssytlhwvrqapgkglewvavissdgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardpppgnmgsmaqhlvllvvfdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4633,NaN,NaN,QRW38907,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtftsyafswvrqapgqglewmggiipifgtsnyaqkfqgrvtisadessstaymelsslrsedtavyycargpayvsgtyywnafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4634,NaN,NaN,QRW38906,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),emqlvesggglvqpggslrlscaasgftfstyemnwvrqapgkglewvsyissstnsiyyagsvqgrftisrgnaknslylqmnslraedtavyycargrddygdyrggdfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4635,NaN,NaN,QRW38905,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkiscegsgysfisywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadrsistaylqwsslkasdtamyycvrsdgdyvighdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4636,NaN,NaN,QRW38904,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycatdggggsyyyahyyygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4637,NaN,NaN,QRW38903,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdlssgwdlfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4638,NaN,NaN,QRW38902,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvisnymswvrqapgkglewvsviyrggstyfadsvkgrftisrdnskntlylqmnslraedtavyycarlasdgsgsyldyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4639,NaN,NaN,QRW38901,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgyrftnywtvwvrqmpgkglewmgiiypgdseirysppfqgqvtisadksistaylqwsslkasdtamyycarhpsnfydsggdyyamdvwgqgtpvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4640,NaN,NaN,QRW38900,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswssgsivyadsvkgrftvsrdnaknslylqmnslrvedtafyycakdmvagphyygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4641,NaN,NaN,QRW38899,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslrtrltiskdtsknlvvltmtnmdpvdtatyycalgragtmdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4642,NaN,NaN,QRW38898,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsnydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtalyycarvgyygsgsyplywyfdlwgrgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4643,NaN,NaN,QRW38897,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycatgrytygygyyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4644,NaN,NaN,QRW38896,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywitwvrqmpgkglecmgridpsdsyskyspsfqghvtisadksistaflqwsslkasdtamyycarlpfcdsascgrahyyygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4645,NaN,NaN,QRW38895,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftlsrywmswvrqapgkglewvanikqdgsekkyvdsvkgrftisrdntknslylqmnslraedtavyycarlmyyygnfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4646,NaN,NaN,QRW38894,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasglivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlniaggfdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4647,NaN,NaN,QRW38893,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsavgvgwirqppgkalewlaliywnddkryspslknrltitkdpsknqvvltmtnmdpvdtatyycahrlapdydfltgyyngddafdvwgpgtmvtiss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4648,NaN,NaN,QRW38892,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvsvgwirqppgkalewlaliywdddkrynpslksrltitkdtsknqvvltmtnmdpvdtatyycahsmvrgvlfgadfdywgqgtlvavss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4649,NaN,NaN,QRW38891,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysiswvrqapgqglewmgriipilgvaddaqkfqgrvtitadkststaymelsslrsedtavyycareagttdwyfdlwgrgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4650,NaN,NaN,QRW38890,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),rilltqsgaevkkpgasakvsckvsgyslsespmhwvrqapgkglewmggfdpedgeiinvqkfkgrvtmtedtssdtaymeltsltsedtavyfcaitslarglkgyfdswgqgtllivss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4651,NaN,NaN,QRW38889,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrwdgvgfdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4652,NaN,NaN,QRW38888,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfnnywmtwvrqapgkglewvanikldgsekyyvdsvkgrftisrdnaknslylqvnslraedtavyycarsphyyggfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4653,NaN,NaN,QRW38887,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywtwirqapgkglewigyiynsgstnynpslrgrvtisvdtsknqfslnlssvtaadtavyycardqgyssgwndafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4654,NaN,NaN,QRW38886,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggfissyywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycarrsmgycsggncysgfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4655,NaN,NaN,QRW38885,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytfttyglswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardygwfgelstegqfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4656,NaN,NaN,QRW38884,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsryglhwvrqapgkglewvgvilydgsdehyadsvkgrftisrdnskntldlqmnslrpedtavyycakqaspycsggscysgnfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4657,NaN,NaN,QRW38883,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissntfywgwirqppgkglewigsihytgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarfitdgyssgsdswgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4658,NaN,NaN,QRW38882,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgiyywswirqppgkglewigyvfysgstnynpslksrvtisvdtsknqfslklrsvtaadtavyycamtyydyiwgrvdpqfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4659,NaN,NaN,QRW38881,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisstshywgwirqppgkglewigsihysgstyynpslksrvtisvdtskkqfslklrsvtaadtavyycarfitdgyssgsdswgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4660,NaN,NaN,QRW38880,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevknpgasvkvsckasgysfinygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrfddtavyycarvqwlrldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4661,NaN,NaN,QRW38879,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsdntnyaqkfqervtitrdmstrtaymelsslrsedtavyycaadrmrivggkgyyygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4662,NaN,NaN,QRW38878,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalqwlaridwdddkyystslktrltiskdtsknqvvltvtnvdpvdtgtyycarvqvaaagspydywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4663,NaN,NaN,QRW38877,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsgkhyadsvkgqftisrdnskntlylqmnslraedtavyycardgvdfgmvtlfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4664,NaN,NaN,QRW38876,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytfttyglswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardygwfgelstegqfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4665,NaN,NaN,QRW38875,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqapgkglewvsgiswnsgsfgyadsvkgrftisrdnaknslylqmnslrpedtalyycakdigcsstscsyyhyygmdvwglgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4666,NaN,NaN,QRW38874,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evmlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycarfrygdypdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4667,NaN,NaN,QRW38873,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvgsggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlflqmnslrpedtavyycardgravagtdwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4668,NaN,NaN,QRW38872,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycgvpycsssscyryygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4669,NaN,NaN,QRW38871,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslktrltitkdtsknqvvltltnmdpvdtatyycahrpagfwsahfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4670,NaN,NaN,QRW38870,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavygrsfsgnswswirqppgkglewigeidhsgstnynpslksrvtisvdtsknqfslklnsvtaadtavyycargwtvpplwvlnwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4671,NaN,NaN,QRW38869,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipilgvanyaqkfqgrvtitadkststaymelsslrsedtavyycaregttiteyfqqwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4672,NaN,NaN,QRW38868,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywddnkryspslksrltitkdtsknqvvltmttmdpvdtatyycahrplfsgpfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4673,NaN,NaN,QRW38867,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvrpsetlsltctvsggsissssyfwgwirqppgkglewigsiyysgtthynpslksritisvdtsknqfslkltsvtaadtavyycatlewlrapfdnwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4674,NaN,NaN,QRW38866,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsggtnfvqkfqgrvtmtrdtsistaymelsrlksddtavyycargtppdsvvvpaaihpynwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4675,NaN,NaN,QRW38865,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasevtvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardglvgatlafdfwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4676,NaN,NaN,QRW38864,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgtevkkpgasvkvsckastytftnfglswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvqefwldpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4677,NaN,NaN,QRW38863,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakd,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4678,NaN,NaN,QRW38862,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevknpgasvkvsckasgysfinygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrfddtavyycarvqwlrldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4679,NaN,NaN,QRW38861,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsgiysggstyyadsvkgrftisrdkskntlylqmnslraedtavyycardggysaytlfysdfafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4680,NaN,NaN,QRW38860,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewmgifnpgagttnypqkfqgrvtmtrdtststvymelsslrsedtavyycardgspwgndydiygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4681,NaN,NaN,QRW38859,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftlsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdkgplffwsgyytdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4682,NaN,NaN,QRW38858,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslktrltitkdtsknqvvltltnmdpvdtatyycahrpagfwsahfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4683,NaN,NaN,QRW38857,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggfiryyywtwirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslnlssvtaadtavyycarrgkygsgspddafdvwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4684,NaN,NaN,QRW38856,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnsyaihwvrqtpgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtalyycardgrifylsfyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4685,NaN,NaN,NaN,QRW39177,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdgvtitcrasqgisnslawyqqkpgkapklllyaastvesgvpsrfsgrgsgtdytltissllpedfatyycqqyysaprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4686,NaN,NaN,NaN,QRW39176,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4687,NaN,NaN,NaN,QRW39175,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspvslpvtpgepasmscrssqsllhsngyiyldwyvqkpgqspqllfylgsnrapgvpvrfsasgsgtdftlkisrveaedvgvyycmqalqmgtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4688,NaN,NaN,NaN,QRW39174,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqtisnylnwyqqkpgkapelliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqthstprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4689,NaN,NaN,NaN,QRW39173,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgitnslawyqqkpgkapklllyaasrlqsgvpsrfsgsgsgtdytltisslqpedfavyycqqdynfpwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4690,NaN,NaN,NaN,QRW39172,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnlwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4691,NaN,NaN,NaN,QRW39171,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsdrfsgsksgntasltisglqaedeadyyccsyagifvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4692,NaN,NaN,NaN,QRW39170,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,rsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapkvliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4693,NaN,NaN,NaN,QRW39169,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqgvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsspqytfgqgtkleir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4694,NaN,NaN,NaN,QRW39168,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnslawyqqkpgtapklllyaastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqyysdpprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4695,NaN,NaN,NaN,QRW39167,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslpasvgdrvtitcrasqsirryinwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedsaiyycqqsfstprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4696,NaN,NaN,NaN,QRW39166,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqppsslsasvgdrvtitcrasqdisnslawyqqkpgkapklllyaasrlesgvpsrfsgsgsgtdytltisslqpedfatyycqqyysiprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4697,NaN,NaN,NaN,QRW39165,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvrsflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpyltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4698,NaN,NaN,NaN,QRW39164,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeraalscrasqgvtstylawyqqkpgqaprlliygvstratgipdrfsgsgsgtdftltisrlepedfavyychqydsspltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4699,NaN,NaN,NaN,QRW39163,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspvtlsvspgeratlscrasqsvssnlawyqqkpgqgprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqyknwppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4700,NaN,NaN,NaN,QRW39162,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsksvhwyqqrpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdtawvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4701,NaN,NaN,NaN,QRW39161,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgnapklmiydvnnrpsgvsdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4702,NaN,NaN,NaN,QRW39160,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktviisctrssgsiasnyvqwyqqrpgsapttviyedslrpsgvphrfsgsidsssnsasltisglmtedeadyycqsydsswvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4703,NaN,NaN,NaN,QRW39159,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitlsctgtssdvgsydlvswyqhhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyycclyaghstyvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4704,NaN,NaN,NaN,QRW39158,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisndlnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqhydnlkvtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4705,NaN,NaN,NaN,QRW39157,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsinnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyfcqqsystppytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4706,NaN,NaN,NaN,QRW39156,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapkfliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpgltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4707,NaN,NaN,NaN,QRW39155,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissleaedfavyycqqrsnwppgmytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4708,NaN,NaN,NaN,QRW39154,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnfsltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4709,NaN,NaN,NaN,QRW39153,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsynilwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4710,NaN,NaN,NaN,QRW39152,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgignslawyqqkpgkapklllyaastlesgvpsrfsgsgsgtdytltisslqpedfatyycqqyystpprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4711,NaN,NaN,NaN,QRW39151,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divltqspgtlslspgeratlscrasqsvsssslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygssplfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4712,NaN,NaN,NaN,QRW39150,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgipasfsgsgsgteftltisslqsedfavyycqqyndwppmytfgqgtkleir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4713,NaN,NaN,NaN,QRW39149,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqllnsdsptfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4714,NaN,NaN,NaN,QRW39148,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsfpitfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4715,NaN,NaN,NaN,QRW39147,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpediatyycqqsyssppwtfgqgakveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4716,NaN,NaN,NaN,QRW39146,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgerttlscrasqsvrgsylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4717,NaN,NaN,NaN,QRW39145,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspdfqsvtpkekvtitcrasqsiasslhwyqqkpdqspkllikyasqsfsgvpsrfsgsgsgtdftltinslepedaatyychqssslpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4718,NaN,NaN,NaN,QRW39144,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkvliydasnletgvpsrfsgsgsgtdftfaisslqpediatyycqqyhnvppafgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4719,NaN,NaN,NaN,QRW39143,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpediatfycqqyhnlpitfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4720,NaN,NaN,NaN,QRW39142,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastlqsgvpsrfsgsgsgthftltisslqpedfatyycqqansfrltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4721,NaN,NaN,NaN,QRW39141,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtefthtisslqsedfavyycqqynnwppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4722,NaN,NaN,NaN,QRW39140,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,vltqppsvsgapgqrvtisctgsssnigagagydvhwyqqfpgtapklliygnnnrpsgvpdrfsgsksgtsasltitglqaedeadyycqsydrslsvlyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4723,NaN,NaN,NaN,QRW39139,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvsdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4724,NaN,NaN,NaN,QRW39138,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvsdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4725,NaN,NaN,NaN,QRW39137,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycttwdasrggwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4726,NaN,NaN,NaN,QRW39136,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliydntnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgntvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4727,NaN,NaN,NaN,QRW39135,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvvtqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvmyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssadhyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4728,NaN,NaN,NaN,QRW39134,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspeqsitisctgtssdvgvynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssslqifgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4729,NaN,NaN,NaN,QRW39133,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadfyctsytgsstsvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4730,NaN,NaN,NaN,QRW39132,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrsnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddsltgpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4731,NaN,NaN,NaN,QRW39131,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqtissylnwfqqkpgkapklliyvasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4732,NaN,NaN,NaN,QRW39130,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqadsfpwtfgqgtrveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4733,NaN,NaN,NaN,QRW39129,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4734,NaN,NaN,NaN,QRW39128,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsinyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysapytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4735,NaN,NaN,NaN,QRW39127,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpgtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4736,NaN,NaN,NaN,QRW39126,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdiskylswyqqkpgkapklliydasnletgvpsrfsgsgsgadftftisslqpediatyycqqydtlpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4737,NaN,NaN,NaN,QRW39125,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgttftftisslqpadiatyycqhynnlpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4738,NaN,NaN,NaN,QRW39124,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkvliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4739,NaN,NaN,NaN,QRW39123,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkqgkapnlliyaasslqsgvpsrfsgsgsgtdftltitslqvedfatyycqqshstpytfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4740,NaN,NaN,NaN,QRW39122,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasmsgspgqsitisctgttsdvgaynyvswyqqhpgkapklmisnvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4741,NaN,NaN,NaN,QRW39121,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsgspgqsvtiscagtssdvgsynrvswyqqppgtaprlmiyevgnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4742,NaN,NaN,NaN,QRW39120,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctasssnigadydvhwyqqlpgtvpklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslrgsvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4743,NaN,NaN,NaN,QRW39119,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgiskwvawyqqkpgkapkiliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfptfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4744,NaN,NaN,NaN,QRW39118,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdtvtitcrasqiinsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4745,NaN,NaN,NaN,QRW39117,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprllifdasnratgiparfsgsgsgtdftltisslepedfavyycqqlgtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4746,NaN,NaN,NaN,QRW39116,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscragqsvsssylawyqqkpgqaprvliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4747,NaN,NaN,NaN,QRW39115,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqslsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4748,NaN,NaN,NaN,QRW39114,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,rsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyscaawddslngwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4749,NaN,NaN,NaN,QRW39113,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvapgktasitcggnnigsksvhwyqqrpgqapvlviyydtdrpsgiperfsgsnsvntatltisrveagdeadyycqvwdsssdhplfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4750,NaN,NaN,NaN,QRW39112,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnnvnwyqqlpgtapkvliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnghvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4751,NaN,NaN,NaN,QRW39111,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyscnsrdssgnhwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4752,NaN,NaN,NaN,QRW39110,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapksliyvasslqsgvpsrfsgsgsgtnftltisslqpedfatyycqqsysiprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4753,NaN,NaN,NaN,QRW39109,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysfwafgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4754,NaN,NaN,NaN,QRW39108,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydssslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyspltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4755,NaN,NaN,NaN,QRW39107,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissalawyqqkpgkapklliydasslesgvpsrfngsgsgtdftltisslqpedfatyycqqfnnflltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4756,NaN,NaN,NaN,QRW39106,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsswtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4757,NaN,NaN,NaN,QRW39105,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4758,NaN,NaN,NaN,QRW39104,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqksgkapklliydasnletgvpsrfsgsgsgadftftisslqpedigtyycqqsdnvpvtfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4759,NaN,NaN,NaN,QRW39103,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqplsasgtpgqrvtiscsgkssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslngrvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4760,NaN,NaN,NaN,QRW39102,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapnlliyaaaslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4761,NaN,NaN,NaN,QRW39101,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvterpsgvsnrfsgsksgntasltisglqaedeadyycssftssstpyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4762,NaN,NaN,NaN,QRW39100,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsaqvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4763,NaN,NaN,NaN,QRW39099,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtvsctgsssnigagydvqwyqhlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdwgvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4764,NaN,NaN,NaN,QRW39098,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnsvnwyqqlpgtapkffmysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4765,NaN,NaN,NaN,QRW39097,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrtsqsirvylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4766,NaN,NaN,NaN,QRW39096,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslstsvgdrvtitcrasqsisrylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtnftltisslqpedfatfycqqsystphtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4767,NaN,NaN,NaN,QRW39095,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqtisrylnwyqqrpgkapklliyiasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4768,NaN,NaN,NaN,QRW39094,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapkllmyaasslqsgvpsrfsgsgsgtdftltinslqpedfatyycqqsystppysfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4769,NaN,NaN,NaN,QRW39093,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,esvltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtsrtfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4770,NaN,NaN,NaN,QRW39092,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsaslgdrvtitcrasqgisgwlawyqqkpgkapmlliyaasslqsgvpsrfsgsgsgtdftlsisslqpedfatyycqqansfpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4771,NaN,NaN,NaN,QRW39091,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslpasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisnlqhedfatyycqqsyntlalsfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4772,NaN,NaN,NaN,QRW39090,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4773,NaN,NaN,NaN,QRW39089,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnslnwyqqktgkapkpliydasileagvpsrfsgsgsgtdftftitslqpediatyycqqydnlppytfgqgtnleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4774,NaN,NaN,NaN,QRW39088,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnclnwyqqkpgkaptlliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllwtfgpgtkmeik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4775,NaN,NaN,NaN,QRW39087,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcraslsigrylnwyqqkpgkapkllisaastlqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsyttplftfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4776,NaN,NaN,NaN,QRW39086,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqniktylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4777,NaN,NaN,NaN,QRW39085,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvapgqtasitcggsnigsknvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatliinrveagdeadyycqvwdsttdlphwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4778,NaN,NaN,NaN,QRW39084,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvapgqtasitcggsnigsknvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatliinrveagdesdyycqvwdsttdlphwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4779,NaN,NaN,NaN,QRW39083,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrvepedfavyycqqygsslwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4780,NaN,NaN,NaN,QRW39082,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqninkylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4781,NaN,NaN,NaN,QRW39081,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4782,NaN,NaN,NaN,QRW39080,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgiapelliydnnkrpsgipgrfsgsrsgtsatlditglqtgdeadyycgtwdtslnvwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4783,NaN,NaN,NaN,QRW39079,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssdsasltisglktedeadyycqsydtsnhwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4784,NaN,NaN,NaN,QRW39078,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqepsfsvspggtvtltcglssgsvstsyyaswyqqtpgqaprtliystntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgsgiwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4785,NaN,NaN,NaN,QRW39077,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvapgqtagitcggddigsknvhwyqqkpgqapvlvvyddhdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4786,NaN,NaN,NaN,QRW39076,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4787,NaN,NaN,NaN,QRW39075,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4788,NaN,NaN,NaN,QRW39074,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnslnwyqqkpgkapklliydasdletgvpsrfsgsgsgtdftftisslqpediatyycqqygnlppiafgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4789,NaN,NaN,NaN,QRW39073,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgdsylnwfqqrpgqsprrliykvsnwdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwppgtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4790,NaN,NaN,NaN,QRW39072,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsistwlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyhcqqynnlytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4791,NaN,NaN,NaN,QRW39071,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4792,NaN,NaN,NaN,QRW39070,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdfiftisslqpediatyycqqydnlprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4793,NaN,NaN,NaN,QRW39069,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaatslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttlaltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4794,NaN,NaN,NaN,QRW39068,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4795,NaN,NaN,NaN,QRW39067,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qivltqspatlslspgeratlscrasqsvttylawyqqkpgqaprlliydashratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppitfgpgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4796,NaN,NaN,NaN,QRW39066,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssniggntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslngrvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4797,NaN,NaN,NaN,QRW39065,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqepsfsvspggtvtltcglssgsvptsyfpswyqqtpgqaprtliygtntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgsgivvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4798,NaN,NaN,NaN,QRW39064,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatlsisrveagdeagyycqvwdtsgdplvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4799,NaN,NaN,NaN,QRW39063,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigadydvhwyqqfpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgswvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4800,NaN,NaN,NaN,QRW39062,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssnvgnydlvswyqqhpgkapklmiyevnkrpsgvsdrfsgsksgntasltisglqaedeadfyccsyagssswvfgggtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4801,NaN,NaN,NaN,QRW39061,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,rsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyscaawddslngwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4802,NaN,NaN,NaN,QRW39060,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapkvliyaasslqsgvpsrfsgsgsgtdftltisslqpgdfatyycqqsysppytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4803,NaN,NaN,NaN,QRW39059,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtpspsslsasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgteftltisslqpedfatyfcqqsysappwtfgqgtrveir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4804,NaN,NaN,NaN,QRW39058,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4805,NaN,NaN,NaN,QRW39057,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliyaastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpetfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4806,NaN,NaN,NaN,QRW39056,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airitqspsslsastgdrvtitcrasqgissylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisrlhsedfatyycqqyygyptfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4807,NaN,NaN,NaN,QRW39055,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnidpitfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4808,NaN,NaN,NaN,QRW39054,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslpasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisnlqpedfatyycqqsyntlalsfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4809,NaN,NaN,NaN,QRW39053,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvseaprqrvtiscsgsssnighnavnwyqqipgkapklliyyddlvpsgvsdrfsgsksgtsaslaisglqsedeaeyycaawddslngpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4810,NaN,NaN,NaN,QRW39052,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliydntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4811,NaN,NaN,NaN,QRW39051,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvniscsgsssnlgnnfvywyqqlpgtapkllsyldsrrpsgvpdrfsgsksgtsasldisglrsedeadyycaawddslsgvifgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4812,NaN,NaN,NaN,QRW39050,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviydknnrpsdipdrfsgsssgntasltitgaqaedeadyycnsrdssinhyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4813,NaN,NaN,NaN,QRW39049,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsvasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsyhnsvwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4814,NaN,NaN,NaN,QRW39048,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyhccsyagsrfwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4815,NaN,NaN,NaN,QRW39047,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapelliyaasslqsgvpsrfsgsesgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4816,NaN,NaN,NaN,QRW39046,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyychqyassprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4817,NaN,NaN,NaN,QRW39045,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqanqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqhdnvpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4818,NaN,NaN,NaN,QRW39044,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspvslpvtlgqpasiscrssqslvhsdgntylnwfqqrpgqsprrliykvsyrhsgvpdrfsgsgsgtdftleisrveaedvgvyycmqgthwpmytfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4819,NaN,NaN,NaN,QRW39043,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvggvyycmqgthwpptfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4820,NaN,NaN,NaN,QRW39042,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsvssylnwyqqnpgkapklliyaastlqsgvpsrfsgsgsgtdftltistlqpedfatyfcqqsystprltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4821,NaN,NaN,NaN,QRW39041,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqhisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyfcqqakgfpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4822,NaN,NaN,NaN,QRW39040,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsitswlawyqqkpgkapklliykastlergvpsrfsgsgsgpeftltisslqpddfatyycqqynsyspgdtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4823,NaN,NaN,NaN,QRW39039,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapnlliyaaaslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4824,NaN,NaN,NaN,QRW39038,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4825,NaN,NaN,NaN,QRW39037,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyycqqrrdftfgpgtrvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4826,NaN,NaN,NaN,QRW39036,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtptfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4827,NaN,NaN,NaN,QRW39035,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisiylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediaiyycqqydnlpsftfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4828,NaN,NaN,NaN,QRW39034,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpvdiatyychqydnlprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4829,NaN,NaN,NaN,QRW39033,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypqatfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4830,NaN,NaN,NaN,QRW39032,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpawtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4831,NaN,NaN,NaN,QRW39031,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlviylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4832,NaN,NaN,NaN,QRW39030,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssltgsvfgggtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4833,NaN,NaN,NaN,QRW39029,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,sfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttliyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsstiifgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4834,NaN,NaN,NaN,QRW39028,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4835,NaN,NaN,NaN,QRW39027,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtlsctgsssnigagydvhwyqqlpgtapkvliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgnfvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4836,NaN,NaN,NaN,QRW39026,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4837,NaN,NaN,NaN,QRW39025,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4838,NaN,NaN,NaN,QRW39024,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyatsslqsgvpsrfsgsgsgtnftltisslqpedfathycqqsystpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4839,NaN,NaN,NaN,QRW39023,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasiscksrqsllhsdgktylywylqkpgqspqlliydvssrfsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgihlptfgqgtrldik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4840,NaN,NaN,NaN,QRW39022,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcragqnissylnwyqqkpgkapklliyatsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysspprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4841,NaN,NaN,NaN,QRW39021,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratvnckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftlnisslqaedvavyycqqyystpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4842,NaN,NaN,NaN,QRW39020,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4843,NaN,NaN,NaN,QRW39019,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsigynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqspytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4844,NaN,NaN,NaN,QRW39018,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkleir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4845,NaN,NaN,NaN,QRW39017,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvnsnyltwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqsdnspftfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
4846,NaN,NaN,QRN77621,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmgglipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycanfigdgynyeedymdvwgkgttvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4847,NaN,NaN,QRN77620,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasakvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqrfqgrvtmtedastdtaymelsslrsedtavyycttvgfpdyydssvylrhfdywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4848,NaN,NaN,QRN77619,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgftftnyyihwvrqapgqglewmgiinpsggstiyaqkfqgrvtmtrdtstrtvymelsslrsedtavyycadllldywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4849,NaN,NaN,QRN77618,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgkslrlscadsgftfssyamhwvrqapgkglewvavisfdgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqwlnwafdywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4850,NaN,NaN,QRN77617,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkdrftisrdnskntlylqmnslraedtavyycvrdlysygmdvwgqgttvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4851,NaN,NaN,QRN77616,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgyslielsmhwvrqapgkglewmggfdpedvetiyaqnlqgrvtmtedtstdtaymelsslrsedtavyycatffavrgalnwfdswgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4852,NaN,NaN,QRN77615,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggitpifhtanyaqkfqgrvtitadeststvymelsslssedtavyycaretgdqgvtapfdlwgrgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4853,NaN,NaN,QRN77614,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlfcaasgftfsdyymswfrqapgkglewvsyisssgsniyyadsvkgrftvsrdnaknslylqmnslraedtavyfcargrlwgwfdpwgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4854,NaN,NaN,QRN77613,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqtpgkglewmggfdpadaetiyaqklqgrvtmtedtstdtaymelsslrsedtavyycatalpitmvrgvqyyyygmdvwgpgttvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4855,NaN,NaN,QRN77612,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlslqmnslraadtavyycatgtydfwsdnhyldywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4856,NaN,NaN,QRN77611,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgpsvkvsckasggtfssytinwvrqapgqglewmgriipmlgiakyaqkfqgrvtitadkststaymelsslrsedtavyycargivgatpgyfdywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4857,NaN,NaN,QRN77610,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsinymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaapllwadsyymdvwgkgttvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4858,NaN,NaN,QRN77609,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntdyvqkfqgrvtitrdmststaymelsslrsedtavyycaapycssttchdgfdiwgqgtmvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4859,NaN,NaN,QRN77608,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgriipildrvmyaqkfqgrvtitadkststaymelsslrsedtavyycarraidsdtyveqshfdywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4860,NaN,NaN,NaN,QRN77635,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppftfgpgtkvdikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4861,NaN,NaN,NaN,QRN77634,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyprtfgqgtkleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4862,NaN,NaN,NaN,QRN77633,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqmtqspsslsasvgdrvtitcrasqginnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynsypftfgqgtrleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4863,NaN,NaN,NaN,QRN77632,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqmtqspsslsasvgdrvtitcragqsissylnwyqqkpgkapklliylastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4864,NaN,NaN,NaN,QRN77631,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqvnsyptfgqgtrleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4865,NaN,NaN,NaN,QRN77630,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratglparfsgsgsgteftltisslqsedfavyycqqynnwppltfgqgtkleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4866,NaN,NaN,NaN,QRN77629,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqlrgnwppwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4867,NaN,NaN,NaN,QRN77628,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpediatyycqqydhllitfgqgtrleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4868,NaN,NaN,NaN,QRN77627,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgiyycmqvtqfpytfgqgtkleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4869,NaN,NaN,NaN,QRN77626,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqmtqspsflsasvgdrvtitcrasqgissslawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypsttfgggtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4870,NaN,NaN,NaN,QRN77625,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspaalsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgswsgteftltisslqsedlavyycqqynnwltfgggtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4871,NaN,NaN,NaN,QRN77624,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,aiqmtqspsslsasvgdrvtitcrasqdirnnlgwfqqkpgkapkrliyaastlqrgvpsrfsgsgsgteftltisslqpedfatyyclqhnsylwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4872,NaN,NaN,NaN,QRN77623,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslapgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4873,NaN,NaN,NaN,QRN77622,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqapslliydasnratgiparfsgsgsgtdftltisslepedfavyycqqpltfgggtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4874,NaN,NaN,QRL72470,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 71 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 71 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4875,NaN,NaN,QRL72469,NaN,['COVID'],Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 70 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 70 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4876,NaN,NaN,QRL72468,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 69 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 69 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4877,NaN,NaN,QRL72467,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 68 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 68 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4878,NaN,NaN,QRL72432,NaN,['COVID'],Unknown.,evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycassnyygsgsyyprsafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 26 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 26 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4879,NaN,NaN,QRL72430,NaN,['COVID'],Unknown.,evqlvqsgaevkkpgasvkvsckasgytfnvyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycardyygsgargfdywgqgtlvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 22 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 22 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4880,NaN,NaN,QRL72428,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarasycsttscasgafdiwgqgtlvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 18 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 18 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4881,NaN,NaN,QRL72426,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstschigafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 14 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 14 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4882,NaN,NaN,QRL72424,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyavswvrqapgqglewvgriipifgkanyaqkfqgrvtitadkststaymelsslrpedtavyycardqgisanfkdafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 10 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 10 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4883,NaN,NaN,QRL72422,NaN,['COVID'],Unknown.,evqlvqsgaevkepgssvkvsckasggtfgsyainwvrqapgqrlewmgwidaangntkysqkfqgrvtitgdtsastaymelsslrsedtavyycardrwmttrafdiwgqgtmvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 6 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 6 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4884,NaN,NaN,QRL72420,NaN,['COVID'],Unknown.,qvqlvqsgggvvqpgrslrlscvaseftfntygmhwvrqapgkglewvaaisydgtkkfyadslkgrftisrdnskntlylqmnslrsedtavyycarsgdsdafdiwgqgtmvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 2 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 2 from patent US 10851155,NaN,2022-10-12,NaN,NaN
4885,NaN,NaN,AZK34220,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 71 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 71 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4886,NaN,NaN,AZK34219,NaN,['COVID'],Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 70 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 70 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4887,NaN,NaN,AZK34218,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 69 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 69 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4888,NaN,NaN,AZK34217,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 68 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 68 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4889,NaN,NaN,AZK34182,NaN,['COVID'],Unknown.,evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycassnyygsgsyyprsafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 26 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 26 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4890,NaN,NaN,AZK34180,NaN,['COVID'],Unknown.,evqlvqsgaevkkpgasvkvsckasgytfnvyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycardyygsgargfdywgqgtlvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 22 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 22 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4891,NaN,NaN,AZK34178,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarasycsttscasgafdiwgqgtlvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 18 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 18 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4892,NaN,NaN,AZK34176,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstschigafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 14 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 14 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4893,NaN,NaN,AZK34174,NaN,['COVID'],Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyavswvrqapgqglewvgriipifgkanyaqkfqgrvtitadkststaymelsslrpedtavyycardqgisanfkdafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 10 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 10 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4894,NaN,NaN,AZK34172,NaN,['COVID'],Unknown.,evqlvqsgaevkepgssvkvsckasggtfgsyainwvrqapgqrlewmgwidaangntkysqkfqgrvtitgdtsastaymelsslrsedtavyycardrwmttrafdiwgqgtmvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 6 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 6 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4895,NaN,NaN,AZK34170,NaN,['COVID'],Unknown.,qvqlvqsgggvvqpgrslrlscvaseftfntygmhwvrqapgkglewvaaisydgtkkfyadslkgrftisrdnskntlylqmnslrsedtavyycarsgdsdafdiwgqgtmvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 2 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 2 from patent US 10131704,NaN,2022-10-12,NaN,NaN
4896,NaN,NaN,NaN,QRL72476,['COVID'],Unknown.,NaN,qagltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsyrnnnrpsgiserlsasrsgntasltitglqpedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 77 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 77 from patent US 10851155,2022-10-12,NaN,NaN
4897,NaN,NaN,NaN,QRL72475,['COVID'],Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 76 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 76 from patent US 10851155,2022-10-12,NaN,NaN
4898,NaN,NaN,NaN,QRL72474,['COVID'],Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 75 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 75 from patent US 10851155,2022-10-12,NaN,NaN
4899,NaN,NaN,NaN,QRL72473,['COVID'],Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 74 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 74 from patent US 10851155,2022-10-12,NaN,NaN
4900,NaN,NaN,NaN,QRL72472,['COVID'],Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 73 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 73 from patent US 10851155,2022-10-12,NaN,NaN
4901,NaN,NaN,NaN,QRL72471,['COVID'],Unknown.,NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 72 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 72 from patent US 10851155,2022-10-12,NaN,NaN
4902,NaN,NaN,NaN,QRL72433,['COVID'],Unknown.,NaN,ettltqspatlsvspgerailscrasqsisndlawyqqkpgqaprlliygassratgipdrfsgsgsgtdftftisrlesedfavyycqqygvspltfgggtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 28 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 28 from patent US 10851155,2022-10-12,NaN,NaN
4903,NaN,NaN,NaN,QRL72431,['COVID'],Unknown.,NaN,qpgltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsytnnnrpsgiserlsasrsgntaslaitglqpedeadyycaswdsslsvwvigggtkltvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 24 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 24 from patent US 10851155,2022-10-12,NaN,NaN
4904,NaN,NaN,NaN,QRL72429,['COVID'],Unknown.,NaN,diqmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasaresgvpdrfsgsgsgtdftltisslqpedvaiyycqqyysvpftfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 20 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 20 from patent US 10851155,2022-10-12,NaN,NaN
4905,NaN,NaN,NaN,QRL72427,['COVID'],Unknown.,NaN,ettltqspgtlslspgeratlscrasqsvsssiawyqqkpgqaprllmfdsstratgipdrfsgsgsgtdftlnisslepedfavyycqqyssspytfgqgtkleik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 16 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 16 from patent US 10851155,2022-10-12,NaN,NaN
4906,NaN,NaN,NaN,QRL72425,['COVID'],Unknown.,NaN,ettltqspatlsvspgeratlscrasesvgsnlawyqqkpgqapslliygastratgipdrfsgsgsgtdftltisslqsedfaayycqqynnwpltfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 12 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 12 from patent US 10851155,2022-10-12,NaN,NaN
4907,NaN,NaN,NaN,QRL72423,['COVID'],Unknown.,NaN,qpvltqppsasgtpgqrvtiscsgsssnigsnyvfwyqqlpgmapkllisrnnqrpsgvpdrfsgsksgtsaslaisgpqsedeadyycaawddslrgpvfgggtrvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 8 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 8 from patent US 10851155,2022-10-12,NaN,NaN
4908,NaN,NaN,NaN,QRL72421,['COVID'],Unknown.,NaN,syeltqppsvsvspgqtatitcsgdelgdkfafwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsnsyvfgtgtkvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 4 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 4 from patent US 10851155,2022-10-12,NaN,NaN
4909,NaN,NaN,NaN,AZK34226,['COVID'],Unknown.,NaN,qagltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsyrnnnrpsgiserlsasrsgntasltitglqpedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 77 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 77 from patent US 10131704,2022-10-12,NaN,NaN
4910,NaN,NaN,NaN,AZK34225,['COVID'],Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 76 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 76 from patent US 10131704,2022-10-12,NaN,NaN
4911,NaN,NaN,NaN,AZK34224,['COVID'],Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 75 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 75 from patent US 10131704,2022-10-12,NaN,NaN
4912,NaN,NaN,NaN,AZK34223,['COVID'],Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 74 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 74 from patent US 10131704,2022-10-12,NaN,NaN
4913,NaN,NaN,NaN,AZK34222,['COVID'],Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 73 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 73 from patent US 10131704,2022-10-12,NaN,NaN
4914,NaN,NaN,NaN,AZK34221,['COVID'],Unknown.,NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 72 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 72 from patent US 10131704,2022-10-12,NaN,NaN
4915,NaN,NaN,NaN,AZK34183,['COVID'],Unknown.,NaN,ettltqspatlsvspgerailscrasqsisndlawyqqkpgqaprlliygassratgipdrfsgsgsgtdftftisrlesedfavyycqqygvspltfgggtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 28 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 28 from patent US 10131704,2022-10-12,NaN,NaN
4916,NaN,NaN,NaN,AZK34181,['COVID'],Unknown.,NaN,qpgltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsytnnnrpsgiserlsasrsgntaslaitglqpedeadyycaswdsslsvwvigggtkltvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 24 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 24 from patent US 10131704,2022-10-12,NaN,NaN
4917,NaN,NaN,NaN,AZK34179,['COVID'],Unknown.,NaN,diqmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasaresgvpdrfsgsgsgtdftltisslqpedvaiyycqqyysvpftfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 20 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 20 from patent US 10131704,2022-10-12,NaN,NaN
4918,NaN,NaN,NaN,AZK34177,['COVID'],Unknown.,NaN,ettltqspgtlslspgeratlscrasqsvsssiawyqqkpgqaprllmfdsstratgipdrfsgsgsgtdftlnisslepedfavyycqqyssspytfgqgtkleik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 16 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 16 from patent US 10131704,2022-10-12,NaN,NaN
4919,NaN,NaN,NaN,AZK34175,['COVID'],Unknown.,NaN,ettltqspatlsvspgeratlscrasesvgsnlawyqqkpgqapslliygastratgipdrfsgsgsgtdftltisslqsedfaayycqqynnwpltfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 12 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 12 from patent US 10131704,2022-10-12,NaN,NaN
4920,NaN,NaN,NaN,AZK34173,['COVID'],Unknown.,NaN,qpvltqppsasgtpgqrvtiscsgsssnigsnyvfwyqqlpgmapkllisrnnqrpsgvpdrfsgsksgtsaslaisgpqsedeadyycaawddslrgpvfgggtrvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 8 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 8 from patent US 10131704,2022-10-12,NaN,NaN
4921,NaN,NaN,NaN,AZK34171,['COVID'],Unknown.,NaN,syeltqppsvsvspgqtatitcsgdelgdkfafwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsnsyvfgtgtkvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 4 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 4 from patent US 10131704,2022-10-12,NaN,NaN
4922,NaN,NaN,QRJ89103,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,NaN,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 96 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",NaN,Sequence 96 from patent US 10822379,NaN,2022-10-12,NaN,NaN
4923,NaN,NaN,QRJ89017,NaN,"['COVID', 'SARS-COV-2']",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 8 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",NaN,Sequence 8 from patent US 10822379,NaN,2022-10-12,NaN,NaN
4924,NaN,NaN,NaN,QRJ89025,"['COVID', 'SARS-COV-2']",Unknown.,NaN,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 16 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",NaN,NaN,Sequence 16 from patent US 10822379,2022-10-12,NaN,NaN
4925,NaN,NaN,QQX23548,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaraywgrgptifgvvsnttryygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4926,NaN,NaN,QQX23547,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwrhssgwdnwyfdlwgrgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4927,NaN,NaN,QQX23546,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgsgsyywgsldywgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4928,NaN,NaN,QQX23545,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwvicsstscytkysyygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4929,NaN,NaN,QQX23544,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgsgsyywgsldywgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4930,NaN,NaN,QQX23543,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvgplmvrgviipwgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4931,NaN,NaN,QQX23542,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgspsggwytldywgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4932,NaN,NaN,QQX23541,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfsfyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarewfgetwegmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4933,NaN,NaN,QQX23540,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpglvkpsetlsltctvsggsissyywswirqppgkglewigniyysgstdynpslksrvtisvdtsknqfslrlssvtaadtavyycareqfsggdyegfdfwgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4934,NaN,NaN,QQX23539,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelgslrsedtavyycaragwsvsplkynwfdpwgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4935,NaN,NaN,QQX23538,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraaygpyygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4936,NaN,NaN,QQX23537,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgfifssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardlrgptgwtfdywgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4937,NaN,NaN,QQX23536,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttegamvrrviygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4938,NaN,NaN,QQX23535,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwvicsstscytkysyygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4939,NaN,NaN,QQX23534,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfsfyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarewfgetwegmdawgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4940,NaN,NaN,QQX23533,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwrssgyhdysyygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4941,NaN,NaN,NaN,QQX23532,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygngnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4942,NaN,NaN,NaN,QQX23531,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdssliarlfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4943,NaN,NaN,NaN,QQX23530,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslnvvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4944,NaN,NaN,NaN,QQX23529,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4945,NaN,NaN,NaN,QQX23528,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvsiscsgstssigrntvswfqqlpgtapklliyrdnqrpsgvpdrfsgsksgtsaslaisglrsedeaeyycsawhdtlngvvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4946,NaN,NaN,NaN,QQX23527,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsisnigsahvswyqqvpgtapklliydnserpsgiparfsafkygtsatlditglqtgdeadyycaswdislsagifgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4947,NaN,NaN,NaN,QQX23526,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,envltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystllgtfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4948,NaN,NaN,NaN,QQX23525,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,envltqspatlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplftfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4949,NaN,NaN,NaN,QQX23524,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliygasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpwtfgqgtkvei,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4950,NaN,NaN,NaN,QQX23523,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrwtfgqgtkveik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4951,NaN,NaN,NaN,QQX23522,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnpitfgqgtrleik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4952,NaN,NaN,NaN,QQX23521,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspiftfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4953,NaN,NaN,NaN,QQX23520,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,envltqspatlslspgeratlscrasqsvsnylawyqqrpgqaprlliydssnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwkitfgqgtrleik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4954,NaN,NaN,NaN,QQX23519,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,envltqspgtlslspgeratlscrarqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspitfgqgtrleik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4955,NaN,NaN,NaN,QQX23518,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwplltfgggtkveik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4956,NaN,NaN,NaN,QQX23517,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprgvtfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4957,NaN,NaN,QQO74752,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgisgsggstyyadsmkgrftisrdnskntlylqmnslraedtavyycakdltrdyydssgyqtgafdiwgqgtmvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4958,NaN,NaN,QQO74751,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgiggsgdstyyadsvkgrftisrdnskntlylqinslraedtavyycakgaapyyyyyygmdvwgqgttvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4959,NaN,NaN,QQO74750,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvrsnymswvrqapgkglewvsliysggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4960,NaN,NaN,QQO74749,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargwatyydiltgyslfdywgqgtlvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4961,NaN,NaN,QQO74748,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggrtyyadsvkgrftisrdnskntlylqmnslraedtavyycakdldivvvitgdafdiwgqgtmvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4962,NaN,NaN,QQO74747,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyfihwvrqapgqglewmgminpsvgsttyaqnfqgrvtmtrdtststvymelsslrsedtaiyycarthvaqlweiwyfdiwgrgtlvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4963,NaN,NaN,QQO74746,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctlsggairsgsyywgwirqtpgkglewigsifhignafynpslksrvtisadkaknqislnvrsvtaadtavyycvrpnnehggfffdywgqgilvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4964,NaN,NaN,QQO74745,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlfcaasgftfssfamswvrqapgkglewvstisgsggrtyyadsvkgrftifrdnskntlylqmnslraedtalyycakdmdivvvitgdafdiwgqgtmvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4965,NaN,NaN,QQO74744,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgpevkkpgasvkvsckasgytftsysinwvrqapgqglewmgwistyngntnyaqrlqgrvtmttdtstgtahmelrslrsddtaiyycareeplycsggscyefqhwgqgtlvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
4966,NaN,NaN,NaN,QQO74743,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syelnqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwggvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4967,NaN,NaN,NaN,QQO74742,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggydyvswyqqhpgkapklmiyevsdrpsgvsnrfsgsksgstasltisglqaedeadyycssytsssalyvfgtgtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4968,NaN,NaN,NaN,QQO74741,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgtefkltisslqpedfatyycqqlnnyppvtfgqgtrleik,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4969,NaN,NaN,NaN,QQO74740,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstphvvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4970,NaN,NaN,NaN,QQO74739,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprhysywyqqkpgqapvlliykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgigtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4971,NaN,NaN,NaN,QQO74738,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgstsnigsnavnwyqqlpgtapklliysdnhrpsgvpdrfsgsrsgtsaslaisrlqsedeadyycaawddslkgvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4972,NaN,NaN,NaN,QQO74737,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppslsvapgktariscggnnigsrsvhwyqqkpgqapvvvisydtdrpseiperfsgsksgntatltisrveagdeadyycqvwvstfdhvvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4973,NaN,NaN,NaN,QQO74736,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgtgtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4974,NaN,NaN,NaN,QQO74735,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqsparlslspgeratlscrasqsvssdlawyqqkpgqaprlliydashratgiparfsgsgsgtdftltisslepedfavyycqqrinwppiftfgpgtkvdik,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
4975,NaN,E111,NaN,3J8D_D,['MERS'],Mus musculus (house mouse),NaN,nivltqspaslavslgqratiscrasesvdsfiywyqqkpgqppklliylasnlesgvparfsgsgsetdftltidsvetddaatyycqqnnedpytfgggtkleikqvqllqpgaelvkpgasmklsckasgytftnwwmhwvrlrpgrglewigridpnsdvnkynekfenrasltvdkhsstaymqltsedsaiyycarwffpwyfdvwgtgttvtvsradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrsakttapsvyplapvcggttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpallqsglytlsssvtvtsntwpsqtitcnvahpasstkvdkkies,"Zhang,X. et al.; Structure of acidic pH dengue virus showing the fusogenic glycoprotein trimers; J. Virol. 89 (1), 743-750 (2015); 2014.",10.1128/JVI.02411-14,NaN,"Chain D, antibody E111 Fab fragment",2022-10-12,NaN,NaN
4976,NaN,E111,NaN,3J8D_A,['MERS'],Mus musculus (house mouse),NaN,nivltqspaslavslgqratiscrasesvdsfiywyqqkpgqppklliylasnlesgvparfsgsgsetdftltidsvetddaatyycqqnnedpytfgggtkleikqvqllqpgaelvkpgasmklsckasgytftnwwmhwvrlrpgrglewigridpnsdvnkynekfenrasltvdkhsstaymqltsedsaiyycarwffpwyfdvwgtgttvtvsradaaptvsifppsseqltsggasvvcflnnfypkdinvkwkidgserqngvlnswtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrsakttapsvyplapvcggttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpallqsglytlsssvtvtsntwpsqtitcnvahpasstkvdkkies,"Zhang,X. et al.; Structure of acidic pH dengue virus showing the fusogenic glycoprotein trimers; J. Virol. 89 (1), 743-750 (2015); 2014.",10.1128/JVI.02411-14,NaN,"Chain A, antibody E111 Fab fragment",2022-10-12,NaN,NaN
4977,D7,NaN,2XA3_A,NaN,unknown,Lama glama (llama),avqlqesggglvqaggslrlsctvsartssshdmgwfrqapgkerefvaaiswsggttnyvdsvkgrfdiskdnaknavylqmnslkpedtavyycaakwrplrysdnpsnsdynywgqgtqvtvss,NaN,"Forsman,A. et al.; Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120; J. Virol. 82 (24), 12069-12081 (2008); 2010.",10.1128/JVI.01379-08,"Chain A, LLAMA HEAVY CHAIN ANTIBODY D7",NaN,2022-10-12,NaN,NaN
4978,NaN,NaN,QPI69476,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Mus musculus (house mouse),qvqlkqsgpslvqpsqslsitctvsgfsltsygvhwvrqspgkglewlgvmwrggntdynaafmsrlsitkdnsksqvffkmnslqtddtaiyycaknggahamdfwgqgtsvtvss,NaN,"Zhang,C. et al.; Direct Submission; Submitted (15-NOV-2020) Unit of Vaccinology & Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; 2020.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin gamma heavy chain variable region, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
4979,NaN,NaN,QPI69474,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Mus musculus (house mouse),evqlqesgpslvkpsqtlsltcsvtgdsitngywnwirkfpgnkleymgyisysgstyyspslksrisitrdtsknqhylqlnsvtsedtatyycasdyhgskyyfdywgqgttltvss,NaN,"Zhang,C. et al.; Direct Submission; Submitted (15-NOV-2020) Unit of Vaccinology & Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; 2020.",NaN,"anti-SARS-CoV-2 RBD immunoglobulin gamma heavy chain variable region, partial [Mus musculus]",NaN,2022-10-12,NaN,NaN
4980,NaN,NaN,NaN,QPI69477,"['COVID', 'SARS-COV-2', 'RBD']",Mus musculus (house mouse),NaN,nivltqspaslavslgqratiscrasesvdsygnsflhwyqqkpgqppklliylasnlesgvparfsgsgsrtdftltidpveaddaatyycqqnnedpftfgsgtkleik,"Zhang,C. et al.; Direct Submission; Submitted (15-NOV-2020) Unit of Vaccinology & Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin kappa light chain variable region, partial [Mus musculus]",2022-10-12,NaN,NaN
4981,NaN,NaN,NaN,QPI69475,"['COVID', 'SARS-COV-2', 'RBD']",Mus musculus (house mouse),NaN,divmtqshkfmstsvghrvsitckasqdvgndvawyqqkpgqspklliywastrhtgvpdrftgsgsgtdftltisnvqsedladyfcqqynrypytfgggtkleik,"Zhang,C. et al.; Direct Submission; Submitted (15-NOV-2020) Unit of Vaccinology & Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD immunoglobulin kappa light chain variable region, partial [Mus musculus]",2022-10-12,NaN,NaN
4982,JLI-G10,NaN,6UHT_D,NaN,unknown,Vicugna pacos (alpaca),gplgsqvqlvesggglvqaggslrlscaasiltydldyyyigwvrqapgkeregvscisstdgatyyadsvkgrftisrnnakntvylqmnnlkpedtaiyycaaaplagrycpasheygywgqgtqvtvssahhsedps,NaN,"Lam,K.H. et al.; Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins; Cell Rep 30 (8), 2526-2539 (2020); 2020.",10.1016/j.celrep.2020.01.107,"Chain D, JLI-G10",NaN,2022-10-12,NaN,NaN
4983,JLI-G10,NaN,6UHT_C,NaN,unknown,Vicugna pacos (alpaca),gplgsqvqlvesggglvqaggslrlscaasiltydldyyyigwvrqapgkeregvscisstdgatyyadsvkgrftisrnnakntvylqmnnlkpedtaiyycaaaplagrycpasheygywgqgtqvtvssahhsedps,NaN,"Lam,K.H. et al.; Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins; Cell Rep 30 (8), 2526-2539 (2020); 2020.",10.1016/j.celrep.2020.01.107,"Chain C, JLI-G10",NaN,2022-10-12,NaN,NaN
4984,JLK-G12,NaN,6UFT_B,NaN,unknown,Vicugna pacos (alpaca),mhhhhhhmasmtggqqmgrgsqvqlvesggglvqaggslrlscaasefraehfavgwfrqapgkeregvscvdasgdstayadsvkgrftisrdnnknvvylqmdslepedtgdyycgasyftvcaksmrkieyrywgqgtqvtvssepktpkpq,NaN,"Lam,K.H. et al.; Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins; Cell Rep 30 (8), 2526-2539 (2020); 2020.",10.1016/j.celrep.2020.01.107,"Chain B, JLK-G12",NaN,2022-10-12,NaN,NaN
4985,JLI-H11,NaN,6UC6_D,NaN,unknown,Vicugna pacos (alpaca),mhhhhhhmasmtggqqmgrgsqvqlvesggglvqpgeslrlscgasgmsldyyaiawyrqapgkeregvscisvsgssaqyldsvrgrfiiskdntkstaylqmnslkpedtavyycaaladcagyasltfdfdswgqgtqvavssahhsedps,NaN,"Lam,K.H. et al.; Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins; Cell Rep 30 (8), 2526-2539 (2020); 2020.",10.1016/j.celrep.2020.01.107,"Chain D, JLI-H11",NaN,2022-10-12,NaN,NaN
4986,JLI-H11,NaN,6UC6_C,NaN,unknown,Vicugna pacos (alpaca),mhhhhhhmasmtggqqmgrgsqvqlvesggglvqpgeslrlscgasgmsldyyaiawyrqapgkeregvscisvsgssaqyldsvrgrfiiskdntkstaylqmnslkpedtavyycaaladcagyasltfdfdswgqgtqvavssahhsedps,NaN,"Lam,K.H. et al.; Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins; Cell Rep 30 (8), 2526-2539 (2020); 2020.",10.1016/j.celrep.2020.01.107,"Chain C, JLI-H11",NaN,2022-10-12,NaN,NaN
4987,NaN,NaN,QNS17516,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqpggslrlscaasgltldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgtyyytchpggmdywgkgtlvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4988,NaN,NaN,QNS17515,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqpggslrlscaasgltldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgtyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4989,NaN,NaN,QNS17514,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesgggsveaggslrlscaasgvtldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtadyycaavpstyysgtyyynchpgamhywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4990,NaN,NaN,QNS17513,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftisrdnakntvylqmnslkpddtavyycaaalseggytidgsswcyhsvygmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4991,NaN,NaN,QNS17512,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqsggslrlscaasgftldyyaigwfrqapgkeregvscitnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycasfpstyysgsyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4992,NaN,NaN,QNS17511,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsggstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4993,NaN,NaN,QNS17510,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtlvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4994,NaN,NaN,QNS17509,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqsggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4995,NaN,NaN,QNS17508,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4996,NaN,NaN,QNS17507,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvacisssdgttyyadsvkgrftisrdnakntvylqmnslkpedtavyycatrpltyysgsyyttcsdygmdywgkgtlvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4997,NaN,NaN,QNS17506,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqpggslrlscaasgltldyytigwfrqapgkeregvscisssddstyyadsvkgrftisrdnakntvylqmnslkpedtavyycatapgtyykgsyypmchyygmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4998,NaN,NaN,QNS17505,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftssrdnakntvylqmnslkpedtavyycaavpstyysgtyyynchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
4999,NaN,NaN,QNS17504,NaN,"['COVID', 'SARS-COV-2']",Lama glama (llama),dvqlqesggdlvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftssrdnakntvylqmnslkpedtavyycaavpstyyngsyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-10-12,NaN,NaN
5000,VHAB8,NaN,QNN25877,NaN,"['COVID', 'SARS-COV-2']",synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,NaN,"Li,W. et al.; High potency of a bivalent human VH domain in SARS-CoV-2 animal models; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.007,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region VHab8, partial [synthetic construct]",NaN,2022-10-12,NaN,NaN
5001,RBD-SPECIFIC,NaN,QLR06781,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssvymnwvrqapgkgpewvsrispnsgnigytdsvkgrftisrdnakntlylqmnnlkpedtalyycaiglnlssssvrgqgtqvtvss,NaN,"Hanke,L. et al.; An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction; Nat Commun 11 (1) (2020) In press; 2020.",10.1038/s41467-020-18174-5,"SARS-CoV-2 RBD-specific neutralizing immunoglobulin heavy chain, partial [Vicugna pacos]",NaN,2022-10-12,NaN,NaN
5002,NaN,NaN,QMI58173,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfssyvmhwvrqapgkgldwvgviwydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycardprdyydfwsgydyyygldvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5003,NaN,NaN,QMI58172,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycakdsgynygyswfdpwgqgtlvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5004,NaN,NaN,QMI58171,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssytmhwvrqapgkglewvaaisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsilygggmdvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5005,NaN,NaN,QMI58170,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyyctragwelrldafdiwgqgtmvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5006,NaN,NaN,QMI58169,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evhlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddaknslylqmnslktedtavyycarvhrwaycingvcfgaysdywgqgtlvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5007,NaN,NaN,QMI58168,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlfyygmdvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5008,NaN,NaN,QMI58167,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahhkierifdywgqgtlvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5009,NaN,NaN,QMI58166,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvsssnyywswirqppgkglewigymyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycarevyyydrsgyyasdgfdiwgqgtmvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5010,NaN,NaN,QMI58165,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsisnyywswirqspgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarsakhwlappgdyyyymdvwgkgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5011,NaN,NaN,QMI58164,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedvetiyaqqfqgrvtmtedtstdtaymelsslrsedtavyycatgwaykstwyfgywgqgtlvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5012,NaN,NaN,QMI58163,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgiavigpppstyyyygmdvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5013,NaN,NaN,QMI58162,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgwavagssdvwyyyygmdvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5014,NaN,NaN,QMI58161,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqllqsgaevkkpgasvkvsckasgysftsyymhwvrqapgqglewmgiinpsgggttyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpgggsyqefdywgqgtlvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5015,NaN,NaN,QMI58160,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgvinpsggstsyaekfrgrvtmtrdtststvymelsslrsedtavyycardrephsdssgywdslkyyyyyaldvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5016,NaN,NaN,QMI58159,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqmfqgrvtmtrdtsistaymevsrlrsddtavyycardrswavvyyymdvwgkgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5017,NaN,NaN,QMI58158,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5018,NaN,NaN,QMI58157,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittaymelrrlrsddtavyycarglgvgcsggncyldyyymdvwgkgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5019,NaN,NaN,QMI58156,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggnipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargvgyrgviplnwfdpwgqgtvvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5020,NaN,NaN,QMI58155,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5021,NaN,NaN,NaN,QMI58192,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5022,NaN,NaN,NaN,QMI58191,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkllisaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlqvtfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5023,NaN,NaN,NaN,QMI58190,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsadalakqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdnsgtypnwvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5024,NaN,NaN,NaN,QMI58189,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrssyaswyqqkpgqapilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgilfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5025,NaN,NaN,NaN,QMI58188,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5026,NaN,NaN,NaN,QMI58187,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspstfgqgtkleik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5027,NaN,NaN,NaN,QMI58186,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgilslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssgaltfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5028,NaN,NaN,NaN,QMI58185,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5029,NaN,NaN,NaN,QMI58184,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgqapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypltfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5030,NaN,NaN,NaN,QMI58183,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypcfgpgtkvdik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5031,NaN,NaN,NaN,QMI58182,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyltfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5032,NaN,NaN,NaN,QMI58181,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapelliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlntypftfgpgtkvdik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5033,NaN,NaN,NaN,QMI58180,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsrmgfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5034,NaN,NaN,NaN,QMI58179,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5035,NaN,NaN,NaN,QMI58178,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsalaqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5036,NaN,NaN,NaN,QMI58177,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5037,NaN,NaN,NaN,QMI58176,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqppsvsgspgqsvtisctgtssdvgsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5038,NaN,NaN,NaN,QMI58175,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5039,NaN,NaN,NaN,QMI58174,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedegdyycssytssstwvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5040,NaN,NaN,QLI62517,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsssaiswvrqapgqglewmggiipilditnyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdllvywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5041,NaN,NaN,QLI62516,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiafagsvkgrftisrdnaknslylqmnslraedtalyycakdqgysygnyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5042,NaN,NaN,QLI62515,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvscmasgytftsyymhwvrqapgqglewmgiispsgggtsyaqkfqgrvtltrdtststvymelsslrsedtavyycarwydstgsidywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5043,NaN,NaN,QLI62514,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsiyaitwvrqapgqglewmggiipiigtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsstrcyfwfdpwgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5044,NaN,NaN,QLI62513,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfatyalnwvrqapgqglewmgwvntntgsptyaqgftgrfvfsfdtsvstaylqirtlkaedtavyycavyyydsgspgwfdpwgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5045,NaN,NaN,QLI62512,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsnyamtwvrqapgkglewvsaissgsgstyyadsvkgrftisrdnskntvylqmnslraedtaiyycakankysssefdfwgqgtlvtiss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5046,NaN,NaN,QLI62511,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfigyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistvymelsrlrsddtavyycarempaamgyyyygmdvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5047,NaN,NaN,QLI62510,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtvsadksistaylqwsslkasdtamyycarvnyydssgypsfhfdywgqgtlvtvs,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5048,NaN,NaN,QLI62509,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgdstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdryyefwsgysnwfdpwgqgtlvtiss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5049,NaN,NaN,QLI62508,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscsasgftfsiygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdrtgnyyygmdvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5050,NaN,NaN,QLI62507,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqgdcsttscaydywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5051,NaN,NaN,QLI62506,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgfaqnmvlltpywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5052,NaN,NaN,QLI62505,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymdlsslrsedtavyycatafsifgvvppdywgqgtlvtvs,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5053,NaN,NaN,QLI62504,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmsslrgedtavyycakdqayydiltgylnppknyyyygmdvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5054,NaN,NaN,QLI62503,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgsgsgsypnyyyyygmdvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5055,NaN,NaN,QLI62502,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarlhcggdcyldywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5056,NaN,NaN,QLI62501,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglegvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakssgsyyyyyygmdvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5057,NaN,NaN,QLI62500,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaliwydgsnknyadsvkgrftisrdnskntldlqmnslraedtavyycardpfpgavagtgylqywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5058,NaN,NaN,QLI62499,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfstyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmsslraedtaiyycardrrrryctngvcyrpeeidywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5059,NaN,NaN,QLI62498,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfnyysmnwvrqapgkglewissistsssfvyyadsvkgrftisrdnaktslylqmnslraedtavyfcarggycsdgscyvqdrliyyysgldvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5060,NaN,NaN,QLI62497,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardpygyssiwdgqgghwgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5061,NaN,NaN,QLI62496,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiysgyymhwvrqapgqglewmgwispdsggtnyaqrfqgrvtmtrdtstttaymelsrlrsddtavyycargprysgtyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5062,NaN,NaN,QLI62495,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifsgyythwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittayvelsglrsddtavyycargprysgtyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5063,NaN,NaN,QLI62494,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiysgyfmhwvrqapgqglewmgwispdsgganyaqtfqgrvtmtrdtstttahmelsrlrsddtavyycargprysgthfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5064,NaN,NaN,QLI62493,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgyifsgyymhwvrqapgqglewmgwispdsggtnyaqnfqgrvtmtrdtsistgymelsrlrsddtamyycargprysgtyfdywgqgvlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5065,NaN,NaN,QLI62492,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifsgyythwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittayvelsglrsddtavyycargprysgtyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5066,NaN,NaN,QLI62491,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvtcktsgyifsgyymhwvrqvpgqglewmgwispdsgatnyaqkfqgrvtmtrdtsittsyveltwlksddtavyycargprysgtyfdfwgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5067,NaN,NaN,QLI62490,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifsgyymhwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittgymelsglrsddtavyycargprysgtyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5068,NaN,NaN,QLI62489,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgyiysgyymhwvrqapgqglewmgwispdsggtnyaqrfqgrvtmtrdtstttaymelsrlrsddtamyycargprysgtyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5069,NaN,NaN,QLI62488,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwispnsggtnyaqkfqgwvtmtrdtsvstaymelsrlrfddtavyycateswvygsgsyssgafdiwgqgtmvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5070,NaN,NaN,QLI62487,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5071,NaN,NaN,QLI62486,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsvfysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardygdlyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5072,NaN,NaN,QLI62485,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5073,NaN,NaN,NaN,QLI62550,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsslwtfgqgtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5074,NaN,NaN,NaN,QLI62549,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qlvltqppsvsvapgktaritcggnnigsksvywyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpyvfgsgtkvtvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5075,NaN,NaN,NaN,QLI62548,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypiltfgggtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5076,NaN,NaN,NaN,QLI62547,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqeagkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5077,NaN,NaN,NaN,QLI62546,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqtassylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsvtdftltisslqpedfatyycqqsystpptfgqgtkvdik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5078,NaN,NaN,NaN,QLI62545,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgaapklliyrndqrpsgvpdrfsgsksgtsvslaisglrsedeadyycaawddslsgwvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5079,NaN,NaN,NaN,QLI62544,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyycysyagsstfvfvfgtgtkvivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5080,NaN,NaN,NaN,QLI62543,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcvsstgavtsgyypnwfqqkpgqapraliystskkhswtparfsgsllggkaaltlsgvqpedeaeyycllyyggaqrwvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5081,NaN,NaN,NaN,QLI62542,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkvlvysndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5082,NaN,NaN,NaN,QLI62541,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpwtfgqgtkveik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5083,NaN,NaN,NaN,QLI62540,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttatltisgvqaedeadyycqsadssgtylvvfgggtklavl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5084,NaN,NaN,NaN,QLI62539,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppitfgqgtrleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5085,NaN,NaN,NaN,QLI62538,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qavvtqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5086,NaN,NaN,NaN,QLI62537,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasstpgqrvtiscsgsssnigsnyvywyqqlpgtapklliytnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgrvvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5087,NaN,NaN,NaN,QLI62536,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqspsvsvapgqtaritcggnnigsksvhwyqrkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdnnsdhlvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5088,NaN,NaN,NaN,QLI62535,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiannyvkwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnheeiwvfgggtklivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5089,NaN,NaN,NaN,QLI62534,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddtdrpsgiperfsgsssgntatltisrveagdeadyycqvwdsssdhpvvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5090,NaN,NaN,NaN,QLI62533,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpwvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5091,NaN,NaN,NaN,QLI62532,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qavltqppsvsgapgqrvtisctgsssnieagydvhwyqqlpgtapklliyvnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgvvfgggtklivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5092,NaN,NaN,NaN,QLI62531,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvfycmqgthwpptfgqgtkvdik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5093,NaN,NaN,NaN,QLI62530,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnfatgvpsrfsgtgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5094,NaN,NaN,NaN,QLI62529,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpdkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsgstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5095,NaN,NaN,NaN,QLI62528,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkvpklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqlfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5096,NaN,NaN,NaN,QLI62527,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsltisctgtssdvggynyvswyqqhpdkapklmiydvnnrpsgvsnrfsgsksgstasltisglqaedeadyycssyagsstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5097,NaN,NaN,NaN,QLI62526,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkvpklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5098,NaN,NaN,NaN,QLI62525,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynhvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqlfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5099,NaN,NaN,NaN,QLI62524,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsltisctgtssdiggfnyvswyqqhpgkapklmifdvskrpsgvpnrfsgsksgntasltisglqaedegdyycssytissaqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5100,NaN,NaN,NaN,QLI62523,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqptsvsgspgqsitisctgtssdvggynyvswyqqhpgkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytvsstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5101,NaN,NaN,NaN,QLI62522,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqpasvsgspgqsitisctgtssdvggynyvswyqqhpdkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeaayycssytssstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5102,NaN,NaN,NaN,QLI62521,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgspgqsvtisctgtssdvggydyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvpglqaedeadyyctsyagsnnfvfgggtklivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5103,NaN,NaN,NaN,QLI62520,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5104,NaN,NaN,NaN,QLI62519,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygvssratgipdrfsgsgsetdftltisrlepeefavyycqqygssprtfgqgtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5105,NaN,NaN,NaN,QLI62518,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkftfgpgtkveik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5106,NaN,NaN,QLI33947,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5107,NaN,NaN,QLI33945,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5108,NaN,NaN,NaN,QLI33948,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5109,NaN,NaN,NaN,QLI33946,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5110,NaN,NaN,QKY76702,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqkfqervtitrdvststaymelsslrsedtavyycaaprcsggscydgfdiwgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5111,NaN,NaN,QKY76701,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvkisckasgyifinyamnwvrqapgqglewmgwintntgnptyaqdftgrfvfsldtslstaylqissleaedtavyycakigsrnslgvwgqgtlvtvsa,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5112,NaN,NaN,QKY76700,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5113,NaN,NaN,QKY76699,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgghlvqpgrslrlscaasgftfddyamhwvrqvpgkglewvsgiswnggilgyadsvkgrftisrdnaknslylqmrslrtddtalyycakdlrrqdyyadwyfdlwgrgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5114,NaN,NaN,QKY76698,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5115,NaN,NaN,QKY76697,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgghlvqpgrslrlscaasgftfddyamhwvrqvpgkglewvsgiswnggildyadsvkgrftisrdnaknslylhmrslrtddtalyycakdlrrqdyyadwyfdlwgrgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5116,NaN,NaN,QKY76696,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssntryytdsvmgrftisrdnaknslflqmnslraedtavyycasskgfcsggscsdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5117,NaN,NaN,QKY76695,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5118,NaN,NaN,QKY76694,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsrytiiwvrqapgqglewmgriipildianyaqkfqgrvtitadkststaymelsslrsedtavyycareggldyfgsrnsgwtytwfdpwgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5119,NaN,NaN,QKY76693,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycatgarfgespfdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5120,NaN,NaN,QKY76692,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgrglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycatgarfgespfdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5121,NaN,NaN,QKY76691,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfrnyamtwvrqapgkglewvsgisdsgdrtynadsvkgrfsisrdnskntlhlqmnslraedtavyycalasgsyfgganywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5122,NaN,NaN,QKY76690,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtglyycakdinydsggyhknyfdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5123,NaN,NaN,QKY76689,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgntnyaqkfqgrvtitrdmstrtaymelsslrsedtamyycaapycsstrcydafdiwgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5124,NaN,NaN,QKY76688,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyffdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5125,NaN,NaN,QKY76687,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardfgdfffdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5126,NaN,NaN,QKY76686,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaatgftfrrygmhwvrqapgkglewvagilfdgsnkyyvdsvkgrftisrdssrntlylqlnslrredtavyycakggdyewelleswgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5127,NaN,NaN,QKY76685,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcssticydgfdiwgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5128,NaN,NaN,QKY76684,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgrnkyyvdsvkgrftisrdnskntlylqisslraedtavyycaraarrpvvtdtmayymdvwgkgttvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5129,NaN,NaN,QKY76683,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytflrfamnwlrqapgqglewmgwidtntgtptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarslrganlvpwgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5130,NaN,NaN,QKY76682,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytflrfamnwlrqapgqglewmgwidtntgtptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarslrganlvpwgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5131,NaN,NaN,QKY76681,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarattdcsstscwsldfwsgyytggrekifdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5132,NaN,NaN,QKY76680,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftnyyihwvrqapgqglewvgwihslsggtsyaqkfqgrvtltrdapirtaymelsglgsddtavyycarasvatitdfdywgqgtlvavss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5133,NaN,NaN,QKY76679,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevknpgasvkvsckasgyiftnyyihwvrqapgqglewvgwihslsggtsyaqkfqgrvtltrdasirtaymelsrlgsddtalyycarasvstitdfdywgqgtlvavss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5134,NaN,NaN,QKY76678,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksivylqmnslktedtavyyctrvrrlwfgsyyygmdvwgqgttvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5135,NaN,NaN,QKY76677,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctrvrrlwfgsyyygmdvwgqgttvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5136,NaN,NaN,QKY76676,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardgellgwfdpwgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5137,NaN,NaN,QKY76675,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvsgydssgywgdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5138,NaN,NaN,NaN,QKY76730,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqhkpgqaprllicgassratgipdrfsgsgsgtgftltisrlepedfavyycqqygsspwtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5139,NaN,NaN,NaN,QKY76729,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrashsvdrsylawyqqkpglaprlliygassratgipdrfsgsgsgtdftltisrlepedfalyycqhfgtssvtfgrgtrleik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5140,NaN,NaN,NaN,QKY76728,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5141,NaN,NaN,NaN,QKY76727,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastllsavpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpftfgpgtkvdv,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5142,NaN,NaN,NaN,QKY76726,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5143,NaN,NaN,NaN,QKY76725,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmiqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastllsavpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpftfgpgtivdv,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5144,NaN,NaN,NaN,QKY76724,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfvvyychqygsspwtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5145,NaN,NaN,NaN,QKY76723,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5146,NaN,NaN,NaN,QKY76722,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqkpgkapnlliyaasslqsgvpprfsgsgsgtdftltisslqpedfatyycqqsystlysfgqgtkleik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5147,NaN,NaN,NaN,QKY76721,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpgtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5148,NaN,NaN,NaN,QKY76720,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpgtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5149,NaN,NaN,NaN,QKY76719,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qavvtqepsltvspggtvtltcgsstgpvtsdhypywfqqkpgqapttliydtnnkhswtparfsgsllggkaaltlsgaqpedeaeyycllsytgarvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5150,NaN,NaN,NaN,QKY76718,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdratitcrasqsissylnwyqekpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5151,NaN,NaN,NaN,QKY76717,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkvei,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5152,NaN,NaN,NaN,QKY76716,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprllisgassraagipdrfsgsgsgtdftltinrlepedfavyycqqygssprtfgqgtkleik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5153,NaN,NaN,NaN,QKY76715,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5154,NaN,NaN,NaN,QKY76714,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstvsasvgdrvtitcrasqsidnwlawyqekpgkapkvliykasslesgvpsrfsgrgsgteftltisslqpgdfatyycqhyhsfpltfgggtkvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5155,NaN,NaN,NaN,QKY76713,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrvepedfavyycqqygsspwtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5156,NaN,NaN,NaN,QKY76712,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscraslslssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpptwtfgqgtkaeik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5157,NaN,NaN,NaN,QKY76711,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdvsnylnwyqqqpgkapklliydafnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5158,NaN,NaN,NaN,QKY76710,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdvsnylnwyqqqpgkapklliydafnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5159,NaN,NaN,NaN,QKY76709,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5160,NaN,NaN,NaN,QKY76708,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtsgdigsynlvswyqqypgkapkliiyeaskrpsgvsnrffasksgntasltisglqaedeadyyccsyagvrtvvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5161,NaN,NaN,NaN,QKY76707,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtsgdvgsynlvswyqqhpgkapklviyeatkrpsgvsnrffasksgntasltisglqaedeadyyccsyagvrtvvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5162,NaN,NaN,NaN,QKY76706,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgpgtkvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5163,NaN,NaN,NaN,QKY76705,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgpgtkvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5164,NaN,NaN,NaN,QKY76704,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5165,NaN,NaN,NaN,QKY76703,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppaltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5166,NaN,NaN,QKY76674,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvagisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaradtmvrgtyfeywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5167,NaN,NaN,QKY76673,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5168,NaN,NaN,QKY76672,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5169,NaN,NaN,QKY76671,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5170,NaN,NaN,QKY76670,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyalfwvrqapgkglewvavisydgnnkyyadsvrgrftisrdnskntlylqmnslrpedtavyycarpytgsyksymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5171,NaN,NaN,QKY76669,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5172,NaN,NaN,QKY76668,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycakdgsiaaadywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5173,NaN,NaN,QKY76667,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5174,NaN,NaN,QKY76666,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5175,NaN,NaN,QKY76665,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfstywmtwvrqapgkglewvanikqdgsekyyvdsvkyrftisrdnaknslylqmnslraedtavyycarvgssswyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5176,NaN,NaN,QKY76664,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5177,NaN,NaN,QKY76663,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgskkdyadsvkgrftisrdnskntlylqmnslraedtavyycardqsqgayiltgyrgygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5178,NaN,NaN,QKY76662,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydmnwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarggiyylvrgfiigyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5179,NaN,NaN,QKY76661,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5180,NaN,NaN,QKY76660,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvagisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaradtmvrgtyfeywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5181,NaN,NaN,QKY76659,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgskkdyadsvkgrftisrdnskntlylqmnslraedtavyycardqsqgayiltgyrgygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5182,NaN,NaN,QKY76658,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsdnigyadsvkgrftisrdiaknslylqmnslraedtalyycakgiyydifmplldwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5183,NaN,NaN,QKY76657,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsyypmhwlwvrqapgkglewvavtsydgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarggatnfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5184,NaN,NaN,QKY76656,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaityyydssgywwddwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5185,NaN,NaN,QKY76655,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckasgytfknygiswvrqapgqglewmgwisaytgntnyaqkfqgrmtmttdtstgtgymelrslrsddtavyycarvqrrrldywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5186,NaN,NaN,QKY76654,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5187,NaN,NaN,QKY76653,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfnnyamswvrqapgkglewvsaiggsggstyyadsvkgrftvsrdnsentlylqmsslraedtavyycarvegdwllggpyyhyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5188,NaN,NaN,QKY76652,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscatsgftfssfalhwvrqapgkglewvtvisddgnnkyyvdsvkgrftisrdnskntlflqmnslrvedtaiyycarasynsnwsigeyfrdwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5189,NaN,NaN,QKY76651,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvtvisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksyngnyydafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5190,NaN,NaN,QKY76650,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgsyywswirqpagkglewigrvyiyssgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargaasfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5191,NaN,NaN,QKY76649,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissgsyywswirqpagkglewigriytsgsttynpslksrvtisvntsknqfslnlssvtaadtavyycarvggispyyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5192,NaN,NaN,QKY76648,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfssydinwvrqatgqglewmgwvnpnsghtgyaqkfqgrvtmtrntsvstaymelsslrsedtavfycargrvgyvgsgsrgyyyyydmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5193,NaN,NaN,QKY76647,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcvvsggsisssnwgwvrqppgkglewigeiylsgttnynpsltsrvtisvdksknqfslklnsvtaadtaiyycarptagaggafdiwgqgtvvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5194,NaN,NaN,QKY76646,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgsyviswvrqapgqglqwmggiipifgkpnyaqkfqgrvtitadeststaymelsslrsedtavyycargwfgellkgtywfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5195,NaN,NaN,QKY76645,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgssyyspslksrvtisadtsknqfslnlrsvtaadtavyycasgppymatfsyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5196,NaN,NaN,QKY76644,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5197,NaN,NaN,QKY76643,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggdlvqpggslrltcaasgftfsshwmtwvrqapgkglewvanikedgrekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarvvvevatnkgihgvdyyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5198,NaN,NaN,QKY76642,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgynkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqggnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5199,NaN,NaN,QKY76641,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5200,NaN,NaN,QKY76640,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscadsaftfssfwmswvrqapgkglewvanikqdgsekfyldsvkgrftisrdnaknslylqmnslraedtavyycarlgrsswnfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5201,NaN,NaN,QKY76639,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifstyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylemnslraedtavyycarprggsyqtcfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5202,NaN,NaN,QKY76638,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvtlisydggnkyyadsvkgrftisrdnskntlylqmnslraedaavyfcarghtgnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5203,NaN,NaN,QKY76637,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqleesgpglvkpsetlsltctvsggsisshywswirqppgkglewigyiqdsgstnynpslksrvtisvdtsknqfslrlssvttadtavyycvrgamawfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5204,NaN,NaN,QKY76636,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgfsfrnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5205,NaN,NaN,QKY76635,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgsyywswirqpagkglewigriftsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarggllwfggagnymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5206,NaN,NaN,QKY76634,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycakdgsiaaadywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5207,NaN,NaN,QKY76633,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarestqwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5208,NaN,NaN,QKY76632,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydginkyyadavkgrftisrdnskntlylqmnslraedtavyycarprsgsyyayfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5209,NaN,NaN,QKY76631,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssfamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaayycarelmsvgwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5210,NaN,NaN,QKY76630,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygmhwvrqapgqrlewmgwinvgngntkysqrfqgrvtitrdtsastaymelsslrsedtavyycamgpsafswldpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5211,NaN,NaN,QKY76629,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmtwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslslqmnslrvedtavyycvrlgvsswyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5212,NaN,NaN,QKY76628,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisndefnkfyansvkgrftisrdnskntvylqlnslrtedtaryycakggdgsgwawdgdnpptdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5213,NaN,NaN,QKY76627,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltcavsgasissgsyywswirqpagkglewigriytsgntnynpslksrvtisvdtsknqfslklssvtaadtavyycatgyigtyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5214,NaN,NaN,QKY76626,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcvvsggsisssnwgwvrqppgkglewigeiyhsgttnynpslrsrvtisvdksknqlslklnsvtaadtaiyycarptagaggafdtwgqgtmvtvsa,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5215,NaN,NaN,QKY76625,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5216,NaN,NaN,QKY76624,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5217,NaN,NaN,QKY76623,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevrkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgtanyaqkfqgrvtitadkststafmelnslrsedtavyycarigsypeyfqhwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5218,NaN,NaN,QKY76622,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfilsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycasvitfggvivrsywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5219,NaN,NaN,QKY76621,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnpkntlylqmnslraedtavyycardtatyvllwsgdfnldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5220,NaN,NaN,QKY76620,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrhamhwvrqapgkglewvavisydgsnkyyadsvkgrfaisrdnskntlylqmnslrpedtavyycardpsplvlitsidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5221,NaN,NaN,QKY76619,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsiywmswvrqapgkglqwvanikqdasekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlggsswhfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5222,NaN,NaN,QKY76618,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsyyailwfrqapgkglewvaiisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycarpqsggyyapldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5223,NaN,NaN,QKY76617,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckasgytfknygiswvrqapgqglewmgwisaytgntnyaqkfqgrmtmttdtstgtgymelrslrsddtavyycarvqrrrldywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5224,NaN,NaN,QKY76616,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikedgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardvggysgydlgfdyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5225,NaN,NaN,QKY76615,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvelvesgggvvqpgrslrlscaasgfifssyamhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqggnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5226,NaN,NaN,QKY76614,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglawvalisydgynkyyadsvrgrftisrinskntlslqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5227,NaN,NaN,QKY76613,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamywvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvnsgsyysyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5228,NaN,NaN,QKY76612,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgsalkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycargrsyglslgywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5229,NaN,NaN,QKY76611,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfttyamnwvrqapgqglewmgwintntgnptyaqdftgrfvfsldtsvstaylqisslkaedtavyycarglvgridpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5230,NaN,NaN,QKY76610,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5231,NaN,NaN,QKY76609,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtskkqfslklssvtaadtavyycageevrgvklyyyyamdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5232,NaN,NaN,QKY76608,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5233,NaN,NaN,QKY76607,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgttnyaqklqgrvtisadeststaymevsslrsedtavyycarvsgygdygaysdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5234,NaN,NaN,QKY76606,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5235,NaN,NaN,QKY76605,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmsslraedtavfycargdgdvynfllvrnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5236,NaN,NaN,QKY76604,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevrkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgtanyaqkfqgrvtitadkststafmelnslrsedtavyycarigsypeyfqhwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5237,NaN,NaN,QKY76603,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsfisgtgdstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdqarvqdyiwgsyrsygmdvwglgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5238,NaN,NaN,QKY76602,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsyypmhwlwvrqapgkglewvavtsydgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarggatnfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5239,NaN,NaN,QKY76601,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkgldwvavisydgsnryyaasvkgrftisrdnskntlylqmnslrtedtavyfcargdgyrsqfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5240,NaN,NaN,QKY76600,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisayngnsnygkkfqgrvtmtadtststaymelrslrsddtavyycardlpikvvvpaadynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5241,NaN,NaN,QKY76599,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyalfwvrqapgkglewvavisydgnnkyyadsvrgrftisrdnskntlylqmnslrpedtavyycarpytgsyksymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5242,NaN,NaN,QKY76598,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),eaqlvesggglvqpgrslrlscaasgftfddsamhwvrqapgkglewvsgiswnsgnvgyadsvkgrftisrdnaknslylqmnslraedtalyyctkasrycssticywnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5243,NaN,NaN,QKY76597,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),eaqlvesggglvqpgrslrlscaasgftfddsamhwvrqapgkglewvsgiswnsgnvgyadsvkgrftisrdnaknslylqmnslraedtalyyctkasrycssticywnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5244,NaN,NaN,QKY76596,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvntaylqisslkaedtavyycararllgycsstscytigwgafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5245,NaN,NaN,QKY76595,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglawvalisydgynkyyadsvrgrftisrinskntlslqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5246,NaN,NaN,QKY76594,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5247,NaN,NaN,QKY76593,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyfvdsvkgrftisrdnaknslylqmnslraedaavyycarlvttvttanglyyysyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5248,NaN,NaN,QKY76592,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarestqwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5249,NaN,NaN,QKY76591,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfafsnyaihwvrqapgkglewvavisydgnnkdyadsvkgrftisrdnskntlylqmnslraedtavyycarvpvmvrgvyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5250,NaN,NaN,QKY76590,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdltivvipaapnfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5251,NaN,NaN,QKY76589,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlsctasgfifgdyamgwvrqapgkglewvgfirgkaydgtteyaasvkgrftisrddskyiahlqmnslktedtavyycirdydfwggyyyhplrafdiwgrgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5252,NaN,NaN,QKY76588,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavissdgsnkyyagsvkgrftisrdnskntlylqmnslraedtavyycakdmveplfshyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5253,NaN,NaN,QKY76587,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgtyywswirqpagkglewigrfytsgstnynpslksrvtisvdasknqfslklssvtaadtavyycararpdyyyyyamdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5254,NaN,NaN,QKY76586,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvqvsceasgytfttyymhwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymdlsslrsedtavyycardrlgdgsylgggyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5255,NaN,NaN,QKY76585,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarpdyssgwfsywyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5256,NaN,NaN,QKY76584,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggavqpgrslrlscaasgftfstyamywvrqapgkglewvavisydgsnryyadsvkgrftisrdnskntlylqmnslrpedtavyycardrsgnyrdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5257,NaN,NaN,QKY76583,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsvyyigstyynpslksrvtmsvdtsknqfslklssvtaadtavyycarapfqlldkyyffyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5258,NaN,NaN,QKY76582,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftshwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasalrergvqlwsvwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5259,NaN,NaN,QKY76581,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydeinkyyadsvkgrftisrdnskttldlqmnslraedtavyycaragggsyrgpfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5260,NaN,NaN,QKY76580,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgtnkyyadsvkgrftisrdnskntlylqmnslraddtavyycakgrgnyltffdswgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5261,NaN,NaN,QKY76579,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsfyaihwvrqapgqglewaaaissdgtykyyadsvkgrftisrdnskntsylqmnslraedtavyycaralnkgfdpwgqgtlltvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5262,NaN,NaN,QKY76578,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknhfslkmnsvtaadtavyycarcrqmgnfyyyymdvwgkgttvtvsp,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5263,NaN,NaN,QKY76577,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5264,NaN,NaN,QKY76576,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggrlvlpggslrlscaasgftfsvyemnwvrqapgkglewlsyigtsgspiyyadsvkgrftvsrdnaknslylqmnslrvedtalyycardrgwnygldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5265,NaN,NaN,QKY76575,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadkststaylqwsslkasdtamyycarrgeaagiwyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5266,NaN,NaN,QKY76574,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarpdyssgwfsywyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5267,NaN,NaN,QKY76573,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnswigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycathrcsggfcylaywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5268,NaN,NaN,QKY76572,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsgnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnspraedtavyycardpsayydiltgysgdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5269,NaN,NaN,QKY76571,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysagstyyadsvkgrfsisrdkskntlylqmnslraedtavyycakeggsgslryyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5270,NaN,NaN,QKY76570,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftshwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasalrergvqlwsvwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5271,NaN,NaN,QKY76569,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitlkesgpplvepkqtltltctfsgfslttsgeavgwirqppgkalewlaliywdddkhyspslrnrltitrdtsknqvvltltnvdpadtgtyycahravilnfdhwgqgflvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5272,NaN,NaN,QKY76568,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrvscaasgftfsshgmhwvrqapgkglewvsviwydgsnkyyadsvkgrftisrdnskntlslqmnslraedtavyycaresadissrldywgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5273,NaN,NaN,QKY76567,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsppasyynpstgyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5274,NaN,NaN,QKY76566,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftrhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycvreygsghplpiwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5275,NaN,NaN,QKY76565,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfsdywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarltfggsgsyyfyyngmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5276,NaN,NaN,QKY76564,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyviswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardqgptyyygsgsphygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5277,NaN,NaN,QKY76563,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnaknslylqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5278,NaN,NaN,QKY76562,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgrnkyyadsvkgrftisrdnskntlylqmsslraedtavyycakegewelrgnaldiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5279,NaN,NaN,QKY76561,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitlkesgptlvkptqtltltctvsgfslstsgvgvgcirqppgkalewlaliywdddkryspslksrltitrdtsknqvvltmtnmdpvdtgtyfcvhrhvsgafdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5280,NaN,NaN,QKY76560,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifstygmhwvrqapgkglewvavisydgsnkynadsvkgrftisrdnskntlylqmnslrvedtavyycaiygyyyygldvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5281,NaN,NaN,QKY76559,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknhfslkmnsvtaadtavyycarcrqmgnfyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5282,NaN,NaN,QKY76558,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qgqlvqsggdvvqpgkslrlscaasgftftnyamhwvrqapgkglewvavisndgsnekyvdsvkgrfslsrdnskntvyldmhslrpedtaiyycardrsnlerlvmtfggiiagafdiwgqgarvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5283,NaN,NaN,QKY76557,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5284,NaN,NaN,QKY76556,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfsdyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarglislfrgaifhyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5285,NaN,NaN,QKY76555,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgrikgktdggttdyaapvkgrftiskddskntlylqmsslntedtavywcttltyyydssaylndafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5286,NaN,NaN,QKY76554,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnyywgwirqppgkglewigtihysgisyynpslksrvtisvdtsnnkfslelssvtaadtavyfcarrtyydlwsaysstayycmdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5287,NaN,NaN,QKY76553,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisndgrnkyyadsvkgrltisrdnskntlylqmnslraedtavyycarpsnwyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5288,NaN,NaN,QKY76552,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycardggnayssgwyryyyhmdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5289,NaN,NaN,QKY76551,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfhnyaiswvrqapgqglewmggfipilgttnyaqkfqgrvtitadeststaymelsslrsedtavyycarvegegvdsyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5290,NaN,NaN,QKY76550,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqiqqwgagvlkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstkynpslksrvtisvdtsknqfslklssvtaadtavyycargppvttffvfsllfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5291,NaN,NaN,QKY76549,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgkslrlscaasgftfssygmhwvrqapgkglewvaviwydgnnkfyvdsvkgrftisrdnskntlymemnslraedtavyycarkgplwrfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5292,NaN,NaN,QKY76548,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapdkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqwpnqafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5293,NaN,NaN,QKY76547,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadkststaylqwsslkasdtamyycarrgeaagiwyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5294,NaN,NaN,QKY76546,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckaseytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarpgkaaafdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5295,NaN,NaN,QKY76545,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqgtyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5296,NaN,NaN,QKY76544,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavvsydgsnkyytdsvkgrftisrdnskntlflqmiglreedtavyycaqgrggyyspfddwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5297,NaN,NaN,QKY76543,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslntngvavgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrrgiltedafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5298,NaN,NaN,QKY76542,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvaviwydgnkkycadsvkgrctisrdnskntlylqmnslraedtavyycaregpfgdreasgafdvwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5299,NaN,NaN,QKY76541,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisgdnskntlylqmnslrvddtavyycardpgsrysggwydyyyamdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5300,NaN,NaN,QKY76540,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssnywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardprvvvtarmynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5301,NaN,NaN,QKY76539,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwtwvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycasrwgdyfdssgaydswgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5302,NaN,NaN,QKY76538,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssylmhwvrqapgkglewvaviwangnryyadsvkgrftisrdiskntlylqmnslraedtamyycardycngvtcnsnywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5303,NaN,NaN,QKY76537,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsglcvswirqppgkalewlaridwdddkyyntslrtrltiskdtsknqvvltmtnmdpvdtatyycarattffygmdvwgqgttatvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5304,NaN,NaN,QKY76536,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvavisfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgsgsyygwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5305,NaN,NaN,QKY76535,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlacaasgftfssygmhwvrqapgkglewvavisydgnnkyyadslkgrftisrddskntlylqmnslraedtavyycakdrtavflffglgdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5306,NaN,NaN,QKY76534,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwfdgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycaregdfwsgyytgwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5307,NaN,NaN,QKY76533,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5308,NaN,NaN,QKY76532,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnswigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycathrcsggfcylaywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5309,NaN,NaN,QKY76531,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5310,NaN,NaN,QKY76530,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaradpyqllgqhyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5311,NaN,NaN,QKY76529,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtalyycarearyfdwifegsdyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5312,NaN,NaN,QKY76528,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5313,NaN,NaN,QKY76527,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklnsvtaadtavyycasrwgdyfdssgaydswgqgtlltvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5314,NaN,NaN,QKY76526,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvadisydgsekyyadsvkgrftiyrdnskntlylqmnslraedtavyycakdfggdntamveyffdfwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5315,NaN,NaN,QKY76525,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5316,NaN,NaN,QKY76524,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiayadsvkgrftisrdnaknslylqmnslraedtalyfcakvgwelsidafdlwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5317,NaN,NaN,QKY76523,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviyydgsnkyyadsvkgrftisrdnskntlylqihslraedtavyycaregqmaattgidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5318,NaN,NaN,QKY76522,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisndefnkfyansvkgrftisrdnskntvylqlnslrtedtaryycakggdgsgwawdgdnpptdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5319,NaN,NaN,QKY76521,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evalvesggglvkpggslrlscaasgfifsnawmtwvrqapgkglewvgrikskseggtpeyaapvkgrfiisrddstnslhlqmnylriedtavyycttggyssyaasdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5320,NaN,NaN,QKY76520,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5321,NaN,NaN,QKY76519,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5322,NaN,NaN,QKY76518,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahnrfqycssttcytllpfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5323,NaN,NaN,QKY76517,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvrdlalfevviqqgvwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5324,NaN,NaN,QKY76516,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrrggigieygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5325,NaN,NaN,QKY76515,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscavsgftfssywmhwvrqapgkglvwvsrinsdgsstsyadsvkgrftisrdnakntlylqmnslraedtavyycareveqlahmvdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5326,NaN,NaN,QKY76514,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftshymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtgdtststvymelsslrsedtavyycardlagvpaalgcwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5327,NaN,NaN,QKY76513,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissttyywgwirqppgkglewiasiyysgstyynpslksrltvsvdtsknqfslklssvtaadtavyycarqwkwfgeawyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5328,NaN,NaN,QKY76512,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfptywigwvrqmpgkglewmgiiypgdsdtrygpsfqgqvtisadksistaylqwsslkasdtamyycarrdtdfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5329,NaN,NaN,QKY76511,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evrllesggglvqpggslrlscaasgftfsdyamnwvrqapgkglewvsaisatggstfyadsvkgrfsisrdnsknslvlqmnslraedtavyycakpygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5330,NaN,NaN,QKY76510,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygihwvrqapgqglewvagiwydgsnkyyvdsvkgrftisrdnskntlylqmnslraedtavyycagssgegglyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5331,NaN,NaN,QKY76509,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfdsygvhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlyvqmnslrtedtavyycardsggnygdsyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5332,NaN,NaN,QKY76508,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfttyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvntaflhigslkaedtavyycardqdsgyptyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5333,NaN,NaN,QKY76507,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftftsyamswvrqapgkglewvsgisisggstyyaasvkgrftisrdnskntlylqmnslraedtavyycakdsrsgiagvdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5334,NaN,NaN,QKY76506,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdmsknqfslklrsvtaadtavyycaraprerlqwgeyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5335,NaN,NaN,QKY76505,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmiglraedtavyycardwaptyydmpsafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5336,NaN,NaN,QKY76504,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlkesgpvlvkptetltltcavsgfslsnakmgvswirqppgkalewlahifsndekaystslktrltiskdtsksqvvltvtnmdpvdtatyycarivlgasgtypspgfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5337,NaN,NaN,QKY76503,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycargwyfdywgqgtlvtvsa,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5338,NaN,NaN,QKY76502,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggslssyywswirqppgkglewigyiydsggasrstnynpslksrvtisvdtsrnqlslklssvtaadtavyycardqrqfqllgrfgwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5339,NaN,NaN,QKY76501,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgssnynpslksrvtisvdtsknqfslklssvtaadtavyycargwgwgavagraeyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5340,NaN,NaN,QKY76500,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycardqewfrelflfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5341,NaN,NaN,QKY76499,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycareandsgsfyngpfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5342,NaN,NaN,QKY76498,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqqfqgrvtmtedtstdtaymelsslksedtalyycatgfavfgraavpywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5343,NaN,NaN,QKY76497,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evrllesggglvqpggslrlscaasgftftsyamswvrqapgkglqwvstisvsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdpasgivgpthfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5344,NaN,NaN,QKY76496,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaavkkpgssvkvsckasggtfssyaiswvrqapgqglewmggivpifgtanyaqkfqgrvtitadestttaymelnslrsedtavyycaredyygsgslvdpyyyyrmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5345,NaN,NaN,QKY76495,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5346,NaN,NaN,QKY76494,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisnsnsfiyyadsmkgrftisrdnaknslylqmnslraedtavyycarvngnsnwnfgsyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5347,NaN,NaN,QKY76493,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissgtyycgwirqppgkglewigstyyggstlynpslrgrvtisvdtsknqfslklssvtaadtavyycarrgnyydsknwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5348,NaN,NaN,QKY76492,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgsaiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarearsryfdwlpsyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5349,NaN,NaN,QKY76491,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftftsyamnwvrqapgkglewvsaisvsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfgsgivgatgfdfwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5350,NaN,NaN,QKY76490,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftftsygmswvrqapgkglewvsaisisggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakllgsgitldndafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5351,NaN,NaN,QKY76489,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyscaslwfgdlysfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5352,NaN,NaN,QKY76488,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsgysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwlqlrsdyyyfgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5353,NaN,NaN,QKY76487,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlkesgpvlvkptetltltctvsgfslsnarmgvswirqppgkalewlahifsgdeksystslksrltiskdtsksqvvltmtnmdpldtatyycarttwgtwiqawyfdiwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5354,NaN,NaN,QKY76486,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarppqaarihyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5355,NaN,NaN,QKY76485,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggpisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklnsvtaadtavyycarhdgsgemdtitwgpiyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5356,NaN,NaN,QKY76484,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlsctasgftfssyamhwvrqapgkglewvalisydgnnkyyadsakgrftisrdnskntlylqmnslrsedtavyycardlgrgldpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5357,NaN,NaN,QKY76483,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsirsssyywgwirqppgkglewiasiyysgstyynsslksrvtisvdtsknqfslkvnsmtaadtavyycailwrgsswadrhyyyysmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5358,NaN,NaN,QKY76482,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllqsggglvqpggslrlscaasgftfrnyamswvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycakneritmlvvvtlfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5359,NaN,NaN,QKY76481,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlsceasgftfssseinwvrqapgkglewvshisssgsiiyyadsvkgrftisrdnaknslylqmnslraedtavyycarrsyrsswyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5360,NaN,NaN,QKY76480,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvhpggslrlscaasgftfssyalswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnrlraedtavyycaqmgplgstssaadywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5361,NaN,NaN,QKY76479,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsinsgnyywswirqpagkglewigrmftsgstnynpsltsrvtmsidtsknqfslnlnsvtaadtamyycarghvaawescyywgqgilvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5362,NaN,NaN,QKY76478,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlkesgpvlvkptetltltcavsgfslsnakmgvswirqppgkalewlahifsndekaystslktrltiskdtsksqvvltvtnmdpvdtatyycarivlgasgtypspgfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5363,NaN,NaN,QKY76477,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarppqaarihyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5364,NaN,NaN,QKY76476,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdmsknqfslklrsvtaadtavyycaraprerlqwgeyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5365,NaN,NaN,QKY76475,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsgysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwlqlrsdyyyfgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5366,NaN,NaN,QKY76474,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisnsnsfiyyadsmkgrftisrdnaknslylqmnslraedtavyycarvngnsnwnfgsyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5367,NaN,NaN,QKY76473,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycardqewfrelflfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5368,NaN,NaN,QKY76472,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqqfqgrvtmtedtstdtaymelsslksedtalyycatgfavfgraavpywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5369,NaN,NaN,QKY76471,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgsaiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarearsryfdwlpsyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5370,NaN,NaN,QKY76470,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmiglraedtavyycardwaptyydmpsafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5371,NaN,NaN,QKY76469,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlsceasgftfssseinwvrqapgkglewvshisssgsiiyyadsvkgrftisrdnaknslylqmnslraedtavyycarrsyrsswyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5372,NaN,NaN,QKY76468,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedgetvyaqkfqgrvtmtedtssdtaymelsslrsedtavyycatsfpirgdpsyyyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5373,NaN,NaN,QKY76467,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsihwvrqapgkglewmggfdpedvetiyaqkfqgrvtmtedtstdtaymelssltsedravyycatqpaaiggtppyywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5374,NaN,NaN,QKY76466,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqnfqgrvtmtedtstdtaymelsslrsedtalyycaaapavmtagwfdpwgqgtlvsvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5375,NaN,NaN,QKY76465,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyfwswirqhpgkglewigsiyysgstyynpslrsritisvdtsknqfslklssvtaadtavyycarggsgsyslfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5376,NaN,NaN,QKY76464,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5377,NaN,NaN,QKY76463,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgnglewigsiyysgstyynpslkgrvsisvdtsknqfslklssvtaadtavyycarilviftlnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5378,NaN,NaN,QKY76462,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvawirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrlptpqllpsfenwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5379,NaN,NaN,QKY76461,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgseltkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintdtgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycardpsycsstrcytvgwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5380,NaN,NaN,QKY76460,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslntsgvgvgwirqppgkalewlaliywdddkrynpslksrltitkdtsknqvvltmtnmdpvdtatyycahrppsyhgwcyfdywgqgnlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5381,NaN,NaN,QKY76459,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavilydgsnryyadsvkgrftisrdnskntlylqmnslraedtavyycakqgglycsgtncwggyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5382,NaN,NaN,QKY76458,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvgiisydasdktyaesvkgrftisrdnskntlylqmnslraedtavyycakvsatyyyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5383,NaN,NaN,QKY76457,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywvgwvrqmpgkglewmgiiypgdsdtrdspsfqgqvtisadksistaylqwsslkasdtamyycarlgseskidyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5384,NaN,NaN,QKY76456,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglecvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardpirdgvwglnendywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5385,NaN,NaN,QKY76455,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftshymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtsdtststvymelsslrsedtamyycardvfwvpaassfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5386,NaN,NaN,QKY76454,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstkrvgvgwirqppgkalewlaliywdddqryspslksrltitkdtsknqvvltmtnmdpvdtatyycahsgppdlspvlsqgwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5387,NaN,NaN,QKY76453,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgitiyyadsvkgrftisrdnaknslylqmnslraedtavyyctgvvaapaeyfqhwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5388,NaN,NaN,QKY76452,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyfwswirqhpgkglewigsiyysgstyynpslrsritisvdtsknqfslklssvtaadtavyycarggsgsyslfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5389,NaN,NaN,QKY76451,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywnwlrqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarvggyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5390,NaN,NaN,QKY76450,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevktpgasvkvsckasgytftsydinwvrqatgqgpewmgwmnpnsgntgyahkfqgrvtmtrntsistaymelsslrsedtavyycargpsiltgfynpldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5391,NaN,NaN,QKY76449,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwagdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5392,NaN,NaN,QKY76448,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytftsydinwvrqatgqglewmgwmnpnsghtgyaqkfqgrvtmtrntsistaymelsslryedtavyycargygltyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5393,NaN,NaN,QKY76447,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfrrygmywvrqapgkglewvavisydgtdkyytdsvkgrftisrdnskntlylqmnslraedtavyycakkggpycgggncyagyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5394,NaN,NaN,QKY76446,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtfssyylhwvrqapgqglqwmgisnpsggsttyaqkfqgrvtmtgdtststvymelsslrsedtavyycargglvpaarnafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5395,NaN,NaN,QKY76445,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiqpgdsdtryspsfqgqvtmsadkststaylqwsslkasdtamyycardliiestiaarpgyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5396,NaN,NaN,QKY76444,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvstigtagdtyypdsvkgrftisrenaknslflqmnslragdtavyycarvdfdiltgyysnwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5397,NaN,NaN,QKY76443,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvrlvqsgaevkkpgssvkvsckasggtfsdyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeftitaymelsslrsedtavyycarlsgsgwlgyamdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5398,NaN,NaN,QKY76442,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsgiswnggntgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwaggafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5399,NaN,NaN,QKY76441,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsryamywvrqapgkglewvalisydgrneyyadsvkgrftisrdnskntlylqmnslragdsavyycardlayhpyrdygdddyyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5400,NaN,NaN,QKY76440,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfddyamhwvrqapgkglewvslisgdggntyyadsvkgrftisrdnsknslylqmnslrtedtalyycakdemayppshhyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5401,NaN,NaN,QKY76439,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsykyfadsvkgrftisrdnskntlylqmnslraedtavyycardqgtvvthfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5402,NaN,NaN,QKY76438,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhggstdynpslksrvtisvdksknqfslkltsvtaadtavyycarvdhvnvrdywgpgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5403,NaN,NaN,QKY76437,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscvasgftfssygmhwvrqapgkglewvavisfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavfycakdlppyasgwyeggfdywgrgtqvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5404,NaN,NaN,QKY76436,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsdyamhwvrqapgkglewvadisfdgsnkyyadsvkgrftisrdssentlylqmdslraddtavyycardlsttwylemwgpdafdiwgqgtvvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5405,NaN,NaN,QKY76435,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5406,NaN,NaN,QKY76434,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsayywswirqppgkglewigeinhsgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycarvgysqgyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5407,NaN,NaN,QKY76433,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),eaqlvesggglvqpggslrlsceasgfifssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarvndgrpnpleyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5408,NaN,NaN,QKY76432,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqsggslrlscaasgftfstygmhwvrqapgkglewvaiisydginkyyadsvkgrftisrdnskntvylqmnslrtedtamyycakgdgsylmdyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5409,NaN,NaN,QKY76431,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargltgssaykdeiyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5410,NaN,NaN,QKY76430,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfnnyamswvrqapgkglewvsaiggsggstyyadsvkgrftvsrdnsentlylqmsslraedtavyycarvegdwllggpyyhyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5411,NaN,NaN,QKY76429,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlkesgpvlvkptetltltctvsgfslsnarmgvswirqppgkalewlahifwndensystslktrltiskdtsksqvvlnmtnmdpvdtatyycartewllsdnwfdswgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5412,NaN,NaN,QKY76428,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfrrygmywvrqapgkglewvavisydgtdkyytdsvkgrftisrdnskntlylqmnslraedtavyycakkggpycgggncyagyfdywgqgilvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5413,NaN,NaN,QKY76427,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypdsvkgrftisrenaknslylqmnslragdtavyycarggdsgydlgawyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5414,NaN,NaN,QKY76426,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5415,NaN,NaN,QKY76425,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgnglewigsiyysgstyynpslkgrvsisvdtsknqfslklssvtaadtavyycarilviftlnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5416,NaN,NaN,QKY76424,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfrsydmhwvrqvtgkglewvstigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarvfetkvirggryyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5417,NaN,NaN,QKY76423,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapgqglewmgilnpgagstsyaqkfqgrvtmtsdtstntvymqlsslksedtavyycardqqivphadgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5418,NaN,NaN,QKY76422,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5419,NaN,NaN,QKY76421,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakvssitsllgyyfdswgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5420,NaN,NaN,QKY76420,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5421,NaN,NaN,QKY76419,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsssdlhwvrqatgkglewvsaigtagdtyylgsvkgrftisrengknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5422,NaN,NaN,QKY76418,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfddyamhwvrqapgkglewvslisgdggntyyadsvkgrftisrdnsknslylqmnslrtedtalyycakdemayppshhyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5423,NaN,NaN,QKY76417,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyylhwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtstsavymelrslrsedtavyycarendygdyveprdyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5424,NaN,NaN,QKY76416,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5425,NaN,NaN,QKY76415,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyisysgstyynpslksrltisvdtsknqfslklssvtaadtavyycardlgdgynlrvpayfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5426,NaN,NaN,QKY76414,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsrhwmtwvrqapgkglewvanikqdgsekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarlgfyyggadywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5427,NaN,NaN,QKY76413,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggdlvkpgrslrlscsasgftfgdytmswfrqapgkglewvafirskayggtteyaasvigrftisrddsksiaylqmnslksedtavyycsrvrgsfygsvgknygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5428,NaN,NaN,QKY76412,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5429,NaN,NaN,QKY76411,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktaggtsssyaiswvrqapgqglewmgriipilgvaiyaqkfqgrvtitadkststaymelnslrsedtavyyctttqggdygdnlyyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5430,NaN,NaN,QKY76410,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5431,NaN,NaN,QKY76409,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtfttyyihwvrqapgqglewmgiinpsggsrsyaqkfqgrismtsdtststvymelsslrsedtavyycargygfvpnvlyyfdywgqgilvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5432,NaN,NaN,QKY76408,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5433,NaN,NaN,QKY76407,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqvvesggglvqpgrslrlscaasgftfedyamhwvrqapgkglewvsgvswnsgiigyadsvkgrftisrdnaknslylqmnslraedtalyycakldvggydfvsghyyafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5434,NaN,NaN,QKY76406,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5435,NaN,NaN,QKY76405,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsdyamhwvrqapgkglewvadisfdgsnkyyadsvkgrftisrdssentlylqmdslraddtavyycardlsttwylemwgpdafdiwgqgtvvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5436,NaN,NaN,QKY76404,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmhwvrqvpgkglvwvsrinsdgsstsyadsvkgrftisrdnakntlylemnslraqdtavyycagspwlrgdidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5437,NaN,NaN,QKY76403,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvhlvqsgaevkkpgasvklsckasgytftnyllhwvrqapgqglewmgnvnpsrgtatypqklddrvtmtsdksastiymelsglrsedtaiyycarersgtyffdywgqgtlltvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5438,NaN,NaN,QKY76402,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkrpgasmnisckasgynfnnnyiywvrqapgqglewmgvvnptgggtayaqgfqdrvtitsdtprntvylgvtglhsedtavyfcarggewrivpggrdyfdywgqgtlvtvsa,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5439,NaN,NaN,QKY76401,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5440,NaN,NaN,QKY76400,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5441,NaN,NaN,QKY76399,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckapgytfttyyihwvrqapgqglewmgiinpsagsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycargfhvpaalrnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5442,NaN,NaN,QKY76398,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycargpepdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5443,NaN,NaN,QKY76397,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5444,NaN,NaN,QKY76396,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5445,NaN,NaN,QKY76395,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissrsstikyadsvkgrftisrdnaknslylqmnslrdedtavyycarvdyygsgsvywyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5446,NaN,NaN,QKY76394,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5447,NaN,NaN,QKY76393,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyaesvkgrftisrdnskntlylqmnslraedtavyycardlhqdwvvvvaanvygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5448,NaN,NaN,QKY76392,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5449,NaN,NaN,QKY76391,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsagstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargtlipahrgafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5450,NaN,NaN,QKY76390,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrsltlscaasgftfddytmhwvrqapgkglewvsgidwnggtigyadsvkgrftisrdnaknslylqmnslraedtalyycakagyyayvwgsyrfeyfdnwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5451,NaN,NaN,QKY76389,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5452,NaN,NaN,QKY76388,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsglcvswirqppgkalewlaridwdddkyyntslrtrltiskdtsknqvvltmtnmdpvdtatyycarattffygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5453,NaN,NaN,QKY76387,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqvvesggglvqpgrslrlscvssgfifddyvmhwvrqrpgkglewvagitynggilgygdsvkgrfiiardnvrgflslqmgdlrtedtalyycardycssttcpaetyyymdvwgkgtavtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5454,NaN,NaN,QKY76386,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggdliqpggslrlscaasgltvssnymswvrqapgkglewvsiiysggstyyadsvkgrfsisrdnsnntlylqmnslraedtavyfcarhipawgykwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5455,NaN,NaN,QKY76385,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarddnspqgsgwyfyyyyamdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5456,NaN,NaN,QKY76384,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqvvqsgpglvkpsetlsltctvsgdpvintnyywgwirqppgkglewigtlsysggthynpslssrvtiavdsskkrfsltlrsvtaadtaiyycarhpvdgynygysdlwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5457,NaN,NaN,QKY76383,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5458,NaN,NaN,QKY76382,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5459,NaN,NaN,QKY76381,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtdss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5460,NaN,NaN,QKY76380,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqagaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargaavpaagefdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5461,NaN,NaN,QKY76379,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytftgyvvhwvrqapgqdlewmgwintgygntkysqkfqgrvtiswdtsattaymelsnlksedkavyycasmtrmseqtyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5462,NaN,NaN,QKY76378,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5463,NaN,NaN,QKY76377,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5464,NaN,NaN,QKY76376,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissgryywswirqhpgkglewigfvyysgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycaretysayemppyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5465,NaN,NaN,QKY76375,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtfttyyihwvrqapgqglewmgiinpsggsrsyaqkfqgrismtsdtststvymelsslrsedtavyycargygfvpnvlyyfdywgqgtlvtvst,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5466,NaN,NaN,QKY76374,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkrpgssvkvsckasggtfssytiswvrqapgqglewmgriipilavanyaqkfqgrvtitadkststaymelsslrsedtavyycardhsgyydstslmspffdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5467,NaN,NaN,QKY76373,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlpltctvsggsissssyywgwirqppgkglqwigniyysgstyynsslksrvtisvdtsknqfslklssvtaadtavyycarqsrgysyawsfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5468,NaN,NaN,QKY76372,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5469,NaN,NaN,QKY76371,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmspnsgntgyaqkfqgrvtmtrdtsistaymelnslrsedtavyycarmrsgwpthgrpddhwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5470,NaN,NaN,QKY76370,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgeslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrfiisrhnskntlylqmnslraedtavyycardlnehgldvwgqgttvsvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5471,NaN,NaN,QKY76369,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsirsyfwnwvrqppgkglewigyiyysgstnykpsfksrvtisldtsknqislklssvtaadtavyycaratwlrdafgiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5472,NaN,NaN,QKY76368,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscvaseftfssywmswfrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslktedtavyycasvitfggvivrsywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5473,NaN,NaN,QKY76367,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqvslklssvtaadtavyycarfrrsygsgsyynisfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5474,NaN,NaN,QKY76366,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5475,NaN,NaN,QKY76365,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgityynpslksrvtisvdtsknqfslklssvtaadtavyycarhqrycsssschvwdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5476,NaN,NaN,QKY76364,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvscqasgytftsydinwvrqatgqglewmgwmksnsgntgyaqkfqgrvtmtrntsistaymeltslrsedtavyycarmrsgwpthgrpddlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5477,NaN,NaN,QKY76363,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipvlgianyaqkfqdrvtitadkststaymelsslrsedtavyycarvgvsgfksgsnwyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5478,NaN,NaN,QKY76362,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycariqyqlngmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5479,NaN,NaN,QKY76361,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5480,NaN,NaN,QKY76360,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5481,NaN,NaN,QKY76359,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),eaqllesggalvqpggslrlscaasgftfsccamgwvrqapgrglewvssihddgvgtfyavsvkgrfsisrdnskntvylqmnglraedtgvyycakwagpivmkyylqywgqgalvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5482,NaN,NaN,QKY76358,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfsvstnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardyrdwiwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5483,NaN,NaN,QKY76357,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycasaklvatisyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5484,NaN,NaN,QKY76356,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgnagygqkfqgrvtmtrntsistaymelsslrsedtavyycarmrsgwpthgrpddywgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5485,NaN,NaN,QKY76355,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakvgytisrqwlvgefdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5486,NaN,NaN,QKY76354,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycartptlynwfhpwgqgtpvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5487,NaN,NaN,QKY76353,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlresgpalvkptqtlsltctfsgfslgtsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycargvvtydywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5488,NaN,NaN,QKY76352,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckapgytfttyyihwvrqapgqglewmgiinpsagsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycargfhvpaalrnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5489,NaN,NaN,QKY76351,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5490,NaN,NaN,QKY76350,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5491,NaN,NaN,QKY76349,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtststaymelssltsddtavyycarmrtgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5492,NaN,NaN,QKY76348,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnpnsgnagyaqkfqgrvtmtrdtsistaymelsslrsedtavyycarmrsgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5493,NaN,NaN,QKY76347,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5494,NaN,NaN,QKY76346,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5495,NaN,NaN,QKY76345,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfgsfdinwvrqatgqglewmgrmnsnsgntayaqkfqgrvtmtrdtstntaymelsslrsedtamyycarmrsgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5496,NaN,NaN,QKY76344,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftshtmnwvrqapgqglewmgwintntgnpmyaqgftgrfvfsldtsgstaylqisslkaedtavyycarwgpdygdyasndywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5497,NaN,NaN,QKY76343,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5498,NaN,NaN,QKY76342,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalissdggnkfyadsvkgrftisrdnskntlylqmnslraedtavyycardvpttvtaftvftywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5499,NaN,NaN,QKY76341,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycararggynwnfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5500,NaN,NaN,QKY76340,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlresgpalvkptqtlsltctfsgfslgtsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycargvvtydywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5501,NaN,NaN,QKY76339,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdttynpsfqgqvtisadkslttaflhwsslkasdtaiyycarrfygpssfdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5502,NaN,NaN,QKY76338,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5503,NaN,NaN,QKY76337,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipvlgianyaqkfqdrvtitadkststaymelsslrsedtavyycarvgvsgfksgsnwyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5504,NaN,NaN,QKY76336,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvscisssssfiyyadsvkgrftisrdnaknslylqmnslraedtavyycardpvwvdgellsggipfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5505,NaN,NaN,QKY76335,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5506,NaN,NaN,QKY76334,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),nvqlvesggglvqpggslrlscaasgftfhhyamhwvrqapgkglewvsgisgssdyrayadslkgrftisrdyaknslwlqmnsltsedtafyycakgvdyggklayfdswgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5507,NaN,NaN,QKY76333,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlresgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavfycarmsrgynyaytfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5508,NaN,NaN,QKY76332,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5509,NaN,NaN,QKY76331,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsayywswirqppgkglewigeinhsgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycarvgysqgyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5510,NaN,NaN,QKY76330,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5511,NaN,NaN,QKY76329,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiaytdsvkgrftisrdnaknslylqmnslraedtalyycakahstghqyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5512,NaN,NaN,QKY76328,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5513,NaN,NaN,QKY76327,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5514,NaN,NaN,QKY76326,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissttyywgwirqppgkglewiasiyysgstyynpslksrltvsvdtsknqfslklssvtaadtavyycarqwkwfgeawyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5515,NaN,NaN,QKY76325,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmggiipifgtanyaqkfqgrvtftadeststaymevsslrsedtavyycarscgdcysadldfwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5516,NaN,NaN,QKY76324,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgfgynftnywigwvrqmpgkglewmgiiypgdsetrnspsfqgqvtisadksmstaylqwsslkasdtamyycarlgvskycsggrclsggsnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5517,NaN,NaN,QKY76323,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfrdysmnwvrqapgkglewvssissggsyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarggsilwwlidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5518,NaN,NaN,QKY76322,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsrhwmtwvrqapgkglewvanikqdgsekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarlgfyyggadywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5519,NaN,NaN,QKY76321,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsmyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarllwlrghfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5520,NaN,NaN,QKY76320,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evhlvgsgggliqpggslrlscaasgftvssnfmswvrqapgkglewvsiihnggdsyytdsvkgrftisrdnskntlylqmnnlraedtavyycassswlrgafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5521,NaN,NaN,QKY76319,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmclswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtgtyycartmatinafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5522,NaN,NaN,QKY76318,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewighiyytgssyynpslksrvtisldtsknqfslklnsvtaadtavyycarlrwlrggidfwgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5523,NaN,NaN,QKY76317,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5524,NaN,NaN,QKY76316,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesgggliqpggslrlscaasgftfsnyamswvrqapgkglewvsgiistsggatynadsvrgrfttsrdnsknilylqmnslrgedtavyycvkglfdwfplwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5525,NaN,NaN,QKY76315,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviyaggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardalyyngpgrdgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5526,NaN,NaN,QKY76314,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftlddyglswvrhapgkglewvsginwnggrtayadsvkgrftisrdnaknslylqmnslraedtalyhcarargpseqyydlltgyydafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5527,NaN,NaN,QKY76313,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslttsgmcvswirqppgkalewlaridwdddkyystslqtrltiskdtsknqvvltmtnmdpvdtatyycaretpvtaidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5528,NaN,NaN,QKY76312,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslrtedtalyycamgpfgellpyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5529,NaN,NaN,QKY76311,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviyaggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardalyyngpgrdgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5530,NaN,NaN,QKY76310,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5531,NaN,NaN,QKY76309,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqqwgagllkpsetlsrtcavygasfsnyywswirqppgkglewigeinhsentnynpslksrvtisvdtsknqfslrlssvtaadtavyycarlrysssgghifdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5532,NaN,NaN,QKY76308,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqllesgggliqpggslrlscaasgftfsnyamswvrqapgkglewvsgiisssggatynadsvrgrfttsrdnsknilylqmnslrgedtavyycvkglfdwfplwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5533,NaN,NaN,QKY76307,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrlsitkdtsknqvvltmtnmdpvdtgtyycarhqivvlfdmwgqgtrvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5534,NaN,NaN,QKY76306,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycargpepdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5535,NaN,NaN,QKY76305,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5536,NaN,NaN,QKY76304,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtststaymelssltsddtavyycarmrtgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5537,NaN,NaN,QKY76303,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5538,NaN,NaN,QKY76302,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaggytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtsistaymelsslrsedtavyycarmrtgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5539,NaN,NaN,QKY76301,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsgiswnggntgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwaggafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5540,NaN,NaN,QKY76300,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvgsnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqlnslraedtavyycarevvgyfdcwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5541,NaN,NaN,QKY76299,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwagdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5542,NaN,NaN,QKY76298,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfvtsgihwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggpnkevlyfgelldygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5543,NaN,NaN,QKY76297,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissagyywswirqhpgkglewigyiyysgrtyynpslksrvtmsvdtsknqfslrlrsvtaadtavyycarvvptrgpvawfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5544,NaN,NaN,QKY76296,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfrdvwmswvrqapgkglewvgrikskidggttdyaapvkgrftisrddskntlylqmnslktedtavyycttagsyyydtvgpglpegkfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5545,NaN,NaN,QKY76295,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5546,NaN,NaN,QKY76294,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglecvsviyaggntyyadsvkgrftisrdnskntlylqmnslraedtavyycargdggyyspfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5547,NaN,NaN,QKY76293,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfgsfdinwvrqatgqglewmgrmnsnsgntayaqkfqgrvtmtrdtstntaymelsslrsedtamyycarmrsgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5548,NaN,NaN,QKY76292,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsgdtsssytvgwvrqapgqglewmgriipilgiaysaqkfqgrltitadkststsymelsslrsedtavyycargvvaatpgwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5549,NaN,NaN,QKY76291,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwiavgsgntnyaqkfqervsitrdmststaymelsslrsedtavyycaapycsrtschdafdiwgqgtkvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5550,NaN,NaN,QKY76290,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),evqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5551,NaN,NaN,QKY76289,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsvssrsyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhtvdcggdcfpndafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5552,NaN,NaN,QKY76288,NaN,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5553,NaN,NaN,NaN,QKY76287,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyccssytssravlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5554,NaN,NaN,NaN,QKY76286,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5555,NaN,NaN,NaN,QKY76285,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5556,NaN,NaN,NaN,QKY76284,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5557,NaN,NaN,NaN,QKY76283,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknslawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5558,NaN,NaN,NaN,QKY76282,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5559,NaN,NaN,NaN,QKY76281,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlhssnnkdslvwyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5560,NaN,NaN,NaN,QKY76280,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5561,NaN,NaN,NaN,QKY76279,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5562,NaN,NaN,NaN,QKY76278,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvvviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5563,NaN,NaN,NaN,QKY76277,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5564,NaN,NaN,NaN,QKY76276,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqfliylgsnrasgvpdrfsgsgsgtdfilkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5565,NaN,NaN,NaN,QKY76275,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5566,NaN,NaN,NaN,QKY76274,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5567,NaN,NaN,NaN,QKY76273,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyccssytssravlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5568,NaN,NaN,NaN,QKY76272,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqfliylgsnrasgvpdrfsgsgsgtdfilkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5569,NaN,NaN,NaN,QKY76271,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstflawyqqkpgqaprllifgassratgipdrfsgsgsgtdftltisrlepedfavyychqygtspytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5570,NaN,NaN,NaN,QKY76270,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktanitcggnnigrksvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpewvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5571,NaN,NaN,NaN,QKY76269,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5572,NaN,NaN,NaN,QKY76268,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divvtqtplslsvtpgqpasisckssetllhsdgktylswylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkigrveaedvglyycmqsiqlafgqgtrleie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5573,NaN,NaN,NaN,QKY76267,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5574,NaN,NaN,NaN,QKY76266,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapkllisrnnqrpsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5575,NaN,NaN,NaN,QKY76265,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsllytsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5576,NaN,NaN,NaN,QKY76264,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscragqtvsssylawyqhkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5577,NaN,NaN,NaN,QKY76263,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsdgytyldwylqkpgqspqlliylgskrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5578,NaN,NaN,NaN,QKY76262,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapkllmyaastlqsgvpsrfsgsgsgteftltintlqpedfatyycqqlnsypitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5579,NaN,NaN,NaN,QKY76261,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkprqapvliisgnnnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhlrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5580,NaN,NaN,NaN,QKY76260,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgtpgqrvtiscsgsnskigsysvnwyqqlpgtapklliyrnnqrpsgvpdrffgsksgtsaslaisglqsedeadyycsvwddslngplfgggtkltfv,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5581,NaN,NaN,NaN,QKY76259,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpgfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5582,NaN,NaN,NaN,QKY76258,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswfqhhpdkaprlmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpfvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5583,NaN,NaN,NaN,QKY76257,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5584,NaN,NaN,NaN,QKY76256,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvvviygknnrpsgipdrfsgsssgnkasltitgaqagdeadyycnsrdnsgnlnwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5585,NaN,NaN,NaN,QKY76255,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigtkgvhwyqqkpgqapvlvvyddsdrpsgipgrfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5586,NaN,NaN,NaN,QKY76254,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5587,NaN,NaN,NaN,QKY76253,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkfvcwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsstgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5588,NaN,NaN,NaN,QKY76252,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5589,NaN,NaN,NaN,QKY76251,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,itcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfggsasgtdftltisslqpedfatyycqqsystftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5590,NaN,NaN,NaN,QKY76250,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagynvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsfdsslsgsdvfgtgtkvsvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5591,NaN,NaN,NaN,QKY76249,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5592,NaN,NaN,NaN,QKY76248,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystppytfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5593,NaN,NaN,NaN,QKY76247,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlhssnnkdslvwyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5594,NaN,NaN,NaN,QKY76246,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrashsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5595,NaN,NaN,NaN,QKY76245,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedvatyycqqynshpptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5596,NaN,NaN,NaN,QKY76244,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigarydvhwyqqlpgtapkllmygnnnrpsgvpdrfsgsksgtsvslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5597,NaN,NaN,NaN,QKY76243,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqhlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwsvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5598,NaN,NaN,NaN,QKY76242,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgssrgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5599,NaN,NaN,NaN,QKY76241,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdflavslgeratisckssqsvlytpknknylawykqkpgqppkvliywastresgvpdrfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtrveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5600,NaN,NaN,NaN,QKY76240,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqsystltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5601,NaN,NaN,NaN,QKY76239,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnskigsysvnwyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycsvwddslngplfgggtkltfl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5602,NaN,NaN,NaN,QKY76238,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystfwtfgqgtnveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5603,NaN,NaN,NaN,QKY76237,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5604,NaN,NaN,NaN,QKY76236,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyychyrsnwppvltfgggtkveie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5605,NaN,NaN,NaN,QKY76235,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqyygsspfgfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5606,NaN,NaN,NaN,QKY76234,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtsgdvgaynyvswyqqhpvkapklmiydvskrpsgvsnrfsgsksgntasltisglqtedeadyycssytssstlwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5607,NaN,NaN,NaN,QKY76233,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprqytywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadtigtywvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5608,NaN,NaN,NaN,QKY76232,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkysswyqqkpgqspvlviyedtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawssstavfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5609,NaN,NaN,NaN,QKY76231,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5610,NaN,NaN,NaN,QKY76230,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divvtqtplslsvtpgqpasisckssetllhsdgktylswylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkigrveaedvglyycmqsiqlafgqgtrleie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5611,NaN,NaN,NaN,QKY76229,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyanwyqqkpgqapvvvifgknnrpsgipdrfsgsnsgntasltitgaqaedeadyycnsrdssgyiwgwmfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5612,NaN,NaN,NaN,QKY76228,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvkvvyhdgdrpsgiperfsgsnsgntatltinrveagdeadyscqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5613,NaN,NaN,NaN,QKY76227,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqtitnylnwyqlksgrapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5614,NaN,NaN,NaN,QKY76226,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5615,NaN,NaN,NaN,QKY76225,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllqftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5616,NaN,NaN,NaN,QKY76224,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnslswyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqydnlllftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5617,NaN,NaN,NaN,QKY76223,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5618,NaN,NaN,NaN,QKY76222,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5619,NaN,NaN,NaN,QKY76221,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5620,NaN,NaN,NaN,QKY76220,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsrflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5621,NaN,NaN,NaN,QKY76219,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5622,NaN,NaN,NaN,QKY76218,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvgnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5623,NaN,NaN,NaN,QKY76217,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyychyrsnwppvltfgggtkveie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5624,NaN,NaN,NaN,QKY76216,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqsphlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5625,NaN,NaN,NaN,QKY76215,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktanitcggnnigrksvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpewvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5626,NaN,NaN,NaN,QKY76214,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5627,NaN,NaN,NaN,QKY76213,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgggtkvqik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5628,NaN,NaN,NaN,QKY76212,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknslawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5629,NaN,NaN,NaN,QKY76211,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygasslqtgvpsrfsgsgsgtdftltirslqpedfasyycqqsystptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5630,NaN,NaN,NaN,QKY76210,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygasslqtgvpsrfsgsgsgtdftltirslqpedfasyycqqsystptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5631,NaN,NaN,NaN,QKY76209,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasldiskylnwyqhkpgkapnlliydafnlergvpsrfsgsgsgtdftftisslqpediatyycqqydnlppgvsttfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5632,NaN,NaN,NaN,QKY76208,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqtitnylnwyqlksgrapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5633,NaN,NaN,NaN,QKY76207,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5634,NaN,NaN,NaN,QKY76206,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsyasslsahvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5635,NaN,NaN,NaN,QKY76205,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrashsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5636,NaN,NaN,NaN,QKY76204,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvvgynyvswyqqhpgkapklmiydvrnrpsgvsnrfsgsksgntasltisglqaedeadyfcisytssrtlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5637,NaN,NaN,NaN,QKY76203,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsrsgntasltisglqaedeadyycssytssstpvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5638,NaN,NaN,NaN,QKY76202,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvtkrpsgvperfsgsksgntasltisglqaedeadysccsyagsytyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5639,NaN,NaN,NaN,QKY76201,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaisglqaedeadyscqsydsslsgyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5640,NaN,NaN,NaN,QKY76200,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsystwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5641,NaN,NaN,NaN,QKY76199,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkrgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5642,NaN,NaN,NaN,QKY76198,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssnflawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5643,NaN,NaN,NaN,QKY76197,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnenylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyssytfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5644,NaN,NaN,NaN,QKY76196,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppgvtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5645,NaN,NaN,NaN,QKY76195,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifinsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslgalfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5646,NaN,NaN,NaN,QKY76194,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltvsglqaedeaeyycsayagsnnlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5647,NaN,NaN,NaN,QKY76193,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5648,NaN,NaN,NaN,QKY76192,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysspytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5649,NaN,NaN,NaN,QKY76191,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgvpgqrvtvsctgsssnigagfdvywyqqflgtapklliygnnnrpsgvpdrfsasksgtsaslaitglqaedeadyycqsfdigrggwifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5650,NaN,NaN,NaN,QKY76190,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvsageratlscrasqsissnlawyhqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynsysltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5651,NaN,NaN,NaN,QKY76189,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqpssvsvspgqtaritcsgdalpkryaywyrqksgqapvlvihedskrpsgiperfsgstsgtmatltitgaqledeadyycfsmdssgdlrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5652,NaN,NaN,NaN,QKY76188,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfeyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5653,NaN,NaN,NaN,QKY76187,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssnflawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5654,NaN,NaN,NaN,QKY76186,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5655,NaN,NaN,NaN,QKY76185,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsinswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqysiyswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5656,NaN,NaN,NaN,QKY76184,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvvtqppsasgtpgqrvtiscsgsssnigynivnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslsisglqsedeadyycaawddslngyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5657,NaN,NaN,NaN,QKY76183,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifinsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslgalfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5658,NaN,NaN,NaN,QKY76182,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,fyeltqppsvsvspgqtagitcsgdklghkyaywyqqkpgqspilliyqddkrpsgiperfsgsnsgtiatltisgtqpvdeadyycqawdndagvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5659,NaN,NaN,NaN,QKY76181,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalptkyaywyqqksgqapvlviyddskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5660,NaN,NaN,NaN,QKY76180,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatfycqqsystpmhtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5661,NaN,NaN,NaN,QKY76179,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsadalskqyaywyqqkpgqapvvviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssshwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5662,NaN,NaN,NaN,QKY76178,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrssgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5663,NaN,NaN,NaN,QKY76177,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmaqtplslpvtpgepasiscrssqslldsddgntyfdwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkinrveaedvgvyycmqriefpwtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5664,NaN,NaN,NaN,QKY76176,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedyatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5665,NaN,NaN,NaN,QKY76175,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsadalpkhyaywyqqrpgqapvlviykdierpsgiperfsgsssgttvtltitgaqaedeadyycqsvdgsgssvvfgggtklavl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5666,NaN,NaN,NaN,QKY76174,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgetyvswyqqkpgqspvlviyedskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstggvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5667,NaN,NaN,NaN,QKY76173,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyfwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5668,NaN,NaN,NaN,QKY76172,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvassylawyqqkpgqaprlliygasgratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5669,NaN,NaN,NaN,QKY76171,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspgtlsvspgeratlscrasqslsshlawyqqkpgqaprlliygvstratgiparfsgsgsgteftlaisslqsedsavyycqqyhvwppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5670,NaN,NaN,NaN,QKY76170,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystfwtfgqgtnveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5671,NaN,NaN,NaN,QKY76169,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggytyvswyqqhpgkapklmiydvnkrpsgvpdrfsgsksgitasltisglqaedeadyyccsyagrytwvfgggttltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5672,NaN,NaN,NaN,QKY76168,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlvisedskrpsgiperfsgsssgtvatltisgaqvedeadyycystdssgnhrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5673,NaN,NaN,NaN,QKY76167,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5674,NaN,NaN,NaN,QKY76166,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyasssivvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5675,NaN,NaN,NaN,QKY76165,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratviparfsgsgsgteftltisslqsedfavyycqqynnwpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5676,NaN,NaN,NaN,QKY76164,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsadalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdssgsyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5677,NaN,NaN,NaN,QKY76163,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyssnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsgwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5678,NaN,NaN,NaN,QKY76162,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqipgtapkllfygnnnrpsgvpdrfsdsksgtsaslaitglqaedeadyycqsydsslsawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5679,NaN,NaN,NaN,QKY76161,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlvihqdsqrpsgiperfsgsnsgntatltisgtqamdeadyycqawdssthvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5680,NaN,NaN,NaN,QKY76160,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfeyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5681,NaN,NaN,NaN,QKY76159,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynfldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrvqaedvgvyycmqalqtpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5682,NaN,NaN,NaN,QKY76158,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyahwyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyyccstdssgnqrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5683,NaN,NaN,NaN,QKY76157,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspgtlsvspgeratlscrasqtlssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyhcqqynnwplafgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5684,NaN,NaN,NaN,QKY76156,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqrpgkapklliyaasslqsgvpsrfsgsgygtdftltisslqpedfatyycqqsyntprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5685,NaN,NaN,NaN,QKY76155,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkytywyqqksgqapvvviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgkgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5686,NaN,NaN,NaN,QKY76154,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5687,NaN,NaN,NaN,QKY76153,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspgtlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgvparfsgsgsgteftltisslqsedfavyycqqynnwppmytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5688,NaN,NaN,NaN,QKY76152,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqrgvpsrfsgsgsgtdftltisslqpedfatyycqqanslpltfgggtkvevk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5689,NaN,NaN,NaN,QKY76151,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dfvmtqspgslavslgeratincrssqsvldnssnknhlawhqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysshwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5690,NaN,NaN,NaN,QKY76150,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5691,NaN,NaN,NaN,QKY76149,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspdfqsvtpkekvtitcrasqnigsslhwyqqkpdqspkviikyasqsfsgvpsrfsgsgsgtdftltinsleaedaatyychqssslpptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5692,NaN,NaN,NaN,QKY76148,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvvvvyddsdrpsglperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5693,NaN,NaN,NaN,QKY76147,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgnrvein,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5694,NaN,NaN,NaN,QKY76146,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgvpgqrvtvsctgsssnigagfdvywyqqflgtapklliygnnnrpsgvpdrfsasksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5695,NaN,NaN,NaN,QKY76145,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5696,NaN,NaN,NaN,QKY76144,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinhylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftitslqpedvatyycqqsdnlpmytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5697,NaN,NaN,NaN,QKY76143,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5698,NaN,NaN,NaN,QKY76142,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqppsvsgspgqsvtisctgtssdvgsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssslrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5699,NaN,NaN,NaN,QKY76141,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5700,NaN,NaN,NaN,QKY76140,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqgnsfpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5701,NaN,NaN,NaN,QKY76139,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysptfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5702,NaN,NaN,NaN,QKY76138,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5703,NaN,NaN,NaN,QKY76137,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylgwyhqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrstfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5704,NaN,NaN,NaN,QKY76136,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvsprqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdtsgnhwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5705,NaN,NaN,NaN,QKY76135,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdflavslgeratisckssqsvlytpknknylawykqkpgqppkvliywastresgvpdrfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtrveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5706,NaN,NaN,NaN,QKY76134,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqlitifcngsisdvggwnyvswyqqhpdkapkmmiydvrhrpsgvssrfsgsksgntasltisglqaedegdyycssftsrgalvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5707,NaN,NaN,NaN,QKY76133,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5708,NaN,NaN,NaN,QKY76132,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5709,NaN,NaN,NaN,QKY76131,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvrdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5710,NaN,NaN,NaN,QKY76130,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5711,NaN,NaN,NaN,QKY76129,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sneltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqstassgtyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5712,NaN,NaN,NaN,QKY76128,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpnqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtswvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5713,NaN,NaN,NaN,QKY76127,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydaykrdtgiparfsgsgsgtdftltisslepedfavyycqqrsnwpliftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5714,NaN,NaN,NaN,QKY76126,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qpvvtqspsasaslgasvkltctldsghrsyaiawhqqrpekgprflmrittdgrhtkgdgipdrfsgsgsgteryltisslqsedeadyycqtwgtfgggtrltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5715,NaN,NaN,NaN,QKY76125,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwfqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5716,NaN,NaN,NaN,QKY76124,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynfvswhqqhpgkapknmiydvskrpsgvsnrfsgsksgntasltisglhtedeadyycssytststpwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5717,NaN,NaN,NaN,QKY76123,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqttritcsgdalpkqygywyqqkagqapilviykdserpsgiperfsgsssgttvtltisgvqaedeahyycqsgdssgtyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5718,NaN,NaN,NaN,QKY76122,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalskqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdrsgtyfnwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5719,NaN,NaN,NaN,QKY76121,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqspqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqppltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5720,NaN,NaN,NaN,QKY76120,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgrtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgskfgntatliisrveagdeadyscqvwdsgsdhvvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5721,NaN,NaN,NaN,QKY76119,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhagkapklmiyevikrpsgvsnrfsgsksgntasltisglqaedeadyyccsyavsttyvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5722,NaN,NaN,NaN,QKY76118,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnignkgvhwyqqkpgqapvlvvdddsdrpsgiperfsgsnsgntatliissvevgdeadfycqvwdsssdhpgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5723,NaN,NaN,NaN,QKY76117,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcassagavtsgyypnwfqqkpgqapraliystankhswtparfsgsllggkaaltlsgvqpedeaeyycllyyggawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5724,NaN,NaN,NaN,QKY76116,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyycysyagsstwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5725,NaN,NaN,NaN,QKY76115,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5726,NaN,NaN,NaN,QKY76114,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwgfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5727,NaN,NaN,NaN,QKY76113,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpptfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5728,NaN,NaN,NaN,QKY76112,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystrtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5729,NaN,NaN,NaN,QKY76111,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcfgdklgdkyacwfqqkpgqspvliiyqgakrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5730,NaN,NaN,NaN,QKY76110,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qlvltqspsasaslgasvkltctlssghttyaiawhqqqpekgprylmklnsdgshtrgdgipdrfsgsssgaeryltisslqsedeadyycqswdtgigvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5731,NaN,NaN,NaN,QKY76109,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkvein,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5732,NaN,NaN,NaN,QKY76108,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkprkapklliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5733,NaN,NaN,NaN,QKY76107,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspailslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfafyycqqrgnwwtfaqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5734,NaN,NaN,NaN,QKY76106,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatvsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsasgsgteftltisslqsedfavyycqqynnwppmytfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5735,NaN,NaN,NaN,QKY76105,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklliydvsnrpsgvstrfsgsksgntasltisglqaedeadyycssytsssthvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5736,NaN,NaN,NaN,QKY76104,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpnqyaywyqqkpgqapvlvmckdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5737,NaN,NaN,NaN,QKY76103,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaatslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystplytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5738,NaN,NaN,NaN,QKY76102,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtftcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgigsgtdftltisslqpedvatyycqkynsapwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5739,NaN,NaN,NaN,QKY76101,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvsnnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqcynwppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5740,NaN,NaN,NaN,QKY76100,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdigsynlvswyqqypgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyaggntfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5741,NaN,NaN,NaN,QKY76099,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5742,NaN,NaN,NaN,QKY76098,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyyvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsstlnvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5743,NaN,NaN,NaN,QKY76097,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqspsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdsqrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5744,NaN,NaN,NaN,QKY76096,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgstsnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgpsaslaisglqsvdeadyycaawddslngwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5745,NaN,NaN,NaN,QKY76095,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyiswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5746,NaN,NaN,NaN,QKY76094,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypvtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5747,NaN,NaN,NaN,QKY76093,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdkmgdkyacwyqqkpgqspvvviyednkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsslvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5748,NaN,NaN,NaN,QKY76092,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nivmtqsplslpvtpgepasiscrssqsllnsngltyldwylqkpgqspqlliyfvsnrasgvsdrfsgsgsgadftltisrveaedvgvyycmqalqtpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5749,NaN,NaN,NaN,QKY76091,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcassagavtsgyypnwfqqkpgqapraliystankhswtlarfsgsllggkaaltlsgvqpedeaeyycllyyggawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5750,NaN,NaN,NaN,QKY76090,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5751,NaN,NaN,NaN,QKY76089,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhagkapklmiyevikrpsgvsnrfsgsksgntasltisglqaedeadyyccsyavsttyvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5752,NaN,NaN,NaN,QKY76088,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvsnnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqcynwppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5753,NaN,NaN,NaN,QKY76087,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspailslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfafyycqqrgnwwtfaqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5754,NaN,NaN,NaN,QKY76086,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpptfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5755,NaN,NaN,NaN,QKY76085,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcfgdklgdkyacwfqqkpgqspvliiyqgakrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5756,NaN,NaN,NaN,QKY76084,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklliydvsnrpsgvstrfsgsksgntasltisglqaedeadyycssytsssthvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5757,NaN,NaN,NaN,QKY76083,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnignkgvhwyqqkpgqapvlvvdddsdrpsgiperfsgsnsgntatliissvevgdeadfycqvwdsssdhpgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5758,NaN,NaN,NaN,QKY76082,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypvtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5759,NaN,NaN,NaN,QKY76081,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgitnylawfqqkpgkapksliyavsslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynsypwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5760,NaN,NaN,NaN,QKY76080,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsghvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5761,NaN,NaN,NaN,QKY76079,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggyhyvswyqhhpgkapkliiydvikrpsgvsnrfsgsksgntasltisglqaedeayyycssytssttwvfgggtrltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5762,NaN,NaN,NaN,QKY76078,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqqydnlysvhfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5763,NaN,NaN,NaN,QKY76077,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5764,NaN,NaN,NaN,QKY76076,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnpifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5765,NaN,NaN,NaN,QKY76075,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvseaprqrvtiscsggssnignnavnwyqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaswddsligpvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5766,NaN,NaN,NaN,QKY76074,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvvvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5767,NaN,NaN,NaN,QKY76073,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysthmstfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5768,NaN,NaN,NaN,QKY76072,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylhwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyhnlppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5769,NaN,NaN,NaN,QKY76071,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdistylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllftfgpgtkvdvk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5770,NaN,NaN,NaN,QKY76070,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrpsqsittylnwyqqkpgkaprlliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5771,NaN,NaN,NaN,QKY76069,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qpvltqsssasaslgssvkltctlssghssyiiawhqqqpgkaprylmklegsgsynkgsgvpdrfsgsssgadcyltisnlqsedeadyycetwdsntrvfaggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5772,NaN,NaN,NaN,QKY76068,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsylgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5773,NaN,NaN,NaN,QKY76067,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviyrdserpsgiperfsgstsgttvtltisgvqaedeadyycqsadstgwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5774,NaN,NaN,NaN,QKY76066,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpfyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5775,NaN,NaN,NaN,QKY76065,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqqydnlysvhfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5776,NaN,NaN,NaN,QKY76064,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftlsisslqpedfatyycqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5777,NaN,NaN,NaN,QKY76063,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsiisylnwyhqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5778,NaN,NaN,NaN,QKY76062,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5779,NaN,NaN,NaN,QKY76061,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssyyhpvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5780,NaN,NaN,NaN,QKY76060,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasigdrvtitcrasqnirsylnwyqhkpgkapklliyaastlqsgvpsrfsgsesgtdftltisslqpedfatyycqqsssspitfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5781,NaN,NaN,NaN,QKY76059,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5782,NaN,NaN,NaN,QKY76058,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdafpkqygywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsrgavfgsgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5783,NaN,NaN,NaN,QKY76057,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dfqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapnllifaasslhsgvpsrfsgsgsgtdftlsisslqpedfatyycqqsyssewtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5784,NaN,NaN,NaN,QKY76056,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyyctsytssstlnvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5785,NaN,NaN,NaN,QKY76055,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5786,NaN,NaN,NaN,QKY76054,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcfgdalpkqyaywyqqkpgqgpvlviykdserpsgiperfsgstsgttvtltisgvqaedeadyycqsadssgtyrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5787,NaN,NaN,NaN,QKY76053,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyphvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5788,NaN,NaN,NaN,QKY76052,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslstsvgdrvtitcrasqsirsylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5789,NaN,NaN,NaN,QKY76051,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssipyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5790,NaN,NaN,NaN,QKY76050,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcasstgavtsgyfpnwfqqkpgqapralifstnnrhswtparfsgsllgdkaaltlsgvqpedeaeyycllyyggpwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5791,NaN,NaN,NaN,QKY76049,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasigdrvtitcrasqsisswlawyqqipgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5792,NaN,NaN,NaN,QKY76048,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5793,NaN,NaN,NaN,QKY76047,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5794,NaN,NaN,NaN,QKY76046,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyhqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtsvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5795,NaN,NaN,NaN,QKY76045,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvsnnlawyqqkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqyddwppevtfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5796,NaN,NaN,NaN,QKY76044,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgsrfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5797,NaN,NaN,NaN,QKY76043,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapkllisrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsswvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5798,NaN,NaN,NaN,QKY76042,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdawpnqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyfcqssdssgvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5799,NaN,NaN,NaN,QKY76041,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkagkapklliydasnletgvpsrfsgsgsgtdftftisslqpddiatyycqqydnlplafgpgtkvdvk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5800,NaN,NaN,NaN,QKY76040,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsvsiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltvsslqpedfatyycqqsysmppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5801,NaN,NaN,NaN,QKY76039,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5802,NaN,NaN,NaN,QKY76038,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnpifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5803,NaN,NaN,NaN,QKY76037,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpsytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5804,NaN,NaN,NaN,QKY76036,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprtwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5805,NaN,NaN,NaN,QKY76035,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5806,NaN,NaN,NaN,QKY76034,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwpprltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5807,NaN,NaN,NaN,QKY76033,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5808,NaN,NaN,NaN,QKY76032,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslksgvpsrfggsgsgtdftltisslqpedfatyycqqsyemppwtfgqgtkveie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5809,NaN,NaN,NaN,QKY76031,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyphvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5810,NaN,NaN,NaN,QKY76030,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssaayvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5811,NaN,NaN,NaN,QKY76029,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpddiatyycqqydnlplafgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5812,NaN,NaN,NaN,QKY76028,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpnqyaywyhqkpgqapvvviykdserpsgipqrfsgsssgttvtltisgvqaedeadyycqsadssgyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5813,NaN,NaN,NaN,QKY76027,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttvisednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5814,NaN,NaN,NaN,QKY76026,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgstrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5815,NaN,NaN,NaN,QKY76025,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysslsitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5816,NaN,NaN,NaN,QKY76024,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syvltqppsvsvapgktasitcegnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdrlyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5817,NaN,NaN,NaN,QKY76023,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5818,NaN,NaN,NaN,QKY76022,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiassyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssdvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5819,NaN,NaN,NaN,QKY76021,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5820,NaN,NaN,NaN,QKY76020,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvssrdsgvpdrfsgsgsgtaftlkisrveaedvgvyycmqgthwpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5821,NaN,NaN,NaN,QKY76019,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5822,NaN,NaN,NaN,QKY76018,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasigdrvtitcrasqsisswlawyqqipgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5823,NaN,NaN,NaN,QKY76017,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglmtedeadyycqsydgsnhavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5824,NaN,NaN,NaN,QKY76016,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqsvtiscsgsssnignnkvnwyqqlpgtapkvliynsnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycavwddslhsyvfgtetkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5825,NaN,NaN,NaN,QKY76015,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,dmevtqfpsslsasigdrvtitcratqsistylnwyqqkpgkapnlliysashlqrgvparfsgsgsgteftltittlqpedvgtyychqsygvpitfgggtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5826,NaN,NaN,NaN,QKY76014,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5827,NaN,NaN,NaN,QKY76013,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5828,NaN,NaN,NaN,QKY76012,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrlsgsksgtsaslaisglqsedeadyycatwddslngpvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5829,NaN,NaN,NaN,QKY76011,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpsytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5830,NaN,NaN,NaN,QKY76010,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5831,NaN,NaN,NaN,QKY76009,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysslsitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5832,NaN,NaN,NaN,QKY76008,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagiwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5833,NaN,NaN,NaN,QKY76007,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5834,NaN,NaN,NaN,QKY76006,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrryyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnprwfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5835,NaN,NaN,NaN,QKY76005,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltva,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5836,NaN,NaN,NaN,QKY76004,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssflawyqqkpgqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavyycqqygnspqfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5837,NaN,NaN,NaN,QKY76003,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklllyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5838,NaN,NaN,NaN,QKY76002,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqekpgqaprllmysassratgipdrfsgsgsatdftltinrlepedfavyycqqyveppftfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5839,NaN,NaN,NaN,QKY76001,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsrynigsnyvywyqqlpgtaprlliysnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsglifgggtkltvq,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5840,NaN,NaN,NaN,QKY76000,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syelaqppsvsvapgetatifcratyigrknvqwyqqkpgqapvlvvyddsdrpsgipgrfsgsnsgdtatltisrieagdeaayycqvwdgindrvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5841,NaN,NaN,NaN,QKY75999,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapelliydasnletgvpsrfsgsgsgtdfiftisslqpediatyychqydylpytfgqgtkldik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5842,NaN,NaN,NaN,QKY75998,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnerpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsayvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5843,NaN,NaN,NaN,QKY75997,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlalsvgeratlscvasqrvssdyiawyqkkpglaprllvyhgsawatgssarfsgsgsgtaftltisslepedfavyycqqygnspftfgpgtkvefk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5844,NaN,NaN,NaN,QKY75996,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5845,NaN,NaN,NaN,QKY75995,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5846,NaN,NaN,NaN,QKY75994,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5847,NaN,NaN,NaN,QKY75993,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5848,NaN,NaN,NaN,QKY75992,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5849,NaN,NaN,NaN,QKY75991,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5850,NaN,NaN,NaN,QKY75990,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5851,NaN,NaN,NaN,QKY75989,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyarsstrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5852,NaN,NaN,NaN,QKY75988,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgitasltisglqaedeadyyccsyagsstwlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5853,NaN,NaN,NaN,QKY75987,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifgntnrpsgvpdrfsgsksgtstslaitglqaedeadyycqsydsslngdvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5854,NaN,NaN,NaN,QKY75986,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgshgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgstsgntasltisglqaedeadyyccsyagivlfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5855,NaN,NaN,NaN,QKY75985,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyycqqsystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5856,NaN,NaN,NaN,QKY75984,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqlpgtapkllifgnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycvawddsrnglvfgggakltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5857,NaN,NaN,NaN,QKY75983,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfptfgqgtrleir,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5858,NaN,NaN,NaN,QKY75982,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgnsgsiasnyvqwyqqrpgsapttviyedsqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsfdsgnvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5859,NaN,NaN,NaN,QKY75981,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedennyycavwddslngvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5860,NaN,NaN,NaN,QKY75980,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyvgsstyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5861,NaN,NaN,NaN,QKY75979,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5862,NaN,NaN,NaN,QKY75978,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5863,NaN,NaN,NaN,QKY75977,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqlpgtapklliydnnqrtsgvpdrlsgsksgtsaslaisglqsedeanyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5864,NaN,NaN,NaN,QKY75976,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtlsctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5865,NaN,NaN,NaN,QKY75975,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5866,NaN,NaN,NaN,QKY75974,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5867,NaN,NaN,NaN,QKY75973,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyychqsyftpqtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5868,NaN,NaN,NaN,QKY75972,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qslltqppsvsgapgqrvtlscagatsnigagsdvhwyqqlpgtapklliyyntnrpsgvpdrfsgsksatsaslvitglqtedeadyycqsydislggwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5869,NaN,NaN,NaN,QKY75971,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliydasnlergvpsrfsgsgsgtdftftisslqaediatyycqqyhnlprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5870,NaN,NaN,NaN,QKY75970,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvseaprqrvtiscsgsssnignnavnwyqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaawddslngvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5871,NaN,NaN,NaN,QKY75969,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtfscsgsnsnigsytvnwyqqlpgtapklliydnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5872,NaN,NaN,NaN,QKY75968,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvgtynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeaeyycsayagsnnlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5873,NaN,NaN,NaN,QKY75967,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnslnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngswvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5874,NaN,NaN,NaN,QKY75966,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsiagylnwyqqkpgkapklliygttslqsgvpvrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5875,NaN,NaN,NaN,QKY75965,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrlsgsksgtsaslaisglqsedeadyycvawddsrnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5876,NaN,NaN,NaN,QKY75964,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyycqqsystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5877,NaN,NaN,NaN,QKY75963,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlesedfalyycqqynnwwrtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5878,NaN,NaN,NaN,QKY75962,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5879,NaN,NaN,NaN,QKY75961,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5880,NaN,NaN,NaN,QKY75960,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5881,NaN,NaN,NaN,QKY75959,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaisglqseaeadyycvawddsrnglvfgggakltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5882,NaN,NaN,NaN,QKY75958,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqapsasgtpgqrvtiscsgsnsnigsytinwyqqlpgtapklliygndqrtsgvpdrfsgskfgtsaslaisglqsedennyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5883,NaN,NaN,NaN,QKY75957,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,syeltqpssvsvspgqtaritcsgdvlaknyarwfqqkpgqapvlviykdserpsgipkrfsgsssgttvtltisgaqvedeadyycysaadnnrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5884,NaN,NaN,NaN,QKY75956,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrviiscsgsssnigsntvkwyhqlpgtapkllicsnnqrpsgvpdrfsgsksdtsaslaisglqsedeadyycaawddslnalvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5885,NaN,NaN,NaN,QKY75955,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedyatyycqqsystpgltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5886,NaN,NaN,NaN,QKY75954,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5887,NaN,NaN,NaN,QKY75953,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsiagylnwyqqkpgkapklliygttslqsgvpvrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5888,NaN,NaN,NaN,QKY75952,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvtitcqgdslrshyaswykvkpgqapllviygrnnrpsgipdrfsgsrsgntasltitgaqvddeadyycssgdsstdhhvvfaggtklavv,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5889,NaN,NaN,NaN,QKY75951,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5890,NaN,NaN,NaN,QKY75950,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtlsctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5891,NaN,NaN,NaN,QKY75949,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssniesnsvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5892,NaN,NaN,NaN,QKY75948,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5893,NaN,NaN,NaN,QKY75947,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhslgynslswylqkpgqsphlliylgsnrasgvpdrfsgsgsatdftlkisrleaedvgvyycmqalqtpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5894,NaN,NaN,NaN,QKY75946,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklkiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5895,NaN,NaN,NaN,QKY75945,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlppvfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5896,NaN,NaN,NaN,QKY75944,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5897,NaN,NaN,NaN,QKY75943,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycvawddsrnglvfgggakltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5898,NaN,NaN,NaN,QKY75942,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaafnlqsgvpsrfsgsgsgtdftltisslqsedfatyycqqsyntpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5899,NaN,NaN,NaN,QKY75941,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,etvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5900,NaN,NaN,NaN,QKY75940,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5901,NaN,NaN,NaN,QKY75939,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeraslscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspftfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5902,NaN,NaN,NaN,QKY75938,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsissflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqrrsnwppftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5903,NaN,NaN,NaN,QKY75937,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppmytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5904,NaN,NaN,NaN,QKY75936,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydstsrvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5905,NaN,NaN,NaN,QKY75935,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttvisednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5906,NaN,NaN,NaN,QKY75934,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnywvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5907,NaN,NaN,NaN,QKY75933,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsskyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5908,NaN,NaN,NaN,QKY75932,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasagdrvtitcrasqsiryylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsfstprtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5909,NaN,NaN,NaN,QKY75931,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,nlmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsnnqvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5910,NaN,NaN,NaN,QKY75930,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdfiftisslqpediatyycqqydnlppvfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5911,NaN,NaN,NaN,QKY75929,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspatlsvspgerailscrasqsvrsnlawyqqkpgqaprllisgastrataiparfsgsgsgteftltitslqsedcavyychqynnwpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5912,NaN,NaN,NaN,QKY75928,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,viqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5913,NaN,NaN,NaN,QKY75927,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscgasqsisssylawyqqkpgqaprlliygassraagipdrfsgsgsgtdftltisrlepedfavyfcqqyggsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5914,NaN,NaN,NaN,QKY75926,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5915,NaN,NaN,NaN,QKY75925,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5916,NaN,NaN,NaN,QKY75924,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,viqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5917,NaN,NaN,NaN,QKY75923,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5918,NaN,NaN,NaN,QKY75922,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqksgkapklliydasnletgvpsrfsgsgsgtdftftinslqpediatyycqqydnlpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5919,NaN,NaN,NaN,QKY75921,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspatlsvspgerailscrasqsvrsnlawyqqkpgqaprllisgastrataiparfsgsgsgteftltitslqsedcavyychqynnwpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5920,NaN,NaN,NaN,QKY75920,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtgsdvggsnyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvlfgggtklsvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5921,NaN,NaN,NaN,QKY75919,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsysfetfgpgtkvaik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5922,NaN,NaN,NaN,QKY75918,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlppvfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5923,NaN,NaN,NaN,QKY75917,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5924,NaN,NaN,NaN,QKY75916,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5925,NaN,NaN,NaN,QKY75915,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeasyyclawddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5926,NaN,NaN,NaN,QKY75914,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5927,NaN,NaN,NaN,QKY75913,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypgytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5928,NaN,NaN,NaN,QKY75912,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5929,NaN,NaN,NaN,QKY75911,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasfsckssqsllhsdgktylywylqkpgqspqlliyavsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5930,NaN,NaN,NaN,QKY75910,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltistlqpedfatyycqqsystllytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5931,NaN,NaN,NaN,QKY75909,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppkllmywastresgvpdrfsgsgsgaeftltisslqaedvaiyycqqyystltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5932,NaN,NaN,NaN,QKY75908,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrviiscsgsssnigsntvkwyhqlpgtapkllicsnnqrpsgvpdrfsgsksdtsaslaisglqsedeadyycaawddslnalvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5933,NaN,NaN,NaN,QKY75907,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkvliyaastmqsgvpsrfrgsgsgtdftltisslqledfatyycqqsystpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5934,NaN,NaN,NaN,QKY75906,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,qsvltqapsasgtpgqrvtiscsgsnsnigsytinwyqqlpgtapklliygndqrtsgvpdrfsgskfgtsaslaisglqsedennyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5935,NaN,NaN,NaN,QKY75905,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivmtqspatlsvspgervtlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgggsgteftltisslqsedfavyycqqynnfltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5936,NaN,NaN,NaN,QKY75904,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,evvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyhcqhfgsssqwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5937,NaN,NaN,NaN,QKY75903,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5938,NaN,NaN,NaN,QKY75902,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapllviygknnrpsgipdrfsgsssgntpsltitgaqaedeadyycnfrdssghhpvfgegtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5939,NaN,NaN,NaN,QKY75901,"['COVID', 'SARS-COV-2', 'Spike protein']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
5940,NaN,NaN,QKQ15231,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesraemkkpgeslkisckgsgytftnhwiawvrqmpgkglewmgiiypgdsdtryspsfegqvtisadksistaylqwsslkasdtamyycarrgytygadfygldvwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5941,NaN,NaN,QKQ15230,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakmgpdpahdygrkndafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5942,NaN,NaN,QKQ15229,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslrlscaasgfiftnywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarerylttdgwfdpwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5943,NaN,NaN,QKQ15228,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakaepevggydyymdvwgkgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5944,NaN,NaN,QKQ15227,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesraevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgitnyaqkfqgrvtitadkststaymelsslrsedtavyycardapdyydssgptyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5945,NaN,NaN,QKQ15226,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycataysvdtamvrgvgywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5946,NaN,NaN,QKQ15225,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvgsvkstagydfwsgdpfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5947,NaN,NaN,QKQ15224,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakeiavagcfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5948,NaN,NaN,QKQ15223,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardweeqwlvafdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5949,NaN,NaN,QKQ15222,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargpaatyyyymdvwgkgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5950,NaN,NaN,QKQ15221,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdsaknslylqmnslraedtalyycakvatyyydrsgyyyggaldywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5951,NaN,NaN,QKQ15220,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctasggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpsglyqllnwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5952,NaN,NaN,QKQ15219,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgaevkkpgasvkisckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargdgdyydssgyyrptlynwldpwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5953,NaN,NaN,QKQ15218,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnsltaedtavyycaregsrqwlviyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5954,NaN,NaN,QKQ15217,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqpgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngdtnyaqklqgrvtmttdtststaymelrslksddtavyycarfdygypysswsvlsidywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5955,NaN,NaN,QKQ15216,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvsgasitsggyywtwirqhpgkglewigyiyysgssfynpslmsrvsisvdtskkqfslklrsvtaadtavyycakegsgggsqnwfdlwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5956,NaN,NaN,QKQ15215,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscsasgftfsnynmdwvrqapgkglewvssisssssyiyladsvkgrftisrdnaknslylqmnslraedtavyycarvqkdivvvpvaladyyyygmdvwgqgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5957,NaN,NaN,QKQ15214,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgssnynpslksrvtisvdksknqfslklnsvtaadtavyycagrycsggrcgwfdpwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5958,NaN,NaN,QKQ15213,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviytggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarahvdtamvesgafdiwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5959,NaN,NaN,QKQ15212,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqsgpglvkpsetlpltctvsggsissssyywgwirqppgkglewigsvfysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycarqvrqwleddafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5960,NaN,NaN,QKQ15211,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckvsgytlpelsmhwvrqapgkgldwmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatspavmsvgwvdpwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5961,NaN,NaN,QKQ15210,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgifypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhnpdyydssgpldywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5962,NaN,NaN,QKQ15209,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnsknmvylqmnslraddtavyycardgsnescsggfcsdswgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5963,NaN,NaN,QKQ15208,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsasgsyygafdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5964,NaN,NaN,QKQ15207,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslrisckgsgysftshwiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarlkvitifgvvrddygmdvwgqgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5965,NaN,NaN,QKQ15206,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgratittdeststaymelsslgsedtavyycarthsydnsgqyfdywgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5966,NaN,NaN,QKQ15205,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgvevkkpgasvkvsckafgytftgqdmhwvrqapgqglewmgwinpssagtnyaqkfqgrvtmtrdtsistaymelsrlrsddtsvyycrkmltifgkvnqtmlliswgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5967,NaN,NaN,QKQ15204,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargvedpvvpaaipwcwfdpwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5968,NaN,NaN,QKQ15203,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssytmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaslpvvpaaigplpafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5969,NaN,NaN,QKQ15202,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmdslraedtamyycakdkappcssgwyyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5970,NaN,NaN,QKQ15201,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarvvgsswypvdafdiwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5971,NaN,NaN,QKQ15200,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrgdsygyyycmdvwgkgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5972,NaN,NaN,QKQ15199,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckvsgytlpelsmhwvrqtpgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgptiaaaatnwfdpggqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5973,NaN,NaN,QKQ15198,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarpnpaggydssgwvdafdiwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5974,NaN,NaN,QKQ15197,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycargprycsstscyagvyfdywgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5975,NaN,NaN,QKQ15196,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsissyywswirqpagkglewigriytsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycarwkyndrfdywgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5976,NaN,NaN,QKQ15195,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslipssvtaadtavyycarggelphynwfdpwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5977,NaN,NaN,QKQ15194,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaspllltppdyyyymdvwgkgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5978,NaN,NaN,QKQ15193,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsysiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycasvvggriaaagclgywgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5979,NaN,NaN,QKQ15192,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtittdeststaymelsslrsedtavyycarvysydssgyyleywgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5980,NaN,NaN,QKQ15191,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyginwvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycasfgddsgdegvrwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5981,NaN,NaN,QKQ15190,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgatvkisckvsgytftdyymhwvqqapgkglewmglvdpedgetiyaekfqgrvtitadtstdtaymelsslrsedtavyycassdssgfvgsrgfdywgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5982,NaN,NaN,QKQ15189,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewasaisgsggstyyadsvegrftisrdnskntlylqmnslraedtavyycakdtgycgddcyiklirggpdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5983,NaN,NaN,QKQ15188,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycarvryydssgyyedywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5984,NaN,NaN,QKQ15187,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldtmggmdvwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5985,NaN,NaN,QKQ15186,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfgsysmswvrqapgkglewvssisrsssyiynadsvrgrltisrdnaknslylqmnslrvedtavyycardqplpdiltgyytgpldywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5986,NaN,NaN,QKQ15185,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqtggilgaevkkpgpsvkvscqagrapsssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycargprgcsstscygsyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5987,NaN,NaN,QKQ15184,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesggglvqpggslklscaasgftfssyamswvrqapgkglewvsaisgsgsntyyadsvkgrftisrdnskntlylqmnslraedtavyycakglrgqqlvipteyfqhwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5988,NaN,NaN,QKQ15183,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsnyywtwirqppgkglewigeidhsgstnynpslksrvtisvdtsknqfslwlssvtaadtavyycargrnyvlqfsewphprahfdnwgqgtlvtiss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5989,NaN,NaN,QKQ15182,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsryamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarviggnyfgafdiwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5990,NaN,NaN,QKQ15181,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvetgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycareaygmdvwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5991,NaN,NaN,QKQ15180,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlpltctvsggsissfywswirqppgkglewigyihnngntnynpslksrvtmsidtsknqfslklssvtaadaavyycarggwsldswgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5992,NaN,NaN,QKQ15179,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqllesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhmrpsiaarpgyqyymdvwgkgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5993,NaN,NaN,QKQ15178,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardleraggmdvwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5994,NaN,NaN,QKQ15177,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycareansdfwsgylgyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5995,NaN,NaN,QKQ15176,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),vqlqqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrstsrwgyyymdvwgkgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5996,NaN,NaN,QKQ15175,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglqwvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarggdrypvgyfdlwgrgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5997,NaN,NaN,QKQ15174,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtpvyycarhnraeewepgfdiwgqgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5998,NaN,NaN,QKQ15173,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsqtlsltctvsggsissggyywswirqlpgkglewigyiyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycarqqldyydssgcfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
5999,NaN,NaN,QKQ15172,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisstsyywgwirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlnydfwsgyysyalyymdvwgkgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6000,NaN,NaN,QKQ15171,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgyrfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwssltasdtaiyycaryyydsrgytsidfwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6001,NaN,NaN,QKQ15170,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardpppddssgwtmgyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6002,NaN,NaN,QKQ15169,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngytnsaqklqgrvtmttdtststaymelrslrsddtavyycardlvdtamvqtlddygmdvwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6003,NaN,NaN,QKQ15168,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdntkntlylqmnslraedtavyycardseyydiltgylapthyyyyymdvwgkgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6004,NaN,NaN,QKQ15167,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrddaknslflqmnslraedtavyycagdqnlycsgdscyyhyygmdvwgqgtvvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6005,NaN,NaN,QKQ15166,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssfiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwksdyydssgyypaafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6006,NaN,NaN,QKQ15165,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarvewaaagtfywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6007,NaN,NaN,QKQ15164,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsgttnyaqrfqgrvtmtrdtsistaymelsrlrsddtavyycareavaarpgnfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6008,NaN,NaN,QKQ15163,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6009,NaN,NaN,QKQ15162,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssnamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntmylqmnslraedtavyycarprggnylagfdpwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6010,NaN,NaN,QKQ15161,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsmnlyywiwirqppgkglewigyvyytgstnynpslksrvtmsvdtsksqfslkmsavtaadtavyycarrgevngyrgafdiwgqgarvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6011,NaN,NaN,QKQ15160,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnrlraedtavyycaretptstyssgwynyyyymdvwgkgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6012,NaN,NaN,QKQ15159,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgtevkkpgasvkvsckasgytfpgyyihwvrqapgqglewmgwinpnsgvaksaqkfqgrvtmtrdssistvyldvtsddtavyycardlvwatvsgtmdvwgqgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6013,NaN,NaN,QKQ15158,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsasgsyygafgywgqrtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6014,NaN,NaN,QKQ15157,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvtstymtwvrrapgkglewvsiiynddttyyadsvkdrvtvsrddskntlylqmnslraedtaiyycarggyyydpsgyysrsfsfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6015,NaN,NaN,QKQ15156,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlvesgpglvkpsetlsltctvsggsissyfwswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarhsqgwlqqavafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6016,NaN,NaN,QKQ15155,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaredyydssgsfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6017,NaN,NaN,QKQ15154,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtlssyaitwvrqapgqglewvggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgysndywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6018,NaN,NaN,QKQ15153,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsggglvqpgrslrlscaasgftfgeyamhwvrqapgkglewvsgiswnsgsidyadsvkgrftisrdnaknslylqmnslraedtalyycakdmgeavagthygmdvwgqgtmvtass,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6019,NaN,NaN,QKQ15152,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatsrvrgvsnwfdpwgqgtpitiss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6020,NaN,NaN,QKQ15151,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaripgydssgyyrgdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6021,NaN,NaN,QKQ15150,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgqyydfwsgylgartnphyyyymdvwgkgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6022,NaN,NaN,QKQ15149,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiyamhwvrqapgkglewvavisydgsnqyyadsvrgrftisrgnskntlylqmnslrpedtavyycararggsyndafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6023,NaN,NaN,QKQ15148,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),hqhqveqgpggveqsetlfltccvsggftisscykrggirqpprkgeewavssyyssstyytpslksrvtisvdksknqfslkmssvtaadtavyycarvssgyyftpfdywgqgtrghrlf,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6024,NaN,NaN,NaN,QKQ15315,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6025,NaN,NaN,NaN,QKQ15314,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspftfgpgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6026,NaN,NaN,NaN,QKQ15313,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6027,NaN,NaN,NaN,QKQ15312,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgpgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6028,NaN,NaN,NaN,QKQ15311,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6029,NaN,NaN,NaN,QKQ15310,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngphwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6030,NaN,NaN,NaN,QKQ15309,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6031,NaN,NaN,NaN,QKQ15308,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6032,NaN,NaN,NaN,QKQ15307,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6033,NaN,NaN,NaN,QKQ15306,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystltfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6034,NaN,NaN,NaN,QKQ15305,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgthftltisslqaedvavyycqqyystppltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6035,NaN,NaN,NaN,QKQ15304,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllsltfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6036,NaN,NaN,NaN,QKQ15303,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6037,NaN,NaN,NaN,QKQ15302,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttfiytfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6038,NaN,NaN,NaN,QKQ15301,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6039,NaN,NaN,NaN,QKQ15300,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvtsnlawyqqkrgqaprlliydasnratgiparfsgsgsgtdftltisglepedfavyycqqrsnwptfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6040,NaN,NaN,NaN,QKQ15299,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqpedfavyycqqcynwppwtfgqgtrvefk,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6041,NaN,NaN,NaN,QKQ15298,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyeaskrpsgisnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkptvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6042,NaN,NaN,NaN,QKQ15297,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6043,NaN,NaN,NaN,QKQ15296,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6044,NaN,NaN,NaN,QKQ15295,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkvliydnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6045,NaN,NaN,NaN,QKQ15294,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsylwtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6046,NaN,NaN,NaN,QKQ15293,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqppsvsvapgqtaritcggdnigskdvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsstdhvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6047,NaN,NaN,NaN,QKQ15292,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qtvvtqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlglyvfgtgtkvtvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6048,NaN,NaN,NaN,QKQ15291,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiydsskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6049,NaN,NaN,NaN,QKQ15290,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6050,NaN,NaN,NaN,QKQ15289,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasiscksgqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpptfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6051,NaN,NaN,NaN,QKQ15288,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwasssvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6052,NaN,NaN,NaN,QKQ15287,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6053,NaN,NaN,NaN,QKQ15286,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywplitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6054,NaN,NaN,NaN,QKQ15285,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6055,NaN,NaN,NaN,QKQ15284,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qlvltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6056,NaN,NaN,NaN,QKQ15283,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsrsgdtasltisglqaedeadyycssytssstwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6057,NaN,NaN,NaN,QKQ15282,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpqtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6058,NaN,NaN,NaN,QKQ15281,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgvtfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6059,NaN,NaN,NaN,QKQ15280,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6060,NaN,NaN,NaN,QKQ15279,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapkvliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysrtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6061,NaN,NaN,NaN,QKQ15278,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspsslsvsvgnivtitcrasqgirndlggisrnqgkplsaiygasslqsgvpsrfrgrgwgteftlpisslqledfaiyyciqhnsylwtfgqgpkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6062,NaN,NaN,NaN,QKQ15277,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtclclqgkshplcrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspntfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6063,NaN,NaN,NaN,QKQ15276,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6064,NaN,NaN,NaN,QKQ15275,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6065,NaN,NaN,NaN,QKQ15274,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypplfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6066,NaN,NaN,NaN,QKQ15273,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqslvysdgntflnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6067,NaN,NaN,NaN,QKQ15272,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqepgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppmytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6068,NaN,NaN,NaN,QKQ15271,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6069,NaN,NaN,NaN,QKQ15270,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliyaastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6070,NaN,NaN,NaN,QKQ15269,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6071,NaN,NaN,NaN,QKQ15268,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslltfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6072,NaN,NaN,NaN,QKQ15267,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlfstnsknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6073,NaN,NaN,NaN,QKQ15266,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfalyycqqydnwplftfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6074,NaN,NaN,NaN,QKQ15265,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgswsgtdftltisrlepedfavyycqqygsspgtfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6075,NaN,NaN,NaN,QKQ15264,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlplspgeratlscrasqsvtnnylawyqqkpgqaprllihatstratgipdrfsgsgsgtdftltisrlepedfavyycqqyggplpytfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6076,NaN,NaN,NaN,QKQ15263,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6077,NaN,NaN,NaN,QKQ15262,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygslytfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6078,NaN,NaN,NaN,QKQ15261,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpqvtfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6079,NaN,NaN,NaN,QKQ15260,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklllyaasdlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysthmstfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6080,NaN,NaN,NaN,QKQ15259,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppvtfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6081,NaN,NaN,NaN,QKQ15258,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspgtlslspgeratlscrasqnvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplftfgpgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6082,NaN,NaN,NaN,QKQ15257,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlhsypltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6083,NaN,NaN,NaN,QKQ15256,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysitfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6084,NaN,NaN,NaN,QKQ15255,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsaapgqkvtiscsgsssnignnfvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdgslsvwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6085,NaN,NaN,NaN,QKQ15254,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtysvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6086,NaN,NaN,NaN,QKQ15253,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlvtyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6087,NaN,NaN,NaN,QKQ15252,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlsyrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppgtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6088,NaN,NaN,NaN,QKQ15251,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6089,NaN,NaN,NaN,QKQ15250,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6090,NaN,NaN,NaN,QKQ15249,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkrswtparfsgsllggkaaltlsgaqpedeaeyycllsysgvwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6091,NaN,NaN,NaN,QKQ15248,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkrswtparfsgsllggkaaltlsgaqpedeaeyycllsysgvwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6092,NaN,NaN,NaN,QKQ15247,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6093,NaN,NaN,NaN,QKQ15246,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllidgassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6094,NaN,NaN,NaN,QKQ15245,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6095,NaN,NaN,NaN,QKQ15244,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,airmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6096,NaN,NaN,NaN,QKQ15243,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdigtynyvswyqqhpgkapklmiyevtkrpsgvpdrfsgsksgntasltvsglqaddegdyycssyvgnnnwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6097,NaN,NaN,NaN,QKQ15242,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6098,NaN,NaN,NaN,QKQ15241,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqpasvsgspgqsitisctgsssdiapytfvswyqqhsgtapkliiydvrnrpsgisdrfsgsrsgntaslsisglqaedeadyycsaytttstswvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6099,NaN,NaN,NaN,QKQ15240,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvrdrvtitcrasqsitsslnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6100,NaN,NaN,NaN,QKQ15239,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrhwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6101,NaN,NaN,NaN,QKQ15238,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprvtfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6102,NaN,NaN,NaN,QKQ15237,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqppsvsvspgqtasipcsgdklgdiyacwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgsttakvfgggtkltvp,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6103,NaN,NaN,NaN,QKQ15236,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccscagsstyvfgtgtkvtvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6104,NaN,NaN,NaN,QKQ15235,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlpiydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprftfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6105,NaN,NaN,NaN,QKQ15234,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsappafgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6106,NaN,NaN,NaN,QKQ15233,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqpasvsgspgqsitisctgassdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpvvfgggteltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6107,NaN,NaN,NaN,QKQ15232,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspppftfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6108,NaN,NaN,QJU69682,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6109,NaN,NaN,QJU69680,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaregycsggscysgyyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6110,NaN,NaN,NaN,QJU69681,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6111,NaN,NaN,NaN,QJU69679,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqtpatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrrnwgtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6112,NaN,NaN,QJU69735,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardimfgddwlqkqpdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6113,NaN,NaN,QJU69734,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytinwvrqapgqglewmgriipilgiadyaqkfqgrvtitadkststaymelsslrsedtavyycardlvedtamvtgaaagtwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6114,NaN,NaN,QJU69733,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisaysgntnyaqklqgrvtmttdtststaymevrslrsddtavyycarvglwwlghpdvfdiwgqgtmvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6115,NaN,NaN,QJU69732,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfnlsnyamhwvrqasgkglewvslisydgsikyytdsvkgrftvsgdnskntlflqmnslrpddsalyycvrggvsgpnsfdmwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6116,NaN,NaN,QJU69731,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvtveaifgvvilplknwfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6117,NaN,NaN,QJU69730,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardltstssspysyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6118,NaN,NaN,QJU69729,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvtvvhfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6119,NaN,NaN,QJU69728,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqkvqgrvtmttdtststaymelrslrsddtavyycardrgyaatfgvfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6120,NaN,NaN,QJU69727,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycartkggsyfapfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6121,NaN,NaN,QJU69726,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfssygiswvrqdpgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvglwwlghpdafdiwgqgtmvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6122,NaN,NaN,QJU69725,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrsmrlscaasgfnlssyamhwvrqasgkglewvslisydgsikyyadsvkgrftvsgdnskntlflqmsslraddsalyycvrggvsgpnafdiwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6123,NaN,NaN,QJU69724,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqtahysssfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6124,NaN,NaN,QJU69723,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycararvaydyiwgsyrykafdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6125,NaN,NaN,QJU69722,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyvqkfqgrvtmtrdtsistaymelnrlrsddtavyfcardltttagtdyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6126,NaN,NaN,QJU69721,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslklssvtaadtavyycartplslrlrynwyfdlwgrgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6127,NaN,NaN,QJU69720,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsyggsyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6128,NaN,NaN,QJU69719,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardsvagiyyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6129,NaN,NaN,QJU69718,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsdvtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycareardyygsgsldywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6130,NaN,NaN,QJU69717,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatappysppsswfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6131,NaN,NaN,QJU69716,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesgggliqpggslrlscaasgvivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldvsggmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6132,NaN,NaN,QJU69713,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsfggsyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6133,NaN,NaN,QJU69712,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardeayydiltgyinapknyyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6134,NaN,NaN,QJU69711,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardhhydfwsgyssyyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6135,NaN,NaN,QJU69710,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatappysppsswfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6136,NaN,NaN,QJU69709,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyycarvwgycsggscyvdafdiwgqgtmvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6137,NaN,NaN,QJU69708,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardresydiltgysmegcfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6138,NaN,NaN,QJU69707,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrvydyiwgsyryldywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6139,NaN,NaN,QJU69706,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycareyyydssvypyyyyamdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6140,NaN,NaN,QJU69705,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycattspivgaitwfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6141,NaN,NaN,QJU69704,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvdygsgsygwgwfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6142,NaN,NaN,QJU69703,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarqssfyssgwysygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6143,NaN,NaN,QJU69702,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardfnsyqllwyyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6144,NaN,NaN,QJU69701,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvklscqasgysftnhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvsttylhisslkaedtavyycarasarpgvatnldfwgqgtlvvvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6145,NaN,NaN,QJU69700,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfnlsnyamhwvrqasgkglewvslisydgsvkyytdsvkgrftvsgdnskntlflqmnslrpddsalyycvrggvsgpnsfdmwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6146,NaN,NaN,QJU69699,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarettghfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6147,NaN,NaN,QJU69698,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltcnvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6148,NaN,NaN,QJU69697,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycathivvvtatpnwyfdlwgrgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6149,NaN,NaN,QJU69696,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarlvptwasyydfwsgypggygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6150,NaN,NaN,QJU69695,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsisgsylgafdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6151,NaN,NaN,QJU69694,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgppycsstscehwfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6152,NaN,NaN,QJU69693,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgaevkkpgasvkvtckasgytftsyylhwvrqapgqglewmgiinpsggttsyaqkfqgrvtmtrdtststvymelsslrsedtavyycaragrrysssddgafdiwgqgtmvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6153,NaN,NaN,QJU69692,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsisgsylgafdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6154,NaN,NaN,QJU69691,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvqsgselkkpgasvklscqasgysftnhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvsttylhisslkaedtavyycarasarpgvatnldfwgqgtlvvvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6155,NaN,NaN,QJU69690,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvrgsyylfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6156,NaN,NaN,QJU69689,NaN,"['COVID', 'SARS-COV-2']",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslklssvtaadtavyycartplslrlrynwyfdlwgrgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-10-12,NaN,NaN
6157,NaN,NaN,NaN,QJU69782,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdkfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6158,NaN,NaN,NaN,QJU69781,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6159,NaN,NaN,NaN,QJU69780,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntyvnwfqqrpgqsprrliyqvsirasgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6160,NaN,NaN,NaN,QJU69779,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkfliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyitaftfgpgtkvdik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6161,NaN,NaN,NaN,QJU69778,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6162,NaN,NaN,NaN,QJU69777,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6163,NaN,NaN,NaN,QJU69776,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntyvnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6164,NaN,NaN,NaN,QJU69775,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppitfgqgtrleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6165,NaN,NaN,NaN,QJU69774,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprfgpgtkvdikr,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6166,NaN,NaN,NaN,QJU69773,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6167,NaN,NaN,NaN,QJU69771,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypftfgpgtkvdik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6168,NaN,NaN,NaN,QJU69770,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6169,NaN,NaN,NaN,QJU69769,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6170,NaN,NaN,NaN,QJU69768,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppkytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6171,NaN,NaN,NaN,QJU69767,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrgtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6172,NaN,NaN,NaN,QJU69766,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnidnylnwyqqkpgkapklliyaasrlhsgvpsrfsgsgsgtdftliisslqpedlatyycqqsysnpltfgpgtkvdir,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6173,NaN,NaN,NaN,QJU69765,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpatiscrssqslvysdgntyvnwfqqrpgqsprrliyqvsirasgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6174,NaN,NaN,NaN,QJU69764,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppiftfgpgtkvdik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6175,NaN,NaN,NaN,QJU69763,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyagspwtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6176,NaN,NaN,NaN,QJU69762,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtrleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6177,NaN,NaN,NaN,QJU69761,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6178,NaN,NaN,NaN,QJU69760,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsssytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6179,NaN,NaN,NaN,QJU69759,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqnvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyitpytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6180,NaN,NaN,NaN,QJU69758,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6181,NaN,NaN,NaN,QJU69757,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnidnylnwyqqkpgkapklliyaasrlhsgvpsrfsgsgsgtdftliisslqpedlatyycqqsysnpltfgpgtkvdir,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6182,NaN,NaN,NaN,QJU69756,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppsltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6183,NaN,NaN,NaN,QJU69755,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnlyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6184,NaN,NaN,NaN,QJU69754,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydssltlyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6185,NaN,NaN,NaN,QJU69753,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvvviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6186,NaN,NaN,NaN,QJU69752,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnwvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6187,NaN,NaN,NaN,QJU69751,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtymifgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6188,NaN,NaN,NaN,QJU69750,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6189,NaN,NaN,NaN,QJU69749,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqphsvsvataqmaritcggnnigskavhwyqqkpgqdpvlviysdsnrpsgiperfsgsnpgntatltisrieagdeadyycqvwdsssdhvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6190,NaN,NaN,NaN,QJU69748,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6191,NaN,NaN,NaN,QJU69747,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6192,NaN,NaN,NaN,QJU69746,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsasyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6193,NaN,NaN,NaN,QJU69744,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6194,NaN,NaN,NaN,QJU69743,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsasyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6195,NaN,NaN,NaN,QJU69742,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6196,NaN,NaN,NaN,QJU69741,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qlvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklnsdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgirvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6197,NaN,NaN,NaN,QJU69740,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagpvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6198,NaN,NaN,NaN,QJU69739,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6199,NaN,NaN,NaN,QJU69738,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytwvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6200,NaN,NaN,NaN,QJU69737,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6201,NaN,NaN,NaN,QJU69736,"['COVID', 'SARS-COV-2']",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-10-12,NaN,NaN
6202,NaN,NaN,QIQ28229,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),qqlkesggrlvtpgtpltltctasgfslssyyvswvrqapgkglewigiipgtgptycaswakgrftisktsttvdlkitspttedtatyfcarvyagfstwlyfdlwgpgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-10-12,NaN,NaN
6203,NaN,NaN,QIQ28228,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctvsgfslssyamswvrqapgkglewigiisksgstyyaswakgrftisktsttvdlkitspttedtatyfcarddilytsssgyyygmdlwgpgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-10-12,NaN,NaN
6204,NaN,NaN,QIQ28227,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctvsgfslssydmiwvrqapgeglewigiidtaggayyaswakgrftisrtsttvdlkitspttedtatyfcarafygsgwgftrldlwgqgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-10-12,NaN,NaN
6205,NaN,NaN,QIQ28226,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),eqlkesggrlvtpgtpltltctvsgfdlsscsmgwvrqapgkgleyigiisssgstyyaswpkgrftisktsttvdlkitspttedtatyfcargfwyfnlwgqgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-10-12,NaN,NaN
6206,NaN,NaN,QIQ28225,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctasgfslssyymswvrqapgkglewigiiyassstnyaswatgrftisktsttvdlkitspttedtatyfcarvyssgwgdafdlwgpgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-10-12,NaN,NaN
6207,NaN,NaN,QIQ28224,NaN,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctvsgfslssywmswvrqapgkglewigiiftggstyyaswakgrftisktsttvdlkitspttedtatyfcartsyydvsgwgvgrldlwgqgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-10-12,NaN,NaN
6208,NaN,NaN,NaN,QIQ28235,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),NaN,dpmltqtaspvsaavggtvtincqasqsisssnwlswyqqkpgqppklliykastlasgvpsrfkgsgsgtqftltisgvqcddaatyyclgyysftsadnafgggtevvvk,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-10-12,NaN,NaN
6209,NaN,NaN,NaN,QIQ28234,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),NaN,alvmtqtpasvsaavggtvtincqasediysnlawyqqkpgqppklliygastlasgvpsrfkgsgsgteytltisgvqcddaatyycqctydsssytfgggteleik,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-10-12,NaN,NaN
6210,NaN,NaN,NaN,QIQ28233,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),NaN,dpvltqtpssasepvggtvnikcqasqsigtrlawyqqkpgqppklliyyastlasgvpsrfkgsgsgteytltisgvqcddaatyyclgehsyssgdgrtafgggtevvvk,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-10-12,NaN,NaN
6211,NaN,NaN,NaN,QIQ28232,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),NaN,alvmtqtpssvsepvggtvtincqasediysnlawyqqkpgqppklliydasnlasgvpsrfsgsgsgteytltisgvqcadaatyycqtyystvtrafgagtkveik,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-10-12,NaN,NaN
6212,NaN,NaN,NaN,QIQ28231,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),NaN,apvltqtpspvsaavggtvtincqaseniysflawyqqkpgqppklliytasklasgvpsrfkgsgsgtqftltisdvqcddaatyycqqtdtysnvdnafgggtevvve,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-10-12,NaN,NaN
6213,NaN,NaN,NaN,QIQ28230,"['COVID', 'SARS-COV-2', 'RBD']",Oryctolagus cuniculus (rabbit),NaN,dpmltqtassvsaavggtvtiscqssqsvydnnwlgwyqqkpgqppklliysastlasgvpsrfkgsgsgtqftltisdlecddaatyycaggysgnifafgggteleil,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-10-12,NaN,NaN
6214,NaN,NaN,NaN,ABG79005,['COVID'],Homo sapiens (human),NaN,eltqspatlslspgeratlscrtsqnigtwlawfqqkpgqtprlliydaskraagiparfsgsgsgtdftltinsleaedfavyycqqrlqwatentfgrgtrldikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Kang,X. et al.; Human neutralizing SARS-CoV specific Fab molecules generated by phage display; Unpublished; 2006.",NaN,NaN,"anti-SARS-CoV S protein immunoglobulin kappa light chain, partial [Homo sapiens]",2022-10-12,NaN,NaN
